PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SHANN, F				SHANN, F			ANTIPYRETICS IN SEVERE SEPSIS	LANCET			English	Editorial Material							ASPIRIN; INFECTION; RABBITS				SHANN, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC,AUSTRALIA.		Shann, Frank/C-9510-2011					ADAM D, 1994, EUR J PEDIATR, V153, P394; Busser FJM, 1978, J VET PHARMACOL THER, V1, P69; ESPOSITO AL, 1984, AM REV RESPIR DIS, V130, P857; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; HSIA J, 1989, B NEW YORK ACAD MED, V65, P45; HUSSEINI RH, 1982, J INFECT DIS, V145, P520, DOI 10.1093/infdis/145.4.520; KUROSAWA S, 1987, J INFECT DIS, V155, P991, DOI 10.1093/infdis/155.5.991; MOGABGAB WJ, 1976, JAMA-J AM MED ASSOC, V235, P801, DOI 10.1001/jama.1976.03260340011003; STANLEY ED, 1975, JAMA-J AM MED ASSOC, V231, P1248, DOI 10.1001/jama.231.12.1248; VAUGHN LK, 1980, BRAIN RES BULL, V5, P69, DOI 10.1016/0361-9230(80)90285-3; VAUGHN LK, 1977, FED PROC, V36, P511; 1993, WHOARI9330	12	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					338	338		10.1016/S0140-6736(95)90337-2	http://dx.doi.org/10.1016/S0140-6736(95)90337-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845113				2022-12-01	WOS:A1995QF72200005
J	SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S				SIDDIQUE, AK; SALAM, A; ISLAM, MS; AKRAM, K; MAJUMDAR, RN; ZAMAN, K; FRONCZAK, N; LASTON, S			WHY TREATMENT CENTERS FAILED TO PREVENT CHOLERA DEATHS AMONG RWANDAN REFUGEES IN GOMA, ZAIRE	LANCET			English	Article							BANGLADESH; EPIDEMIC	In July, 1994, in one of the worst cholera outbreaks in recent times, an estimated 12 000 Rwandan refugees died in Goma in eastern Zaire, The Vibrio cholerae strains were resistant to tetracycline and doxycycline, the commonly used drugs for cholera treatment. Despite the efforts of international organisations, which provided medical relief by establishing treatment centres in Goma, mortality from the disease was much higher than expected. In the area of Muganga camp, which had the largest concentration of refugees and where most of the medical aid organisations were active, the highest reported case-fatality ratio for a single day was 48%. The slow rate of rehydration, inadequate use of oral rehydration therapy, use of inappropriate intravenous fluids, and inadequate experience of health workers in management of severe cholera are thought to be some of the factors associated with the failure to prevent so many deaths during the epidemic. In one of the temporary treatment centres with the worst case-fatality record, our team showed that improvement of these factors could increase the odds of survival of cholera patients even in a disaster setting.	INT CTR DIARRHOEAL DIS RES, DIV CLIN SCI, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV SCI LAB, DHAKA 1000, BANGLADESH; INT CTR DIARRHOEAL DIS RES, DIV FAMILY PLANNING & POPULAT, DHAKA 1000, BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	SIDDIQUE, AK (corresponding author), INT CTR DIARRHOEAL DIS RES, DIV COMMUNITY HLTH, GPO BOX 128, DHAKA 1000, BANGLADESH.		Salam, Abdul/GWC-1029-2022					BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; PIERCE NF, 1969, ANN INTERN MED, V70, P1173, DOI 10.7326/0003-4819-70-6-1173; SACK R B, 1970, Bulletin of the World Health Organization, V43, P351; SIDDIQUE AK, 1990, TROP DOCT, V20, P83, DOI 10.1177/004947559002000215; SIDDIQUE AK, 1989, TROP GEOGR MED, V41, P377; SIDDIQUE AK, 1992, J DIARRHOEAL DIS RES, V10, P79; SIDDIQUE AK, 1991, J DIARRHOEAL DIS RES, V9, P310; 1987, MANUAL LABORATORY IN; 1992, WEEKLY EPIDEMIOL REC, V67, P253	9	122	124	3	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 11	1995	345	8946					359	361		10.1016/S0140-6736(95)90344-5	http://dx.doi.org/10.1016/S0140-6736(95)90344-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7646639				2022-12-01	WOS:A1995QF72200012
J	TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM				TONG, P; THOMAS, T; BERRISH, T; HUMPHRISS, D; BARRIOCANAL, L; STEWART, M; WALKER, M; WILKINSON, R; ALBERTI, KGMM			CELL-MEMBRANE DYNAMICS AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							FLUIDITY; PROTEINS	Insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) could be ralated to changes in cell membrane properties. We measured insulin sensitivity and mononuclear leucocyte membrane fluidity by fluorescence polarisation in fifteen NIDDM patients and twenty-one normal subjects. Core-region anisotropy was significantly lower in leucocytes from diabetic subjects (mean 0.164 vs 0.174, p<0.001). Insulin sensitivity was positively correlated with such anisotropy before and after acute invitro insulin treatment. There was no difference in superficial membrane anisotropy. This study suggests that altered membrane dynamics in NIDDM may contribute to insulin resistance.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,SUBDEPT NEPHROL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	TONG, P (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.							AKINMOKUN A, 1992, DIABETIC MED, V9, P432, DOI 10.1111/j.1464-5491.1992.tb01813.x; BECKNIELSEN H, 1977, DIABETOLOGIA, V13, P563, DOI 10.1007/BF01236308; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DANEMAN D, 1992, DIABETES, V41, P227, DOI 10.2337/diabetes.41.2.227; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; LONNROTH P, 1991, J INTERN MED, V229, P23; TONG P, 1994, BIOCHEM MED METAB B, V52, P132, DOI 10.1006/bmmb.1994.1044; WATALA C, 1992, EUR J CLIN CHEM CLIN, V30, P513; WATALA C, 1993, DIABETIC MED, V10, P13, DOI 10.1111/j.1464-5491.1993.tb01990.x; WINOCOUR PD, 1992, J LAB CLIN MED, V120, P921	10	56	59	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					357	358		10.1016/S0140-6736(95)90343-7	http://dx.doi.org/10.1016/S0140-6736(95)90343-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7845118				2022-12-01	WOS:A1995QF72200011
J	BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC				BERLIN, C; BARGATZE, RF; CAMPBELL, JJ; VONANDRIAN, UH; SZABO, MC; HASSLEN, SR; NELSON, RD; BERG, EL; ERLANDSEN, SL; BUTCHER, EC			ALPHA-4 INTEGRINS MEDIATE LYMPHOCYTE ATTACHMENT AND ROLLING UNDER PHYSIOLOGICAL FLOW	CELL			English	Article							HIGH ENDOTHELIAL VENULES; VASCULAR ADDRESSIN; SELECTIN; ADHESION; MADCAM-1; LECAM-1; SPECIFICITY; LEUKOCYTES; MECHANISMS; EXPRESSION	Of the several families of adhesion receptors involved in leukocyte-endoethelial cell interactions, only the selectins have been shown to initiate leukocyte interaction under physiologic shear; indeed, beta 2 (CD18) integrins responsible for neutrophil arrest are unable to engage without prior selectin-mediated rolling. In contrast, alpha 4 (CD49d) integrins are shown here to initiate lymphocyte contact (''tethering'') In vitro under shear and in the absence of a selectin contribution. The alpha 4 integrin ligands MAdCAM-1 and VCAM-1 support loose reversible interactions including rolling, as well as rapid sticking and arrest that is favored following integrin activation. Moreover, alpha 4 beta 7 mediates L-selectin (CD62L)-independent attachment of blood-borne lymphocytes to lamina propria venules in situ. Scanning electron microscopy of alpha 4 beta 7(hi) lymphoid cells reveals that, like L-selectin, alpha 4 beta 7 is highly concentrated on microvillous sites of initial cellular contact, whereas the beta 2 integrin LFA-1 is excluded from villi. Thus, alpha 4 but not beta 2 integrins can initiate leukocyte adhesion under flow, a capacity that may be in part a function of topographic presentation on microvilli.	VET AFFAIRS MED CTR,CTR MOLEC BIOL & MED,FOOTHILL RES CTR,PALO ALTO,CA 94304; MONTANA STATE UNIV,VET MOLEC BIOL LAB,BOZEMAN,MT 59717; UNIV MINNESOTA,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT DERMATOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; CTR BLOOD RES,BOSTON,MA 02115; PROT DESIGN LABS,MT VIEW,CA 94043	US Department of Veterans Affairs; Veterans Health Administration (VHA); Montana State University System; Montana State University Bozeman; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		von Andrian, Ulrich H/A-5775-2008; Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957, R01AI037832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037734, R01GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957, AI37832] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASSI O, 1993, BLOOD CELLS, V19, P245; ALON R, 1995, IN PRESS J CELL BIOL; ANDREW DP, 1994, J IMMUNOL, V153, P3847; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DUNON D, 1993, BLOOD, V81, P1; ERLANDSEN SL, 1993, J HISTOCHEM CYTOCHEM, V41, P327, DOI 10.1177/41.3.7679125; ERLE DJ, 1994, J IMMUNOL, V153, P517; HAMANN A, 1994, J IMMUNOL, V52, P3282; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; JONES DA, 1995, IN PRESS J CLIN INVE; JUTILA MA, 1989, CELL IMMUNOL, V132, P201; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POSTIGO AA, 1993, RES IMMUNOL, V144, P723, DOI 10.1016/S0923-2494(93)80057-6; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SRIRAMARAO P, 1994, J IMMUNOL, V153, P4238; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; VANEWIJK WV, 1980, DIBA F S, V71, P21; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1993, AGENT ACTION SUPPL, V41, P153; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WOLBER F, 1993, FASEB J, V7, P3704	38	868	890	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					413	422		10.1016/0092-8674(95)90491-3	http://dx.doi.org/10.1016/0092-8674(95)90491-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7532110	Bronze			2022-12-01	WOS:A1995QG47000007
J	BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ				BOUDREAU, N; SYMPSON, CJ; WERB, Z; BISSELL, MJ			SUPPRESSION OF ICE AND APOPTOSIS IN MAMMARY EPITHELIAL-CELLS BY EXTRACELLULAR-MATRIX	SCIENCE			English	Article							DEATH GENE CED-3; INVOLUTION; ENZYME; DIFFERENTIATION; GLYCOPROTEINS; PROTEINASES; COLLAGENASE; INHIBITION; SECRETION; ENCODES	Apoptosis (programmed cell death) plays a major role in development and tissue regeneration. Basement membrane extracellular matrix (ECM), but not fibronectin or collagen, was shown to suppress apoptosis of mammary epithelial cells in tissue culture and in vivo. Apoptosis was induced by antibodies to beta(1) integrins or by overexpression of stromelysin-1, which degrades ECM. Expression of interleukin-1 beta converting enzyme (ICE) correlated with the loss of ECM, and inhibitors of ICE activity prevented apoptosis. These results suggest that ECM regulates apoptosis in mammary epithelial cells through an integrin-dependent negative regulation of ICE expression.	UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BOUDREAU, N (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,1 CYCLOTRON RD,BLDG 83,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA 57621, R01 CA057621, R01 CA057621-07] Funding Source: Medline; NIEHS NIH HHS [ES 07106, T32 ES007106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOUDREAU N, UNPUB; DAMSKY CH, 1982, J CELL BIOCHEM, V18, P1, DOI 10.1002/jcb.1982.240180102; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HENTGARTNER MO, 1994, CELL, V76, P665; KLEINMAN H, 1986, BIOCHEMISTRY-US, V26, P312; KORSMEYER SJ, 1992, CANCER SURV, V5, P105; KRAMER RH, 1985, J CELL PHYSIOL, V123, P1, DOI 10.1002/jcp.1041230102; LI LM, 1987, P NATL ACAD SCI USA, V84, P136; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	27	1095	1133	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					891	893		10.1126/science.7531366	http://dx.doi.org/10.1126/science.7531366			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531366	Green Accepted, Green Submitted			2022-12-01	WOS:A1995QG20700060
J	CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T				CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T			PHYLLOPOD FUNCTIONS IN THE FATE DETERMINATION OF A SUBSET OF PHOTORECEPTORS IN DROSOPHILA	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; DEVELOPING EYE; COMPOUND EYE; CELL FATE; GENE; RAS; MELANOGASTER; ACTIVATION; EXPRESSION	phyllopod (phyl) encodes a novel protein required for fate determination of photoreceptors R1, R6, and R7, the last three photoreceptors to be recruited into the ommatidia of the developing Drosophila eye. Genetic data suggests that phyl acts downstream of Ras1, raf, and van to promote neuronal differentiation in this subset of photoreceptors. Ectopic expression of phyl in the cone cell precursors mimics the effect of ectopic activation of Ras1, suggesting that phyl expression is regulated by Ras1. phyl is also required for embryonic nervous system and sensory bristle development.			CHANG, HC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HAY BA, 1994, DEVELOPMENT, V120, P2121; Jan Yuh Nung, 1993, P1207; KARPEN GH, 1992, GENETICS, V132, P737; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	95	98	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					463	472		10.1016/0092-8674(95)90497-2	http://dx.doi.org/10.1016/0092-8674(95)90497-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7888014	Bronze			2022-12-01	WOS:A1995QG47000013
J	DEFELIPE, C; PINNOCK, RD; HUNT, SP				DEFELIPE, C; PINNOCK, RD; HUNT, SP			MODULATION OF CHEMOTROPISM IN THE DEVELOPING SPINAL-CORD BY SUBSTANCE-P	SCIENCE			English	Article							DEVELOPING AXONS; NEURONS; GROWTH; EXTENSION; RECEPTORS; GUIDANCE; CELLS	Developing axons find their targets through direct contact with cues in the extracellular environment and in response to gradients of diffusible factors. The floor plate, a neuroepithelial structure, guides developing commissural axons in the spinal cord by release of chemoattractants. Floor plate cells express neurokinin-1 receptors, and a transiently appearing subpopulation of commissural axons contains substance P, the neuropeptide ligand for this receptor, Substance P increases the amount of axon outgrowth from dorsal horn explants cocultured with floor plate explants. Results of experiments with embryonic rats suggest that substance P released from pioneering neuronal pathways may regulate the release of chemoattractants from floor plate cells.	MRC,DIV NEUROBIOL,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; PARKE DAVIS & CO,NEUROSCI RES UNIT,CAMBRIDGE CB2 2QB,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			HUNT, STEPHEN P/C-1646-2008; de Felipe, Carmen/D-3813-2012	Hunt, Stephen/0000-0001-9453-5505				ALTMAN J, 1984, DEV RAT SPINAL CORD; BOLOVENTA P, 1990, DEVELOPMENT, V109, P435; CAJAL SRY, 1909, HIST SYSTEME NERVEUX, V1, P592; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; DEFELIPE C, UNPUB; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; GHOSH A, 1993, DEVELOPMENT, V117, P1031; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; NAGY JI, 1982, NEUROSCIENCE, V7, P89, DOI 10.1016/0306-4522(82)90155-5; NARUMI S, 1978, J NEUROCHEM, V30, P1321, DOI 10.1111/j.1471-4159.1978.tb10462.x; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PERNOW B, 1983, PHARMACOL REV, V35, P85; PLACZEK M, 1990, DEVELOPMENT, V110, P19; SEABROOK GR, 1993, NEUROSCI LETT, V152, P9, DOI 10.1016/0304-3940(93)90470-6; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VIGNA SR, 1994, J NEUROSCI, V14, P834	24	44	44	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					899	902		10.1126/science.7531367	http://dx.doi.org/10.1126/science.7531367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531367				2022-12-01	WOS:A1995QG20700063
J	DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E				DICKSON, BJ; DOMINGUEZ, M; VANDERSTRATEN, A; HAFEN, E			CONTROL OF DROSOPHILA PHOTORECEPTOR CELL FATES BY PHYLLOPOD, A NOVEL NUCLEAR-PROTEIN ACTING DOWNSTREAM OF THE RAF KINASE	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; POSITIONAL INFORMATION; COMPOUND EYE; R7 CELL; EXPRESSION; GENE; ACTIVATION; DISK; RAS1	The phyllopod (phyl) gene regulates the fates of a subset of cells in the developing Drosophila eye; in the absence of phyl function, the R1, R6, and R7 photoreceptors are transformed into additional cone cells, whereas ectopic phyl expression in the cone cell precursors transforms these cells into additional R7 cells. Within this group of cells, phyl expression thus mimics activation of the Raf pathway in its ability to induce photoreceptor rather than cone cell development. Furthermore, the transformation of cone cells into R7 cells in response to Raf activation is both accompanied by and dependent upon ectopic phyl expression. phyl thus represents a possible target gene of the Raf pathway during eye development, controlling the fates of a novel subset of photoreceptors.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich			Dickson, Barry/AAE-7632-2019; Dominguez, Maria/G-2171-2014	Dickson, Barry/0000-0003-0715-892X; Dominguez, Maria/0000-0002-3329-7862				BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Cagan Ross Leigh, 1992, P189; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEILER R, 1992, J NEUROSCI, V12, P3862; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MEINICK MB, 1993, DEVELOPMENT, V118, P127; MLODZIK M, 1992, MECH DEVELOP, V37, P37, DOI 10.1016/0925-4773(92)90013-A; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PIROTTA V, 1988, VECTORS SURVEY MOL C, P438; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	93	94	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					453	462		10.1016/0092-8674(95)90496-4	http://dx.doi.org/10.1016/0092-8674(95)90496-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859287	Bronze, Green Accepted			2022-12-01	WOS:A1995QG47000012
J	FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ				FERVEUR, JF; STORTKUHL, KF; STOCKER, RF; GREENSPAN, RJ			GENETIC FEMINIZATION OF BRAIN STRUCTURES AND CHANGED SEXUAL ORIENTATION IN MALE DROSOPHILA	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; MOTH MANDUCA-SEXTA; ANTENNAL LOBE; REPRODUCTIVE-BEHAVIOR; OLFACTORY GLOMERULI; COURTSHIP BEHAVIOR; MELANOGASTER; MOSAICS; RECOGNITION; INFORMATION	The neural basis of sexual orientation in Drosophila was studied by the production of males with regionally feminized brains. Such flies express the female form of the sex determination gene transformer in a limited number oi neurons under the control of GAL4 enhancer trap inserts. This method facilitated the creation of lines with a stable pattern of feminization. In tests of sexual preferences, flies that were feminized in a portion of the antennal lobes or in a subset of the corpora pedunculata (mushroom bodies) courted both males and females. These two brain structures, both of which are involved in olfactory processing, may function in the recognition of sex-specific pheromones, in the control of sex-specific behaviors, or both.	NYU,DEPT BIOL,NEW YORK,NY 10003; NYU,CTR NEURAL SCI,NEW YORK,NY 10003; UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	New York University; New York University; University of Fribourg								BAKER BS, 1980, GENETICS, V94, P383; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHRISTENSEN TA, 1993, J COMP PHYSIOL A, V173, P385, DOI 10.1007/BF00193512; COBB M, 1990, ANIM BEHAV, V39, P1058, DOI 10.1016/S0003-3472(05)80778-X; COBB M, 1985, BEHAVIOUR, V97, P182; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; EWING AW, 1983, BIOL REV, V58, P275, DOI 10.1111/j.1469-185X.1983.tb00390.x; FERVEUR JF, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P397; FERVEUR JF, UNPUB; FISCHBACH KF, 1984, J EXP BIOL, V112, P65; FISHER JA, 1988, NATURE, V332, P853; FOELIX RF, 1989, CELL TISSUE RES, V258, P277, DOI 10.1007/BF00239448; GAILEY DA, 1989, GENETICS, V121, P773; HALL JC, 1977, BEHAV GENET, V7, P291, DOI 10.1007/BF01066800; HALL JC, 1979, GENETICS, V92, P437; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HALL JC, 1978, BEHAV GENET, V8, P125, DOI 10.1007/BF01066870; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOMBERG U, 1989, ANNU REV ENTOMOL, V34, P477, DOI 10.1146/annurev.en.34.010189.002401; HOTTA Y, 1972, NATURE, V240, P527, DOI 10.1038/240527a0; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; JALLON JM, 1984, BEHAV GENET, V14, P441, DOI 10.1007/BF01065444; JALLON JM, 1982, CR HEBD ACAD SCI, V292, P1147; JALLON JM, 1979, BEHAV GENET, V9, P487; KELLEY DB, 1988, ANNU REV NEUROSCI, V11, P225; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MCROBERT SP, 1983, BEHAV GENET, V13, P517, DOI 10.1007/BF01065927; PAILLETTE M, 1991, Bioacoustics, V3, P247; PECHINE JM, 1988, J CHEM ECOL, V14, P1071, DOI 10.1007/BF01019336; POSSIDENTE DR, 1989, DEV BIOL, V132, P448, DOI 10.1016/0012-1606(89)90241-8; ROBERTSON HM, 1988, GENETICS, V118, P461; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROSPARS JP, 1983, J COMP NEUROL, V220, P80, DOI 10.1002/cne.902200108; SCOTT D, 1988, ANIM BEHAV, V36, P1164, DOI 10.1016/S0003-3472(88)80075-7; SIEGEL RW, 1979, P NATL ACAD SCI USA, V76, P3430, DOI 10.1073/pnas.76.7.3430; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SINGH RN, 1985, INT J INSECT MORPHOL, V14, P296; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; STOCKER RF, 1989, BEHAV GENET, V19, P371, DOI 10.1007/BF01066165; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TOMPKINS L, 1986, TRENDS GENET, V2, P14, DOI 10.1016/0168-9525(86)90162-9; TOMPKINS L, 1983, GENETICS, V103, P179; VENARD R, 1989, NEUROBIOLOGY OF SENSORY SYSTEMS, P377; WITHERS GS, 1993, NATURE, V364, P238, DOI 10.1038/364238a0	55	188	190	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					902	905		10.1126/science.7846534	http://dx.doi.org/10.1126/science.7846534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846534				2022-12-01	WOS:A1995QG20700064
J	GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D				GALLAY, P; SWINGLER, S; AIKEN, C; TRONO, D			HIV-I INFECTION OF NONDIVIDING CELLS - C-TERMINAL TYROSINE PHOSPHORYLATION OF THE VIRAL MATRIX PROTEIN IS A KEY REGULATOR	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR LOCATION; PLASMA-MEMBRANE; GROWTH-FACTOR; DNA; ACID; TRANSCRIPTION; SEQUENCE; IMPORT; CYCLE	The HIV-1 matrix (MA) protein contains two subcellular localization signals with opposing effects. A myristoylated N-terminus governs particle assembly at the plasma membrane, and a nucleophilic motif facilitates import of the viral preintegration complex into the nucleus of nondividing cells. Here, we show that myristoylation acts as the MA dominant targeting signal in HIV-1 producer cells. During virus assembly, a subset of MA is phosphorylated on the C-terminal tyrosine by a virion-associated cellular protein kinase. Tyrosine-phosphorylated MA is then preferentially transported to the nucleus of target cells. An MA tyrosine mutant virus grows normally in dividing cells, but is blocked for nuclear import in terminally differentiated macrophages. MA tyrosine phosphorylation thus reveals the karyophilic properties of this protein within the HIV-1 preintegration complex, thereby playing a critical role for infection of nondividing cells.			GALLAY, P (corresponding author), SALK INST BIOL STUDIES, INFECT DIS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AIDEN C, 1994, CELL, V76, P853; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GARTNER S, 1990, RETROVIRUSES, V8, P1017; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001; GULIZIA J, 1994, J VIROL, V68, P2021, DOI 10.1128/JVI.68.3.2021-2025.1994; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUMPHRIES EH, 1972, J VIROL, V10, P82, DOI 10.1128/JVI.10.1.82-87.1972; HUMPHRIES EH, 1974, J VIROL, V14, P531, DOI 10.1128/JVI.14.3.531-546.1974; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LIN PH, 1991, METHOD ENZYMOL, V198, P251; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MYERS G, 1992, HUMAN RETROVIRUSES A; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHAROVA N, 1991, AIDS RES HUM RETROV, V7, P303, DOI 10.1089/aid.1991.7.303; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; SUGASAWA K, 1990, J VIROL, V64, P4820, DOI 10.1128/JVI.64.10.4820-4829.1990; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WALKER F, 1993, J BIOL CHEM, V268, P19552; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	45	297	306	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					379	388		10.1016/0092-8674(95)90488-3	http://dx.doi.org/10.1016/0092-8674(95)90488-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859280	Bronze			2022-12-01	WOS:A1995QG47000004
J	GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH				GERASIMENKO, OV; GERASIMENKO, JV; TEPIKIN, AV; PETERSEN, OH			ATP-DEPENDENT ACCUMULATION AND INOSITOL TRISPHOSPHATE-MEDIATED OR CYCLIC ADP-RIBOSE-MEDIATED RELEASE OF CA2+ FROM THE NUCLEAR-ENVELOPE	CELL			English	Article							RAT-LIVER NUCLEI; IP(3) RECEPTOR; CALCIUM; CELLS; OSCILLATIONS; CHANNELS; MEMBRANE; WAVES; EGGS	Uptake and release of Ca2+ from isolated liver nuclei were studied with fluorescent probes. We show with the help of digital imaging and confocal microscopy that the Ca2+-sensitive fluorescent probe Fura 2 is concentrated in or around the nuclear envelope and that the distribution of Fura 2 fluorescence is similar to that of an endoplasmic reticulum marker. The previously demonstrated ATP-dependent uptake of Ca2+ into isolated nuclei and release of the accumulated Ca2+ by inositol 1,4,5-trisphosphate (IP3) are therefore due to transport of Ca2+ into and out of the nuclear envelope and not the nucleoplasm. Dextrans labeled with fluorescent Ca2+ indicators (calcium-Green 1 and Fura 2) are distributed uniformly in the nucleoplasm and can be used to show that changes in the external Ca2+ concentration produce rapid changes in the nucleoplasmic Ca2+ concentration. Nevertheless, IP3 and cyclic ADP-ribose evoke transient intranuclear Ca2+ elevations. The release from the Ca2+ stores in or around the nuclear envelope appears to be directed into the nucleoplasm from where it can diffuse out through the permeable nuclear pore complexes.			GERASIMENKO, OV (corresponding author), UNIV LIVERPOOL,PHYSIOL LAB,MRC,SECRETORY CONTROL RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Gerasimenko, Oleg/A-6622-2010; Gerasimenko, Julia/A-7688-2010; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Petersen, Ole/0000-0002-6998-0380; Gerasimenko, Julia/0000-0002-2262-2543; Tepikin, Alexei/0000-0002-8172-7513				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; GILLOT I, 1993, J EXP BIOL, V184, P213; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEE HC, 1989, J BIOL CHEM, V264, P1608; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P8858; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799	27	332	343	3	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					439	444		10.1016/0092-8674(95)90494-8	http://dx.doi.org/10.1016/0092-8674(95)90494-8			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859285	Bronze			2022-12-01	WOS:A1995QG47000010
J	KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L				KENNEDY, BK; AUSTRIACO, NR; ZHANG, JS; GUARENTE, L			MUTATION IN THE SILENCING GENE SIR4 CAN DELAY AGING IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL STATES; INDEFINITE DIVISION; CELLULAR SENESCENCE; HUMAN FIBROBLASTS; YEAST TELOMERES; DNA-SEQUENCES	Aging in S. cerevisiae is exemplified by the fixed number of cell divisions that mother cells undergo (termed their life span). We have exploited a correlation between life span and stress resistance to identify mutations in four genes that extend life span. One of these, SIR4, encodes a component of the silencing apparatus at HM loci and telomeres. The sir4-42 mutation extends life span by more than 30% and is semidominant. Our findings suggest that sir4-42 extends life span by preventing recruitment of the SIR proteins to HM loci and telomeres, thereby increasing their concentration at other chromosomal regions. Maintaining silencing at these other regions may be critical in preventing aging. Consistent with this view, expression of only the carboxyl terminus of SIR4 interferes with silencing at HM loci and telomeres, which also extends life span. Possible links among silencing, telomere maintenance, and aging in other organisms are discussed.			KENNEDY, BK (corresponding author), MIT, DEPT BIOL, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA.			Austriaco, Nicanor/0000-0003-1854-8181; Kennedy, Brian/0000-0002-5754-1874	NATIONAL INSTITUTE ON AGING [R01AG011119, R37AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline; NIGMS NIH HHS [GM3054] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COMPANY M, 1988, MOL CELL BIOL, V8, P2545, DOI 10.1128/MCB.8.6.2545; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; EGILMEZ NK, 1990, J GERONTOL, V45, pB9, DOI 10.1093/geronj/45.1.B9; Finch CE., 1990, LONGEVITY SENESCENCE; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Gompertz B., 1825, PHILOS T ROY SOC LON, V115, P513, DOI [10.1098/rspl.1815.0271, DOI 10.1098/RSTL.1825.0026]; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GROVE GL, 1977, J CELL PHYSIOL, V90, P415, DOI 10.1002/jcp.1040900305; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; HERSKOWITZ I, 1991, P132; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JAZWINSKI SM, 1989, EXP GERONTOL, V24, P423; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSTON JR, 1966, ANTON VAN LEE J M S, V32, P94, DOI 10.1007/BF02097448; KENNEDY BK, 1994, IN PRESS J CELL BIOL; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1980, MECH AGEING DEV, V12, P47, DOI 10.1016/0047-6374(80)90028-7; MULLER I, 1971, ARCH MIKROBIOL, V77, P20, DOI 10.1007/BF00407985; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PLESSET J, 1982, BIOCHEM BIOPH RES CO, V108, P1340, DOI 10.1016/0006-291X(82)92147-7; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RILES L, 1993, GENETICS, V134, P81; RINE J, 1987, GENETICS, V116, P9; ROSE MR, 1981, GENETICS, V97, P172; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; SCHWARTZ HS, 1993, CANCER GENET CYTOGEN, V71, P132, DOI 10.1016/0165-4608(93)90018-H; SHERMAN F, 1979, METHODS YEAST GENETI; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; SIKORSKI RS, 1989, GENETICS, V122, P19; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; VOWELS JJ, 1992, GENETICS, V130, P105; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILSON VL, 1983, SCIENCE, V220, P1054	65	381	391	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					485	496		10.1016/0092-8674(95)90499-9	http://dx.doi.org/10.1016/0092-8674(95)90499-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859289	Bronze			2022-12-01	WOS:A1995QG47000015
J	LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T				LI, P; ALLEN, H; BANERJEE, S; FRANKLIN, S; HERZOG, L; JOHNSTON, C; MCDOWELL, J; PASKIND, M; RODMAN, L; SALFELD, J; TOWNE, E; TRACEY, D; WARDWELL, S; WEI, FY; WONG, W; KAMEN, R; SESHADRI, T			MICE DEFICIENT IN IL-1-BETA-CONVERTING ENZYME ARE DEFECTIVE IN PRODUCTION OF MATURE IL-1-BETA AND RESISTANT TO ENDOTOXIC-SHOCK	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; APOPTOSIS; PROTEASE; PRECURSOR; RECEPTOR; SURVIVAL; IDENTIFICATION; MONOCYTOGENES	IL-1 beta-converting enzyme (ICE) cleaves pro-IL-1 beta to generate mature IL-1 beta. ICE is homologous to other proteins that have been implicated in apoptosis, including CED-3 and Nedd-2/Ich-1. We generated ICE-deficient mice and observed that they are overtly normal but have a major defect in the production of mature IL-1 beta after stimulation with lipopolysaccharide. IL-1 alpha production is also impaired. ICE-deficient mice are resistant to endotoxic shock. Thymocytes and macrophages from the ICE-deficient animals undergo apoptosis normally. ICE therefore plays a dominant role in the generation of mature IL-1 beta, a previously unsuspected role in production of IL-1 alpha, but has no autonomous function in apoptosis.			LI, P (corresponding author), BASF BIORES CORP,100 RES DR,WORCESTER,MA 01605, USA.							ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; AYALA JM, 1994, J IMMUNOL, V53, P2592; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J., 1989, MOL CLONING LAB MANU; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STRANGE R, 1992, DEVELOPMENT, V115, P49; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Togni PD, 1994, SCIENCE, V264, P703; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	1277	1328	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					401	411		10.1016/0092-8674(95)90490-5	http://dx.doi.org/10.1016/0092-8674(95)90490-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859282	Bronze			2022-12-01	WOS:A1995QG47000006
J	LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR				LI, Y; LACERDA, DA; WARMAN, ML; BEIER, DR; YOSHIOKA, H; NINOMIYA, Y; OXFORD, JT; MORRIS, NP; ANDRIKOPOULOS, K; RAMIREZ, F; WARDELL, BB; LIFFERTH, GD; TEUSCHER, C; WOODWARD, SR; TAYLOR, BA; SEEGMILLER, RE; OLSEN, BR			A FIBRILLAR COLLAGEN GENE, COL11A1, IS ESSENTIAL FOR SKELETAL MORPHOGENESIS	CELL			English	Article							XI COLLAGEN; II COLLAGEN; V COLLAGEN; CARTILAGE; MICE; ORGANIZATION; EXPRESSION; CLONING; REVEALS; TISSUE	Mice that are homozygous for the autosomal recessive chondrodysplasia (cho) mutation die at birth with abnormalities in cartilage of limbs, ribs, mandible, and trachea. Limb bones of newborn cho/cho mice are wider at the metaphyses than normal bones and only about half the normal length. By linkage analysis, the cho gene and the gene encoding the alpha 1(XI) chain of cartilage collagen XI were mapped to the same region of chromosome 3. Deletion of a cytidine residue about 570 nt downstream of the translation initiation codon in cho alpha 1(XI) mRNA causes a reading frame shift and introduces a premature stop codon. The data demonstrate that collagen XI is essential for normal formation of cartilage collagen fibrils and the cohesive properties of cartilage. The results also suggest that the normal differentiation and spatial organization of growth plate chondrocytes is critially dependent on the presence of type XI collagen in cartilage extracellular matrix.	BRIGHAM & WOMENS HOSP,DIV GENET,BOSTON,MA 02115; OKAYAMA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,OKAYAMA 700,JAPAN; SHRINERS HOSP CRIPPLED CHILDRENS,RES DEPT,PORTLAND,OR 97201; MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; BRIGHAM YOUNG UNIV,DEPT MICROBIOL,PROVO,UT 84602; BRIGHAM YOUNG UNIV,DEPT ZOOL,PROVO,UT 84602; JACKSON LAB,BAR HARBOR,ME 04609	Harvard University; Brigham & Women's Hospital; Okayama University; Icahn School of Medicine at Mount Sinai; Brigham Young University; Brigham Young University; Jackson Laboratory	LI, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569	NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline; NIGMS NIH HHS [GM38862] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036820, R01AR036819, R01AR036820, R37AR036819] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BROEK DL, 1985, J BIOL CHEM, V260, P555; BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; BURTON BK, 1986, J PEDIATR-US, V109, P642, DOI 10.1016/S0022-3476(86)80228-1; DIETRICH W, 1992, GENETICS, V131, P423; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GAROFALO S, 1993, P NATL ACAD SCI USA, V90, P3825, DOI 10.1073/pnas.90.9.3825; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; HAUSSER I, 1994, HUM GENET, V93, P394; HENRY I, 1988, Genomics, V3, P87, DOI 10.1016/0888-7543(88)90165-6; HEPWORTH W B, 1990, Pediatric Pathology, V10, P919; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MONSON CB, 1981, J BONE JOINT SURG AM, V63, P637, DOI 10.2106/00004623-198163040-00015; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SEEGMILLER RE, 1981, CONNECT TISSUE RES, V9, P69, DOI 10.3109/03008208109160242; SEEGMILLER RE, 1986, TERATOLOGY, V33, P339, DOI 10.1002/tera.1420330313; SELDIN MF, 1993, GENOME, V4, pS47; SHAW LM, 1990, TRENDS BIOCHEM SCI, V16, P191; SHEREN SB, 1986, COMP BIOCHEM PHYS B, V85, P5, DOI 10.1016/0305-0491(86)90214-2; SMITH GN, 1985, J BIOL CHEM, V260, P761; SPRANGER J, 1990, ADV HUM GENET, P1; STEPHENS TD, 1976, TERATOLOGY, V13, P317, DOI 10.1002/tera.1420130312; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X	36	281	290	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					423	430		10.1016/0092-8674(95)90492-1	http://dx.doi.org/10.1016/0092-8674(95)90492-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859283	Bronze			2022-12-01	WOS:A1995QG47000008
J	MATIC, I; RAYSSIGUIER, C; RADMAN, M				MATIC, I; RAYSSIGUIER, C; RADMAN, M			INTERSPECIES GENE EXCHANGE IN BACTERIA - THE ROLE OF SOS AND MISMATCH REPAIR SYSTEMS IN EVOLUTION OF SPECIES	CELL			English	Article							ESCHERICHIA-COLI K-12; CONSTITUTIVELY ACTIVATED RECA; SALMONELLA-TYPHIMURIUM; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; CODON USAGE; STRAINS; PROTEIN; INDUCTION; MUTANTS	Analysis of interspecies matings between S. typhimurium and E. coli indicates that the genetic barrier that separates these (and perhaps many other) related species is primarily recombinational. The structural component of this barrier is genomic sequence divergence. The mismatch repair enzymes act as potent inhibitors of interspecies recombination, whereas the SOS system acts as an inducible positive regulator. Interspecies mating triggers a RecBC-dependent SOS response in female bacteria that increases recombination mainly through overproduction of the RecA protein. Mismatch repair acts to reduce the mutation rate and recombination between similar sequences, whereas SOS acts to increase both. These opposing activities allow mismatch repair and SOS systems to determine both the rate of accumulation of sequence divergence and the extent of genetic isolation, which are the key components of the speciation process.			MATIC, I (corresponding author), INST JACQUES MONOD,MUTAGENESE LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE.		Radman, Miroslav/HDM-5955-2022	Radman, Miroslav/0000-0003-0216-3148; Radman, Miroslav/0000-0002-7034-4365				BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAGDASARIAN M, 1986, P NATL ACAD SCI USA, V83, P5723, DOI 10.1073/pnas.83.15.5723; BARON LS, 1968, BACTERIOL REV, V32, P362, DOI 10.1128/MMBR.32.4_Pt_1.362-369.1968; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BUVINGER WE, 1984, J BACTERIOL, V159, P618, DOI 10.1128/JB.159.2.618-623.1984; CAILLETFAUQUET P, 1984, EMBO J, V3, P707, DOI 10.1002/j.1460-2075.1984.tb01873.x; CASAREGOLA S, 1982, MOL GEN GENET, V185, P430, DOI 10.1007/BF00334135; CHAO L, 1983, EVOLUTION, V37, P125, DOI 10.1111/j.1558-5646.1983.tb05521.x; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; DIMPFL J, 1989, GENETICS, V123, P255; ECHOLS H, 1981, CELL, V25, P1, DOI 10.1016/0092-8674(81)90223-3; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GOULD SJ, 1993, NATURE, V366, P223, DOI 10.1038/366223a0; GROSS MD, 1981, MUTAT RES, V91, P107, DOI 10.1016/0165-7992(81)90081-6; HEINEMANN JA, 1991, TRENDS GENET, V7, P181, DOI 10.1016/0168-9525(91)90122-7; HERRLICH P, 1984, HUM GENET, V67, P360, DOI 10.1007/BF00291392; HORII ZI, 1973, J MOL BIOL, V80, P327, DOI 10.1016/0022-2836(73)90176-9; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; JACOB F, 1961, SEXUALITY GENETICS B, P93; JONES AL, 1992, MOL MICROBIOL, V6, P605, DOI 10.1111/j.1365-2958.1992.tb01507.x; JYSSUM K., 1960, ACTA PATHOL ET MICROBIOL SCAND, V48, P113; KAHN PL, 1968, J BACTERIOL, V96, P205; KARU AE, 1982, MOL GEN GENET, V185, P275, DOI 10.1007/BF00330798; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRICKER MC, 1992, P NATL ACAD SCI USA, V89, P1075, DOI 10.1073/pnas.89.3.1075; KUAN CT, 1992, J BACTERIOL, V174, P6872, DOI 10.1128/JB.174.21.6872-6877.1992; Kucherlapati R, 1988, GENETIC RECOMBINATIO, P1; KUSHNER SR, 1971, P NATL ACAD SCI USA, V67, P824; LEHNER AF, 1985, GENETICS, V110, P365; LEHNER AF, 1984, J BACTERIOL, V160, P682, DOI 10.1128/JB.160.2.682-686.1984; LENSKI RE, 1992, ENCY MICROBIOLOGY, V2, P125; LICHTEN M, 1984, P NATL ACAD SCI-BIOL, V81, P7180, DOI 10.1073/pnas.81.22.7180; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LLOYD RG, 1983, MOL GEN GENET, V190, P156, DOI 10.1007/BF00330339; LLOYD RG, 1978, J BACTERIOL, V134, P929, DOI 10.1128/JB.134.3.929-935.1978; LOVETT ST, 1984, J BACTERIOL, V157, P190, DOI 10.1128/JB.157.1.190-196.1984; MAHAJAN SK, 1988, GENETIC RECOMBINATIO, P87; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MATIC I, 1994, GENETICS, V136, P17; MAYNARDSMITH J, 1991, NATURE, V349, P29; Mayr E., 1982, GROWTH BIOL THOUGHT; MEDIGUE C, 1991, J MOL BIOL, V222, P851, DOI 10.1016/0022-2836(91)90575-Q; Miller JH., 1972, EXPT MOL GENETICS; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MOUNT DW, 1972, J BACTERIOL, V112, P886, DOI 10.1128/JB.112.2.886-893.1972; NINIO J, 1991, GENETICS, V129, P957; OHKI M, 1969, COLD SPRING HARB SYM, V33, P651; OISHI M, 1988, RECOMBINATION GENETI, P445; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PETIT MA, 1991, GENETICS, V129, P327; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RADMAN M, 1980, PHOTOCHEM PHOTOBIOL, V32, P823, DOI 10.1111/j.1751-1097.1980.tb04062.x; RADMAN M, 1993, GENOME ANAL, V7, P139; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; Radman M., 1974, MOL ENV ASPECTS MUTA, P128; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RAYSSIGUIER C, 1991, BIOCHIMIE, V73, P371, DOI 10.1016/0300-9084(91)90103-8; REENAN RAG, 1992, GENETICS, V132, P963; Roberts Michael S., 1993, Genetics, V134, P401; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RYDER L, 1994, J BACTERIOL, V176, P1570, DOI 10.1128/jb.176.6.1570-1577.1994; SANDERSON KE, 1972, BACTERIOL REV, V36, P608, DOI 10.1128/MMBR.36.4.608-637.1972; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SEDGWICK SG, 1982, MOL GEN GENET, V185, P93, DOI 10.1007/BF00333796; SEDGWICK SG, 1988, J BACTERIOL, V170, P1610, DOI 10.1128/jb.170.4.1610-1616.1988; SERVICE RF, 1994, SCIENCE, V263, P1559, DOI 10.1126/science.8128240; SHARP PM, 1987, MOL BIOL EVOL, V4, P222; SHARP PM, 1991, J MOL EVOL, V33, P23, DOI 10.1007/BF02100192; SHEN P, 1986, GENETICS, V112, P441; SHEN P, 1989, MOL GEN GENET, V218, P358, DOI 10.1007/BF00331291; SIEGEL EC, 1982, MUTAT RES, V92, P25; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH NH, 1990, J BACTERIOL, V172, P2209, DOI 10.1128/jb.172.5.2209-2216.1990; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TROBNER W, 1984, MOL GEN GENET, V198, P177, DOI 10.1007/BF00328720; VERMA N, 1989, J BACTERIOL, V171, P5694, DOI 10.1128/jb.171.10.5694-5701.1989; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6; WHITTAM TS, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P223; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	86	245	252	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					507	515		10.1016/0092-8674(95)90501-4	http://dx.doi.org/10.1016/0092-8674(95)90501-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859291	Bronze			2022-12-01	WOS:A1995QG47000017
J	MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM				MIYAMOTO, S; AKIYAMA, SK; YAMADA, KM			SYNERGISTIC ROLES FOR RECEPTOR OCCUPANCY AND AGGREGATION IN INTEGRIN TRANSMEMBRANE FUNCTION	SCIENCE			English	Article							FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FIBROBLASTS; ANTIBODIES; BINDING; PROTEIN; MATRIX; GROWTH	Integrin receptors mediate cell adhesion, signal transduction, and cytoskeletal organization. How a single transmembrane receptor can fulfill multiple functions was clarified by comparing roles of receptor occupancy and aggregation. Integrin occupancy by monovalent ligand induced receptor redistribution, but minimal tyrosine phosphorylation signaling or cytoskeletal protein redistribution. Aggregation of integrins by noninhibitory monoclonal antibodies on beads induced intracellular accumulations of pp125(FAK) and tensin, as well as phosphorylation, but no accumulation of other cytoskeletal proteins such as talin. Combining antibody-mediated clustering with monovalent ligand occupancy induced accumulation of seven cytoskeletal proteins, including alpha-actinin, talin, and F-actin, thereby mimicking multivalent interactions with fibronectin or polyvalent peptides. Integrins therefore mediate a complex repertoire of functions through the distinct effects of receptor aggregation, receptor occupancy, or both together.	NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; CHERESH DA, 1992, CLIN LAB MED, V12, P217, DOI 10.1016/S0272-2712(18)30514-6; COUCHMAN JR, 1979, J CELL SCI, V39, P149; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; METZGER H, 1992, J IMMUNOL, V149, P1477; MIYAMOTO S, UNPUB; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8	28	815	825	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					883	885		10.1126/science.7846531	http://dx.doi.org/10.1126/science.7846531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846531				2022-12-01	WOS:A1995QG20700058
J	MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E				MOSIALOS, G; BIRKENBACH, M; YALAMANCHILI, R; VANARSDALE, T; WARE, C; KIEFF, E			THE EPSTEIN-BARR-VIRUS TRANSFORMING PROTEIN LMP1 ENGAGES SIGNALING PROTEINS FOR THE TUMOR-NECROSIS-FACTOR RECEPTOR FAMILY	CELL			English	Article							FACTOR TNF RECEPTOR; LYMPHOCYTE GROWTH TRANSFORMATION; MEMBRANE-PROTEIN; CELL-LINES; NASOPHARYNGEAL CARCINOMA; MONOCLONAL-ANTIBODIES; NUCLEAR PROTEIN-2; HODGKINS-DISEASE; B TRANSFORMATION; SOLUBLE FORM	The cytoplasmic C-terminus of Epstein-Barr virus (EBV) latent infection membrane protein 1 (LMP1) is essential for B lymphocyte growth transformation and is now shown to interact with a novel human protein (LMP1-associated protein 1 [LAP1]). LAP1 is homologous to a murine protein, tumor necrosis factor receptor-associated factor 2 (TRAF2), implicated in growth signaling from the p80 TNFR. A second novel protein (EBI6), induced by EBV infection, is the human homolog of a second murine TNFR-associated protein (TRAF1). LMP1 expression causes LAP1 and EBI6 to localize to LMP1 clusters in lymphoblast plasma membranes, and LMP1 coimmunoprecipitates with these proteins. LAP1 binds to the p80 TNFR, CD40, and the lymphotoxin-p receptor, while EBI6 associates with the pan TNFR. The interaction of LMP1 with these TNFR family-associated proteins is further evidence for their role in signaling and links LMP1-mediated transformation to signal transduction from the TNFR family.	UNIV CHICAGO, MARJORIE B KOVLER VIRAL ONCOL LABS, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of Chicago; University of California System; University of California Riverside	MOSIALOS, G (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, DEPT MED, BOSTON, MA 02115 USA.				NCI NIH HHS [5K11CA01341, CA47006] Funding Source: Medline; NIAID NIH HHS [AI08548-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047006, R35CA047006, K11CA001341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CARDE P, 1990, EUR J CANCER, V26, P474, DOI 10.1016/0277-5379(90)90019-P; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FROESE P, 1987, J IMMUNOL, V139, P2081; GALIBERT L, 1994, J IMMUNOL, V152, P22; GIBBONS DL, 1994, EUR J IMMUNOL, V24, P1879, DOI 10.1002/eji.1830240825; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOODING LR, 1992, CELL, V71, P5; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HARPER JW, 1993, CELL, V75, P805; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1990, VIROLOGY, P1889; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LONGNECKER R, 1993, J VIROL, V67, P5068, DOI 10.1128/JVI.67.8.5068-5074.1993; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MILLER G, 1990, VIROLOGY, P1921; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OGRADY JT, 1994, AM J PATHOL, V144, P21; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFREUNDSCHUH M, 1989, ONKOLOGIE, V12, P30, DOI 10.1159/000216681; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROBERTSON ES, 1994, J VIROL, V68, P1449, DOI 10.1128/JVI.68.3.1449-1458.1994; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; SAELAND S, 1993, J EXP MED, V178, P113, DOI 10.1084/jem.178.1.113; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TRUMPER L, 1994, ANN ONCOL, V5, pS93, DOI 10.1093/annonc/5.suppl_1.S93; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WARE CF, 1991, J IMMUNOL, V147, P4229; WARE CF, 1995, CURRENT TOPICS MICRO, V198; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	83	882	925	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					389	399		10.1016/0092-8674(95)90489-1	http://dx.doi.org/10.1016/0092-8674(95)90489-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859281	Bronze			2022-12-01	WOS:A1995QG47000005
J	NAITO, T; KUSANO, K; KOBAYASHI, I				NAITO, T; KUSANO, K; KOBAYASHI, I			SELFISH BEHAVIOR OF RESTRICTION-MODIFICATION SYSTEMS	SCIENCE			English	Article							GENES; ENDONUCLEASE	Plasmids carrying gene pairs encoding type II DNA restriction endonucleases and their cognate modification enzymes were shown to have increased stability in Escherichia coli. The descendants of cells that had lost these genes appeared unable to modify a sufficient number of recognition sites in their chromosomes to protect them from lethal attack by the remaining restriction enzyme molecules. The capacity of these genes to act as a selfish symbiont is likely to have contributed to the evolution of restriction-modification gene pairs.	UNIV TOKYO,INST MED SCI,DEPT MOLEC BIOL,TOKYO 108,JAPAN	University of Tokyo			Kobayashi, Ichizo/GVT-8377-2022	Kobayashi, Ichizo/0000-0002-3854-1879				BETLACH M, 1976, FED PROC, V35, P2037; GILLEN JR, 1981, J BACTERIOL, V157, P521; GINGERAS TR, 1983, P NATL ACAD SCI-BIOL, V80, P402, DOI 10.1073/pnas.80.2.402; HASHIMOTOGOTOH T, 1981, GENE, V16, P227, DOI 10.1016/0378-1119(81)90079-2; HEITMAN J, 1989, P NATL ACAD SCI USA, V86, P2281, DOI 10.1073/pnas.86.7.2281; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, GENE, V138, P17; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Nordstrom K., 1993, PLASMIDS PRACTICAL A, P1; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; ROBBINS LG, 1994, GENETICS, V138, P401; Roberts R, 1993, NUCLEASES, P35; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P355, DOI 10.1093/nar/16.1.355	15	277	284	0	31	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					897	899		10.1126/science.7846533	http://dx.doi.org/10.1126/science.7846533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846533				2022-12-01	WOS:A1995QG20700062
J	SELDIN, DC; LEDER, P				SELDIN, DC; LEDER, P			CASEIN KINASE II-ALPHA TRANSGENE-INDUCED MURINE LYMPHOMA - RELATION TO THEILERIOSIS IN CATTLE	SCIENCE			English	Article							INTRACELLULAR PROTOZOAN PARASITE; C-MYC GENE; E-MU-MYC; V-RAF; MICE BEARING; B-CELLS; N-MYC; TUMORS; TRANSFORMATION; PARVA	Infection of cattle with the protozoan parasite Theileria parva results in a fatal lymphoproliferative syndrome that is associated with the overexpression of casein kinase II. The role of this enzyme in the pathogenesis of lymphoproliferative disorders was investigated by expressing the catalytic subunit in lymphocytes of transgenic mice. Adult transgenic mice displayed a stochastic propensity to develop lymphoma; co-expression of a c-myc transgene in addition to casein kinase II resulted in neonatal leukemia. Thus, the casein kinase II gene can serve as an oncogene, and its dysregulated expression is capable of transforming lymphocytes in a two-step pathway with c-myc.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Seldin, David C/0000-0003-0168-2333	NHLBI NIH HHS [1-K08-HL0286-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FRIEDRICH TD, 1989, BIOCHIM BIOPHYS ACTA, V992, P41, DOI 10.1016/0304-4165(89)90048-2; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KURIE JM, 1990, ONCOGENE, V5, P577; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Mertens F., 1991, CATALOG CHROMOSOME A; MOROY T, 1991, ONCOGENE, V6, P1941; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1989, ANN NY ACAD SCI, V569, P174, DOI 10.1111/j.1749-6632.1989.tb27367.x; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1989, EXP PARASITOL, V69, P204, DOI 10.1016/0014-4894(89)90067-2; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; YANGFENG TL, 1990, GENOMICS, V8, P741, DOI 10.1016/0888-7543(90)90266-W; YANGFENG TL, 1994, GENOMICS, V19, P173, DOI 10.1006/geno.1994.1032	32	353	372	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					894	897		10.1126/science.7846532	http://dx.doi.org/10.1126/science.7846532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846532				2022-12-01	WOS:A1995QG20700061
J	STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC				STRITTMATTER, SM; FANKHAUSER, C; HUANG, PL; MASHIMO, H; FISHMAN, MC			NEURONAL PATHFINDING IS ABNORMAL IN MICE LACKING THE NEURONAL GROWTH CONE PROTEIN GAP-43	CELL			English	Article							IMMUNO-CYTOCHEMICAL LOCALIZATION; CALMODULIN-BINDING-PROTEIN; CENTRAL NERVOUS-SYSTEM; PRENATAL RAT-BRAIN; NEURITE OUTGROWTH; TYROSINE-HYDROXYLASE; OPTIC CHIASM; PC12 CELLS; MOUSE; GUIDANCE	GAP-43 has been termed a ''growth'' or ''plasticity'' protein because it is expressed at high levels in neuronal growth cones during development and during axonal regeneration. By homologous recombination, we generated mice lacking GAP-43. The mice die in the early postnatal period. GAP-43-deficient retinal axons remain trapped in the chiasm for 6 days, unable to navigate past this midline decision point. Over the subsequent weeks of life, most GAP-43-deficient axons do enter the appropriate tracts, and the adult CNS is grossly normal. There is no evidence for interference with nerve growth rate, and cultured neurons extend neurites and growth cones in a fashion indistinguishable from controls. Thus, the GAP-43 protein is not essential for axonal outgrowth or growth cone formation pet se, but is required at certain decision points, such as the optic chiasm. This is compatible with the hypothesis that GAP-43 serves to amplify pathfinding signals from the growth cone.	HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEPT NEUROL, BOSTON, MA 02129 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT NEUROBIOL, NEW HAVEN, CT 06520 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University	STRITTMATTER, SM (corresponding author), HARVARD UNIV, MASSACHUSETTS GEN HOSP E, SCH MED, DEV BIOL LAB, BOSTON, MA 02129 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; ARGIRO V, 1982, J NEUROSCI, V2, P503; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; COLELLO RJ, 1992, J COMP NEUROL, V317, P357, DOI 10.1002/cne.903170404; DAVIES A, 1984, J COMP NEUROL, V223, P124, DOI 10.1002/cne.902230110; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; HONIG MG, 1993, DEV BIOL, V156, P454, DOI 10.1006/dbio.1993.1092; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KROGER S, 1990, J NEUROSCI, V10, P3118; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SHEA TB, 1991, J NEUROSCI, V11, P1685; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SRETAVAN DW, 1994, NEURON, V12, P957, DOI 10.1016/0896-6273(94)90307-7; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; STITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; WIZENMANN A, 1993, DEVELOPMENT, V117, P725; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062	47	342	348	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					445	452		10.1016/0092-8674(95)90495-6	http://dx.doi.org/10.1016/0092-8674(95)90495-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859286	hybrid			2022-12-01	WOS:A1995QG47000011
J	STRUBIN, M; NEWELL, JW; MATTHIAS, P				STRUBIN, M; NEWELL, JW; MATTHIAS, P			OBF-1, A NOVEL B-CELL-SPECIFIC COACTIVATOR THAT STIMULATES IMMUNOGLOBULIN PROMOTER ACTIVITY THROUGH ASSOCIATION WITH OCTAMER-BINDING PROTEINS	CELL			English	Article							REMOTE ENHANCER POSITION; TRANSCRIPTION FACTOR; POU-DOMAIN; CONSERVED REGION; GENETIC-EVIDENCE; CYCLE REGULATION; TATA ELEMENT; HOMEO DOMAIN; HELA-CELLS; STEM-CELLS	Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity. Using a genetic screen in yeast, we have isolated a cell-derived cDNAs encoding Oct-binding factor 1 (OBF-1), a novel protein that specifically associates with Oct-1 and Oct-2. Biochemical studies demonstrate that OBF-1 has no intrinsic DNA-binding activity and recognizes the POU domains of Oct-1 and Oct-2, but not those of Oct-4 and Oct-6. The OBF-1 mRNA is expressed in a highly cell-specific manner, being most abundant in B cells and essentially absent In most of the other cells or tissues tested. Furthermore, expression of OBF-1 in HeLa cells selectively stimulates the activity of a natural immunoglobulin promoter in an octamer site-dependent manner. Thus, OBF-1 has all the properties expected for a B cell-specific transcriptional coactivator protein.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research	STRUBIN, M (corresponding author), UNIV GENEVA,MED CTR,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND.							ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TANESE N, 1993, COLD SPRING HARB SYM, V58, P179, DOI 10.1101/SQB.1993.058.01.022; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0	58	353	361	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					497	506		10.1016/0092-8674(95)90500-6	http://dx.doi.org/10.1016/0092-8674(95)90500-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859290	Bronze			2022-12-01	WOS:A1995QG47000016
J	TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY				TANG, TL; FREEMAN, RM; OREILLY, AM; NEEL, BG; SOKOL, SY			THE SH2-CONTAINING PROTEIN-TYROSINE-PHOSPHATASE SH-PTP2 IS REQUIRED UPSTREAM OF MAP KINASE FOR EARLY XENOPUS DEVELOPMENT	CELL			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; MESODERM INDUCTION; SH3 DOMAINS; MOTH-EATEN; PHOSPHORYLATION; EMBRYOS; GENE; ENCODES	SH-PTP2, the vertebrate homolog of Drosophila cork screw, associates with several activated growth factor receptors, but its biological function is unknown. We assayed the effects of injection of wild-type and mutant SH-PTP2 RNAs on Xenopus embryogenesis. An internal phosphatase domain deletion (Delta P) acts as a dominant negative mutant, causing severe posterior truncations. This phenotype is rescued by SH-PTP2, but not by the closely related SH-PTP1. In ectodermal explants, Delta P blocks fibroblast growth factor (FGF)and activin-mediated induction of mesoderm and FGF-induced mitogen-activated protein (MAP) kinase activation. Our results indicate that SH-PTP2 is required for early vertebrate development, acting as a positive component in FGF signaling downstream of the FGF receptor and upstream of MAP kinase.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	TANG, TL (corresponding author), HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Sokol, Sergei/0000-0002-3963-9202; Freeman, Robert/0000-0003-1463-9748	NCI NIH HHS [CA49152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152, R37CA049152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAWID IB, 1991, MESODERM INDUCTION; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAN M, 1990, GENETICS, V126, P899; HARTLEY RS, 1994, DEV BIOL, V163, P521, DOI 10.1006/dbio.1994.1168; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; INNIS MA, 1990, PCR PROTOCOLS; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ITOH K, 1994, DEVELOPMENT, V120, P2703; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LABONNE C, 1994, DEVELOPMENT, V120, P463; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	80	301	309	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 10	1995	80	3					473	483		10.1016/0092-8674(95)90498-0	http://dx.doi.org/10.1016/0092-8674(95)90498-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859288	Bronze			2022-12-01	WOS:A1995QG47000014
J	TULJAPURKAR, S; LI, N; FELDMAN, MW				TULJAPURKAR, S; LI, N; FELDMAN, MW			HIGH SEX-RATIOS IN CHINA FUTURE	SCIENCE			English	Article							RECENT TRENDS; FERTILITY; POPULATION; BANGLADESH; PREFERENCE; MORTALITY; CHILDREN; BIRTH	In China in recent years, male live births have exceeded those of females by amounts far greater than those that occur naturally in human populations, a trend with significant demographic consequences. The resulting imbalance in the first-marriage market is estimated to be about 1 million males per year after 2010. These ''excess'' males were not easily accommodated in models with substantial changes in first-marriage patterns, The current sex ratio at birth has little effect on a couple's probability of having at least one son, so future increases in the sex ratio may well occur, especially given increasing access to sex-selective abortion.	XIAN JIAOTONG UNIV,INST POPULAT RES,XIAN 710049,PEOPLES R CHINA	Xi'an Jiaotong University	TULJAPURKAR, S (corresponding author), STANFORD UNIV,MORRISON INST POPULAT & RESOURCE STUDIES,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Tuljapurkar, Shripad/0000-0001-5549-4245	NICHD NIH HHS [HD-16640] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016640] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANISTER J, 1990, CHANGING FAMILY STRU, P263; BENNETT NG, 1983, SEX SELECTION CHILDR; BITTLES AH, 1993, URBAN ECOLOGY HLTH T, P244; CANGPING W, 1992, 1990 INT SEM CHIN PO; CHAHNAZARIAN A, SOC BIOL, V35, P214; CHOWDHURY MK, 1990, POPUL DEV REV, V16, P749, DOI 10.2307/1972966; COALE A, 1992, 1990 INT SEM CHIN PO; Coale A., 1984, RAPID POPULATION CHA; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; COALE AJ, 1991, SCIENCE, V251, P389, DOI 10.1126/science.251.4992.389; DASGUPTA M, 1987, POPUL DEV REV, V13, P77; DICKEMAN M, 1975, ANNU REV ECOL SYST, V6, P107, DOI 10.1146/annurev.es.06.110175.000543; FEENEY G, 1989, POPUL DEV REV, V15, P297, DOI 10.2307/1973706; GOLDMAN N, 1984, POPUL INDEX, V50, P5, DOI 10.2307/2736903; GREENHALGH S, 1994, POPUL DEV REV, V20, P365, DOI 10.2307/2137523; HULL TH, 1990, POPUL DEV REV, V16, P63, DOI 10.2307/1972529; JOHANSSON S, 1991, POPUL DEV REV, V17, P35, DOI 10.2307/1972351; JOHANSSON S, 1991, J OFFICIAL STAT, V7, P25; KEYFITZ N, 1990, WORLD POPULATION ANA; LAVELY W, 1990, DEMOGRAPHY, V27, P357, DOI 10.2307/2061373; LI J, 1994, MAY ANN M POP ASS AM; MUHURI PK, 1991, POPUL DEV REV, V17, P415, DOI 10.2307/1971948; PARK CB, 1983, DEMOGRAPHY, V20, P333, DOI 10.2307/2061246; PENG Y, 1994, 27TH SESS UN POP COM; SCHOEN R, 1981, DEMOGRAPHY, V18, P201, DOI 10.2307/2061093; SEN A, 1993, SCI AM, V268, P40, DOI 10.1038/scientificamerican0593-40; SWEET JA, 1987, AM FAMILIES HOUSEHOL, pCH2; ZENG Y, 1993, POPUL DEV REV, V19, P283; 1991, 10 PERCENT SAMPLING; 1983, MANUAL X INDIRECT TE	30	87	92	2	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					874	876		10.1126/science.7846529	http://dx.doi.org/10.1126/science.7846529			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QG207	7846529				2022-12-01	WOS:A1995QG20700055
J	UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE				UCKUN, FM; EVANS, WE; FORSYTH, CJ; WADDICK, KG; AHLGREN, LT; CHELSTROM, LM; BURKHARDT, A; BOLEN, J; MYERS, DE			BIOTHERAPY OF B-CELL PRECURSOR LEUKEMIA BY TARGETING GENISTEIN TO CD19-ASSOCIATED TYROSINE KINASES	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; POKEWEED ANTIVIRAL PROTEIN; SEVERE COMBINED IMMUNODEFICIENCY; DISCRETE DEVELOPMENTAL STAGES; EXPRESS FUNCTIONAL RECEPTORS; BONE-MARROW TRANSPLANTATION; SIGNAL-TRANSDUCTION COMPLEX; LYMPHOCYTES-B; GROWTH-FACTOR; PROGENITOR CELLS	B-cell precursor (BCP) leukemia is the most common form of childhood cancer and the second most common form of acute leukemia in adults. Human BCP leukemia was treated in a severe combined immunodeficient mouse model by targeting of the tyrosine kinase inhibitor Genistein (Gen) to the B cell-specific receptor CD19 with the monoclonal antibody B43. The B43-Gen immunoconjugate bound with high affinity to BCP leukemia cells, selectively inhibited CD19-associated tyrosine kinases, and triggered rapid apoptotic cell death. At less than one-tenth the maximum tolerated dose more than 99.999 percent of human BCP leukemia cells were killed, which led to 100 percent long-term event-free survival from an otherwise invariably fatal leukemia. The B43-Gen immunoconjugate might be useful in eliminating leukemia cells in patients who have failed conventional therapy.	UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, CHILDRENS CANC GRP, CENTRALIZED IMMUNOCONJUGATE REFERENCE LAB, MINNEAPOLIS, MN 55455 USA; ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA; UNIV MINNESOTA, DEPT CHEM, MINNEAPOLIS, MN 55455 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, SIGNAL TRANSDUCT LAB, PRINCETON, NJ 08543 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; University of Minnesota System; University of Minnesota Twin Cities; Bristol-Myers Squibb	UCKUN, FM (corresponding author), UNIV MINNESOTA, DEPT THERAPEUT RADIOL RADIAT ONCOL, BIOTHERAPY PROGRAM, MINNEAPOLIS, MN 55455 USA.		Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322; Uckun, Fatih M./0000-0001-9334-183X	NATIONAL CANCER INSTITUTE [R01CA051425, R01CA042111, R29CA042111, R01CA042633] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42111, CA-42633, CA-51425] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1991, CLIN CHIM ACTA, V199, P263, DOI 10.1016/0009-8981(91)90120-2; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; BURKE TR, 1993, J MED CHEM, V36, P425, DOI 10.1021/jm00056a001; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; COHEN DI, 1992, SCIENCE, V256, P542, DOI 10.1126/science.1570514; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; DICKSON RB, 1983, BIOCHEMISTRY-US, V22, P5667, DOI 10.1021/bi00293a033; EVANS CA, 1993, CANCER RES, V53, P1735; GERLOWSKI LE, 1983, J PHARM SCI, V72, P1103, DOI 10.1002/jps.2600721003; GREAVES M, 1993, BLOOD, V82, P1043; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jin J., UNPUB; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; MANSKE J, 1986, THESIS U MINNESOTA; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MYERS DE, UNPUB KINASE RENATUR; MYERS DE, 1987, BLOOD, V70, P1020; NADLER LM, 1983, J IMMUNOL, V131, P244; OTANI H, 1993, J BIOL CHEM, V268, P22733; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PETTERSSON H, 1984, J ASSOC OFF ANA CHEM, V67, P503; REAMAN G, IN PRESS LEUKEMIA LY; RENNER C, 1994, SCIENCE, V264, P833, DOI 10.1126/science.8171337; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; TEDDER TF, 1989, J IMMUNOL, V143, P712; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1992, BLOOD, V79, P3369; UCKUN FM, 1993, BRIT J HAEMATOL, V85, P435; UCKUN FM, 1985, J IMMUNOL, V134, P3504; UCKUN FM, 1992, BLOOD, V79, P2201; UCKUN FM, 1992, BLOOD, V79, P3116; UCKUN FM, 1993, BLOOD, V81, P1323; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; UCKUN FM, 1989, BLOOD, V73, P533; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1989, BLOOD, V74, P761; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1986, J EXP MED, V163, P347, DOI 10.1084/jem.163.2.347; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UCKUN FM, UNPUB; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828	64	256	284	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 10	1995	267	5199					886	891		10.1126/science.7531365	http://dx.doi.org/10.1126/science.7531365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7531365				2022-12-01	WOS:A1995QG20700059
J	VALONE, TJ; BROWN, JH				VALONE, TJ; BROWN, JH			EFFECTS OF COMPETITION, COLONIZATION, AND EXTINCTION ON RODENT SPECIES-DIVERSITY	SCIENCE			English	Article							CHIHUAHUAN DESERT; FOOD ADDITION; PRODUCTIVITY; COMMUNITY; REMOVAL	Analyses of long-term experimental data from the Chihuahuan desert. revealed that species diversity of other rodents was higher on plots from which kangaroo rats (Dipodomys spp.) had been removed. The difference was due to consistently higher colonization and lower extinction probabilities of small granivorous rodents in the absence of competitively dominant kangaroo rats. The results of this ecosystem experiment demonstrate the importance of both competitive exclusion and metapopulation dynamics for biological diversity in a natural community.	UNIV NEW MEXICO,DEPT BIOL,ALBUQUERQUE,NM 87131	University of New Mexico				Valone, Thomas/0000-0002-7657-3126				BOWERS MA, 1987, OECOLOGIA, V72, P77, DOI 10.1007/BF00385048; BOWERS MA, 1981, ECOLOGY, V63, P391; BOWERS MA, 1993, OECOLOGIA, V92, P242; BROWN JH, 1985, ECOLOGY, V66, P1545, DOI 10.2307/1938017; BROWN JH, 1989, ECOLOGY, V70, P1507, DOI 10.2307/1938209; BROWN JH, 1990, SCIENCE, V250, P1705, DOI 10.1126/science.250.4988.1705; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; CARPENTER S R, 1988, P119; CARPENTER SR, 1985, BIOSCIENCE, V35, P634, DOI 10.2307/1309989; CLARK CW, 1994, AM NAT, V143, P583, DOI 10.1086/285621; Cody M. L., 1975, ECOLOGY EVOLUTION CO; CONNELL JH, 1961, ECOLOGY, V42, P710, DOI 10.2307/1933500; Diamond J.M., 1986, COMMUNITY ECOLOGY; Drake, 1986, ECOLOGY BIOL INVASIO; FRYE RJ, 1983, OECOLOGIA, V59, P74, DOI 10.1007/BF00388076; Gause G.F., 1934, STRUGGLE EXISTENCE; Gilpin M.E., 1991, METAPOPULATION DYNAM; HAIRSTON NG, 1989, ECOLOGICAL EXPT; HANSKI I, 1982, OIKOS, V38, P210, DOI 10.2307/3544021; HESKE EJ, 1993, OECOLOGIA, V95, P520, DOI 10.1007/BF00317436; HESKE EJ, 1994, ECOLOGY, V75, P438, DOI 10.2307/1939547; Hoffmeister D. F., 1986, MAMMALS ARIZONA; HORN HS, 1972, ECOLOGY, V53, P749, DOI 10.2307/1934797; Keddy P.A., 1989, COMPETITION; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Ludwig JA., 1988, STAT ECOLOGY; MAC ARTHUR ROBERT H., 1967; MacArthur R.H., 1972, pvii; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; PARK T, 1948, ECOL MONOGR, V18, P265, DOI 10.2307/1948641; Pimm S.L., 1982, FOOD WEBS; Pimm S.L., 1991, BALANCE NATURE ECOLO; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; SIMBERLOFF D, 1979, ECOLOGICAL DIVERSITY, P159; SLATKIN M, 1974, ECOLOGY, V55, P128, DOI 10.2307/1934625; TILMAN D, 1993, ECOLOGY, V74, P2179, DOI 10.2307/1939572; VANDERMEER JH, 1969, ECOLOGY, V50, P362, DOI 10.2307/1933884; [No title captured]	40	68	70	1	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 10	1995	267	5199					880	883		10.1126/science.7846530	http://dx.doi.org/10.1126/science.7846530			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QG207	7846530				2022-12-01	WOS:A1995QG20700057
J	VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG				VIKKULA, M; MARIMAN, ECM; LUI, VCH; ZHIDKOVA, NI; TILLER, GE; GOLDRING, MB; VANBEERSUM, SEC; MALEFIJT, MCD; VANDENHOOGEN, FHJ; ROPERS, HH; MAYNE, R; CHEAH, KSE; OLSEN, BR; WARMAN, ML; BRUNNER, HG			AUTOSOMAL-DOMINANT AND RECESSIVE OSTEOCHONDRODYSPLASIAS ASSOCIATED WITH THE COL11A2 LOCUS	CELL			English	Article							COLLAGEN; MUTATIONS; HUMANS	Identifying mutations that cause specific osteochondrodysplasias will provide novel insights into the function of genes that are essential for skeletal morphogenesis. We report here that an autosomal dominant form of Stickler syndrome, characterized by mild spondyloepiphyseal dysplasia, osteoarthritis, and sensorineural hearing loss, but no eye involvement, is caused by a splice donor site mutation resulting in ''in-frame'' exon skipping within the COL11A2 gene, encoding the alpha 2(XI) chain of the quantitatively minor fibrillar collagen XI. We also show that an autosomal recessive disorder with similar, but more severe, characteristics is linked to the COL11A2 locus and is caused by a glycine to arginine substitution In alpha 2(XI) collagen. The results suggest that mutations in collagen XI genes are associated with a spectrum of abnormalities in human skeletal development and support the conclusion of others, based on studies of murine chondrodysplasia, that collagen XI is essential for skeletal morphogenesis.	UNIV NIJMEGEN HOSP,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS; UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; VANDERBILT UNIV,MED CTR,DIV GENET,NASHVILLE,TN 37232; MASSACHUSETTS GEN HOSP E,ARTHRITIS RES MED SERV,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV NIJMEGEN HOSP,DEPT ORTHOPED SURG,6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; University of Hong Kong; University of Alabama System; University of Alabama Birmingham; Vanderbilt University; Harvard University; Harvard Medical School; Radboud University Nijmegen; Radboud University Nijmegen	VIKKULA, M (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		van Beersum, Sylvia E.C./P-8653-2015; Brunner, Han/C-9928-2013; Vikkula, Miikka/Q-1038-2018; Cheah, Kathryn/C-4222-2009; /C-4359-2009	van Beersum, Sylvia E.C./0000-0002-4552-2908; Vikkula, Miikka/0000-0002-6236-338X; /0000-0002-1758-8854	NIAMS NIH HHS [AR03564, AR30481, ARO1925] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030481, K08AR001925, P01AR003564, R37AR030481] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRUNNER HG, 1994, HUM MOL GENET, V3, P1561, DOI 10.1093/hmg/3.9.1561; DOLZ R, 1990, ANN NY ACAD SCI, V580, P421, DOI 10.1111/j.1749-6632.1990.tb17948.x; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GIEDION A, 1982, HELV PAEDIATR ACTA, V37, P361; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MAYNE R, 1993, J BIOL CHEM, V268, P9381; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SNEAD MP, 1994, IN PRESS EYE, V6; SPRANGER J, 1985, ENDOCRINE GENETICS G, P315; STICKLER GB, 1965, MAYO CLIN PROC, V40, P433; TALERICO M, 1990, MOL CELL BIOL, V10, P6299, DOI 10.1128/MCB.10.12.6299; VIKKULA M, 1994, ANN MED, V26, P107; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79	20	282	290	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					431	437		10.1016/0092-8674(95)90493-X	http://dx.doi.org/10.1016/0092-8674(95)90493-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7859284	Green Published, Bronze			2022-12-01	WOS:A1995QG47000009
J	ASSAD, JA; MAUNSELL, JHR				ASSAD, JA; MAUNSELL, JHR			NEURONAL CORRELATES OF INFERRED MOTION IN PRIMATE POSTERIOR PARIETAL CARTER	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE POSITION; 7A	FOR many types of behaviours, it is necessary to monitor the position or movement of objects that are temporarily occluded. The primate posterior parietal cortex contains neurons that are active during visual guidance tasks: in some cases, even if the visual target disappears transiently(1,2). It has been proposed that activity of this sort could be related to current or planned eye movements(1,2), but it might also provide a more generalized abstract representation of the spatial disposition of targets, even when they are not visible. We have recorded from monkey posterior parietal cortex while the animal viewed a visual stimulus that disappeared, and then, depending on experimental context, could be inferred to be either moving or stationary. During this temporary absence of the stimulus, about half of the neurons were found to be significantly more active on those trials in which the stimulus could be presumed to be moving rather than stationary. The activity was thus present in the absence of either sensory input or motor output, suggesting that it may indeed constitute a generalized representation of target motion.			ASSAD, JA (corresponding author), BAYLOR COLL MED,DIV NEUROSCI S603,HOUSTON,TX 77030, USA.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; CRIST CF, 1988, J NEUROSCI METH, V26, P117, DOI 10.1016/0165-0270(88)90160-4; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROBINSON DL, 1978, J NEUROPHYSIOL, V41, P910, DOI 10.1152/jn.1978.41.4.910	9	173	174	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					518	521		10.1038/373518a0	http://dx.doi.org/10.1038/373518a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845463				2022-12-01	WOS:A1995QF72400058
J	BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D				BURKLY, L; HESSION, C; OGATA, L; REILLY, C; MARCONI, LA; OLSON, D; TIZARD, R; CATE, R; LO, D			EXPRESSION OF RELB IS REQUIRED FOR THE DEVELOPMENT OF THYMIC MEDULLA AND DENDRITIC CELLS	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; EPITHELIAL-CELLS; T-CELLS; GENE; MOUSE	DENDRITIC cells (DC) derived from bone marrow are critical in the function of the immune system, for they are the primary antigen-presenting cells in the activation of T-lymphocyte response. Their differentiation from precursor cells has not been defined at a molecular level, but recent studies have shown an association between expression of the relB subunit of the NF-kappa B complex(1-5) and the presence of DC in specific regions of normal unstimulated lymphoid tissues(4-6). Here we show that relB expression also correlates with differentiation of DC in autoimmune infiltrates in situ, and that a mutation disrupting the relB gene results in mice with impaired antigen-presenting cell function, and a syndrome of excess production of granulocytes and macrophages. Thymic UEA-1(+) medullary epithelial cells from normal mice show striking similarities to DC and, interestingly, these cells are also absent in relB mutant mice. Taken together, these results suggest that relB is critical in the coordinated activation of genes necessary for the differentiation of two unrelated but phenotypically similar cells (DC and thymic UEA-1(+) medullary epithelial cells) and is therefore a candidate for a gene determining lineage commitment in the immune system.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA	Scripps Research Institute; Biogen								ARNOLD B, 1984, NUCLEIC ACIDS RES, V12, P9473, DOI 10.1093/nar/12.24.9473; BURKLY LC, 1993, J IMMUNOL, V151, P3954; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COUTELIER JP, 1987, J EXP MED, V165, P64, DOI 10.1084/jem.165.1.64; DEGERMANN S, 1994, J IMMUNOL, V152, P3254; FARR AG, 1985, J IMMUNOL, V134, P2971; GRILLI M, 1993, INT REV CYTOL, V143, P1; HOCART MJ, 1989, J GEN VIROL, V70, P809, DOI 10.1099/0022-1317-70-4-809; HOFFMAN MW, 1992, P NATL ACAD SCI USA, V89, P2536; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JANEWAY CA, 1988, IMMUNOL REV, V101, P39, DOI 10.1111/j.1600-065X.1988.tb00732.x; KNIGHT SC, 1993, CURR OPIN IMMUNOL, V5, P374, DOI 10.1016/0952-7915(93)90056-X; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEVIN D, 1993, J IMMUNOL, V151, P6742; LO D, 1992, AM J PATHOL, V141, P1237; LO D, 1993, EUR J IMMUNOL, V23, P1693, DOI 10.1002/eji.1830230744; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; NELSON AJ, 1993, J IMMUNOL, V151, P2453; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; POIRIER B, 1994, J IMMUNITY, V1, P385; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; Sprent J, 1989, Int Immunol, V1, P517, DOI 10.1093/intimm/1.5.517; SURH CD, 1992, J EXP MED, V176, P495, DOI 10.1084/jem.176.2.495	29	648	670	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					531	536		10.1038/373531a0	http://dx.doi.org/10.1038/373531a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845467				2022-12-01	WOS:A1995QF72400062
J	GABUNIA, L; VEKUA, A				GABUNIA, L; VEKUA, A			A PLIOPLEISTOCENE HOMINID FROM DMANISI, EAST GEORGIA, CAUCASUS	NATURE			English	Article								ARCHAEOLOGICAL excavations at the mediaeval site of Dmanisi (East Georgia) revealed that the town was built on a series of deposits yielding Late Villafranchian mammalian fossils and led to the discovery in late 1991 of a well preserved early human mandible. Dmanisi, where excavations are being carried out by a joint expedition of the Archaeological Research Centre of the Georgian Academy of Sciences and the Romisch-Germanisches Zentralmuseum (Mainz, Germany), is located southwest of Tbilisi, at about 44 degrees 20' N, 41 degrees 20' E (Fig. 1). The fossils date Ifo the latest Pliocene (or perhaps to the earliest Pleistocene), probably between 1.8 and 1.6 million years ago (Myr). Here we identify the mandible as belonging to the species Home erectus, of which it is the earliest known representative in western Eurasia. It shows a number of similarities to the African and Chinese representatives of this species.			GABUNIA, L (corresponding author), GEORGIAN ACAD SCI, INST PALEOBIOL, 9 SULKHAN SABA, TBILISI 380007, GEORGIA.							AN ZH, 1989, QUATERNARY RES, V32, P213, DOI 10.1016/0033-5894(89)90077-X; BOSINSKI G, 1991, JB ROMISCH GERMAN ZE, V36, P76; BOSINSKI G, 1991, JB ROMISCH GERMANISC, V36, P93; Brown Barbara, 1993, P161; GABUNIA L, 1993, DMANISI MAN ACCOMPAN, P1; MAJSURADZE G, 1991, JB ROMISCH GERMAN ZE, V36, P74; MUSKHELISHVITI A, IN PRESS JB ROMISCH; Rightmire, 1990, EVOLUTION HOMO ERECT; ROEBROEKS W, 1994, CURR ANTHROPOL, V35, P301, DOI 10.1086/204279; SOLOGASHVILI D, IN PRESS JB ROMISCH; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; VEROSUB KL, 1991, 1 EUROPEENS, P237; Walker Alan, 1993, P63; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; Wood B., 1991, HOMINID CRANIAL REMA, V4	15	230	239	3	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					509	512		10.1038/373509a0	http://dx.doi.org/10.1038/373509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845461				2022-12-01	WOS:A1995QF72400055
J	GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J				GAMES, D; ADAMS, D; ALESSANDRINI, R; BARBOUR, R; BERTHELETTE, P; BLACKWELL, C; CARR, T; CLEMENS, J; DONALDSON, T; GILLESPIE, F; GUIDO, T; HAGOPIAN, S; JOHNSONWOOD, K; KHAN, K; LEE, M; LEIBOWITZ, P; LIEBERBURG, I; LITTLE, S; MASLIAH, E; MCCONLOGUE, L; MONTOYAZAVALA, M; MUCKE, L; PAGANINI, L; PENNIMAN, E; POWER, M; SCHENK, D; SEUBERT, P; SNYDER, B; SORIANO, F; TAN, H; VITALE, J; WADSWORTH, S; WOLOZIN, B; ZHAO, J			ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN	NATURE			English	Article							SENILE PLAQUES; DISEASE; IDENTIFICATION; EXPRESSION; PATHOLOGY; DEPOSITS; PEPTIDE; CHAIN; BRAIN; GENE	ALZHEIMER'S disease (AD) is the most common cause of progressive intellectual failure in aged humans. AD brains contain numerous amyloid plaques surrounded by dystrophic neurites, and show profound synaptic loss, neurofibrillary tangle formation and gliosis. The amyloid plaques are composed of amyloid beta-peptide (A beta), a 40-42-amino-acid fragment of the beta-amyloid precursor protein (APP)(1). A primary pathogenic role for APP/A beta is suggested by missense mutations in APP that are tightly linked to autosomal dominant forms of AD(2,3). A major obstacle to elucidating and treating AD has been the lack of an animal model. Animals transgenic for APP have previously failed to show extensive AD-type neuropathology(4-10), but we now report the production of transgenic mice that express high levels of human mutant APP (with valine at residue 717 substituted by phenylalanine) and which progressively develop many of the pathological hallmarks of AD, including numerous extracellular thioflavin S-positive AP deposits, neuritic plaques, synaptic loss, astrocytosis and microgliosis. These mice support a primary role for APP/A beta in the genesis of AD and could provide a preclinical model for testing therapeutic drugs.	ATHENA NEUROSCI INC, San Francisco, CA 94080 USA; EXEMPLAR CORP, WORCESTER, MA 01605 USA; ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA; SCRIPPS RES INST, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA; NIMH, CLIN SCI LAB, BETHESDA, MD 20892 USA	Eli Lilly; Scripps Research Institute; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Mucke, Lennart/0000-0001-6256-9559				ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORK LC, 1988, J NEUROPATH EXP NEUR, V47, P629, DOI 10.1097/00005072-198811000-00006; DICKSON DW, 1990, ACTA NEUROPATHOL, V79, P486, DOI 10.1007/BF00296107; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; HARDY J, 1994, CLIN GERIATR MED, V10, P239, DOI 10.1016/S0749-0690(18)30343-4; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; Hogan B., 1986, MANIPULATING MOUSE E; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANN DMA, 1992, NEURODEGENERATION, V1, P201; MASLIAH E, 1991, AM J PATHOL, V138, P235; MASLIAH E, 1991, ACTA NEUROPATHOL, V81, P428, DOI 10.1007/BF00293464; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MCCONLOGUE L, 1994, NEUROBIOL AGING, V15, pS12; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; SANHU FA, 1991, J BIOL CHEM, V266, P21331; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SELKOE DJ, 1994, REV NEUROSCI, V17, P489; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	29	2117	2280	2	169	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					523	527		10.1038/373523a0	http://dx.doi.org/10.1038/373523a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845465				2022-12-01	WOS:A1995QF72400060
J	JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI				JONES, EY; HARLOS, K; BOTTOMLEY, MJ; ROBINSON, RC; DRISCOLL, PC; EDWARDS, RM; CLEMENTS, JM; DUDGEON, TJ; STUART, DI			CRYSTAL-STRUCTURE OF AN INTEGRIN-BINDING FRAGMENT OF VASCULAR CELL-ADHESION MOLECULE-1 AT 1.8 ANGSTROM RESOLUTION	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAINS; SOLUBLE FORM; HUMAN CD4; PROTEIN; FIBRONECTIN; SITE; KINASE	THE cell-surface glycoprotein vascular cell adhesion molecule-1 (VCAM-1; ref. 1) mediates intercellular adhesion(2) by specific binding to the integrin very-late antigen-4 (VLA-4, alpha(4) beta(1); ref. 3). VCAM-1, with the intercellular adhesion molecules ICAM-1, ICAM-2, ICAM-3 and the mucosal vascular addressin MAd-CAM-1, forms an integrin-binding subgroup of the immunoglobulin superfamily. In addition to their clinical relevance in inflammation, these molecules act as cellular receptors for viral and parasitic agents(2). The predominant form of VCAM-1 in vivo has an amino-terminal extracellular region comprising seven immunoglobulin-like domains. Functional studies(4-7) have identified a conserved integrin-binding motif in domains 1 and 4, variants of which are present in the N-terminal domain of all members of the immunoglobulin superfamily subgroup. We report here the crystal structure of a VLA-4-binding fragment composed of the first two domains of VCAM-1. The integrin-binding motif (Q38IDSPL) is highly exposed and forms the N-terminal region of the loop between beta-strands C and D of domain 1. This motif exhibits a distinctive conformation which we predict will be common to all the integrin-binding IgSF molecules. These, and additional data, map VLA-4 binding to the face of the CFG beta-sheet, the surface previously identified(8) as the site for intercellular adhesive interactions between members of the immunoglobulin superfamily.	UNIV OXFORD, CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND; NEURES LTD, ABINGDON OX14 3YS, OXON, ENGLAND	University of Oxford; University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Driscoll, Paul C/B-8007-2010; Robinson, Robert/G-9702-2011; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Driscoll, Paul C/0000-0002-4124-6950; Robinson, Robert/0000-0001-6367-6903; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOTTOMLEY MJ, 1994, J MOL BIOL, V244, P464, DOI 10.1006/jmbi.1994.1743; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; DUDGEON TJ, 1994, EUR J BIOCHEM, V226, P517, DOI 10.1111/j.1432-1033.1994.tb20076.x; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOLNESS CL, IN PRESS J BIOL CHEM; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	28	180	184	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					539	544		10.1038/373539a0	http://dx.doi.org/10.1038/373539a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7531291				2022-12-01	WOS:A1995QF72400064
J	PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ				PUSCH, M; LUDEWIG, U; REHFELDT, A; JENTSCH, TJ			GATING OF THE VOLTAGE-DEPENDENT CHLORIDE CHANNEL CIC-O BY THE PERMEANT ANION	NATURE			English	Article							POTASSIUM CHANNEL; SODIUM-CHANNEL; AMINO-ACIDS; K+ CHANNELS; INACTIVATION; ACTIVATION; EXPRESSION; MUTATIONS; CLONING	CHLORIDE channels of the ClC family are important for the control of membrane excitability(1-3), cell volume regulation(4,5), and possibly transepithelial transport lacking the typical voltage-sensor found in cation gating of ClC channels is clearly voltage-dependent. For the prototype Torpedo channel ClC-0 (refs 11-15) we now show that channel opening is strongly facilitated by external chloride. Other less permeable anions can substitute for chloride with less efficiency. ClC-0 conductance shows an anomalous mole fraction behaviour with Cl-/NO3- mixtures, suggesting a multi-ion pore. Gating shows a similar anomalous behaviour, tightly linking permeation to gating. Eliminating a positive charge at the cytoplasmic end of domain D12 changes kinetics, concentration dependence and halide selectivity of gating, and alters pore properties such as ion selectivity, single-channel conductance and rectification. Taken together, our results strongly suggest that in these channels voltage-dependent gating is conferred by the permeating ion itself, acting as the gating charge.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY	University of Hamburg				Pusch, Michael/0000-0002-8644-8847; Jentsch, Thomas/0000-0002-3509-2553				BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAGIWARA S, 1979, J GEN PHYSIOL, V67, P621; HANKE W, 1983, J GEN PHYSIOL, V82, P25, DOI 10.1085/jgp.82.1.25; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PUSCH M, 1994, BIOPHYS J, V86, P149; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WHITE MM, 1979, J BIOL CHEM, V254, P161; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	29	301	305	2	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					527	531		10.1038/373527a0	http://dx.doi.org/10.1038/373527a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845466				2022-12-01	WOS:A1995QF72400061
J	SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L				SAVVA, R; MCAULEYHECHT, K; BROWN, T; PEARL, L			THE STRUCTURAL BASIS OF SPECIFIC BASE-EXCISION REPAIR BY URACIL-DNA GLYCOSYLASE	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; ESCHERICHIA-COLI; N-GLYCOSIDASE; SEQUENCE; PURIFICATION; NUCLEAR; ENZYME; ERRORS; CELLS; GENE	The 1.75-Angstrom crystal structure of the uracil-DNA glycosylase from herpes simplex virus type-L reveals a new fold, distantly related to dinucleotide-binding proteins. Complexes with a trideoxynucleotide, and with uracil, define the DNA-binding site and allow a detailed understanding of the exquisitely specific recognition of uracil in DNA. The overall structure suggests binding models for elongated single- and double-stranded DNA substrates. Conserved residues close to the uracil-binding site suggest a catalytic mechanism for hydrolytic base excision.	UCL, DEPT BIOCHEM & MOLEC BIOL, STRUCT BIOCHEM SECT, LONDON WC1E 6BT, ENGLAND; UNIV EDINBURGH, DEPT CHEM, EDINBURGH EH9 3JJ, MIDLOTHIAN, SCOTLAND	University of London; University College London; University of Edinburgh			Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; McAuley, Katherine/0000-0002-9545-072X; Brown, Tom/0000-0002-6538-3036; Pearl, Laurence/0000-0002-6910-1809; Savva, Renos/0000-0001-7375-2340	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARADONNA S, 1987, J VIROL, V61, P3040, DOI 10.1128/JVI.61.10.3040-3047.1987; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CROSBY B, 1981, NUCLEIC ACIDS RES, V9, P5797, DOI 10.1093/nar/9.21.5797; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABOEV OK, 1985, J BACTERIOL, V164, P421, DOI 10.1128/JB.164.1.421-424.1985; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KROKAN HE, 1993, JUL P NY AC SCI ABST; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1994, MOSFLM USERS GUIDE; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; MULLANEY J, 1989, J GEN VIROL, V70, P449, DOI 10.1099/0022-1317-70-2-449; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; OTWINOWSKI Z, 1991, ISOMORPHOUS REPLACEM, P23; PFLUGRATH JW, 1992, MUNICH AREA DETECTOR; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAVVA R, 1993, J MOL BIOL, V234, P910, DOI 10.1006/jmbi.1993.1642; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775	38	355	398	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					487	493		10.1038/373487a0	http://dx.doi.org/10.1038/373487a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845459				2022-12-01	WOS:A1995QF72400048
J	SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC				SONGYANG, Z; CARRAWAY, KL; ECK, MJ; HARRISON, SC; FELDMAN, RA; MOHAMMADI, M; SCHLESSINGER, J; HUBBARD, SR; SMITH, DP; ENG, C; LORENZO, MJ; PONDER, BAJ; MAYER, BJ; CANTLEY, LC			CATALYTIC SPECIFICITY OF PROTEIN-TYROSINE KINASES IS CRITICAL FOR SELECTIVE SIGNALING	NATURE			English	Article							SUBSTRATE-SPECIFICITY; PHOSPHORYLATION; DOMAINS; INVITRO; ANTIGEN; SITES	How do distinct protein-tyrosine kinases activate specific downstream events? Src-homology-2 (SH2) domains on tyrosine kinases or targets of tyrosine kinases recognize phosphotyrosine in a specific sequence context and thereby provide some specificity(1-3). The role of the catalytic site of tyrosine kinases in determining target specificity has not been fully investigated. Here we use a degenerate peptide library to show that each of nine tyrosine kinases investigated has a unique optimal peptide substrate. We find that the cytosolic tyrosine kinases preferentially phosphorylate peptides recognized by their own SH2 domains or closely related SH2 domains (group I; ref. 3), whereas receptor tyrosine kinases preferentially phosphorylate peptides recognized by subsets of group In SH2 domains(3). The importance of these findings for human disease is underscored by our observation that a point mutation in the RET receptor-type tyrosine kinase, which causes multiple endocrine neoplasia type 2B, results in a shift in peptide substrate specificity.	BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP, MOLEC MED LAB, BOSTON, MA 02115 USA; UNIV MARYLAND, SCH MED, DEPT MICROBIOL & IMMUNOL, BALTIMORE, MD 21201 USA; UNIV MARYLAND, MARYLAND BIOTECHNOL INST, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tufts University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; New York University; Columbia University; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Mohammadi, Moosa/ABA-6745-2020; Cantley, Lewis C/D-1800-2014; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Cantley, Lewis C/0000-0002-1298-7653; Eng, Charis/0000-0002-3693-5145; Lorenzo, Maria Jesus/0000-0003-4416-0615; Feldman, Ricardo A./0000-0001-6090-0439				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DUYSTER J, IN PRESS P NATN ACAD; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TILT JH, 1994, J BIOL CHEM, V269, P7423; TINKER DA, 1992, ANTICANCER RES, V12, P123; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	817	843	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 9	1995	373	6514					536	539		10.1038/373536a0	http://dx.doi.org/10.1038/373536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845468				2022-12-01	WOS:A1995QF72400063
J	VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A				VAADIA, E; HAALMAN, I; ABELES, M; BERGMAN, H; PRUT, Y; SLOVIN, H; AERTSEN, A			DYNAMICS OF NEURONAL INTERACTIONS IN MONKEY CORTEX IN RELATION TO BEHAVIORAL EVENTS	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; CAT STRIATE CORTEX; VISUAL-CORTEX; SYNCHRONIZATION; CONNECTIVITY; NETWORK	IT is possible that brain cortical function is mediated by dynamic modulation of coherent firing in groups of neurons. Indeed, a correlation of firing between cortical neurons, seen following sensory stimuli or during motor behaviour, has been described(1-5). However, the time course of modifications of correlation in relation to behaviour was not evaluated systematically. Here we show that correlated firing between single neurons, recorded simultaneously in the frontal cortex of monkeys performing a behavioural task, evolves within a fraction of a second, and in systematic relation to behavioural events. Moreover, the dynamic patterns of correlation depend on the distance between neurons, and can emerge even without modulation of the firing rates. These findings support the notion that neurons can associate rapidly into a functional group in order to perform a computational task, at the same time becoming dissociated from concurrently activated competing groups. Thus, they call for a revision of prevailing models of neural coding that rely solely on single neuron firing rates(6-8).	HEBREW UNIV JERUSALEM,CTR NEURAL COMPUTAT,IL-91010 JERUSALEM,ISRAEL; WEIZMANN INST SCI,CTR RES HIGHER BRAIN FUNCT,IL-76100 REHOVOT,ISRAEL	Hebrew University of Jerusalem; Weizmann Institute of Science	VAADIA, E (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91010 JERUSALEM,ISRAEL.		Vaadia, Eilon/E-9347-2011					ABELES M, 1993, BRAIN THEORY, P149; ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; AERTSEN A, 1994, PHYSICA D, V75, P103, DOI 10.1016/0167-2789(94)90278-X; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Barlow H.B., 1992, INFORMATION PROCESSI, P169; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FETZ E, 1991, CEREB CORTEX, V9, P1; GRA CM, 1992, VIS NEUROSCI, V8, P37; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HANSEL D, 1992, PHYS REV LETT, V68, P718, DOI 10.1103/PhysRevLett.68.718; KANEKO K, 1990, PHYSICA D, V41, P137, DOI 10.1016/0167-2789(90)90119-A; KRUGER J, 1990, VISUAL NEUROSCI, V5, P135, DOI 10.1017/S0952523800000171; MICHALSKI A, 1983, EXP BRAIN RES, V51, P97; MURTHY VN, IN PRESS OSCILLATORY; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; PALM G, 1988, BIOL CYBERN, V59, P1, DOI 10.1007/BF00336885; SELEMON LD, 1990, J COMP NEUROL, V297, P359, DOI 10.1002/cne.902970304; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; TOYAMA K, 1981, J NEUROPHYSIOL, V46, P191, DOI 10.1152/jn.1981.46.2.191; TSO DY, 1986, J NEUROSCI, V6, P1160; Vaadia E, 1992, INFORMATION PROCESSI, P81	24	603	613	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					515	518		10.1038/373515a0	http://dx.doi.org/10.1038/373515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845462				2022-12-01	WOS:A1995QF72400057
J	ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH				ZUCKERMAN, B; FORVEILLE, T; KASTNER, JH			INHIBITION OF GIANT-PLANET FORMATION BY RAPID GAS DEPLETION AROUND YOUNG STARS	NATURE			English	Article							T-TAURI STARS; POINT-SOURCE CATALOG; SAO STARS; GG-TAURI; DISK; EVOLUTION; ROTATION; EMISSION; HD-98800; NEBULA	ALTHOUGH stars form from clouds of gas and dust, there are insignificant amounts of gas around ordinary (Sun-like) stars. This suggests that hydrogen and helium, the primary constituents of planets such as Jupiter and Saturn, are not easily retained in orbit as a star matures. The gas-giant planets in the Solar System must therefore have formed rapidly. Models of their formation generally suggest that a solid core formed in less than or equal to 10(6) yr, followed by the accretion of the massive gaseous envelope in similar to 10(7) yr (refs 1-5). But how and when the gas of the solar nebula dissipated, and how this compares with the predicted timescale of gas-giant formation, remains unclear(6,7), in part because direct observations of circumstellar gas have been made only for stars either younger or older than the critical range of 10(6)-10(7) yr (refs 8-15). Here we report observations of the molecular gas surrounding 20 stars whose ages are likely to be in this range. The gas dissipates rapidly; after a few million years the mass remaining is typically much less than the mass of Jupiter. Thus, if gas-giant planets are common in the Galaxy, they must form even more quickly than present models suggest.	OBSERV GRENOBLE,ASTROPHYS GRP,F-38041 GRENOBLE,FRANCE; MIT,CTR SPACE RES,CAMBRIDGE,MA 02139	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Massachusetts Institute of Technology (MIT)	ZUCKERMAN, B (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90024, USA.							Adams F.C., 1993, PROTOSTARS PLANETS, P721; Beckwith S. V. W., 1993, PROTOSTARS PLANETS, VIII, P521; BECKWITH SVW, 1993, ASTROPHYS J, V402, P280, DOI 10.1086/172131; CHIAR JE, 1994, ASTROPHYS J, V426, P240, DOI 10.1086/174058; DANTONA F, 1994, ASTROPHYS J SUPPL S, V90, P467, DOI 10.1086/191867; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; FEKEL FC, 1993, ASTROPHYS J, V419, pL89, DOI 10.1086/187144; FRANCHINI M, 1992, ASTRON ASTROPHYS, V256, P525; GREGORIOHETEM J, 1992, ASTRON J, V103, P549, DOI 10.1086/116082; HERBST W, 1988, ASTRON J, V96, P1949, DOI 10.1086/114941; HOBBS LM, 1985, ASTROPHYS J, V293, pL29, DOI 10.1086/184485; JENSEN ELN, 1994, ASTROPHYS J, V429, pL29, DOI 10.1086/187405; JURA M, 1993, ASTROPHYS J, V418, pL37, DOI 10.1086/187110; KAWABE R, 1993, ASTROPHYS J, V404, pL63, DOI 10.1086/186744; KOERNER DW, 1993, ASTROPHYS J, V408, pL93, DOI 10.1086/186839; KOERNER DW, 1993, ICARUS, V106, P2, DOI 10.1006/icar.1993.1154; Lin D. N. C., 1985, PROTOSTARPLANETS, VII, P981; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, IN PRESS NEPTUNE; OMODAKA T, 1992, ASTROPHYS J, V396, pL87, DOI 10.1086/186523; OUDMAIJER RD, 1992, ASTRON ASTROPHYS SUP, V96, P625; Podolak M., 1993, PROTOSTARS PLANETS, P1109; PRINN RG, 1993, PROTOSTARS PLANETS, V3, P1005; RUDEN SP, 1991, ASTROPHYS J, V375, P740, DOI 10.1086/170239; SARGENT AI, 1991, ASTROPHYS J, V382, pL31, DOI 10.1086/186207; SARGENT AI, 1993, ANNU REV ASTRON ASTR, V31, P297; SAVOLDINI M, 1994, ASTRON ASTROPHYS, V285, P467; SKRUTSKIE MF, 1991, ASTRON J, V102, P1749, DOI 10.1086/115997; SODERBLOM DR, 1993, ASTROPHYS J SUPPL S, V85, P315, DOI 10.1086/191767; STENCEL RE, 1991, ASTROPHYS J SUPPL S, V75, P905, DOI 10.1086/191553; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STROM SE, 1994, REV MEX ASTRON ASTR, V29, P23; TIELENS AGGM, 1991, ASTROPHYS J, V381, P181, DOI 10.1086/170640; WEINTRAUB DA, 1989, ASTROPHYS J, V344, P915, DOI 10.1086/167859; WETHERILL GW, 1991, SCIENCE, V253, P535, DOI 10.1126/science.253.5019.535; WETHERILL GW, IN PRESS PLANETARY S; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; YAMASHITA T, 1993, ASTROPHYS J, V402, pL65, DOI 10.1086/186701; ZUCKERMAN B, 1993, ASTROPHYS J, V406, pL25, DOI 10.1086/186778; ZUCKERMAN B, 1994, ASTROPHYS J, V414, P793; ZUCKERMAN B, IN PRESS CIRCUMSTELL	42	318	318	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 9	1995	373	6514					494	496		10.1038/373494a0	http://dx.doi.org/10.1038/373494a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QF724	7845460				2022-12-01	WOS:A1995QF72400049
J	FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P				FREED, GL; CLARK, SJ; SORENSON, J; LOHR, JA; CEFALO, R; CURTIS, P			NATIONAL ASSESSMENT OF PHYSICIANS BREAST-FEEDING KNOWLEDGE, ATTITUDES, TRAINING, AND EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; MANAGEMENT; HEALTH; CARE	Objective.-Previous reports have demonstrated that physician counseling can improve rates of breast-feeding initiation and duration but suggest that physicians are ill-prepared for this role. It is unclear whether residency training for pediatricians, obstetrician/gynecologists, and family physicians provides the knowledge and skills necessary for effective breast-feeding promotion. Design.-Survey. Participants.-A national random sample of 3115 residents and 1920 practicing physicians in pediatrics, obstetrics/gynecology, and family medicine. Outcomes.-Assessment of breast-feeding knowledge, attitudes, training, and experience. Results.-Overall response rate was 68%. All groups demonstrated significant deficits in knowledge of breast-feeding benefits and clinical management; for example, less than 50% of residents chose appropriate clinical management for a breast-fed jaundiced infant or a breast abscess. Practicing physicians performed slightly better, but still more than 30% chose incorrect advice for mothers with low milk supply. Residents reported that their breast-feeding instruction consisted mainly of didactic lecture, not patient experience. Only 55% of senior residents recalled even one instance of precepting related to breast-feeding, and less than 20% had demonstrated breast-feeding techniques at least five times during residency. Regarding preparation for breast-feeding counseling, more than 50% of all practicing physicians rated their residency training as inadequate. Overall, physician involvement in breast-feeding promotion was endorsed by 90% of respondents, yet only half rated themselves as effective in counseling breast-feeding patients. The greatest predictor of physician self-confidence was previous personal or spousal breast-feeding experience. Conclusions.-In this national sample of residents and practicing physicians in three specialties, physicians were ill-prepared to counsel breast-feeding mothers. Deliberate efforts must be made to incorporate clinically based breast-feeding training into residency programs and continuing education workshops to better prepare physicians for their role in breast-feeding promotion.	UNIV N CAROLINA,DEPT HLTH BEHAV & HLTH EDUC,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT OBSTET & GYNECOL,CHAPEL HILL,NC; UNIV N CAROLINA,DEPT FAMILY MED,CHAPEL HILL,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	FREED, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,DIV COMMUNITY PEDIAT,CB 7590,CHAPEL HILL,NC 27599, USA.				NICHD NIH HHS [1-R29-HD-29555-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029555] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson E, 1991, J Obstet Gynecol Neonatal Nurs, V20, P58, DOI 10.1111/j.1552-6909.1991.tb01677.x; APPLEBAUM RM, 1975, REPROD MED, V14, P93; BENTLEY JD, 1989, NEW ENGL J MED, V320, P1531, DOI 10.1056/NEJM198906083202306; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; FREED GL, 1993, JAMA-J AM MED ASSOC, V269, P243, DOI 10.1001/jama.269.2.243; FREED GL, 1992, SOUTHERN MED J, V85, P483, DOI 10.1097/00007611-199205000-00006; FREED GL, 1991, AM J DIS CHILD, V145, P917, DOI 10.1001/archpedi.1991.02160080095027; GOLDSTEIN AO, 1993, FAM MED, V25, P254; HAYES B, 1981, J OBSTET GYNECOL NEO, V10, P480; HELLIKER K, 1994, WALL STREET J   0822, pA1; HOLLEN B K, 1976, Journal of Tropical Pediatrics and Environmental Child Health, V22, P288; KISTIN N, 1990, PEDIATRICS, V86, P741; Lawrence R A, 1989, Pediatr Rev, V11, P163, DOI 10.1542/pir.11-6-163; LAWRENCE RA, 1982, PEDIATRICS, V70, P912; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; Lewinski C A, 1992, J Hum Lact, V8, P143, DOI 10.1177/089033449200800319; MITCHELMAN DF, 1990, AM J HEALTH PROMOT, V4, P181; NEIFERT MR, 1986, PEDIATR CLIN N AM, V33, P743; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; Simon J L, 1988, Fam Med, V20, P224; 1978, PEDIATRICS, V62, P591; 1993, GRADUATE MED ED DIRE; 1994, AM FAM PHYSICIAN, V50, P457; 1993, HLTH US 1992; 1990, HLTH PEOPLE 2000; 1992, GUIDELINES PERINATAL	26	200	204	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					472	476		10.1001/jama.273.6.472	http://dx.doi.org/10.1001/jama.273.6.472			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837365				2022-12-01	WOS:A1995QE49800030
J	KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI				KOHN, MA; FARLEY, TA; ANDO, T; CURTIS, M; WILSON, SA; JIN, Q; MONROE, SS; BARON, RC; MCFARLAND, LM; GLASS, RI			AN OUTBREAK OF NORWALK VIRUS GASTROENTERITIS ASSOCIATED WITH EATING RAW OYSTERS - IMPLICATIONS FOR MAINTAINING SAFE OYSTER BEDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTIOUS NONBACTERIAL GASTROENTERITIS; POLYMERASE CHAIN-REACTION; TO-PERSON TRANSMISSION; VIRAL GASTROENTERITIS; WATER-SYSTEM; CRUISE SHIP; CONSUMPTION; COMMUNITY; SPECIMENS; ILLNESS	Objective.-To determine the characteristics and the cause of an outbreak of gastroenteritis associated with eating raw oysters. Design.-Survey of groups of persons reporting illness to the health department after eating oysters; survey of convenience sample of oyster harvesters; and tracing of implicated oysters. Setting.-General community. Main Outcome Measures.-Relative risk for illness after oyster consumption, source bed of contaminated oysters, presence of antibodies to Norwalk virus in serum, presence of a Norwalk virus in stool by direct electron microscopy and reverse transcription-polymerase chain reaction (RT-PCR), and DNA sequences of RT-PCR products. Results.-Seventy (83%) of 84 persons who ate raw oysters became ill vs three (7%) of 43 people who did not eat raw oysters (relative risk, 11.9; 95% confidence interval, 4.0 to 34.2). Eleven (79%) of 14 serum pairs had at least a fourfold increase in antibody to Norwalk virus. All 12 stool samples tested were positive by electron microscopy and/or RT-PCR for Norwalk virus. The RT-PCR products from all seven stool samples tested had identical DNA sequences. Implicated oysters were harvested November 9 through 13, 1993, from a remote oyster bed. Crews from 22 (85%) of 26 oyster harvesting boats working in this area reported routine overboard disposal of sewage. One harvester with a high level of antibodies to Norwalk virus reported having gastroenteritis November 7 through 10 and overboard disposal of feces into the oyster bed. Conclusions.-This outbreak was caused by contamination of oysters in the oyster bed, probably by stool from one or more ill harvesters. Education of oyster harvesters and enforcement of regulations governing waste disposal by oyster harvesting boats might prevent similar outbreaks.	CTR DIS CONTROL & PREVENT, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, MED STUDENT ELECT PROGRAM, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	KOHN, MA (corresponding author), LOUISIANA DEPT HLTH & HOSP, OFF PUBL HLTH, EPIDEMIOL SECT, POB 60630, NEW ORLEANS, LA 70160 USA.			Monroe, Stephan/0000-0002-5424-716X				ADLER JL, 1969, J INFECT DIS, V119, P668, DOI 10.1093/infdis/119.6.668; ANDO T, 1994, ARCH VIROL, V135, P217, DOI 10.1007/BF01309781; ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; APPLETON H, 1977, LANCET, V1, P409; ATMAR RL, 1993, APPL ENVIRON MICROB, V59, P631, DOI 10.1128/AEM.59.2.631-635.1993; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BLACKLOW NR, 1991, NEW ENGL J MED, V325, P252, DOI 10.1056/NEJM199107253250406; Burkhardt W, 1992, J SHELLFISH RES, V11, P105; CANNON RO, 1991, J INFECT DIS, V164, P860, DOI 10.1093/infdis/164.5.860; DELEON R, 1992, J CLIN MICROBIOL, V30, P3151, DOI 10.1128/JCM.30.12.3151-3157.1992; DOANE FW, 1987, ELECTRON MICROS, P15; DOLIN R, 1972, P SOC EXP BIOL MED, V140, P578, DOI 10.3181/00379727-140-36508; ERDMAN DD, 1989, J CLIN MICROBIOL, V27, P1417, DOI 10.1128/JCM.27.6.1417-1418.1989; GILL ON, 1983, BRIT MED J, V287, P1532, DOI 10.1136/bmj.287.6404.1532; GOODMAN RA, 1982, ARCH ENVIRON HEALTH, V37, P358, DOI 10.1080/00039896.1982.10667591; GOYAL SM, 1979, APPL ENVIRON MICROB, V37, P572, DOI 10.1128/AEM.37.3.572-581.1979; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; GUNN RA, 1982, AM J EPIDEMIOL, V115, P348, DOI 10.1093/oxfordjournals.aje.a113311; GUNN RA, 1980, AM J EPIDEMIOL, V112, P820, DOI 10.1093/oxfordjournals.aje.a113054; HERWALDT BL, 1994, J CLIN MICROBIOL, V32, P861, DOI 10.1128/JCM.32.4.861-866.1994; HO MS, 1989, LANCET, V2, P961; JIANG X, 1990, Science (Washington D C), V250, P1580; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; Kapikian AZ, 1990, VIROLOGY, P671; KAPLAN JE, 1982, AM J EPIDEMIOL, V116, P940, DOI 10.1093/oxfordjournals.aje.a113496; KAPLAN JE, 1982, J INFECT DIS, V146, P190, DOI 10.1093/infdis/146.2.190; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KHAN AS, 1994, J CLIN MICROBIOL, V32, P318, DOI 10.1128/JCM.32.2.318-322.1994; KOOPMAN JS, 1982, AM J EPIDEMIOL, V115, P173, DOI 10.1093/oxfordjournals.aje.a113288; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; LAWSON HW, 1991, LANCET, V337, P1200, DOI 10.1016/0140-6736(91)92868-3; LIU OC, 1966, P SOC EXP BIOL MED, V123, P481, DOI 10.3181/00379727-123-31520; LOWRY PW, 1989, J INFECT DIS, V160, P978, DOI 10.1093/infdis/160.6.978; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MOE CL, 1994, J CLIN MICROBIOL, V32, P642, DOI 10.1128/JCM.32.3.642-648.1994; MONROE SS, 1993, J CLIN MICROBIOL, V31, P2866, DOI 10.1128/JCM.31.11.2866-2872.1993; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; MURPHY AM, 1979, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1979.tb104133.x; NELSON M, 1986, J ENVIRON HEALTH, V49, P7; REEVE G, 1989, NEW ENGL J MED, V321, P224, DOI 10.1056/NEJM198907273210404; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; WILSON R, 1982, AM J PUBLIC HEALTH, V72, P72, DOI 10.2105/AJPH.72.1.72; XI J, 1992, J CLIN MICROBIOL, V30, P2529, DOI 10.1128/JCM.30.10.2529-2534.1992	45	125	130	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					466	471		10.1001/jama.273.6.466	http://dx.doi.org/10.1001/jama.273.6.466			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837364				2022-12-01	WOS:A1995QE49800029
J	SPATARO, JA; VANHORN, L				SPATARO, JA; VANHORN, L			EXERCISE TO REDUCE POTBELLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BODY-COMPOSITION				SPATARO, JA (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA.							FOSTER WR, 1985, ANN INTERN MED, V103, P981; FRONTERA WR, 1988, J APPL PHYSIOL, V64, P1038, DOI 10.1152/jappl.1988.64.3.1038; MOREY MC, 1989, J AM GERIATR SOC, V37, P348, DOI 10.1111/j.1532-5415.1989.tb05503.x; NIEMAN DC, 1990, ANN SPORTS MED, V3, P2; POLLOCK ML, 1987, J APPL PHYSIOL, V62, P725, DOI 10.1152/jappl.1987.62.2.725; SIDNEY KH, 1977, AM J CLIN NUTR, V30, P326, DOI 10.1093/ajcn/30.3.326; Stamford B A, 1988, Exerc Sport Sci Rev, V16, P341	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					503	503		10.1001/jama.273.6.503	http://dx.doi.org/10.1001/jama.273.6.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7837371				2022-12-01	WOS:A1995QE49800037
J	WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				WILLETT, WC; MANSON, JE; STAMPFER, MJ; COLDITZ, GA; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			WEIGHT, WEIGHT CHANGE, AND CORONARY HEART-DISEASE IN WOMEN - RISK WITHIN THE NORMAL-WEIGHT RANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT DISTRIBUTION; FOLLOW-UP; BODY; MORTALITY; OBESITY	Objective.-To assess the validity of the 1990 US weight guidelines for women that support a substantial gain in weight at approximately 35 years of age and recommend a range of body mass index (BMI) (defined as weight in kilograms divided by the square of height in meters) from 21 to 27 kg/m(2), in terms of coronary heart disease (CHD) risk in women. Design.-Prospective cohort study. Setting.-Female registered nurses in the United States. Participants.-A total of 115 818 women aged 30 to 55 years in 1976 and without a history of previous CHD. Main Outcome Measure.-Incidence of CHD defined as nonfatal myocardial infarction or fatal CHD. Results.-During 14 years of follow-up, 1292 cases of CHD were ascertained. After controlling for age, smoking, menopausal status, postmenopausal hormone use, and parental history of CHD and using as a reference women with a BMI of less than 21 kg/m(2), relative risks (RRs) and 95% confidence intervals (Cls) for CHD were 1.19 (0.97 to 1.44) for a BMI of 21 to 22.9 kg/m(2), 1.46 (1.20 to 1.77) for a BMI of 23 to 24.9 kg/m(2), 2.06 (1.72 to 2.48) for a BMI of 25 to 28.9 kg/m(2), and 3.56 (2.96 to 4.29) for a BMI of 29 kg/m(2) or more. Women who gained weight from 18 years of age were compared with those with stable weight (+/-5 kg) in analyses that controlled for the same variables as well as BMI at 18 years of age. The RRs and Cls were 1.25 (1.01 to 1.55) for a 5- to 7.9-kg gain, 1.64 (1.33 to 2.04) for an 8- to 10.9-kg gain, 1.92 (1.61 to 2.29) for an 11- to 19-kg gain, and 2.65 (2.17 to 3.22) for a gain of 20 kg or more. Among women within the BMI range of 18 to 25 kg/m(2), weight gain after 18 years of age remained a strong predictor of CHD risk. Conclusions.-Higher levels of body weight within the ''normal'' range, as well as modest weight gains after 18 years of age, appear to increase risks of CHD in middle-aged women. These data provide evidence that current US weight guidelines may be falsely reassuring to the large proportion of women of der than 35 years who are within the current guidelines but have potentially avoidable risks of CHD.	BRIGHAM & WOMENS HOSP, CHANNING LAB, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	WILLETT, WC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594, HL 24074] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100, DOI 10.1093/ajcn/51.6.1100; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; GARRISON RJ, 1993, INT J OBESITY, V17, P417; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; RIMM EB, 1993, AM J EPIDEMIOL, V138, P601; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303, DOI 10.1093/oxfordjournals.aje.a117252; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; WOOD PD, 1993, CRIT REV FOOD SCI, V33, P369, DOI 10.1080/10408399309527635; 1960, BUILD BLOOD PRESSURE, V1; 1985, NUTRITION YOUR HLTH; 1990, NUTRITION YOUR HLTH; 1960, BUILD BLOOD PRESSURE, V2; 1994, J NUTR, V124, P2240	23	744	759	1	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 8	1995	273	6					461	465		10.1001/jama.273.6.461	http://dx.doi.org/10.1001/jama.273.6.461			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE498	7654270				2022-12-01	WOS:A1995QE49800028
J	ALTMAN, DG; BLAND, JM				ALTMAN, DG; BLAND, JM			THE NORMAL-DISTRIBUTION	BRITISH MEDICAL JOURNAL			English	Note											ALTMAN, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT LAB,POB 123,LONDON WC2A 3PX,ENGLAND.							Altman DG., 1991, PRACTICAL STAT MED R, P132; GARDNER MJ, 1989, STATISTICS CONFIDENC, P17; Gardner MJ, 1989, STAT CONFIDENCE, P28	3	176	179	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					298	298		10.1136/bmj.310.6975.298	http://dx.doi.org/10.1136/bmj.310.6975.298			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866172	Green Published, Bronze			2022-12-01	WOS:A1995QF71700027
J	BAIRD, RN				BAIRD, RN			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - TREATMENT AVOIDS MUCH MORBIDITY .19.	BRITISH MEDICAL JOURNAL			English	Article														Lambert, Mark/0000-0003-3528-9070				BAMFORD J, SEMINAR DISTRICT STR; BARNETT HJM, 1990, STROKE, V21, P2; BEEBE HG, 1989, STROKE, V20, P314; DENNIS M, 1990, STROKE, V21, P848, DOI 10.1161/01.STR.21.6.848; MAGEE TR, 1992, ANN ROY COLL SURG, V74, P430; MURIE JA, 1994, BRIT J SURG, V81, P827, DOI 10.1002/bjs.1800810612; PEARCE JMS, 1978, BRIT MED J, V1, P969, DOI 10.1136/bmj.1.6118.969; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	10	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					316	317		10.1136/bmj.310.6975.316	http://dx.doi.org/10.1136/bmj.310.6975.316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866177	Green Published			2022-12-01	WOS:A1995QF71700040
J	BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND				BRABIN, L; KEMP, J; OBUNGE, OK; IKIMALO, J; DOLLIMORE, N; ODU, NN; HART, CA; BRIGGS, ND			REPRODUCTIVE-TRACT INFECTIONS AND ABORTION AMONG ADOLESCENT GIRLS IN RURAL NIGERIA	LANCET			English	Article							FEMALE ADOLESCENTS; SEXUAL-BEHAVIOR; PREVALENCE; POPULATION; COMMUNITY; DISEASES; HEALTH; WOMEN	Few studies from developing countries have investigated reproductive tract infections or other indicators of sexual health among unmarried adolescent girls in rural areas. We have obtained baseline demographic, clinical, and microbiological data on reproductive tract infections and induced abortion in girls in a rural area of southeast Nigeria, in order to assess the need for health care for adolescents. 868 females attended for interview and examination: 458 aged 20 and above and 410 aged 12-19, the latter representing 93.4% of the adolescent population. 43.6% of those <17 and 80.1% aged 17-19 years were sexually active and at least 24.1% had undergone an induced abortion; only 5.3% had ever used in modern contraceptive. Vaginal discharge was reported by 82.4%, though few sought treatment. 94.1% of sexually active adolescents and 97.6% of sexually active women 20 years old or older were gynaecologically examined and screened for reproductive tract infections. Of those aged less than 17, 19.8% had symptomatic candida and 11.1% trichomonas infections. Among those aged 17-19 years, chlamydia was detected in 10.5%, and symptomatic candidosis in 25.6%; this was the group most likely to have any infection (43.8%). 42.1% of sexually active adolescents had experienced either an abortion or a sexually transmitted disease. Syphilis was the only infection for which the incidence clearly increased with age. Health-care services for adolescents in this community are needed and should include sex education, contraceptive provision (especially barrier methods), and access to treatment for reproductive tract infections. Investments in health for this age group will have an effect on subsequent reproductive health.	UNIV PORT HARCOURT,PORT HARCOURT,NIGERIA; COMMISS WOMEN,PORT HARCOURT,NIGERIA; UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Port Harcourt; University of Liverpool	BRABIN, L (corresponding author), UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,PEMBROKE PL,LIVERPOOL L3 5QA,MERSEYSIDE,ENGLAND.		Harry, Tubonye/A-2107-2012	Harry, Tubonye/0000-0003-3773-5230; Brabin, Loretta/0000-0003-4478-6503				ADETORO O O, 1991, African Journal of Medicine and Medical Sciences, V20, P149; [Anonymous], 1993, WORLD DEV REPORT; Anosike J. C., 1993, Applied Parasitology, V34, P19; ARNO JN, 1994, SEX TRANSM DIS, V21, P47, DOI 10.1097/00007435-199401000-00010; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BANG RA, 1989, LANCET, V1, P85; BARKER GK, 1992, STUD FAMILY PLANN, V23, P199, DOI 10.2307/1966728; BLACKWELL AL, 1993, LANCET, V342, P206, DOI 10.1016/0140-6736(93)92299-9; BLYTHE MJ, 1988, J PEDIATR-US, V112, P1000, DOI 10.1016/S0022-3476(88)80236-1; BLYTHE MJ, 1992, J PEDIATR-US, V121, P487, DOI 10.1016/S0022-3476(05)81812-8; CATES W, 1993, SEX TRANSM DIS, V20, P174, DOI 10.1097/00007435-199305000-00011; Feachem RGA, 1992, HLTH ADULTS DEV WORL; KINSMAN OS, 1986, INFECT IMMUN, V53, P498, DOI 10.1128/IAI.53.3.498-504.1986; LAGA M, 1994, SEX TRANSM DIS, V21, pS45; LAGA M, 1993, AIDS, V3, P95; MOSHA F, 1993, GENITOURIN MED, V69, P415; NICHOLS D, 1986, STUD FAMILY PLANN, V17, P100, DOI 10.2307/1967070; OGBONNA C I C, 1991, Angewandte Parasitologie, V32, P198; OH MK, 1993, SEX TRANSM DIS, V20, P45, DOI 10.1097/00007435-199301000-00009; OLALEYE OD, 1993, J INFECT DIS, V167, P710, DOI 10.1093/infdis/167.3.710; OSOBU AO, 1973, W AFR MED J, V22, P23; ROSENBERG MJ, 1993, SEX TRANSM DIS, V20, P41, DOI 10.1097/00007435-199301000-00008; Singh B, 1977, ADV PLANNED PARENTHO, V12, P45; SINGLETON AF, 1980, CLIN PEDIATR, V19, P799, DOI 10.1177/000992288001901204; SOBEL J, 1990, SEXUALLY TRANSMITTED; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232; WHOADH931 DIV FAM HL; 1987, BARRIER CONTRACEPTIV; 1991, PREVENTION ORBIDITY; 1990, GUIDELINES TRAINING; 1992, 1990 NIG DEM HLTH SU	33	91	93	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					300	304		10.1016/S0140-6736(95)90281-3	http://dx.doi.org/10.1016/S0140-6736(95)90281-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837866				2022-12-01	WOS:A1995QE73100015
J	CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA				CROFTS, N; STEWART, T; HEARNE, P; PING, XY; BRESCHKIN, AM; LOCARNINI, SA			SPREAD OF BLOODBORNE VIRUSES AMONG AUSTRALIAN PRISON ENTRANTS	BRITISH MEDICAL JOURNAL			English	Article							HEPATITIS-C VIRUS; INTRAVENOUS-DRUG-USERS; HIV TRANSMISSION; UNITED-STATES; PREVALENCE; INFECTION; VACCINATION; ANTIBODIES; HEROIN; JAIL	Objectives-To assess spread of bloodborne viruses among prison entrants in Victoria, Australia. Design-Voluntary confidential testing of all prison entrants for markers of exposure to bloodborne viruses with collection of minimal data on demography and risk factors over 12 months. Setting-Her Majesty's Prisons, Pentridge and Fairlea, Victoria, Australia. Subjects-3429 male and 198 female prison entrants (> 99% of all prison entrants); 344 entered prison and were tested more than once. Main outcome measures-Prevalence and incidence of antibodies to HIV, hepatitis B, and hepatitis C viruses, and minimal data on risk factors. Results-1562 (46%) gave a history of use of injected drugs, 1171 (33%) had antibody to hepatitis B core antigen, 1418 (39%) were anti-hepatitis C positive including 914 (64%) of the men who injected drugs, 91 (2.5%) were positive for hepatitis B surface antigen, and 17 (0.47%) were positive for antibody to HIV. Incidence rates for infection with hepatitis B and C virus were 12.6 and 18.3 per 100 person years, respectively; in men who injected drugs and were aged less than 30 years (29% of all prison entrants) these were 21 and 41 per 100 person years. Seroconversion to hepatitis B or C was associated with young age and shorter stay in prison. Only 5% of those who were not immune to hepatitis B reported hepatitis B immunisation. Conclusions-Hepatitis B and C are spreading rapidly through some populations of injecting drug users in Victoria, particularly among men aged less than 30 years at risk of imprisonment in whom rates of spread are extreme; this group constitutes a sizeable at risk population for spread of HIV. This spread is occurring in a context of integrated harm reduction measures outside prisons for prevention of viral spread but few programmes within or on transition from prisons; it poses an urgent challenge to these programmes.	PENTRIDGE HOSP,HER MAJESTYS PRISON,COBURG,VIC 3058,AUSTRALIA; FAIRFIELD HOSP,DEPT VIROL,VICTORIAN INFECT DIS REFERENCE LAB,FAIRFIELD,VIC 3078,AUSTRALIA	Victorian Infectious Diseases Reference Laboratory	CROFTS, N (corresponding author), MACFARLANE BURNET CTR MED RES,EPIDEMIOL & INT HLTH UNIT,POB 65,FAIRFIELD,VIC 3078,AUSTRALIA.							BAYAS JM, 1993, VACCINE, V11, P1441, DOI 10.1016/0264-410X(93)90174-V; BELL J, 1990, MED J AUSTRALIA, V152, P361, DOI 10.5694/j.1326-5377.1990.tb125185.x; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1991, AIDS, V8, P1345; BRESLOW NE, 1980, STATISTICAL METHODS; CHRISTIE B, 1993, BRIT MED J, V307, P151; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P81; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; DECKER MD, 1985, J INFECT DIS, V152, P214, DOI 10.1093/infdis/152.1.214; DOBINSON I, 1986, J DRUG ISSUES, V16, P249, DOI 10.1177/002204268601600211; DONOGHOE M C, 1989, AIDS Care, V1, P51, DOI 10.1080/09540128908260235; GAUGHWIN MD, 1991, AIDS, V5, P845, DOI 10.1097/00002030-199107000-00008; GAUGHWIN MD, 1992, HIV AIDS AUSTR PRISO; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; HOLSEN DS, 1993, EUR J CLIN MICROBIOL, V12, P673, DOI 10.1007/BF02009378; INDERMAUER D, 1988, AUSTR NZ J CRIMINOLO, V3, P144; INDERMAUER D, 1990, SUBSTANCE ABUSE HIST; Kaldor J, 1993, Drug Alcohol Rev, V12, P175, DOI 10.1080/09595239300185611; OKAMOTO H, 1990, JPN J EXP MED, V60, P223; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; SUGITANI M, 1992, LANCET, V339, P1018, DOI 10.1016/0140-6736(92)90538-E; THOMPSON SC, 1993, MED J AUSTRALIA, V159, P562, DOI 10.5694/j.1326-5377.1993.tb138023.x; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; WATSON PG, 1973, MED J AUSTRALIA, V2, P421, DOI 10.5694/j.1326-5377.1973.tb115203.x; WOLK J, 1990, MED J AUSTRALIA, V152, P453, DOI 10.5694/j.1326-5377.1990.tb125302.x; 1993, NATIONAL HIV AIDS ST; 1990, NATIONAL HIV SEROPRE	29	132	134	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					285	288		10.1136/bmj.310.6975.285	http://dx.doi.org/10.1136/bmj.310.6975.285			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866168	Green Published			2022-12-01	WOS:A1995QF71700022
J	FLETCHER, JC; SPENCER, EM				FLETCHER, JC; SPENCER, EM			INCOMPETENT PATIENT ON THE SLIPPERY SLOPE	LANCET			English	Editorial Material							ADVANCE DIRECTIVES				FLETCHER, JC (corresponding author), UNIV VIRGINIA,SCH MED,CTR BIOMED ETH,CHARLOTTESVILLE,VA 22908, USA.							Beauchamp T. L., 1994, PRINCIPLES BIOMEDICA, P178; BROCK DW, 1994, J CLIN ETHIC, V5, P57; DRESSER R, 1994, HASTINGS CENT REP, V24, P6, DOI 10.2307/3562836; EMANUEL L, 1993, J CLIN ETHIC, V4, P8; FAGAN J, 1992, J CLIN EXP NEUROPSYC, V14, P36; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; NIEMIRA D, 1993, HASTINGS CENT REP, V23, P14, DOI 10.2307/3563361; TENO JM, 1994, J CLIN ETHIC, V5, P23	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					271	272		10.1016/S0140-6736(95)90271-6	http://dx.doi.org/10.1016/S0140-6736(95)90271-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837859				2022-12-01	WOS:A1995QE73100005
J	GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J				GORE, SM; BIRD, AG; BURNS, SM; GOLDBERG, DJ; ROSS, AJ; MACGREGOR, J			DRUG INJECTION AND HIV PREVALENCE IN INMATES OF GLENOCHIL PRISON	BRITISH MEDICAL JOURNAL			English	Article							SAUGHTON-PRISON; SURVEILLANCE; EDINBURGH; JAIL	Objective-To determine prevalence of HIV infection and drug injecting behaviour among inmates of Glenochil Prison on a specified date a year after an outbreak of hepatitis B and HIV infection. Design-Cross sectional: voluntary, anonymous HIV salivary antibody surveillance and Linked self completion questionnaire on risk factors. Setting-Glenochil prison, Scotland, a year after an outbreak of hepatitis B and HIV transmission related to drug injection. Subjects-352 prisoners, of whom 295 (84%) took part; 284 questionnaires (96%) passed logical checks. Main outcome measures-HIV prevalence; proportion of all inmates who had ever injected drugs, had ever injected inside prison, had started injecting drugs while inside prison. Results-More than half (150/284) the current inmates were also in Glenochil Prison during the critical period of January to June 1993, when hepatitis B and HIV were transmitted. Similar proportions of current inmates and men who were also in Glenochil during the critical period were drug users (27% (75/278) v 30% (44/149)). A quarter of injecting drug users (18/72) had first injected inside prison, irrespective of whether they were in Glenochil in January to June 1993 and regardless of the calendar period when they first injected. Significantly more inmates from Glasgow (41%; 56/138) than from Edinburgh (21%; 7/34) or elsewhere (11%; 12/106) were injecting drug users. On testing for HIV, seven saliva samples out of 293 gave positive results-four were presumed to be from inmates known to be infected with HIV, and the others from injecting drug users from Glasgow, all of whom had been in Glenochil during January to June 1993, when two of the three had injected drugs and had been tested for HIV, with negative results. The ratio of overall (2.4%) to disclosed (1.4%) HIV prevalence was 1.7. For men who had injected drugs in Glenochil during January to June 1993, HIV prevalence was estimated at 29%. Conclusion-Between a quarter and a third of prisoners who injected drugs in Glenochil in January to June 1993 were infected with HIV. There is widespread ongoing risk of bloodborne virus infection within prisons, which is probably long standing but demands urgent attention.	CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND; CITY HOSP EDINBURGH,REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; CTR HIV RES,MRC,BIOSTAT INITIAT AIDS & HIV SCOTLAND,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND; HM PRISON & YOUNG OFFENDERS INST,ALLOA FK10 3AD,CLACK,SCOTLAND	University of Oxford	GORE, SM (corresponding author), INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND.							BIRD AG, 1993, AIDS, V7, P1277, DOI 10.1097/00002030-199309000-00025; BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021; CARRELL S, 1994, SCOTSMAN        0808, P2; CHRISTIE B, 1993, BRIT MED J, V307, P151; GORE SM, 1993, BRIT MED J, V307, P147, DOI 10.1136/bmj.307.6897.147; GORE SM, IN PRESS DEATHS CUST, V2; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289	9	84	88	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					293	296		10.1136/bmj.310.6975.293	http://dx.doi.org/10.1136/bmj.310.6975.293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866170	Green Published			2022-12-01	WOS:A1995QF71700024
J	HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C				HINDLER, C; NAZARETH, I; KING, M; COHEN, J; FARMER, R; GERADA, C			DRUG-USERS VIEWS ON GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									UCL, WHITTINGTON HOSP, SCH MED, DEPT PRIMARY CARE, LONDON N19 5NF, ENGLAND; ST GEORGE HOSP, SCH MED, LONDON SW17 0RE, ENGLAND; HURLEY CLIN, LONDON SE11 4HJ, ENGLAND	University of London; University College London; UCL Medical School; St Georges University London	HINDLER, C (corresponding author), ROYAL FREE HOSP, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND.		King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628				BENNETT T, 1986, BRIT J ADDICT, V81, P757; RICHARDS T, 1988, BRIT MED J, V296, P1082, DOI 10.1136/bmj.296.6629.1082; TELFER I, 1990, BRIT J ADDICT, V85, P137; 1993, REPORT AIDS DRUG MIS, P16	4	22	22	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					302	302		10.1136/bmj.310.6975.302	http://dx.doi.org/10.1136/bmj.310.6975.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7646645	Green Published			2022-12-01	WOS:A1995QF71700029
J	JENKINSON, D				JENKINSON, D			NATURAL COURSE OF 500 CONSECUTIVE CASES OF WHOOPING-COUGH - A GENERAL-PRACTICE POPULATION STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERTUSSIS	Objective-To describe the natural course of whooping cough. Design-Observational study of a general practice population. Setting-Discrete semirural East Midlands practice of 11 500 patients. Subjects-500 consecutive cases of whooping cough diagnosed clinically during 1977-92. Main outcome measures-Incidence of vomiting, whooping, apnoea, admission to hospital, and complications; duration and frequency of paroxysms. Pattern of spread. Results-The incidence in the practice population was 4347/100 000 population compared with a notification rate for England and Wales of 717/100 000. Most cases were relatively mild. 284 patients vomited after paroxysms, 242 whooped, and 57 had apnoea. Duration and frequency of paroxysms varied widely. Female and unimmunised patients suffered more severe disease. Bordetella was isolated from fewer immunised patients (24/96 v 63/122 unimmunised). Infection was usually spread through contacts with someone with clinical whooping cough. Five patients developed pneumonia, three of whom had been immunised. Three patients required hospital admission. Conclusions-Most cases of whooping cough are relatively mild. Such cases are difficult to diagnose without a high index of suspicion because doctors are unlikely to hear the characteristic cough, which may be the only symptom. Parents can be reassured that a serious outcome is unlikely. Adults also get whooping cough, especially from their children, and get the same symptoms as children. The difficulty of early diagnosis and probability of missed cases reinforces the need to keep the incidence low through immunisation in order to protect infants, who are the most vulnerable.			JENKINSON, D (corresponding author), KEYWORTH HLTH CTR,NOTTINGHAM NG12 5JU,ENGLAND.							CHRISTIE AB, 1970, INFECT DIS, P726; GROB PR, 1981, BRIT MED J, V282, P1925, DOI 10.1136/bmj.282.6280.1925; JENKINSON D, 1978, BRIT MED J, V2, P577; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; JENKINSON D, 1983, BRIT MED J, V287, P185, DOI 10.1136/bmj.287.6386.185; Kendrick P, 1939, AM J HYG, V29, P133, DOI 10.1093/oxfordjournals.aje.a118485; MARCOVITCH H, 1986, BRIT MED J, V292, P360, DOI 10.1136/bmj.292.6517.360; MILLER C, 1976, BRIT MED J, V2, P117; MILLER E, 1992, CDR REV, V2, P152; VESSELINOVAJENK.CK, 1978, J EPIDEMIOL COMMUNIT, V32, P194; 1981, BRIT MED J, V232, P23	11	48	50	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					299	302		10.1136/bmj.310.6975.299	http://dx.doi.org/10.1136/bmj.310.6975.299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866173	Green Published			2022-12-01	WOS:A1995QF71700028
J	LAMBERT, M				LAMBERT, M			CONTROVERSIES IN MANAGEMENT - SHOULD CAROTID ENDARTERECTOMY BE PURCHASED - PURCHASERS NEED A BROADER PERSPECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBROVASCULAR-DISEASE; STROKE; ANGIOGRAPHY; OXFORDSHIRE				LAMBERT, M (corresponding author), WAKEFIELD HLTH AUTHOR, WHITE ROSE HOUSE, WAKEFIELD WF1 1LT, W YORKSHIRE, ENGLAND.			Lambert, Mark/0000-0003-3528-9070				ASPLUND K, 1993, CEREBROVASC DIS, V3, P34, DOI 10.1159/000108747; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BROWN MM, 1992, BMJ-BRIT MED J, V305, P1071, DOI 10.1136/bmj.305.6861.1071; CAMPLING EA, 1992, REPORT NATIONAL CONF; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HOWARD G, 1991, J STROKE CEREBROVASC, V40, P166; MURIE JA, 1991, BRIT J SURG, V78, P397, DOI 10.1002/bjs.1800780406; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TURNIPSEED WD, 1993, SURGERY, V114, P643; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1991, CM1523; 1990, CM555	15	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	1995	310	6975					317	318		10.1136/bmj.310.6975.317	http://dx.doi.org/10.1136/bmj.310.6975.317			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866178	Green Published			2022-12-01	WOS:A1995QF71700041
J	MULHOLLAND, K				MULHOLLAND, K			MEASLES AND PERTUSSIS IN DEVELOPING-COUNTRIES WITH GOOD VACCINE COVERAGE	LANCET			English	Editorial Material							EPIDEMIC; IMMUNITY; CHILDREN; IMMUNIZATION; POLICY; AGE				MULHOLLAND, K (corresponding author), MRC LABS,POB 273,BANJUL,GAMBIA.							ADCOCK LM, 1992, INFECT DIS CLIN N AM, V6, P133; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BASS JW, 1994, PEDIATR INFECT DIS J, V13, P343, DOI 10.1097/00006454-199405000-00002; BLACK FL, 1984, B WORLD HEALTH ORGAN, V62, P315; BLACK FL, 1986, AM J EPIDEMIOL, V124, P442, DOI 10.1093/oxfordjournals.aje.a114415; BOTTIGER M, 1993, SCAND J INFECT DIS, V25, P239, DOI 10.3109/00365549309008490; CARTER H, 1992, BRIT MED J, V304, P637, DOI 10.1136/bmj.304.6827.637; Clements C. John, 1992, World Health Statistics Quarterly, V45, P285; COHEN P, 1946, J PEDIATR-US, V29, P609, DOI 10.1016/S0022-3476(46)80128-8; ENGLUND JA, IN PRESS J INFECT DI; KAMBARAMI RA, 1991, B WORLD HEALTH ORGAN, V69, P213; LAMB WH, 1988, REV INFECT DIS, V10, P457; LINNEMANN CC, 1982, PEDIATRICS, V69, P332; MCLEAN AR, 1995, LANCET, V345, P272, DOI 10.1016/S0140-6736(95)90272-4; PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004; PRESTON NW, 1994, LANCET, V344, P491, DOI 10.1016/S0140-6736(94)91894-5; PROVENZANO RW, 1965, NEW ENGL J MED, V273, P959, DOI 10.1056/NEJM196510282731804; REYNOLDS DW, 1972, AM J DIS CHILD, V124, P848, DOI 10.1001/archpedi.1972.02110180050006; SCHOUB BD, 1993, S AFR MED J, V83, P82; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; 1994, CVI FORUM, V7, P2; 1992, LANCET, V340, P232	22	37	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					305	307		10.1016/S0140-6736(95)90282-1	http://dx.doi.org/10.1016/S0140-6736(95)90282-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837867				2022-12-01	WOS:A1995QE73100016
J	ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC				ROBERTS, TL; WOOD, DA; RIEMERSMA, RA; GALLAGHER, PJ; LAMPE, FC			TRANS ISOMERS OF OLEIC AND LINOLEIC ACIDS IN ADIPOSE-TISSUE AND SUDDEN CARDIAC DEATH	LANCET			English	Article							CORONARY HEART-DISEASE; TRANSUNSATURATED FATTY-ACIDS; BODY TISSUE; LIPIDS; WOMEN; RISK; OILS; MEN	Trans isomers of unsaturated fatty acids are formed by biological or industrial hydrogenation. A population case-control study of sudden cardiac death in men was done to test the hypothesis that trans isomers of oleic acid and linoleic acid increase the risk of sudden cardiac death due to coronary artery disease. In adipose tissue obtained at necropsy from 66 cases of sudden cardiac death and taken from 286 healthy age and sex matched controls, the proportions of trans isomers of oleic and linoleic acid were measured by gas-liquid chromatography. In cases, the mean (SE) percentage of total trans fatty acids (C18:1 plus C18:2), expressed as a proportion of all fatty acids, was significantly lower (2.68 [0.08]%) than in healthy controls (2.86 [0.04]%; p<0.05). Trans C18:1 was 2.1 (0.7)% in cases compared with 2.27 (0.04)% (p<0.05) in controls. The proportion of all trans isomers of linoleic acid was 0.58 (0.02)% in cases compared with 0.59 (0.01)% in controls (p=0.98). The estimated relative risk for sudden cardiac death of trans C18:1 and C18:2 fatty acids combined did not differ significantly from 1.0 in relation to the distribution of these trans isomers by quintile in the control population. The relative risk (95% CI) of sudden cardiac death in the top quintile was 0.40 (0.15-1.02) for C18:1 and 1.08 (0.48-2.74) for C18:2 compared with the bottom quintiles of their respective control distributions. When these univariate relations for irans fatty acids were adjusted for coronary risk factors, smoking was the only factor that remained independently associated with risk of sudden cardiac death (2.27 [1.23-4.17]). Overall, there was no evidence of a relation between trans isomers of oleic and linoleic acids combined and sudden cardiac death. However, trans oleic acid was negatively associated with risk of sudden cardiac death, whereas no association with trans forms of linoleic acid was seen. This study does not support the hypothesis that trans isomers increase the risk of sudden cardiac death.	ROYAL BROMPTON HOSP,NATL HEART & LUNG INST,DEPT CLIN EPIDEMIOL,LONDON SW3 6LY,ENGLAND; UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON,HANTS,ENGLAND; SOUTHAMPTON UNIV HOSP,SOUTHAMPTON GEN HOSP,DEPT MED STAT & COMP,SOUTHAMPTON,HANTS,ENGLAND	Imperial College London; Royal Brompton Hospital; University of Edinburgh; University of Southampton; University of Southampton			Lampe, Fiona/I-5826-2019; Robles-Sardin, Alma E/M-7714-2015	Lampe, Fiona/0000-0001-6851-5471; Robles-Sardin, Alma E/0000-0003-2044-7793	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		HOLMAN RT, 1956, P SOC EXP BIOL MED, V93, P175, DOI 10.3181/00379727-93-22699; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACINTYRE DE, 1984, BLOOD, V63, P848; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; MCLENNAN PL, 1988, AM HEART J, V116, P709, DOI 10.1016/0002-8703(88)90328-6; MCLENNAN PL, 1985, CAN J PHYSIOL PHARM, V63, P1411, DOI 10.1139/y85-232; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1991, EUR J CLIN NUTR, V45, P375; PRIVETT OS, 1955, ARCH BIOCHEM BIOPHYS, V57, P156, DOI 10.1016/0003-9861(55)90188-0; ROBERTS TL, 1993, BRIT HEART J, V70, P524; SARGENT CA, 1990, BIOCHEM SOC T, V18, P1077, DOI 10.1042/bst0181077; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P22, DOI 10.1136/jech.37.1.22; THOMAS LH, 1992, J EPIDEMIOL COMMUN H, V46, P78, DOI 10.1136/jech.46.1.78; THOMAS LH, 1981, AM J CLIN NUTR, V34, P877, DOI 10.1093/ajcn/34.5.877; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; THOMAS LH, 1981, J EPIDEMIOL COMMUNIT, V35, P252; VESTER I, 1991, P SCAND FORUM LIP RE, V1, P39; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD DA, 1987, LANCET, V1, P177; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD R, 1993, J LIPID RES, V34, P1; 1987, REPORT BRIT NUTRITIO	22	122	127	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					278	282		10.1016/S0140-6736(95)90274-0	http://dx.doi.org/10.1016/S0140-6736(95)90274-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837861				2022-12-01	WOS:A1995QE73100008
J	ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH				ROSSING, P; TARNOW, L; NIELSEN, FS; BOELSKIFTE, S; BRENNER, BM; PARVING, HH			SHORT STATURE AND DIABETIC NEPHROPATHY	BRITISH MEDICAL JOURNAL			English	Article							MICROALBUMINURIA; HYPERTENSION; HEIGHT		DANISH COMP CTR RES & EDUC,UNI C,DK-8200 AARHUS N,DENMARK; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	ROSSING, P (corresponding author), STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK.		rossing, peter/AAZ-3415-2021; rossing, peter/AAH-7879-2021	rossing, peter/0000-0002-1531-4294; Tarnow, Lise/0000-0002-8735-966X				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BRENNER BM, 1994, AM J KIDNEY DIS, V23, P171, DOI 10.1016/S0272-6386(12)80967-X; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156	5	64	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					296	297		10.1136/bmj.310.6975.296	http://dx.doi.org/10.1136/bmj.310.6975.296			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF717	7866171	Green Published			2022-12-01	WOS:A1995QF71700025
J	STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O				STUCKI, A; CORDEY, AS; MONAI, N; DEFLAUGERGUES, JC; SCHAPIRA, H; SPERTINI, O			CLEAVED L-SELECTIN CONCENTRATIONS IN MENINGEAL LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CEREBROSPINAL-FLUID; CHILDHOOD; RELAPSE; CELLS	Involvement of the central nervous system has important therapeutic implications in acute leukaemia. Because the identification of blast cells in cerebrospinal fluid (CSF) is often difficult, there is a need for sensitive markers of leukaemic infiltration. Since the shed form of L-selectin (sL-selectin) is frequently increased in acute leukaemia (sL-selectin(+) leukaemia), we examined whether assay of sL-selectin in CSF could improve our ability to detect such meningeal involvement. CSF sL-selectin was significantly (p<0.001) higher in 15 patients with sL-selectin(+) meningeal leukaemia (median 60 ng/ml, range 34-150) than in 20 patients with acute leukaemia without meningeal involvement (12 ng/mL, 1-39) or 88 control patients (14 ng/ml, 0-37). Serial measurements of sL-selectin in patients with sL-selectin(+) leukaemic meningitis showed increased CSF concentrations of the cleaved receptor in 4 patients with therapy-resistant meningeal leukaemia and sustained normal concentrations in 9 patients in remission. Our results suggest that CSF sL-selectin may be a useful marker in the detection of meningeal involvement by blast cells in patients with sL-selectin(+) leukaemia.	CHU VAUDOIS,DIV HAEMATOL,CH-1011 LAUSANNE,SWITZERLAND; CHU VAUDOIS,SERV NEUROL,CH-1011 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ADAMS DH, 1994, LANCET, V343, P831, DOI 10.1016/S0140-6736(94)92029-X; BENETT JM, 1985, ANN INTERN MED, V103, P620; BIGNER SH, 1981, ACTA CYTOL, V25, P335; BLEYER WA, 1988, PEDIATR CLIN N AM, V35, P789; DONELLY SC, 1994, LANCET, V344, P215; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; KOMADA Y, 1990, BLOOD, V76, P112; LASKY LA, 1992, SCIENCE, V258, P962; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; NIES BA, 1965, CANCER, V18, P546, DOI 10.1002/1097-0142(196505)18:5<546::AID-CNCR2820180503>3.0.CO;2-E; OCHS JJ, 1985, J CLIN ONCOL, V3, P622, DOI 10.1200/JCO.1985.3.5.622; ORTEGA JA, 1987, J CLIN ONCOL, V5, P1646, DOI 10.1200/JCO.1987.5.10.1646; PINKEL D, 1994, BLOOD, V84, P355, DOI 10.1182/blood.V84.2.355.bloodjournal842355; SAIKIA TK, 1993, AM J HEMATOL, V43, P10, DOI 10.1002/ajh.2830430104; SPERTINI O, 1994, BLOOD, V84, P1249, DOI 10.1182/blood.V84.4.1249.bloodjournal8441249; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	17	30	32	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					286	289		10.1016/S0140-6736(95)90276-7	http://dx.doi.org/10.1016/S0140-6736(95)90276-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530792				2022-12-01	WOS:A1995QE73100010
J	TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G				TADDIO, A; GOLDBACH, M; IPP, M; STEVENS, B; KOREN, G			EFFECT OF NEONATAL CIRCUMCISION ON PAIN RESPONSES DURING VACCINATION IN BOYS	LANCET			English	Note							STRESS; SLEEP	Using date from one of our randomised trials, we investigated post-hoc whether male neonatal circumcision is associated with a greater pain response to routine vaccination at 4 or 6 months. Pain response during routine vaccination with diphtheria-pertussis-tetanus (DPT) alone or DPT followed by Haemophilus influenzae type b conjugate (HIB) was scored blind. 42 boys received DPT acid 18 also received HIB. After DPT, median visual analogue scores by an observer were higher in the circumcised group (40 vs 26 mm. p=0.03) After HIB, circumcised infants had higher behavioural pain scores (8 vs 6, p=0.01) and cried longer (53 vs 19 s, p=0.02). Thus neonatal circumcision may affect pain response several months after the event.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANDERS TF, 1974, PSYCHOSOM MED, V36, P174, DOI 10.1097/00006842-197403000-00009; BRACKBILL Y, 1975, CHILD DEV, V46, P364; DIXON S, 1984, J DEV BEHAV PEDIATR, V5, P246; EMDE RN, 1971, PSYCHOSOM MED, V33, P491, DOI 10.1097/00006842-197111000-00002; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MARSHALL RE, 1982, EARLY HUM DEV, V7, P367, DOI 10.1016/0378-3782(82)90038-X; TADDIO A, 1994, J PEDIATR-US, V124, P643, DOI 10.1016/S0022-3476(05)83150-6; ZELTZER LK, 1992, PEDIATRICS, V90, P816	9	282	285	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					291	292		10.1016/S0140-6736(95)90278-3	http://dx.doi.org/10.1016/S0140-6736(95)90278-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE731	7837863				2022-12-01	WOS:A1995QE73100012
J	TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J				TAYLOR, A; GOLDBERG, D; EMSLIE, J; WRENCH, J; GRUER, L; CAMERON, S; BLACK, J; DAVIS, B; MCGREGOR, J; FOLLETT, E; HARVEY, J; BASSON, J; MCGAVIGAN, J			OUTBREAK OF HIV-INFECTION IN A SCOTTISH PRISON	BRITISH MEDICAL JOURNAL			English	Article							INJECTING DRUG-USERS; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; INMATES; AIDS; SEROPOSITIVITY; SURVEILLANCE	Objectives-To investigate the possible spread of HIV infection and its route of transmission among prison inmates. Design-In response to an outbreak of acute clinical hepatitis B and two seroconversions to HIV infection, counselling and testing for HIV were offered to all inmates over a two week period in July 1993. Information was sought about drug injecting, sexual behaviour, and previous HIV testing. Setting-HM Prison Glenochil in Scotland. Subjects-Adult male prisoners. Main outcome measures-Uptake of HIV counselling and testing; occurrence and mode of HIV transmission within the prison. Results-Of a total 378 inmates, 227 (60%) were counselled and 162 (43%) tested for HIV. Twelve (7%) of those tested were positive for antibody to HIV. One third (76) of those counselled had injected drugs at some time, of whom 33 (43%) had injected in Glenochil; all 12 seropositive men belonged to this latter group. Thirty two of these 33 had shared needles and syringes in the prison. A further two inmates who injected in the prison were diagnosed as positive for HIV two months previously. Evidence based on sequential results and time of entry into prison indicated that eight transmissions definitely occurred within prison in the first half of 1993. Conclusion-This is the first report of an outbreak of HIV infection occurring within a prison. Restricted access to injecting equipment resulted in random sharing and placed injectors at high risk of becoming infected with HIV. Measures to prevent further spread of infection among prison injectors are urgently required.	FORTH VALLEY HLTH BOARD,STIRLING FK8 1DX,SCOTLAND; RUCHILL HOSP,HIV & ADDICT RESOURCE CTR,GLASGOW,LANARK,SCOTLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; RUCHILL HOSP,HIV & ADDICT CLIN DIRECTORATE,HIV COUNSELING CLIN,GLASGOW,LANARK,SCOTLAND; HLTH CTR,ALLOA FK10 1AB,CLACK,SCOTLAND; FALKIRK & DIST ROYAL INFIRM,FORTH VALLEY HLTH BOARD,FALKIRK FK1 5QE,SCOTLAND; ROYAL INFIRM,STIRLING FK8 2AU,SCOTLAND; SCOTTISH HOME & HLTH DEPT,EDINBURGH EH1 3DE,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh	TAYLOR, A (corresponding author), RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND.			Gruer, Laurence/0000-0002-1089-2896				BIRD AG, 1993, BRIT MED J, V307, P228, DOI 10.1136/bmj.307.6898.228; BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383; CASTRO K, 1991, 7 INT C AIDS FLOR 16, P314; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; CONTORREGI C, 1993, 9TH INT C AIDS BERL; COVELL RG, 1993, DRUG ALCOHOL DEPEN, V32, P9, DOI 10.1016/0376-8716(93)90017-K; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; DOLAN K, 1994, 5TH P INT C RED DRUG; DOLAN K, 1992, 8TH INT C AIDS AMST; DYE S, 1991, BRIT MED J, V302, P1506, DOI 10.1136/bmj.302.6791.1506; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; GELLERT GA, 1993, AM J PUBLIC HEALTH, V83, P1454, DOI 10.2105/AJPH.83.10.1454; GREEN ST, 1991, ANSWER SCOTTISH CTR; Hankins C, 1991, Can Dis Wkly Rep, V17, P233; HARDING TW, 1987, LANCET, V2, P1260; HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209; KALL KI, 1990, AIDS, V4, P153, DOI 10.1097/00002030-199002000-00009; KENNEDY D, 1991, BRIT MED J, V312, P1507; MARTIN V, 1990, AIDS, V4, P1023, DOI 10.1097/00002030-199010000-00013; MCKEE KJ, 1992, SCOT MED J, V37, P132, DOI 10.1177/003693309203700502; NAIK TN, 1991, AIDS, V5, P117, DOI 10.1097/00002030-199101000-00026; POWER KG, 1992, BRIT J ADDICT, V87, P35; RICHARDSON C, 1993, AIDS, V7, P1485, DOI 10.1097/00002030-199311000-00013; TAYLOR A, 1994, INT J STD AIDS, V5, P105, DOI 10.1177/095646249400500205; TAYLOR A, 1993, BRIT MED J, V307, P623, DOI 10.1136/bmj.307.6904.623; Turnbull P. J., 1991, PRISON HIV AIDS RISK; VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129; 1989, MMWR-MORBID MORTAL W, V38, P1	30	172	174	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 4	1995	310	6975					289	292		10.1136/bmj.310.6975.289	http://dx.doi.org/10.1136/bmj.310.6975.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QF717	7866169	Green Published			2022-12-01	WOS:A1995QF71700023
J	ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B				ZANETTI, AR; TANZI, E; PACCAGNINI, S; PRINCIPI, N; PIZZOCOLO, G; CACCAMO, ML; DAMICO, E; CAMBIE, G; VECCHI, L; BRESCIANI, S; MARIN, MG; PADULA, D; RODELLA, A; BULGARELLI, I; CHIODO, F; MAGLIANO, E; MIOTTO, G; MUGGIASCA, ML; PILLOTON, E; POZZOLI, R; PREGLIASCO, F; ROMANO, L; STRINGHI, C; DAGOSTINO, F; PAOLILLO, F; ZAPPAROLI, B			MOTHER-TO-INFANT TRANSMISSION OF HEPATITIS-C VIRUS	LANCET			English	Note							VERTICAL TRANSMISSION	To assess the risk of mother-to-infant transmission of hepatitis C virus (HCV), we followed up 116 babies of anti-HCV positive mothers, of whom 22 were coinfected with HIV and 94 had HCV alone. None of the babies whose mothers had HCV alone required HCV, while 8 babies (36%; p<0.001) of mothers co-infected with HIV acquired HCV (5 babies) or HCV and HIV (3). There was no association between any specific maternal HCV genotype and enhanced risk of neonatal infection. HCV-RNA levels were significantly higher (p<0.05) in mothers with HIV coinfection than in those with HCV alone. These data indicate that maternal HIV status correlates with enhanced level of viraemia which favours neonatal infection.	UNIV MILAN,DEPT PAEDIAT 4,I-20133 MILAN,ITALY; UNIV BRESCIA,SCH MED,INST CHEM,BRESCIA,ITALY; UNIV MILAN,HOSP L MANGIAGALLI,DEPT OBSTET & GYNAECOL,MILAN,ITALY; HOSP NIGUARDA CA GRANDA,DEPT PAEDIAT,MILAN,ITALY; HOSP MAGGIORE,CTR BLOOD TRANSFUS,LODI,ITALY; HOSP S GERARDO,CLIN PATHOL LAB,MONZA,ITALY	University of Milan; University of Brescia; University of Milan	ZANETTI, AR (corresponding author), UNIV MILAN,INST VIROL,VIA C PASCAL 38,I-20133 MILAN,ITALY.		pregliasco, fabrizio/AAD-7499-2022; Pregliasco, Fabrizio Ernesto/D-1642-2012	Pregliasco, Fabrizio Ernesto/0000-0002-3919-0679				KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LAM JPH, 1993, J INFECT DIS, V167, P572, DOI 10.1093/infdis/167.3.572; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; PUOTI M, 1992, HEPATOLOGY, V4, P877; REINUS JF, 1992, ANN INTERN MED, V117, P881, DOI 10.7326/0003-4819-117-11-881; ROMANO L, 1994, INFECTION, V22, P350, DOI 10.1007/BF01715545; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; WEINTRUB PS, 1991, J PEDIATR-US, V119, P869, DOI 10.1016/S0022-3476(05)83035-5; Wejstal R, 1992, ANN INTERN MED, V117, P887, DOI 10.7326/0003-4819-117-11-887; 1992, MMWR-MORBID MORTAL W, V41, P1	10	315	323	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					289	291		10.1016/S0140-6736(95)90277-5	http://dx.doi.org/10.1016/S0140-6736(95)90277-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7530793				2022-12-01	WOS:A1995QE73100011
J	DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM				DEKOK, YJM; VANDERMAAREL, SM; BITNERGLINDZICZ, M; HUBER, I; MONACO, AP; MALCOLM, S; PEMBREY, ME; ROPERS, HH; CREMERS, FPM			ASSOCIATION BETWEEN X-LINKED MIXED DEAFNESS AND MUTATIONS IN THE POU DOMAIN GENE POU3F4	SCIENCE			English	Article							PERILYMPHATIC GUSHER; STAPES SURGERY; EXPRESSION; CHOROIDEREMIA; LINKAGE; COMPLEX; BRAIN; XQ21	Deafness with fixation of the stapes (DFN3) is the most frequent X-linked form of hearing impairment. The underlying gene has been localized to a 500-kilobase segment of the Xq21 band. Here, it is reported that a candidate gene for this disorder, Brain 4 (POU3F4), which encodes a transcription factor with a POU domain, maps to the same interval. In five unrelated patients with DFN3 but not in 50 normal controls, small mutations were found that result in truncation of the predicted protein or in nonconservative amino acid substitutions. These findings indicate that POU3F4 mutations are a molecular cause of DFN3.	UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS; UNIV LONDON, INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, OXFORD OX3 9DU, ENGLAND	Radboud University Nijmegen; University of London; University College London; University of Oxford			Cremers, Frans/A-5625-2014; Bitner-Glindzicz, Maria/A-4231-2009; Monaco, Anthony P/A-4495-2010	Cremers, Frans/0000-0002-4954-5592; Monaco, Anthony P/0000-0001-7480-3197; van der Maarel, Silvere/0000-0001-8103-711X				BACH I, 1992, AM J HUM GENET, V51, P38; BACH I, 1992, HUM GENET, V89, P620; Bergstrom L, 1971, Otolaryngol Clin North Am, V4, P369; BITNERGLINDZICZ M, 1994, J MED GENET, V31, P916, DOI 10.1136/jmg.31.12.916; BRUNNER HG, 1988, HUM GENET, V80, P337, DOI 10.1007/BF00273647; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; COUCKE P, 1994, NEW ENGL J MED, V331, P425, DOI 10.1056/NEJM199408183310702; CREMERS CWRJ, 1985, ARCH OTOLARYNGOL, V111, P249; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1989, GENOMICS, V4, P41, DOI 10.1016/0888-7543(89)90312-1; DEKOK YJM, UNPUB; DOUVILLE PJ, 1994, MAMM GENOME, V5, P180, DOI 10.1007/BF00352353; FRIEDMAN TB, 1994, AM J HUM GENET, V55; GLASSCOC.ME, 1973, ARCH OTOLARYNGOL, V98, P82; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HUBER I, 1994, HUM MOL GENET, V3, P1151, DOI 10.1093/hmg/3.7.1151; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LALWANI AK, 1993, AM J HUM GENET, V53, P1027; LEMOINE C, 1992, P NATL ACAD SCI USA, V89, P3285, DOI 10.1073/pnas.89.8.3285; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; OKAMOTO K, 1993, J BIOL CHEM, V268, P7449; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PHELPS PD, 1991, NEURORADIOLOGY, V33, P326, DOI 10.1007/BF00587816; PIUSSAN C, IN PRESS AM J HUM GE; REARDON W, 1991, GENOMICS, V11, P885, DOI 10.1016/0888-7543(91)90011-3; RYAN AF, 1991, ANN NY ACAD SCI, V630, P129, DOI 10.1111/j.1749-6632.1991.tb19581.x; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SHAVERARNOS K, COMMUNICATION; THORPE P, 1974, S AFR MED J, V48, P587; WALLIS C, 1988, GENOMICS, V3, P299, DOI 10.1016/0888-7543(88)90119-X	37	318	328	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					685	688		10.1126/science.7839145	http://dx.doi.org/10.1126/science.7839145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839145	Green Submitted			2022-12-01	WOS:A1995QE73300040
J	DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ				DERIJARD, B; RAINGEAUD, J; BARRETT, T; WU, IH; HAN, JH; ULEVITCH, RJ; DAVIS, RJ			INDEPENDENT HUMAN MAP KINASE SIGNAL-TRANSDUCTION PATHWAYS DEFINED BY MEK AND MKK ISOFORMS	SCIENCE			English	Article							PROTEIN-KINASE; CLONING; YEAST	Mammalian mitogen-activated protein (MAP) kinases include extracellular signal-regulated protein kinase (ERK), c-Jun amino-terminal kinase (JNK), and p38 subgroups. These MAP kinase isoforms are activated by dual phosphorylation on threonine and tyrosine. Two human MAP kinase kinases (MKK3 and MKK4) were cloned that phosphorylate and activate p38 MAP kinase. These MKK isoforms did not activate the ERK subgroup of MAP kinases, but MKK4 did activate JNK. These data demonstrate that the activators of p38 (MKK3 and MKK4), JNK (MKK4), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Scripps Research Institute			Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010		NCI NIH HHS [CA58396] Funding Source: Medline; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, UNPUB; DRESSLER H, 1992, BIOTECHNIQUES, V13, P866; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V389; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; RAINGEAUD J, UNPUB; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	31	1397	1441	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					682	685		10.1126/science.7839144	http://dx.doi.org/10.1126/science.7839144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839144				2022-12-01	WOS:A1995QE73300039
J	FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J				FRAGNETO, G; THOMAS, RK; RENNIE, AR; PENFOLD, J			NEUTRON REFLECTION STUDY OF BOVINE BETA-CASEIN ADSORBED ON OTS SELF-ASSEMBLED MONOLAYERS	SCIENCE			English	Article							AQUEOUS PERMANGANATE INTERACTION; PENETRATION-CONTROLLED REACTIONS; LANGMUIR-BLODGETT MONOLAYERS; SILICA WATER INTERFACE; LONG-CHAIN SURFACTANTS; PROTEIN ADSORPTION; POLYSTYRENE LATEX; SPECULAR REFLECTION; ORGANIC MONOLAYERS; SERUM-ALBUMIN	Specular neutron reflection has been used to determine the structure and composition of bovine beta-casein adsorbed on a solid surface from an aqueous phosphate-buffered solution at pH 7. The protein was adsorbed on a hydrophobic monolayer self-assembled from deuterated octadecyltrichlorosilane solution on a silicon (111) surface. A two-layer structure formed consisting of one dense layer of thickness 23 +/- 1 angstroms and a surface coverage of 1.9 milligrams per square meter adjacent to the surface and an external layer protruding into the solution of thickness 35 +/- 1 angstroms and 12 percent protein volume fraction. The structure of the (beta-casein) layer is explained in terms of the charge distribution in the protein.	UNIV CAMBRIDGE,CAVENDISH LAB,CAMBRIDGE CB3 OHE,ENGLAND; UNIV OXFORD,PHYS CHEM LAB,OXFORD OX1 3QZ,ENGLAND; RUTHERFORD APPLETON LAB,DIDCOT OX11 0QX,OXON,ENGLAND	University of Cambridge; University of Oxford; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory								BENJAMINS J, 1975, FARADAY DISCUSS, V59, P218, DOI 10.1039/dc9755900218; BORETOS JW, 1980, SYNTHETIC BIOMEDICAL, P187; BRASH JL, 1985, MAKROMOL CHEM S, V9, P69; BROOKSBANK DV, 1993, J CHEM SOC FARADAY T, V89, P3419, DOI 10.1039/ft9938903419; CALDWELL KD, 1992, J CHROMATOGR, V604, P63, DOI 10.1016/0021-9673(92)85529-3; CARLES C, 1988, FEBS LETT, V229, P265, DOI 10.1016/0014-5793(88)81138-4; CUYPERS PA, 1978, ANAL BIOCHEM, V84, P56, DOI 10.1016/0003-2697(78)90483-9; DICKINSON E, 1993, LANGMUIR, V9, P242, DOI 10.1021/la00025a046; DILLMAN WJ, 1973, J COLLOID INTERF SCI, V44, P221, DOI 10.1016/0021-9797(73)90215-4; FAIR BD, 1980, J COLLOID INTERF SCI, V77, P525, DOI 10.1016/0021-9797(80)90325-2; Feijter J. A. D., 1978, BIOPOLYMERS, V17, P1759; FRAGNETO G, UNPUB; GAN CS, 1994, J COLLOID INTERF SCI, V162, P214; GRAHAM DE, 1979, J COLLOID INTERF SCI, V70, P415, DOI 10.1016/0021-9797(79)90049-3; GUN J, 1984, J COLLOID INTERF SCI, V101, P201, DOI 10.1016/0021-9797(84)90020-1; Heavens O., 1955, OPTICAL PROPERTIES T; HENCKEVORT HJ, 1984, J COLLOID INTERF SCI, V98, P138; Horbett T. A., 2019, HYDROGELS MED PHARM, P127; IVARSSON B, 1986, CRIT REV BIOCOMPAT, V2, P1; JENNISSEN HP, 1989, BER BUNSEN PHYS CHEM, V93, P948, DOI 10.1002/bbpc.19890930905; JONSSON U, 1985, J COLLOID INTERF SCI, V103, P60; KERN W, 1990, J ELECTROCHEM SOC, V137, P1887, DOI 10.1149/1.2086825; LEE EM, 1989, CHEM PHYS LETT, V162, P196, DOI 10.1016/0009-2614(89)85124-3; LEE EM, 1990, EUROPHYS LETT, V13, P135, DOI 10.1209/0295-5075/13/2/007; MACKIE AR, 1991, J CHEM SOC FARADAY T, V87, P3043, DOI 10.1039/ft9918703043; MAOZ R, 1987, LANGMUIR, V3, P1045, DOI 10.1021/la00078a028; MAOZ R, 1987, LANGMUIR, V3, P1034, DOI 10.1021/la00078a027; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; MATRITCHIE F, 1972, J COLLOID INTERF SCI, V38, P484; MCDERMOTT DB, UNPUB; MCDERMOTT DC, 1994, J COLLOID INTERF SCI, V162, P304, DOI 10.1006/jcis.1994.1043; MCDERMOTT DC, 1992, LANGMUIR, V8, P1204, DOI 10.1021/la00040a031; MIZUTANI T, 1985, J LIQ CHROMATOGR, V8, P925, DOI 10.1080/01483918508067122; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; NETZER L, 1983, THIN SOLID FILMS, V99, P235, DOI 10.1016/0040-6090(83)90386-3; NETZER L, 1983, THIN SOLID FILMS, V100, P67, DOI 10.1016/0040-6090(83)90230-4; NORDE W, 1978, J COLLOID INTERF SCI, V66, P257, DOI 10.1016/0021-9797(78)90303-X; NYLANDER T, 1994, J COLLOID INTERF SCI, V162, P151, DOI 10.1006/jcis.1994.1020; PENFOLD J, 1990, J PHYS-CONDENS MAT, V2, P1369, DOI 10.1088/0953-8984/2/6/001; PORATH J, 1987, BIOTECHNOL PROGR, V3, P14, DOI 10.1002/btpr.5420030104; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; PRIME KL, 1991, SCIENCE, V252, P1164, DOI 10.1126/science.252.5009.1164; RENNIE AR, 1990, LANGMUIR, V6, P1031, DOI 10.1021/la00095a025; SAGIV J, 1980, J AM CHEM SOC, V102, P92, DOI 10.1021/ja00521a016; SCHMIDT DG, 1972, J COLLOID INTERF SCI, V39, P655, DOI 10.1016/0021-9797(72)90073-2; SEARS VF, 1993, NEUTRON NEWS, V3, P26; SEVASTIANOV VI, 1988, CRIT REV BIOCOMPAT, V4, P109; SODERQUIST ME, 1980, J COLLOID INTERF SCI, V75, P386, DOI 10.1016/0021-9797(80)90463-4; SUZAWA T, 1982, J COLLOID INTERF SCI, V86, P144, DOI 10.1016/0021-9797(82)90049-2; TIDSWELL IM, 1990, PHYS REV B, V41, P1111, DOI 10.1103/PhysRevB.41.1111; WATANABE N, 1986, COLLOID POLYM SCI, V264, P903, DOI 10.1007/BF01410642; WEAST RC, 1973, HDB CHEM PHYSICS B; WEAST RC, 1973, HDB CHEM PHYSICS C; WU XZ, 1993, PHYS REV LETT, V70, P958, DOI 10.1103/PhysRevLett.70.958	54	136	137	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					657	660		10.1126/science.7839141	http://dx.doi.org/10.1126/science.7839141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839141				2022-12-01	WOS:A1995QE73300032
J	ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M				ILLANGASEKARE, M; SANCHEZ, G; NICKLES, T; YARUS, M			AMINOACYL-RNA SYNTHESIS CATALYZED BY AN RNA	SCIENCE			English	Article							NUCLEOTIDES; TETRAHYMENA; POLYMERASE; BINDING	An RNA has been selected that rapidly aminoacylates its 2'(3') terminus when provided with phenylalanyl-adenosine monophosphate. That is, the RNA accelerates the same aminoacyl group transfer catalyzed by protein aminoacyl-transfer RNA synthetases. The best characterized RNA reaction requires both Mg2+ and Ca2+. These results confirm a necessary prediction of the RNA world hypothesis and represent efficient RNA reaction (greater than or equal to 10(5) times accelerated) at a carbonyl carbon, exemplifying a little explored type of RNA catalysis.			ILLANGASEKARE, M (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.		Yarus, Michael/Q-9813-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030881, R37GM030881, R01GM048080] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30881, GM48080] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BERG P, 1958, J BIOL CHEM, V233, P608; BROWN EA, 1980, ACTA CRYSTALLOGR B, V36, P2597, DOI 10.1107/S0567740880009508; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GILLAM I, 1968, BIOCHEMISTRY-US, V7, P3459, DOI 10.1021/bi00850a022; GOTTIKH BP, 1970, TETRAHEDRON, V26, P4419, DOI 10.1016/S0040-4020(01)93090-X; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCLAUGHLIN CS, 1965, BIOCHEMISTRY-US, V4, P1442, DOI 10.1021/bi00883a032; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEBER AL, 1975, J MOL EVOL, V6, P309, DOI 10.1007/BF01794637; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; WICKRAMASINGHE NSMD, 1991, BIOCHEMISTRY-US, V30, P2768, DOI 10.1021/bi00225a005; WOLFENDEN R, 1964, BIOCHEMISTRY-US, V3, P329, DOI 10.1021/bi00891a006; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205	28	269	286	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					643	647		10.1126/science.7530860	http://dx.doi.org/10.1126/science.7530860			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7530860				2022-12-01	WOS:A1995QE73300028
J	JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O				JOHN, SWM; KREGE, JH; OLIVER, PM; HAGAMAN, JR; HODGIN, JB; PANG, SC; FLYNN, TG; SMITHIES, O			GENETIC DECREASES IN ATRIAL-NATRIURETIC-PEPTIDE AND SALT-SENSITIVE HYPERTENSION	SCIENCE			English	Article							SODIUM-EXCRETION; LOCUS; RATS; POLYMORPHISM; ATRIOPEPTIN; DISRUPTION; RENIN; CELLS; HPND; SITE	To determine if defects in the atrial natriuretic peptide (ANP) system can cause hypertension, mice were generated with a disruption of the proANP gene. Homozygous mutants had no circulating or atrial ANP, and their blood pressures were elevated by 8 to 23 millimeters of mercury when they were fed standard (0.5 percent sodium chloride) and intermediate (2 percent sodium chloride) salt diets. On standard salt diets, heterozygotes had normal amounts of circulating ANP and normal blood pressures. However, on high (8 percent sodium chloride) salt diets they were hypertensive, with blood pressures elevated by 27 millimeters of mercury. These results demonstrate that genetically reduced production of ANP can lead to salt-sensitive hypertension.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599; QUEENS UNIV,DEPT ANAT & CELL BIOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Queens University - Canada; Queens University - Canada					NHLBI NIH HHS [HL49277] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020069, R37GM020069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLERMANN BJ, 1991, KIDNEY, pCH14; BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BLAINE EH, 1990, HYPERTENSION, V15, P2036; FERRARI P, 1990, J CLIN ENDOCR METAB, V71, P944, DOI 10.1210/jcem-71-4-944; GARCIA R, 1982, EXPERIENTIA, V38, P1071, DOI 10.1007/BF01955373; GOETZ KL, 1990, HYPERTENSION, V15, P9, DOI 10.1161/01.HYP.15.1.9; GRANGER JP, 1986, HYPERTENSION, V8, P112; GREENWALD JE, 1988, J CLIN INVEST, V81, P1036, DOI 10.1172/JCI113414; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHN S., COMMUNICATION; KREGE JH, IN PRESS HYPERTENSIO; LARAGH JH, 1990, HYPERTENSION PATHOPH, V1; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRIS BJ, 1993, CLIN SCI, V85, P189, DOI 10.1042/cs0850189; NARUSE M, 1985, BIOCHEM BIOPH RES CO, V132, P954, DOI 10.1016/0006-291X(85)91900-X; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8696, DOI 10.1093/nar/14.21.8696; NEMER M, 1986, NUCLEIC ACIDS RES, V14, P8697, DOI 10.1093/nar/14.21.8697; PANG SC, 1986, J HYPERTENS, V4, pS119; RAMASAWMY R, 1993, HUM GENET, V91, P509; RAMASAWMY R, 1994, HUM GENET, V93, P355, DOI 10.1007/BF00212041; RAMASAWMY R, 1992, HUM GENET, V90, P323; RICHARDS AM, 1988, J CLIN ENDOCR METAB, V66, P465, DOI 10.1210/jcem-66-3-465; SARDA IR, 1989, CLIN BIOCHEM, V22, P11, DOI 10.1016/S0009-9120(89)80063-3; SHEHEE WR, 1993, P NATL ACAD SCI USA, V90, P3177, DOI 10.1073/pnas.90.8.3177; VENANCE SL, 1989, HISTOL HISTOPATHOL, V4, P325; WEIDMANN P, 1991, CAN J PHYSIOL PHARM, V69, P1582, DOI 10.1139/y91-235; 1988, BRIT MED J, V297, P319	27	506	523	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					679	681		10.1126/science.7839143	http://dx.doi.org/10.1126/science.7839143			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839143				2022-12-01	WOS:A1995QE73300038
J	LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN				LILLY, B; ZHAO, B; RANGANAYAKULU, G; PATERSON, BM; SCHULZ, RA; OLSON, EN			REQUIREMENT OF MADS DOMAIN TRANSCRIPTION FACTOR D-MEF2 FOR MUSCLE FORMATION IN DROSOPHILA	SCIENCE			English	Article							ENHANCER-BINDING-FACTOR; FACTOR MEF-2; GENE; EXPRESSION; PROTEINS; ENCODES; MEMBER; FAMILY; EMBRYOGENESIS; TRANSPOSITION	Members of the myocyte enhancer binding factor-2 (MEF2) family of MADS (MCM1, agamous, deficiens, and serum response factor) box transcription factors are expressed in the skeletal, cardiac, and smooth muscle lineages of vertebrate and Drosophila embryos. These factors bind an adenine-thymidine-rich DNA sequence associated with muscle-specific genes. The function of MEF2 was determined by generating a loss-of-function of the single mef2 gene in Drosophila (D-mef2). In loss-of-function embryos, somatic, cardiac, and visceral muscle cells did not differentiate, but myoblasts were normally specified and positioned. These results demonstrate that different muscle cell types share a common myogenic differentiation program controlled by MEF2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; NCI,BIOCHEM LAB,BETHESDA,MD 20892	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			LILLY, BRENDA/N-6867-2015	LILLY, BRENDA/0000-0002-3125-7496				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BATE M, 1993, DEV DROSOPHILA MELAN, V3, P1013; BODMER R, 1993, DEVELOPMENT, V118, P719; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS R, COMMUNICATION; DOHRMANN C, 1990, GENE DEV, V4, P2098, DOI 10.1101/gad.4.12a.2098; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, THESIS U TEXAS HOUST; Martin J., UNPUB; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, UNPUB; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; TOWER J, 1993, GENETICS, V133, P347; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WRIGHT WE, 1993, CURR OPIN GENET DEV, V2, P243; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHANG P, 1993, GENETICS, V133, P361	46	412	426	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					688	693		10.1126/science.7839146	http://dx.doi.org/10.1126/science.7839146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839146				2022-12-01	WOS:A1995QE73300041
J	LYONS, JR				LYONS, JR			METAL-IONS IN THE ATMOSPHERE OF NEPTUNE	SCIENCE			English	Article							PLANETARY-ATMOSPHERES; INTERSTELLAR CLOUDS; POSITIVE-IONS; VOYAGER-2; LAYERS; IONOSPHERE; MESOSPHERE; CATIONS	Microwave propagation experiments performed with Voyager 2 at Neptune revealed sharp layers of electrons in Neptune's lower ionosphere with densities of similar to 10(4) per cubic centimeter. These layers are reminiscent of the sporadic-E layers in the Earth's ionosphere, and when taken together with data from the other giant planets, these data confirm the importance of the magnetic field in layer formation, A photochemical model that incorporates species produced by meteoroid ablation predicts that singly ionized magnesium is the most likely metal to be found in the layers, although laboratory data on the kinetics of metallic atoms and ions in a reducing environment are lacking. The metal chemistry discussed here is directly relevant to the abundant metals observed at the impact site of the G fragment of comet Shoemaker Levy 9 on Jupiter.			LYONS, JR (corresponding author), CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA.							ALLEN M, 1981, J GEOPHYS RES-SPACE, V86, P3617, DOI 10.1029/JA086iA05p03617; ANICICH VG, 1993, J PHYS CHEM REF DATA, V22, P1469, DOI 10.1063/1.555940; ATREYE SK, 1986, ATMOSPHERES IONOSPHE; BARTH CA, 1992, MARS, P1054; BAUSCHLICHER CW, 1990, INT REV PHYS CHEM, V9, P149, DOI 10.1080/01442359009353245; BRACE LH, 1991, SPACE SCI REV, V55, P81, DOI 10.1007/BF00177136; BRISTOW WA, 1991, GEOPHYS RES LETT, V18, P404, DOI 10.1029/90GL02588; CANOSA A, 1992, J CHEM PHYS, V97, P1028, DOI 10.1063/1.463282; CHEN RH, 1981, J GEOPHYS RES-SPACE, V86, P7792, DOI 10.1029/JA086iA09p07792; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1991, J GEOPHYS RES-PLANET, V96, P19023, DOI 10.1029/91JA01165; FERGUSON EE, 1968, J GEOPHYS RES, V73, P6215, DOI 10.1029/JA073i019p06215; FJELDBO G, 1965, J GEOPHYS RES, V70, P3701, DOI 10.1029/JZ070i015p03701; HAIL GA, IN PRESS INT J IMAGI; HUNTEN DM, 1980, J ATMOS SCI, V37, P1342, DOI 10.1175/1520-0469(1980)037<1342:SADPOM>2.0.CO;2; HUNTRESS WT, 1977, ASTROPHYS J SUPPL S, V33, P495, DOI 10.1086/190439; JESSBERGER EK, 1991, ASTROPHYS SPACE SC L, V167, P1075, DOI 10.1017/S0252921100012823; Kelley, 2020, PHONETICSJL; KIM YH, 1991, GEOPHYS RES LETT, V18, P123, DOI 10.1029/90GL02587; KIRKWOOD S, 1989, J ATMOS TERR PHYS, V51, P259, DOI 10.1016/0021-9169(89)90077-9; LINDAL GF, 1992, ASTRON J, V103, P967, DOI 10.1086/116119; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lyons J. L., UNPUB; MAJEED T, 1991, PLANET SPACE SCI, V39, P1715, DOI 10.1016/0032-0633(91)90031-5; MOSES JI, 1992, ICARUS, V99, P368, DOI 10.1016/0019-1035(92)90153-X; NOLL K, 1994, 6038 INT ASTR UN CIR; OHANESSIAN G, 1990, ACCOUNTS CHEM RES, V23, P386, DOI 10.1021/ar00179a007; ROMANL PN, 1994, ICARUS, V106, P442; ROQUES F, 1994, ASTRON ASTROPHYS, V288, P985; SICARDY B, 1992, B AM ASTRON SOC, V24, P963; STONE EC, 1989, SCIENCE, V246, P1417, DOI 10.1126/science.246.4936.1417; STROBEL DF, 1991, URANUS, P65; TYLER GL, 1989, SCIENCE, V246, P1466, DOI 10.1126/science.246.4936.1466; WEAST RC, 1986, CRC HDB CHEM PHYSICS, pF167; WHITEHEAD J, 1961, J ATMOS TERR PHYS, V20, P49, DOI 10.1016/0021-9169(61)90097-6	35	46	46	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					648	651						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839139				2022-12-01	WOS:A1995QE73300029
J	PAUL, WE				PAUL, WE			REEXAMINING AIDS RESEARCH PRIORITIES	SCIENCE			English	Editorial Material							MECHANISM; INFECTION; VACCINE; CELLS; GENE; HIV				PAUL, WE (corresponding author), NIH, OFF AIDS RES, BETHESDA, MD 20892 USA.							BABA TW, IN PRESS SCIENCE; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; CAO Y, IN PRESS N ENGL J ME; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CZERKINSKY C, 1993, CLIN INFECT DIS, V16, pS106, DOI 10.1093/clinids/16.Supplement_2.S106; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIELDS BN, 1994, NATURE, V369, P95, DOI 10.1038/369095a0; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLUGMAN KP, 1987, LANCET, V2, P1165; LAZARO I, 1994, J VIROL, V68, P6535, DOI 10.1128/JVI.68.10.6535-6546.1994; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MERSON MH, 1994, INT C AIDS, V10, P4; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; PANTALEO G, IN PRESS N ENGL J ME; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PLUMMER FA, 1993, INT C AIDS, V9, P23; ROMAGNANI S, 1994, AIDS RES HUM RETROV, V10, pR3, DOI 10.1089/aid.1994.10.iii; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; UMLAUF SW, 1993, IMMUNOL REV, V133, P177, DOI 10.1111/j.1600-065X.1993.tb01516.x; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WINKELSTEIN WJ, 1993, INT C AIDS, V9, P88; 1994, HIV AIDS SURVEILLANC, V6, P1	29	31	34	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					633	636		10.1126/science.7839138	http://dx.doi.org/10.1126/science.7839138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839138				2022-12-01	WOS:A1995QE73300025
J	STOOP, R; POO, MM				STOOP, R; POO, MM			POTENTIATION OF TRANSMITTER RELEASE BY CILIARY NEUROTROPHIC FACTOR REQUIRES SOMATIC SIGNALING	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; SPINAL-CORD NEURONS; NEUROMUSCULAR SYNAPSES; SYMPATHETIC NEURONS; RECEPTOR COMPONENT; SCIATIC-NERVE; FACTOR CNTF; ADULT-RAT; CULTURE; EXPRESSION	Neurotrophic factors participate in the development and maintenance of the nervous system. Application of ciliary neurotrophic factor (CNTF), a protein that promotes survival of motor neurons, resulted in an immediate potentiation of spontaneous and impulse-evoked transmitter release at developing neuromuscular synapses in Xenopus cell cultures. When CNTF was applied al the synapse, the onset of the potentiation was slower than that produced by application at the cell body of the presynaptic neuron. The potentiation effect was abolished when-the neurite shaft was severed from the cell body. Thus, transmitter secretion from the nerve terminals is under immediate somatic control and can be regulated by CNTF.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University								ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALLEN RD, 1982, SCIENCE, V218, P1127, DOI 10.1126/science.6183744; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLAIR LAC, 1983, J NEUROSCI, V3, P1430; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; COHEN MW, 1987, J NEUROSCI, V7, P2849; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; EVERS J, 1989, J NEUROSCI, V9, P1523; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GRAFI G, 1993, FEBS LETT, V336, P403, DOI 10.1016/0014-5793(93)80846-M; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Jessell T., 1991, PRINCIPLES NEURAL SC; KALBERG C, 1993, J NEUROCHEM, V60, P145, DOI 10.1111/j.1471-4159.1993.tb05832.x; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; ODOWD DK, 1983, NATURE, V303, P619, DOI 10.1038/303619a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; Tabti N., 1991, CULTURING NERVE CELL, P137; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	44	119	121	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 3	1995	267	5198					695	699		10.1126/science.7839148	http://dx.doi.org/10.1126/science.7839148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839148				2022-12-01	WOS:A1995QE73300043
J	STROBEL, SA; CECH, TR				STROBEL, SA; CECH, TR			MINOR-GROOVE RECOGNITION OF THE CONSERVED G-CENTER-DOT-U PAIR AT THE TETRAHYMENA RIBOZYME REACTION SITE	SCIENCE			English	Article							5' SPLICE-SITE; GROUP-I INTRON; RNA SUBSTRATE; 2'-HYDROXYL GROUPS; ACTIVE-SITE; TERTIARY INTERACTIONS; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; CHEMICAL SYNTHESIS; CATALYTIC INTRONS	The guanine uracil (G.U) base pair that helps to define the 5'-splice site of group I introns is phylogenetically highly conserved. In such a wobble base pair, G makes two hydrogen bonds with U in a geometry shifted from that of a canonical Watson-Crick pair. The contribution made by individual functional groups of the G.U pair in the context of the Tetrahymena ribozyme was examined by replacement of the G.U pair with synthetic base pairs that maintain a wobble configuration, but that systematically alter functional groups in the major and minor grooves of the duplex. The substitutions demonstrate that the exocyclic amine of G, when presented on the minor groove surface by the wobble base pair conformation, contributes substantially (2 kilocalories.mole(-1)) to binding by making a tertiary interaction with the ribozyme active site. It contributes additionally to transition state stabilization. The ribozyme active site also makes tertiary contacts with a tripod of 2'-hydroxyls on the minor groove surface of the splice site helix. This suggests that the ribozyme binds the duplex primarily in the minor groove. The alanyl aminoacyl transfer RNA (tRNA) synthetase recognizes the exocyclic amine of an invariant G.U pair and contacts a similar array of 2'-hydroxyls when binding the tRNA(Ala) acceptor stem, providing an unanticipated parallel between protein-RNA and RNA-RNA interactions,	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1993, P NATL ACAD SCI USA, V90, P8357, DOI 10.1073/pnas.90.18.8357; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; FU DJ, 1993, BIOCHEMISTRY-US, V32, P10629, DOI 10.1021/bi00091a013; GREEN R, 1991, NUCLEIC ACIDS RES, V19, P4161, DOI 10.1093/nar/19.15.4161; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8312, DOI 10.1021/bi00083a035; HICKEY DR, 1985, BIOCHEMISTRY-US, V24, P3987, DOI 10.1021/bi00336a028; HOLBROOK SR, 1978, J MOL BIOL, V123, P631, DOI 10.1016/0022-2836(78)90210-3; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; KNITT S, 1994, BIOCHEMISTRY-US, V33, P13864; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MCCONNELL TS, 1993, P NATL ACAD SCI USA, V90, P8362, DOI 10.1073/pnas.90.18.8362; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P13856, DOI 10.1021/bi00250a040; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JL, 1992, J BIOL CHEM, V267, P2845; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; STROBEL SA, 1994, BIOCHEMISTRY-US, V33, P13824, DOI 10.1021/bi00250a037; STROBEL SM, UNPUB; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	50	154	167	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					675	679		10.1126/science.7839142	http://dx.doi.org/10.1126/science.7839142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE733	7839142				2022-12-01	WOS:A1995QE73300037
J	VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN				VANDERMEER, ALH; VANDERWEEL, FR; LEE, DN			THE FUNCTIONAL-SIGNIFICANCE OF ARM MOVEMENTS IN NEONATES	SCIENCE			English	Article							VISUAL GUIDANCE; AFFORDANCES	Arm movements made by newborn babies are usually dismissed as unintentional, purposeless, or reflexive, Spontaneous arm-waving movements were recorded while newborns lay supine facing to one side. They were allowed to see only the arm they were facing, only the opposite arm on a video monitor, or neither arm. Small forces pulled on their wrists in the direction of the toes. The babies opposed the perturbing force so as to keep an arm up and moving normally, but only when they could see the arm, either directly or on the video monitor. The findings indicate that newborns can purposely control their arm movements in the face of external forces and that development of visual control of arm movement is underway soon after birth.			VANDERMEER, ALH (corresponding author), UNIV EDINBURGH,DEPT PSYCHOL,PERCEPT ACT LABS,7 GEORGE SQ,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.							Bernshtein N. A, 1967, COORDINATION REGULAT; BOWER TGR, 1970, NATURE, V228, P679, DOI 10.1038/228679a0; BUTTERWORTH G, 1988, BRIT J DEV PSYCHOL, V6, P303, DOI 10.1111/j.2044-835X.1988.tb01103.x; Fraiberg S., 1977, INSIGHTS BLIND; Gesell A., 1947, DEV DIAGNOSIS; GIBSON EJ, 1988, ANNU REV PSYCHOL, V39, P1, DOI 10.1146/annurev.ps.39.020188.000245; Gibson J.J., 1979, ECOLOGICAL APPROACH; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; Piaget J., 1952, ORIGINS INTELLIGENCE; THELEN E, 1990, SENSORY MOTOR ORG DE, V1, P39; TREVARTHEN C, 1974, Neurosciences Research Program Bulletin, V12, P570; VONHOFSTEN C, 1982, DEV PSYCHOL, V18, P450, DOI 10.1037/0012-1649.18.3.450; WARREN WH, 1984, J EXP PSYCHOL HUMAN, V10, P683, DOI 10.1037/0096-1523.10.5.683; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371; WHITE BL, 1964, CHILD DEV, V35, P349, DOI 10.1111/j.1467-8624.1964.tb05944.x; Winter DA, 1979, BIOMECHANICS HUMAN M	16	150	152	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1995	267	5198					693	695		10.1126/science.7839147	http://dx.doi.org/10.1126/science.7839147			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QE733	7839147				2022-12-01	WOS:A1995QE73300042
J	AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P				AUGER, J; KUNSTMANN, JM; CZYGLIK, F; JOUANNET, P			DECLINE IN SEMEN QUALITY AMONG FERTILE MEN IN PARIS DURING THE PAST 20 YEARS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPERM COUNTS; REPRODUCTIVE-TRACT; HUMAN TESTIS; DIETHYLSTILBESTROL	Background. Several studies have suggested a population-wide decline in the quality of semen over the past 50 years, but clear evidence of decreasing semen quality in recent decades is lacking. Methods. From 1973 through 1992 we measured the volume of seminal fluid, the sperm concentration, and the percentages of motile and morphologically normal spermatozoa in 1351 healthy fertile men. The data on the semen samples were collected at one sperm bank in Paris. The data in each calendar year were analyzed as a function of the year of donation, the age of each patient, the year of birth, and the duration of sexual abstinence before semen collection. Results. There was no change in semen volume during the study period, The mean concentration of sperm decreased by 2.1 percent per year, from 89x10(6) per milliliter in 1973 to 60x10(6) per milliliter in 1992 (P<0.001). During the same period the percentages of motile and normal spermatozoa decreased by 0.6 percent and 0.5 percent per year, respectively (both P<0.001). After adjustment in multiple regression analyses for age and the duration of sexual abstinence, each successive calendar year of birth accounted for 2.6 percent of the yearly decline in the sperm concentration and for 0.3 percent and 0.7 percent, respectively, of the yearly declines in the percentages of motile and normal spermatozoa (all P<0.001). Conclusions. During the past 20 years, there has been a decline in the concentration and motility of sperm and in the percentage of morphologically normal spermatozoa in fertile men that is independent of the age of the men.	UNIV PARIS SUD,CTR HOSP,CTR ETUD & CONSERVAT OEUFS & SPERME HUMAINS,F-94275 LE KREMLIN BICETR,FRANCE	UDICE-French Research Universities; Universite Paris Saclay			Auger, Jacques/AAA-1375-2019	Auger, Jacques/0000-0002-4521-3363				BENDVOLD E, 1989, INT J FERTIL, V34, P401; BOSTOFTE E, 1983, INT J FERTIL, V28, P91; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BROMWICH P, 1994, BRIT MED J, V309, P19, DOI 10.1136/bmj.309.6946.19; CANLORBE P, 1966, ANN PEDIATR-PARIS, V42, P969; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; COLEMAN MP, 1993, IARC SCI PUBL, V121, P521; COOPER TG, 1992, FERTIL STERIL, V58, P172; David G., 1975, J GYN OBST BIOL R S1, V1, P17; DIXON WJ, 1988, BMDP STATISTICAL SOF; FARROW S, 1994, BRIT MED J, V309, P1; GINSBURG J, 1994, LANCET, V343, P230, DOI 10.1016/S0140-6736(94)91012-X; GIWERCMAN A, 1992, INT J ANDROL, V15, P373, DOI 10.1111/j.1365-2605.1992.tb01351.x; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; IRVINE DS, 1994, BRIT MED J, V309, P476, DOI 10.1136/bmj.309.6952.476; JACKSON MB, 1988, HORM RES, V30, P153, DOI 10.1159/000181052; JAMES WH, 1980, ANDROLOGIA, V12, P381; JARDIN A, 1992, Journal of Urology, V147, p386A; JOHNSON L, 1986, J ANDROL, V7, P331; JOUANNET P, 1977, ANDROLOGIA, V9, P36; JOUANNET P, 1981, INT J ANDROL, V4, P440, DOI 10.1111/j.1365-2605.1981.tb00728.x; MIEUSSET R, 1989, J CLIN ENDOCR METAB, V68, P419, DOI 10.1210/jcem-68-2-419; MIEUSSET R, 1991, TEMPERATURE ENV EFFE, P233; SCHWARTZ D, 1983, FERTIL STERIL, V39, P530; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SPIRA A, 1983, REV EPIDEMIOL SANTE, V31, P249; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; 1992, WHO LABORATORY MANUA	29	835	883	1	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					281	285		10.1056/NEJM199502023320501	http://dx.doi.org/10.1056/NEJM199502023320501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816062				2022-12-01	WOS:A1995QD39600001
J	BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR				BRUNNER, T; MOGIL, RJ; LAFACE, D; YOO, NJ; MAHBOUBI, A; ECHEVERRI, F; MARTIN, SJ; FORCE, WR; LYNCH, DH; WARE, CF; GREEN, DR			CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; DNA FRAGMENTATION; CYCLOSPORINE-A; CYCLE BLOCK; DEATH; RECEPTOR; REQUIREMENTS; INVOLVEMENT; THYMOCYTES	A NUMBER of murine T-cell hybridomas undergo apoptosis within a few hours of activation by specific antigens, mitogens, antibodies against the T-cell antigen receptor, or a combination of phorbol ester and calcium ionophore(1-3). This phenomenon has been extensively studied as a model for cional deletion in the immune system, in which potentially autoreactive T cells eliminate themselves by apoptosis after activation, either in the thymus(4) or in the periphery(5). Here we show that the Fas/CD95 receptor, which can transduce a potent apoptotic signal when ligated(6,7), is rapidly expressed following activation of T-cell hybridomas, as is its functional, membrane-bound ligands, Interference with the ensuing Fas/Fas-ligand interaction inhibits activation-induced apoptosis, Because T-cell receptor ligation can induce apoptosis in a single T hybridoma cell, we suggest that the Fas/Fas-ligand interaction can induce cell death in a cell-autonomous manner.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101	University of California System; University of California Riverside	BRUNNER, T (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,11149 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417; Martin, Seamus/0000-0002-8539-3143				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; FOTEDAR R, MOL CELL BIOL; Green D R, 1992, Semin Immunol, V4, P379; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; IWATA M, 1991, J IMMUNOL, V149, P3302; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCGAHON AJ, IN PRESS CELL DEATH; MERCEP M, 1989, J IMMUNOL, V142, P4085; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; RAMSDELL F, 1994, INT IMMUNOL, V6, P1545, DOI 10.1093/intimm/6.10.1545; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V88, P4409; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UCKER DS, 1989, J IMMUNOL, V143, P3461; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	30	1253	1273	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					441	444		10.1038/373441a0	http://dx.doi.org/10.1038/373441a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530336				2022-12-01	WOS:A1995QE67000060
J	DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH				DHEIN, J; WALCZAK, H; BAUMLER, C; DEBATIN, KM; KRAMMER, PH			AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95)	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; SURFACE ANTIGEN; MOLECULAR-CLONING; FAS ANTIGEN; APOPTOSIS; RECEPTOR; INDUCTION; MEMBER; MICE	THE APO-1/(Fas/CD95) cell surface receptor is a member of the nerve growth factor (NGF)/tumour necrosis factor (TNF) receptor superfamily and mediates apoptosis(1-4). Peripheral activated T cells (ATC) from lymphoproliferation (lpr/lpr) mutant mice that express a reduced number of APO-1 receptors have a defect in T-cell receptor (TCR)-induced apoptosis(5,6). This suggests that TCR-induced apoptosis involves APO-1. We tested this hypothesis in various human T cells: (1) malignant Jurkat cells, (2) an alloreactive T-cell clone (S13), and (3) peripheral ATC. TCR triggering through immobilized anti-CD3 antibodies or Staphylococcus enterotoxin B (SEB) superantigen induced expression of the APO-1 ligand and apoptosis in these cells. Anti-CD3-induced apoptosis of Jurkat cells was demonstrated even in single-cell cultures. In all cases apoptosis was substantially inhibited by blocking anti-APO-1 antibody fragments and soluble APO-I receptor decoys. The APO-1 ligand was found in the supernatant of activated Jurkat cells as a soluble cytokine. We propose that TCR-induced apoptosis in ATC can occur through an APO-1 ligand-mediated autocrine suicide. These results provide a mechanism for suppression of the immune response and for peripheral tolerance by T-cell deletion.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,CHILDRENS HOSP,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Walczak, Henning/AAV-2214-2020; Debatin, Klaus-Michael/J-9704-2014	Walczak, Henning/0000-0002-6312-4591; Debatin, Klaus-Michael/0000-0002-8397-1886; Dhein, Jens/0000-0002-7200-2967				DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DHEIN J, 1992, J IMMUNOL, V149, P3166; GILLETTEFERGUSO.I, 1994, EUR J IMMUNOL, V24, P1181; Haight F.A., 1967, HDB POISSON DISTRIBU; HANABUCHI S, 1994, P NATL ACAD SCI USA, V91, P4930, DOI 10.1073/pnas.91.11.4930; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; KABELITZ D, 1989, J EXP MED, V170, P559, DOI 10.1084/jem.170.2.559; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	25	1570	1611	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					438	441		10.1038/373438a0	http://dx.doi.org/10.1038/373438a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530335				2022-12-01	WOS:A1995QE67000059
J	HOUSMAN, D				HOUSMAN, D			HUMAN DNA POLYMORPHISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HOUSMAN, D (corresponding author), MIT,CTR CANC RES,BLDG E17,RM 543,40 AMES ST,CAMBRIDGE,MA 02139, USA.							GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; WEBER JL, 1989, AM J HUM GENET, V44, P388	3	32	32	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					318	320		10.1056/NEJM199502023320508	http://dx.doi.org/10.1056/NEJM199502023320508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816069				2022-12-01	WOS:A1995QD39600007
J	JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A				JU, ST; PANKA, DJ; CUI, HL; ETTINGER, R; ELKHATIB, M; SHERR, DH; STANGER, BZ; MARSHAKROTHSTEIN, A			FAS(CD95) FASL INTERACTIONS REQUIRED FOR PROGRAMMED CELL-DEATH AFTER T-CELL ACTIVATION	NATURE			English	Article							THYMOCYTE DEVELOPMENT; CYCLOSPORINE-A; HYBRIDOMAS; EXPRESSION; MICE; ANTIGEN; LYMPHOCYTE; PATHWAYS; SUICIDE; LPR	RECEPTOR crosslinking of T-cell hybridomas induces cell activation followed by apoptosis(1-6). This activation-induced cell death requires de novo synthesis of RNA and proteins(1-3), but the actual gene products that provide the death signal have not been identified(4-6). We show here that receptor crosslinking induces Fas ligand and upregulates Fas, and that the ensuing engagement of Fas by Fas ligand activates the cell-death programme. Cell death, but not activation, can be selectively prevented by a soluble Fas-immunoglobulin fusion protein. Thus, Fas and Fas ligand are the death-gene products, and their interaction accounts for the molecular mechanism of activation-induced T-cell death.	BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard Medical School	JU, ST (corresponding author), BOSTON UNIV,SCH MED,CTR ARTHRITIS,80 E CONCORD ST,BOSTON,MA 02118, USA.			Sherr, David/0000-0003-3353-0553				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRINER TJ, 1989, THESIS MIT; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GAO EK, 1988, NATURE, V336, P176, DOI 10.1038/336176a0; JENKINS MK, 1988, SCIENCE, V241, P1655, DOI 10.1126/science.3262237; JU ST, 1990, J IMMUNOL, V144, P23; JU ST, 1994, P NATL ACAD SCI USA, V91, P4185, DOI 10.1073/pnas.91.10.4185; JU ST, 1988, CELL IMMUNOL, V117, P399, DOI 10.1016/0008-8749(88)90129-3; KOZIN RL, 1988, J EXP MED, V168, P2221; LEO O, 1986, J IMMUNOL, V137, P3874; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SARIN A, 1994, J IMMUNOL, V153, P862; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGER PA, 1989, J EXP MED, V170, P1869, DOI 10.1084/jem.170.6.1869; STALDER T, 1994, J IMMUNOL, V152, P1127; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; UCKER DS, 1989, J IMMUNOL, V143, P3461; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; ZHOU T, 1991, J IMMUNOL, V147, P466	30	1423	1484	2	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					444	448		10.1038/373444a0	http://dx.doi.org/10.1038/373444a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7530337				2022-12-01	WOS:A1995QE67000061
J	MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID				MADDUX, BA; SBRACCIA, P; KUMAKURA, S; SASSON, S; YOUNGREN, J; FISHER, A; SPENCER, S; GRUPE, A; HENZEL, W; STEWART, TA; REAVEN, GM; GOLDFINE, ID			MEMBRANE GLYCOPROTEIN PC-1 AND INSULIN-RESISTANCE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NATURE			English	Article							RECEPTOR TYROSINE KINASE; NUCLEOTIDE PYROPHOSPHATASE; FIBROBLASTS; MECHANISMS; EXPRESSION; GLUCOSE; CLONING; NIDDM; GENE	MOST patients with non-insulin-dependent diabetes mellitus are resistant to both endogenous and exogenous insulin(1). Insulin resistance precedes the onset of this disease(2-4), suggesting that it may be an initial abnormality. Insulin-receptor kinase activity is impaired in muscle, fibroblasts and other tissues of many patients with non-insulin-dependent diabetes mellitus(5), but abnormalities in the insulin-receptor gene do not appear to be the cause of this decreased kinase activity(6,7). Skin fibroblasts from certain insulin-resistant patients contain an inhibitor of insulin-receptor tyrosine kinase(8,9). Here we show that this inhibitor is a membrane glycoprotein, termed PC-1 (refs 10,11). We find that PC-1 activity is increased in fibroblasts from seven of nine patients with typical non-insulin-dependent diabetes mellitus. In addition, overexpression of PC-1 in transfected cultured cells reduces insulin-stimulated tyrosine kinase activity. These studies raise the possibility that PC-1 has a role in the insulin resistance of non-insulin-dependent diabetes mellitus.	UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94115; GENENTECH INC,S SAN FRANCISCO,CA 94080; STANFORD UNIV,VET ADM MED CTR,PALO ALTO,CA 94304	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Roche Holding; Genentech; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Sasson, Shlomo/0000-0002-9343-526X; Henzel, William/0000-0003-2940-3797				BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; FORSAYETH J, 1986, DIABETES, V35, P837, DOI 10.2337/diabetes.35.7.837; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; Greene S F, 1994, Obes Res, V2, P432; HARING H, 1989, DIABETES METAB REV, V5, P431; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HUANG R, 1994, J CLIN INVEST, V94, P560, DOI 10.1172/JCI117370; MADDUX BA, 1993, J CLIN ENDOCR METAB, V77, P73, DOI 10.1210/jc.77.1.73; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MILAZZO G, 1992, CANCER RES, V52, P3924; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; ODA Y, 1991, J BIOL CHEM, V266, P16791; REAVEN GM, 1988, DIABETES, V35, P1595; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; SBRACCIA P, 1991, DIABETES, V40, P295, DOI 10.2337/diabetes.40.2.295; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; YOSHIDA H, 1983, J BIOCHEM-TOKYO, V93, P1641, DOI 10.1093/oxfordjournals.jbchem.a134303	21	288	299	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					448	451		10.1038/373448a0	http://dx.doi.org/10.1038/373448a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830796				2022-12-01	WOS:A1995QE67000062
J	MENINI, A; PICCO, C; FIRESTEIN, S				MENINI, A; PICCO, C; FIRESTEIN, S			QUANTAL-LIKE CURRENT FLUCTUATIONS INDUCED BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							MONKEY MACACA-FASCICULARIS; VISUAL TRANSDUCTION; TIGER SALAMANDER; RETINAL RODS; CONDUCTANCE; CHANNELS; CILIA	MANY sensory systems have evolved signal detection capabilities that are limited only by the physical attributes of the stimulus(1). For example, 'hair' cells of the inner ear can detect displacements of atomic dimensions(2). Likewise, both in vertebrates and in invertebrates photoreceptors can detect a single photon(3,4). The olfactory stimulus also has a quantal unit, the single odorant molecule, Insects are reportedly able to detect a single pheromone molecule(5), whereas quantal responses in vertebrate olfactory receptor cells have not been reported yet. Psychophysical measurements indicate that a minimum of 50 odorant molecules are necessary for human olfactory detection, suggesting that an individual receptor may be activated ba a single odorant molecule(6). We report here measurements of current fluctuations induced by odorants that suggest a quantal event of about 03-1 pA, presumably triggered by the binding of a single odorant molecule.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University	MENINI, A (corresponding author), CNR, IST CIBERNET & BIOFIS, I-16146 GENOA, ITALY.			Picco, Cristiana/0000-0002-6512-1802; Menini, Anna/0000-0001-9304-0412				BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLOCK SM, 1992, SOC GEN PHY, V47, P1; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; DEVRIES H, 1961, SENS COMMUN, P159; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1987, P NATL ACAD SCI USA, V84, P6292, DOI 10.1073/pnas.84.17.6292; FUORTES MGF, 1964, J GEN PHYSIOL, V47, P443, DOI 10.1085/jgp.47.3.443; KALSSLING KE, 1986, A REV NEUROSCI, V9, P121; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LYNCH JW, 1989, BIOPHYS J, V55, P755, DOI 10.1016/S0006-3495(89)82874-7; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NUNN BJ, 1982, NATURE, V299, P726, DOI 10.1038/299726a0; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; TROTIER D, 1986, PFLUG ARCH EUR J PHY, V407, P589, DOI 10.1007/BF00582636; ZUFALL F, 1991, J NEUROSCI, V11, P3573	19	69	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					435	437		10.1038/373435a0	http://dx.doi.org/10.1038/373435a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830795				2022-12-01	WOS:A1995QE67000058
J	MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA				MUGLIA, L; JACOBSON, L; DIKKES, P; MAJZOUB, JA			CORTICOTROPIN-RELEASING HORMONE DEFICIENCY REVEALS MAJOR FETAL BUT NOT ADULT GLUCOCORTICOID NEED	NATURE			English	Article							RESPIRATORY-DISTRESS SYNDROME; SURFACTANT; DEXAMETHASONE; EXPRESSION; SECRETION; STRESS	The body responds to stress by activation of the hypothalamic-pituitary-adrenal (HPA) axis and release of glucocorticoids. Glucocorticoid production in the adult regulates carbohydrate and amino-acid metabolism, maintains blood pressure, and restrains the inflammatory response(1). In the fetus, exogenous glucocorticoids accelerate maturation of lung(2) and gastrointestinal enzyme systems(3) and promote hepatic glycogen deposition(4). Corticotropin-releasing hormone (CRH), a 41-amino-acid neuropeptide produced in the paraventricular nucleus of the hypothalamus and many regions of the cerebral cortex(5,6), has been implicated in both the HPA axis(7) and behavioural responses(8) to stress. To define the importance of CRH in the response of the HPA axis to stress and fetal development, we have constructed a mammalian model of CRH deficiency by targeted mutation in embryonic stem (ES) cells(9). We report here that corticotropin-releasing hormone-deficient mice reveal a fetal glucocorticoid requirement for lung maturation. Postnatally, despite marked glucocorticoid deficiency, these mice exhibit normal growth, fertility and longevity, suggesting that the major role of glucocorticoid is during fetal rather than postnatal life.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	MUGLIA, L (corresponding author), HARVARD UNIV, SCH MED, DIV ENDOCRINOL, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AVERY ME, 1984, J PEDIATR-US, V104, P240, DOI 10.1016/S0022-3476(84)81000-8; BALLARD PL, 1989, ENDOCR REV, V10, P165, DOI 10.1210/edrv-10-2-165; BALLARD PL, 1979, GLUCOCORTICOID HORMO, P493; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRITCHLOW V, 1963, AM J PHYSIOL, V205, P807, DOI 10.1152/ajplegacy.1963.205.5.807; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DALLMAN MF, 1987, RECENT PROG HORM RES, V43, P113; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GERTZ BJ, 1987, ENDOCRINOLOGY, V120, P381, DOI 10.1210/endo-120-1-381; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOOB GF, 1993, CIBA F SYMP, V172, P277; LIGGINS GC, 1972, PEDIATRICS, V50, P515; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MOOG F, 1953, J EXP ZOOL, V124, P329, DOI 10.1002/jez.1401240209; MUGLIA LJ, 1994, J CLIN INVEST, V93, P2066, DOI 10.1172/JCI117201; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Orth DN KW., 1992, WILLIAMS TXB ENDOCRI, V8th Edition ed, P489; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; POST M, 1986, J BIOL CHEM, V261, P2179; ROBERTS MM, 1993, NEUROENDOCRINOLOGY, V57, P388, DOI 10.1159/000126384; SASAKI A, 1984, J CLIN ENDOCR METAB, V59, P812; SEASHOLTZ A F, 1991, Molecular and Cellular Neuroscience, V2, P266, DOI 10.1016/1044-7431(91)90054-R; SPINEDI E, 1992, ENDOCRINOLOGY, V131, P2430, DOI 10.1210/en.131.5.2430; SUDA T, 1984, J CLIN ENDOCR METAB, V59, P861, DOI 10.1210/jcem-59-5-861; THOMPSON RC, 1987, MOL ENDOCRINOL, V1, P363, DOI 10.1210/mend-1-5-363; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAMVAKOPOULOS NC, 1994, ENDOCR REV, V15, P409, DOI 10.1210/er.15.4.409; VENKATESH VC, 1993, AM J RESP CELL MOL, V8, P222, DOI 10.1165/ajrcmb/8.2.222	30	427	429	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					427	432		10.1038/373427a0	http://dx.doi.org/10.1038/373427a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830793				2022-12-01	WOS:A1995QE67000056
J	ROSE, S				ROSE, S			THE RISE OF NEUROGENETIC DETERMINISM	NATURE			English	Editorial Material											ROSE, S (corresponding author), OPEN UNIV, DEPT BIOL, MILTON KEYNES MK7 6AA, BUCKS, ENGLAND.							BIGNAMI G, 1982, BIOL DETERMINISM, P94; BREGGIN PR, 1993, INT J PSYCHOL PSYCHO, V11, P59; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CHIPKIN RE, 1994, TRENDS NEUROSCI, V17, P50, DOI 10.1016/0166-2236(94)90070-1; COHEN D, 1994, OUT BLUE DEPRESSION; Dawkins R., 1976, SELFISH GENE; DELGADO JMW, 1971, PHYSICAL CONTROL MIN; GALANTER M, 1993, RECENT DEV ALCOHOLIS; Hamer D., 1994, SCI DESIRE SEARCH GA; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; HARRISON G, 1990, SCHIZOPHRENIA BULL, V16, P663, DOI 10.1093/schbul/16.4.663; Herrnstein Richard J., 1994, BELL CURVE INTELLIGE; Kitcher P, 1985, VALUING AMBITION; Kramer PD, 1994, LISTENING PROZAC; Le Vay S., 1993, THE SEXUAL BRAIN; MANN CC, 1994, SCIENCE, V264, P1686, DOI 10.1126/science.8209246; Mark V. H., 1970, VIOLENCE BRAIN; Nelkin D, 1987, SELLING SCI; PERUTZ MF, 1988, TRENDS BIOCHEM SCI, V13, P206, DOI 10.1016/0968-0004(88)90083-7; Reiss A., 1993, UNDERSTANDING PREVEN; ROSE S, 1987, TRENDS NEUROSCI, V10, P152; Rose S, 1984, NOT IN OUR GENES; SWAAB DF, 1994, EUR J NEUROSCI, V7, P126; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; Wilson E.O., 1975, P1	25	76	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 2	1995	373	6513					380	382		10.1038/373380a0	http://dx.doi.org/10.1038/373380a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830787				2022-12-01	WOS:A1995QE67000026
J	SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH				SELHUB, J; JACQUES, PF; BOSTOM, AG; DAGOSTINO, RB; WILSON, PWF; BELANGER, AJ; OLEARY, DH; WOLF, PA; SCHAEFER, EJ; ROSENBERG, IH			ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE CONCENTRATIONS AND EXTRACRANIAL CAROTID-ARTERY STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ATHEROTHROMBOTIC BRAIN INFARCTION; RISK-FACTORS; CARDIOVASCULAR HEALTH; ATHEROSCLEROSIS RISK; VASCULAR-DISEASE; ELDERLY PATIENTS; FOLLOW-UP; ULTRASOUND; FOLATE	Background. Epidemiologic studies have identified hyperhomocysteinemia as a possible risk factor for atherosclerosis. We determined the risk of carotid-artery atherosclerosis in relation to both plasma homocysteine concentrations and nutritional determinants of hyperhomocysteinemia. Methods. We performed a cross-sectional study of 1041 elderly subjects (418 men and 623 women; age range, 67 to 96 years) from the Framingham Heart Study. We examined the relation between the maximal degree of stenosis of the extracranial carotid arteries (as assessed by ultrasonography) and plasma homocysteine concentrations, as well as plasma concentrations and intakes of vitamins involved in homocysteine metabolism, including folate, vitamin B-12, and vitamin B-6. The subjects were classified into two categories according to the findings in the more diseased of the two carotid vessels: stenosis of 0 to 24 percent and stenosis of 25 to 100 percent. Results. The prevalence of carotid stenosis of less than or equal to 25 percent was 43 percent in the men and 34 percent in the women. The odds ratio for stenosis of greater than or equal to 25 percent was 2.0 (95 percent confidence interval, 1.4 to 2.9) for subjects with the highest plasma homocysteine concentrations (greater than or equal to 14.4 mu mol per liter) as compared with those with the lowest concentrations (less than or equal to 9.1 mu mol per liter), after adjustment for sex, age, plasma high-density lipoprotein cholesterol concentration, systolic blood pressure, and smoking status (P<0.001 for trend). Plasma concentrations of folate and pyridoxal-5'-phosphate (the coenzyme form of vitamin B-6) and the level of folate intake were inversely associated with carotid-artery stenosis after adjustment for age, sex, and other risk factors. Conclusions. High plasma homocysteine concentrations and low concentrations of folate and vitamin B,, through their role in homocysteine metabolism, are associated with an increased risk of extracranial carotid-artery stenosis in the elderly.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA; BOSTON UNIV, DEPT MATH, STAT & CONSULTING UNIT, BOSTON, MA 02215 USA; GEISINGER MED CTR, DEPT RADIOL, DANVILLE, PA 17822 USA; BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, EVANS MEM DEPT CLIN RES, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; UNIV BOSTON HOSP, DEPT MED, BOSTON, MA 02118 USA	Framingham Heart Study; Boston University; Geisinger Medical Center; Boston University	SELHUB, J (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, 711 WASHINGTON ST, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038, R01-HL-40423-05] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARONOW WS, 1992, NEW YORK STATE J MED, V92, P424; ARONOW WS, 1993, AM J CARDIOL, V71, P999, DOI 10.1016/0002-9149(93)90923-Z; ARONOW WS, 1993, AM J CARDIOL, V71, P1479, DOI 10.1016/0002-9149(93)90622-J; ARONOW WS, 1992, CORONARY ARTERY DIS, V3, P249, DOI 10.1097/00019501-199203000-00012; BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; BOND MG, 1989, AM J MED, V86, P33; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; CAMP VM, 1983, CLIN CHEM, V29, P642; CHAMBLESS LE, 1993, AM J EPIDEMIOL, V138, P660; CLARKE R, 1992, IRISH J MED SCI, V161, P61, DOI 10.1007/BF02983714; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; FALKE P, 1989, INT ANGIOL, V8, P175; FINEEDELSTEIN JS, 1994, NEUROLOGY, V44, P1046, DOI 10.1212/WNL.44.6.1046; FURBERG CD, 1993, CIRCULATION S1, V88, P1; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; JOOSTEN E, 1993, AM J CLIN NUTR, V58, P468, DOI 10.1093/ajcn/58.4.468; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837; O'Leary D H, 1992, Ann Epidemiol, V2, P147, DOI 10.1016/1047-2797(92)90049-V; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; SALONEN JT, 1991, ARTERIOSCLER THROMB, V11, P1245, DOI 10.1161/01.ATV.11.5.1245; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; UBBINK JB, 1993, AM J CLIN NUTR, V57, P47, DOI 10.1093/ajcn/57.1.47; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; WARNICK GR, 1982, CLIN CHEM, V28, P1379; 1990, SAS PROCEDURES GUIDE; 1990, MONOGRAPHS EPIDEMIOL, V15, P92	40	1006	1052	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					286	291		10.1056/NEJM199502023320502	http://dx.doi.org/10.1056/NEJM199502023320502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816063	Bronze			2022-12-01	WOS:A1995QD39600002
J	SHIVDASANI, RA; MAYER, EL; ORKIN, SH				SHIVDASANI, RA; MAYER, EL; ORKIN, SH			ABSENCE OF BLOOD FORMATION IN MICE LACKING THE T-CELL LEUKEMIA ONCOPROTEIN TAL-1/SCL	NATURE			English	Article							DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; ERYTHROID-DIFFERENTIATION; TARGETED MUTATION; GENE SCL; EXPRESSION; LEUKEMIA; PROTEIN; HEMATOPOIESIS; RECOMBINATION	CHROMOSOMAL translocations associated with malignancies often result in deregulated expression of genes encoding transcription factors(1). In human T-cell leukaemias such regulators belong to diverse protein families and may normally be expressed widely (for example, Ttg-1/rbtn1, Ttg-2/rbtn2)(2'3), exclusively outside the haematopoietic system (for example, Hox11)(4), or specifically in haematopoietic cells and other selected sites (for example, tal-1/ SCL, lyl-1)(5,6). Aberrant expression within T cells is thought to interfere with programmes of normal maturation. The most frequently activated gene in acute T-cell leukaemias, tal-1 (also called SCL)(7,8), encodes a candidate regulator of haematopoietic development(9), a basic-helix-loop-helix protein(5), related to critical myogenic(10) and neurogenic(11) factors. Here we show by targeted gene disruption in mice(12) that tal-1 is essential for embryonic blood formation in vivo. With respect to embryonic erythropoiesis, tal-1 deficiency resembles loss of the erythroid transcription factor GATA-(13,14) or the LIM protein rbtn2(15). Profound reduction in myeloid cells cultured in vivo from tal-1 null yolk sacs suggests a broader defect manifest at the myelo-erythroid or multipotential progenitor cell level.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	SHIVDASANI, RA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115, USA.							APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBEL FM, 1987, CURR PROT MOL BIOL; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLER G, 1993, MOL CELL BIOL, V13, P472; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	30	747	774	2	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					432	434		10.1038/373432a0	http://dx.doi.org/10.1038/373432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830794				2022-12-01	WOS:A1995QE67000057
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE (VOL 373, PG R39, 1995)	NATURE			English	Correction, Addition								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology, notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work but are the product of a fertile tile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they may have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic wars of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.							WADA A, 1995, NATURE, V373, pR39	1	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					R35	R36						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830774				2022-12-01	WOS:A1995QE67000065
J	WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA				WESTLEY, MS; BARAGIOLA, RA; JOHNSON, RE; BARATTA, GA			PHOTODESORPTION FROM LOW-TEMPERATURE WATER ICE IN INTERSTELLAR AND CIRCUMSOLAR GRAINS	NATURE			English	Article							MOLECULAR CLOUDS; RADIATION-FIELD; DENSE CLOUDS; LIGHT-IONS; DUST; MAGNETOSPHERE; DESORPTION	Dust grains in the interstellar medium(1) and the outer Solar System(2-4) commonly have a coating of water ice, which affects their optical properties and surface chemistry, The thickness of these icy mantles may be determined in part by the extent of photodesorption (photosputtering) by background ultraviolet radiation, But this process is poorly understood, with theoretical estimates of the photodesorption rate spanning several orders of magnitude(5,6). Here we report measurements of the absolute ultraviolet photodesorption yield of low-temperature water ice, Our results indicate that the rate of photodesorption is appreciable. In particular, it can account for the absence of icy mantles on grains in diffuse interstellar clouds, it exceeds solar-wind ion erosion and sublimation in the outer Solar System, and it is important in determining the lifetimes of icy mantles in dense molecular clouds.	UNIV CATANIA,OSSERVATORIO ASTROFIS,CATANIA,ITALY	Istituto Nazionale Astrofisica (INAF); University of Catania	WESTLEY, MS (corresponding author), UNIV VIRGINIA,THORNTON HALL,CHARLOTTESVILLE,VA 22901, USA.		Baratta, Giuseppe/AAY-6188-2021	Baratta, Giuseppe/0000-0002-3688-160X				BROWN WL, 1980, PHYS REV LETT, V45, P1632, DOI 10.1103/PhysRevLett.45.1632; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; BROWN WL, 1978, PHYS REV LETT, V40, P1027, DOI 10.1103/PhysRevLett.40.1027; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; COMBI MR, 1987, ICARUS, V71, P178, DOI 10.1016/0019-1035(87)90171-0; DHENDECOURT LB, 1982, ASTRON ASTROPHYS, V109, pL12; DRAINE BT, 1979, ASTROPHYS J, V231, P438, DOI 10.1086/157206; EVIATAR A, 1986, ASTRON J, V300, pL9; FLOURNOY JM, 1962, J CHEM PHYS, V36, P2229, DOI 10.1063/1.1732861; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HARTQUIST TW, 1990, MON NOT R ASTRON SOC, V247, P343; HEIDE HG, 1984, ULTRAMICROSCOPY, V14, P271, DOI 10.1016/0304-3991(84)90095-0; Johnson R. E., 1993, EOS, V74, P572; JOHNSON RE, 1990, ENERGETIC PARTICLE I; LEGER A, 1985, ASTRON ASTROPHYS, V144, P147; MATHIS JS, 1983, ASTRON ASTROPHYS, V128, P212; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NISHI N, 1984, J CHEM PHYS, V80, P3898, DOI 10.1063/1.447172; NORMAN C, 1980, ASTROPHYS J, V238, P158, DOI 10.1086/157969; PRASAD SS, 1983, ASTROPHYS J, V267, P603, DOI 10.1086/160896; SACK NJ, 1993, PHYS REV B, V48, P9973, DOI 10.1103/PhysRevB.48.9973; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SMITH RG, 1993, MON NOT R ASTRON SOC, V263, P749, DOI 10.1093/mnras/263.3.749; STERNBERG A, 1987, ASTROPHYS J, V320, P676, DOI 10.1086/165585; TAUB IA, 1968, J CHEM PHYS, V49, P2499, DOI 10.1063/1.1670446; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WATSON WD, 1972, ASTROPHYS J, V174, P321, DOI 10.1086/151492; Whittet D. C. B., 1992, DUST GALACTIC ENV	29	219	220	0	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 2	1995	373	6513					405	407		10.1038/373405a0	http://dx.doi.org/10.1038/373405a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QE670	7830792				2022-12-01	WOS:A1995QE67000048
J	JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD				JACKSON, LA; SCHUCHAT, A; REEVES, MW; WENGER, JD			SEROGROUP-C MENINGOCOCCAL OUTBREAKS IN THE UNITED-STATES - AN EMERGING THREAT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; POLYSACCHARIDE VACCINE; DISEASE; EPIDEMIC; INFLUENZA; AGE; MYCOPLASMA; INFECTIONS; CARRIAGE; CANADA	Objective.-Multiple outbreaks of serogroup C Neisseria meningitidis have recently been reported from diverse areas of the United States. To better define the characteristics of this increasingly important problem, we reviewed data on all known serogroup C outbreaks in the United States from January 1980 through June 1993. Data Sources.-MEDLINE searches, Centers for Disease Control and Prevention records, state health department officials, infectious disease experts, and the meningococcal vaccine manufacturer. Definition of an Outbreak.-Three or more cases of serogroup C meningococcal disease within a 3-month period, either among members of a community or persons attending a single school or other institution, for which those cases represented an attack rate of at least five per 100 000 population. Results.-Twenty-one outbreaks of serogroup C meningococcal disease were identified; eight occurred since 1991. In 1992 and the first half of 1993, approximately 180 000 doses of vaccine were administered for outbreak control, compared with approximately 34 000 doses from 1980 to 1991. Approximately 50% of community-outbreak cases were between the ages of 5 and 24 years, compared with only 19% of sporadic serogroup C cases (P<.001). Subtyping of patient isolates indicates that outbreaks are clonal; however, at least five distinct but closely related strains have caused recent outbreaks. Conclusions.-Serogroup C outbreaks are occurring more frequently in the United States. The effectiveness of preventive measures depends on early recognition; therefore, physicians should promptly report all cases of suspected meningococcal disease, and the causative serogroup should be established for every case.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; Dean A. G., 1990, EPI INFO VERSION 5 W; DEMORAIS JS, 1974, J INFECT DIS, V129, P568; EDMOND MB, 1993, 33RD INT C ANT AG CH; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; GILMORE A, 1992, CAN MED ASSOC J, V147, P729; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; GUILMETTE P, 1993, CAN DIS WKLY REP, V17, P295; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOUCK P, IN PRESS PUBLIC HLTH; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; IMREY PB, 1993, 3RD ANN M SOC HOSP E; JACOBS D, 1990, 15TH P ANN SAS US GR, P1413; JACOBSON JA, 1977, J INFECT DIS, V136, P104, DOI 10.1093/infdis/136.1.104; JAFARI H, 1993, 33RD INT C ANT AG CH; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; MASTERTON RG, 1988, J INFECTION, V17, P177, DOI 10.1016/S0163-4453(88)91907-X; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MOORE PS, 1989, LANCET, V2, P260; MORROW HW, 1991, MISS MORB REP, V9, P1; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; PELTOLA H, 1982, LANCET, V2, P595; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; REINGOLD AL, 1985, LANCET, V2, P114; RONNE T, 1993, SCAND J INFECT DIS, V25, P331, DOI 10.3109/00365549309008507; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SAEZNIETO JA, 1984, J INFECTION, V8, P49, DOI 10.1016/S0163-4453(84)93327-9; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; TAPPERO JW, 1994, 34TH INT C ANT AG CH; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645; WENGER JD, 1994, INFECT DIS CLIN PRAC, V3, P136, DOI 10.1097/00019048-199403000-00022; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; ZEIT, 1993, 33RD INT C ANT AG CH; 1993, MMWR-MORBID MORTAL W, V42, P21; 1985, MMWR-MORBID MORTAL W, V34, P255	40	201	206	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					383	389		10.1001/jama.273.5.383	http://dx.doi.org/10.1001/jama.273.5.383			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD203	7823383				2022-12-01	WOS:A1995QD20300022
J	NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M				NOUSBAUM, JB; POL, S; NALPAS, B; LANDAIS, P; BERTHELOT, P; BRECHOT, C; GIGOU, M; FERAY, C; THIERS, V; OKAMOTO, H; MISHIRO, S; POUSSIN, K; PATERLINI, P; RUMI, M; COLOMBO, M			HEPATITIS-C VIRUS TYPE-1B(II) INFECTION IN FRANCE AND ITALY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUS; HEPATITIS C; GENOTYPE; DNA, VIRAL; POLYMERASE CHAIN REACTION	RECOMBINANT INTERFERON-ALFA; POLYMERASE CHAIN-REACTION; HEPATOCELLULAR-CARCINOMA; B VIRUS; CONTROLLED TRIAL; GENOTYPES; SEQUENCE; LIVER; RNA; VARIABILITY	Objective: To analyze the distribution of hepatitis C virus (HCV) genotypes among patients positive for antibody to HCV (anti-HCV) according to age, severity of liver disease, and duration of infection; to investigate the influence of HCV genotypes on response to interferon-alpha therapy; and to study HCV viremia levels in relation to genotypes and severity of liver disease. Design: Cross-sectional study. Setting: 3 university hospitals and 2 research units. Patients: 3 groups of French and Italian patients with chronic HCV infection and detectable serum HCV RNA: Group 1 included 35 patients with hepatocellular carcinoma; group 2, 71 patients with cirrhosis who did not have hepatocellular carcinoma; and group 3, 114 patients with chronic active hepatitis. 106 of the patients with chronic hepatitis or cirrhosis were treated with interferon-alpha (3 MU subcutaneously 3 times/wk for greater than or equal to 6 months). Measurements: Genotyping by polymerase chain reaction with capsid-specific primers; serum HCV RNA by branched DNA (bDNA) signal amplification. Results: Hepatitis C virus genotype 1b (II) was the most prevalent genotype (61.8%). In a univariate analysis, it was associated with older age (<40 years, 47.4%; greater than or equal to 60 years, 80.4%; P = 0.001), longer duration of disease (less than or equal to 10 years, 40.4%; greater than or equal to 20 years, 86.7%; P = 0.005), and cirrhosis with or without hepatocellular carcinoma 78.4% compared with 53.8% for chronic hepatitis; P < 0.001). Viremia levels did not differ between patients infected with HCV type 1b (II) and those infected with other HCV genotypes. Patients with HCV type 1b (II) responded to interferon-alpha therapy significantly less than did patients with other HCV genotypes (P = 0.01). In a multivariate analysis, age and cirrhosis were independently associated with HCV genotype 1b (II). Genotype and HCV viremia level were independent predictors of response to interferon-alpha therapy. Conclusions: The prevalence of HCV genotypes in French and Italian patients has been changing; the prevalence of HCV type 1b (II) infection has progressively decreased, although it still accounts for most HCV-related cirrhosis and hepatocellular carcinoma. High HCV viremia levels and HCV genotype type 1b (II) are independent predictors for poor response to interferon-alpha therapy and should be considered in the management of patients with HCV infection.	HOP NECKER ENFANTS MALAD, F-75015 PARIS, FRANCE; INST PASTEUR, PARIS, FRANCE; JICHI MED SCH, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; UNIV MILAN, MILAN, ITALY; HOP P BROUSSE, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Jichi Medical University; University of Milan			Nalpas, Bertrand/M-4981-2018; Okamoto, Hiroaki/H-4371-2011; Feray, Cyrille/S-2559-2018	Okamoto, Hiroaki/0000-0003-0827-0964; Nalpas, Bertrand/0000-0002-8215-2942				Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; COLLETT MS, 1989, J GEN VIROL, V70, P253, DOI 10.1099/0022-1317-70-2-253; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, GASTROENTEROLOGY, V104, P549, DOI 10.1016/0016-5085(93)90425-C; KATO N, 1993, J VIROL, V67, P3923, DOI 10.1128/JVI.67.7.3923-3930.1993; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LI JS, 1991, GENE, V105, P167; LOK ASF, 1990, HEPATOLOGY, V12, P582, DOI 10.1002/hep.1840120322; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; POZZATO G, 1992, Journal of Hepatology, V16, pS3; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHERMAN KE, 1993, J CLIN MICROBIOL, V31, P2679, DOI 10.1128/JCM.31.10.2679-2682.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Urdea M S, 1991, Nucleic Acids Symp Ser, P197; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	39	516	528	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					161	+		10.7326/0003-4819-122-3-199502010-00001	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810932				2022-12-01	WOS:A1995QD73300001
J	PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D				PAWLOTSKY, JM; ROUDOTTHORAVAL, F; SIMMONDS, P; MELLOR, J; BENYAHIA, M; ANDRE, C; VOISIN, MC; INTRATOR, L; ZAFRANI, ES; DUVAL, J; DHUMEAUX, D			EXTRAHEPATIC IMMUNOLOGICAL MANIFESTATIONS IN CHRONIC HEPATITIS-C AND HEPATITIS-C VIRUS SEROTYPES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C; HEPATITIS C VIRUSES; HEPATITIS, CHRONIC ACTIVE; SEROTYPING; CRYOGLOBULINEMIA	ESSENTIAL MIXED CRYOGLOBULINEMIA; POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA THERAPY; INFECTION; GENOTYPES; SEQUENCE; HCV; AUTOANTIBODIES; REGION; TYPE-1	Objective: To determine, using a serotyping assay, whether the occurrence of extrahepatic immunologic disorders in patients with chronic hepatitis C is dependent on hepatitis C virus serotype. II Design: Prospective study. Setting: Liver unit and virology laboratory of a university hospital. Patients: 59 consecutive patients with chronic hepatitis C. Measurements: Hepatitis C virus serotype was determined using a recently developed immunoenzymatic assay that detects antibodies directed to serotype-specific immunodominant epitopes. Cryoglobulin, rheumatoid factor, and numerous antitissue antibodies were sought. Biopsies of labial salivary glands were done in 49 of the 59 patients. Results: Prevalence was 59% for serotype 1, 10% for serotype 2, 12% for serotype 3, and 3% for mixed infection. Fifteen percent of patients could not be serotyped. Cryoglobulinemia was found in 36% of patients and rheumatoid factor was found in the serum of 71%. At least one antitissue antibody was found in the serum of 41% of patients; salivary gland biopsy showed lymphocytic capillaritis in 49% of patients. These immunologic abnormalities were seen in patients infected with any of the three serotypes, and prevalences of the abnormalities did not differ significantly among patients infected with different serotypes. Conclusions: We confirm that the prevalence of extrahepatic immunologic abnormalities is high in patients with chronic hepatitis C. These abnormalities may occur in patients infected with any of the three major hepatitis C virus serotypes now present in developed countries.	UNIV PARIS 12, CRETEIL, FRANCE; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); University of Edinburgh			Pawlotsky, Jean-Michel/R-8159-2018	Simmonds, Peter/0000-0002-7964-4700; Pawlotsky, Jean-Michel/0000-0003-0745-7559				ABUAF N, 1993, J HEPATOL, V18, P359, DOI 10.1016/S0168-8278(05)80281-8; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALONSO C, 1994, J CLIN MICROBIOL, V32, P211, DOI 10.1128/JCM.32.1.211-212.1994; AUTHIER FJ, 1993, ANN NEUROL, V34, P749, DOI 10.1002/ana.410340524; BRECHOT C, 1993, J HEPATOL, V17, P265, DOI 10.1016/S0168-8278(05)80203-X; BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CZAJA AJ, 1992, GASTROENTEROLOGY, V103, P1290, DOI 10.1016/0016-5085(92)91518-9; DAMMACCO F, 1992, CLIN EXP IMMUNOL, V87, P352, DOI 10.1111/j.1365-2249.1992.tb03001.x; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FERAY C, 1993, HEPATOLOGY, V18, pA59, DOI 10.1016/0270-9139(93)91763-I; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JUBERT C, 1994, ARCH DERMATOL, V130, P73, DOI 10.1001/archderm.130.1.73; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LI JS, 1991, GENE, V105, P167; LUNEL F, 1994, GASTROENTEROLOGY, V106, P1291, DOI 10.1016/0016-5085(94)90022-1; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MAGRIN S, 1991, J HEPATOL, V13, P364, DOI 10.1016/0168-8278(91)90082-M; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MARCELLIN P, 1993, GASTROENTEROLOGY, V104, P272, DOI 10.1016/0016-5085(93)90862-7; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; PAWLOTSKY JM, 1994, HEPATOLOGY, V19, P841, DOI 10.1016/0270-9139(94)90281-X; PAWLOTSKY JM, 1993, GUT, V34, pS66, DOI 10.1136/gut.34.2_Suppl.S66; PISTELLO M, 1994, J CLIN MICROBIOL, V32, P232, DOI 10.1128/JCM.32.1.232-234.1994; ROITT IM, 1972, WHO BOOKLET IMMUNOLO, P1; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1002/hep.1840190538; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1993, J HEPATOL, V17, P277, DOI 10.1016/S0168-8278(05)80205-3; TRAN A, 1993, HEPATOLOGY, V18, P253, DOI 10.1002/hep.1840180205; YAMAMOTO AM, 1993, GASTROENTEROLOGY, V104, P1762, DOI 10.1016/0016-5085(93)90657-X; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	48	317	324	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					169	173		10.7326/0003-4819-122-3-199502010-00002	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810933				2022-12-01	WOS:A1995QD73300002
J	SCHILLING, RF				SCHILLING, RF			ESTIMATING THE RISK FOR SEPSIS AFTER SPLENECTOMY IN HEREDITARY SPHEROCYTOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							INFECTIONS; ADULTS				SCHILLING, RF (corresponding author), UNIV WISCONSIN, DEPT MED, 1300 UNIV AVE, MADISON, WI 53706 USA.							Gardner M, 1989, BRIT MED J; GARDNER MJ, 1989, BRIT MED J, P52; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; KONRADSEN HB, 1991, ACTA PAEDIATR SCAND, V80, P423, DOI 10.1111/j.1651-2227.1991.tb11877.x; MACKINNEY AA, 1962, J CLIN INVEST, V41, P554, DOI 10.1172/JCI104509; ONEAL BJ, 1981, ANN SURG, V194, P775, DOI 10.1097/00000658-198112000-00020; SCHILLING RF, 1976, SEMIN HEMATOL, V13, P169; SCHWARTZ PE, 1982, JAMA-J AM MED ASSOC, V248, P2279, DOI 10.1001/jama.248.18.2279; Singer D B, 1973, Perspect Pediatr Pathol, V1, P285; TEARE L, 1992, LANCET, V340, P1362, DOI 10.1016/0140-6736(92)92555-T; ZARRABI MH, 1984, ARCH INTERN MED, V144, P1421, DOI 10.1001/archinte.144.7.1421	11	65	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					187	188		10.7326/0003-4819-122-3-199502010-00005	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810936				2022-12-01	WOS:A1995QD73300005
J	WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F				WHALEN, CM; HOCKIN, JC; RYAN, A; ASHTON, F			THE CHANGING EPIDEMIOLOGY OF INVASIVE MENINGOCOCCAL-DISEASE IN CANADA, 1985 THROUGH 1992 - EMERGENCE OF A VIRULENT CLONE OF NEISSERIA-MENINGITIDIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECEMBER 1991; FEBRUARY 1992; INFLUENZA-A; INFECTIONS; OUTBREAK; AGE	Objective.-To describe the occurrence of invasive meningococcal disease (IMD) in Canada with respect to demographic variables and characteristics of the isolated strains of Neisseria meningitidis. Design.-National surveillance case series. Setting.-Canada, 1985 through 1992. Outcome Measures.-Morbidity and mortality. Main Results.-The incidence of IMD averaged 1.38 per 100 000 person-years, with considerable regional variation. In 1988, serogroup C organisms became more common, with one strain of the electrophoretic type 37 (ET-37) complex of N meningitidis,termed ET-15, the predominant group C strain identified. With the increase in group C disease, a greater proportion of cases were older than 5 years. By 1991, ET-15 was the most common strain identified in most parts of the country. Electrophoretic type 15 had a case fatality of 17.8% vs 8.1% for all other IMD (P<.001). Among cases 20 years and older the case fatality for ET-15 was 22.4%. Conclusions.-The group C, ET-15 strain of N meningitidis, first identified in Canada, was more virulent than other prevalent strains during this period, Active surveillance, rapid identification, and typing of N meningitidis will assist public health decision making in the control of emerging strains.	HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR COMMUNICABLE DIS EPIDEMIOL,OTTAWA,ON K1A 0L2,CANADA; HLTH & WELF CANADA,HLTH PROTECT BRANCH,LAB CTR DIS CONTROL,BUR MICROBIOL,NATL LAB BACTERIOL,OTTAWA,ON K1A 0L2,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA	University of Ottawa								ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BAKER CJ, 1983, PEDIATRICS, V71, P923; BOUCHARD F, 1992, CAN J PUBLIC HEALTH, V83, P131; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CORBETTFEENEY G, 1991, IRISH J MED SCI, V160, P134, DOI 10.1007/BF02965936; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1988, J MED MICROBIOL, V26, P161; FARLEY JD, 1992, CAN J PUBLIC HEALTH, V83, P138; GEMMILL I, 1992, CAN J PUBLIC HEALTH, V83, P134; GOLD R, 1992, CAN J PUBLIC HEALTH, V83, P5; HOCKIN J, 1993, 3RD NAT M CAN SOC EP; HUBERT B, 1992, J INFECT DIS, V166, P542, DOI 10.1093/infdis/166.3.542; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; JAFARI H, 1993, 33RD P INT C ANT AG; Jones D M, 1988, J Med Microbiol, V26, P165; Jones D M, 1994, Commun Dis Rep CDR Rev, V4, pR97; KRANSINSKI K, 1987, AM J EPIDEMIOL, V125, P499; LABIN LL, 1978, STATISTICS MODERN BU, P561; Le Saux N, 1992, Can J Infect Dis, V3, P60; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; PELTOLA H, 1982, LANCET, V2, P595; REILLY S, 1991, LANCET, V338, P1143, DOI 10.1016/0140-6736(91)91999-B; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P837; STROFFOLINI T, 1989, J INFECTION, V19, P69, DOI 10.1016/S0163-4453(89)94980-3; SWEET L, 1992, CAN J PUBLIC HEALTH, V83, P129; Varughese P V, 1989, Can Dis Wkly Rep, V15, P89; VARUGHESE PV, 1987, EVOLUTION MENINGOCOC, V1, P47; Varughese PV, 1983, CAN DIS WKLY REP, V9, P177; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320; WHITE K, 1992, CAN J PUBLIC HEALTH, V83, P141; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1985, 84208 DEP SUPPL SERV; 1991, NOTIFIABLE DISEASES; 1994, CAN COMMUNICABLE DIS, V20, P17; 1994, B INFORM MALAD INFEC, V1, P5; 1993, CAN COMMUNICABLE DIS, V19, P184; 1991, CAN DIS WKLY REP, V17, P295; 1991, CAN DIS WKLY REP, V17, P293; 1992, CAN COMMUNICABLE DIS, V18, P137; 1991, CAN DIS WKLY REP S3, V17, P24; 1994, 1993 DEP SUPPL SERV; 1989, CAN MED ASSOC J, V141, P567	43	147	150	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	1995	273	5					390	394		10.1001/jama.273.5.390	http://dx.doi.org/10.1001/jama.273.5.390			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD203	7823384				2022-12-01	WOS:A1995QD20300023
J	ARNOW, P; CHAMBERLIN, W				ARNOW, P; CHAMBERLIN, W			DEBUGGING COMPUTER-ASSISTED ANTIBIOTIC PRESCRIBING	LANCET			English	Editorial Material									MICHAEL REESE HOSP & MED CTR,CHICAGO,IL 60616	Michael Reese Hospital & Medical Center	ARNOW, P (corresponding author), UNIV CHICAGO HOSP & CLIN,DEPT MED,CHICAGO,IL 60637, USA.							EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; GARDNER FT, 1979, ARCH SURG-CHICAGO, V114, P883; GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MOSS FM, 1981, LANCET, V2, P407; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; STURM AW, 1988, J ANTIMICROB CHEMOTH, V22, P257, DOI 10.1093/jac/22.2.257; YU VI, 1976, JAMA-J AM MED ASSOC, V242, P1279; YU VL, 1991, AM J MED SCI, V301, P165, DOI 10.1097/00000441-199103000-00003; 1994, J ANTIMICROB CHEMOTH, V34, P21	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	208		10.1016/S0140-6736(95)90219-8	http://dx.doi.org/10.1016/S0140-6736(95)90219-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823711				2022-12-01	WOS:A1995QD53200005
J	BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL				BUCKLEY, NA; DAWSON, AH; WHYTE, IM; OCONNELL, DL			RELATIVE TOXICITY OF BENZODIAZEPINES IN OVERDOSE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TEMAZEPAM	Objective-To assess the sedative effects in overdose of temazepam and oxazepam compared with other benzodiazepines to determine if this explains reported differences in fatal toxicity. Design-Cohort study of patients admitted with benzodiazepine poisoning. Setting-Newcastle, Australia. Subjects-303 patients who had ingested benzodiazepine alone or in combination with alcohol and presented to a general hospital which served a well defined geographical area. Main outcome measures-Degree of sedation: Glasgow coma score, McCarron Score, and whether patients were stuporose or comatose. Results-Oxazepam produced less and temazepam more sedation than other benzodiazepines. Unadjusted odds ratios for coma with oxazepam and temazepam compared with other benzodiazepines were 0.0 (95% confidence interval 0.0 to 0.85) and 1.86 (0.68 to 4.77) respectively, chi(2) = 7.08, 2df, P = 0.03. After adjustment for potentially confounding effects of age, dose ingested, and coingestion of alcohol, the odds ratios were 0.22 (0.0 to 1.43) for oxazepam and 1.94 (0.57 to 6.23) for temazepam. Similar results were obtained for other measures of sedation. Conclusions-These results were in accordance with fatal toxicity indices derived from coroners' data on mortality and rates of prescription. The relative safety of benzodiazepines in overdose should be a consideration when they are prescribed.	UNIV NEWCASTLE, DEPT PHARMACOL, NEWCASTLE, NSW 2298, AUSTRALIA; NEWCASTLE MATER MISERICORDIAE HOSP, NEWCASTLE, NSW 2298, AUSTRALIA; UNIV NEWCASTLE, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW, AUSTRALIA	University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle	BUCKLEY, NA (corresponding author), UNIV NEWCASTLE, DEPT CLIN TOXICOL, NEWCASTLE, NSW 2298, AUSTRALIA.		Dawson, Andrew/D-5085-2012; Dawson, Andrew H/U-8041-2019; Whyte, Ian/A-1621-2010; Buckley, Nicholas A/D-4030-2012	Dawson, Andrew/0000-0002-8047-397X; Dawson, Andrew H/0000-0002-8047-397X; Whyte, Ian/0000-0001-7693-3948; Buckley, Nicholas A/0000-0002-6326-4711				ALEXANDER B, 1991, J SUBST ABUSE TREAT, V8, P9, DOI 10.1016/0740-5472(91)90022-3; BUCKLEY NA, IN PRESS MED J AUST; BUSTO U, 1980, AM J PSYCHIAT, V137, P224; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CROME P, 1993, ACTA PSYCHIAT SCAND, V87, P33, DOI 10.1111/j.1600-0447.1993.tb05371.x; Dwyer P S, 1984, Hum Toxicol, V3 Suppl, p145S; FORREST ARW, 1986, LANCET, V2, P226; FUCCELLA LM, 1977, EUR J CLIN PHARMACOL, V12, P383, DOI 10.1007/BF00562455; GAUDREAULT P, 1991, DRUG SAFETY, V6, P247, DOI 10.2165/00002018-199106040-00003; GREENBLATT DJ, 1989, ARCH GEN PSYCHIAT, V46, P326; HOJER J, 1989, J INTERN MED, V226, P117; JOHNS MW, 1977, BRIT MED J, V1, P1128, DOI 10.1136/bmj.1.6069.1128; MARTIN CD, 1986, J ANAL TOXICOL, V10, P77, DOI 10.1093/jat/10.2.77; MCCARRON MM, 1982, JAMA-J AM MED ASSOC, V248, P55, DOI 10.1001/jama.248.1.55; MEHTA C, 1993, LOGXACT VERSION 1 1; MITLER MM, 1981, PHARMACOTHERAPY, V1, P3; SERFATY M, 1993, BRIT J PSYCHIAT, V163, P386, DOI 10.1192/bjp.163.3.386; 1994, DATA AUSTR DRUG UTIL	18	52	55	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	1995	310	6974					219	221		10.1136/bmj.310.6974.219	http://dx.doi.org/10.1136/bmj.310.6974.219			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866122	Green Published			2022-12-01	WOS:A1995QE49600020
J	CATANZARO, A				CATANZARO, A			PREVENTING NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	LANCET			English	Editorial Material									UNIV CALIF SAN DIEGO,MED CTR,DEPT FAMILY & PREVENT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego	CATANZARO, A (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DEPT MED,SAN DIEGO,CA 92103, USA.							ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; 1995, LANCET, V345, P235; 1993, FED REGISTER, V58, P52810	5	10	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					204	205		10.1016/S0140-6736(95)90216-3	http://dx.doi.org/10.1016/S0140-6736(95)90216-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823708				2022-12-01	WOS:A1995QD53200002
J	GENUIS, SJ; GENUIS, SK				GENUIS, SJ; GENUIS, SK			ADOLESCENT SEXUAL INVOLVEMENT - TIME FOR PRIMARY PREVENTION	LANCET			English	Editorial Material							EDUCATION; SWEDEN; SCHOOL											BOWIE WR, 1993, CAN J OBSTET GYNECOL, V5, P399; GENUIS SJ, 1993, J SOC OBSTET GYNECOL, V15, P552; GRIFFIN GC, 1993, POSTGRAD MED, V93, P21; GULLY PR, 1992, CAN MED ASSOC J, V147, P893; HAUSSER D, 1994, PEDIATRICS, V93, P580; HERLITZ C, 1992, SCAND J SOC MED, V20, P102, DOI 10.1177/140349489202000207; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; KLEIN J, 1994, NEWSWEEK, V123, P29; MCKEOWN DJ, 1993, SEXUAL HLTH DATA REP; PERSSON E, 1992, GENITOURIN MED, V68, P26; POWELL MG, 1993, CAN J OBSTET GYNECOL, V5, P383; POWELL MG, 1993, TREAT FEMALE PATIENT, V7, P10; ROSENFELD WD, 1991, PEDIATR ANN, V20, P303, DOI 10.3928/0090-4481-19910601-07; STOUT JW, 1989, PEDIATRICS, V83, P375; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1993, PROG HUM REPROD RES, V27, P6; 1991, MMWR-MORBID MORTAL W, V39, P929	17	14	14	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					240	241		10.1016/S0140-6736(95)90229-5	http://dx.doi.org/10.1016/S0140-6736(95)90229-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD532	7741863				2022-12-01	WOS:A1995QD53200015
J	HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T				HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T			AGGRESSIVENESS OF SCREEN-DETECTED BREAST CANCERS	LANCET			English	Article							DNA FLOW-CYTOMETRY; PROGNOSTIC VALUE; MAMMOGRAPHY; EXPRESSION; FEATURES; SURVIVAL	It is not clear whether screening for breast cancer works as public hearth policy and whether early indicators of effect predict an ultimate reduction in mortality. The malignant potentials of 248 breast cancers detected by the screening service in Finland were compared with those of 490 control cancers diagnosed before the screening service was established. Aggressiveness was assessed by DNA flow cytometry and clinical status by cancer size and node involvement. After the first screening round, the results of DNA flow cytometry were the same in cancers diagnosed by screening and in controls; these findings are consistent with the hypothesis that the biological aggressiveness of breast cancer remains constant as the cancer progresses. The proportion of patients with node-negative and small T1 cancers after the first screening was higher among the screened population than among controls, indicating earliness of diagnosis among those screened. Cancers diagnosed in the first round had a low malignant potential, as indicated by the DNA flow-cytometry and by clinical stage. Lower aggressiveness of cancers found by screening than of control cancers would indicate overdiagnosis or length-biased sampling, but not earliness of diagnosis. Screening with mammography is practised as a public health policy in Finland. The results predict that the mortality reduction found in randomised trials can be repeated with a screening service.	FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; UNIV TAMPERE, DEPT BIOMED SCI, SF-33101 TAMPERE, FINLAND; PIRKANMAA CANC SOC, TAMPERE, FINLAND; HATANPAA HOSP, TAMPERE, FINLAND; SATAKUNTA CANC SOC, PORI, FINLAND; KYMENLAAKSO CANC SOC, KOTKA, FINLAND	Finnish Cancer Registry; Tampere University; Tampere University Hospital; Tampere University	HAKAMA, M (corresponding author), UNIV TAMPERE, DEPT PUBL HLTH, BOX 607, SF-33101 TAMPERE, FINLAND.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332				CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COLE P, 1978, SCREENING CANCER REP; DAY NE, 1991, CANCER SCREENING, P391; DAY NE, 1988, SCREENING BREAST CAN; DONN AS, 1985, B CANCER, V72, P381; HAKAMA M, 1991, BRIT J CANCER, V64, P962, DOI 10.1038/bjc.1991.436; ISOLA J, 1993, J CLIN ONCOL, V11, P36, DOI 10.1200/JCO.1993.11.1.36; ISOLA J, 1992, J NATL CANCER I, V84, P874; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KALLIONIEMI OP, 1991, CYTOMETRY, V12, P413, DOI 10.1002/cyto.990120506; KALLIONIEMI OP, 1988, INT J CANCER, V42, P697, DOI 10.1002/ijc.2910420511; KALLIONIEMI OP, 1988, CANCER, V62, P88; MILLER AB, 1991, CANCER SCREENING, P1; PEETERS PHM, 1989, INT J EPIDEMIOL, V18, P295, DOI 10.1093/ije/18.2.295; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; SAXEN E, 1964, ANN MED EXP BIOL FEN, V42, P1; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; UYTERLINDE AM, 1991, INT J CANCER, V48, P173, DOI 10.1002/ijc.2910480204; Zelen M., 1976, BREAST CANCER TRENDS, P287	20	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					221	224						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7741862				2022-12-01	WOS:A1995QD53200009
J	JICK, SS; DEAN, AD; JICK, H				JICK, SS; DEAN, AD; JICK, H			ANTIDEPRESSANTS AND SUICIDE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To estimate the rate and means of suicide among people taking 10 commonly prescribed antidepressant drugs: dothiepin, amitriptyline, clomipramine, imipramine, flupenthixol, lofepramine, mianserin, fluoxetine, doxepin, and trazodone. Design-Open cohort study with a nested case-control analysis. Setting-General practices in the United Kingdom that used VAMP computers to maintain their patient records from January 1988 to February 1993. Subjects-172 598 people who had at least one prescription for one of the 10 antidepresssants during the study period. Main outcome measure-Suicide confirmed by general practitioner or on death certificate, or both. Results-143 people committed suicide. The overall rate of suicide was estimated to be 8.5 per 10 000 person years (95% confidence interval 7.2 to 10.0). Rates of suicide were higher in men than women (relative risk 2.8 (95% confidence interval 1.9 to 4.0)), people with a history of feeling suicidal (19.2 (9.5 to 38.7)), and people who had taken several different antidepressants (2.8 (1.8 to 4.3)). People who received high doses of antidepressants and those who had had a prescription in the 30 days before they committed suicide were also at higher risk than those who had received low doses and had had their prescriptions 30 or more days previously (2.3 (1.4 to 3.7) and 2.3 (1.6 to 3.4)) respectively. Rates of suicide were higher in patients who received fluoxetine, but this may be explained by selection biases which were present for those drug users. Conclusion-Several factors correlate with the risk of suicide in people taking antidepressants. After controlling for these factors, the risk of suicide was similar among the 10 study antidepressants. Overdose with antidepressants accounted for only 14% of the suicides.			JICK, SS (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				CASSIDY S, 1982, BRIT MED J, V295, P1021; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1992, PHARMACOTHERAPY, V12, P451; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; LEONARD BE, 1986, LANCET, V1, P1105; MONTGOMERY SA, 1992, INT CLIN PSYCHOPHARM, V95, P22; PAYNE CD, 1986, GENERALISED LINEAR I; Perry J, 1978, OXMIS PROBLEM CODES; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; TEICHER MN, 1991, J CLIN PSYCHIAT, V52, P108; 1993, EPILOG PLUS VERSION	15	205	208	2	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					215	218		10.1136/bmj.310.6974.215	http://dx.doi.org/10.1136/bmj.310.6974.215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7677826	Green Published			2022-12-01	WOS:A1995QE49600018
J	SCOTT, G				SCOTT, G			NONINVASIVE TESTS FOR CHLAMYDIA-TRACHOMATIS	LANCET			English	Editorial Material							URINE SPECIMENS				SCOTT, G (corresponding author), ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH,MIDLOTHIAN,SCOTLAND.							CHERNESKY MA, 1994, J INFECT DIS, V170, P1308, DOI 10.1093/infdis/170.5.1308; JASCHEK G, 1993, J CLIN MICROBIOL, V31, P1209, DOI 10.1128/JCM.31.5.1209-1212.1993; JONES RB, 1986, J CLIN MICROBIOL, V24, P1029, DOI 10.1128/JCM.24.6.1029-1033.1986; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; MOSS TR, 1993, SEX TRANSM DIS, V20, P61, DOI 10.1097/00007435-199303000-00001; SCHACHTER J, 1992, SEX TRANSM DIS, V19, P243, DOI 10.1097/00007435-199209000-00001; SVENSSON LO, 1991, GENITOURIN MED, V67, P117; 1995, LANCET, V345, P213	8	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	207		10.1016/S0140-6736(95)90218-X	http://dx.doi.org/10.1016/S0140-6736(95)90218-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823710				2022-12-01	WOS:A1995QD53200004
J	SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J				SOYSETH, V; KONGERUD, J; HAARR, D; STRAND, O; BOLLE, R; BOE, J			RELATION OF EXPOSURE TO AIRWAY IRRITANTS IN INFANCY TO PREVALENCE OF BRONCHIAL HYPERRESPONSIVENESS IN SCHOOLCHILDREN	LANCET			English	Article							INHALED HISTAMINE; ASTHMA; CHILDREN; SYMPTOMS	To find out whether exposure to sulphur dioxide during infancy is related to the prevalence of bronchial hyperresponsiveness (BHR), we studied schoolchildren (aged 7-13 years) from two areas of Norway-a Valley containing a sulphur-dioxide-emitting aluminium smelter and a similar but non-industrialised valley. Bronchial responsiveness was assessed in 529 of the 620 participants. The median exposures to sulphur dioxide and fluoride were 37.1 mu g/m(3) and 4.4 mu g/m(3) at ages 0-12 months and 37.9 mu g/m(3) and 4.4 mu g/m(3) at 13-36 months. The risk of BHR increased with exposure to sulphur dioxide and fluoride at these ages; the odds ratio for a 10 mu g/m(3) increase in sulphur dioxide exposure at 0-12 months was 1.62 (95% CI 1.11-2.35) and that for a 1 mu g/m(3) increase in fluoride exposure was 1.35 (1.07-1.70) at 0-12 months and 1.38 (1.05-1.82) at 13-36 months. Exposure to these low concentrations of airway irritants during early childhood is associated with an increased prevalence of BHR in schoolchildren.	UNIV OSLO, RIKSHOSP, DEPT THORAC MED, N-0027 OSLO, NORWAY; ARDAL MUNICIPAL, PRIMARY HLTH CARE UNIT, ARDALSTANGEN, NORWAY; REG HOSP, DEPT PAEDIAT, TROMSO, NORWAY	University of Oslo; National Hospital Norway	SOYSETH, V (corresponding author), HYDRO ALUMINIUM ARDAL, N-5870 OVRE ARDAL, NORWAY.							ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BELIN L, 1985, ALLERGY S4, V40, P60; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION, P340; DAVIES RJ, 1993, AGENT ACTION SUPPL, V43, P87; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; ERNST P, 1986, AM REV RESPIR DIS, V133, P307; FERRIS BG, 1988, EPIDEMIOLOGY HLTH RI, P120; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; KONGERUD J, 1991, EUR RESPIR J, V4, P159; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MANTEL N, 1959, J NATL CANCER I, V22, P719; Miettinen O.S., 1985, THEORETICAL EPIDEMIO; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; ROBINS JM, 1986, BIOMETRICS, V68, P525; RONNEBERG A, 1994, INT J EPIDEMIOL, V23, P267, DOI 10.1093/ije/23.2.267; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P84; SHEPPARD D, 1988, J ALLERGY CLIN IMMUN, V82, P961, DOI 10.1016/0091-6749(88)90131-5; SOYSETH V, IN PRESS CHEST; STEENJOHNSEN J, 1993, NOR J EPIDEMIOL, V3, P44; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WEINBERG CR, 1993, AM J EPIDEMIOL, V137, P1	25	40	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					217	220		10.1016/S0140-6736(95)90222-8	http://dx.doi.org/10.1016/S0140-6736(95)90222-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823714				2022-12-01	WOS:A1995QD53200008
J	STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG				STEIN, A; STEIN, J; WALTERS, EA; FAIRBURN, CG			EATING HABITS AND ATTITUDES AMONG MOTHERS OF CHILDREN WITH FEEDING DISORDERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,PARK HOSP CHILDREN,CHILD & ADOLESCENT PSYCHIAT SECT,OXFORD OX3 7LQ,ENGLAND; UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND	University of Oxford; University of Oxford			Fairburn, Christopher/AAM-9792-2020; Fairburn, Christopher/AAG-6234-2019	Fairburn, Christopher/0000-0002-9673-9795; Stein, Alan/0000-0001-8207-2822; Stein, Jurgen/0000-0003-3558-3341	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1992, ICD 10 CLASSIFICATIO; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FAIRBURN CG, IN PRESS INT J EAT D; SKUSE D, 1994, CHILD ADOL PSYCH CL, P467; STEIN A, 1994, J CHILD PSYCHOL PSYC, V35, P733, DOI 10.1111/j.1469-7610.1994.tb01218.x	5	29	29	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					228	228		10.1136/bmj.310.6974.228	http://dx.doi.org/10.1136/bmj.310.6974.228			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QE496	7866126	Green Published			2022-12-01	WOS:A1995QE49600024
J	THOMAS, BA				THOMAS, BA			POPULATION BREAST-CANCER SCREENING - THEORY, PRACTICE, AND SERVICE IMPLICATIONS	LANCET			English	Editorial Material											THOMAS, BA (corresponding author), JARVIS BREAST SCREENING TRAINING & DIAGNOST CTR, GUILDFORD, SURREY, ENGLAND.							HAKAMA M, 1995, LANCET, V345, P221; Moss S M, 1994, J Med Screen, V1, P193; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; THOMAS BA, 1989, INT CONGR SER, V865, P11; Wald NJ, 1993, BREAST, V2, P209; YOUNG KC, 1994, CLIN RADIOL, V49, P461, DOI 10.1016/S0009-9260(05)81741-6; 1993, STANDARDS NHS BREAST; 1991, CMO91, P15	10	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 28	1995	345	8944					205	207		10.1016/S0140-6736(95)90217-1	http://dx.doi.org/10.1016/S0140-6736(95)90217-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823709				2022-12-01	WOS:A1995QD53200003
J	WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR				WENGER, PN; OTTEN, J; BREEDEN, A; ORFAS, D; BECKSAGUE, CM; JARVIS, WR			CONTROL OF NOSOCOMIAL TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AMONG HEALTH-CARE WORKERS AND HIV-INFECTED PATIENTS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; OUTBREAK; RISK	From 1988 to 1990, an outbreak of multidrug-resistant tuberculosis (MDR-TB) among patients, and an increased number of tuberculin-skin-test conversions among healthcare workers, occurred on the HIV ward of Jackson Memorial Hospital, Miami, Florida, USA. Measures similar to those subsequently recommended in the 1990 Centers for Disease Control and Prevention guidelines were implemented on the HIV ward by June, 1990, and in September, 1992, we evaluated the efficacy of these control measures. Among MDR-TB patients and healthcare workers with tuberculin-skin-test conversions on the HIV ward, we looked for evidence of exposure to HIV ward MDR-TB patients positive for acid-fast bacilli in sputum during initial January-May, 1990) and follow-up (June, 1990-June, 1992) periods. Exposure before implementation of control measures to an infectious MDR-TB patient on the HIV ward was recorded in 12 of 15 (80%) MDR-TB patients during the initial period and 5 of 11(45%) MDR-TB patients during follow-up. After implementation of control measures, no episodes of MDR-TB could be traced to contact with infectious MDR-TB patients on the HIV ward. Skin-test conversions among workers on the HIV ward declined from 7 of 25 (28%) during the initial period to 3 of 17 (18%) in the early (June, 1990-February, 1998) and 0 of 23 in the late (March, 1991-June, 1992) follow-up periods (p<0.01). Skin-test conversions among healthcare workers were not associated with increased exposure to MDR-TB patients, and were not significantly higher among workers on the HIV ward than on a control ward without tuberculosis patients (3/27 vs 0/16). These data demonstrate that implementation of measures similar to the Centers for Disease Control and Prevention 1990 tuberculosis-control guidelines were effective in halting transmission of MDR-TB to healthcare workers and HIV-infected patients.	JACKSON MEM HOSP,OFF TB CONTROL,MIAMI,FL 33136; JACKSON MEM HOSP,OFF EMPLOYEE HLTH,MIAMI,FL 33136					Beck-Sague, Consuelo/0000-0001-9082-0165				BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RUDNIK J, 1993, 3RD ANN M SOC HOSP E; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1990, MMWR-MORBID MORTAL W, V39, P1; 1990, MMWR MORB MORTAL WKL, V39; 1990, AM REV RESPIR DIS, V142, P725; 1991, MMWR-MORBID MORTAL W, V40, P585	19	149	149	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					235	240		10.1016/S0140-6736(95)90228-7	http://dx.doi.org/10.1016/S0140-6736(95)90228-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823719	Bronze			2022-12-01	WOS:A1995QD53200014
J	WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P				WOODMAN, CBJ; THRELFALL, AG; BOGGIS, CRM; PRIOR, P			IS THE 3-YEAR BREAST SCREENING INTERVAL TOO LONG - OCCURRENCE OF INTERVAL CANCERS IN NHS BREAST SCREENING PROGRAMS NORTH-WESTERN REGION	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; TRIAL	Objective-To report the detection rate of interval cancers in women screened by the NHS breast screening programme. Design-Detection of interval cancers by computer Linkage of records held by the screening centres in the North Western Regional Health Authority with breast cancer registrations at the regional cancer registry. Setting-North Western Regional Health Authority. Subjects-137421 women screened between 1 March 1988 and 31 March 1992 who had a negative screening result. Results-297 invasive interval cancers were detected. The rate of detection of interval cancers expressed as a proportion of the underlying incidence was 31% in the first 12 months after screening, 52% between 12 and 24 months, and 82% between 24 and 36 months. Conclusion-The incidence of interval cancers in the third year after breast screening approaches that which would have been expected in the absence of screening and suggests that the three year interval between screens is too long.	WITHINGTON HOSP,MANCHESTER BREAST SCREENING SERV,MANCHESTER M20 0PT,LANCS,ENGLAND		WOODMAN, CBJ (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND.							ANDERSSON I, 1978, AM J ROENTGENOL, V130, P349, DOI 10.2214/ajr.130.2.349; BASSETT LW, 1987, RADIOLOGY, V165, P95, DOI 10.1148/radiology.165.1.3628795; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FRISELL J, 1987, BREAST CANCER RES TR, V9, P219, DOI 10.1007/BF01806383; PATNICK J, 1994, NHS BREAST SCREENING, P16; PEETERS PHM, 1989, BRIT J CANCER, V59, P929, DOI 10.1038/bjc.1989.196; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1985, LANCET, V2, P829; VANDIJCK JAAM, 1993, CANCER, V72, P1933, DOI 10.1002/1097-0142(19930915)72:6<1933::AID-CNCR2820720623>3.0.CO;2-N; VERBEEK ALM, 1984, LANCET, V1, P1222	13	120	120	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 28	1995	310	6974					224	226		10.1136/bmj.310.6974.224	http://dx.doi.org/10.1136/bmj.310.6974.224			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE496	7866124	Green Published			2022-12-01	WOS:A1995QE49600022
J	BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M				BOEHMELT, G; MADRUGA, J; DORFLER, P; BRIEGEL, K; SCHWARZ, H; ENRIETTO, PJ; ZENKE, M			DENDRITIC CELL PROGENITOR IS TRANSFORMED BY A CONDITIONAL V-REL ESTROGEN-RECEPTOR FUSION PROTEIN V-REIER	CELL			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; ANTIVIMENTIN MONOCLONAL-ANTIBODY; MOUSE BONE-MARROW; RETROVIRAL TRANSFORMATION; LYMPHOID-CELLS; EXPRESSION; ONCOGENE; GENE; DIFFERENTIATION; INVITRO	A conditional v-Rel estrogen receptor fusion protein, v-RelER, causes estrogen-dependent but otherwise unaltered v-rel-specific transformation of chicken bone marrow cells. Here, we demonstrate that such v-relER-transformed cells exhibit B lymphoid determinants in line with earlier studies on v-rel-transformed cells. However, following inactivation of v-RelER oncoprotein activity by administration of an estrogen antagonist, cells differentiate into antigen-presenting dendritic cells as judged by several morphological and functional criteria. Additionally, under yet different culture conditions, v-relER cells differentiate into cells resembling polymorphonuclear neutrophils. Our studies therefore suggest that the conditional v-RelER, and probably also the authentic v-Rel, transform a common progenitor for neutrophils and dendritic cells.	INST MOLEC PATHOL, A-1030 VIENNA, AUSTRIA; MAX PLANCK INST ENTWICKLUNGSBIOL, D-72076 TUBINGEN, GERMANY; SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARKA T, 1962, J HISTOCHEM CYTOCHEM, V10, P741, DOI 10.1177/10.6.741; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BENATAR T, 1991, EUR J IMMUNOL, V21, P2529, DOI 10.1002/eji.1830211033; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1982, J CELL PHYSIOL, P195; BEUG H, 1989, EUR J CLIN INVEST, V19, P491, DOI 10.1111/j.1365-2362.1989.tb00265.x; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOEHMELT G, 1994, IN PRESS P AVIAN IMM; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; CHEN CLH, 1982, J IMMUNOL, V129, P2580; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JEURISSEN SHM, 1992, IMMUNOLOGY, V77, P75; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Lucas A.M., 1961, ATLAS AVIAN HEMATOLO; MARMOR MD, 1993, J EXP MED, V177, P647, DOI 10.1084/jem.177.3.647; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; MUSSMAN HC, 1971, AVIAN DIS, V15, P483, DOI 10.2307/1588725; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OLAH I, 1992, ANAT RECORD, V232, P121, DOI 10.1002/ar.1092320113; OLAH I, 1992, ANAT RECORD, V233, P111, DOI 10.1002/ar.1092330115; OLAH I, 1992, ANAT RECORD, V233, P577, DOI 10.1002/ar.1092330412; OLSON LD, 1967, AM J VET RES, V28, P1501; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAPPERSBERGER K, 1990, J INVEST DERMATOL, V94, P700, DOI 10.1111/1523-1747.ep12876275; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHAT KA, 1992, AVIAN DIS, V36, P432, DOI 10.2307/1591524; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; ZHANG J, 1991, VIROLOGY, V183, P457, DOI 10.1016/0042-6822(91)90975-H; ZOOROB R, 1990, IMMUNOGENETICS, V31, P179, DOI 10.1007/BF00211553; ZUCKERFRANKLIN D, 1988, ATLAS BLOOD CELLS FU, V1, P157	53	52	54	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					341	352		10.1016/0092-8674(95)90417-4	http://dx.doi.org/10.1016/0092-8674(95)90417-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834754	Bronze			2022-12-01	WOS:A1995QD92400017
J	CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM				CHANG, MW; BARR, E; SELTZER, J; JIANG, YQ; NABEL, GJ; NABEL, EG; PARMACEK, MS; LEIDEN, JM			CYTOSTATIC GENE-THERAPY FOR VASCULAR PROLIFERATIVE DISORDERS WITH A CONSTITUTIVELY ACTIVE FORM OF THE RETINOBLASTOMA GENE-PRODUCT	SCIENCE			English	Article							MUSCLE CELL-PROLIFERATION; TRANSCRIPTION FACTOR; CYCLE; ATHEROSCLEROSIS; RESTENOSIS; PROTEIN; P53; OLIGONUCLEOTIDES; BINDING; INJURY	Vascular smooth muscle cell (SMC) proliferation in response to injury is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis after balloon angioplasty. The retinoblastoma gene product (Rb) is present in the unphosphorylated and active form in quiescent primary arterial SMCs, but is rapidly inactivated by phosphorylation in response to growth factor stimulation in vitro, A replication-defective adenovirus encoding a nonphosphorylatable, constitutively active form of Rb was constructed. Infection of cultured primary rat aortic SMCs with this virus inhibited growth factor-stimulated cell proliferation in vitro. Localized arterial infection with the virus at the time of balloon angioplasty significantly reduced SMC proliferation and neointima formation in both the rat carotid and porcine femoral artery models of restenosis, These results demonstrate the role of Rb in regulating vascular SMC proliferation and suggest a gene therapy approach for vascular proliferative disorders associated with arterial injury.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA; UNIV MICHIGAN, MED CTR, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Chicago; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Parmacek, Michael/0000-0003-1449-4665				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARR E, 1994, GENE THER, V1, P51; BARR E, 1994, TRENDS CARDIOVAS MED, V4, P57, DOI 10.1016/1050-1738(94)90010-8; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Chang M.-W., UNPUB; CHANG MW, IN PRESS MOL MED; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLOWES AW, 1983, LAB INVEST, V49, P327; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EPSTEIN SE, 1993, CIRCULATION, V88, P1351, DOI 10.1161/01.CIR.88.3.1351; FAULDS D, 1990, DRUGS, V39, P597, DOI 10.2165/00003495-199039040-00008; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GUZMAN LA, 1994, CIRCULATION, V90, P147; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; IP JH, 1990, J AM COLL CARDIOL, V15, P1667, DOI 10.1016/0735-1097(90)92845-S; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARPINSKI BA, 1989, MOL CELL BIOL, V9, P2588, DOI 10.1128/MCB.9.6.2588; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KIM DW, 1993, GENE, V134, P307; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIBBY P, 1992, CIRCULATION, V86, P47; LINDNER V, 1992, J CLIN INVEST, V90, P2044, DOI 10.1172/JCI116085; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480	57	417	455	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					518	522		10.1126/science.7824950	http://dx.doi.org/10.1126/science.7824950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824950				2022-12-01	WOS:A1995QD40300040
J	CHIANG, CM; ROEDER, RG				CHIANG, CM; ROEDER, RG			CLONING OF AN INTRINSIC HUMAN TFIID SUBUNIT THAT INTERACTS WITH MULTIPLE TRANSCRIPTIONAL ACTIVATORS	SCIENCE			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; NF-KAPPA-B; FUNCTIONAL-ANALYSIS; LESS PROMOTER; EXPRESSION; COMPLEX; VP16; IDENTIFICATION; COACTIVATORS	TFIID is a multisubunit protein complex comprised of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs). The TAFs in TFIID are essential for activator-dependent transcription, The cloning of a complementary DNA encoding a human TFIID TAF, TAF(II)55, that has no known homolog in Drosophila TFIID is now described. TAF(II)55 is shown to interact with the largest subunit(TAF(II)230) of human TFIID through its central region and with multiple activators-including Sp1, YY1, USF, CTF, adenoviral E1A, and human immunodeficiency virus-type 1 Tat proteins-through a distinct amino-terminal domain. The TAF(II)55-interacting region of Sp1 was localized to its DNA-binding domain, which is distinct from the glutamine-rich activation domains previously shown to interact with Drosophila TAF(II)110. Thus, this human TFIID TAF may be a co-activator that mediates a response to multiple activators through a distinct mechanism.	ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Rockefeller University								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chiang C M, 1993, Methods Mol Biol, V15, P189, DOI 10.1385/0-89603-244-2:189; Chiang C.-W., UNPUB; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REINBERG D, 1987, J BIOL CHEM, V262, P3310; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	49	362	369	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					531	536		10.1126/science.7824954	http://dx.doi.org/10.1126/science.7824954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824954				2022-12-01	WOS:A1995QD40300044
J	COFFIN, JM				COFFIN, JM			HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL SHUTTLE VECTOR; SINGLE REPLICATION CYCLE; REVERSE-TRANSCRIPTASE; T-CELL; INSITU HYBRIDIZATION; MUTATIONAL HOTSPOTS; BROAD-SPECTRUM; INFECTION; TYPE-1	Several recent reports indicate that the long, clinically latent phase that characterizes human immunodeficiency virus (HIV) infection of humans is not a period of viral inactivity, but an active process in which cells are being infected and dying at a high rate and in large numbers. These results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual. This turnover drives both the pathogenic process and (even more than mutation rate) the development of genetic variation. This variation includes the inevitable and, in principle, predictable accumulation of mutations such as those conferring resistance to antiviral drugs whose presence before therapy must be considered in the design of therapeutic strategies,			COFFIN, JM (corresponding author), TUFTS UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,136 HARRISON AVE,BOSTON,MA 02111, USA.				NCI NIH HHS [R35 CA 44385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Coffin J M, 1980, Ann N Y Acad Sci, V354, P410, DOI 10.1111/j.1749-6632.1980.tb27982.x; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JP, UNPUB; CRISE B, 1992, J VIROL, V66, P2296, DOI 10.1128/JVI.66.4.2296-2301.1992; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DOOLITTLE RF, 1990, CURR TOP MICROBIOL, V157, P1; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; ELGEN M, 1990, AIDS S1, V4, P585; ELGEN M, 1988, RNA GENETICS, V3, P3; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357; EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P655; FENYO EM, 1988, J VIROL, V62, P4414; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOJOBORI T, 1990, P NATL ACAD SCI USA, V87, P10015, DOI 10.1073/pnas.87.24.10015; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; LOVEDAY C, COMMUNICATION; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1992, CLIN IMMUNOL IMMUNOP, V64, P23, DOI 10.1016/0090-1229(92)90054-R; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; MONK RJ, 1992, J VIROL, V66, P3683, DOI 10.1128/JVI.66.6.3683-3689.1992; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYERS G, 1992, RETROVIRIDAE, P51; NAJERA I, 1995, J VIROL, V69, P23; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9839; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHMAN D, COMMUNICATION; RICHMAN DD, 1992, CURR TOP MICROBIOL, V176, P131; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SALSELA K, 1993, J VIROL, V67, P7423; SCHINAZI R, 1994, INT ANTIVIRAL NEWS, V2, P72; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUURMANN R, UNPUB; SCHWARTZ S, 1989, P NATL ACAD SCI USA, V86, P7200, DOI 10.1073/pnas.86.18.7200; SMITH TF, 1988, NATURE, V333, P573, DOI 10.1038/333573a0; TANTILLO J, 1994, J MOL BIOL, V243, P364; TARPLEY WG, COMMUNICATION; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; WAINHOBSON S, 1992, CURR TOP MICROBIOL, V176, P181; WEI X, 1995, NATURE, V373, P17; WOLINSKY SM, COMMUNICATION; 1994, LANCET, V343, P871	69	1629	1703	3	111	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					483	489		10.1126/science.7824947	http://dx.doi.org/10.1126/science.7824947			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824947				2022-12-01	WOS:A1995QD40300031
J	GUARINO, LA; SMITH, G; DONG, W				GUARINO, LA; SMITH, G; DONG, W			UBIQUITIN IS ATTACHED TO MEMBRANES OF BACULOVIRUS PARTICLES BY A NOVEL TYPE OF PHOSPHOLIPID ANCHOR	CELL			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; FATTY-ACID ACYLATION; CAPSID PROTEIN VP4; RNA-POLYMERASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; NUCLEOTIDE-SEQUENCE; GENE REGION; IDENTIFICATION; SITE; CHROMATOGRAPHY	Purified budded virions of Autographa californica nuclear polyhedrosis virus (AcNPV) contain abundant amounts of free ubiquitin, which has an altered electrophoretic mobility on SDS gels as compared with standard ubiquitin. Phase extraction of virion proteins with Triton X-114 indicated that the modified form of ubiquitin behaved as an integral membrane protein. The membrane-bound form of ubiquitin was labeled with both phosphate and palmitate, and its electrophoretic mobility was altered by treatment with phospholipase A2 and a phosphatidylcholine-specific phospholipase D. Mild trypsin digestion indicated that the acyl group was not linked to the C-terminus of the protein. Acylated ubiquitin could not be radiolabeled with a membrane-impermeable Bolton-Hunter reagent unless virus was pretreated with detergent. Together, these experiments suggest that ubiquitin is attached to the inner face of the viral membrane by a novel type of phospholipid anchor.	INST BIOSCI & TECHNOL, CTR ADV INVERTEBRATE MOLEC SCI, COLLEGE STN, TX 77843 USA		GUARINO, LA (corresponding author), TEXAS A&M UNIV, DEPT ENTOMOL, COLLEGE STN, TX 77843 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DITMER JC, 1969, METHOD ENZYMOL, V14, P482; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUARINO LA, 1990, P NATL ACAD SCI USA, V87, P409, DOI 10.1073/pnas.87.1.409; GUARINO LA, 1990, VIROLOGY, V179, P1, DOI 10.1016/0042-6822(90)90266-T; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGAMP PM, 1995, IN PRESS J VIROL, V69; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KEMP LM, 1988, VIROLOGY, V166, P258, DOI 10.1016/0042-6822(88)90170-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEYERS G, 1991, VIROLOGY, V180, P602, DOI 10.1016/0042-6822(91)90074-L; PAUL AV, 1987, P NATL ACAD SCI USA, V84, P7827, DOI 10.1073/pnas.84.22.7827; PUTTERMAN D, 1990, VIROLOGY, V176, P633, DOI 10.1016/0042-6822(90)90035-P; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBERTS TE, 1989, VIROLOGY, V172, P377, DOI 10.1016/0042-6822(89)90145-1; RODRIGUEZ JM, 1992, VIROLOGY, V186, P40, DOI 10.1016/0042-6822(92)90059-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL RLQ, 1993, J GEN VIROL, V74, P1191, DOI 10.1099/0022-1317-74-6-1191; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	49	67	86	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					301	309		10.1016/0092-8674(95)90413-1	http://dx.doi.org/10.1016/0092-8674(95)90413-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834750	Bronze			2022-12-01	WOS:A1995QD92400013
J	HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D				HUBER, M; RETTLER, I; BERNASCONI, K; FRENK, E; LAVRIJSEN, SPM; PONEC, M; BON, A; LAUTENSCHLAGER, S; SCHORDERET, DF; HOHL, D			MUTATIONS OF KERATINOCYTE TRANSGLUTAMINASE IN LAMELLAR ICHTHYOSIS	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE ANCHORAGE; EPIDERMAL-CELLS; DIFFERENTIATION; ENVELOPE; CLONING; EXPRESSION; GENE	Lamellar ichthyosis Is a severe congenital skin disorder characterized by generalized large scales and variable redness. Affected individuals in three families exhibited drastically reduced keratinocyte transglutaminase (TGK) activity. In two of these families, expression of TGK transcripts was diminished or abnormal and no TGK protein was detected. Homozygous or compound heterozygous mutations of the TGK gene were identified in all families. These data suggest that defects in TGK cause lamellar ichthyosis and that intact cross-linkage of cornified cell envelopes is required for epidermal tissue homeostasis.	CHU VAUDOIS, HOP BEAUMONT, DEPT DERMATOL, CUTANEOUS BIOL LAB, CH-1011 LAUSANNE, SWITZERLAND; LEIDEN UNIV HOSP, DEPT DERMATOL, 2333 AA LEIDEN, NETHERLANDS; MUNICIPAL DERMATOL CLIN, CH-8000 ZURICH, SWITZERLAND; CHU VAUDOIS, DEPT MED GENET, CH-1011 LAUSANNE, SWITZERLAND; CHU VAUDOIS, MOLEC GENET UNIT, CH-1011 LAUSANNE, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Leiden University; Leiden University Medical Center (LUMC); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)			Huber, Marcel/M-8822-2016; Hohl, Daniel M/N-7554-2016	Huber, Marcel/0000-0003-3821-2378; 				CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; COOPER DN, 1993, ANN MED, V25, P11, DOI 10.3109/07853899309147851; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; FROST P, 1966, ARCH DERMATOL, V94, P113, DOI 10.1001/archderm.94.2.113; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1993, ARCH DERMATOL, V129, P618, DOI 10.1001/archderm.129.5.618; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOHL D, 1993, MOL BIOL SKIN, pCH5; HUBER ME, UNPUB; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1992, J BIOL CHEM, V267, P7710; LAVRIJSEN APM, 1993, IN PRESS ARCH DERMAT; LICHTI U, 1985, J BIOL CHEM, V260, P1422; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; MIKKOLA H, 1994, BLOOD, V84, P517; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; PHILLIPS SB, 1993, DERMATOLOGY GENERAL, pCH42; REICHERT U, 1993, MOL BIOL SKIN, pCH4; Sambrook J., 1989, MOL CLONING LAB MANU; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; TRAUPE H, 1989, ICHTHYOSES, P111; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804	28	377	394	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					525	528		10.1126/science.7824952	http://dx.doi.org/10.1126/science.7824952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824952				2022-12-01	WOS:A1995QD40300042
J	KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF				KEMPIN, SA; SAVIDGE, B; YANOFSKY, MF			MOLECULAR-BASIS OF THE CAULIFLOWER PHENOTYPE IN ARABIDOPSIS	SCIENCE			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; THALIANA; APETALA1; LEAFY	Genetic studies demonstrate that two Arabidopsis genes, CAULIFLOWER and APETALA1, encode partially redundant activities involved in the formation of floral meristems, the first step in the development of flowers. Isolation of the CAULIFLOWER gene from Arabidopsis reveals that it is closely related in sequence to APETALA1. Like APETALA1, CAULIFLOWER is expressed in young flower primordia and encodes a MADS-domain, indicating that it may function as a transcription factor. Analysis of the cultivated garden variety of cauliflower (Brassica oleracea var. botrytis) reveals that its CAULIFLOWER gene homolog is not functional, suggesting a molecular basis for one of the oldest recognized flower abnormalities.	UNIV CALIF SAN DIEGO,DEPT BIOL,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,SAN DIEGO,CA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM07313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWMAN JL, 1993, DEVELOPMENT, V119, P721; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL M, UNPUB; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; RIETER RS, 1992, P NATL ACAD SCI USA, V89, P1477; SADIK S, 1962, AM J BOT, V49, P290, DOI 10.2307/2439552; SAVIDGE B, UNPUB; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILLIAMS PH, 1986, SCIENCE, V232, P1385, DOI 10.1126/science.232.4756.1385; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YARNELL SH, 1956, BOT REV, V22, P81, DOI 10.1007/BF02872468	20	392	436	1	81	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 27	1995	267	5197					522	525		10.1126/science.7824951	http://dx.doi.org/10.1126/science.7824951			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824951				2022-12-01	WOS:A1995QD40300041
J	MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN				MADRENAS, J; WANGE, RL; WANG, JL; ISAKOV, N; SAMELSON, LE; GERMAIN, RN			ZETA-PHOSPHORYLATION WITHOUT ZAP-70 ACTIVATION-INDUCED BY TCR ANTAGONISTS OR PARTIAL AGONISTS	SCIENCE			English	Article							T-CELL-RECEPTOR; ANTIGEN-PRESENTING CELLS; TYROSINE PHOSPHORYLATION; CYTOCHROME-C; COMPLEX; CHAIN; LIGAND; COMPONENTS; ANALOG; KINASE	Small changes in the peptide-major histocompatibility complex (MHC) molecule ligands recognized by antigen-specific T cell receptors (TCRs) can convert fully activating complexes into partially activating or even inhibitory ones, This study examined early TCR-dependent signals induced by such partial agonists or antagonists, In contrast to typical agonist ligands, both an antagonist and several partial agonists stimulated a distinct pattern of zeta chain phosphorylation and failed to activate associated ZAP-70 kinase, These results identify a specific step in the early tyrosine phosphorylation cascade that is altered after TCR engagement with modified peptide-MHC molecule complexes, This finding may explain the different biological responses to TCR occupancy by these variant ligands.	NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	MADRENAS, J (corresponding author), NIAID, IMMUNOL LAB, LYMPHOCYTE BIOL SECT, BLDG 10, BETHESDA, MD 20892 USA.		Madrenas, Quim/P-5008-2019; Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019	Wange, Ronald/0000-0001-9593-3572; Isakov, Noah/0000-0002-1412-0957				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BERGMAN RN, 1978, J BIOL CHEM, V253, P3238; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHO EA, 1993, J IMMUNOL, V151, P20; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DING L, 1993, J IMMUNOL, V151, P1224; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GERMAIN RN, 1993, CURR BIOL, V3, P586, DOI 10.1016/0960-9822(93)90004-8; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; MADRENAS J, UNPUB; MATIS LA, 1983, J IMMUNOL, V130, P1527; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAGE DM, 1994, P NATL ACAD SCI USA, V91, P4057, DOI 10.1073/pnas.91.9.4057; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUPPERT J, 1993, P NATL ACAD SCI USA, V90, P2671, DOI 10.1073/pnas.90.7.2671; SAMELSON LE, 1987, J IMMUNOL, V139, P2708; SAMELSON LE, 1992, ADV EXP MED BIOL, V323, P9; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHWARTZ RH, 1985, J IMMUNOL, V135, P2598; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANOERS NSC, 1994, IMMUNITY, V1, P675, DOI 10.1016/1074-7613(94)90038-8; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YOON ST, 1994, IMMUNITY, V1, P563	49	505	511	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 27	1995	267	5197					515	518		10.1126/science.7824949	http://dx.doi.org/10.1126/science.7824949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD403	7824949				2022-12-01	WOS:A1995QD40300039
J	SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D				SHA, WC; LIOU, HC; TUOMANEN, EI; BALTIMORE, D			TARGETED DISRUPTION OF THE P50 SUBUNIT OF NF-KAPPA-B LEADS TO MULTIFOCAL DEFECTS IN IMMUNE-RESPONSES	CELL			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTORS; ENHANCER; PROMOTER; GENE; REL; INHIBITION; EXPRESSION; DORSAL; INVOLVEMENT	NF-kappa B, a heterodimeric transcription factor composed of p50 and p65 subunits, can be activated in many cell types and is thought to regulate a wide variety of genes involved in immune function and development, Mice lacking the p50 subunit of NF-kappa B show no developmental abnormalities, but exhibit multifocal defects in immune responses involving B lymphocytes and nonspecific responses to infection. B cells do not proliferate in response to bacterial lipopolysaccharide and are defective in basal and specific antibody production. Mice lacking p50 are unable effectively to clear L. monocytogenes and are more susceptible to infection with S. pneumoniae, but are more resistant to infection with murine encephalomyocarditis virus. These data support the role of NF-kappa B as a vital transcription factor for both specific and nonspecific immune responses, but do not indicate a developmental role for the factor.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CORNELL UNIV,COLL MED,DEPT CELL BIOL,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC INFECT DIS LAB,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Cornell University; Cornell University; Rockefeller University			Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08724-02] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; Coligan J.E., 1993, CURRENT PROTOCOLS IM; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GRILLI M, 1991, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU JL, 1991, J IMMUNOL, V146, P1685; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MANIATIS T, 1992, POSITIVE NEGATIVE RE; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1987, MOL CELL BIOL, V7, P1989, DOI 10.1128/MCB.7.5.1989; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6	38	1021	1048	1	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					321	330		10.1016/0092-8674(95)90415-8	http://dx.doi.org/10.1016/0092-8674(95)90415-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834752	hybrid			2022-12-01	WOS:A1995QD92400015
J	TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC				TAKAYAMA, S; SATO, T; KRAJEWSKI, S; KOCHEL, K; IRIE, S; MILLAN, JA; REED, JC			CLONING AND FUNCTIONAL-ANALYSIS OF BAG-1 - A NOVEL BCL-2-BINDING PROTEIN WITH ANTI-CELL DEATH ACTIVITY	CELL			English	Article							GENE CED-3; BCL-2; APOPTOSIS; UBIQUITIN; ELEGANS; PATHWAY; ENCODES; ENZYME; LINES; DNA	Using a protein interaction cloning technique, we identified cDNAs that encode a novel Bcl-2-binding protein, termed BAG-1. The BAG-1 protein shares no significant homology with Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers. In gene transfer experiments using a human lymphoid cell line, Jurkat, coexpression of BAG-1 and Bcl-2 provided markedly increased protection from cell death induced by several stimuli, including staurosporine, anti-fas antibody, and cytolytic T cells, relative to cells that contained gene transfer-mediated elevations in either BAG-1 or Bcl-2 protein alone. BAG-transfected 3T3 fibroblasts also exhibited prolonged cell survival in response to an apoptotic stimulus, The findings indicate that bag-1 represents a new type of anti-cell death gene and suggest that some routes of apoptosis induction previously ascribed to Bcl-5-independent pathways may instead reflect a need for the combination of Bcl-2 and BAG-1.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA060181] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60181] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; ITOH N, 1993, J IMMUNOL, V151, P621; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1992, CANCER RES, V52, P5407; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OITVAI ZN, 1993, CELL, V74, P609; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PALAZZOLO MJ, 1990, GENE, V66, P25; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; REED JC, 1992, ANAL BIOCHEM, V205, P70, DOI 10.1016/0003-2697(92)90580-Z; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SARIN A, 1994, J IMMUNOL, V153, P862; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI S, 1993, EUR J IMMUNOL, V23, P1935, DOI 10.1002/eji.1830230831; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; TORIGOE T, 1994, CANCER RES, V54, P4851; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1992, INT IMMUNOL, V4, P821, DOI 10.1093/intimm/4.7.821; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	29	785	837	3	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 27	1995	80	2					279	284		10.1016/0092-8674(95)90410-7	http://dx.doi.org/10.1016/0092-8674(95)90410-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834747	Bronze			2022-12-01	WOS:A1995QD92400010
J	TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T				TANAKA, T; AKIRA, S; YOSHIDA, K; UMEMOTO, M; YONEDA, Y; SHIRAFUJI, N; FUJIWARA, H; SUEMATSU, S; YOSHIDA, N; KISHIMOTO, T			TARGETED DISRUPTION OF THE NF-IL6 GENE DISCLOSES ITS ESSENTIAL ROLE IN BACTERIA KILLING AND TUMOR-CYTOTOXICITY BY MACROPHAGES	CELL			English	Article							C/EBP FAMILY MEMBERS; NF-KAPPA-B; LISTERIA-MONOCYTOGENES; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; NECROSIS-FACTOR; INFLAMMATORY CYTOKINES; MYELOMONOCYTIC CELLS; BINDING PROTEIN; NUCLEAR FACTOR	To investigate the role of NF-IL6 in vivo, we have generated NF-IL6 (-/-) mice by gene targeting. NF-IL6 (-/-) mice were highly susceptible to infection by Listeria monocytogenes. Electron microscopic observation revealed the escape of a large number of pathogens from the phagosome to the cytoplasm in activated macrophages from NF-IL6 (-/-) mice. Furthermore, the tumor cytotoxicity of macrophages from NF-IL6 (-/-) mice was severely impaired. However, cytokines involved in macrophage activation, such as TNF and IFN gamma, were induced normally in NF-IL6 (-/-) mice. Nitric oxide (NO) formation was induced to a similar extent in macrophages from both wild-type and NF-IL6 (-/-) mice. These results demonstrate the crucial role of NF-IL6 in macrophage bactericidal and tumoricidal activities as well as the existence of a NO-independent mechanism of these activities. We also demonstrate that NF-IL6 is essential for the induction of G-CSF in macrophages and fibroblasts.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, OSAKA 59002, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University			Kishimoto, Tadamitsu/C-8470-2009; Tanaka, Takashi/O-8254-2015; Akira, Shizuo/C-3134-2009					ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DING AH, 1988, J IMMUNOL, V141, P2407; HARPE JD, 1985, J IMMUNOL METHODS, V78, P323; HAVELL EA, 1987, J IMMUNOL, V139, P4225; HIBBS JB, 1987, J IMMUNOL, V138, P550; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KAPLAN AM, 1981, METHODS STUDYING MON, P775; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MELTZER MS, 1981, METHODS STUDYING MON, P785; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIZAWA M, 1990, MOL CELL BIOL, V10, P2002, DOI 10.1128/MCB.10.5.2002; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SCOTT LM, 1992, BLOOD, V80, P1725; SERUSHAGO BA, 1992, IMMUNOLOGY, V75, P475; Shannon MF, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046923; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TSUNAWAKI S, 1984, J BIOL CHEM, V259, P4305; UMEMOTO M, 1993, ACTA OTO-LARYNGOL, P66; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	50	472	479	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					353	361		10.1016/0092-8674(95)90418-2	http://dx.doi.org/10.1016/0092-8674(95)90418-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7530603	Bronze			2022-12-01	WOS:A1995QD92400018
J	WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R				WEIH, F; CARRASCO, D; DURHAM, SK; BARTON, DS; RIZZO, CA; RYSECK, RP; LIRA, SA; BRAVO, R			MULTIORGAN INFLAMMATION AND HEMATOPOIETIC ABNORMALITIES IN MICE WITH A TARGETED DISRUPTION OF RELB, A MEMBER OF THE NF-KAPPA-B/REL FAMILY	CELL			English	Article							DENDRITIC CELLS; TRANSCRIPTION FACTORS; BONE-MARROW; B PROTEINS; STEM-CELLS; GENE; EXPRESSION; ANTIGEN; TRANSACTIVATION; DISEASE	RelB, a member of the NF-kappa B/Rel family of transcription factors, has been implicated in the constitutive expression of kappa B-regulated genes in lymphoid tissues. We have generated mice carrying a germline mutation of the relB gene, resulting in the absence of RelB protein and a dramatic reduction of constitutive kappa B-binding activity in thymus and spleen. Mice homozygous for the disrupted relB locus had phenotypic abnormalities including multifocal, mixed inflammatory cell infiltration in several organs, myeloid hyperplasia, splenomegaly due to extramedullary hematopoiesis, and a reduced population of thymic dendritic cells. RelB-deficient animals also had an impaired cellular immunity, as observed in contact sensitivity experiments. Thus, RelB plays a decisive role in the hematopoietic system, and its absence cannot be functionally compensated by any other member of the NF-kappa B/Rel family.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT EXPTL PATHOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb	WEIH, F (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, POB 4000, PRINCETON, NJ 08543 USA.							AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BREEL M, 1987, EUR J IMMUNOL, V17, P1555, DOI 10.1002/eji.1830171105; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUSCHWITZ MS, 1992, J INVEST DERMATOL, V99, P114, DOI 10.1111/1523-1747.ep12611890; HESTDAL K, 1991, J IMMUNOL, V147, P22; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; ISSEKUTZ TB, 1992, CURR OPIN IMMUNOL, V4, P287, DOI 10.1016/0952-7915(92)90078-S; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Muller H K, 1992, Semin Immunol, V4, P205; OGARRA A, 1993, CURR OPIN IMMUNOL, V5, P880, DOI 10.1016/0952-7915(93)90100-7; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sambrook J., 1989, MOL CLONING LAB MANU; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WEIH F, 1994, ONCOGENE, V9, P3289; Wurst W., 1993, Gene targeting: a practical approach., P33	37	682	694	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 27	1995	80	2					331	340		10.1016/0092-8674(95)90416-6	http://dx.doi.org/10.1016/0092-8674(95)90416-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QD924	7834753	Bronze			2022-12-01	WOS:A1995QD92400016
J	BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F				BECK, KD; VALVERDE, J; ALEXI, T; POULSEN, K; MOFFAT, B; VANDLEN, RA; ROSENTHAL, A; HEFTI, F			MESENCEPHALIC DOPAMINERGIC-NEURONS PROTECTED BY GDNF FROM AXOTOMY-INDUCED DEGENERATION IN THE ADULT BRAIN	NATURE			English	Article							NEUROTROPHIC FACTOR PREVENTS; FIBROBLAST GROWTH-FACTOR; MOTOR NEURONS; IN-VIVO; FIMBRIAL TRANSECTIONS; MOTONEURONS; SURVIVAL; SYSTEM; DEATH; PROMOTES	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF) promotes survival of embryonic dopaminergic neurons in culture(1), and its expression pattern suggests a role as a transient target-derived trophic factor for dopaminergic neurons of the substantia nigra(2-4). These neurons participate in the control of motor activity, emotional status and cognition(5), and they degenerate in Parkinson's disease for unknown reasons. To test whether GDNF has a trophic effect on dopaminergic neurons in the adult brain, we used a rat model in which these neurons are induced to degenerate by transecting their axons within the medial forebrain bundle(6). We report here that axotomy resulted in loss of half the tyrosine hydroxylase-expressing neurons in the substantia nigra. This loss was largely prevented by repeated injections of GDNF adjacent to the substantia nigra. Our findings suggest that GDNF or related molecules may be useful for the treatment of Parkinson's disease.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089	Roche Holding; Genentech; Roche Holding; Genentech; University of Southern California	BECK, KD (corresponding author), GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080, USA.							ALEXI T, 1993, NEUROSCIENCE, V55, P903, DOI 10.1016/0306-4522(93)90307-2; ARAUJO DM, 1993, J NEUROCHEM, V61, P899, DOI 10.1111/j.1471-4159.1993.tb03601.x; Bjorklund A, 1984, HDB CHEM NEUROANATOM, P55; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; CUMMINGS BJ, 1992, BRAIN RES, V591, P271, DOI 10.1016/0006-8993(92)91707-L; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; HAGG T, 1993, P NATL ACAD SCI USA, V90, P6315, DOI 10.1073/pnas.90.13.6315; HAGG T, 1994, SOC NEUR ABS, V20; HEFTI F, 1986, J NEUROSCI, V6, P2155; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; HYNES MA, 1994, J NEUROSCI RES, V37, P144, DOI 10.1002/jnr.490370118; KNUSEL B, 1990, J NEUROSCI, V10, P558; KNUSEL B, 1992, J NEUROSCI, V12, P4391; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; OTTO D, 1990, J NEUROSCI, V10, P1912; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	24	612	654	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					339	341		10.1038/373339a0	http://dx.doi.org/10.1038/373339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830767				2022-12-01	WOS:A1995QD40400058
J	CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD				CAO, YZ; QIN, LM; ZHANG, LQ; SAFRIT, J; HO, DD			VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONONUCLEAR-CELLS; HIV-1 INFECTION; HOMOSEXUAL MEN; MESSENGER-RNA; T-LYMPHOCYTES; BISEXUAL MEN; REPLICATION; AIDS; INDIVIDUALS; CORRELATE	Background. In most subjects infected with human immunodeficiency virus type 1 (HIV-1), clinical or laboratory evidence of immunodeficiency develops within 10 years of seroconversion, but a few infected people remain healthy and immunologically normal for more than a decade. Studies of these subjects, termed long-term survivors, may yield important clues for the development of prophylactic and therapeutic interventions against the acquired immunodeficiency syndrome. Methods and Results. We studied 10 seropositive subjects who remained asymptomatic with normal and stable CD4+ lymphocyte counts despite 12 to 15 years of HIV-1 infection. Plasma cultures were uniformly negative for infectious virus. However, particle-associated HIV-1 RNA was detected in four subjects with a sensitive branched-DNA signal-amplification assay, whereas in five others the levels of HIV-1 RNA were too low to detect. Infectious HIV-1 was detected in peripheral-blood mononuclear cells (PBMC) of three subjects by standard limiting-dilution cultures, and infectious virus was recovered from another subject with use of a CD8-depleted culture. The other six subjects had no detectable infectious virus in their PBMC. A quantitative polymerase-chain-reaction assay revealed that all subjects had detectable but low titers of viral DNA in PBMC. Overall, the viral burden in the plasma and PBMC of long-term survivors was orders of magnitude lower than that typically found in subjects with progressive disease. There was no in vitro evidence of resistance by host CD4+ lymphocytes to HIV-1 infection. However, longterm survivors had a vigorous, virus-inhibitory CD8+ lymphocyte response and a strong neutralizing-antibody response. In two subjects the kinetics of viral replication was consistent with the presence of a substantially attenuated strain of HIV-1. Conclusions. Subjects who remain asymptomatic for many years despite HIV-1 infection have low levels of HIV-1 and a combination of strong virus-specific immune responses with some degree of attenuation of the virus.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,NEW YORK,NY 10016	New York University					NIAID NIH HHS [AI24030, AI25541, AI32427] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025541, R01AI032427, R01AI024030] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CAO Y, IN PRESS AIDS RES HU; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FULTZ T, 1995, 2ND NAT C HUM RETR R; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HO DD, 1991, J VIROL, V65, P489, DOI 10.1128/JVI.65.1.489-493.1991; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; JASSOY C, 1993, J VIROL, V67, P2844, DOI 10.1128/JVI.67.5.2844-2852.1993; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KEET IPM, 1994, J INFECT DIS, V169, P1236, DOI 10.1093/infdis/169.6.1236; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; LIFSON AR, 1988, J INFECT DIS, V158, P1360, DOI 10.1093/infdis/158.6.1360; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MOORE J, IN PRESS J VIROL; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; PACHL C, IN PRESS J ACQUIR IM; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SCHRAGER LK, 1994, AIDS S, V1, pS95; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; WALKER CM, 1991, CELL IMMUNOL, V137, P420, DOI 10.1016/0008-8749(91)90090-X; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WALKER CM, 1991, J VIROL, V65, P5921, DOI 10.1128/JVI.65.11.5921-5927.1991; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	39	922	950	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					201	208		10.1056/NEJM199501263320401	http://dx.doi.org/10.1056/NEJM199501263320401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808485				2022-12-01	WOS:A1995QC27000001
J	CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E				CASSE, M; LEHOUCQ, R; VANGIONIFLAM, E			PRODUCTION AND EVOLUTION OF LIGHT-ELEMENTS IN ACTIVE STAR-FORMING REGIONS	NATURE			English	Article							MASSIVE STARS; COSMIC-RAYS; GAMMA-RAYS; SOLAR; MODELS	COLLISIONS between cosmic rays (energetic protons and alpha-particles) and carbon, nitrogen and oxygen in the interstellar medium have been considered(1) to be the main source of lithium, beryllium and boron, through fragmentation of the larger nuclei. But this mechanism is unable to account for the observed Solar System abundances of the isotopes Li-7 and B-11. The recent detection of an excess of gamma-rays(2) in the direction of the star-forming region in the Orion cloud has been interpreted(3) as arising from the excitation of carbon and oxygen nuclei ejected from supernovae when they collide with the surrounding gas, which is primarily molecular and atomic hydrogen. Here we investigate the consequences of the two-body interactions of the ejected carbon and oxygen nuclei (and the alpha-particles ejected with them) with the hydrogen and helium in the surrounding gas, using a model developed previously(4-6). We show that these interactions offer a way to make lithium, beryllium and boron that is independent of the abundance of heavy elements in the surrounding medium. Such supernova-driven interactions, combined with the effect of galactic cosmic rays, can explain the observed Solar System abundances of these light elements.	CNRS,INST ASTROPHYS PARIS,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	CASSE, M (corresponding author), CTR ETUD SACLAY,DSM,DAPNIA,SERV ASTROPHYS,F-91191 GIF SUR YVETTE,FRANCE.							ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BLOCMEN H, 1984, ASTRON ASTROPHYS, V139, P37; BLOEMEN H, 1994, ASTRON ASTROPHYS, V281, pL5; BROWN AGA, 1994, ASTRON ASTROPHYS, V289, P101; BURROWS DN, 1993, ASTROPHYS J, V406, P97, DOI 10.1086/172423; BYKOV A, 1994, ASTRON ASTROPHYS, V283, pL1; CASSE M, IN PRESS NCULEI COSM; CLAYTON DD, 1994, NATURE, V368, P222, DOI 10.1038/368222a0; CUNHA K, 1994, ASTROPHYS J, V426, P170, DOI 10.1086/174053; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, IN PRESS ASTR ASTROP; FIELDS BD, IN PRESS ASTROPHYS J; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; KOZLOVSKY B, 1974, ASTROPHYS J, V191, pL43, DOI 10.1086/181542; MARTI K, IN PRESS NUCLEI COSM; MENEGUZZI M, 1971, ASTRON ASTROPHYS, V15, P337; MENEGUZZI M, 1975, ASTRON ASTROPHYS, V40, P99; MURPHY RJ, 1990, ASTROPHYS J, V351, P299, DOI 10.1086/168466; RAMATY R, 1979, ASTROPHYS J SUPPL S, V40, P487, DOI 10.1086/190596; RAMATY R, 1975, SPACE SCI REV, V18, P341, DOI 10.1007/BF00212911; RAMATY R, IN PRESS ASTROPHYS J; READ SM, 1984, ATOM DATA NUCL DATA, V31, P359, DOI 10.1016/0092-640X(84)90009-3; REEVES H, 1994, REV MOD PHYS, V66, P193, DOI 10.1103/RevModPhys.66.193; RYAN S, 1994, APJ, V388, P184; SPITE F, 1993, ORIGIN EVOLUTION ELE, P201; VANGIONIFLAM E, 1990, ASTROPHYS J, V364, P568, DOI 10.1086/169439; WEAVER TA, 1993, PHYS REP, V227, P65, DOI 10.1016/0370-1573(93)90058-L; WOOSLEY SE, 1993, ASTROPHYS J, V411, P823, DOI 10.1086/172886	28	114	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					318	319		10.1038/373318a0	http://dx.doi.org/10.1038/373318a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830765				2022-12-01	WOS:A1995QD40400050
J	GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB				GHOSH, G; VANDUYNE, G; GHOSH, S; SIGLER, PB			STRUCTURE OF NF-KAPPA-B P50 HOMODIMER BOUND TO A KAPPA-B SITE	NATURE			English	Article							DNA-BINDING SUBUNIT; CRYSTAL-STRUCTURE; PROTEIN MODELS; COGNATE DNA; REL; INHIBITION; ACTIVATION; COMPLEX; ERRORS; MOTIF	The 2.3-Angstrom crystal structure of the transcription factor NF-kappa B p50 homodimer bound to a palindromic kappa B site reveals that the Rel homology region folds into two distinct domains, similar to those in the immunoglobulin superfamily. The p50 dimer envelopes an undistorted B-DNA helix, making specific contacts along the 10-base-pair kappa B recognition site mainly through loops connecting secondary structure elements in both domains. The carboxy-terminal domains form a dimerization interface between beta-sheets using residues that are strongly conserved in the Rel family.	YALE UNIV, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA; YALE UNIV, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University								BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWNELL E, 1989, ONCOGENE, V4, P935; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIMITRIS T, 1992, CELL, V71, P777; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HULTMARK D, 1994, NATURE, V367, P116, DOI 10.1038/367116a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOPP E, 1994, ADV IMMUNOL, V58, P1; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TONY Y, 1993, CELL, V75, P753; VANROEY P, 1989, P NATL ACAD SCI USA, V86, P6587, DOI 10.1073/pnas.86.17.6587; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	506	532	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 26	1995	373	6512					303	310		10.1038/373303a0	http://dx.doi.org/10.1038/373303a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530332				2022-12-01	WOS:A1995QD40400048
J	GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM				GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM			A B-CELL COACTIVATOR OF OCTAMER-BINDING TRANSCRIPTION FACTORS	NATURE			English	Article							IMMUNOGLOBULIN PROMOTERS; REMOTE ENHANCER; DNA MOTIF; ACTIVATION; EXPRESSION; DOMAINS; SEQUENCES; CLONING; OTF-2; OCT-2	THE octamer motif (ATGCAAAT) paradoxically plays a central role in mediating the activity of both B-cell specific and ubiquitous promoters. It has been widely assumed that the predominantly lymphoid-restricted octamer-binding factor Oct-2 mediates tissue-specific promoter activity, whereas the ubiquitously expressed Oct-1 mediates general promoter activity, but this view has been challenged(1-6). Here we use a modified yeast one-hybrid assay to isolate a B-cell factor, Bob1, which associates with either Oct-2 or Oct-1. In transfection experiments, this factor boosts Oct-1-mediated promoter activity and to a lesser extent, that of Oct-2. This coactivation is strictly dependent on the specific interaction with Oct-1 or Oct-2 because deletion of the octamer motif abolishes coactivation. We conclude that Bob1 could represent a new tissue-specific transcriptional coactivator which may convert a ubiquitously expressed transcription factor to a cell-type-specific activator.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Hovens, Christopher/0000-0002-0610-1289				ARNOSTI DN, 1993, NUCLEIC ACIDS RES, V21, P5570, DOI 10.1093/nar/21.24.5570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; STRUBIN M, IN PRESS CELL; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0	21	286	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					360	362		10.1038/373360a0	http://dx.doi.org/10.1038/373360a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7779176				2022-12-01	WOS:A1995QD40400065
J	HAMPTON, HL				HAMPTON, HL			CURRENT CONCEPTS - CARE OF THE WOMAN WHO HAS BEEN RAPED	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEXUAL ASSAULT; VICTIMS; WOMEN				HAMPTON, HL (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT OBSTET & GYNECOL,2500 N STATE ST,JACKSON,MS 39216, USA.							Burgess AW, 1974, RAPE VICTIMS CRISIS, P37; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; DAVIS TC, 1993, J ADOLESCENT HEALTH, V14, P220, DOI 10.1016/1054-139X(93)90009-E; DEMING JE, 1983, J FORENSIC SCI, V28, P572; Geist R F, 1988, Emerg Med Clin North Am, V6, P439; GRAVES HCB, 1985, NEW ENGL J MED, V312, P338, DOI 10.1056/NEJM198502073120603; JENNY C, 1990, NEW ENGL J MED, V322, P713, DOI 10.1056/NEJM199003153221101; MARCHBANKS PA, 1990, AM J EPIDEMIOL, V132, P540, DOI 10.1093/oxfordjournals.aje.a115690; MCCAULEY J, 1986, PEDIATRICS, V78, P1039; MIRABILE PJ, 1980, TULANE LAW REV, V54, P456; RAMBOW B, 1992, ANN EMERG MED, V21, P727, DOI 10.1016/S0196-0644(05)82788-X; RAMIN SM, 1992, OBSTET GYNECOL, V80, P860; SCHWARCZ SK, 1990, REV INFECT DIS, V12, pS682; SCHWARTZ IL, 1991, AM J PREV MED, V7, P363, DOI 10.1016/S0749-3797(18)30873-0; SLAUGHTER L, 1992, AM J OBSTET GYNECOL, V166, P83, DOI 10.1016/0002-9378(92)91834-W; WARNER CG, 1980, RAPE SEXUAL ASSAULT, P47; YOUNG WW, 1992, OBSTET GYNECOL, V80, P878; YUZPE AA, 1982, FERTIL STERIL, V37, P508; 1993, MMWR-MORBID MORTAL W, V42, P8; 1988, UNIFORM CRIME REPORT, P46; 1993, MMWR-MORBID MORTAL W, V42, P1	21	45	46	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					234	237		10.1056/NEJM199501263320407	http://dx.doi.org/10.1056/NEJM199501263320407			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7619112				2022-12-01	WOS:A1995QC27000007
J	HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C				HOLLANDER, GA; WANG, BP; NICHOGIANNOPOULOU, A; PLATENBURG, PP; VANEWIJK, W; BURAKOFF, SJ; GUTIERREZRAMOS, JC; TERHORST, C			DEVELOPMENTAL CONTROL POINT IN INDUCTION OF THYMIC CORTEX REGULATED BY A SUBPOPULATION OF PROTHYMOCYTES	NATURE			English	Article							T-CELL DEVELOPMENT; LYMPHOCYTES-T; MICE; MICROENVIRONMENT; DIFFERENTIATION; RESTORATION; RECEPTOR	T LYMPHOCYTES Of the alpha/beta T-cell receptor (TCR) lineage mature in the thymus, where they undergo a series of differentiation, expansion and selection events(1-7). For normal T-cell ontogeny to occur, thymocytes must interact physically with cortical and medullary thymic stroma cells(8-10). In parallel, interactions of the thymic stromal cells with TCR-positive thymocytes are necessary for the development of the thymic medulla(10-12). Comparable requirements for the differentiation of the cortex have not been defined, however. Here me analyse mutant mouse strains to assess the function of early prothymocytes in the induction of the thymic cortex. We find that animals with a developmental block at the earliest stage of T-lineage commitment lack a functional thymic cortex. This abnormality could be corrected in fetal but not adult animals by transplantation of either fetal or adult wild-type haematopoietic stem cells. Thus a developmentally restricted interaction of fetal stromal cells with early prothymocytes is required for the induction of a cortical microenvironment. In addition, a normal thymic architecture is necessary for sustained T-cell ontogeny.	BETH ISRAEL HOSP,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; ERASMUS UNIV ROTTERDAM,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Erasmus University Rotterdam	HOLLANDER, GA (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115, USA.			Hollander, Georg/0000-0002-8790-0874				BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BUDD RC, 1987, J IMMUNOL, V138, P3120; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; Jenkinson E J, 1990, Semin Immunol, V2, P51; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEZELOF C, 1992, HISTOPATHOLOGY, V21, P499, DOI 10.1111/j.1365-2559.1992.tb00437.x; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; ROBERTS R, 1990, MOUSE ITS REPRODUCTI, P253; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; Shortman K, 1990, Semin Immunol, V2, P3; VANEWIJK W, 1984, AM J ANAT, V170, P311, DOI 10.1002/aja.1001700307; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; VANVLIET E, 1985, EUR J IMMUNOL, V15, P677; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WANG B, IN PRESS INT IMMUN; WANG BP, 1994, P NATL ACAD SCI USA, V91, P9402, DOI 10.1073/pnas.91.20.9402; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369	27	236	239	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					350	353		10.1038/373350a0	http://dx.doi.org/10.1038/373350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830770				2022-12-01	WOS:A1995QD40400062
J	HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A				HUIZINGA, JD; THUNEBERG, L; KLUPPEL, M; MALYSZ, J; MIKKELSEN, HB; BERNSTEIN, A			W/KIT GENE REQUIRED FOR INTERSTITIAL-CELLS OF CAJAL AND FOR INTESTINAL PACEMAKER ACTIVITY	NATURE			English	Article							C-KIT; CANINE COLON; W-LOCUS; PROTO-ONCOGENE; PROTOONCOGENE; EXPRESSION; MUSCLE	THE pacemaker activity in the mammalian gut is responsible for generating anally propagating phasic contractions, The cellular basis for this intrinsic activity is unknown. The smooth muscle cells of the external muscle layers and the innervated cellular network of interstitial cells of Cajal, which is closely associated with the external muscle layers of the mammalian gut, have both been proposed to stimulate pacemaker activity(1-5). The interstitial cells of Cajal were identified in the last century but their developmental origin and function have remained unclear. Here we show that the interstitial cells of Cajal express the Kit receptor tyrosine kinase. Furthermore, mice with mutations in the dominant white spotting (W) locus, which have cellular defects in haematopoiesis, melanogenesis and gametogenesis(6) as a result of mutations in the Kit gene(7,8) also lack the network of intestitial cells of Cajal associated with Auerbach's nerve plexus and intestinal pacemaker activity.	UNIV COPENHAGEN,DEPT ANAT,COPENHAGEN,DENMARK; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Copenhagen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	HUIZINGA, JD (corresponding author), MCMASTER UNIV,DEPT BIOMED SCI,INTESTINAL DIS RES UNIT,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.							BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DURDLE NG, 1983, GASTROENTEROLOGY, V84, P375; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HUIZINGA JD, 1991, J PHYSIOL-LONDON, V442, P15, DOI 10.1113/jphysiol.1991.sp018779; LIU LWC, 1993, J PHYSIOL-LONDON, V470, P445, DOI 10.1113/jphysiol.1993.sp019868; LIU LWC, 1994, AM J PHYSIOL, V266, pG485, DOI 10.1152/ajpgi.1994.266.3.G485; MAEDA H, 1992, DEVELOPMENT, V116, P369; MIKKELSEN HB, 1993, CELL TISSUE RES, V274, P249, DOI 10.1007/BF00318744; MIKKELSEN HB, 1988, ANAT EMBRYOL, V17, P191; MOTRO B, 1991, DEVELOPMENT, V113, P1207; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; REITH AD, 1991, GENOME ANAL, V3, P105; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; THUNEBERG L, 1992, GASTROENTEROLOGY, V103, P1388, DOI 10.1016/0016-5085(92)91601-Y; THUNEBERG L, 1989, HDB PHYSL GASTROINTE, P349	21	1130	1174	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					347	349						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7530333				2022-12-01	WOS:A1995QD40400061
J	LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P				LUESCHER, IF; VIVIER, E; LAYER, A; MAHIOU, J; GODEAU, F; MALISSEN, B; ROMERO, P			CD8 MODULATION OF T-CELL ANTIGEN RECEPTOR-LIGAND INTERACTIONS ON LIVING CYTOTOXIC T-LYMPHOCYTES	NATURE			English	Article							PHYSICAL ASSOCIATION; BETA-CHAIN; MOLECULES; BINDING; ACTIVATION; EXPRESSION; COMPLEX; KINASE; CD45	THYMOCYTES and class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes express predominantly heterodimeric alpha/beta CD8(1,2). By interacting with non-polymorphic regions of MHC class I molecules CD8 can mediate adhesion(3-6) or by binding the same MHC molecules that interact with the T-cell antigen receptor (TCR) function as coreceptor in TCR-ligand binding and T-cell activation(1,2). Using TCR photoaffinity labelling with a soluble, monomeric photoreactive H-2K(d)-peptide derivative complex(7), we report here that the avidity of TCR-ligand interactions on cloned cytotoxic T cells is very greatly strengthened by CD8. This is primarily explained by coordinate binding of ligand molecules by CD8 and TCR, because substitution of Asp 227 of K-d with LYS severely impaired the TCR-ligand binding on CD8(+), but not CD8(-) cells. Kinetic studies on CD8(+) and CD8(-) cells further showed that CD8 imposes distinct dynamics and a remarkable temperature dependence on TCR-ligand interactions. We propose that the ability of CD8 to act as coreceptor can be modulated by CD8-TCR interactions.	CTR IMMUNOL,INSERM CNRS MARSEILLE LUMINY,F-13288 MARSEILLE 9,FRANCE; FAC MED NECKER ENFANTS MALAD,INSERM,U373,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	LUESCHER, IF (corresponding author), UNIV LAUSANNE,LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND.		Romero, Pedro/S-6015-2017; Vivier, Eric/F-8939-2010; Malissen, Bernard/AAK-4659-2020	Romero, Pedro/0000-0002-9688-2882; Vivier, Eric/0000-0001-7022-8287; Malissen, Bernard/0000-0003-1340-9342				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; CARBONE AM, 1988, J IMMUNOL, V141, P1369; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIANZANI U, 1992, J IMMUNOL, V148, P678; EICHMANN K, 1991, J IMMUNOL, V147, P2075; GALLAGHER PF, 1989, P NATL ACAD SCI USA, V86, P10044, DOI 10.1073/pnas.86.24.10044; GOLSTEIN P, 1982, IMMUNOL REV, V68, P5, DOI 10.1111/j.1600-065X.1982.tb01058.x; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KARAKI S, 1992, J IMMUNOL, V149, P1613; LUESCHER IF, 1994, J BIOL CHEM, V269, P5574; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; NAKAYAMA K, 1994, SCIENCE, V263, P1131, DOI 10.1126/science.8108731; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OROURKE AM, 1993, IMMUNOL TODAY, V14, P183; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; ROMERO P, 1993, J EXP MED, V177, P1247, DOI 10.1084/jem.177.5.1247; ROMERO P, 1993, J IMMUNOL, V150, P3825; ROMERO P, 1994, J IMMUNOL METHODS, V171, P73, DOI 10.1016/0022-1759(94)90230-5; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; SUZUKI S, 1992, EUR J IMMUNOL, V22, P2475, DOI 10.1002/eji.1830221002; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TOMONARI K, 1990, INT IMMUNOL, V2, P1189, DOI 10.1093/intimm/2.12.1189; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHEELER CJ, 1992, NATURE, V357, P247, DOI 10.1038/357247a0; WHITE J, 1989, J IMMUNOL, V143, P1822; YAMANE Y, 1991, CELL IMMUNOL, V136, P496, DOI 10.1016/0008-8749(91)90370-Q	30	207	211	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					353	356		10.1038/373353a0	http://dx.doi.org/10.1038/373353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830771				2022-12-01	WOS:A1995QD40400063
J	MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC				MULLER, CW; REY, FA; SODEOKA, M; VERDINE, GL; HARRISON, SC			STRUCTURE OF THE NF-KAPPA-B P50 HOMODIMER BOUND TO DNA	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATION; 3-DIMENSIONAL STRUCTURE; CYTOPLASMIC RETENTION; NUCLEIC-ACIDS; P65 SUBUNIT; PROTEIN; REL; GENE	The structure of a large fragment of the p50 subunit of the human transcription factor NF-kappa B, bound as a homodimer to DNA, reveals that the Rel-homology region has two beta-barrel domains that grip DNA in the major groove. Both domains contact the DNA backbone. The amino-terminal specificity domain contains a recognition loop that interacts with DNA bases; the carboxy-terminal dimerization domain bears the site of I-kappa B interaction. The folds of these domains are related to immunoglobulin-like modules. The amino-terminal domain also resembles the core domain of p53.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	Harvard University; Harvard University; University of Tokyo	MULLER, CW (corresponding author), HOWARD HUGHES MED INST,7 DIVINITY AVE,CAMBRIDGE,MA 02138, USA.		Müller, Christoph W/I-7420-2012; Sodeoka, Mikiko/A-9952-2008; Rey, Felix/B-6497-2012	Müller, Christoph W/0000-0003-2176-8337; Sodeoka, Mikiko/0000-0002-1344-364X; 				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIDD S, 1992, CELL, V1, P623; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEHMING N, UNPUB EMBO J; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; Liu J, 1994, CHEM BIOL, V1, P47, DOI 10.1016/1074-5521(94)90040-X; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SODEOKA M, 1993, BIOORG MED CHEM LETT, V3, P1095, DOI 10.1016/S0960-894X(00)80294-2; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x	48	470	494	1	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					311	317		10.1038/373311a0	http://dx.doi.org/10.1038/373311a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830764				2022-12-01	WOS:A1995QD40400049
J	NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT				NADEAU, JH; GRANT, PL; MANKALA, S; REINER, AH; RICHARDSON, JE; EPPIG, JT			A ROSETTA-STONE OF MAMMALIAN GENETICS	NATURE			English	Article							MAP	Mammalian Comparative Database provides genetic maps of mammalian species. Comparative maps are valuable aids for predicting linkages, developing animal models and studying genome organization and evolution.	LINNEAN TECHNOL,ENFIELD,NH 03748		NADEAU, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.							[Anonymous], 1994, MOUSE GENOME DATABAS; ARCHIBALD AL, 1994, CURR OPIN GENET DEV, V4, P395, DOI 10.1016/0959-437X(94)90027-2; BROAD TE, 1994, BRIT VET J, V150, P237, DOI 10.1016/S0007-1935(05)80004-1; Castle WE, 1924, GENETICS, V9, P1; CHAPMAN VM, 1993, MAMM GENOME, V4, pS1; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; EPPIG JT, IN PRESS MAMMAL GENO; HETZEL J, 1993, NAT GENET, V4, P327, DOI 10.1038/ng0893-327; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; OBRIEN SJ, 1993, GENETIC MAPS	11	25	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					363	365		10.1038/373363a0	http://dx.doi.org/10.1038/373363a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830773				2022-12-01	WOS:A1995QD40400066
J	OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW				OPPENHEIM, RW; HOUENOU, LJ; JOHNSON, JE; LIN, LFH; LI, LX; LO, AC; NEWSOME, AL; PREVETTE, DM; WANG, SW			DEVELOPING MOTOR-NEURONS RESCUED FROM PROGRAMMED AND AXOTOMY-INDUCED CELL-DEATH BY GDNF	NATURE			English	Article							NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; SURVIVAL; MUSCLE; MOTONEURONS; SUPPORT; CULTURE; INVIVO	DURING normal development of the vertebrate nervous system, large numbers of neurons in the central and peripheral nervous system undergo naturally occurring cell death(1). For example, about half of all spinal motor neurons die over a period of a few days in developing avian, rat and mouse embryos(1). Previous studies have shown that extracts from muscle and brain, secreted factors from glia, as well as several growth factors and neurotrophic agents, including muscle-derived factors, can promote the survival of developing motor neurons in vitro and in vivo(2-15). But because neurotrophins and other known trophic agents administered alone or in combination are insufficient to rescue all developing motor neurons from cell deaths(8), other neurotrophic molecules are probably essential for the survival and differentiation of motor neurons. Here we report that glial-cell-line-derived neurotrophic factor (GDNF), a potent neurotrophic factor that enhances survival of mammalian midbrain dopaminergic neurons(16,17), rescues developing avian motor neurons from natural programmed cell death in vivo and promotes the survival of enriched populations of cultured motor neurons. Furthermore, treatment with this agent in vivo also prevents the induced death and atrophy of both avian and mouse spinal motor neurons following peripheral axotomy.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27157; SYNERGEN INC,BOULDER,CO 80301	Wake Forest University; Wake Forest Baptist Medical Center	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27157, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BLOCHGALLEGO E, 1993, DEVELOPMENT, V111, P221; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V118, P209, DOI 10.1016/0012-1606(86)90089-8; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOUENOU LJ, 1994, PROG BRAIN RES, V102, P209; JOHNSON J, 1994, CURR BIOL, V4, P662, DOI 10.1016/S0960-9822(00)00149-4; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANCEJONES C, 1982, DEV BRAIN RES, V4, P473, DOI 10.1016/0165-3806(82)90192-4; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1986, DEV BIOL, V114, P425; OPPENHEIM RW, 1991, SCIENCE, V257, P1616; RIECKE GK, 1982, PHYSIOL BEHAV, V28, P755; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V360, P755; SPRINGER JE, 1994, Q EXPL NEUROL, V127, P167; STOMBERG I, 1993, EXP NEUROL, V124, P401; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YIN QW, 1994, J NEUROSCI, V14, P7629	30	619	673	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					344	346		10.1038/373344a0	http://dx.doi.org/10.1038/373344a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830769				2022-12-01	WOS:A1995QD40400060
J	PHILLIPS, DM				PHILLIPS, DM			HUMAN-IMMUNODEFICIENCY-VIRUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					233	233		10.1056/NEJM199501263320406	http://dx.doi.org/10.1056/NEJM199501263320406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808490				2022-12-01	WOS:A1995QC27000006
J	RUDEL, T; SCHEUERPFLUG, I; MEYER, TF				RUDEL, T; SCHEUERPFLUG, I; MEYER, TF			NEISSERIA PILC PROTEIN IDENTIFIED AS TYPE-4 PILUS TIP LOCATED ADHESIN	NATURE			English	Article							HUMAN EPITHELIAL-CELLS; ANTIGENIC VARIATION; ESCHERICHIA-COLI; VIBRIO-CHOLERAE; PHASE VARIATION; GONORRHOEAE; SEQUENCE; GENE; MENINGITIDIS; ORGANIZATION	TYPE-4 pilus-mediated adherence of Neisseria gonorrhoeae and Neisseria meningitidis is considered to be a crucial early event in neisserial infections(1,2). In addition to the principal pilus subunit (pilin or PilE), both pathogens produce low quantities of a phase-variable PilC protein which is implicated in pilus biogenesis and pilus-mediated epithelial cell adherence(3,4). The identity, however, of the pilus adhesin has remained obscure(4,5). Here we describe the isolation of a PilC protein from a gonococcal overproducing strain and demonstrate its specific interaction with human epithelial cells. Our results are consistent with the cell and species tropisms of neisserial infections. Binding of PilC effectively competes with pilus-mediated, but not Opa-mediated(6), attachment of N. gonorrhoeae and of N. meningitidis, indicating that both pathogens interact with identical or very similar epithelial cell receptors. Immunogold electron microscopy using antisera raised against purified PilC and synthetic peptides locates PilC at the tip of gonococcal pill. PilC thus represents an essential pilus-associated adhesin, providing a rationale for selective protection against neisserial infections.	MAX PLANCK INST INFEKT BIOL,D-10117 BERLIN,GERMANY	Max Planck Society	RUDEL, T (corresponding author), MAX PLANCK INST BIOL,INFEKT BIOL ABT,SPEMANNSTR 34,D-72076 TUBINGEN,GERMANY.		Meyer, Thomas F. F/J-2485-2013	Meyer, Thomas F. F/0000-0002-6120-8679				GIRON JA, 1994, MOL MICROBIOL, V12, P71, DOI 10.1111/j.1365-2958.1994.tb00996.x; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; HAAS R, 1992, MOL MICROBIOL, V6, P197, DOI 10.1111/j.1365-2958.1992.tb02001.x; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON SC, 1991, J INFECT DIS, V163, P128, DOI 10.1093/infdis/163.1.128; JONSSON AB, 1991, EMBO J, V10, P477, DOI 10.1002/j.1460-2075.1991.tb07970.x; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; Meyer T F, 1994, Curr Top Microbiol Immunol, V192, P283; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MUIR LL, 1988, INFECT IMMUN, V56, P1743, DOI 10.1128/IAI.56.7.1743-1747.1988; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; NASSIF X, 1993, MOL MICROBIOL, V8, P719, DOI 10.1111/j.1365-2958.1993.tb01615.x; OGIERMAN MA, 1993, GENE, V126, P51, DOI 10.1016/0378-1119(93)90589-U; PARGE HE, 1990, J BIOL CHEM, V265, P2278; POHLNER J, 1993, GENE, V130, P121, DOI 10.1016/0378-1119(93)90354-6; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; SASTRY PA, 1983, FEBS LETT, V151, P253, DOI 10.1016/0014-5793(83)80080-5; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; SWANSON J, 1987, J EXP MED, V165, P1016, DOI 10.1084/jem.165.4.1016; VIRJI M, 1992, MOL MICROBIOL, V6, P1271, DOI 10.1111/j.1365-2958.1992.tb00848.x; VIRJI M, 1993, MOL MICROBIOL, V10, P10131; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992	27	239	246	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					357	359		10.1038/373357a0	http://dx.doi.org/10.1038/373357a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830772				2022-12-01	WOS:A1995QD40400064
J	TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L				TOMAC, A; LINDQVIST, E; LIN, LFH; OGREN, SO; YOUNG, D; HOFFER, BJ; OLSON, L			PROTECTION AND REPAIR OF THE NIGROSTRIATAL DOPAMINERGIC SYSTEM BY GDNF IN-VIVO	NATURE			English	Article							CENTRAL CATECHOLAMINE NEURONS; FIBROBLAST GROWTH-FACTOR; NEUROTROPHIC FACTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; SUBSTANTIA-NIGRA; MICE; CULTURE; RAT	GLIAL-CELL-LINE-DERIVED neurotrophic factor (GDNF), a recently cloned new member of the transforming growth factor-beta superfamily, promotes survival of cultured fetal mesencephalic dopamine neurons(1) and is expressed in the developing striatum(2,3). There have, however, been no reports about effects of GDNF in situ. We have used the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces parkinsonian symptoms in man, to determine whether GDNF might exert protective or regenerative effects in vivo in the adult nigrostriatal dopamine system in C57/Bl mice. GDNF injected over the substantia nigra or in striatum before MPTP potently protects the dopamine system, as shown by numbers of mesencephalic dopamine nerve cell bodies, dopamine nerve terminal densities and dopamine levels. When GDNF is given after MPTP, dopamine levels and fibre densities are significantly restored. In both cases, motor behaviour is increased above,normal levels. We conclude that intracerebral GDNF administration exerts both protective and reparative effects on the nigrostriatal dopamine system, which may have implications for the development of new treatment strategies for Parkinson's disease.	SYNERGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT PREVENT MED & BIOSTAT,DENVER,CO 80217	University of Colorado System; University of Colorado Denver	TOMAC, A (corresponding author), KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN.			Ogren, Sven Ove/0000-0003-2573-5276				BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1; FERRARI G, 1991, J NEUROSCI RES, V30, P493, DOI 10.1002/jnr.490300306; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hudson J., 1993, Society for Neuroscience Abstracts, V19, P652; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; JONSSON G, 1985, N-S ARCH PHARMACOL, V331, P1, DOI 10.1007/BF00498844; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MAGAL E, 1993, NEUROSCIENCE, V52, P867, DOI 10.1016/0306-4522(93)90535-N; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; OGREN SO, 1979, DOPAMINERGIC ERGOT D, P187; OTTO D, 1990, J NEUROSCI, V10, P1912; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; SUNDSTROM E, 1987, BRAIN RES, V405, P26; SUNDSTROM E, 1990, BRAIN RES, V528, P181, DOI 10.1016/0006-8993(90)91656-2	21	1002	1079	0	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					335	339		10.1038/373335a0	http://dx.doi.org/10.1038/373335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830766	Bronze			2022-12-01	WOS:A1995QD40400057
J	VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K				VILLE, Y; HYETT, J; HECHER, K; NICOLAIDES, K			PRELIMINARY EXPERIENCE WITH ENDOSCOPIC LASER-SURGERY FOR SEVERE TWIN-TWIN TRANSFUSION SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC AMNIOCENTESIS; NEUROLOGIC DAMAGE; ANTENATAL ORIGIN; NEWBORN-INFANTS; STUCK TWIN; PREGNANCY; VOLUME	Background. In monozygotic twin pregnancies, there are placental vascular communications between the two fetuses. In 15 percent of such pregnancies there is an imbalance in net blood flow between the twins, resulting in the twin-twin transfusion syndrome. The recipient twin may have severe hydramnios during the second trimester of pregnancy, and there is a high risk of perinatal death and cerebral palsy in survivors. This condition can now be treated by endoscopic coagulation of the vascular anastomoses responsible for fetofetal transfusion with a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser. Methods. We performed intrauterine surgery in 45 pregnant women carrying twins at 15 to 28 weeks of gestation (median, 21); in each case there was severe hydramnios in one fetus due to the twin-twin transfusion syndrome. With the use of local anesthesia and continuous ultrasound visualization, a rigid fetoscope 2 mm in diameter, housed in a 2.7-mm cannula, was introduced transabdominally into the amniotic cavity of the recipient twin. A systematic search was made for all vessels approaching or crossing the membrane between the twins, and these were coagulated with an Nd:YAG laser by means of a fiber in the side arm of the cannula. Results. Coagulation of the communicating vessels was successful in all cases. The total number of fetuses who survived to delivery was 48 (53 percent), and the number of pregnancies with at least 1 survivor was 32 (71 percent). Among the live-born infants, the median gestational age at delivery was 35 weeks (range, 25 to 40), and the median birth weight was 2098 g (range, 550 to 4252). The median interval between the endoscopic laser procedure and delivery was 14 weeks (range, 0 to 21). All the survivors were developing normally at a median age of 12 months (range, 2 to 24). Conclusions. Our preliminary experience suggests that the twin-twin transfusion syndrome can be treated effectively by endoscopic laser coagulation of the communicating placental vessels.	UNIV LONDON KINGS COLL,SCH MED,HARRIS BIRTHRIGHT RES CTR FETAL MED,LONDON SE5 8RX,ENGLAND	University of London; King's College London				Nicolaides, Kypros/0000-0003-1266-0711				BEJAR R, 1988, AM J OBSTET GYNECOL, V159, P357, DOI 10.1016/S0002-9378(88)80084-X; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; BENDON R W, 1989, Pediatric Pathology, V9, P591; BENIRSCHKE K, 1973, NEW ENGL J MED, V288, P1276, DOI 10.1056/NEJM197306142882406; DELIA JE, 1990, OBSTET GYNECOL, V75, P1046; ELLIOTT JP, 1991, OBSTET GYNECOL, V77, P537; FUSI L, 1991, OBSTET GYNECOL, V78, P517; GOLDBERG RN, 1980, J PEDIATR-US, V96, P1060, DOI 10.1016/S0022-3476(80)80642-1; HADLOCK FP, 1985, AM J OBSTET GYNECOL, V151, P333, DOI 10.1016/0002-9378(85)90298-4; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; LARROCHE JC, 1990, BIOL NEONATE, V57, P261; PATTEN RM, 1989, RADIOLOGY, V172, P153, DOI 10.1148/radiology.172.1.2662249; PINETTE MG, 1993, OBSTET GYNECOL, V82, P841; REISNER DP, 1993, AM J OBSTET GYNECOL, V169, P991, DOI 10.1016/0002-9378(93)90041-G; SAUDNERS NJ, 1991, FETAL DIAGN THER, V6, P34; SAUNDERS NJ, 1992, AM J OBSTET GYNECOL, V166, P820, DOI 10.1016/0002-9378(92)91340-G; VILLE Y, 1992, ULTRASOUND OBST GYN, V2, P429, DOI 10.1046/j.1469-0705.1992.02060429.x; WEIR PE, 1979, BRIT J OBSTET GYNAEC, V86, P849, DOI 10.1111/j.1471-0528.1979.tb10710.x	18	262	266	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	1995	332	4					224	227		10.1056/NEJM199501263320404	http://dx.doi.org/10.1056/NEJM199501263320404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC270	7808488	Bronze			2022-12-01	WOS:A1995QC27000004
J	WADA, A				WADA, A			A SPACE-TIME SLIDE-RULE	NATURE			English	Article								Akiyoshi Wada retired some years ago as a professor of physics at Tokyo University, where he was for many years one of those in Japan urging the fuller use of physical techniques in molecular biology notably in the automatic sequencing of DNA. Now he is the director of the interdisciplinary Sagami Chemical Research Center near Tokyo. The Wadarules reproduced on these pages (together with an explanatory note by Professor Wada) do not arise directly from the author's professional work, but are the product of a fertile and ingenious imagination exercised, in part no doubt, on long aircraft journeys. They are offered without restriction to those who may have use for them. It is simply necessary to photocopy the diagrams, to separate the main rule from the reference rule and to mount each part on stiff card in such a way as to be able to slide the latter against the former. While the Wadarules may have a general heuristic value for those who have the time to play with them, they mag have a particular educational value for young children and may be particularly useful for, say, science writers forever seeking graphic ways of dramatizing the large or small scale of some phenomenon (as in the phrase ''seems no bigger than a dime at a distance of 1 mile''). The rules can readily be amended to include objects with dimensions other than those shown. The annotation of the time rule leaves ample room for the addition of extra items, such as the average duration of the human heart-beat, the period of oscillation of ''middle C'' (0.00178 seconds) and the like.			WADA, A (corresponding author), SAGAMI CHEM RES CTR,4-4-1 NISHIOHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN.								0	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					R39	R40						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830749				2022-12-01	WOS:A1995QD40400047
J	YAN, Q; MATHESON, C; LOPEZ, OT				YAN, Q; MATHESON, C; LOPEZ, OT			IN-VIVO NEUROTROPHIC EFFECTS OF GDNF ON NEONATAL AND ADULT FACIAL MOTOR-NEURONS	NATURE			English	Article							OCCURRING MOTONEURON DEATH; FACTOR PREVENTS; CELL-DEATH; IN-VIVO; AXOTOMY; DEGENERATION; SURVIVAL; RATS	MOTOR neurons require neurotrophic factor(s) for their survival during development and for maintenance of function in adulthood(1-3). In vivo studies have shown that motor neurons respond to a variety of molecules, including ciliary neurotrophic factor, members of the neurotrophin family, and the insulin growth factor IGF-1 (refs 3-13). Here we investigate the potential motor neuron neurotrophic effects of glial-cell-line-derived neurotrophic factor (GDNF), initially identified as a neurotrophic factor for substantia nigra dopaminergic neurons(14). We find that GDNF is retrogradely transported, in a receptor-mediated fashion, by spinal cord motor neurons in neonatal rats. Local application of GDNF to the transected nerve prevents the massive motor neuron cell death and atrophy that normally follows axotomy in the neonatal period. In adult rats, GDNF administered locally or systemically can markedly attenuate the lesion-induced decrease of choline acetyltransferase immunoreactivity in the facial nucleus. Our data indicate that GDNF has very profound neurotrophic effects in vivo on developing as well as on adult motor neurons, and is the most potent motor neuron trophic factor found so far.			YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,DEPT NEUROBIOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LAMS BE, 1988, BRAIN RES, V475, P401, DOI 10.1016/0006-8993(88)90635-X; LI L, 1994, J NEUROBIOL, V35, P759; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; NEFF NT, 1993, J NEUROBIOL, V24, P1578, DOI 10.1002/neu.480241203; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; OPPENHEIM RW, 1993, J NEUROBIOL, V24, P1065, DOI 10.1002/neu.480240806; OPPENHEIM RW, 1989, TRENDS NEUROSCI, V12, P252, DOI 10.1016/0166-2236(89)90021-0; SCHAAR DG, 1993, EXP NEUROL, V124, P368, DOI 10.1006/exnr.1993.1207; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1993, EXP NEUROL, V124, P47, DOI 10.1006/exnr.1993.1173; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202; YAN Q, 1994, J NEUROSCI, V14, P5281; YAN Q, 1988, J NEUROSCI, V8, P3481	21	548	616	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					341	344		10.1038/373341a0	http://dx.doi.org/10.1038/373341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7830768				2022-12-01	WOS:A1995QD40400059
J	GANN, PH; HENNEKENS, CH; STAMPFER, MJ				GANN, PH; HENNEKENS, CH; STAMPFER, MJ			A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; RADICAL PROSTATECTOMY; SCREENING-TEST; DIAGNOSIS; SERUM; ULTRASONOGRAPHY; ADENOCARCINOMA; DISEASE; TRENDS; MEN	Objective.-To evaluate the validity of prostate-specific antigen (PSA) in identifying men who subsequently were or were not clinically diagnosed with prostate cancer, assess optimal test cutoff, measure lead time, and estimate relative risks (RRs) associated with discrete PSA levels. Design.-Nested case-control study of men providing plasma samples before a 10-year follow-up. Setting.-The Physicians' Health Study, an ongoing randomized trial that enrolled 22071 men aged 40 to 84 years in 1982. Participants.-A total of 366 men (cases) diagnosed with prostate cancer and 1098 men (three controls per case), matched by age, randomly selected from all cohort members at risk at the time of case diagnosis. Main Outcome Measures.-Sensitivity and specificity for each year of followup and for aggressive and nonaggressive cancers separately. Results.-At a cutoff of 4.0 ng/mL, sensitivity for the entire 10-year follow-up was 46% for total cases. Sensitivities for detection of total, aggressive, and nonaggressive cancers occurring in the first 4 years were 73%, 87%, and 53%. Overall, specificity was 91% and changed little by year of follow-up. Optimal validity was achieved at a cutoff of 3.3 ng/mL, Estimated mean lead time for all cancers was 5.5 years. Only 40% of cancers detected more than 5 years from baseline were nonaggressive. Compared with men with PSA levels less than 1.0 ng/mL, those with PSA levels between 2.0 and 3.0 ng/mL had an RR of 5.5 (95% confidence interval, 3.7 to 9.2). Conclusions.-A single PSA measurement had a relatively high sensitivity and specificity for detection of prostate cancers that arose within 4 years. prostate-specific antigen values less than the usual cutoff were associated with substantial increases in risk compared with the lowest levels. Final evaluation of PSA screening must also consider cost and the ability of current treatments to improve the prognosis of screen-detected cases.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BABAIAN RJ, 1992, CANCER, V69, P1195; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1987, ARCH INTERN MED, V147, P361, DOI 10.1001/archinte.147.2.361; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GRAVES HCB, 1990, J UROLOGY, V144, P1516, DOI 10.1016/S0022-5347(17)39789-6; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; HOLUND B, 1980, SCAND J UROL NEPHROL, V14, P29, DOI 10.3109/00365598009181186; HORTIN GL, 1988, J UROLOGY, V139, P762, DOI 10.1016/S0022-5347(17)42627-9; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LIEDTKE RJ, 1984, CLIN CHEM, V30, P649; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MORRISON AS, 1992, SCREENING CHRONIC DI; MURPHY GP, 1994, CA-CANCER J CLIN, V44, P91, DOI 10.3322/canjclin.44.2.91; RUCKLE HC, 1994, MAYO CLIN PROC, V69, P59, DOI 10.1016/S0025-6196(12)61614-0; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALTER SD, 1983, AM J EPIDEMIOL, V118, P865, DOI 10.1093/oxfordjournals.aje.a113705; 1992, AM UROLOGICAL ASS EX; 1976, CAN MED ASSOC J, V114, P1003	28	569	590	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					289	294		10.1001/jama.273.4.289	http://dx.doi.org/10.1001/jama.273.4.289			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7529341				2022-12-01	WOS:A1995QC05700026
J	MCNAMARA, RM; MONTI, S; KELLY, JJ				MCNAMARA, RM; MONTI, S; KELLY, JJ			REQUESTING CONSENT FOR AN INVASIVE PROCEDURE IN NEWLY DECEASED ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							INTUBATION; INFANTS; TEACH; DEAD	Objective.-Ethical concerns exist over the performance of medical procedures, such as endotracheal intubation, on newly deceased patients without family consent. This study examined the process of obtaining consent for the purpose of performing an invasive procedure in newly deceased adults. Design.-A prospective case series. Participants.-The families of patients who died during a 5-month period were requested to provide consent to perform wire-guided retrograde tracheal intubation. Main Outcome Measures.-Differences between success and failure in obtaining consent including information on the deceased, family reasons for their decision, and the experience of those requesting consent. Results.-Consent was requested from 44 families and 26 (59%) agreed to the procedure. This success rate was achieved despite the lack of a prior relationship with the family by the persons requesting consent. Consent was obtained more frequently in unexpected than expected deaths (77% vs 41%, P=.03). There were no differences in success rates for consent for age, race, sex, or do-not-resuscitate status of the deceased. Spouses consented more frequently than children (77% vs 50%, P=.25). The two physicians reported greater comfort in requesting consent than the nurse anesthetist investigator. In one instance, the consent process may have increased the emotional distress of the family. Conclusion.-Consent can frequently be obtained from families for an invasive procedure in newly deceased adults. Physicians should reconsider the practice of performing postmortem procedures without obtaining family consent.	MED COLL PENN,DEPT ANESTHESIOL,PHILADELPHIA,PA 19129	Drexel University	MCNAMARA, RM (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BURNS JP, 1994, NEW ENGL J MED, V331, P1652, DOI 10.1056/NEJM199412153312411; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; ISERSON KV, 1993, J MED ETHICS, V19, P92, DOI 10.1136/jme.19.2.92; MCNAMARA RM, 1987, ANN EMERG MED, V16, P680, DOI 10.1016/S0196-0644(87)80071-9; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; REITZ NN, 1993, J NATL MED ASSOC, V85, P353; SCHILLACI RF, 1976, NEW ENGL J MED, V295, P488, DOI 10.1056/NEJM197608262950907; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; TOLLE SW, 1984, ARCH INTERN MED, V144, P2389, DOI 10.1001/archinte.144.12.2389; TONKS A, 1992, BRIT MED J, V305, P332	12	47	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					310	312		10.1001/jama.273.4.310	http://dx.doi.org/10.1001/jama.273.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815659				2022-12-01	WOS:A1995QC05700030
J	MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD				MILBERG, JA; DAVIS, DR; STEINBERG, KP; HUDSON, LD			IMPROVED SURVIVAL OF PATIENTS WITH ACUTE RESPIRATORY-DISTRESS-SYNDROME (ARDS) - 1983-1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTILATION; SEVERITY	Objective.-To analyze temporal trends in acute respiratory distress syndrome (ARDS) fatality rates since 1983 at one institution. Design.-Cohort. Setting.-Intensive care units of a large county hospital. Patients.-Consecutive adult patients (greater than or equal to 18 years of age) meeting ARDS criteria were identified through daily surveillance of intensive care units (N=918 from 1983 through 1993). The major causes were sepsis syndrome in 37% and major trauma in 25%; 37% had other risks. Sixty-five percent were male. The median age was 45 years (range, 18 to 92 years); 70% were younger than 60 years. Main Outcome Measure.-Hospital mortality. Results.-Overall fatality rates showed no trend from 1983 to 1987, declined slightly in 1988 and 1989, and decreased to a low of 36% in 1993 (95% confidence interval, 25% to 46%). The crude rates were largely unchanged after adjustment for age, ARDS risk, and gender distribution. While patients both younger than 60 years and 60 years or older experienced declines in fatality rate, the larger decrease occurred in the younger cohort. In sepsis patients, ARDS fatality rates declined steadily, from 67% in 1990 to 40% in 1993 (95% confidence interval, 23% to 57%). The decline in sepsis-related ARDS fatality was confined largely to patients less than 60 years of age. Trauma patients and all other patients also experienced declines in fatality rates after 1987, although these trends were not as strong and consistent as in the sepsis population. Conclusions.-In this large series, we observed a significant decrease in fatality rates occurring largely in patients younger than 60 years and in those with sepsis syndrome as their risk for ARDS. We are unable to determine the extent to which experimental therapies or other changes in treatment have contributed to the observed decline in the ARDS fatality rate, institution-specific rates and temporal trends in ARDS fatality rates should be considered in clinical trials designed to prevent ARDS and the high mortality associated with this syndrome.			MILBERG, JA (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT MED,DIV PULM & CRIT CARE MED,ZA-62,325 9TH AVE,SEATTLE,WA 98104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATO MBP, 1993, AM REV RESPIR DIS, V147, pA890; ARMITAGE P, 1987, STATISTICAL METHODS; ARTIGAS A, 1990, ACUTE RESPIRATORY FA, P37; ASHBAUGH DG, 1967, LANCET, V2, P319; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIDANI A, 1994, JAMA-J AM MED ASSOC, V272, P957, DOI 10.1001/jama.272.12.957; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; Hosmer DW, 1989, APPL LOGISTIC REGRES, P140; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; SELVIN S, 1991, STATISTICAL ANAL EPI; SUCHYTA MR, 1991, CHEST, V99, P951, DOI 10.1378/chest.99.4.951; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; ZAPOL WM, 1990, ACUTE RESPIRATORY FA, P367	17	502	532	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	1995	273	4					306	309		10.1001/jama.273.4.306	http://dx.doi.org/10.1001/jama.273.4.306			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC057	7815658				2022-12-01	WOS:A1995QC05700029
J	FRYER, CJH				FRYER, CJH			PELVIC RHABDOMYOSARCOMA - PAYING THE PRICE OF BLADDER PRESERVATION	LANCET			English	Editorial Material							SEQUELAE		BRITISH COLUMBIA CHILDRENS HOSP,VANCOUVER,BC,CANADA	BC Childrens Hospital; University of British Columbia	FRYER, CJH (corresponding author), UNIV BRITISH COLUMBIA,DIV PEDIAT HEMATOL ONCOL,VANCOUVER,BC,CANADA.							ATRA A, 1994, BRIT J CANCER, V70, P1004, DOI 10.1038/bjc.1994.438; DONALDSON S, 1994, MED PEDIATR ONCOL, V23, P3; FLAMANT F, 1990, J CLIN ONCOL, V8, P1847, DOI 10.1200/JCO.1990.8.11.1847; FONTANESI J, 1991, ENDOCURIETH HYPERTH, V7, P195; HAYS DM, IN PRESS AM J PEDIAT; HAYS DM, 1991, MED PEDIATR ONCOL, V19, P423; RANEY B, 1993, CANCER, V71, P2387, DOI 10.1002/1097-0142(19930401)71:7<2387::AID-CNCR2820710734>3.0.CO;2-A; YEUNG CK, 1994, BRIT J CANCER, V70, P1000, DOI 10.1038/bjc.1994.437	8	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					141	142		10.1016/S0140-6736(95)90162-0	http://dx.doi.org/10.1016/S0140-6736(95)90162-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823666				2022-12-01	WOS:A1995QC55000005
J	GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D				GRIFFITHS, E; CORTES, A; GILBERT, N; STEVENSON, P; MACDONALD, S; PEPPER, D			HEMOGLOBIN-BASED BLOOD SUBSTITUTES AND SEPSIS	LANCET			English	Note							HEMOGLOBIN	An important concern that has received little attention is the possible increased susceptibility to bacterial infections of patients infused with cell-free haemoglobin-based blood substitutes. We show that pyridoxalated polymerised human haemoglobin promotes fulminating Escherichia coli septicaemia in mice, which draws attention to the potential danger of such products in the clinic.	NATL INST BIOL STAND & CONTROLS,S MIMMS,HERTS,ENGLAND; SCOTTISH NATL BLOOD TRANSFUS SERV,NATL SCI LAB,EDINBURGH,MIDLOTHIAN,SCOTLAND	National Institute for Biological Standards & Control				Gilbert, Nick/0000-0003-0505-6081				Bullen J.J., 1987, IRON INFECTION MOL P; CROWLEY JP, 1993, CIRC SHOCK, V41, P144; HOYT DB, 1981, J TRAUMA, V21, P938, DOI 10.1097/00005373-198111000-00005; KIM YM, 1994, ARCH BIOCHEM BIOPHYS, V309, P308, DOI 10.1006/abbi.1994.1118; LEE JT, 1979, SURGERY, V86, P41; LOOKER D, 1992, NATURE, V356, P258, DOI 10.1038/356258a0; MACDONALD SL, 1994, METHOD ENZYMOL, V231, P287; OTTO BR, 1992, NATURE, V358, P23, DOI 10.1038/358023b0; ROBSON MC, 1973, J SURG RES, V14, P426, DOI 10.1016/0022-4804(73)90049-8; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403	10	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					158	160		10.1016/S0140-6736(95)90168-X	http://dx.doi.org/10.1016/S0140-6736(95)90168-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823671				2022-12-01	WOS:A1995QC55000011
J	HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H				HAWTON, K; WARE, C; MISTRY, H; HEWITT, J; KINGSBURY, S; ROBERTS, D; WEITZEL, H			WHY PATIENTS CHOOSE PARACETAMOL FOR SELF-POISONING AND THEIR KNOWLEDGE OF ITS DANGERS	BRITISH MEDICAL JOURNAL			English	Article									JOHN RADCLIFFE HOSP,DEPT PSYCHOL MED,BARNES UNIT,OXFORD OX3 9DX,ENGLAND	University of Oxford	HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							BRAY GP, 1993, BRIT MED J, V306, P157, DOI 10.1136/bmj.306.6871.157; GAZZARD BG, 1976, BRIT MED J, V1, P212, DOI 10.1136/bmj.1.6003.212; HAWTON K, 1992, BRIT MED J, V304, P1409, DOI 10.1136/bmj.304.6839.1409; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; SPOONER JB, 1993, PHARM J, V250, P706	5	84	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					164	164		10.1136/bmj.310.6973.164	http://dx.doi.org/10.1136/bmj.310.6973.164			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833757	Green Published			2022-12-01	WOS:A1995QD20100023
J	KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR				KOSTER, T; BLANN, AD; BRIET, E; VANDENBROUCKE, JP; ROSENDAAL, FR			ROLE OF CLOTTING FACTOR-VIII IN EFFECT OF VON-WILLEBRAND-FACTOR ON OCCURRENCE OF DEEP-VEIN THROMBOSIS	LANCET			English	Article							POOR ANTICOAGULANT RESPONSE; ISCHEMIC-HEART-DISEASE; ACTIVATED PROTEIN-C; BLOOD GROUP-A; VONWILLEBRAND-FACTOR; VENOUS THROMBOSIS; RISK-FACTORS; GROUP-B; ATHEROSCLEROSIS; THROMBOPHILIA	To elucidate the roles of the ABO blood group, von Willebrand factor (vWF), and clotting factor VIII in the process of deep-vein thrombosis we undertook a population-based patient-control study in which 301 consecutive patients younger than 70 with a first, objectively diagnosed episode of venous thrombosis and without an underlying malignant disorder were compared with 301 healthy controls matched for age and sex. In univariate analysis, blood group, vWF concentration, and factor VIII concentrations were all related to deep-vein thrombosis. The risk of thrombosis increased with increasing vWF or factor VIII concentration and was higher in subjects of non-O blood groups than in those of group O. In multivariate analysis only factor VIII remained as a risk factor, and the dose-response relation between factor VIII concentration and risk of thrombosis persisted (subjects with factor VIII concentrations above 1500 IU/L had an adjusted odds ratio of 4.8 [95% CI 2.3-10.0]). By contrast, the adjusted odds ratio for each vWF stratum did not differ from 1, and that for blood group was 1.5 (1.0-2.2). Our findings point to an effect on thrombosis risk of vWF and blood group, the former fully and the latter at least partly mediated through factor VIII. The 25% prevalence of factor VIII concentrations above 1500 IU/L among unselected consecutive thrombosis patients and the high adjusted relative risk for thrombosis lead to the conclusion that high factor VIII concentrations are common and represent a clear increase in risk of thrombosis, similar to the risks conferred by deficiencies of the coagulation-inhibiting proteins and activated protein C resistance.	UNIV LEIDEN HOSP,CTR HEMOSTASIS & THROMBOSIS RES,LEIDEN,NETHERLANDS; UNIV S MANCHESTER HOSP,DEPT SURG,MANCHESTER,LANCS,ENGLAND	Leiden University; Leiden University Medical Center (LUMC); Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	KOSTER, T (corresponding author), UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,BLDG 1 CO-P-43,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLANN AD, 1993, INT J OBESITY, V17, P723; BLANN AD, 1994, EUR J VASCULAR SURG, P10; CAEKEBEKEPEERLI.KM, 1989, BRIT J HAEMATOL, V73, P217; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CUCUIANU MP, 1983, THROMB RES, V30, P487, DOI 10.1016/0049-3848(83)90183-4; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; GILL JC, 1987, BLOOD, V69, P1691; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KINGSBURY KJ, 1971, LANCET, V1, P199; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEDALIE JH, 1981, NEW ENGL J MED, V285, P1348; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; OBRIEN JR, 1990, THROMB RES, V59, P221, DOI 10.1016/0049-3848(90)90288-N; ROSENDAAL FR, 1990, BRIT J HAEMATOL, V75, P525, DOI 10.1111/j.1365-2141.1990.tb07793.x; ROSENDAAL FR, 1989, BRIT J HAEMATOL, V71, P71, DOI 10.1111/j.1365-2141.1989.tb06277.x; SHORT PE, 1982, MED LAB SCI, V32, P351; SODETZ JM, 1979, J BIOL CHEM, V254, P754; TALBOT S, 1970, LANCET, V1, P1257; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	26	940	957	0	21	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					152	155		10.1016/S0140-6736(95)90166-3	http://dx.doi.org/10.1016/S0140-6736(95)90166-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823669				2022-12-01	WOS:A1995QC55000009
J	MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM				MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM			HOMOCYSTEINE METABOLISM IN PREGNANCIES COMPLICATED BY NEURAL-TUBE DEFECTS	LANCET			English	Article							VITAMIN SUPPLEMENTATION; PLASMA; PREVENTION; METHIONINE; FOLATE; SERUM; ACID	Folic acid taken around the time of conception can prevent many neural-tube defects, Women with low-normal vitamin B-12 values may also be at increased risk. We considered whether homocysteine metabolism via the enzyme methionine synthase, which requires both folate and B-12, could be the critical defect in folate-related neural tube defects. Blood was obtained during pregnancies that produced 81 infants with neural-tube defects and 323 normal children, Samples were assayed for homocysteine, methylmalonic acid, plasma folate, red-cell folate, and B-12. Mothers of children with neural-tube defects had significantly higher homocysteine values (8.62 [SD 2.8] mu mol/L) than did B-12-matched controls (7.96 [2.5] mu mol/L, p=0.03). The difference was significant (p=0.004) in the lower half of the B-12 distribution after adjusting for plasma folate. Our study shows that an abnormality in homocysteine metabolism, apparently related to methionine synthase, is present in many women who give birth to children with neural-tube defects. Overcoming this abnormality is likely to be the mechanism by which folic acid prevents neural-tube defects. These findings suggest that the most effective periconceptional prophylaxis to prevent neural-tube defects may require B-12 as well as fotic acid.	HLTH RES BOARD,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT CLIN MED,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN,IRELAND	Health Research Board - Ireland; Trinity College Dublin; Trinity College Dublin	MILLS, JL (corresponding author), NICHHD,DESPR,PEDIAT EPIDEMIOL SECT,EPIDEMIOL BRANCH,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				ADAMS MJ, 1993 SOC EP RES ANN; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; COELHO CND, 1989, J NUTR, V119, P1716, DOI 10.1093/jn/119.11.1716; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; KANG SS, 1991, AM J HUM GENET, V48, P546; KIRKE PN, 1993, Q J MED, V86, P703; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; SMITHELLS RW, 1983, LANCET, V1, P1027; STEEGERSTHEUNIS.RP, 1991, NEW ENGL J MED, V324, P199; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; 1991, LANCET, V338, P131	13	560	576	0	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					149	151		10.1016/S0140-6736(95)90165-5	http://dx.doi.org/10.1016/S0140-6736(95)90165-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741859				2022-12-01	WOS:A1995QC55000008
J	SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D				SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D			PARTICULATE AIR-POLLUTION AND ACUTE HEALTH-EFFECTS	LANCET			English	Note							TIME-SERIES ANALYSIS; RESPIRATORY HEALTH; PULMONARY TOXICITY; PM-10 POLLUTION; PARTICLES; MORTALITY; ULTRAFINE; CHILDREN; DISEASE; UTAH	Epidemiological studies have consistently shown an association between particulate air pollution and not only exacerbations of illness in people with respiratory disease but also rises in the numbers of deaths from cardiovascular and respiratory disease among older people. Meta-analyses of these studies indicate associations are unlikely to be explained any confounder, and suggest that they represent cause and effect. We propose that the explanation lies in the nature of the urban particulate cloud, which may contain up to 100000 nanometer-sized particles per mt, in what may be a gravimetric concentration of only 100-200 mu g/m3 of pollutant. We suggest that such ultra-fine particles are able to provoke alveolar inflammation, with release of mediators capable, in susceptible individuals, of causing exacerbations of lung disease and of increasing blood coagulability, thus also explaining the observed increases in cardiovascular deaths associated with urban pollution episodes. This hypothesis is testable both experimentally and epidemiologically.	UNIV EDINBURGH,EDINBURGH,MIDLOTHIAN,SCOTLAND; NAPIER UNIV,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Edinburgh Napier University	SEATON, A (corresponding author), UNIV ABERDEEN,SCH MED,DEPT ENVIRONM & OCCUPAT MED,FORESTERHILL,ABERDEEN AB9 2ZD,SCOTLAND.			MacNee, William/0000-0002-3692-1448				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], [No title captured]; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; BRAUER M, 1989, ENVIRON SCI TECHNOL, V23, P1408, DOI 10.1021/es00069a013; CHOU JC, 1992, ATMOS ENVIRON, V24, P693; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; FERIN J, 1990, J AEROSOL SCI, V21, P381, DOI 10.1016/0021-8502(90)90064-5; FERIN J, 1992, AM J RESP CELL MOL, V6, P535, DOI 10.1165/ajrcmb/6.5.535; HELIN H, 1986, MED BIOL, V64, P167; HILLS BA, 1982, THORAX, V37, P713, DOI 10.1136/thx.37.10.713; HURLEY JF, 1990, MORTALITY 1967 1987; LAWTHER PJ, 1968, PROC R SOC LON SER-A, V307, P223, DOI 10.1098/rspa.1968.0186; LOWE GDO, 1993, THROMBOSIS AND ITS MANAGEMENT, P31; LOWE GDO, 1992, CLIN HEMORHEOL, V12, P535; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MILLER BG, 1985, BRIT J IND MED, V42, P723; OTTAWAY CA, 1984, J CLIN IMMUNOL, V4, P348, DOI 10.1007/BF00917137; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336, DOI 10.1164/ajrccm/147.6_Pt_1.1336; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; RUOSS K, 1991, J AEROSOL SCI, V22, pS629, DOI 10.1016/S0021-8502(05)80180-6; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; TEPPER JS, 1994, AM J RESP CRIT CARE, V149, pA839; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WARHEIT DB, 1990, EXP MOL PATHOL, V52, P309, DOI 10.1016/0014-4800(90)90072-L	30	1527	1588	4	252	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					176	178		10.1016/S0140-6736(95)90173-6	http://dx.doi.org/10.1016/S0140-6736(95)90173-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741860				2022-12-01	WOS:A1995QC55000016
J	SHUSTER, S				SHUSTER, S			CAPSAICIN AND THE CAUSE OF CAUSALGIA	LANCET			English	Note							PAIN	From self-experimentation, I propose that the pain which occurs after application of capsaicin is causalgia and that this ''capsaicin causalgia'' is due to actual or functional depletion of neuropeptides such as substance P. This idea could provide an objective definition of the causalgic syndromes and improve the means of diagnosis. The analogy with capsaicin causalgia could also be extended to the pain of epidermal necrolysis, solar and thermal burns, and leprosy. the concept could lead to a better treatment of these causalgic syndromes by modulation of neuropeptide concentration of responsivity, or by mitigation of the consequences of its depletion.			SHUSTER, S (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE2 4BW,TYNE & WEAR,ENGLAND.							BARBUT D, 1981, BRAIN RES, V205, P289, DOI 10.1016/0006-8993(81)90340-1; BRENEMAN DL, 1992, J AM ACAD DERMATOL, V26, P91, DOI 10.1016/0190-9622(92)70013-6; DOTSON RM, 1993, MUSCLE NERVE, V16, P1049, DOI 10.1002/mus.880161008; LEWIS T, 1927, BLOOD VESSELS HUMAN, P69; LYNN B, 1990, PAIN, V51, P61; PORTER R, 1982, CIBA F S, V91; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SIMONE DA, 1989, PAIN, V38, P99, DOI 10.1016/0304-3959(89)90079-1; WALTON J, 1993, BRAINS DISEASES NERV, P563; 1986, CLASSIFICATION CH S3, V26, pS29	10	8	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					160	161		10.1016/S0140-6736(95)90169-8	http://dx.doi.org/10.1016/S0140-6736(95)90169-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823672				2022-12-01	WOS:A1995QC55000012
J	BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE				BOWYER, P; CLARKE, BR; LUNNESS, P; DANIELS, MJ; OSBOURN, AE			HOST-RANGE OF A PLANT-PATHOGENIC FUNGUS DETERMINED BY A SAPONIN DETOXIFYING ENZYME	SCIENCE			English	Article							GAEUMANNOMYCES-GRAMINIS; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; TRANSFORMATION; RESISTANCE; CLONING; ACID; GENE	Antifungal saponins occur in many plant species and may provide a preformed chemical barrier to attack by phytopathogenic fungi. Some fungal pathogens can enzymatically detoxify host plant saponins, which suggests that saponin detoxification may determine the host range of these fungi. A gene encoding a saponin detoxifying enzyme was cloned from the cereal-infecting fungus Gaeumannomyces graminis. Fungal mutants generated by targeted gene disruption were no longer able to infect the saponin-containing host oats but retained full pathogenicity to wheat (which does not contain saponins). Thus, the ability of a phytopathogenic fungus to detoxify a plant saponin can determine its host range.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center				bowyer, paul/0000-0002-1083-9286				ARNESON PA, 1968, PHYTOPATHOLOGY, V58, P536; AUSTIN B, 1990, EXP MYCOL, V14, P9, DOI 10.1016/0147-5975(90)90082-5; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLANCE DJ, 1986, MOL GEN GENET, V202, P271, DOI 10.1007/BF00331649; BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0; BOWYER PK, UNPUB; BUXTON FP, 1983, MOL GEN GENET, V190, P403, DOI 10.1007/BF00331067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROMBIE WML, 1986, PHYTOCHEMISTRY, V25, P2075, DOI 10.1016/0031-9422(86)80069-3; DOURMASHKIN RR, 1962, NATURE, V194, P1116, DOI 10.1038/1941116a0; DURBIN RD, 1969, BIOCHIM BIOPHYS ACTA, V191, P176, DOI 10.1016/0005-2744(69)90331-3; FORD JE, 1977, PHYTOCHEMISTRY, V16, P545, DOI 10.1016/0031-9422(77)80011-3; FRITIG B, 1993, MECHANISMS PLANT DEF, V2; HENSON JM, 1988, CURR GENET, V14, P113, DOI 10.1007/BF00569334; MAHATO SB, 1991, PHYTOCHEMISTRY, V30, P1357, DOI 10.1016/0031-9422(91)84170-W; MAHATO SB, 1988, PHYTOCHEMISTRY, V28, P3037; OSBOURN AE, 1991, PHYSIOL MOL PLANT P, V38, P301, DOI 10.1016/S0885-5765(05)80121-3; OSBOURN AE, 1994, PHYSIOL MOL PLANT P, V45, P457, DOI 10.1016/S0885-5765(05)80042-6; PEGG GF, 1986, PHYSIOL MOL PLANT P, V28, P187, DOI 10.1016/S0048-4059(86)80063-7; PRICE KR, 1991, CRC CRIT REV FOOD SC, V26, P27; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; RAEDER U, 1985, LETT APPL MICROBIOL, V1, P17, DOI 10.1111/j.1472-765X.1985.tb01479.x; SCHONBECK F, 1976, PHYSL PLANT PATHOLOG, P653; TURNER EM, 1961, J EXP BOT, V12, P169, DOI 10.1093/jxb/12.1.169; VERHOEFF K, 1975, PHYTOPATHOL Z, V82, P333; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	191	201	0	42	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					371	374		10.1126/science.7824933	http://dx.doi.org/10.1126/science.7824933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824933				2022-12-01	WOS:A1995QC27300033
J	CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI				CHEN, J; MAKINO, CL; PEACHEY, NS; BAYLOR, DA; SIMON, MI			MECHANISMS OF RHODOPSIN INACTIVATION IN-VIVO AS REVEALED BY A COOH-TERMINAL TRUNCATION MUTANT	SCIENCE			English	Article							DOMINANT RETINITIS-PIGMENTOSA; ROD OUTER SEGMENTS; COUPLED RECEPTOR KINASES; PHOSPHORYLATION SITES; TRANSGENIC MICE; PROTEIN; GENE; DESENSITIZATION; PHOTORECEPTORS; TRANSDUCTION	Although biochemical experiments suggest that rhodopsin and other receptors coupled to heterotrimeric guanosine triphosphate-binding proteins (G proteins) are inactivated by phosphorylation near the carboxyl (COOH)-terminus and the subsequent binding of a capping protein, little is known about the quenching process in vivo. Flash responses were recorded from rods of transgenic mice in which a fraction of the rhodopsin molecules lacked the COOH-terminal phosphorylation sites. In the single photon regime, abnormally prolonged responses, attributed to activation of individual truncated rhodopsins, occurred interspersed with normal responses. The occurrence of the prolonged responses suggests that phosphorylation is required for normal shutoff. Comparison of normal and prolonged single photon responses indicated that rhodopsin begins to be quenched before the peak of the electrical response and that quenching limits the response amplitude.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; EDWARD HINES JR VET ADM HOSP,HINES,IL 60141; LOYOLA UNIV,STRITCH SCH MED,DEPT NEUROL,MAYWOOD,IL 60153	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	CHEN, J (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Peachey, Neal/G-5533-2010; Makino, Clint Lawrence/H-8428-2019	Peachey, Neal/0000-0002-4419-7226; Makino, Clint Lawrence/0000-0002-6005-9069	NATIONAL EYE INSTITUTE [F32EY006405] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012288] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY06405, EY0570] Funding Source: Medline; NIA NIH HHS [AG12288] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; APFELSTEDTSYLLA E, 1993, BRIT J OPHTHALMOL, V77, P495, DOI 10.1136/bjo.77.8.495; BAUMANN C, 1973, J PHYSIOL-LONDON, V235, P761, DOI 10.1113/jphysiol.1973.sp010415; BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BENNETT N, 1980, BIOCHEM BIOPH RES CO, V96, P1695, DOI 10.1016/0006-291X(80)91369-8; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRETON ME, 1994, INVEST OPHTH VIS SCI, V35, P295; CHEN J, 1993, INVEST OPHTH VIS SCI, V34, P768; CONE RA, 1969, NATURE, V221, P820, DOI 10.1038/221820a0; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HORN M, 1992, HUM GENET, V90, P255; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM RY, 1993, ARCH OPHTHALMOL-CHIC, V111, P1518, DOI 10.1001/archopht.1993.01090110084030; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCDOWELL JH, 1985, INVEST OPHTH VIS SCI, V26, P291; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEACHEY NS, UNPUB; PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0; RESTAGNO G, 1993, HUM MOL GENET, V2, P207, DOI 10.1093/hmg/2.2.207; SUNG CH, 1994, J NEUROSCI, V14, P5818; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WEHNER M, 1987, ADV BIOSCI, V62, P345; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1989, EXP EYE RES, V49, P439, DOI 10.1016/0014-4835(89)90052-3; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	39	258	262	1	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					374	377		10.1126/science.7824934	http://dx.doi.org/10.1126/science.7824934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824934				2022-12-01	WOS:A1995QC27300034
J	CLACKSON, T; WELLS, JA				CLACKSON, T; WELLS, JA			A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; ANTIBODY-ANTIGEN INTERACTIONS; PROTEIN-PROTEIN RECOGNITION; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; SCANNING MUTAGENESIS; FUNCTIONAL EPITOPE; RATIONAL DESIGN; COMPLEX; RESOLUTION	The x-ray crystal structure of the complex between human growth hormone (hGH) and the extracellular domain of its first bound receptor (hGHbp) shows that about 30 side chains from each protein make contact. Individual replacement of contact residues in the hGHbp with alanine showed that a central hydrophobic region, dominated by two tryptophan residues, accounts for more than three-quarters of the binding free energy. This ''functional epitope'' is surrounded by less important contact residues that are generally hydrophilic and partially hydrated, so that the interface resembles a cross section through a globular protein. The functionally important residues on the hGHbp directly contact those on hGH. Thus, only a small and complementary set of contact residues maintains binding affinity, a property that may be general to protein-protein interfaces.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech			Wells, Jim A/O-9854-2016					ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ATWELL S, UNPUB; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BUCKLE AM, 1994, BIOCHEMISTRY-US, V33, P8878, DOI 10.1021/bi00196a004; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1974, NATURE, V254, P101; CLACKSON T, UNPUB; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS AM, UNPUB; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HORTON N, 1992, PROTEIN SCI, V1, P169; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WELLS JC, UNPUB; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; YOUNG L, 1994, PROTEIN SCI, V3, P717	43	1705	1824	5	204	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 20	1995	267	5196					383	386		10.1126/science.7529940	http://dx.doi.org/10.1126/science.7529940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7529940				2022-12-01	WOS:A1995QC27300037
J	FINZI, L; GELLES, J				FINZI, L; GELLES, J			MEASUREMENT OF LACTOSE REPRESSOR-MEDIATED LOOP FORMATION AND BREAKDOWN IN SINGLE DNA-MOLECULES	SCIENCE			English	Article							LAC REPRESSOR; OPERATORS; STABILITY; COMPLEX; PROTEIN; INVITRO; OPERON	In gene regulatory systems in which proteins bind to multiple sites on a DNA molecule, the characterization of chemical mechanisms and single-step reaction rates is difficult because many chemical species may exist simultaneously in a molecular ensemble. This problem was circumvented by detecting DNA looping by the lactose repressor protein of Escherichia coli in single DNA molecules. The looping was detected by monitoring the nanometer-scale Brownian motion of microscopic particles linked to the ends of individual DNA molecules. This allowed the determination of the rates of formation and breakdown of a protein-mediated DNA loop in vitro. The measurements reveal that mechanical strain stored in the loop does not substantially accelerate loop breakdown, and the measurements also show that subunit dissociation of tetrameric repressor is not the predominant loop breakdown pathway.	BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University; Brandeis University								BERLINER E, 1994, J BIOL CHEM, V269, P8610; BERLINER E, IN PRESS NATURE; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; BRENOWITZ M, 1993, BIOCHEMISTRY-US, V32, P8693, DOI 10.1021/bi00084a041; BRENOWITZ M, 1991, BIOCHEMISTRY-US, V30, P5986, DOI 10.1021/bi00238a024; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; EISMANN E, 1987, J MOL BIOL, V195, P949, DOI 10.1016/0022-2836(87)90499-2; FINZI L, UNPUB; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HSIEH WT, 1987, J BIOL CHEM, V262, P14583; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MOSSING MC, 1986, SCIENCE, V233, P889, DOI 10.1126/science.3090685; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	19	182	191	0	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					378	380		10.1126/science.7824935	http://dx.doi.org/10.1126/science.7824935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824935				2022-12-01	WOS:A1995QC27300035
J	GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ				GUPTA, S; CAMPBELL, D; DERIJARD, B; DAVIS, RJ			TRANSCRIPTION FACTOR ATF2 REGULATION BY THE JNK SIGNAL-TRANSDUCTION PATHWAY	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-BINDING SPECIFICITY; LEUCINE ZIPPER PROTEINS; C-JUN; HETERODIMER FORMATION; TAX PROTEIN; CREB; FAMILY; E1A; PHOSPHORYLATION	Treatment of cells with pro-inflammatory cytokines or ultraviolet radiation causes activation of the c-Jun NH2-terminal protein kinase (JNK). Activating transcription factor-2 (ATF2) was found to be a target of the JNK signal transduction pathway. ATF2 was phosphorylated by JNK on two closely spaced threonine residues within the NH2-terminal activation domain. The replacement of these phosphorylation sites with alanine inhibited the transcriptional activity of ATF2. These mutations also inhibited ATF2-stimulated gene expression mediated by the retinoblastoma (Rb) tumor suppressor and the adenovirus early region 1A (E1A) oncoprotein. Furthermore, expression of dominant-negative JNK inhibited ATF2 transcriptional activity. Together, these data demonstrate a role for the JNK signal transduction pathway in transcriptional responses mediated by ATF2.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FLINT KJ, 1991, ONCOGENE, V6, P2019; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Gupta SK, UNPUB; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, IN PRESS GENES DEV; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SETH A, 1992, J BIOL CHEM, V267, P24796; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DH, 1985, MOL CELL BIOL, V5, P2684, DOI 10.1128/MCB.5.10.2684; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	40	1341	1359	1	39	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					389	393		10.1126/science.7824938	http://dx.doi.org/10.1126/science.7824938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824938				2022-12-01	WOS:A1995QC27300039
J	OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M				OVERDUIN, M; HARVEY, TS; BAGBY, S; TONG, KI; YAU, P; TAKEICHI, M; IKURA, M			SOLUTION STRUCTURE OF THE EPITHELIAL CADHERIN DOMAIN RESPONSIBLE FOR SELECTIVE CELL-ADHESION	SCIENCE			English	Article							BINDING-SITE; MOLECULE UVOMORULIN; CYTOPLASMIC DOMAIN; HUMAN CD2; PROTEINS; FACE	Cadherins are calcium-dependent cell adhesion molecules containing extracellular repeats of approximately 110 amino acids. The three-dimensional structure of the amino-terminal repeat of mouse epithelial cadherin was determined by multidimensional heteronuclear magnetic resonance spectroscopy. The calcium ion was bound by a short alpha helix and by loops at one end of the seven-stranded beta-barrel structure. An exposed concave face is in a position to provide homophilic binding specificity and was also sensitive to calcium ligation. Unexpected structural similarities with the immunoglobulin fold suggest an evolutionary relation between calcium-dependent and calcium-independent cell adhesion molecules.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Kyoto University			Harvey, Timothy S/F-9863-2013; Overduin, Michael/AAG-3632-2020	Harvey, Timothy S/0000-0001-6270-1943; Overduin, Michael/0000-0002-3114-6585; Ikura, Mitsuhiko/0000-0002-9524-1303; Bagby, Stefan/0000-0003-2302-9511				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger AT, 1993, X PLOR VERSION 3 1 S; EDELMAN M, 1991, ANNU REV BIOCHEM, V60, P155; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, UNPUB; OZAWA M, 1990, MECH DEVELOP, V33, P49, DOI 10.1016/0925-4773(90)90134-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PASCAL S, 1994, J MAGN RESON, V101, P197; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TONG KI, 1994, FEBS LETT, V352, P318; WISHART DS, 1993, J BIOMOL NMR, V4, P171; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	30	363	380	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					386	389		10.1126/science.7824937	http://dx.doi.org/10.1126/science.7824937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824937				2022-12-01	WOS:A1995QC27300038
J	SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP				SANTORO, M; CARLOMAGNO, F; ROMANO, A; BOTTARO, DP; DATHAN, NA; GRIECO, M; FUSCO, A; VECCHIO, G; MATOSKOVA, B; KRAUS, MH; DIFIORE, PP			ACTIVATION OF RET AS A DOMINANT TRANSFORMING GENE BY GERMLINE MUTATIONS OF MEN2A AND MEN2B	SCIENCE			English	Article							CELLS; PROTOONCOGENE; RECEPTOR; ONCOGENE; KINASE	Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinoma are dominantly inherited cancer syndromes. All three syndromes are associated with mutations in RET, which encodes a receptor-like tyrosine kinase. The altered RET alleles were shown to be transforming genes in NIH 3T3 cells as a consequence of constitutive activation of the RET kinase. The MEN2A mutation resulted in RET dimerization at steady state, whereas the MEN2B mutation altered RET catalytic properties both quantitatively and qualitatively. Oncogenic conversion RET in these neoplastic syndromes establishes germline transmission of dominant transforming genes in human cancer.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV NAPLES,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,NAPLES,ITALY; UNIV NAPLES,DEPT BIOL & PATOL CELLULARE & MOLEC L CALIFANO,NAPLES,ITALY; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATANZARO,ITALY; NCI,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010; Di Fiore, Pier Paolo/K-2130-2012	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Di Fiore, Pier Paolo/0000-0002-2252-0950; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197				CARLOMAGNO F, UNPUB; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COCHET C, 1988, J BIOL CHEM, V263, P3290; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; ROMANO A, 1994, ONCOGENE, V9, P2923; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, UNPUB; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TAKAHASHI M, 1988, ONCOGENE, V4, P805; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	20	715	728	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 20	1995	267	5196					381	383		10.1126/science.7824936	http://dx.doi.org/10.1126/science.7824936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC273	7824936	Green Submitted			2022-12-01	WOS:A1995QC27300036
J	CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L				CHAPMAN, T; LIDDLE, LF; KALB, JM; WOLFNER, MF; PARTRIDGE, L			COST OF MATING IN DROSOPHILA-MELANOGASTER FEMALES IS MEDIATED BY MALE ACCESSORY-GLAND PRODUCTS	NATURE			English	Article							REPRODUCTIVE-BEHAVIOR; EXPRESSION; GENE; PEPTIDE; EXPOSURE; SPERM	FEMALE Drosophila melanogaster with environmentally(1-3) or genetically(4) elevated rates of mating die younger than controls. This cost of mating is not attributable to receipt of sperm(5). We demonstrate here that seminal fluid products from the main cells of the male accessory gland are responsible for the cost of mating in females, and that increasing exposure to these products increases female death rate. Main-cell products are also involved in elevating the rate of female egg-laying, in reducing female receptivity to further matings and in removing or destroying sperm of previous mates(6-12). The cost of mating to females may therefore represent a side-effect of evolutionary conflict between males(13).	UNIV LONDON UNIV COLL,DEPT GENET & BIOMETRY,LONDON NW1 2HE,ENGLAND; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	University of London; University College London; University of Edinburgh; Cornell University			Partridge, Linda/A-5501-2010; Chapman, Tracey/E-5100-2011	Partridge, Linda/0000-0001-9615-0094				AGUADE M, 1992, GENETICS, V132, P755; AIGAKI T, 1991, NEURON, V7, P557, DOI 10.1016/0896-6273(91)90368-A; BALRATI A, 1970, DROSOPHILA INFORMATI, V45, P67; BERTRAM MJ, 1992, MECH DEVELOP, V38, P33, DOI 10.1016/0925-4773(92)90036-J; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CAVENER DR, 1983, P NATL ACAD SCI-BIOL, V80, P6286, DOI 10.1073/pnas.80.20.6286; CHAPMAN T, 1994, J EVOLUTION BIOL, V7, P51, DOI 10.1046/j.1420-9101.1994.7010051.x; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1993, P ROY SOC B-BIOL SCI, V253, P211, DOI 10.1098/rspb.1993.0105; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; DIBENEDETTO AJ, 1990, DEV BIOL, V139, P134, DOI 10.1016/0012-1606(90)90284-P; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; FOWLER K, 1989, NATURE, V338, P760, DOI 10.1038/338760a0; HARSHMAN LG, IN PRESS EVOLUTION; HIHARA F, 1981, Zoological Magazine (Tokyo), V90, P307; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; LUDWIG MZ, 1991, BIOCHEM GENET, V29, P215, DOI 10.1007/BF00590103; MANNING A, 1967, ANIM BEHAV, V15, P239, DOI 10.1016/0003-3472(67)90006-1; MEIKLE DB, 1990, J INSECT PHYSIOL, V36, P93, DOI 10.1016/0022-1910(90)90179-J; MONSMA SA, 1988, GENE DEV, V2, P1063, DOI 10.1101/gad.2.9.1063; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; TREVITT S, 1988, J INSECT PHYSIOL, V34, P821, DOI 10.1016/0022-1910(88)90157-6; TREVITT S, 1989, THESIS U EDINBURGH; Trivers R.L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; VANVALEN LM, 1985, EVOL THEOR, V7, P93	28	1070	1091	2	248	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					241	244		10.1038/373241a0	http://dx.doi.org/10.1038/373241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816137				2022-12-01	WOS:A1995QC27800062
J	CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M				CHEN, C; NAGY, Z; RADIC, MZ; HARDY, RR; HUSZAR, D; CAMPER, SA; WEIGERT, M			THE SITE AND STAGE OF ANTI-DNA B-CELL DELETION	NATURE			English	Article							REACTIVE LYMPHOCYTES-B; SOMATIC MUTATION; ESCAPE TOLERANCE; AUTOIMMUNE MICE; CLONAL DELETION; BONE-MARROW; MOUSE; ANTIBODIES; AUTOANTIBODIES; ELIMINATION	ANTIBODIES to DNA and nucleoproteins are found in sera of individuals with systemic autoimmune disease. In the population (and in the autoimmune mouse strain MRL/lpr) there is a great variety of such antinuclear antibodies, but individuals with systemic lupus erythematosus or single MRL mice express a subset only of the antinuclear specificities found in the population. These observations have been interpreted to mean that these antibodies arise by immunization(1) The oligoclonal nature of the autoantibody response and the evidence of selection acting on somatically mutated autoantibodies favour this interpretation(2,3). Specific activation of autoantibodies in disease implies either that autoantibodies are regulated in non-diseased individuals or that autoantigen availability is variable. The former has been demonstrated in anti-DNA transgenic mice. In normal mice, transgene-encoded antibodies against double-stranded (ds) DNA are not expressed in serum or on B cells(4-6). Here we describe modified anti-dsDNA transgenic mice which allow us to study the site and developmental stage at which such B-cell regulation occurs. This model shows that in normal mice B cells expressing anti-DNA specificity are deleted in the bone marrow at a pre-B to immature B transitional stage.	MED COLL PENN,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19129; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; GENPHARM INT INC,MT VIEW,CA 94043; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	Drexel University; Fox Chase Cancer Center; University of Michigan System; University of Michigan	CHEN, C (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Camper, Sally/0000-0001-8556-3379; Radic, Marko/0000-0002-8004-282X				ALLMAN DM, 1993, J IMMUNOL, V151, P4431; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHEN C, 1994, J IMMUNOL, V152, P1970; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EILAT D, 1988, J IMMUNOL, V141, P1745; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; MARION TN, 1990, J IMMUNOL, V145, P2322; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; RADIC MZ, 1991, J IMMUNOL, V146, P176; RADIC MZ, 1993, J IMMUNOL, V150, P4966; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RADIC MZ, 1994, REV IMMUNOL, V12, P487; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009	24	261	264	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					252	255		10.1038/373252a0	http://dx.doi.org/10.1038/373252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816141	Green Submitted			2022-12-01	WOS:A1995QC27800066
J	COWEY, A; STOERIG, P				COWEY, A; STOERIG, P			BLINDSIGHT IN MONKEYS	NATURE			English	Article							RESIDUAL VISION	BLINDSIGHT, the visually evoked voluntary responses of patients with striate cortical destruction that are demonstrated despite a phenomenal blindness, has attracted attention from neuroscientists and philosophers interested in problems of perceptual consciousness and its neuronal basis(1-3). It is assumed to be mediated by the numerous extra-geniculostriate cortical retinofugal pathways whose properties are studied primarily in monkeys(4). Like patients with blindsight(4-7), monkeys with lesions of the primary visual cortex can learn to detect, localize and distinguish between visual stimuli presented within their visual field defects(4,8-11). Although the patients deny seeing the stimuli they can nevertheless respond to (by forced-choice guessing) in their phenomenally blind fields, it is not known whether the monkeys experience the same absence of phenomenal vision. To determine whether they too have blindsight, or whether they actuary see the stimuli in their held defects, monkeys who showed excellent detection in tasks where a visual stimulus was presented on every trial, albeit at different positions, were tested in a signal-detection task(12) in which half the trials were blank trials, with no visual stimulus. They classified the visual stimuli presented in the field defect as blank trials, demonstrating, like patients, blindsight rather than degraded real vision.	UNIV MUNICH,INST MED PSYCHOL,D-80336 MUNICH,GERMANY	University of Munich	COWEY, A (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.							BARBUR JL, 1980, BRAIN, V103, P905, DOI 10.1093/brain/103.4.905; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BLYTHE IM, 1987, BRAIN, V110, P887, DOI 10.1093/brain/110.4.887; COWEY A, 1963, Q J EXP PSYCHOL, V15, P91, DOI 10.1080/17470216308416561; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; FENDRICH R, 1992, SCIENCE, V258, P1489, DOI 10.1126/science.1439839; Kluver H, 1941, J PSYCHOL, V11, P23; MOHLER CW, 1977, J NEUROPHYSIOL, V40, P74, DOI 10.1152/jn.1977.40.1.74; NELKIN N, 1993, PHILOS SCI, V60, P419, DOI 10.1086/289744; PASIK P, 1982, CONTRIBUTIONS SENSOR, V7, P147; STOERIG P, 1993, THEOR MED, V14, P117, DOI 10.1007/BF00997271; STOERIG P, 1991, BRAIN, V114, P1489; Swets J. A., 1982, EVALUATION DIAGNOSTI; WEISKRANTZ L, 1990, PROC R SOC SER B-BIO, V239, P247, DOI 10.1098/rspb.1990.0016; Weiskrantz L., 1986, BLINDSIGHT CASE STUD	16	213	215	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					247	249		10.1038/373247a0	http://dx.doi.org/10.1038/373247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QC278	7816139				2022-12-01	WOS:A1995QC27800064
J	DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME				DREVETS, WC; BURTON, H; VIDEEN, TO; SNYDER, AZ; SIMPSON, JR; RAICHLE, ME			BLOOD-FLOW CHANGES IN HUMAN SOMATOSENSORY CORTEX DURING ANTICIPATED STIMULATION	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; SOMATIC SENSORY TRANSMISSION; PET IMAGES; SELECTIVE ATTENTION; BRAIN; RESPONSES; MOVEMENT; PERFORMANCE; (H2O)-O-15; MODULATION	POSITRON emission tomography (PET) measurements of brain blood flow were used to monitor changes in the human primary and secondary somatosensory cortices during the period when somatosensory stimuli were expected. In anticipation of either focal or innocuous touching, or localized, painful shocks, blood flow decreased in parts of the primary somatosensory cortex map located outside the representation of the skin area that was the target of the expected stimulus. Specifically, attending to an impending stimulus to the fingers produced a significant decrease in blood flow in the somatosensory zones for the face, whereas attending to stimulation of the toe produced decreases in the zones for the fingers and face. Decreases were more prominent in the side ipsilateral to the location of the expected stimulus. No significant changes in blood flow occurred in the region of the cortex representing the skin locus of the awaited stimulation. These results are concurrent with a model of spatial attention in which potential signal enhancement may rely on, generalized suppression of background activity(1).	ST LOUIS UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; ST LOUIS UNIV,SCH MED,DEPT NEUROL & NEUROL SURG NEUROL,ST LOUIS,MO 63110	Saint Louis University; Saint Louis University; Saint Louis University	DREVETS, WC (corresponding author), ST LOUIS UNIV,SCH MED,MALLINCKRODT INST RADIOL,DIV RADIAT SCI,ST LOUIS,MO 63110, USA.							BURTON H, 1993, SOMATOSENS MOT RES, V10, P297, DOI 10.3109/08990229309028839; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPMAN CE, 1988, EXP BRAIN RES, V72, P316; CHAPMAN CE, 1987, EXP BRAIN RES, V68, P516; CHAPMAN CE, 1991, EXP BRAIN RES, V87, P319; COQUERY J M, 1971, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V165, P1946; Coquery J-M, 1978, ACTIVE TOUCH MECHANI, P161; DREVETS WC, 1992, SCIENCE, V256, P1696, DOI 10.1126/science.256.5064.1696; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1987, J NEUROSURG, V67, P34, DOI 10.3171/jns.1987.67.1.0034; HERSCOVITCH P, 1983, J NUCL MED, V14, P782; NELSON RJ, 1980, J COMP NEUROL, V192, P611, DOI 10.1002/cne.901920402; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROLAND PE, 1981, J NEUROPHYSIOL, V46, P744, DOI 10.1152/jn.1981.46.4.744; SATHIAN K, 1991, PERCEPT PSYCHOPHYS, V50, P237, DOI 10.3758/BF03206747; SINCLAIR RJ, 1991, J NEUROPHYSIOL, V66, P153, DOI 10.1152/jn.1991.66.1.153; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; Talairach J., 1988, COPLANAR STEREOTAXIC, P1; WHANG KC, 1991, PERCEPT PSYCHOPHYS, V50, P157, DOI 10.3758/BF03212216; YAMAMOTO M, 1982, IEEE T NUCL SCI, V29, P529, DOI 10.1109/TNS.1982.4335901	24	231	238	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					249	252		10.1038/373249a0	http://dx.doi.org/10.1038/373249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816140				2022-12-01	WOS:A1995QC27800065
J	DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE				DUGGLEBY, HJ; TOLLEY, SP; HILL, CP; DODSON, EJ; DODSON, G; MOODY, PCE			PENICILLIN ACYLASE HAS A SINGLE-AMINO-ACID CATALYTIC CENTER	NATURE			English	Article							ESCHERICHIA-COLI ATCC-11105; HYDROLYSIS; MECHANISM; SUBUNITS; SERINE	PENICILLIN acylase (penicillin amidohydrolase, EC3.5.1.11) is widely distributed among microorganisms, including bacteria, yeast and filamentous fungi. It is used on an industrial scale for the production of 6-aminopenicillanic acid, the starting material for the synthesis of semi-synthetic penicillins. Its in vivo role remains unclear, however, and the observation that expression of the Escherichia coli enzyme in vivo is regulated by both temperature and phenylacetic acid has prompted speculation that the enzyme could be involved in the assimilation of aromatic compounds as carbon sources in the organism's free-living mode(1). The mature E. coli enzyme is a periplasmic 80K heterodimer of A and B chains (209 and 566 amino acids, respectively(2,3)) synthesized as a single cytoplasmic precursor containing a 26-amino-acid signal sequence to direct export to the cytoplasm and a 54-amino-acid spacer between the A and B chains which may influence the final folding of the chains(5). The N-terminal serine of the B chain reacts with phenylmethylsulphonyl fluoride, which is consistent with a catalytic role for the serine hydrouyl group. Modifying this serine to a cysteine(6,7) inactivates the enzyme, whereas threonine, arginine or glycine substitution prevents in vivo processing of the enzyme indicating that this must be an important recognition site for cleavage. Here we report the crystal structure of penicillin acylase at 1.9 Angstrom resolution. Our analysis shows that the environment of the catalytically active N-terminal serine of the B chain contains no adjacent histidine equivalent to that found in the serine proteases. The nearest base to the hydroxyl of this serine is its own alpha-amino group, which may act by a new mechanism to endow the enzyme with its catalytic properties.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK			Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P135, DOI 10.1016/0378-1097(83)90182-9; BOCK A, 1983, FEMS MICROBIOL LETT, V20, P140; BRUNGER AT, 1987, SCIENCE, V23, P458; BURLINGAME R, 1983, J BACTERIOL, V155, P113, DOI 10.1128/JB.155.1.113-121.1983; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; COLE M, 1969, BIOCHEM J, V155, P733; DAUMY GO, 1985, J BACTERIOL, V163, P1279, DOI 10.1128/JB.163.3.1279-1281.1985; HUANG HT, 1963, APPL MICROBIOL, V11, P1; HUNT PD, 1990, PROTEIN ENG, V3, P635, DOI 10.1093/protein/3.7.635; KONECNY J, 1981, BIOTECHNOL LETT, V3, P112; KRAULIS PJ, 1990, J APPL CRYSTALLOGR, V24, P946; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUTZBACH C, 1974, HOPPESEYLERS Z PHYSL, V354, P45; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MARTIN J, 1990, BIOCHIM BIOPHYS ACTA, V1037, P133, DOI 10.1016/0167-4838(90)90158-C; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Savidge T A, 1975, Methods Enzymol, V43, P705; SCHUMACHER G, 1986, NUCLEIC ACIDS RES, V14, P5713, DOI 10.1093/nar/14.14.5713; SLADE A, 1991, EUR J BIOCHEM, V197, P75, DOI 10.1111/j.1432-1033.1991.tb15884.x; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TANFORD C, 1962, ADV PROTEIN CHEM, V17, P69; Virden R, 1990, BIOTECHNOL GENET, V8, P189, DOI [10.1080/02648725.1990.10647869, DOI 10.1080/02648725.1990.10647869]	25	418	433	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					264	268		10.1038/373264a0	http://dx.doi.org/10.1038/373264a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816145				2022-12-01	WOS:A1995QC27800070
J	FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H				FERRICK, DA; SCHRENZEL, MD; MULVANIA, T; HSIEH, B; FERLIN, WG; LEPPER, H			DIFFERENTIAL PRODUCTION OF INTERFERON-GAMMA AND INTERLEUKIN-4 IN RESPONSE TO TH1-STIMULATING AND TH2-STIMULATING PATHOGENS BY GAMMA-DELTA T-CELLS IN-VIVO	NATURE			English	Article							ALPHA-BETA; LISTERIA-MONOCYTOGENES; PROTECTIVE IMMUNITY; INFECTION; CYTOKINES; MICE; TUBERCULOSIS; EOSINOPHILIA; APPEARANCE; ELEVATION	EXPOSURE to various pathogens can stimulate at least two patterns of cytokine production by CD4-positive T cells(1-4) Responses that result in secretion of interferon-gamma (IFN-gamma), lymphotoxin and interleukin-2 (IL-2) are classified as T-helper-1 (Th1)(5,6); CD4(+) T-cell production of IL-4, IL-5, IL-9, IL-10 and IL-13 is called a T-helper-2 response (Th2)(5,6). Differentiation of CD4(+) T cells into either Th1 or Th2 cells is influenced by the cytokine milieu in which the initial antigen priming occurs(7-9). Here we use flow cytometry to identify the presence of intracellular cytokines (cytoflow) and analyse T-cell production of IFN-gamma and IL-4 from mice infected with Listeria monocytogenes or Nippostrongylus brasiliensis. We show that T cells bearing ya receptors discriminate early in infection between these two pathogens by producing cytokines associated with the appropriate T-helper response. Our results demonstrate that gamma delta T cells are involved in establishing primary immune responses.			FERRICK, DA (corresponding author), UNIV CALIF DAVIS,SCH VET MED,DEPT PATHOL MICROBIOL & IMMUNOL,DAVIS,CA 95616, USA.							BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; ENSOR JE, 1994, AM J PHYSIOL, V266, P967; FU YX, 1994, J IMMUNOL, V153, P3101; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KATONA IM, 1988, J IMMUNOL, V140, P3206; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MOSER R, 1993, J LAB CLIN MED, V122, P567; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; OHGA S, 1990, EUR J IMMUNOL, V20, P533, DOI 10.1002/eji.1830200311; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; ROCKEN M, 1992, J IMMUNOL, V148, P1031; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SVETIC A, 1993, J IMMUNOL, V150, P3434; TWOMEY BM, 1993, CLIN EXP IMMUNOL, V93, P178; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; WEN L, 1994, NATURE, V369, P654, DOI 10.1038/369654a0; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582	30	590	599	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					255	257		10.1038/373255a0	http://dx.doi.org/10.1038/373255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816142				2022-12-01	WOS:A1995QC27800067
J	GLOVER, JNM; HARRISON, SC				GLOVER, JNM; HARRISON, SC			CRYSTAL-STRUCTURE OF THE HETERODIMERIC BZIP TRANSCRIPTION FACTOR C-FOS-C-JUN BOUND TO DNA	NATURE			English	Article							X-RAY STRUCTURE; LEUCINE ZIPPER; BASIC REGION; BINDING DOMAINS; COILED-COIL; PROTEIN; COMPLEX; RECOGNITION; SPECIFICITY; EXPRESSION	THE FOS and Jun families of eukaryotic transcription factors heterodimerize to form complexes capable of binding 5'-TGAGTCA-3' DNA elements. We have determined the X-ray crystal structure of a heterodimer of the bZIP regions of c-Fos and c-Jun bound to DNA. Both subunits form continuous alpha-helices. The carboxy-terminal regions form an asymmetric coiled-coil, and the amino-terminal regions make base-specific contacts with DNA in the major groove. Comparison of the two crystallographically distinct protein-DNA complexes show that the coiled-coil is flexibly joined to the basic regions and that the Fos-Jun heterodimer does not recognize the asymmetric 5'-TGAGTCA-3' recognition element in a unique orientation. There is an extensive network of electrostatic interactions between subunits within the coiled-coil, consistent with proposals that these interactions determine preferential formation of the heterodimer over either of the homodimers.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	GLOVER, JNM (corresponding author), HARVARD UNIV,HOWARD HUGHES MED INST,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1990, SCIENCE, V248, P1157; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; 1979, CCP 4 SUITE PROGRAMS	28	653	691	1	43	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					257	261		10.1038/373257a0	http://dx.doi.org/10.1038/373257a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816143				2022-12-01	WOS:A1995QC27800068
J	JOHNSON, RP; CRAIG, SW				JOHNSON, RP; CRAIG, SW			F-ACTIN BINDING-SITE MASKED BY THE INTRAMOLECULAR ASSOCIATION OF VINCULIN HEAD AND TAIL DOMAINS	NATURE			English	Article							SELF-ASSOCIATION; ESCHERICHIA-COLI; ALPHA-ACTININ; SMOOTH-MUSCLE; PURIFICATION; PROTEINS; METAVINCULIN; FILAMENTS; SEQUENCE; CDNA	ALTHOUGH vinculin is present at all sites of F-actin attachment to plasma membranes(1) acid is required for linkage of myofibrils to sarcolemma(2), it is unclear how it promotes attachment of actin to membranes. Because biochemical evidence for a direct interaction of vinculin with F-actin is controversial(3-9), current models of actin-membrane linkages depict only an indirect role for vinculin, as a tether for alpha-actinin(10). We demonstrate here that an intramolecular association between the 95K head and 30K tail domains of vinculin(11) masks an F-actin binding site present in the carboxyterminal tail domain. Cosedimentation and crosslinking assays, and direct visualization by transmission electron microscopy, reveal an interaction between F-actin and a bacterially expressed fusion protein containing amino acids 811-1066 of vinculin, and between F-actin and a proteolytic fragment of vinculin containing amino acids 858-1066. Vinculin itself neither cosediments with nor crosslinks F-actin. The amino-terminal 95K head fragment of vinculin, but not intact vinculin, inhibits both cosedimentation and crosslinking. We propose that assembly of vinculin into an adherens junction involves disruption of the head-tail interaction, revealing a site that mediates microfilament attachment.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								BARSTEAD RJ, 1991, J CELL BIOL, V114, P715, DOI 10.1083/jcb.114.4.715; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; CRITCHLEY DR, 1991, BIOCHEM SOC T, V19, P1028, DOI 10.1042/bst0191028; EVANS RR, 1984, J BIOL CHEM, V259, P3916; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GIMONA M, 1988, EMBO J, V7, P2329, DOI 10.1002/j.1460-2075.1988.tb03076.x; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; MENKEL AR, 1993, EUR J CELL BIOL S37, V60, P38; MILAM LM, 1985, J MOL BIOL, V184, P543, DOI 10.1016/0022-2836(85)90301-8; MOLONY L, 1985, J CELL BIOCHEM, V29, P31, DOI 10.1002/jcb.240290104; OTTO JJ, 1986, CELL MOTIL CYTOSKEL, V6, P48, DOI 10.1002/cm.970060107; PRICE GJ, 1987, BIOCHEM J, V245, P595, DOI 10.1042/bj2450595; PRICE GJ, 1989, BIOCHEM J, V259, P453, DOI 10.1042/bj2590453; RUHNAU K, 1988, FEBS LETT, V228, P105, DOI 10.1016/0014-5793(88)80595-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WILKINS JA, 1982, CELL, V28, P83, DOI 10.1016/0092-8674(82)90377-4; WILKINS JA, 1986, J CELL BIOL, V102, P1085, DOI 10.1083/jcb.102.3.1085	30	322	323	1	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					261	264		10.1038/373261a0	http://dx.doi.org/10.1038/373261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816144				2022-12-01	WOS:A1995QC27800069
J	KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K				KOMIYAMA, NH; MIYAZAKI, G; TAME, J; NAGAI, K			TRANSPLANTING A UNIQUE ALLOSTERIC EFFECT FROM CROCODILE INTO HUMAN HEMOGLOBIN	NATURE			English	Article							ESCHERICHIA-COLI; CARBON-DIOXIDE; HEMOGLOBIN; BINDING	CROCODILES are able to remain under water for more than one hour without surfacing to breathe(1,2) and often kill their prey by drowning it. How do crocodiles stay under water for a long time? When they hold their breath, bicarbonate ions, the final product of respiration, accumulate and drastically reduce the oxygen affinity of haemoglobin, releasing it large fraction of haemoglobin-bound oxygen into the tissues(3,4). We have now located the bicarbonate-ion-binding site at the alpha(1) beta(2)-subunit interface by making various human-crocodile chimaeric haemoglobins. Furthermore, we have been able to transplant the bicarbonate effect into human haemoglobin by replacing only a few residues, even though the amino-acid sequence identity between crocodile (Crocodylus niloticus) and human haemoglobins is only 68% for the alpha- and 51% for the beta-subunit(5). These results indicate that an entirely new function which enables species to adapt to a new environment could evolve in a protein by a relatively small number of amino-acid substitutions in key positions(6).	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS,TOYONAKA,OSAKA 560,JAPAN	MRC Laboratory Molecular Biology; Osaka University				Tame, Jeremy/0000-0002-9341-7280				ANDERSEN HT, 1961, ACTA PHYSIOL SCAND, V53, P23, DOI 10.1111/j.1748-1716.1961.tb02261.x; BAUER C, 1977, NATURE, V269, P825, DOI 10.1038/269825a0; BAUER C, 1981, J BIOL CHEM, V256, P8429; COTT H. B., 1961, TRANS ZOOL SOC LONDON, V29, P211; FEMI G, 1981, ATLAS MOL STRUCTURE, V2; GRIGG GC, 1993, J EXP BIOL, V175, P15; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; Imai K, 1981, Methods Enzymol, V76, P438; KIMURA M, 1971, SCI AM, V241, P94; KOMIYAMA NH, 1991, NATURE, V352, P349, DOI 10.1038/352349a0; Kooyman GL., 1989, DIVERSE DIVERS PHYSL; LECLERCQ F, 1981, H-S Z PHYSIOL CHEM, V362, P1151; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1981, NATURE, V291, P682, DOI 10.1038/291682a0; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; TAME JRH, 1989, THESIS U CAMBRIDGE; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	19	72	73	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					244	246		10.1038/373244a0	http://dx.doi.org/10.1038/373244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816138				2022-12-01	WOS:A1995QC27800063
J	LEFKOWITZ, RJ				LEFKOWITZ, RJ			CLINICAL IMPLICATIONS OF BASIC RESEARCH - G-PROTEINS IN MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIGNAL-TRANSDUCTION				LEFKOWITZ, RJ (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021					IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LINDER ME, 1992, SCI AM, V267, P56; LINDER ME, 1992, SCI AM, V267, P64; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680	6	23	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					186	187		10.1056/NEJM199501193320312	http://dx.doi.org/10.1056/NEJM199501193320312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800014				2022-12-01	WOS:A1995QB16000012
J	MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE				MACKALL, CL; FLEISHER, TA; BROWN, MR; ANDRICH, MP; CHEN, CC; FEUERSTEIN, IM; HOROWITZ, ME; MAGRATH, IT; SHAD, AT; STEINBERG, SM; WEXLER, LH; GRESS, RE			AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; IMMUNODEFICIENCY-VIRUS INFECTION; ISOFORM EXPRESSION; CELL REGENERATION; SUBSETS; THYMECTOMY; DEPLETION; PROGENY; THERAPY; THYMUS	Background. Inadequate reconstitution of CD4+ T lymphocytes is an important clinical problem complicating chemotherapy, human immunodeficiency virus infection, and bone marrow transplantation, but relatively little is known about how CD4+ T lymphocytes regenerate. There are two main possibilities: bone marrow-derived progenitors could reconstitute the lymphocyte population using a thymus-dependent pathway, or thymus-independent pathways could predominate. Previous studies have suggested that the CD45RA glycoprotein on CD4+ T lymphocytes is a marker for progeny generated by a thymus-dependent pathway. Methods. We studied 15 patients 1 to 24 years of age who had undergone intensive chemotherapy for cancer. The absolute numbers of CD4+ T lymphocytes in peripheral blood and the expression of CD45 isoforms (CD45RA and CD45RO) on these lymphocytes were studied serially during lymphocyte regeneration after the completion of therapy. Radiographic imaging of the thymus was performed concomitantly. Results. There was an inverse relation between the patients' ages and the CD4+ T-lymphocyte counts six months after therapy was completed (r=-0.92). The CD4+ recovery correlated quantitatively with the appearance of CD45RA+CD4+ T lymphocytes in the blood (r=0.64). There was a higher proportion of CD45RA+CD4+ T lymphocytes in patients with thymic enlargement after chemotherapy than in patients without such enlargement (two-sided P=0.015). Conclusions. Thymus-dependent regeneration of CD4+ T lymphocytes occurs primarily in children, whereas even young adults have deficiencies in this pathway. Our results suggest that rapid T-cell regeneration requires residual thymic function in patients receiving high-dose chemotherapy.	NCI, DIV CANC BIOL DIAG & CTR, EXPTL IMMUNOL BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, MED BRANCH, BETHESDA, MD USA; NCI, DIV CANC TREATMENT, PEDIAT BRANCH, BETHESDA, MD USA; NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD USA; NIH, CTR CLIN, DEPT NUCL MED, BETHESDA, MD 20892 USA; NIH, CTR CLIN, DEPT CLIN PATHOL, BETHESDA, MD 20892 USA; UNIFORMED SERV UNIV HLTH SCI, HENRY M JACKSON FDN ADV MIL MED, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; Uniformed Services University of the Health Sciences - USA	MACKALL, CL (corresponding author), NIH, CTR CLIN, DEPT RADIOL, BLDG 10, RM 4B14, BETHESDA, MD 20892 USA.							ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; ATKINSON K, 1982, BLOOD, V59, P1292; BREARLEY S, 1987, CLIN EXP IMMUNOL, V70, P322; BUCHSCHACHER GL, 1993, JAMA-J AM MED ASSOC, V269, P2880, DOI 10.1001/jama.269.22.2880; CHOYKE PL, 1987, AM J ROENTGENOL, V149, P269, DOI 10.2214/ajr.149.2.269; Civin C I, 1992, Prog Clin Biol Res, V377, P461; DEGAST GC, 1985, BLOOD, V66, P428; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FANCI AS, 1988, SCIENCE, V239, P617; FAVROT M, 1983, CLIN EXP IMMUNOL, V54, P59; FORMAN SJ, 1982, TRANSPLANTATION, V34, P96; FUJII Y, 1992, EUR J IMMUNOL, V22, P1843, DOI 10.1002/eji.1830220725; ISRAEL O, 1993, J NUCL MED, V34, P1330; JOHNSTON MI, 1993, SCIENCE, V260, P1286, DOI 10.1126/science.7684163; MACKALL CL, 1994, BLOOD, V84, P2221; MACKALL CL, 1993, BLOOD, V82, P2585; MELMS A, 1993, J NEUROL NEUROSUR PS, V56, P46, DOI 10.1136/jnnp.56.1.46; MILLER JF, 1961, LANCET, V2, P748; MOSES RD, 1989, TRANSPLANTATION, V47, P435, DOI 10.1097/00007890-198903000-00007; MUELLER BU, 1994, PEDIATRICS, V94, P724; PAPIERNIK M, 1992, PEDIATRICS, V89, P297; PEYLANRAMU N, 1989, J CLIN ONCOL, V7, P1800, DOI 10.1200/JCO.1989.7.12.1800; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SPRENT J, 1989, FUNDAMENTAL IMMUNOLO, P84; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STUTMAN O, 1986, IMMUNOL REV, V91, P159, DOI 10.1111/j.1600-065X.1986.tb01488.x; ZINKERNAGEL RM, 1980, J IMMUNOL, V124, P2356	28	902	920	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					143	149		10.1056/NEJM199501193320303	http://dx.doi.org/10.1056/NEJM199501193320303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800006				2022-12-01	WOS:A1995QB16000003
J	MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M				MARTINEZ, FD; WRIGHT, AL; TAUSSIG, LM; HOLBERG, CJ; HALONEN, M; MORGAN, WJ; BEAN, J; BIANCHI, H; CURTISS, J; EY, J; SANGUINETI, A; SMITH, B; VONDRAK, T; WEST, N; MCLELLAN, M			ASTHMA AND WHEEZING IN THE FIRST 6 YEARS OF LIFE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-SPECIFIC IGE; RESPIRATORY ILLNESS; PULMONARY-FUNCTION; LUNG-FUNCTION; SERUM IGE; AIRWAY RESPONSIVENESS; 1ST YEAR; CHILDREN; SUBSEQUENT; CHILDHOOD	Background. Many young children wheeze during viral respiratory infections, but the pathogenesis of these episodes and their relation to the development of asthma later in life are not well understood. Methods. In a prospective study, we investigated the factors affecting wheezing before the age of three years and their relation to wheezing at six years of age. Of 1246 newborns in the Tucson, Arizona, area enrolled between May 1980 and October 1984, follow-up data at both three and six years of age were available for 826. For these children, assessments in infancy included measurement of cord-serum IgE levels (measured in 750 children), pulmonary-function testing before any lower respiratory tract illness had occurred (125), measurement of serum IgE levels at nine months of age (672), and questionnaires completed by the children's parents when the children were one year old (800), Assessments at six years of age included measurement of serum IgE levels (in 460), pulmonary-function testing (526), and skin allergy testing (629). Results. At the age of six years, 425 children (51.5 percent) had never wheezed, 164 (19.9 percent) had had at least one lower respiratory tract illness with wheezing during the first three years of life but had no wheezing at six years of age, 124 (15.0 percent) had no wheezing before the age of three years but had wheezing at the age of six years, and 113 (13.7 percent) had wheezing both before three years of age and at six years of age. The children who had wheezing before three years of age but not at the age of six had diminished airway function (length-adjusted maximal expiratory flow at functional residual capacity [V(max)FRC]) both before the age of one year and at the age of six years, were more likely than the other children to have mothers who smoked but not mothers with asthma, and did not have elevated serum IgE levels or skin-test reactivity. Children who started wheezing in early life and continued to wheeze at the age of six were more likely than the children who never wheezed to have mothers with a history of asthma (P<0.001), to have elevated serum IgE levels (P<0.01) and normal lung function in the first year of life, and to have elevated serum IgE levels (P<0.001) and diminished values for V(max)FRC (P<0.01) at six years of age. Conclusions. The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life, In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	UNIV ARIZONA, COLL MED, DEPT PEDIAT, TUCSON, AZ USA	University of Arizona	MARTINEZ, FD (corresponding author), UNIV ARIZONA, ARIZONA HLTH SCI CTR, COLL MED, CTR RESP SCI, 1501 N CAMPBELL AVE, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE P, 1987, STATISTICAL METHODS; BERBERICH MA, 1993, AM REV RESPIR DIS, V148, P1105; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MARTINEZ FD, 1994, 5 P BRONCH INT S GRO, P161; MERKUS PJFM, 1993, AM REV RESPIR DIS, V148, P1484, DOI 10.1164/ajrccm/148.6_Pt_1.1484; PATTEMORE PK, 1993, CLIN EXP ALLERGY, V23, P886, DOI 10.1111/j.1365-2222.1993.tb00273.x; REDLINE S, 1989, AM REV RESPIR DIS, V140, P179, DOI 10.1164/ajrccm/140.1.179; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1977, AM REV RESPIR DIS, V116, P1031; TEPPER RS, 1987, AM REV RESPIR DIS, V136, P800; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; Woolf B, 1954, ANN HUM GENET, V19, P251; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	24	2821	2899	6	285	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 19	1995	332	3					133	138		10.1056/NEJM199501193320301	http://dx.doi.org/10.1056/NEJM199501193320301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB160	7800004				2022-12-01	WOS:A1995QB16000001
J	THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D				THORN, SN; DANIELS, RG; AUDITOR, MTM; HILVERT, D			LARGE RATE ACCELERATIONS IN ANTIBODY CATALYSIS BY STRATEGIC USE OF HAPTENIC CHARGE	NATURE			English	Article							PHYSICAL ORGANIC-CHEMISTRY; BENZISOXAZOLES; ENERGY	GENERAL acid-base catalysis contributes substantially to the efficacy of many enzymes, enabling an impressive array of eliminations, isomerizations, racemizations, hydrolyses and carbon-carbon bond-forming reactions to be carried out with high rates and selectivities(1). The fundamental challenge of exploiting similar effects in designed catalysts such as catalytic antibodies(2,3) is that of correctly positioning the catalytic groups in an appropriate active-site microenvironment, Charge complementarity between antibody and hapten (the template used to induce an antibody) has been used successfully in a number of instances to elicit acids and bases within immunoglobulin combining sites(4-9), but the activities of the catalysts obtained by this strategy are generally considerably lower than those of natural enzymes, Here we report that by optimizing hapten design and efficiently screening the immune response, antibodies can be obtained that act effectively as general base catalysts. Thus a cationic hapten correctly mimicking the transition-state geometry of all reacting bonds and bearing little resemblance to the reaction product has yielded carboxylate-containing antibodies that catalyse an E2 elimination with more than 10(3) turnovers per active site and rate accelerations of greater than 10(8). These results demonstrate that very large effects can be achieved by strategic use of haptenic charge.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								AHRLOW E, 1988, ANTIBODIES LABORATOR; CASEY ML, 1973, J ORG CHEM, V38, P2295; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GERIT JA, 1991, J AM CHEM SOC, V113, P9667; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1994, CURR OPIN STRUC BIOL, V4, P612, DOI 10.1016/S0959-440X(94)90226-7; JACKSON DY, 1991, J AM CHEM SOC, V113, P2319, DOI 10.1021/ja00006a070; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; KEMP DS, 1973, J AM CHEM SOC, V95, P6670, DOI 10.1021/ja00801a024; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; KULIOPULOS A, 1990, BIOCHEMISTRY-US, V29, P10271, DOI 10.1021/bi00496a017; LAUER RC, 1974, EXPERIENTIA, V30, P560, DOI 10.1007/BF01926352; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LUNDBLAD RL, 1991, CHEM REAGENTS PROTEI, P267; PARKER AJ, 1969, CHEM REV, V69, P1, DOI 10.1021/cr60257a001; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; SHOKAT K, 1994, J AM CHEM SOC, V116, P2261, DOI 10.1021/ja00085a004; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; WALSH CT, 1979, ENZYMATIC REACTION M; WARSHELL A, 1991, COMPUTER MODELING CH, P153	24	133	138	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 19	1995	373	6511					228	230		10.1038/373228a0	http://dx.doi.org/10.1038/373228a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QC278	7816136				2022-12-01	WOS:A1995QC27800057
J	WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS				WU, L; NIEMEYER, B; COLLEY, N; SOCOLICH, M; ZUKER, CS			REGULATION OF PLC-MEDIATED SIGNALING IN-VIVO BY CDP-DIACYLGLYCEROL SYNTHASE	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; DIGLYCERIDE SYNTHETASE; VISUAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE	CDP-diacylglycerol synthase (CDS) is an enzyme required for the regeneration of the signalling molecule phosphatidylinositol-4,5-bisphosphate (PtdlnsP(2)) from phosphatidic acid. A photoreceptor cell-specific isoform of CDS from Drosophila is a key regulator of phototransduction, a G-protein-coupled signalling cascade mediated by phospholipase C, cds mutants cannot sustain a light-activated current as a result of depletion of PtdlnsP(2). Overexpression of CDS increases the amplitude of the light response, demonstrating that availability of PtdlnsP(2) is a determinant in the gain of this pathway. cds mutants undergo light-dependent retinal degeneration which can be suppressed by a mutation in phospholipase C. Thus, enzymes involved in PtdlnsP(2) metabolism regulate phosphoinositide-mediated signalling cascades in vivo.	UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT NEUROSCI, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego			Niemeyer, Barbara A./AAL-8972-2021	Socolich, Michael/0000-0002-0702-1061; Wu, Louisa/0000-0001-8609-3081	NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHBRUNER M, 1989, DROSOPHILA LABORATOR; BAUMANN O, 1989, CELL TISSUE RES, V255, P511, DOI 10.1007/BF00218786; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; ELDRED WD, 1983, J HISTOCHEM CYTOCHEM, V31, P285, DOI 10.1177/31.2.6339606; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FEILER R, 1992, J NEUROSCI, V12, P3862; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; ICHO T, 1985, J BIOL CHEM, V260, P2078; INOUE H, 1989, J BIOL CHEM, V264, P5996; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENT C, 1991, FASEB J, V5, P2258, DOI 10.1096/fasebj.5.9.1860617; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; MARGOLSKEE RF, 1993, BIOESSAYS, V15, P645, DOI 10.1002/bies.950151003; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MASAI I, 1992, P NATL ACAD SCI USA, V89, P6030, DOI 10.1073/pnas.89.13.6030; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MCCABE MJ, 1992, ANN NY ACAD SCI, V663, P269, DOI 10.1111/j.1749-6632.1992.tb38670.x; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; PETERS KG, 1992, COLD SPRING HARB SYM, V57, P63, DOI 10.1101/SQB.1992.057.01.008; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V97, P1251, DOI 10.1093/oxfordjournals.jbchem.a135171; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	50	146	151	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 19	1995	373	6511					216	222		10.1038/373216a0	http://dx.doi.org/10.1038/373216a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QC278	7816135				2022-12-01	WOS:A1995QC27800054
J	EBERT, DA; HECKERLING, PS				EBERT, DA; HECKERLING, PS			COMMUNICATION WITH DEAF PATIENTS - KNOWLEDGE, BELIEFS, AND PRACTICES OF PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SERVICES	Objective.-To assess physicians' knowledge and beliefs regarding communication with deaf people and compare their knowledge and beliefs with their methods of communicating with deaf patients in their practices. Design.-Survey. Setting.-University medical center. Subjects.-Attending physicians in an internal medicine department. Interventions.-Physicians were surveyed regarding prior contacts with deaf patients and with deaf people outside the medical setting, and regarding their knowledge and beliefs concerning methods of communicating with deaf people. Physicians were asked to estimate the fraction of encounters in which they communicated with deaf patients by lipreading, writing, translation by a relative or friend, a sign language interpreter, or other methods. Results.-Writing was the method used most frequently in communicating with deaf patients. Although 63% of physicians knew that signing should be the initial method of communicating with deaf patients who sign, only 22% used sign language interpreters more frequently than other methods in their practices. Past contact with deaf people (P=.05), belief that communication by signing was the best means of communication (P=.04), and knowledge of the inefficiency of lipreading (P=.04) were predictors of the use of sign language interpreters for deaf patients. Physicians who used sign language interpreters more frequently than other methods believed that much more time and effort were involved in caring for deaf than for hearing patients compared with those who used interpreters less frequently (P=.08). Conclusion.-Although most physicians believed that use of sign language interpreters was preferable, only a minority used them in their practices. Greater recognition of the advantages of signing over other methods and greater availability of sign language interpreters should read to more effective communication between deaf patients and physicians.			EBERT, DA (corresponding author), UNIV ILLINOIS,DEPT MED,GEN INTERNAL MED SECT,M-C 787,840 S WOOD ST,CHICAGO,IL 60612, USA.							DAVENPORT SLH, 1977, J FAM PRACTICE, V4, P1065; DIPIETRO LJ, 1981, AM ANN DEAF, V126, P106, DOI 10.1353/aad.2012.1505; ENGELMAN L, 1988, BMDP STATISTICAL SOF, P941; GOLDEN P, 1978, HOSPITALS, V52, P86; HAFFNER L, 1992, WESTERN J MED, V157, P255; KLINE F, 1980, AM J PSYCHIAT, V137, P1530; LASS LG, 1978, AM ANN DEAF, V123, P960; MCENTEE MK, 1993, AM ANN DEAF, V138, P26, DOI 10.1353/aad.2012.0569; MCEWEN E, 1988, J FAM PRACTICE, V26, P289; MINDEL ED, 1971, THEY GROW SILENCE, P96; REISMAN G, 1977, JAMA-J AM MED ASSOC, V237, P2397; SCHEIN JD, 1980, DEAF AM, V32, P5; VERNON M, 1970, REHABIL LIT, V31, P258; WARNER HC, 1986, AM ANN DEAF, V131, P365, DOI 10.1353/aad.2012.1033	14	76	76	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					227	229						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB234	7807662				2022-12-01	WOS:A1995QB23400027
J	MCCAIG, LF; HUGHES, JM				MCCAIG, LF; HUGHES, JM			TRENDS IN ANTIMICROBIAL DRUG PRESCRIBING AMONG OFFICE-BASED PHYSICIANS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIBIOTIC USE; RESISTANCE; EPIDEMIOLOGY; GUIDELINES; AGENTS	Objective.-To assess changes in oral antimicrobial drug prescribing by office-based physicians from 1980 through 1992, with emphasis on the treatment of otitis media and sinusitis and on the possible impact of demographic variables on such use. Design.-The National Ambulatory Medical Care Survey is a sample survey of office-based physicians in the United States conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. Setting.-Physicians' offices. Patients or Other Participants.-Physicians sampled for the 1980, 1985, 1989, and 1992 National Ambulatory Medical Care Surveys, which included groups of 2959, 5032, 2540, and 3000 physicians, respectively. Sample physicians responding in 1980, 1985, 1989, and 1999 reported data for 46 081, 71 594, 38 384, and 34 606 sample office visits, respectively, including information on antimicrobial drug prescribing. Main Outcome Measure.-Trends in the antimicrobial drug prescription rates. Results.-From 1980 through 1992, increasing prescribing measured by the annual drug prescription rate per 1000 population, was found for the more expensive, broad-spectrum antimicrobial drugs, such as the cephalosporins; decreasing rates were observed for less expensive antimicrobial drugs with a narrower spectrum, such as the penicillins. No trend was found for trimethoprim-sulfamethoxazole, the erythromycins, or the tetracyclines. During the decade, an increasing trend in the visit rate to office-based physicians for otitis media was observed, while the visit rate for sinusitis among adults was found to be higher in 1992 than in each of the other study years. Conclusions.-The increased use of broader-spectrum and more expensive antimicrobial drugs have implications for all patients because of the impact on health care costs and the potential for the emergence of antimicrobial resistance. The data suggest that the incidence of otitis media and sinusitis is increasing.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH CARE STAT, AMBULATORY CARE STAT BRANCH, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)								ADAMS PF, 1992, VITAL HLTH STAT 184, V10; BENSON V, 1994, VITAL HLTH STAT 189, V10; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BILLUPS NF, 1989, AM DRUG INDEX; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BRYANT E, 1988, VITAL HLTH STAT 108, V2; CHRETIEN JH, 1975, ARCH INTERN MED, V135, P1063, DOI 10.1001/archinte.135.8.1063; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; ENA J, 1993, JAMA-J AM MED ASSOC, V269, P598, DOI 10.1001/jama.269.5.598; FARYNA A, 1987, J GEN INTERN MED, V2, P102, DOI 10.1007/BF02596306; HAHN B, 1992, PHS AHCPR930007 PUBL; HOLMBERG SD, 1987, REV INFECT DIS, V9, P1065; INFANTERIVARD C, 1983, EPIDEMIOL REV, V15, P44; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; KUNIN CM, 1985, J INFECT DIS, V151, P388, DOI 10.1093/infdis/151.3.388; KUNIN CM, 1990, PRINCIPLES PRACTICE; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MCAIG LF, 1994, ADV DATA VITAL HLTH, V245; MCEVOY GK, 1988, AM HOSPITAL FORMULAR; MELNICK SL, 1992, ANN PHARMACOTHER, V26, P1292, DOI 10.1177/106002809202601020; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PHELPS CE, 1989, MED CARE, V27, P194, DOI 10.1097/00005650-198902000-00009; RICHTSMEIER WJ, 1992, ANN OTO RHINOL LARYN, V101, P46, DOI 10.1177/00034894921010S110; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SCHAPPERT S, 1992, ADV DATA VITAL HLTH, V214; SIMBERKOFF MS, 1994, JAMA-J AM MED ASSOC, V271, P1875, DOI 10.1001/jama.271.23.1875; SIRKEN MG, 1990, MANUAL STANDARDS PRO; SOYKA LF, 1975, PEDIATRICS, V55, P552; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; WILLETT LR, 1994, J GEN INTERN MED, V9, P38, DOI 10.1007/BF02599141; WYATT TD, 1990, BRIT MED J, V300, P441, DOI 10.1136/bmj.300.6722.441; 1990, DRUG EVALUATIONS SUB; 1992, PHYSICIANS DESK REFE; 1992, EMERGING INFECTIONS; 1988, DRUG FACTS COMP; 1994, ADRESSING EMERGING I; 1994, MED LETT, V36, P19; 1985, VITAL HLTH STAT 50, V10; 1988, PHYSICIANS DESK REFE; 1992, NATIONAL AMBULATORY	44	607	618	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					214	219		10.1001/jama.273.3.214	http://dx.doi.org/10.1001/jama.273.3.214			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807660				2022-12-01	WOS:A1995QB23400025
J	RAVIGLIONE, MC; SNIDER, DE; KOCHI, A				RAVIGLIONE, MC; SNIDER, DE; KOCHI, A			GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS - MORBIDITY AND MORTALITY OF A WORLDWIDE EPIDEMIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; IMMUNE-DEFICIENCY-SYNDROME; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; EMERGENCE; DEATHS	This article describes the global epidemiology of tuberculosis and reviews recent estimates of tuberculosis incidence and mortality in the world. The highest prevalence of tuberculosis infection and estimated annual risk of tuberculosis infection are in sub-Saharan Africa and Southeast Asia. Overall, almost 3.8 million cases of tuberculosis were reported in the world in 1990, of which 49% were in Southeast Asia. From the period 1984 through 1986 to the period 1989 through 1991, notification rates increased in ail World Health Organization regions, except the American and the European regions. In 1990, there were an estimated 7.5 million cases of tuberculosis and 2.5 million deaths worldwide. The human immunodeficiency virus epidemic is causing increases in the number of tuberculosis cases, particularly in Africa, although increases are also expected in Southeast Asia. In many industrialized countries, tuberculosis has recently failed to decline, and in eastern Europe and the former Soviet Union, cases and deaths are increasing. Drug resistance is a serious problem, especially in the United States. If worldwide control of tuberculosis does not improve, 90 million new cases and 30 million deaths are expected in the decade 1990 through 1999.	CTR DIS CONTROL & PREVENT, ATLANTA, GA 30341 USA	Centers for Disease Control & Prevention - USA	RAVIGLIONE, MC (corresponding author), WHO, TB PROGRAMME, CH-1211 GENEVA 27, SWITZERLAND.			RAVIGLIONE, Mario/0000-0002-9331-2067				AISU T, 1992, 1992 WORLD C TUB BET; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1994, MMWR MORB MORTAL WKL; BAMRUNGTRAKUL T, 1993, 17TH E REG C TUB RES; BOUVET E, 1991, B EPIDEMIOLOGIQUE HE, V45, P196; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CAUTHEN GM, 1988, WHO TB88154 PUBL; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P961; CHUM HL, 1992, NOV WORLD C TUB BETH; CLERMONT HC, 1990, 6TH INT C AIDS SAN F; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; Dalcomo Margareth Pretti, 1993, Revista Argentina del Torax, V54, P29; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; DIDILESCU C, 1993, TUBERCULOZA ROMANIA; DIPERRI G, 1989, LANCET, V2, P1502; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; DOLIN PJ, 1993, WHOTB93173 PUBL; DROLET GJ, 1938, AM REV TUBERC, V87, P125; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; Enarson D A, 1991, Bull Int Union Tuberc Lung Dis, V66, P195; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GIRARDI E, 1993, 9TH INT C AIDS HIV S; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410; Hargreaves J., 1994, Communicable Diseases Intelligence, V18, P330; HONG YP, 1993, TUBERCLE LUNG DIS, V74, P323, DOI 10.1016/0962-8479(93)90107-9; HUMPHRIES MJ, 1984, BRIT J DIS CHEST, V78, P149, DOI 10.1016/0007-0971(84)90115-3; HURET B, 1993, B EPIDEMIOL HEBDOMAD, V52, P243; Jain NK, 1992, IND J TUBERC, V92, P145; JESSURUN J, 1990, J ACQ IMMUN DEF SYND, V3, P579; KAUR A, 1992, J ACQ IMMUN DEF SYND, V5, P883; KOCHI A, 1993, RES MICROBIOL, V144, P104, DOI 10.1016/0923-2508(93)90023-U; KRITSKI AL, 1993, J ACQ IMMUN DEF SYND, V6, P1008; LINDHART M, 1939, STATISTICS PULMONARY; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MBAGA JM, 1990, E AFR MED J, V67, P95; MCLEOD DT, 1989, T ROY SOC TROP MED H, V83, P694, DOI 10.1016/0035-9203(89)90400-8; MOHANTY KC, 1993, 17TH E REG C TUB RES; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; ONORATO I, 1993, 33RD INT C ANT AG CH; PAPE JW, 1985, ANN INTERN MED, V103, P674, DOI 10.7326/0003-4819-103-5-674; PAYANANDANA V, 1993, 1993 MIN PUBL HLTH D; Raviglione M. C., 1993, Morbidity and Mortality Weekly Report, V42, P628; RAVIGLIONE MC, 1994, TUBERCLE LUNG DIS, V75, P400, DOI 10.1016/0962-8479(94)90113-9; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHWOEBEL V, 1993, BEH, V50, P235; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SINGH II, 1993, 17TH E REG C TUB RES; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1993, HEART LUNG, V22, P365; SPRINGETT V H, 1971, Tubercle, V52, P73, DOI 10.1016/0041-3879(71)90015-8; STYBLO K, 1969, Bulletin of the International Union Against Tuberculosis, V42, P5; STYBLO K, 1981, Bulletin of the International Union Against Tuberculosis, V56, P118; Styblo K, 1985, B INT UNION TUBERC L, V60, P117; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; Sutherland I, 1976, Adv Tuberc Res, V19, P1; TANSUPHASWASDIK.S, 1993, 17TH P E REG C TUB R; WURBURTON ARE, 1993, COMMUNICAB DIS REP, V3, pR175; 1992, MMWR-MORBID MORTAL W, V41, P13; 1991, MMWR-MORBID MORTAL W, V40, P485; 1974, B WORLD HEALTH ORGAN, V51, P473; 1991, 44TH WORLD HLTH ASS; 1989, CHILDHOOD TUBERCULOS; 1990, MMWR-MORBID MORTAL W, V39, P7; 1989, MMWR-MORBID MORTAL W, V38, P313; 1994, WHOTB94175 PUBL; 1994, WHOTB94179 PUBL; 1993, 1993 WORLD BANK WORL, P1; 1993, B OFFICE FEDERAL SAN, V41, P739; 1993, TUBERCULOSIS STATIST; 1994, WKLY EPIDEMIOL REC, V69, P189	80	1251	1301	1	58	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					220	226		10.1001/jama.273.3.220	http://dx.doi.org/10.1001/jama.273.3.220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807661				2022-12-01	WOS:A1995QB23400026
J	WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA				WACHTER, RM; LUCE, JM; SAFRIN, S; BERRIOS, DC; CHARLEBOIS, E; SCITOVSKY, AA			COST AND OUTCOME OF INTENSIVE-CARE FOR PATIENTS WITH AIDS, PNEUMOCYSTIS-CARINII PNEUMONIA, AND SEVERE RESPIRATORY-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MECHANICAL VENTILATION; VIRUS INFECTION; CONTROLLED TRIAL; TERM SURVIVAL; MEDICAL-CARE; HIV; CORTICOSTEROIDS; PATTERNS; THERAPY	Objective.-To determine the costs and outcomes associated with intensive care unit (ICU) admission for patients with acquired immunodeficiency syndrome (AIDS)-related Pneumocystis carinii pneumonia (PCP), and severe respiratory failure. Design.-Survival and cost-effectiveness analysis. Setting.-A large municipal teaching hospital serving an indigent population. Patients.-Consecutive patients intubated and mechanically ventilated for AIDS, PCP, and respiratory failure from 1981 through 1991 (n=113). The cohort was separated into three groups for analysis: patients admitted to the ICU in 1981 through 1985 (era I, n=43), those admitted in 1986 through 1988 (era II, n=33), and those admitted in 1989 through 1991 (era III, n=37). Main Outcome Measures.-Hospital charges and survival time; cost per year of life saved, using a zero-cost, zero-life assumption. Results.-Twenty-eight (25%) of the 113 patients mechanically ventilated for PCP and respiratory failure survived to hospital discharge: six (14%) of 43 in era I, 13 (39%) of 33 in era II, and nine (24%) of 37 in era III (P=.04). Post-ICU admission charges averaged $57 874 for the entire cohort, remaining relatively stable across the three eras. Cost of care for survivors was significantly more expensive than for those dying before discharge. The cost of ICU admission and subsequent hospitalization averaged $174 781 per year of life saved; $305 795 in era 1, $94 528 in era II, and $215 233 in era III. Improved survival rates and shorter lengths of ICU stay led to the improved cost-effectiveness in era II, while the opposite trends resulted in worsening cost-effectiveness in recent years. The strongest predictors of hospital mortality in era III were low CD4 cell counts on hospital admission and the development of pneumothorax during mechanical ventilation. Conclusions.-The cost-effectiveness of intensive care for patients with PCP and severe respiratory failure improved during the first 8 years of the AIDS epidemic but fell in recent years such that it is now below that of many accepted medical interventions.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOSTAT & EPIDEMIOL,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,MED SERV,SAN FRANCISCO,CA 94110; PALO ALTO MED FDN,DIV HLTH ECON,PALO ALTO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Palo Alto Medical Foundation Research Institute	WACHTER, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0862,SAN FRANCISCO,CA 94143, USA.							ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BAGGOTT LA, 1987, CHEST S, V92; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BENNETT RL, 1993, J ACQ IMMUN DEF SYND, V6, P1319; BONE RC, 1991, ARCH INTERN MED, V151, P1061, DOI 10.1001/archinte.151.6.1061; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; BOZZETTE SA, 1992, CHEST, V101, P1404, DOI 10.1378/chest.101.5.1404; CALLAHAN D, 1991, J AM GERIATR SOC, V39, P622, DOI 10.1111/j.1532-5415.1991.tb03605.x; CLEMENT M, 1989, American Review of Respiratory Disease, V139, pA250; CURTIS JR, 1994, AM J RESP CRIT CARE, V150, P1305, DOI 10.1164/ajrccm.150.5.7952557; DANIELS N, 1991, JAMA-J AM MED ASSOC, V265, P2232, DOI 10.1001/jama.265.17.2232; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; EFFEREN LS, 1989, AM J MED, V87, P401, DOI 10.1016/S0002-9343(89)80821-6; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; FRIEDMAN Y, 1989, CHEST, V96, P862, DOI 10.1378/chest.96.4.862; FRIEDMAN Y, 1991, JAMA-J AM MED ASSOC, V266, P89, DOI 10.1001/jama.266.1.89; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; GARAY S, 1986, AM REV RESPIR DIS, V133, pA344; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARDY AM, 1986, JAMA-J AM MED ASSOC, V255, P209, DOI 10.1001/jama.255.2.209; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HAWLEY PH, 1994, CHEST, V106, P1456, DOI 10.1378/chest.106.5.1456; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOPEWELL PC, 1988, J INFECT DIS, V157, P1115, DOI 10.1093/infdis/157.6.1115; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine M E, 1989, Crit Care Nurs Q, V12, P82; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1573, DOI 10.1056/NEJM198412133112412; LEVINSKY NG, 1993, NEW ENGL J MED, V329, P1395, DOI 10.1056/NEJM199311043291907; MANDELBLATT JS, 1988, JAMA-J AM MED ASSOC, V259, P2409, DOI 10.1001/jama.259.16.2409; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; MONTANER JSG, 1989, CHEST, V95, P881, DOI 10.1378/chest.95.4.881; MONTANER JSG, 1992, CHEST, V102, P1823, DOI 10.1378/chest.102.6.1823; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PEAR R, 1993, NY TIMES        0320, P11; PERUZZI WT, 1991, CRIT CARE MED, V19, P892, DOI 10.1097/00003246-199107000-00012; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; RELMAN AS, 1990, NEW ENGL J MED, V323, P911, DOI 10.1056/NEJM199009273231310; ROGERS PL, 1989, CRIT CARE MED, V17, P113, DOI 10.1097/00003246-198902000-00001; ROSEN MJ, 1986, J INTENSIVE CARE MED, V1, P55; SCHAPIRA DV, 1993, JAMA-J AM MED ASSOC, V269, P783, DOI 10.1001/jama.269.6.783; SCHEIN RMH, 1986, CRIT CARE MED, V14, P1026, DOI 10.1097/00003246-198612000-00006; SCHULMAN KA, 1991, ANN INTERN MED, V114, P798, DOI 10.7326/0003-4819-114-9-798; SCITOVSKY AA, 1986, JAMA-J AM MED ASSOC, V256, P3103, DOI 10.1001/jama.256.22.3103; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; STAIKOWSKY F, 1993, CHEST, V104, P756, DOI 10.1378/chest.104.3.756; STEIN M, 1992, AM J MED, V93, P387, DOI 10.1016/0002-9343(92)90167-A; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STOVER DE, 1985, AM J MED, V78, P429, DOI 10.1016/0002-9343(85)90334-1; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; TUCKER KJ, 1992, WESTERN J MED, V157, P637; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WACHTER RM, 1988, ARCH INTERN MED, V148, P149, DOI 10.1001/archinte.148.1.149; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; WACHTER RM, 1991, AM REV RESPIR DIS, V143, P251, DOI 10.1164/ajrccm/143.2.251; WACHTER RM, 1986, AM REV RESPIR DIS, V134, P891, DOI 10.1164/arrd.1986.134.5.891; WACHTER RM, 1992, JAMA-J AM MED ASSOC, V267, P541, DOI 10.1001/jama.267.4.541; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; 1991, PRIORITIZATION HLTH	73	81	82	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					230	235		10.1001/jama.273.3.230	http://dx.doi.org/10.1001/jama.273.3.230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807663				2022-12-01	WOS:A1995QB23400028
J	BALFOUR, HH				BALFOUR, HH			NO REASON NOT TO TREAT	BRITISH MEDICAL JOURNAL			English	Article							VARICELLA-ZOSTER VIRUS; ACYCLOVIR TREATMENT; HEALTHY-CHILDREN; CONTROLLED TRIAL; CHICKENPOX; RESISTANT; RESPONSES				BALFOUR, HH (corresponding author), UNIV MINNESOTA,SCH MED,BOX 437,UMHC,15-144 PWB HARVARD ST & E RIVER PKWY,MINNEAPOLIS,MN 55455, USA.							ABZUG MJ, 1993, J PEDIATR-US, V123, P577, DOI 10.1016/S0022-3476(05)80954-0; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; COLE NL, 1986, J INFECT DIS, V153, P605, DOI 10.1093/infdis/153.3.605; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; ENGLUND JA, 1990, J CLIN MICROBIOL, V28, P2327, DOI 10.1128/JCM.28.10.2327-2330.1990; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; ROTBART HA, 1993, J INFECT DIS, V167, P195, DOI 10.1093/infdis/167.1.195; WALLACE MR, 1992, ANN INTERN MED, V117, P358, DOI 10.7326/0003-4819-117-5-358	9	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					109	110		10.1136/bmj.310.6972.109	http://dx.doi.org/10.1136/bmj.310.6972.109			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833701	Green Published			2022-12-01	WOS:A1995QC22300028
J	BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV				BURGER, MPM; HOLLEMA, H; PIETERS, WJLM; QUINT, WGV			PREDICTIVE VALUE OF HUMAN PAPILLOMAVIRUS TYPE FOR HISTOLOGICAL DIAGNOSIS OF WOMEN WITH CERVICAL CYTOLOGICAL ABNORMALITIES	BRITISH MEDICAL JOURNAL			English	Article									SSZOG,PATHOL LAB,9675 HJ WINSCHOTEN,NETHERLANDS; SSDZ,CTR DIAGNOST,2625 AD DELFT,NETHERLANDS		BURGER, MPM (corresponding author), UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,ONCOL GYNAECOL SECT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							BURGER MPM, 1993, BRIT MED J, V306, P749, DOI 10.1136/bmj.306.6880.749; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; GENEST DR, 1993, HUM PATHOL, V24, P760; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; VANRANST M, 1992, J GEN VIROL, V73, P2653, DOI 10.1099/0022-1317-73-10-2653	5	26	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					94	95		10.1136/bmj.310.6972.94	http://dx.doi.org/10.1136/bmj.310.6972.94			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833734	Green Published			2022-12-01	WOS:A1995QC22300020
J	GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT				GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT			BOTTLE-FEEDING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; UNEXPECTED DEATH; RISK-FACTORS; BREAST-MILK; COT DEATH; EPIDEMIOLOGY; CHILDREN; PRETERM	Objective-To determine whether the risk of the sudden infant death syndrome is increased in bottle fed babies. Design-Population based case-control study matching for age and time. Subjects-All babies aged 1 week to 1 year dying of sudden infant death syndrome during November 1987 to April 1989 or February 1990 to June 1991 and two live controls. Setting-Avon and north Somerset. Main outcome measures-Breast or bottle feeding, sleeping position, maternal smoking, parental employment, and length of gestation. Results-Compared with being fully breast fed, the crude odds ratio for sudden infant death in fully bottle fed babies was 3.1 and for mixed breast and bottle fed babies 1.5. These odds ratios fell to 1.8 (95% confidence interval 0.7 to 4.8) and 1.2 (0.5 to 2.7) respectively after maternal smoking, parental employment, preterm gestation, and sleeping position had been adjusted for. Sleeping position partly masked the effect of being bottle fed on sudden infant death as breast fed babies were more likely to have slept prone than bottle fed babies. Conclusions-Bottle feeding is not a significant independent risk factor for the sudden infant death syndrome. Patterns of maternal smoking, preterm gestation, and parental employment status account for most of the apparent association with bottle feeding.	ST MICHAELS HOSP, DEPT CHILD HLTH, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL UNITED HOSP, BATH UNIT RES PAEDIAT, BATH BA1 3NG, AVON, ENGLAND; ST MICHAELS HOSP, DEPT PAEDIAT PATHOL, BRISTOL BS2 8EG, AVON, ENGLAND		GILBERT, RE (corresponding author), INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1N 1EH, ENGLAND.		Fleming, Peter J/A-9081-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BIERINGSORENSEN F, 1978, ACTA PAEDIATR SCAND, V67, P129, DOI 10.1111/j.1651-2227.1978.tb16292.x; BROOKS JG, 1994, PEDIATRICS, V94, P456; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1991, THESIS; FEDRICK J, 1974, BRIT J PREV SOC MED, V28, P164; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; FROGART P, 1971, BR J PREV SOC MED, V49, P119; HARRIS JDC, 1982, J EPIDEMIOL COMMUN H, V36, P162, DOI 10.1136/jech.36.3.162; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; KNOWELDEN J, 1984, MULTICENTRE STUDY PO; KRAUS AS, 1971, C J PUBLIC HEALTH, V62, P210; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL EA, 1992, AUST J PUBLIC HEALTH, V16, P158; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; POLLOCK JI, 1992, EFFECTS SMOKING FETU, P108; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; RHEAD WJ, 1973, BMJ-BRIT MED J, V4, P548, DOI 10.1136/bmj.4.5891.548-d; SAVAGE F, 1992, MIDIRS MIDWIFERY DIG, V2, P3; WATSON E, 1981, MED SCI LAW, V21, P78, DOI 10.1177/002580248102100202; WHITE AS, 1992, INFANT FEEDING 1990; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; 1993, REPORT CHIEF MED OFF	31	47	48	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	1995	310	6972					88	90		10.1136/bmj.310.6972.88	http://dx.doi.org/10.1136/bmj.310.6972.88			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833732	Green Published			2022-12-01	WOS:A1995QC22300018
J	GOSDEN, CM				GOSDEN, CM			WHEN AMNIOTIC-FLUID CELLS DO NOT GROW	LANCET			English	Editorial Material							FETAL				GOSDEN, CM (corresponding author), UNIV LIVERPOOL,DEPT OBSTET & GYNAECOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.							GOSDEN C, 1978, J MED GENET, V15, P262, DOI 10.1136/jmg.15.4.262; MARTEAU TM, 1992, PRENATAL DIAG, V12, P205, DOI 10.1002/pd.1970120309; NICOLAIDES KH, 1992, LANCET, V340, P704, DOI 10.1016/0140-6736(92)92240-G	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					78	78		10.1016/S0140-6736(95)90058-6	http://dx.doi.org/10.1016/S0140-6736(95)90058-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815884				2022-12-01	WOS:A1995QB80400005
J	LAROSA, JC				LAROSA, JC			HAS HRT COME OF AGE	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; HORMONE-THERAPY; DISEASE				LAROSA, JC (corresponding author), TULANE UNIV,MED CTR,NEW ORLEANS,LA, USA.							BAR J, 1993, OBSTET GYNECOL, V81, P261; CLARKSON RB, 1994, DRUGS S2, V47, P42; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; SPAGNOLI LG, 1980, ATHEROSCLEROSIS, V82, P27; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; VANDERMOOREN MJ, 1994, METABOLISM, V43, P799, DOI 10.1016/0026-0495(94)90256-9; WAGNER JD, 1992, ARTERIOSCLER THROMB, V12, P717, DOI 10.1161/01.ATV.12.6.717; WHITCROFT SI, 1994, OBSTET GYNECOL, V84, P222; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1985, VITAL STATISTICS US, V2, P258	15	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					76	77		10.1016/S0140-6736(95)90056-X	http://dx.doi.org/10.1016/S0140-6736(95)90056-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7632206				2022-12-01	WOS:A1995QB80400003
J	LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL				LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL			EFFECT ON PARKINSONIAN SIGNS AND SYMPTOMS OF BILATERAL SUBTHALAMIC NUCLEUS STIMULATION	LANCET			English	Article							INTERMEDIATE THALAMIC NUCLEUS; MOVEMENT-DISORDERS; DISEASE; PRIMATE; TREMOR; DYSKINESIAS; REVERSAL; LESIONS	In monkeys rendered parkinsonian, lesions and electrical stimulation of the subthalamic nucleus reduce all major motor disturbances, The effect of electrical stimulation of the subthalamic nucleus was assessed in three patients with disabling akinetic-rigid Parkinson's disease and severe motor fluctuations. Quadripolar electrodes connected to a pulse generator were implanted in the subthalamic nuclei on both sides, Patients were evaluated with the unified Parkinson's disease rating scale and timed motor tests. 3 months after surgery, activities of daily living scores had improved by 58-88% and motor scores by 42-84%. This improvement was maintained for up to 8 months in the first patient operated upon. One patient was confused for 2 weeks after surgery, and another developed neuropsychological impairment related to a thalamic infarction which improved over 3 months, In one patient, stimulation could induce ballism that was stopped by reduction of stimulation. This is the first demonstration in human beings of the part played by the subthalamic nuclei in the pathophysiology of Parkinson's disease.	UNIV GRENOBLE 1,DEPT CLIN & BIOL NEUROSCI,F-38041 GRENOBLE,FRANCE; HOP NEUROL,LYON,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon			Benazzouz, Abdelhamid/E-5050-2016; Broussolle, Emmanuel/H-1592-2017	Broussolle, Emmanuel/0000-0002-0410-9519				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; CAPARROSLEFEBVRE D, 1993, J NEUROL NEUROSUR PS, V56, P268, DOI 10.1136/jnnp.56.3.268; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DELONG MR, 1985, J NEUROPHYSIOL, V53, P530, DOI 10.1152/jn.1985.53.2.530; FAHN S, 1992, NEW ENGL J MED, V327, P1589, DOI 10.1056/NEJM199211263272209; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; HAMADA I, 1992, J NEUROPHYSIOL, V68, P1850, DOI 10.1152/jn.1992.68.5.1850; HITCHCOCK ER, 1988, LANCET, V1, P1274; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NGUYEN JP, 1993, ARCH NEUROL-CHICAGO, V50, P498, DOI 10.1001/archneur.1993.00540050050014; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; POLLAK P, 1993, ADV NEUROL, V60, P408; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003; Talairach J, 1957, ATLAS ANATOMIE STERE; 1992, MOV DISORD, V7, P2	25	1058	1101	2	65	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					91	95		10.1016/S0140-6736(95)90062-4	http://dx.doi.org/10.1016/S0140-6736(95)90062-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815888				2022-12-01	WOS:A1995QB80400009
J	LONGSTRETH, GF; FEITELBERG, SP				LONGSTRETH, GF; FEITELBERG, SP			OUTPATIENT CARE OF SELECTED PATIENTS WITH ACUTE NONVARICEAL UPPER GASTROINTESTINAL HEMORRHAGE	LANCET			English	Article								Patients with upper gastrointestinal haemorrhage (UGIH) are usually cared for in hospital. To evaluate the efficacy and safety of outpatient care of selected patients with acute non-variceal UGIH who had endoscopy, we retrospectively analysed 4.5 years' experience of patients treated without hospital admission. We developed practice guidelines for outpatient care, and prospectively studied patients treated during the first 6 months of their use. 78 (8.4%) of 933 patients in the retrospective series and 34 (24.1%) of 141 in the prospective series received outpatient care. The guidelines comprised early notification of a gastroenterologist, urgent endoscopy, clinical, laboratory, and endoscopic criteria for outpatient care, and details of care. In the prospective study patients treated as outpatients were younger than those admitted (52.8 [SE 3.6] vs 63.0 [1.5] years) and had a slightly longer time from onset of bleeding to endoscopy (2.4 [0.2] vs 2.1 [0.2] days). Outpatients were less likely to have alcoholism, other major concomitant disease, syncope or presyncope, or supine tachycardia. Outpatients had higher haemoglobin concentrations than inpatients (125 [4] vs 106 [3] g/L). Most patients in both groups had peptic ulcers. There were no complications in the retrospective series; 1 of the 34 prospective outpatients was admitted with rebleeding. All outpatients survived. The estimated hospital cost saved per outpatient was about $990. A substantial proportion of carefully selected patients with acute non-variceal UGIH can be effectively cared for without admission to hospital.			LONGSTRETH, GF (corresponding author), KAISER PERMANENTE MED CTR,DEPT MED,SAN DIEGO,CA 92120, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CUTLER JA, 1981, DIG DIS SCI S, V26, P90; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; GILBERT DA, 1990, DIG DIS SCI S, V36, P8; GOSTOUT CJ, 1992, SEMIN GASTROINTEST D, V33, P53; GUPTA PK, 1993, MED CLIN N AM, V77, P973, DOI 10.1016/S0025-7125(16)30206-1; HARLAND R, 1992, J ROY SOC MED, V85, P26; JOHNSTON JH, 1990, GASTROINTEST ENDOS S, V36, P16; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LICHTENSTEIN DR, 1992, GASTROINTESTINAL EME, P92; LONGSTRETH GF, 1994, J CLIN GASTROENTEROL, V19, P189, DOI 10.1097/00004836-199410000-00003; LONGSTRETH GF, 1986, J CLIN GASTROENTEROL, V8, P23, DOI 10.1097/00004836-198602000-00006; LONGSTRETH GF, IN PRESS AM J GASTRO; TERBLANCHE J, 1992, ANNU REV MED, V43, P69, DOI 10.1146/annurev.med.43.1.69; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1989, JAMA-J AM MED ASSOC, V262, P1369	19	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					108	111		10.1016/S0140-6736(95)90068-3	http://dx.doi.org/10.1016/S0140-6736(95)90068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815854				2022-12-01	WOS:A1995QB80400015
J	NAISH, J; STURDY, P; TOON, P				NAISH, J; STURDY, P; TOON, P			APPROPRIATE PRESCRIBING IN ASTHMA AND ITS RELATED COST IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT	Objectives-To determine the patterns of preventive to reactive prescribing for asthma among general practices in the City and East London Family Health Services Authority area and their relation to prescribing cost. Design-Descriptive study of asthma prescribing during April 1992 to March 1993. Prescribing data were linked with general practice and population data on one database. Setting-City and East London Family Health Services Authority area, including all general practices in contract with the authority, which covers the inner city London Boroughs of Hackney, Tower Hamlets, and Newham and the Corporation of the City of London. Subjects-All 163 general practices as at 1 June 1993. Main outcome measures-Ratios of prescribed inhaled corticosteroids plus cromoglycates (prophylactic treatment) to bronchodilators; distribution of the cost of asthma prescribing; distribution of overall generic prescribing; proportion of asthma generic prescribing; distribution of cost of overall drugs prescribed per prescribing unit. Results-Practices approved for band 3 health promotion or asthma surveillance and those with a general practitioner trainer had on average higher ratios of prophylactic to bronchodilator treatment and significantly higher asthma drug costs than other practices. Those practices with high levels of overall generic prescribing had significantly higher prophylactic to bronchodilator ratios than those with lower levels of generic prescribing. Practices with higher levels of asthma drug generic prescribing also had significantly higher prophylactic prescribing. However, the proportion of generically prescribed asthma drugs was lower than overall generic prescribing. There was no correlation between the ratio of prophylactic to bronchodilator asthma prescribing and the proportion of overall drugs expenditure, but high spending practices spent significantly more on asthma drugs. Conclusions-Pressure to reduce the cost of asthma prescribing may lead to a lowering of the ratio of prophylactic to bronchodilator treatments. However, reducing prophylactic prescribing would run contrary to the British Thoracic Society guidelines and might worsen the quality of asthma care.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	NAISH, J (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HAY IFC, 1987, LANCET, V2, P609; HORN CR, 1989, RESP MED, V83, P67, DOI 10.1016/S0954-6111(89)80062-9; Jones K, 1992, Qual Health Care, V1, P110, DOI 10.1136/qshc.1.2.110; MCGAVOCK H, 1988, BRIT MED J, V296, P90; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; 1994, PRESCRIPTION IMPROVE; 1993, BRIT MED J, V306, P776; 1992, BRIT NATIONAL FORMUL, V23; 1994, HLTH E END ANN PUBLI; 1993, HLTH SERVICE INDICAT	17	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					97	100		10.1136/bmj.310.6972.97	http://dx.doi.org/10.1136/bmj.310.6972.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833736	Green Published			2022-12-01	WOS:A1995QC22300023
J	ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC				ORSCHESCHEK, K; MERZ, H; HELL, J; BINDER, T; BARTELS, H; FELLER, AC			LARGE-CELL ANAPLASTIC LYMPHOMA-SPECIFIC TRANSLOCATION (T[2-5] [P23-Q35]) IN HODGKINS-DISEASE - INDICATION OF A COMMON PATHOGENESIS	LANCET			English	Article							KI-1 LYMPHOMA; RECEPTOR; EXPRESSION; 5Q35	Chromosomal aberrations are characteristic and specific events; the detection of chromosomal abnormalities often provides information on diagnosis and prognosis of disease. Some patients with large-cell anaplastic lymphoma (Ki 1 lymphoma) have the translocation t(2;5) (p23; q35), involving a possible growth-regulating tyrosine kinase. We found this translocation in 11 patients with Hodgkin's disease of nodular sclerosis and mixed-cellularity types. This finding has implications for the understanding of the relation between large-cell anaplastic lymphoma and Hodgkin's disease, diseases with morphological and immunophenotypical similarities. Study of this translocation may help understanding of the origins of cancer and cancer growth. It also allows a more precise definition of Hodgkin's disease and may be used as an indicator for clonality-which has long been sought.	UNIV LUBECK,DEPT PATHOL,D-23538 LUBECK,GERMANY; UNIV ULM,DEPT INTERNAL MED 3,W-7900 ULM,GERMANY; STADT KRANKENHAUS SUD,DEPT HEMATOL ONCOL,LUBECK,GERMANY	University of Lubeck; Ulm University			Feller, Alfred/E-3853-2010					ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; FISCHER P, 1988, BLOOD, V72, P234; FONATSCH C, 1986, CANCER GENET CYTOGEN, V20, P39, DOI 10.1016/0165-4608(86)90106-8; JUCKER M, 1991, BLOOD, V77, P2413; KADIN ME, 1985, LANCET, V123, P864; LADANYI M, 1991, GENE CHROMOSOME CANC, V3, P294, DOI 10.1002/gcc.2870030408; Lennert K, 1992, HISTOPATHOLOGY NONHO; MACLENNAN KA, 1992, INT REV EXP PATHOL, V33, P27; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MERZ H, 1991, BLOOD, V78, P1311; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; ORSCHESCHEK K, 1994, EUR J IMMUNOL, V24, P2682, DOI 10.1002/eji.1830241117; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	17	100	100	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					87	90		10.1016/S0140-6736(95)90061-6	http://dx.doi.org/10.1016/S0140-6736(95)90061-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815887				2022-12-01	WOS:A1995QB80400008
J	PERSUTTE, WH; LENKE, RR				PERSUTTE, WH; LENKE, RR			FAILURE OF AMNIOTIC-FLUID CELL-GROWTH - IS IT RELATED TO FETAL ANEUPLOIDY	LANCET			English	Note							AMNIOCENTESIS; DIAGNOSIS	We investigated outcome in patients whose amniotic-fluid-cell samples showed unexplained growth failure in culture, 32 of 7872 amniocentesis samples were classified as unexplained growth failures. 10 women did not have repeat cytogenetic testing, but among their pregnancies there were 4 abnormal outcomes (1 fetal bladder-outlet obstruction, 2 stillbirths, and 1 acardiac twin). Of the 2 2 patients who had repeat karyotypic analysis, 18 had normal fetal karyotypes, However, 4 fetuses were aneuploid (2 trisomy 21, 1 trisomy 13, and 1 Pallister-Killian syndrome).			PERSUTTE, WH (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT OBSTET & GYNAECOL,CAMPUS BOX E-197,4200 E 9TH AVE,DENVER,CO 80262, USA.							ASSEL BG, 1992, OBSTET GYNECOL, V79, P940; BELL JA, 1987, MED J AUSTRALIA, V146, P12, DOI 10.5694/j.1326-5377.1987.tb120118.x; BENACERRAF BR, 1988, RADIOLOGY, V169, P709, DOI 10.1148/radiology.169.3.3055033; BENIRSCHKE K, 1977, TERATOLOGY, V15, P311, DOI 10.1002/tera.1420150313; DEACON JS, 1980, AM J MED GENET, V5, P85, DOI 10.1002/ajmg.1320050112; DONNELFELD AE, 1993, BRIT J OBSTET GYNAEC, V100, pS26; NICOLAIDES KH, 1986, LANCET, V1, P283; REBELLO MT, 1991, PRENATAL DIAG, V11, P35, DOI 10.1002/pd.1970110107	8	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					96	97		10.1016/S0140-6736(95)90064-0	http://dx.doi.org/10.1016/S0140-6736(95)90064-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815890				2022-12-01	WOS:A1995QB80400011
J	ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I				ROBERTS, I; NORTON, R; JACKSON, R; DUNN, R; HASSALL, I			EFFECT OF ENVIRONMENTAL-FACTORS ON RISK OF INJURY OF CHILD PEDESTRIANS BY MOTOR-VEHICLES - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							ACCIDENTS; MORTALITY	Objective-To identify and assess contribution of environmental risk factors for injury of child pedestrians by motor vehicles. Design-Community based case-control study. Environmental characteristics of sites of child pedestrian injury were compared with the environmental characteristics of selected comparison sites. Each comparison site was the same distance and direction from home of control child as was the injury site from home of relevant case child. Two control sites were selected for each injury site. Setting-Auckland region of New Zealand. Subjects-Cases were 190child pedestrians aged < 15 who were killed or hospitalised after collision with a motor vehicle on a public road during two years and two months. Controls were 380 children randomly sampled from population and frequency matched for age and sex. Main outcome measures-Traffic volume and speed and level of parking on curbs at injury sites and comparison sites. Results-Risk of injury of child pedestrians was strongly associated with traffic volume: risk of injury at sites with highest traffic volumes was 14 times greater than that at least busy sites (odds ratio 14.30; 95% confidence interval 6.98 to 29.20), and risk increased with increasing traffic volume. High density of curb parking was also associated with increased risk (odds ratio 8.12; 3.32 to 19.90). Risk was increased at sites with mean speeds over 40 km/h (odds ratio 2.68; 1.26 to 5.69), although risk did not increase further with increasing speed. Conclusion-Reducing traffic volume in urban areas could significantly reduce rates of child pedestrian injury. Restricting curb parking may also be effective.	DEPT COMMUNITY HLTH,INJURY PREVENT RES CTR,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT CIVIL & RESOURCE ENGN,AUCKLAND,NEW ZEALAND; OFF COMMISSIONER CHILDREN,WELLINGTON,NEW ZEALAND	University of Auckland; University of Auckland				Jackson, Rod/0000-0001-5914-6934				ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; ENGEL U, 1992, ACCIDENT ANAL PREV, V24, P17, DOI 10.1016/0001-4575(92)90068-T; KENDRICK D, 1993, ARCH DIS CHILD, V68, P669, DOI 10.1136/adc.68.5.669; Lawson S., 1990, ACCIDENTS YOUNG PEDE; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; Preston B., 1992, CUTTING PEDESTRIAN C; RIVARA FP, 1985, PEDIATRICS, V76, P375; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; ROBERTS I, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283; ROBERTS I, 1993, J PAEDIATR CHILD H, V29, P233, DOI 10.1111/j.1440-1754.1993.tb00494.x; ROBERTS I, 1992, NEW ZEAL MED J, V105, P51; ROBERTS I, 1993, BRIT MED J, V306, P1737, DOI 10.1136/bmj.306.6894.1737; ROBERTS I, 1991, NEW ZEAL MED J, V104, P247; ROBERTS I, 1994, SOC SCI MED, V38, P749, DOI 10.1016/0277-9536(94)90465-0; ROBERTS I, 1993, EPIDEMIOLOGY, V4, P477, DOI 10.1097/00001648-199309000-00015; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P43; ROBERTS I, IN PRESS PEDIATRICS; ROBERTS IG, 1993, ARCH DIS CHILD, V68, P190, DOI 10.1136/adc.68.2.190; 1991, CENSUS POPULATION DW; 1983, ROAD TRANSPORT RES T	21	161	164	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					91	94		10.1136/bmj.310.6972.91	http://dx.doi.org/10.1136/bmj.310.6972.91			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QC223	7833733	Green Published			2022-12-01	WOS:A1995QC22300019
J	TRACEY, KJ				TRACEY, KJ			TNF AND WEST,MAE OR - DEATH FROM TOO MUCH OF A GOOD THING	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM; FACTOR-ALPHA; CACHECTIN; SHOCK; INTERLEUKIN-1; INFECTION; RECEPTOR; MALARIA; SERUM		PICOWER INST MED RES,MANHASSET,NY	Northwell Health	TRACEY, KJ (corresponding author), N SHORE UNIV HOSP,DEPT SURG,BIOMED SCI LAB,MANHASSET,NY 11030, USA.							BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; CLARK IA, 1992, LANCET, V340, P894, DOI 10.1016/0140-6736(92)93295-X; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; MARANO MA, 1990, SURG GYNECOL OBSTET, V170, P32; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P705, DOI 10.1111/j.1365-3083.1988.tb02404.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICOT F, 1993, EUR J IMMUNOL, V23, P224; Tracey K.J., 1992, TUMOR NECROSIS FACTO, P255; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89	15	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					75	76		10.1016/S0140-6736(95)90055-1	http://dx.doi.org/10.1016/S0140-6736(95)90055-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815882				2022-12-01	WOS:A1995QB80400002
J	VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ				VRIELINK, H; VANDERPOEL, CL; REESINK, HW; ZAAIJER, HL; SCHOLTEN, E; KREMER, LCM; CUYPERS, HTM; LELIE, PN; VANOERS, MHJ			LOOK-BACK STUDY OF INFECTIVITY OF ANTI-HCV ELISA-POSITIVE BLOOD COMPONENTS	LANCET			English	Note							HEPATITIS-C VIRUS; RECOMBINANT IMMUNOBLOT ASSAY	The infectivity of blood components from donors who were later found to be anti-HCV ELISA-positive was investigated in recipients who were enrolled in a look-back programme. Recipients received ELISA-positive blood components from donors who were PCR-positive and/or RIBA-2-positive (n=22, group A) or PCR-negative and indeterminate or negative on RIBA-2 (n=105, group B). 26 of 32 (81%) recipients of group A donors and none of 140 of group B were HCV-infected. All stored serum samples of previous donations (n=172) of group A donors were anti-HCV-positive in RIBA-3, indicating a chronic carrier state of HCV in these donors.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VRIELINK, H (corresponding author), NETHERLANDS RED CROSS,BLOOD BANK AMSTERDAM,POSTBOX 9137,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Kremer, Leontien/0000-0001-7422-3248				BUSCH MP, 1991, TRANSFUSION, V31, P655, DOI 10.1046/j.1537-2995.1991.31791368346.x; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; EBELING F, 1990, LANCET, V335, P982, DOI 10.1016/0140-6736(90)91055-F; SAMSON S, 1990, TRANSFUSION, V30, P214, DOI 10.1046/j.1537-2995.1990.30390194339.x; UYTTENDAELE S, 1994, VOX SANG, V66, P122, DOI 10.1111/j.1423-0410.1994.tb00293.x; VANDERPOEL C, 1991, TRANSFUSION, V31, P777; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; ZAAIJER HL, 1994, TRANSFUSION, V34, P603, DOI 10.1046/j.1537-2995.1994.34794330015.x	8	56	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					95	96		10.1016/S0140-6736(95)90063-2	http://dx.doi.org/10.1016/S0140-6736(95)90063-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815889				2022-12-01	WOS:A1995QB80400010
J	WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H				WETTERVIK, C; CLAES, G; DROTT, C; EMANUELSSON, H; LOMSKY, M; RADBERG, G; TYGESEN, H			ENDOSCOPIC TRANSTHORACIC SYMPATHICOTOMY FOR SEVERE ANGINA	LANCET			English	Note							SYMPATHETIC CHAIN; PAIN	We evaluated the antianginal effects of endoscopic transthoracic sympathicotomy (ETS) in 24 patients not eligible for coronary bypass surgery or angioplasty. In this procedure, the sympathetic chain is electrocoagulated under general anaesthesia. No major surgical complications occurred. The frequency of anginal attacks was significantly reduced (p=0.001). The mean increase in maximum exercise capacity was 13 (SD 21) W (p=0.009). ST depression at maximum comparable workload was reduced by 0.052 (0.10) mV (p=0.005). Global ejection fraction during exercise and metaiodobenzylguanidine uptake were unchanged. Heart rate variability analysis showed a reduction of the ratio between low and high frequencies at tilt test (-1.00 [0.96]; p<0.001). We conclude that ETS can be done without major complications, alleviates angina, and increases maximum working capacity in patients with advanced coronary disease.	SAHLGRENS UNIV HOSP,DIV CARDIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV CLIN PHYSIOL,S-41345 GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DIV THORAC SURG,S-41345 GOTHENBURG,SWEDEN; BORAS CTY HOSP,DEPT MED,BORAS,SWEDEN; BORAS CTY HOSP,DEPT SURG,BORAS,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital								AKSELROD S, 1985, AM J PHYSIOL, V249, pH867, DOI 10.1152/ajpheart.1985.249.4.H867; BLOMBERG S, 1989, ANESTH ANALG, V69, P558; BLOMBERG S, 1990, ANESTHESIOLOGY, V74, P840; CLAES G, 1991, BRIT J SURG, V78, P760, DOI 10.1002/bjs.1800780634; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; FAGRET D, 1993, J NUCL MED, V34, P57; KOCK M, 1992, ANESTH ANALG, V71, P625; LINDGREN I, 1950, ACTA MED SCAND, P1; MASERI A, 1992, PROG CARDIOVASC DIS, V35, P1, DOI 10.1016/0033-0620(92)90031-T; TOFT P, 1987, INTENS CARE MED, V13, P388	10	51	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					97	98		10.1016/S0140-6736(95)90065-9	http://dx.doi.org/10.1016/S0140-6736(95)90065-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815891				2022-12-01	WOS:A1995QB80400012
J	BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y				BLECHMAN, JM; LEV, S; BARG, J; EISENSTEIN, M; VAKS, B; VOGEL, Z; GIVOL, D; YARDEN, Y			THE 4TH IMMUNOGLOBULIN DOMAIN OF THE STEM-CELL FACTOR-RECEPTOR COUPLES LIGAND-BINDING TO SIGNAL-TRANSDUCTION	CELL			English	Article							GROWTH-FACTOR RECEPTORS; ACTIN REORGANIZATION; INDUCED DIMERIZATION; CRYSTAL-STRUCTURE; KIT RECEPTOR; ACTIVATION; PROTEIN; KINASE; SITE; HETERODIMERIZATION	Receptor dimerization is ubiquitous to the action of all receptor tyrosine kinases, and in the case of dimeric ligands, such as the stem cell factor (SCF), it was attributed to ligand bivalency. However, by using a dimerization-inhibitory monoclonal antibody to the SCF receptor, we confined a putative dimerization site to the nonstandard fourth immunoglobulin-like domain of the receptor. Deletion of this domain not only abolished ligand-induced dimerization and completely inhibited signal transduction, but also provided insights into the mechanism of the coupling of ligand binding to dimer formation. These results identify an intrinsic receptor dimerization site and suggest that similar sites may exist in other receptors.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,EDITH WOLFSON MED CTR,SCH MED,CARDIOVASC & HYPERTENS RES LAB,IL-58100 HOLON,ISRAEL; BIOMAKOR,IL-76326 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University			YARDEN, YOSEF/K-1467-2012; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330				AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BENLEVY R, 1992, J BIOL CHEM, V265, P17304; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; COCHET C, 1988, J BIOL CHEM, V263, P3290; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V420, P2361; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HERREN B, 1993, J BIOL CHEM, V268, P15088; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; LEVITT M, 1983, J MOL BIOL, V168, P595, DOI 10.1016/S0022-2836(83)80304-0; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; RAMACHANDRAN GN, 1968, ADV PROTEIN CHEM, V28, P283; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	35	131	146	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					103	113		10.1016/0092-8674(95)90455-7	http://dx.doi.org/10.1016/0092-8674(95)90455-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529140	Bronze			2022-12-01	WOS:A1995QB91000014
J	CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR				CHEN, JH; RAUCH, CA; WHITE, JH; ENGLUND, PT; COZZARELLI, NR			THE TOPOLOGY OF THE KINETOPLAST DNA NETWORK	CELL			English	Article							LEISHMANIA-TARENTOLAE; TRYPANOSOMA-BRUCEI; REPLICATION; MINICIRCLES; HYBRIDIZATION; CATENANES; PROTEIN; GYRASE	Kinetoplast DNA (kDNA) of trypanosomatid parasites is a network of similar to 5000 catenated DNA minicircles and similar to 25 maxicircles. We developed the following strategy to deduce the topological linkage of the minicircles of the Crithidia fasciculata network. First, we used graph theory to provide precise models of possible network structures. Second, on the basis of these models, we predicted the frequencies of minicircle oligomers expected from random network breakage. Third, we determined the fragmentation pattern of kDNA networks as a function of the extent of digestion. Fourth, by comparison of the results with the predictions, we identified the model that best represents the network. We conclude that each minicircle is linked on average to three other minicircles. A honeycomb arrangement probably results, with each minicircle typically at the vertex of a hexagonal cell. This topology has implications for the assembly, structure, and function of kDNA networks.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, DEPT MATH, LOS ANGELES, CA 90024 USA	Johns Hopkins University; University of California System; University of California Los Angeles	CHEN, JH (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.		Chen, Junghuei/B-5217-2011		NIEHS NIH HHS [ES01896-15] Funding Source: Medline; NIGMS NIH HHS [GM27608, GM31657] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031657, R37GM027608, R01GM031657, R01GM027608] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORST P, 1980, BIOCHIM BIOPHYS ACTA, V610, P197, DOI 10.1016/0005-2787(80)90001-5; BORST P, 1979, PLASMID, V2, P20, DOI 10.1016/0147-619X(79)90003-9; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; GIBSON W, 1990, MOL BIOCHEM PARASIT, V42, P45, DOI 10.1016/0166-6851(90)90111-X; HAJDUK SL, 1984, CELL, V36, P483, DOI 10.1016/0092-8674(84)90241-1; HAJDUK SL, 1986, MOL CELL BIOL, V6, P4372, DOI 10.1128/MCB.6.12.4372; HOEIJMAKERS JHJ, 1980, PLASMID, V4, P97, DOI 10.1016/0147-619X(80)90086-4; KRASNOW MA, 1983, NATURE, V304, P559, DOI 10.1038/304559a0; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; MARINI JC, 1980, J BIOL CHEM, V255, P4976; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MOREL C, 1980, P NATL ACAD SCI-BIOL, V77, P6810, DOI 10.1073/pnas.77.11.6810; PEREZMORGA D, 1993, J CELL BIOL, V123, P1069, DOI 10.1083/jcb.123.5.1069; RAUCH CA, 1991, THESIS JOHNS HOPKINS; RAUCH GA, 1991, EMBO J, V12, P403; RAY DS, 1987, PLASMID, V17, P177, DOI 10.1016/0147-619X(87)90026-6; RENGER HC, 1972, J CELL BIOL, V54, P346, DOI 10.1083/jcb.54.2.346; RYAN KA, 1988, ANNU REV MICROBIOL, V42, P339, DOI 10.1146/annurev.mi.42.100188.002011; SIMPSON L, 1974, J PROTOZOOL, V21, P382, DOI 10.1111/j.1550-7408.1974.tb03675.x; SIMPSON L, 1971, J MOL BIOL, V56, P443, DOI 10.1016/0022-2836(71)90394-9; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; STUART K, 1992, INT REV CYTOL, V141, P65, DOI 10.1016/S0074-7696(08)62063-X; SUGISAKI H, 1987, MOL BIOCHEM PARASIT, V23, P253, DOI 10.1016/0166-6851(87)90032-6; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; THRESHER RJ, 1990, P NATL ACAD SCI USA, V87, P5056, DOI 10.1073/pnas.87.13.5056; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; WIRTH DF, 1982, P NATL ACAD SCI-BIOL, V79, P6999, DOI 10.1073/pnas.79.22.6999	29	118	118	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					61	69		10.1016/0092-8674(95)90451-4	http://dx.doi.org/10.1016/0092-8674(95)90451-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813018	hybrid			2022-12-01	WOS:A1995QB91000010
J	COPI, CJ; SCHRAMM, DN; TURNER, MS				COPI, CJ; SCHRAMM, DN; TURNER, MS			BIG-BANG NUCLEOSYNTHESIS AND THE BARYON DENSITY OF THE UNIVERSE	SCIENCE			English	Article							METAL-DEFICIENT DWARFS; PRIMORDIAL NUCLEOSYNTHESIS; DARK-MATTER; GALACTIC HALO; IRAS GALAXIES; STARS; ABUNDANCES; BERYLLIUM; LITHIUM; ORIGIN	For almost 30 years, the predictions of big-bang nucleosynthesis have been used to test the big-bang model to within a fraction of a second of the bang. The agreement between the predicted and observed abundances of deuterium, helium-3, helium-4, and lithium-7 confirms the standard cosmology model and allows accurate determination of the baryon density, between 1.7 x 10(-31) and 4.1 x 10(-31) grams per cubic centimeter (corresponding to about 1 to 15 percent of the critical density). This measurement of the density of ordinary matter is pivotal to the establishment of two dark-matter problems: (i) most of the baryons are dark, and (ii) if the total mass density is greater than about 15 percent of the critical density, as many determinations indicate, the bulk of the dark matter must be ''nonbaryonic,'' composed of elementary particles left from the earliest moments.	FERMILAB NATL ACCELERATOR LAB, NASA, FERMILAB ASTROPHYS CTR, BATAVIA, IL 60510 USA; UNIV CHICAGO, ENRICO FERMI INST, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA	National Aeronautics & Space Administration (NASA); United States Department of Energy (DOE); University of Chicago; Fermi National Accelerator Laboratory; University of Chicago	COPI, CJ (corresponding author), UNIV CHICAGO, DEPT PHYS, CHICAGO, IL 60637 USA.							ALCOCK C, 1993, NATURE, V365, P621, DOI 10.1038/365621a0; ALPHER RA, 1949, PHYS REV, V75, P1089, DOI 10.1103/PhysRev.75.1089; ALPHER RA, 1948, PHYS REV, V73, P803, DOI 10.1103/PhysRev.73.803; APPLEGATE JH, 1988, ASTROPHYS J, V329, P572, DOI 10.1086/166404; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; BALSER DS, 1994, 1994 P ESO M LIGHT E; BLACK DC, 1972, GEOCHIM COSMOCHIM AC, V36, P347, DOI 10.1016/0016-7037(72)90028-2; BOYD RN, 1989, ASTROPHYS J, V336, pL55, DOI 10.1086/185360; BRUNE CR, 1994, PHYS REV C, V50, P2205, DOI 10.1103/PhysRevC.50.2205; CARSWELL RF, 1994, MON NOT R ASTRON SOC, V268, pL1, DOI 10.1093/mnras/268.1.L1; CARSWELL RF, COMMUNICATION; CHARBONNEL C, 1992, ASTRON ASTROPHYS, V265, P55; DAVIDSON K, 1985, ASTROPHYS J SUPPL S, V58, P321, DOI 10.1086/191044; DEARBORN DSP, 1986, ASTROPHYS J, V302, P35, DOI 10.1086/163969; DEKEL A, 1994, ANNU REV ASTRON ASTR, V32, P371; DODELSON S, 1994, PHYS REV D, V49, P5068, DOI 10.1103/PhysRevD.49.5068; DUNCAN DK, 1992, ASTROPHYS J, V401, P584, DOI 10.1086/172088; EDVARDSSON B, 1989, GEOCHIM COSMOCHIM AC, V53, P197; EPSTEIN RI, 1976, NATURE, V263, P198, DOI 10.1038/263198a0; FABER SM, 1979, ANNU REV ASTRON ASTR, V17, P135, DOI 10.1146/annurev.aa.17.090179.001031; FOWLER WA, 1962, GEOPHYS J ROY ASTR S, V6, P148, DOI 10.1111/j.1365-246X.1962.tb02977.x; GAMOW G, 1946, PHYS REV, V70, P527; GEISS J, 1972, ASTRON ASTROPHYS, V18, P126; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; GILMORE G, 1992, NATURE, V357, P379, DOI 10.1038/357379a0; GILMORE G, 1991, ASTROPHYS J, V378, P17, DOI 10.1086/170402; HOBBS LM, 1994, ASTROPHYS J, V428, pL25, DOI 10.1086/187384; HOBBS LM, 1988, ASTROPHYS J, V326, pL23, DOI 10.1086/185115; HOYLE F, 1964, NATURE, V203, P1108, DOI 10.1038/2031108a0; IBEN I, 1978, ASTROPHYS J, V220, P980, DOI 10.1086/155986; JAKOBSEN P, 1994, NATURE, V370, P35, DOI 10.1038/370035a0; JEDAMZIK K, 1994, ASTROPHYS J, V422, P423, DOI 10.1086/173738; KAISER N, 1991, MON NOT R ASTRON SOC, V252, P1; KAWASAKI M, 1994, NUCL PHYS B, V419, P105, DOI 10.1016/0550-3213(94)90359-X; KERNAN PJ, 1994, PHYS REV LETT, V72, P3309, DOI 10.1103/PhysRevLett.72.3309; Kurki-Suonio H., 1990, Astrophysical Journal, V353, P406, DOI 10.1086/168626; LIDDLE AR, 1993, PHYS REP, V231, P1, DOI 10.1016/0370-1573(93)90114-S; LINSKY JL, 1993, ASTROPHYS J, V402, P694, DOI 10.1086/172170; MALANEY RA, 1993, PHYS REP, V229, P147; MAMPE W, 1993, JETP LETT+, V57, P82; MATHER JC, 1994, ASTROPHYS J, V420, P439, DOI 10.1086/173574; MONTANET L, 1994, PHYS REV D, V50, P1680; OLIVE KA, IN PRESS ASTROPHYS S; OSTRIKER JP, 1993, ANNU REV ASTRON ASTR, V31, P689; PAGEL BEJ, 1992, MON NOT R ASTRON SOC, V255, P325, DOI 10.1093/mnras/255.2.325; PEEBLES PJE, 1966, ASTROPHYS J, V146, P542, DOI 10.1086/148918; PINSONNEAULT MH, 1992, ASTROPHYS J SUPPL S, V78, P179, DOI 10.1086/191624; PISONNEAULT MH, 1992, ASTROPHYS J SUPL SER, V78, P179; REBOLO R, 1988, ASTRON ASTROPHYS, V193, P193; REBOLO R, 1988, ASTRON ASTROPHYS, V192, P192; REEVES H, 1970, NATURE, V226, P727, DOI 10.1038/226727a0; REEVES H, 1973, ASTROPHYS J, V179, P909, DOI 10.1086/151928; REIMERS D, 1993, ASTRON ASTROPHYS, V276, pL13; ROGERSON JB, 1973, ASTROPHYS J, V186, pL95, DOI 10.1086/181366; RYAN SG, 1990, ASTROPHYS J, V348, pL57, DOI 10.1086/185630; RYAN SG, 1992, ASTROPHYS J, V388, P184, DOI 10.1086/171141; SASSELOV D, IN PRESS ASTROPHYS J; SATO K, 1991, PHYS SCR TOP ISSUES, V136, P60; SKILLMAN ED, 1993, ASTROPHYS J, V411, P655, DOI 10.1086/172868; SKILLMAN ED, 1993, ANN NY ACAD SCI, V688, P739, DOI 10.1111/j.1749-6632.1993.tb43965.x; SKILLMAN ED, IN PRESS ASTROPHYS J; SKILLMAN ED, IN PRESS; SMITH MS, 1993, ASTROPHYS J SUPPL S, V85, P219, DOI 10.1086/191763; SMITH PF, 1990, PHYS REP, V187, P203, DOI 10.1016/0370-1573(90)90081-C; SMITH VV, 1993, ASTROPHYS J, V408, P262, DOI 10.1086/172585; SONGAILA A, 1994, NATURE, V368, P599, DOI 10.1038/368599a0; SPITE F, 1982, ASTRON ASTROPHYS, V115, P357; SPITE M, 1984, ASTRON ASTROPHYS, V141, P56; STEIGMAN G, 1994, MON NOT R ASTRON SOC, V269, pL53, DOI 10.1093/mnras/269.1.L53; STEIGMAN G, 1993, ASTROPHYS J, V415, pL35, DOI 10.1086/187026; STEIGMAN G, 1977, PHYS LETT B, V66, P202, DOI 10.1016/0370-2693(77)90176-9; STRAUSS MA, 1992, ASTROPHYS J, V397, P395, DOI 10.1086/171796; THOMAS D, 1993, ASTROPHYS J, V406, P569, DOI 10.1086/172469; THORBURN JA, 1994, ASTROPHYS J, V421, P318, DOI 10.1086/173650; TURNER MS, 1993, P NATL ACAD SCI USA, V90, P4827, DOI 10.1073/pnas.90.11.4827; TYTLER D, COMMUNICATION; UDALSKI A, 1993, ACTA ASTRONOM, V43, P289; VANGIONIFLAM E, 1994, ASTROPHYS J, V427, P618, DOI 10.1086/174171; WAGONER RV, 1967, ASTROPHYS J, V148, P3, DOI 10.1086/149126; WALKER TP, 1991, ASTROPHYS J, V376, P51, DOI 10.1086/170255; WHITE SDM, 1993, NATURE, V366, P429, DOI 10.1038/366429a0; WILSON TL, 1983, P ESO WORKSHOP PRIMO, P379; WITTEN E, 1984, PHYS REV D, V30, P272, DOI 10.1103/PhysRevD.30.272; YANG J, 1984, ASTROPHYS J, V281, P493, DOI 10.1086/162123	84	347	349	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					192	199		10.1126/science.7809624	http://dx.doi.org/10.1126/science.7809624			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809624				2022-12-01	WOS:A1995QB15300023
J	DAI, XC; DEMESMAEKER, A; JOYCE, GF				DAI, XC; DEMESMAEKER, A; JOYCE, GF			CLEAVAGE OF AN AMIDE BOND BY A RIBOZYME	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA WORLD; CATALYSIS; BINDING; EVOLUTION; SUBSTRATE; SEQUENCE; ANTIBODY; ENZYME; ORIGIN	A variant form of a group I ribozyme, optimized by in vitro evolution for its ability to catalyze magnesium-dependent phosphoester transfer reactions involving DNA substrates, also catalyzes the cleavage of an unactivated alkyl amide when that linkage is presented in the context of an oligodeoxynucleotide analog. Substrates containing an amide bond that joins either two DNA oligos, or a DNA oligo and a short peptide, are cleaved in a magnesium-dependent fashion to generate the expected products. The first-order rate constant, k(cat), is 0.1 x 10(-5) min(-1) to 1 x 10(-5) min(-1) for the DNA-flanked substrates, which corresponds to a rate acceleration of more than 10(3) as compared with the uncatalyzed reaction.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; CIBA GEIGY LTD, CENT RES LABS, BASEL, SWITZERLAND	Scripps Research Institute; Scripps Research Institute; Novartis								BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; CECH TR, 1992, J BIOL CHEM, V267, P17479; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; IVERSON BL, 1989, SCIENCE, V243, P1184, DOI 10.1126/science.2922606; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1994, CURR OPIN STRUC BIOL, V4, P331, DOI 10.1016/S0959-440X(94)90100-7; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LEBRETON J, 1993, TETRAHEDRON LETT, V34, P6383, DOI 10.1016/0040-4039(93)85051-W; MARTIN MT, 1994, J AM CHEM SOC, V116, P6508, DOI 10.1021/ja00094a003; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, NATURE, V353, P302, DOI 10.1038/353302a0; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAILLARD SA, UNPUB; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TSANG J, 1994, BIOCHEMISTRY-US, V33, P5966, DOI 10.1021/bi00185a038; TSANG JC, UNPUB; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YAMANA T, 1972, CHEM PHARM BULL, V20, P881; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZIEBOLL G, 1994, J MOL EVOL, V38, P561	35	91	108	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					237	240		10.1126/science.7809628	http://dx.doi.org/10.1126/science.7809628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809628				2022-12-01	WOS:A1995QB15300035
J	FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP				FAKLER, B; BRANDLE, U; GLOWATZKI, E; WEIDEMANN, S; ZENNER, HP; RUPPERSBERG, JP			STRONG VOLTAGE-DEPENDENT INWARD RECTIFICATION OF INWARD RECTIFIER K+ CHANNELS IS CAUSED BY INTRACELLULAR SPERMINE	CELL			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; IK(A) CHANNELS; CELL-MEMBRANE; INACTIVATION; MAGNESIUM; IONS; POLYAMINES; EXPRESSION; COMPLEX	Inward rectifier K+ channels mediate the K+ conductance at resting potential in many types of cell. Since these K+ channels do not pass outward currents (inward rectification) when the cell membrane is depolarized beyond a trigger threshold, they play an important role in controlling excitability. Both a highly voltage-dependent block by intracellular Mg2+ and an endogenous gating process are presently assumed to underly inward rectification. It is shown that strong voltage dependence of rectification found under physiological conditions is predominantly due to the effect of intracellular spermine. Physiological concentrations of free spermine mediate strong rectification of IRK1 inward rectifier K+ channels even in the absence of free Mg2+ and in IRK1 mutant channels that have no endogenous rectification.	UNIV TUBINGEN HOSP, EAR NOSE & THROAT CLIN, DEPT SENSORY BIOPHYS, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital				Glowatzki, Elisabeth/0000-0003-3135-658X				BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; CHO SW, 1991, EUR J BIOCHEM, V202, P107, DOI 10.1111/j.1432-1033.1991.tb16350.x; ELAM TR, 1993, BIOPHYS J, V64, pA227; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; GIANNAKOUROS T, 1990, MOL CELL BIOCHEM, V99, P9, DOI 10.1007/BF01261388; GUTTERIDGE JMC, 1990, BIOCHEM J, V269, P169, DOI 10.1042/bj2690169; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KELLY MEM, 1992, J MEMBRANE BIOL, V126, P171; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; LOPATIN AN, 1994, J PHYSL, V477, P86; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; RUPPERSBERG JP, 1994, SEMIN NEUROSCI, V6, P87; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WATANABE S, 1991, J BIOL CHEM, V266, P20803	30	312	313	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					149	154		10.1016/0092-8674(95)90459-X	http://dx.doi.org/10.1016/0092-8674(95)90459-X			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813010	Bronze			2022-12-01	WOS:A1995QB91000018
J	FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M				FELDMAN, B; POUEYMIROU, W; PAPAIOANNOU, VE; DECHIARA, TM; GOLDFARB, M			REQUIREMENT OF FGF-4 FOR POSTIMPLANTATION MOUSE DEVELOPMENT	SCIENCE			English	Article							GROWTH-FACTOR FAMILY; EMBRYONAL CARCINOMA-CELLS; EXPRESSION; PROTOONCOGENE; LIMB; GENE; GASTRULATION; ONCOGENE; INT-2; DIFFERENTIATION	Fibroblast growth factors (FGFs) are thought to influence many processes in vertebrate development because of their diverse sites of expression and wide range of biological activities in in vitro culture systems. As a means of elucidating embryonic functions of FGF-4, gene targeting was used to generate mice harboring a disrupted Fgf4 gene. Embryos homozygous for the null allele underwent uterine implantation and induced uterine decidualization but did not develop substantially thereafter. As was consistent with their behavior in vivo, Fgf4 null embryos cultured in vitro displayed severely impaired proliferation of the inner cell mass, whereas growth and differentiation of the inner cell mass were rescued when null embryos were cultured in the presence of FGF-4 protein.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA; COLUMBIA UNIV, COLL PHYS & SURG, INTEGRATED PROGRAM CELLULAR MOLEC & BIOPHYS STUDI, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	Regeneron; Columbia University; Columbia University				Papaioannou, Virginia/0000-0001-7558-8601; Feldman, Benjamin/0000-0003-4838-8641	NICHD NIH HHS [HD27198, HD21988] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD021988, R01HD027198] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; FELDMAN B, UNPUB; GAO G, UNPUB; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HALABAN R, 1988, ONCOGENE RES, V3, P177; HAUB O, 1991, DEVELOPMENT, V112, P397; HEATH JK, 1989, DEVELOPMENT, V107, P113; Heath JK, 1991, CURR OPIN CELL BIOL, V3, P935, DOI 10.1016/0955-0674(91)90110-K; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HEBERT JM, 1991, DEVELOPMENT, V112, P407; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIYAGAWA K, 1988, ONCOGENE, V3, P383; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NISWANDER L, 1993, DEVELOPMENT, V119, P287; PATERNO GD, 1989, DEVELOPMENT, V106, P79; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; VOGEL A, 1993, DEVELOPMENT, V119, P199; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	36	608	626	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					246	249		10.1126/science.7809630	http://dx.doi.org/10.1126/science.7809630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809630				2022-12-01	WOS:A1995QB15300038
J	HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY				HARPER, CL; NYQUIST, LE; BANSAL, B; WIESMANN, H; SHIH, CY			RAPID ACCRETION AND EARLY DIFFERENTIATION OF MARS INDICATED BY ND-142 ND-144 IN SNC METEORITES	SCIENCE			English	Article							ND ISOTOPIC EVOLUTION; SM-ND; MARTIAN ORIGIN; PB SYSTEMATICS; SHERGOTTITES; PLANET; AGE; ACHONDRITES; CHONDRITES; ABUNDANCES	Small differences in the ratio of neodymium-142 to neodymium-144 in early formed mantle reservoirs in planetary bodies are the result of in situ decay of the extinct radionuclide samarium-146 and can be used to constrain early planetary differentiation and therefore the time scale of planetary accretion. The martian meteorite Nakhla (similar to 1.3 billion years old), the type sample of the nakhlite subgroup of the Shergottite-Nakhlite-Chassigny (SNC) meteorites, exhibits a 59 +/- 13 parts per million excess in the ratio of neodymium-142 to neodymium-144 relative to normal neodymium. This anomaly records differentiation in the martian mantle before 4539 million years ago and implies that Mars experienced no giant impacts at any time later than 27 million years after the origin of the solar system.	NASA, LYNDON B JOHNSON SPACE CTR, HOUSTON, TX 77058 USA; LOCKHEED ENGN & SCI CO, HOUSTON, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Lockheed Martin	HARPER, CL (corresponding author), HARVARD UNIV, DEPT EARTH & PLANETARY SCI, 20 OXFORD ST, CAMBRIDGE, MA 02138 USA.							AARSETH SJ, 1993, ASTROPHYS J, V403, P351, DOI 10.1086/172208; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; BOGARD DD, 1977, GEOPHYS RES LETT, V4, P69, DOI 10.1029/GL004i002p00069; BOGARD DD, 1979, METEORITICS, V14, P356; CHEN JH, 1986, GEOCHIM COSMOCHIM AC, V50, P955, DOI 10.1016/0016-7037(86)90376-5; DONES L, 1993, ICARUS, V103, P67, DOI 10.1006/icar.1993.1059; GALE NH, 1975, EARTH PLANET SC LETT, V26, P195, DOI 10.1016/0012-821X(75)90087-4; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; HARPER CL, 1992, NATURE, V360, P728, DOI 10.1038/360728a0; HARPER CL, UNPUB; HARPER CL, 1994, LPS, V25, P509; HARPER CL, 1993, LUNAR PLANET SCI, V24, P607; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; JACOBSEN SB, 1984, EARTH PLANET SC LETT, V67, P137, DOI 10.1016/0012-821X(84)90109-2; JAGOUTZ E, 1991, SPACE SCI REV, V56, P13, DOI 10.1007/BF00178386; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; JONES JH, 1986, GEOCHIM COSMOCHIM AC, V50, P969, DOI 10.1016/0016-7037(86)90377-7; JONES JH, 1989, P LUNAR PLANET SCI C, V19, P465; JONES JH, 1990, 9004 LUN PLAN I TECH, P35; LARSON RB, 1989, FORMATION EVOLUTION, P31; Lee T, 1974, GEOPHYS RES LETT, V1, P225, DOI 10.1029/GL001i006p00225; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; LISSAUER JJ, 1987, ICARUS, V69, P249, DOI 10.1016/0019-1035(87)90104-7; LISSAUER JJ, 1991, ICARUS, V93, P288, DOI 10.1016/0019-1035(91)90213-D; LISSAUER JJ, IN PRESS NEPTUNE TRI; LONGHI J, 1991, P LUNAR PLANET SCI, V21, P695; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOUGINISMARK PJ, 1992, J GEOPHYS RES-PLANET, V97, P10213, DOI 10.1029/92JE00612; MUSSELWHITE DS, 1991, NATURE, V352, P697, DOI 10.1038/352697a0; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NAKAMURA N, 1982, METEORITICS, V17, P257; NORMAN MD, 1992, LUNAR PLANET SCI, V23, P999; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; NYQUIST LE, 1991, METEORITICS, V26, P381; NYQUIST LE, 1994, LUNAR PLANET SCI, V25, P1017; NYQUIST LE, UNPUB; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; PAL DK, 1986, GEOCHIM COSMOCHIM AC, V50, P2405, DOI 10.1016/0016-7037(86)90022-0; PODOSEK FA, 1973, EARTH PLANET SC LETT, V19, P135, DOI 10.1016/0012-821X(73)90108-8; PRINZHOFER A, 1992, GEOCHIM COSMOCHIM AC, V56, P797, DOI 10.1016/0016-7037(92)90099-5; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; SPAUTE D, 1991, ICARUS, V92, P147, DOI 10.1016/0019-1035(91)90041-Q; STEVENSON DJ, 1988, ICARUS, V75, P146, DOI 10.1016/0019-1035(88)90133-9; STEWART BW, 1994, GEOCHIM COSMOCHIM AC, V58, P3487, DOI 10.1016/0016-7037(94)90100-7; TONKS WB, 1993, J GEOPHYS RES-PLANET, V98, P5319, DOI 10.1029/92JE02726; WADHWA M, 1994, GEOCHIM COSMOCHIM AC, V58, P4213, DOI 10.1016/0016-7037(94)90274-7; WASSERBURG GJ, 1981, GEOCHIM COSMOCHIM AC, V45, P2311, DOI 10.1016/0016-7037(81)90085-5; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WETHERILL GW, 1989, ICARUS, V77, P330, DOI 10.1016/0019-1035(89)90093-6; WETHERILL GW, 1993, ICARUS, V106, P190, DOI 10.1006/icar.1993.1166; WETHERILL GW, 1992, ICARUS, V100, P307, DOI 10.1016/0019-1035(92)90103-E; Wetherill GW, 1986, ORIGIN MOON, P519; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1; [No title captured]; [No title captured]; [No title captured]	59	131	131	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					213	217		10.1126/science.7809625	http://dx.doi.org/10.1126/science.7809625			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809625				2022-12-01	WOS:A1995QB15300027
J	HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR				HARWOOD, AJ; PLYTE, SE; WOODGETT, J; STRUTT, H; KAY, RR			GLYCOGEN-SYNTHASE KINASE-3 REGULATES CELL FATE IN DICTYOSTELIUM	CELL			English	Article							CYCLIC-AMP; GENE-EXPRESSION; STALK-CELL; PRESTALK CELLS; DISCOIDEUM; DIFFERENTIATION; INDUCTION; PRESPORE; PHOSPHORYLATION; TRANSFORMATION	Extracellular cyclic AMP (cAMP) induces the formation of prespore cells in Dictyostelium but inhibits stalk cell formation. We have cloned gskA, which encodes the Dictyostelium homolog of glycogen synthase kinase 3 (GSK-3), and discovered that it is required for both cAMP effects. Disruption of gskA creates a mutant that aggregates but forms few spores and an abnormally high number of stalk cells. These stalk cells probably arise from an expanded prestalk B (pstB) cell population, which normally produces the basal disc of the fruiting body. In cultured mutant cells, cAMP neither inhibits pstB cell differentiation nor induces efficient prespore cell differentiation. We propose that cAMP acts through a common pathway that requires GSK-3 and determines the proportion of prespore and pstB cells.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	HARWOOD, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Woodgett, Jim/F-1087-2010; Harwood, Adrian/A-4350-2010	Woodgett, Jim/0000-0003-3731-5797; Harwood, Adrian/0000-0003-3124-5169; Strutt, Helen/0000-0003-4365-2271; Kay, Robert R/0000-0001-9836-7967				BARKLIS E, 1983, CELL, V32, P1139, DOI 10.1016/0092-8674(83)90297-0; BERKS M, 1988, DEV BIOL, V126, P108, DOI 10.1016/0012-1606(88)90244-8; BERKS M, 1990, DEVELOPMENT, V110, P977; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; BIANCHI MW, 1994, MOL GEN GENET, V242, P337, DOI 10.1007/BF00280424; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEGROOT RP, 1993, ONCOGENE, V8, P841; DIAZBENJUMEE F, 1994, GENE, V85, P353; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, DEVELOPMENT, V103, P519; EARLY AE, 1993, DEVELOPMENT, V118, P353; HANKS S, 1991, METHOD ENZYMOL, V300, P38; HARLOW E, 1988, ANTIBODIES LABORATOR; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JOLY E, 1993, TRENDS GENET, V9, P157, DOI 10.1016/0168-9525(93)90152-8; KAY RR, 1992, BIOCHEM J, V281, P155, DOI 10.1042/bj2810155; KAY RR, 1978, NATURE, V271, P58, DOI 10.1038/271058a0; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOPACHIK WJ, 1985, DIFFERENTIATION, V28, P209, DOI 10.1111/j.1432-0436.1985.tb00827.x; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; SAXE CL, 1991, DEV GENET, V12, P6, DOI 10.1002/dvg.1020120104; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V354, P825; SIMPSON P, 1993, DEVELOPMENT, P29; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x	49	180	188	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					139	148		10.1016/0092-8674(95)90458-1	http://dx.doi.org/10.1016/0092-8674(95)90458-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813009	Bronze			2022-12-01	WOS:A1995QB91000017
J	HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A				HYNES, M; POULSEN, K; TESSIERLAVIGNE, M; ROSENTHAL, A			CONTROL OF NEURONAL DIVERSITY BY THE FLOOR PLATE - CONTACT-MEDIATED INDUCTION OF MIDBRAIN DOPAMINERGIC-NEURONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE-HYDROXYLASE; CELL PATTERN; SUBSTANTIA-NIGRA; RAT; DIFFERENTIATION; EXPRESSION; SIGNALS; LOCALIZATION; RECEPTORS	The notochord and floor plate contribute to patterning the ventral neural tube in part by expressing a diffusible factor that induces motoneurons. To determine the mechanisms that direct the development of other classes of ventral neurons, we studied the development of dopaminergic neurons that reside near motoneurons in the ventral midbrain. We provide evidence that dopaminergic neurons develop in the vicinity of the floor plate and that they can be specified by the floor plate in vitro and in vivo. Unlike motoneurons, efficient induction of dopaminergic neurons requires contact with floor plate cells. These results suggest that neuronal diversification along the dorsal-ventral axis may be achieved partly through the concerted action of diffusible and contact-dependent signals from a single organizing center, the floor plate.	GENENTECH INC,DEPT NEUROSCI,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,PROGRAM CELL BIOL,SAN FRANCISCO,CA 94143	Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hynes, Mary/0000-0001-6623-6727				ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BAPTISTA CA, 1994, NEURON, V12, P243, DOI 10.1016/0896-6273(94)90268-2; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREENBERG D, 1974, SCIENCE, V184, P1243; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LUMSDEN A, 1994, DEVELOPMENT, V120, P1581; LUSKIN MB, 1993, J NEUROSCI, V13, P1730; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARCHAND R, 1983, NEUROSCIENCE, V9, P373, DOI 10.1016/0306-4522(83)90300-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; PICKEL VM, 1975, J HISTOCHEM CYTOCHEM, V23, P1, DOI 10.1177/23.1.234988; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; SPECHT LA, 1981, J COMP NEUROL, V199, P255, DOI 10.1002/cne.901990208; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; VOORN P, 1988, NEUROSCIENCE, V25, P857, DOI 10.1016/0306-4522(88)90041-3; WATANABE T, 1990, NEURON, V2, P461; YAGINUMA H, 1991, J COMP NEUROL, V304, P78, DOI 10.1002/cne.903040107; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	204	212	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					95	101		10.1016/0092-8674(95)90454-9	http://dx.doi.org/10.1016/0092-8674(95)90454-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813022	Bronze			2022-12-01	WOS:A1995QB91000013
J	JONES, PH; HARPER, S; WATT, FM				JONES, PH; HARPER, S; WATT, FM			STEM-CELL PATTERNING AND FATE IN HUMAN EPIDERMIS	CELL			English	Article							INTEGRINS ALPHA-3-BETA-1; FIBRONECTIN RECEPTOR; MESSENGER-RNA; ADHESION; EXPRESSION; KERATINOCYTES; MIGRATION; CYTOSKELETAL; ANTIGEN; ROLES	Within human epidermis there are two types of proliferating keratinocyte: stem cells, which have high proliferative potential, and transit-amplifying cells, which are destined to undergo terminal differentiation after a few rounds of division. We show that, in vivo, stem cells express higher levels of the alpha(2) beta(1) and alpha(3) beta(1) integrins than transit-amplifying cells and that this can be used both to determine the location of stem cells within the epidermis and to isolate them directly from the tissue. The distribution of stem cells and transit-amplifying cells is not random: patches of integrin-bright and integrin-dull cells have a specific location with respect to the epidermal-dermal junction that varies between body sites and that correlates with the distribution of S phase cells. Stem cell patterning can be recreated in culture, in the absence of dermis, and appears to be subject to autoregulation.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; LEICESTER GEN HOSP, DEPT NEPHROL, LEICESTER LE5 4PW, LEICS, ENGLAND	Cancer Research UK; University Hospitals of Leicester NHS Trust; Leicester General Hospital			Jones, Philip/D-2464-2009; Watt, Fiona/AHB-0226-2022	Jones, Philip/0000-0002-5904-795X; Watt, Fiona/0000-0001-9151-5154	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; DESTROOPER B, 1988, CELL BIOL INT REP, V12, P9, DOI 10.1016/0309-1651(88)90106-3; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HALL PA, 1989, DEVELOPMENT, V106, P619; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Holbrook K.A., 1991, PHYSL BIOCH MOL BIOL, P63; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; LANE EB, 1991, ANN NY ACAD SCI, V642, P197; LAVKER RM, 1983, J INVEST DERMATOL, V81, pS121, DOI 10.1111/1523-1747.ep12540880; OFARRELL PH, 1994, NATURE, V368, P188, DOI 10.1038/368188a0; POTTEN CS, 1988, J CELL SCI, P45; POTTEN CS, 1974, CELL TISSUE KINET, V7, P77, DOI 10.1111/j.1365-2184.1974.tb00401.x; PRINGLE JH, 1990, J PATHOL, V162, P197, DOI 10.1002/path.1711620305; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROCHAT A, 1994, INT J DEV BIOL, V76, P1063; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; YANG JS, 1993, J INVEST DERMATOL, V101, P652, DOI 10.1111/1523-1747.ep12371671; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	37	673	731	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					83	93		10.1016/0092-8674(95)90453-0	http://dx.doi.org/10.1016/0092-8674(95)90453-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813021	Bronze			2022-12-01	WOS:A1995QB91000012
J	KOVACSOVICSBANKOWSKI, M; ROCK, KL				KOVACSOVICSBANKOWSKI, M; ROCK, KL			A PHAGOSOME-TO-CYTOSOL PATHWAY FOR EXOGENOUS ANTIGENS PRESENTED ON MHC CLASS-I MOLECULES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CELLS; PROTEIN; EXPRESSION; GELONIN	Peptides from endogenous proteins are presented by major histocompatibility complex class I molecules, but antigens (Ags) in the extracellular fluids are generally not. However, pathogens or particulate Ags that are internalized into phagosomes of macrophages (MOs) stimulate CD8 T cells. The presentation of these Ags is resistant to chloroquine but is blocked by inhibitors of the proteasome, a mutation in the TAP1-TAP2 transporter, and brefeldin A. Moreover, phagocytosis of a ribosomal-inactivating protein inhibited MM protein synthesis. These results demonstrate that MOs transfer Ags from phagosomes into the cytosol and that endogenous and exogenous Ags use a final common pathway for class I presentation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031337, R01AI020248, R37AI020248] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31337, AI20248] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACIK I, 1994, J IMMUNOL, V152, P381; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CARTER VC, 1981, J IMMUNOL, V126, P1655; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; KNOP K, 1993, CURR OPIN CELL BIOL, V5, P990; KOVACSOVICSBANK.M, 1994, EUR J IMMUNOL, V24, P2421; KOVACSOVICSBANK.M, UNPUB; KOVACSOVICSBANKOWS, 1993, P NATL ACAD SCI USA, V90, P4942; LAMBERT JM, 1985, J BIOL CHEM, V260, P2035; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; STAERZ UD, 1987, NATURE, V329, P449, DOI 10.1038/329449a0; STIRPE F, 1980, J BIOL CHEM, V255, P6947; SZALAY G, 1994, EUR J IMMUNOL, V24, P1471, DOI 10.1002/eji.1830240703; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	27	712	726	0	25	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					243	246		10.1126/science.7809629	http://dx.doi.org/10.1126/science.7809629			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809629				2022-12-01	WOS:A1995QB15300037
J	LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J				LEFEBVRE, S; BURGLEN, L; REBOULLET, S; CLERMONT, O; BURLET, P; VIOLLET, L; BENICHOU, B; CRUAUD, C; MILLASSEAU, P; ZEVIANI, M; LEPASLIER, D; FREZAL, J; COHEN, D; WEISSENBACH, J; MUNNICH, A; MELKI, J			IDENTIFICATION AND CHARACTERIZATION OF A SPINAL MUSCULAR ATROPHY-DETERMINING GENE	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE MAP; CHROMOSOME-5; LOCUS; FREQUENCY; MARKERS; CONTIG; REGION; 5Q13	Spinal muscular atrophy (SMA) is a common fatal autosomal recessive disorder characterized by degeneration of lower motor neurons, leading to progressive paralysis with muscular atrophy. The gene for SMA has been mapped to chromosome 5q13, where large-scale deletions have been reported. We describe here the inverted duplication of a 500 kb element in normal chromosomes and narrow the critical region to 140 kb within the telomeric region. This interval contains a 20 kb gene encoding a novel protein of 294 amino acids. An highly homologous gene is present in the centromeric element of 95% of controls. The telomeric gene is either lacking or interrupted in 226 of 229 patients, and patients retaining this gene (3 of 229) carry either a point mutation (Y272C) or short deletions in the consensus splice sites of introns 6 and 7. These data suggest that this gene, termed the survival motor neuron (SMN) gene, is an SMA-determining gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; GENETHON,F-91002 EVRY,FRANCE		LEFEBVRE, S (corresponding author), HOP NECKER ENFANTS MALAD,INST NECKER,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS 15,FRANCE.		Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021; Lefebvre, Suzie/D-5092-2017	Zeviani, Massimo/0000-0002-9067-5508; Le Paslier, Denis/0000-0003-4335-9956; BERNARD, BENICHOU/0000-0002-9331-0926; Cruaud, Corinne/0000-0002-4752-7278				BOTTEMA CDK, 1990, AM J HUM GENET, V47, P835; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; CARLOCK LR, 1985, AM J HUM GENET, V37, P839; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; HERRMANN BG, 1987, CELL, V48, P813, DOI 10.1016/0092-8674(87)90078-X; HIGASHI Y, 1988, AM J HUM GENET, V42, P17; Hoffmann J., 1900, MUENCHEN MED WSCHR, V47, P1649; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KUGELBERG E, 1956, ARCH NEURO PSYCHIATR, V75, P500, DOI 10.1001/archneurpsyc.1956.02330230050005; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MELKI J, 1993, GENOMICS, V15, P521, DOI 10.1006/geno.1993.1103; MORRISON KE, 1992, AM J HUM GENET, V50, P520; Munsat TL., 1991, NEUROMUSCULAR DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; MURRU S, 1991, BLOOD, V77, P1342; Orkin S., 1987, MOL BASIS BLOOD DISE, P106; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sambrook J., 1989, MOL CLONING LAB MANU; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; Werdnig G., 1894, ARCH PSYCHIAT, V26, P706	36	2774	2901	12	134	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					155	165		10.1016/0092-8674(95)90460-3	http://dx.doi.org/10.1016/0092-8674(95)90460-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813012	Bronze			2022-12-01	WOS:A1995QB91000019
J	MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S				MATSUFUJI, S; MATSUFUJI, T; MIYAZAKI, Y; MURAKAMI, Y; ATKINS, JF; GESTELAND, RF; HAYASHI, S			AUTOREGULATORY FRAMESHIFTING IN DECODING MAMMALIAN ORNITHINE DECARBOXYLASE ANTIZYME	CELL			English	Article							RELEASE FACTOR-II; MESSENGER-RNA; INHIBITORY PROTEIN; GENE-EXPRESSION; RAT-LIVER; POLYAMINES; DEGRADATION; CELLS; PSEUDOKNOT; SEQUENCE	Rat antizyme gene expression requires programmed, ribosomal frameshifting. A novel autoregulatory mechanism enables modulation of frameshifting according to the cellular concentration of polyamines. Antizyme binds to, and destabilizes, ornithine decarboxylase, a key enzyme in polyamine synthesis, Rapid degradation ensues, thus completing a regulatory circuit. In vitro experiments with a fusion construct using reticulocyte lysates demonstrate polyamine-dependent expression with a frameshift efficiency of 19% at the optimal concentration of spermidine. The frameshift is +1 and occurs at the codon just preceding the terminator of the initiating frame. Both the termination codon of the initiating frame and a pseudoknot downstream in the mRNA have a stimulatory effect. The shift site sequence, UCC-UGA-U, is not similar to other known frameshift sites. The mechanism does not seem to involve re-pairing of peptidyl-tRNA in the new frame but rather reading or occlusion of a fourth base.	UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; JIKEI UNIV, SCH MED, DEPT NUTR, MINATO KU, TOKYO 105, JAPAN	Utah System of Higher Education; University of Utah; Jikei University	MATSUFUJI, S (corresponding author), UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.			Atkins, John/0000-0001-7933-0165	NIGMS NIH HHS [R01-GM48152] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST P, 1981, J MOL BIOL, V153, P23, DOI 10.1016/0022-2836(81)90524-6; Atkins J. F., 1995, P471; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BRAULT V, 1992, P NATL ACAD SCI USA, V89, P2262, DOI 10.1073/pnas.89.6.2262; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GESTELAND RF, 1992, ANNU REV BIOCHEM, V45, P747; GORLACH M, 1989, EUR J BIOCHEM, V184, P589, DOI 10.1111/j.1432-1033.1989.tb15054.x; Hayashi S., 1989, ORNITHINE DECARBOXYL, P35; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; JANDA M, 1987, VIROLOGY, V158, P259, DOI 10.1016/0042-6822(87)90265-0; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KITANI T, 1984, J BIOL CHEM, V259, P36; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROM E, 1994, P NATL ACAD SCI USA, V91, P9195; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078	46	421	435	2	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					51	60		10.1016/0092-8674(95)90450-6	http://dx.doi.org/10.1016/0092-8674(95)90450-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813017	Green Published, Bronze			2022-12-01	WOS:A1995QB91000009
J	MAYER, A; NEUPERT, W; LILL, R				MAYER, A; NEUPERT, W; LILL, R			MITOCHONDRIAL PROTEIN IMPORT - REVERSIBLE BINDING OF THE PRESEQUENCE AT THE TRANS SIDE OF THE OUTER-MEMBRANE DRIVES PARTIAL TRANSLOCATION AND UNFOLDING	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; C HEME LYASE; PRECURSOR PROTEINS; INTERMEMBRANE SPACE; RECEPTOR COMPLEX; INNER MEMBRANE; CYTOCHROME-C; INSERTION; YEAST; MATRIX	The mechanism of translocation of matrix-targeted, cleavable preproteins across the mitochondrial outer membrane was studied using purified outer membrane vesicles. The N-terminal presequence interacts in a sequential and reversible fashion with two specific binding sites. The first one is provided by protease-sensitive receptors on the surface of the membrane (cis site); the second one is located at the inner face of the outer membrane (trans site). Binding to the trans site drives translocation of the N-terminal portion of the preprotein and, at the same time, unfolding of its mature part. We suggest that the outer membrane protein import machinery forms a translocation channel that permits reversible sliding of preproteins and prevents their lateral aggregation in the membrane. Although translocation can be initiated by the outer membrane, its completion requires coupling to the energetic system of the inner membrane. Our data assign an essential role to the presequence, not only for efficient targeting, but also for the translocation step.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHMEM & ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich			Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X; Lill, Roland/0000-0002-8345-6518				ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK B, 1991, ANNU REV GENET, V25, P21; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1991, J BIOL CHEM, V266, P21083; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MAYER A, 1994, CELL BIOL LABORATORY; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NICHOLSON DW, 1987, EUR J BIOCHEM, V164, P147, DOI 10.1111/j.1432-1033.1987.tb11006.x; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1991, TRENDS BIOCHEM SCI, V16, P63, DOI 10.1016/0968-0004(91)90026-R; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SEGUIREAL B, 1992, FEBS LETT, V313, P2, DOI 10.1016/0014-5793(92)81171-H; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.biochem.60.1.101	43	144	144	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					127	137		10.1016/0092-8674(95)90457-3	http://dx.doi.org/10.1016/0092-8674(95)90457-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813008	Bronze			2022-12-01	WOS:A1995QB91000016
J	MITNIK, L; HELLER, C; PROST, J; VIOVY, JL				MITNIK, L; HELLER, C; PROST, J; VIOVY, JL			SEGREGATION IN DNA SOLUTIONS INDUCED BY ELECTRIC-FIELDS	SCIENCE			English	Article							ELECTROPHORESIS	DNA solutions subjected to an electric field exhibit an instability that leads to DNA segregation in aggregates tilted with regard to the field. With the use of epifluorescence videomicroscopy, the evolution of DNA patterns in capillaries as a function of DNA concentration, DNA size, field strength, and field frequency was studied. The field threshold for segregation was decreased when the frequency was lowered or when the DNA molecular weight or concentration was increased. Aggregation is attributed to an electrohydrodynamic instability triggered by the dipole-dipole interaction. This phenomenon explains the failure of earlier attempts to separate large DNA in capillaries.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 1382, PHYSICOCHIM THEOR LAB, F-75231 PARIS 05, FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, CNRS, UA 278, PHYSICOCHIM STRUCT & MACROMOLEC LAB, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Universite Paris Cite				Viovy, Jean-Louis/0000-0002-8223-4040; Heller, Christoph/0000-0002-9434-8192				BROCHARDWYART F, 1988, CR ACAD SCI II, V307, P1497; Colburn J.C., 1992, CAPILLARY ELECTROPHO; GUSZCZYNSKI T, 1993, ELECTROPHORESIS, V14, P523, DOI 10.1002/elps.1150140180; HJERTEN S, 1991, FEB HIGH PERF CAP EL; HU Y, 1994, J CHEM PHYS, V100, P4674, DOI 10.1063/1.466250; JONSSON M, 1993, J CHEM SOC FARADAY T, V89, P2791, DOI 10.1039/ft9938902791; KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106; Mandel M, 1977, Ann N Y Acad Sci, V303, P74, DOI 10.1111/j.1749-6632.1977.tb55921.x; POHL HA, 1978, DIELECTROPHORESIS, P135; SONG L, 1991, J BIOMOL STRUCT DYN, V9, P87, DOI 10.1080/07391102.1991.10507895; WANG ZL, 1990, MACROMOLECULES, V23, P790, DOI 10.1021/ma00205a016	11	79	80	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					219	222		10.1126/science.7809626	http://dx.doi.org/10.1126/science.7809626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809626				2022-12-01	WOS:A1995QB15300029
J	MURGUIA, JR; BELLES, JM; SERRANO, R				MURGUIA, JR; BELLES, JM; SERRANO, R			A SALT-SENSITIVE 3'(2'),5'-BISPHOSPHATE NUCLEOTIDASE INVOLVED IN SULFATE ACTIVATION	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; TRANSGENIC TOBACCO; TOLERANCE; LITHIUM; ION; INHIBITION; PROTEINS; GENETICS; YEAST; CROPS	Overexpression of a yeast gene, HAL2, allows the cells to tolerate higher than normal extracellular salt concentrations. HAL2 encodes a 3'(2')5'-bisphosphate nucleotidase that serves to remove the end products of sulfate transfer during cellular metabolism. The enzyme is inhibited by lithium and sodium and is activated by potassium. Metabolic systems that are sensitive to salt, as well as those governing osmolyte synthesis and ion transport, offer routes by which genetic engineering can be used to improve the tolerance of various organisms to salt.	UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institute of Molecular & Cellular Biology of Plants (IBMCP); Universitat Politecnica de Valencia	SERRANO, R (corresponding author), UNIV POLITECN VALENCIA, CSIC, Inst Biol Mol & Celular Plantas, Camino Vera, E-46022 VALENCIA, SPAIN.		Bellés, José María/H-4734-2015; Murguia, Jose R./H-4419-2015	Bellés, José María/0000-0003-0362-9616; Murguia, Jose R./0000-0001-9364-4603				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; DOWNTON WJS, 1984, CRC CR REV PLANT SCI, V1, P183, DOI 10.1080/07352688409382177; EPSTEIN E, 1980, SCIENCE, V210, P399, DOI 10.1126/science.210.4468.399; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HALLCHER LM, 1980, J BIOL CHEM, V255, P896; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; INHORN RC, 1987, J BIOL CHEM, V262, P15946; JONES RGW, 1986, OUTLOOK AGR, V15, P33; JONES RGW, 1983, ENCY PLANT PHYSL, V15, pCH4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI F, 1989, J CHROMATOGR, V461, P353, DOI 10.1016/S0021-9673(00)94302-4; MCCUE KF, 1990, TRENDS BIOTECHNOL, V8, P358, DOI 10.1016/0167-7799(90)90225-M; METZLER DE, 1977, BIOCHEMISTRY-US, P636; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NEUWALD AF, 1991, FEBS LETT, V294, P16, DOI 10.1016/0014-5793(91)81332-3; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; STAPLES RC, 1984, SALINITY TOLERANCE C; TAL M, 1985, PLANT SOIL, V89, P199, DOI 10.1007/BF02182243; TARCZYNSKI MC, 1992, P NATL ACAD SCI USA, V89, P2600, DOI 10.1073/pnas.89.7.2600; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; 1992, ENZYME NOMENCLATURE, P318	34	166	177	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					232	234						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809627				2022-12-01	WOS:A1995QB15300033
J	NAVAS, TA; ZHOU, Z; ELLEDGE, SJ				NAVAS, TA; ZHOU, Z; ELLEDGE, SJ			DNA-POLYMERASE-EPSILON LINKS THE DNA-REPLICATION MACHINERY TO THE S-PHASE CHECKPOINT	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; RIBONUCLEOTIDE REDUCTASE; ATAXIA-TELANGIECTASIA; REPAIR SYNTHESIS; YEAST; GENE; DAMAGE; MITOSIS; P53	Inhibition of DNA synthesis induces transcription of DNA damage-inducible genes and prevents mitotic entry through the action of the S phase checkpoint. We have isolated a mutant, dun2, defective for both of these responses. DUN2 is identical to POL2, encoding DNA polymerase epsilon (pol epsilon). Unlike sad1 mutants defective for multiple cell cycle checkpoints, pol2 mutants are defective only for the S phase checkpoint and the activation of DUN1 kinase necessary for the transcriptional response to damage. Interallelic complementation and mutation analysis indicate that pol epsilon contains two separable essential domains, an N-terminal polymerase domain and a C-terminal checkpoint domain unique to epsilon polymerases. We propose that DNA pol epsilon acts as a sensor of DNA replication that coordinates the transcriptional and cell cycle responses to replication blocks.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine					NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KESTI T, 1993, J BIOL CHEM, V268, P10238; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORRISON AL, 1990, CELL, V62, P1142; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBERGE M, 1992, Trends in Cell Biology, V2, P277, DOI 10.1016/0962-8924(92)90201-W; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	43	371	375	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					29	39		10.1016/0092-8674(95)90448-4	http://dx.doi.org/10.1016/0092-8674(95)90448-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813016	Bronze			2022-12-01	WOS:A1995QB91000007
J	PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L				PREDKI, PF; NAYAK, LM; GOTTLIEB, MBC; REGAN, L			DISSECTING RNA-PROTEIN INTERACTIONS - RNA-RNA RECOGNITION BY ROP	CELL			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; COLE1 PLASMID REPLICATION; CRYSTAL-STRUCTURE; PRIMER TRANSCRIPT; STEM-LOOPS; BINDING; SYNTHETASE; RESOLUTION; DNA; IDENTIFICATION	The ColE1 plasmid of E. coli encodes a small RNA-binding protein, Rop, which is involved in the regulation of plasmid copy number, Rop, a 4-helix bundle protein, facilitates sense-antisense RNA pairing by binding to the transiently formed hairpin pairs of RNA I and the complementary RNA II. We have identified the residues of Rop that are involved in RNA recognition. The residues form a narrow stripe down one face of the bundle and are symmetrically arranged, with recognition centered about two phenylalanine residues. Our results suggest that these phenylalanine residues interact with the loop region of the hairpin pair, with additional interactions between eight polar residues and the phosphate backbone. By modifying the identity of residue 14, we have created a variant of Rop that displays altered RNA binding specificity. The results of our studies allow us to present a detailed picture of RNA-protein recognition in a novel model system.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM49146, GM45340] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049146, R29GM049146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRICK P, 1988, J MOL BIOL, V208, P83; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CASTAGNOLI L, 1989, EMBO J, V8, P621, DOI 10.1002/j.1460-2075.1989.tb03417.x; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; EBERLE W, 1991, Journal of Biomolecular NMR, V1, P71, DOI 10.1007/BF01874570; EBERLE W, 1990, BIOCHEMISTRY-US, V29, P7402, DOI 10.1021/bi00484a007; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X; FOLKERS PJM, 1991, EUR J BIOCHEM, V200, P139, DOI 10.1111/j.1432-1033.1991.tb21060.x; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LYU PC, 1990, SCIENCE, V260, P669; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MUNSON M, 1994, GENE, V144, P59, DOI 10.1016/0378-1119(94)90203-8; MUNSON M, 1994, IN PRESS PROT SCI; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; RUTENBER E, 1993, PROT STRUCT FUNCT GE, V10, P240; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH CK, 1994, IN PRESS TECH PROT C; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TOMIZAWA J, 1981, CELL, V31, P575; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	45	90	91	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					41	50		10.1016/0092-8674(95)90449-2	http://dx.doi.org/10.1016/0092-8674(95)90449-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7529141	hybrid			2022-12-01	WOS:A1995QB91000008
J	REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC				REYNAUD, CA; GARCIA, C; HEIN, WR; WEILL, JC			HYPERMUTATION GENERATING THE SHEEP IMMUNOGLOBULIN REPERTOIRE IS AN ANTIGEN-INDEPENDENT PROCESS	CELL			English	Article							PEYERS-PATCHES; LYMPHOCYTE-B; GENES; EXPRESSION; MICE; CELLS; ILEAL; SEQUENCES; TOLERANCE; DIVERSITY	Somatic hypermutation of light chain V genes during development of B cells in sheep ileal Peyer's patches was studied in three experimental conditions: in sterile fragments of the ileum surgically isolated from the gut during fetal life, in germ-free sheep, and in animals thymectomized during early fetal life. The somatic mutation pattern was found identical to control tissues in all three experiments. The same age-dependent amount of mutations, a higher than theoretical R/S ratio in complementarity-determining regions (CDRs), and a similar clustering of mutations in CDRs were observed. The mechanism, as estimated from the silent mutation pattern, appears to target mutations to CDRs; moreover, the major V lambda genes have a specific codon usage with a high purine content at the first two bases of the codons and a low content at the third position, which, together with a specific targeting of mutations to purines, favors replacement mutations in CDRs.	BASEL INST IMMUNOL,CH-4002 BASEL,SWITZERLAND		REYNAUD, CA (corresponding author), UNIV PARIS 05,FAC MED NECKER ENFANTS MALAD,INST NECKER,INSERM,U373,F-75730 PARIS 15,FRANCE.		Cordier, Corinne/F-9966-2018; Hein, Wayne/E-9090-2013	Cordier, Corinne/0000-0003-4799-6143; Hein, Wayne/0000-0003-0769-6525				BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BETZ AG, 1993, IMMUNOL TODAY, V14, P405, DOI 10.1016/0167-5699(93)90144-A; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BOS NA, 1989, EUR J IMMUNOL, V19, P1811, DOI 10.1002/eji.1830191008; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; DEENEN GJ, 1993, INT IMMUNOL, V5, P735, DOI 10.1093/intimm/5.7.735; EKINO S, 1993, EUR J IMMUNOL, V23, P772, DOI 10.1002/eji.1830230331; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HEIN WR, 1989, IMMUNOLOGY, V68, P365; HEIN WR, 1990, EUR J IMMUNOL, V20, P1805, DOI 10.1002/eji.1830200827; HUETZ F, 1993, EMBO J, V12, P1819, DOI 10.1002/j.1460-2075.1993.tb05830.x; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSVERK T, 1987, IMMUNOL CELL BIOL, V65, P251, DOI 10.1038/icb.1987.28; Lawton A R 3rd, 1974, Contemp Top Immunobiol, V3, P193; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NOSSAL GJV, 1975, J EXP MED, V141, P904; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; REYNOLDS JD, 1983, EUR J IMMUNOL, V13, P627, DOI 10.1002/eji.1830130805; REYNOLDS JD, 1983, IMMUNOLOGY, V49, P501; REYNOLDS JD, 1986, J IMMUNOL, V136, P2005; REYNOLDS JD, 1976, THESIS AUSTR NATIONA; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; VIALE AC, 1992, J EXP MED, V175, P1449, DOI 10.1084/jem.175.6.1449	28	265	270	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					115	125		10.1016/0092-8674(95)90456-5	http://dx.doi.org/10.1016/0092-8674(95)90456-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813007	Bronze			2022-12-01	WOS:A1995QB91000015
J	RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ				RHIND, NR; MILLER, LM; KOPCZYNSKI, JB; MEYER, BJ			XOL-1 ACTS AS AN EARLY SWITCH IN THE C-ELEGANS MALE HERMAPHRODITE DECISION	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SEX DETERMINATION SIGNAL; X-CHROMOSOME DOSAGE; GENE-EXPRESSION; DROSOPHILA; COMPENSATION; MORPHOGEN; DOMAINS	xol-1 is the earliest-acting gene in the known hierarchy that controls C. elegans sex determination and dosage compensation. We show that the primary sex-determining signal (the WA ratio) directs the choice of sexual fate by regulating xol-1 transcript levels: high xol-1 expression during gastrulation triggers male development, whereas low expression at that time permits hermaphrodite development. Inappropriately high xol-1 expression causes hermaphrodites to activate the male program of development and die from a disruption in dosage compensation. These results demonstrate that xol-1 functions as an early developmental switch to set the choice of sexual fate and suggest that assessment of the WA ratio occurs only early in embryogenesis to determine sex. Moreover, sdc-2, a gene that must be repressed by xol-1 to ensure male development, may be a direct target of negative regulation by xol-1.			RHIND, NR (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.			Meyer, Barbara/0000-0002-6530-4588; Rhind, Nicholas/0000-0003-1758-7736	NIGMS NIH HHS [GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERIB CC, 1994, GENETICS, V138, P1105; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELOTE JM, 1983, DEV BIOL, V95, P512, DOI 10.1016/0012-1606(83)90054-4; Bull J.J., 1983, EVOLUTION SEX DETERM; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HODGES D, 1994, ADV GENET, V31, P243; HODGKIN J, 1979, GENETICS, V91, P67; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; HSU DR, 1994, GENETICS, V137, P999; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; Sambrook J., 1989, MOL CLONING LAB MANU; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VILLENEUVE AM, 1990, GENETICS, V124, P91	25	75	79	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					71	82		10.1016/0092-8674(95)90452-2	http://dx.doi.org/10.1016/0092-8674(95)90452-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813020	Bronze			2022-12-01	WOS:A1995QB91000011
J	ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A				ROY, N; MAHADEVAN, MS; MCLEAN, M; SHUTLER, G; YARAGHI, Z; FARAHANI, R; BAIRD, S; BESNERJOHNSTON, A; LEFEBVRE, C; KANG, XL; SALIH, M; AUBRY, H; TAMAI, K; GUAN, XP; IOANNOU, P; CRAWFORD, TO; DEJONG, PJ; SURH, L; IKEDA, JE; KORNELUK, RG; MACKENZIE, A			THE GENE FOR NEURONAL APOPTOSIS INHIBITORY PROTEIN IS PARTIALLY DELETED IN INDIVIDUALS WITH SPINAL MUSCULAR-ATROPHY	CELL			English	Article							WERDNIG-HOFFMANN DISEASE; LINKAGE ANALYSIS; REGION; LOCUS; 5Q13; POLYMORPHISMS; CHROMOSOME-5; BACULOVIRUS; INTERVAL; MARKERS	The spinal muscular atrophies (SMAs), characterized by spinal cord motor neuron depletion, are among the most common autosomal recessive disorders. One model of SMA pathogenesis invokes an inappropriate persistence of normally occurring motor neuron apop tosis. Consistent with this hypothesis, the novel gene for neuronal apoptosis inhibitory protein (NAIP) has been mapped to the SMA region of chromosome 5q13.1 and is homologous with baculoviral apoptosis inhibitor proteins. The two first coding exons of this gene are deleted in approximately 67% of type I SMA chromosomes compared with 2% of non-SMA chromosomes. Furthermore, RT-PCR analysis reveals internally deleted and mutated forms of the NAIP transcript in type I SMA individuals and not in unaffected individuals. These findings suggest that mutations in the NAIP locus may lead to a failure of a normally occurring inhibition of motor neuron apoptosis resulting in or contributing to the SMA phenotype.	CHILDRENS HOSP EASTERN ONTARIO, GENET MOLEC LAB, OTTAWA, ON K1H 8L1, CANADA; UNIV OTTAWA, DEPT BIOCHEM, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT PEDIAT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, IKEDA GENOSPHERE PROJECT, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT MICROBIOL, OTTAWA, ON K1H 8M5, CANADA; UNIV OTTAWA, DEPT IMMUNOL, OTTAWA, ON K1H 8M5, CANADA; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; JOHNS HOPKINS UNIV, DEPT NEUROL, BALTIMORE, MD 21205 USA; TOKAI UNIV, INST MED SCI, DEPT MED & MOLEC GENET, ISEHARA, KANAGAWA 25911, JAPAN	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Roswell Park Cancer Institute; Johns Hopkins University; Tokai University			Crawford, Thomas/E-6307-2012; Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911	CSR NIH HHS [1R01RG01165-01] Funding Source: Medline	CSR NIH HHS		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BRAHE C, 1994, HUM GENET, V93, P494, DOI 10.1007/BF00202811; BROOKE MH, 1986, CLIN VIEW NEUROMUSCU; BRZUSTOWICZ LM, 1992, GENOMICS, V13, P991, DOI 10.1016/0888-7543(92)90012-H; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; BURGHES AHM, 1994, GENOMICS, V21, P394, DOI 10.1006/geno.1994.1282; BURGHES AHM, 1994, HUM GENET, V93, P305, DOI 10.1007/BF00212028; CHEN EY, 1993, GENOMICS, V17, P651, DOI 10.1006/geno.1993.1385; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CLEM RJ, 1993, J VIROL, V67, P3730, DOI 10.1128/JVI.67.7.3730-3738.1993; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEM RJ, 1994, APOPTOSIS, V2, P89; CLERMONT O, 1994, AM J HUM GENET, V54, P687; COLLIER S, 1993, NAT GENET, V3, P260, DOI 10.1038/ng0393-260; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DIDONATO CJ, 1994, AM J HUM GENET, V55, P1218; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GILLIAM TC, 1989, GENOMICS, V5, P940, DOI 10.1016/0888-7543(89)90138-9; GLATT K, 1994, GENOMICS, V19, P157, DOI 10.1006/geno.1994.1027; GLEESON R, 1991, NUCLEIC ACIDS RES, V19, P6491; HEDRICK PW, 1987, GENETICS, V117, P331; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LIEN LL, 1991, P NATL ACAD SCI USA, V88, P7873, DOI 10.1073/pnas.88.17.7873; MACKENZIE A, 1993, HUM GENET, V90, P501; MCLEAN MD, 1994, HUM MOL GENET, V3, P1951; MELKI J, 1990, NATURE, V344, P767, DOI 10.1038/344767a0; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982; MURAYAMA S, 1991, ACTA NEUROPATHOL, V81, P408, DOI 10.1007/BF00293462; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PERESS NS, 1986, CLIN NEUROPATHOL, V5, P69; Podolsky L., 1994, American Journal of Human Genetics, V55, pA161; ROY N, 1995, IN PRESS GENOMICS; SARNAT HB, 1983, PROGR SPINAL MUSCULA, P91; SHETH P, 1991, AM J HUM GENET, V48, P764; SOARES VM, 1993, GENOMICS, V15, P365, DOI 10.1006/geno.1993.1069; THOMPSON TG, 1993, HUM MOL GENET, V2, P1169, DOI 10.1093/hmg/2.8.1169; TOWFIGHI J, 1985, ACTA NEUROPATHOL, V65, P270, DOI 10.1007/BF00687008; WEDELL A, 1993, HUM GENET, V91, P236; WIRTH B, 1993, GENOMICS, V15, P113, DOI 10.1006/geno.1993.1018; WIRTH B, 1994, GENOMICS, V20, P84, DOI 10.1006/geno.1994.1130; [No title captured]; [No title captured]	53	825	869	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 13	1995	80	1					167	178		10.1016/0092-8674(95)90461-1	http://dx.doi.org/10.1016/0092-8674(95)90461-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813013	hybrid			2022-12-01	WOS:A1995QB91000020
J	SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D				SERRANO, M; GOMEZLAHOZ, E; DEPINHO, RA; BEACH, D; BARSAGI, D			INHIBITION OF RAS-INDUCED PROLIFERATION AND CELLULAR-TRANSFORMATION BY P16(INK4)	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CYCLIN-DEPENDENT KINASES; C-MYC; ADENOVIRUS E1A; PROTEIN; BINDING; G(1); P21; PHOSPHORYLATION; FIBROBLASTS	The cyclin-dependent kinase 4 (CDK4) regulates progression through the G(1) phase of the cell cycle. The activity of CDK4 is controlled by the opposing effects of the D-type cyclin, an activating subunit, and p16(INK4), inhibitory subunit. Ectopic expression of p16(INK4) blocked entry into S phase of the cell cycle induced by oncogenic Ha-Ras, and this block was relieved by coexpression of a catalytically inactive CDK4 mutant. Expression of p16(INK4) suppressed cellular transformation of primary rat embryo fibroblasts by oncogenic Ha-Ras and Myc, but not by Ha-Ras and E1a. Together, these observations provide direct evidence that p16(INK4) inhibit cell growth.	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; ALBERT EINSTEIN COLL MED,DEPT IMMUNOL & MICROBIOL,NEW YORK,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MED,NEW YORK,NY 10461	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Yeshiva University; Yeshiva University			Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; Bar-Sagi, Dafna/0000-0003-2597-8948; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA55360] Funding Source: Medline; NEI NIH HHS [EY09300-01] Funding Source: Medline; NICHD NIH HHS [HD28317-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA055360, R37CA055360] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZLAHOZ E, UNPUB; GOMEZLAHOZ E, 1994, P NATL ACAD SCI USA, V91, P5503; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HARPER JW, 1993, CELL, V75, P805; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUKAS J, 1994, ONCOGENE, V9, P707; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAM SW, 1994, CANCER RES, V54, P5816; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	418	440	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 13	1995	267	5195					249	252		10.1126/science.7809631	http://dx.doi.org/10.1126/science.7809631			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7809631				2022-12-01	WOS:A1995QB15300039
J	SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD				SVEJSTRUP, JQ; WANG, ZG; FEAVER, WJ; WU, XH; BUSHNELL, DA; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD			DIFFERENT FORMS OF TFIIH FOR TRANSCRIPTION AND DNA-REPAIR - HOLO-TFIIH AND A NUCLEOTIDE EXCISION REPAIROSOME	CELL			English	Article							RNA POLYMERASE-II; FACTOR-B; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CTD KINASE; DHFR GENE; YEAST; PURIFICATION; RECOMBINATION; DOMAIN	Yeast TFIIH that is active in transcription can be dissociated into three components: a 5-subunit core, the SSL2 gene product, and a complex of 47 kDa, 45 kDa, and 33 kDa polypeptides that possesses protein kinase activity directed towards the C-terminal repeat domain of RNA polymerase II. These three components can reconstitute fully functional TFIIH, and all three are required for transcription in vitro. By contrast, TFIIH that is highly active in nucleotide excision repair (NER) lacks the kinase complex and instead contains the products of all other genes known to be required for NER in yeast: RAD1, RAD2, RAD4, RAD10, and RAD14. This repairosome is not active in reconstituted transcription in vitro and is significantly more active than any of the constituent polypeptides in correcting defective repair in extracts from strains mutated in NER genes.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305; UNIV TEXAS,SW MED CTR,DEPT PATHOL,MOLEC PATHOL LAB,DALLAS,TX 75235; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington				Svejstrup, Jesper/0000-0003-4964-6147	NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032263, R37GM036659, R01GM036659] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM36659, GM32263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NAEGELI H, 1992, BIOCHEMISTRY-US, V32, P613; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; Qui H., 1993, GENE DEV, V7, P2161; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; SUNG P, 1984, P NATL ACAD SCI USA, V84, P8951; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; VANGOOL AJ, 1994, IN PRESS EMBO J; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907	55	248	252	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 13	1995	80	1					21	28		10.1016/0092-8674(95)90447-6	http://dx.doi.org/10.1016/0092-8674(95)90447-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QB910	7813015	Bronze			2022-12-01	WOS:A1995QB91000006
J	VONAHSEN, U; NOLLER, HF				VONAHSEN, U; NOLLER, HF			IDENTIFICATION OF BASES IN 16S-RIBOSOMAL RNA ESSENTIAL FOR TRANSFER-RNA BINDING AT THE 30S-RIBOSOMAL P-SITE	SCIENCE			English	Article							ANTICODON INTERACTION SITE; TRANSFER-RNA; SUBUNIT; LOCALIZATION; CROSSLINKING; NUCLEOTIDES	Previous studies suggest that the mechanism of action of the ribosome in translation involves crucial transfer RNA (tRNA)-ribosomal RNA (rRNA) interactions. Here, a selection scheme was developed to identify bases in 16S rRNA that are essential for tRNA binding to the P site of the small (30S) ribosamal subunit. Modification of the N-1 and N-2 positions of 2-methylguanine 966 and of the N-7 position of guanine 1401 interfered with messenger RNA (mRNA)-dependent binding of tRNA to the P site. Modification of the same positions as well as of the N-1 and N-2 positions of guanine 926 interfered with mRNA-independent binding of tRNA at high magnesium ion concentration. These results suggest that these three bases are involved in intermolecular contacts between ribosomes and tRNA.	UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA	University of California System; University of California Santa Cruz					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P7629, DOI 10.1021/bi00148a026; DENMAN R, 1988, NUCLEIC ACIDS RES, V16, P165, DOI 10.1093/nar/16.1.165; GORNICKI P, 1984, J BIOL CHEM, V259, P493; GRAJEVSKAJA RA, 1973, FEBS LETT, V33, P11, DOI 10.1016/0014-5793(73)80147-4; HERR W, 1979, J MOL BIOL, V130, P433, DOI 10.1016/0022-2836(79)90433-9; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3021, DOI 10.1093/nar/21.13.3021; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1972, P NATL ACAD SCI USA, V69, P3115, DOI 10.1073/pnas.69.11.3115; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; VONAHSEN U, UNPUB; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0	18	103	105	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 13	1995	267	5195					234	237		10.1126/science.7528943	http://dx.doi.org/10.1126/science.7528943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB153	7528943				2022-12-01	WOS:A1995QB15300034
J	BULLITT, E; MAKOWSKI, L				BULLITT, E; MAKOWSKI, L			STRUCTURAL POLYMORPHISM OF BACTERIAL ADHESION PILI	NATURE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; SUBUNIT; IMAGES; PROTEINS; FLAGELLA; TIP	BACTERIAL adhesion pill are designed to bind specifically and maintain attachment of bacteria to target cells. Uropathogenic P-pili are sufficiently mechanically resilient to resist the cleansing action of urine flow that removes most other bacteria(1). P-pili are 68 Angstrom in diameter and similar to 1 mu m long(2), and are composed of similar to 1,000 copies of the principal structural protein, PapA(3). They are attached to the outer membrane by a minor structural protein, PapH(4) and are terminated by an similar to 20 Angstrom diameter fibrillus composed of PapK, PapE and PapF, which presents the host-binding adhesin PapG(5-7). The amino-acid sequences of PapA(3,8), PapE(9), and PapF(9) are similar, with highly conserved C-termini being responsible for binding to PapD(10-12), the periplasmic chaperone. Our three-dimensional reconstruction indicates that pill are formed by the tight winding of a much thinner structure. A structural transition allows the pilus to unravel without depolymerizing, producing a thin, extended structure five times the length of the original pilus.	FLORIDA STATE UNIV, INST MOLEC BIOPHYS, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University	BULLITT, E (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOPHYS, BOSTON, MA 02118 USA.							AMOS LA, 1975, J MOL BIOL, V99, P51, DOI 10.1016/S0022-2836(75)80158-6; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BAGA M, 1984, J BACTERIOL, V157, P330; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; CALLADINE CR, 1978, J MOL BIOL, V118, P457, DOI 10.1016/0022-2836(78)90285-1; DENICH K, 1991, INFECT IMMUN, V59, P3849, DOI 10.1128/IAI.59.11.3849-3858.1991; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; EGELMAN EH, 1986, ULTRAMICROSCOPY, V19, P367, DOI 10.1016/0304-3991(86)90096-3; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; HULTGREN SJ, 1993, ADV PROTEIN CHEM, V44, P99, DOI 10.1016/S0065-3233(08)60565-3; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; KAMIYA R, 1976, J MOL BIOL, V106, P167, DOI 10.1016/0022-2836(76)90306-5; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LINDBERG F, 1987, NATURE, V328, P84, DOI 10.1038/328084a0; LINDBERG F, 1986, P NATL ACAD SCI USA, V83, P1891, DOI 10.1073/pnas.83.6.1891; MACNAB RM, 1977, J MOL BIOL, V112, P1, DOI 10.1016/S0022-2836(77)80153-8; MAKOWSKI L, 1992, J MOL BIOL, V228, P885, DOI 10.1016/0022-2836(92)90872-H; MARKLUND BI, 1992, J BACTERIOL, V157, P330; MORGAN DG, 1992, ULTRAMICROSCOPY, V46, P263, DOI 10.1016/0304-3991(92)90019-G; ORSKOV I, 1980, INFECT IMMUN, V27, P657, DOI 10.1128/IAI.27.2.657-666.1980; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x	24	180	195	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	1995	373	6510					164	167		10.1038/373164a0	http://dx.doi.org/10.1038/373164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816100				2022-12-01	WOS:A1995QB06300063
J	EILERS, J; AUGUSTINE, GJ; KONNERTH, A				EILERS, J; AUGUSTINE, GJ; KONNERTH, A			SUBTHRESHOLD SYNAPTIC CA2+ SIGNALING IN FINE DENDRITES AND SPINES OF CEREBELLAR PURKINJE NEURONS	NATURE			English	Article							GLUTAMATE-RECEPTOR CHANNELS; CENTRAL-NERVOUS-SYSTEM; CALCIUM TRANSIENTS; CELLS; CURRENTS; INVITRO; ACTIVATION; SLICES	THE conventional view of synaptic integration is that it results from the simple summation of electrical signals produced by each active synapse innervating a given neuron(1). However, because synaptic action can go beyond the production of postsynaptic electrical signals, to include intracellular biochemical events such as the generation of second messengers, it is possible that synaptic integration could occur at another level(2). We have considered this possibility by examining changes in the dendritic concentration of the second messenger, calcium, resulting from subthreshold excitatory synaptic activity in cerebellar Purkinje neurons. We report here clear evidence that such non-electrical synaptic integration occurs and that it takes place in restricted dendritic compartments consisting of spines and adjacent fine dendrites.	UNIV SAARLAND,INST PHYSIOL 1,D-66421 HOMBURG,GERMANY; DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Saarland University; Duke University			Augustine, George James/J-9228-2013; Eilers, Jens/E-6251-2012	Eilers, Jens/0000-0003-0497-5625				ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; ECCLES JC, 1964, PHYSL SYNAPSES, V4, P101; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Eilers Jens, 1995, P213; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M, 1991, Curr Opin Neurobiol, V1, P616, DOI 10.1016/S0959-4388(05)80038-8; ITO M, 1984, CEREBELLUM NEURAL CO, P36; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LLINAS R, 1976, P NATL ACAD SCI USA, V73, P2520, DOI 10.1073/pnas.73.7.2520; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS RR, 1990, SYNAPTIC ORG BRAIN, P214; MIDTGAARD J, 1993, J NEUROPHYSIOL, V70, P2455, DOI 10.1152/jn.1993.70.6.2455; MIYAKAWA H, 1992, J NEUROPHYSIOL, V68, P1178, DOI 10.1152/jn.1992.68.4.1178; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; PALAY SL, 1974, CEREBELLAR CORTEX, P79; ROSS WN, 1987, J PHYSIOL-LONDON, V389, P319, DOI 10.1113/jphysiol.1987.sp016659; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; SUGIMORI M, 1990, P NATL ACAD SCI USA, V87, P5084, DOI 10.1073/pnas.87.13.5084; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	29	235	239	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					155	158		10.1038/373155a0	http://dx.doi.org/10.1038/373155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816097				2022-12-01	WOS:A1995QB06300060
J	GODFREY, J				GODFREY, J			THE POPE AND THE ONTOGENY OF PERSONS	NATURE			English	Editorial Material									UNIV EDINBURGH,CTR HUMAN ECOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND	University of Edinburgh								AQUINAS T, SOMME THEOLOGIQUE; JOHNPAUL II, CROSSING THRESHOLD H; 1994, NATURE, V371, P185	3	23	23	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					100	100		10.1038/373100a0	http://dx.doi.org/10.1038/373100a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7646629	Bronze			2022-12-01	WOS:A1995QB06300026
J	GRIMES, J; BASAK, AK; ROY, P; STUART, D				GRIMES, J; BASAK, AK; ROY, P; STUART, D			THE CRYSTAL-STRUCTURE OF BLUETONGUE VIRUS VP7	NATURE			English	Article							CORE-LIKE PARTICLES; RESOLUTION; PROTEIN; SURFACE	BLUETONGUE virus (BTV), a representative of the orbivirus genus of the Reoviridae, is considerably larger (at 80 nm across), and structurally more complex, than any virus for which we have comprehensive structural information. Orbiviruses infect mammalian hosts through insect vectors and cause economically important diseases of domesticated animals(1). They possess a segmented double-stranded RNA genome within a capsid composed of four major types of polypeptide chains(1). An outer layer of VP2 and VP5 is removed as the virus enters the target cell, to leave an intact core within the cell. This fore is 70 nm across and composed of 78O copies of VP7 (M(r) 38K) that, as trimers, form 260 'bristly' capsomeres clothing an inner scaffold constructed from VP3 (M(r)103K)(2). We report here the crystal structure of VP7 from BTV serotype 10, which reveals a molecular architecture not seen previously in viral structural proteins. Each subunit consists of two domains, one a beta-sandwich, the other a bundle of alpha-helices, and a short carboxy-terminal arm which might tie trimers together during capsid formation. A concentration of methionine residues at the core of the molecule could provide plasticity, relieving structural mismatches during assembly.	OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham	GRIMES, J (corresponding author), UNIV OXFORD,MOLEC BIOPHYS LAB,REX RICHARDS BLDG,S PARKS RD,OXFORD OX1 3QU,ENGLAND.			Grimes, Jonathan Mark/0000-0001-9698-0389; Roy, Polly/0000-0001-6535-6911; Stuart, David/0000-0002-3426-4210				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, XPLOR VERSION 3 0; Creighton T.E., 1993, PROTEINS; EATON BT, 1991, VIROLOGY, V180, P687, DOI 10.1016/0042-6822(91)90082-M; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HEWAT EA, 1992, VIROLOGY, V189, P10, DOI 10.1016/0042-6822(92)90676-G; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KNUDSON EL, 1990, VIROLOGY, P1405; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEBLOIS H, 1993, J VIROL, V67, P353, DOI 10.1128/JVI.67.1.353-359.1993; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LOGAN D, 1993, NATURE, V362, P566, DOI 10.1038/362566a0; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MERTENS PPC, 1993, INFECTION CULICOIDES; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1983, J MOL BIOL, V165, P711, DOI 10.1016/S0022-2836(83)80276-9; ROY R, 1990, BLUETONGUE VIRUS, P43; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WISTOW G, 1983, J MOL BIOL, V170, P175, DOI 10.1016/S0022-2836(83)80232-0	30	137	147	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					167	170		10.1038/373167a0	http://dx.doi.org/10.1038/373167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816101				2022-12-01	WOS:A1995QB06300064
J	HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M				HO, DD; NEUMANN, AU; PERELSON, AS; CHEN, W; LEONARD, JM; MARKOWITZ, M			RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION	NATURE			English	Article							CELLS; AIDS; INDIVIDUALS; PCR	Treatment of infected patients with ABT-538, an inhibitor of the protease of human immunodeficiency virus type 1 (HIV-1), causes plasma HIV-1 levels to decrease exponentially (mean half-life, 2.1 +/- 0.4 days) and CD4 lymphocyte counts to rise substantially. Minimum estimates of HIV-1 production and clearance and of CD4 lymphocyte turnover indicate that replication of HIV-1 in vivo is continuous and highly productive, driving the rapid turnover of CD4 lymphocytes.	SANTA FE INST,SANTA FE,NM 87501; LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory; Abbott Laboratories	HO, DD (corresponding author), NYU,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016, USA.		Perelson, Alan S/Z-1959-2019	Perelson, Alan S/0000-0002-2455-0002				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CAO Y, IN PRESS AIDS RES HU; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRODY WW, 1985, AM J CLIN PATHOL, V84, P85, DOI 10.1093/ajcp/84.1.85; HAASE AT, 1994, ANN NY ACAD SCI, V724, P75, DOI 10.1111/j.1749-6632.1994.tb38897.x; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KEMPF D, IN PRESS P NATN ACAD; MARKOWITZ M, IN PRESS J VIROL; PACHL C, IN PRESS J AIDS; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PAUL WE, 1985, FUNDAMENTAL IMMUNOLO; PERELSON AS, 1993, MATH BIOSCI, V114, P81, DOI 10.1016/0025-5564(93)90043-A; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; WAINHOBSON S, 1993, NATURE, V366, P22, DOI 10.1038/366022b0; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571	20	3707	3789	3	231	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					123	126		10.1038/373123a0	http://dx.doi.org/10.1038/373123a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816094				2022-12-01	WOS:A1995QB06300049
J	JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ				JO, SA; ZHU, XJ; MARCHIONNI, MA; BURDEN, SJ			NEUREGULINS ARE CONCENTRATED AT NERVE-MUSCLE SYNAPSES AND ACTIVATE ACH-RECEPTOR GENE-EXPRESSION	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SUBUNIT GENE; TRANSGENIC MICE; EPSILON-SUBUNIT; BASAL LAMINA; FAMILY; PROTEIN; MEMBER; NEU; HER4/P180(ERBB4)	Two different signalling pathways mediate the localization of acetylcholine receptors (AChRs) to synaptic sites in skeletal muscle. The signal for one pathway is agrin, a protein that triggers a redistribution of previously unlocalized cell surface AChRs to synaptic sites(1). The signal for the other pathway is not known, but this signal stimulates transcription of AChR genes in myofibre nuclei near the synaptic site(2). Neuregulins, identified originally as a potential ligand for erbB2 (Neu differentiation factor, NDF)(3), stimulate proliferation of Schwann cells (glial growth factor, GGF)(4), increase the rate of AChR synthesis in cultured muscle cells (AChR-inducing activity)(5) and are expressed in motor neurons(4,5). These results raise the possibility that neuregulin is the signal that activates AChR genes in synaptic nuclei. Here we show that neuregulin activates AChR gene expression in C2 muscle cells and that the neuregulin response element in the AChR delta-subunit gene is contained in the same 181 base pairs that confer synapse-specific expression in transgenic mice. We use antibodies to show that neuregulins are concentrated at synaptic sites and that, like the extracellular signal that stimulates synapse-specific expression, neuregulins remain at synaptic sites in the absence of nerve and muscle. We show that C2 muscle cells contain erbB2 and erbB3 messenger RNA but little or no erbB4 mRNA, and that neuregulin stimulates tyrosine phosphorylation of erbB2 and erbB3, indicating that neuregulin signalling in skeletal muscle may be mediated by a complex of erbB2 and erbB3.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; CAMBRIDGE NEUROSCI INC,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	JO, SA (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,200 LONGWOOD AVE,BOSTON,MA 02115, USA.			Burden, Steven/0000-0002-3550-6891				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1993, TRENDS GENET, V9, P12, DOI 10.1016/0168-9525(93)90066-Q; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1992, DEVELOPMENT, V115, P673; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SIMON AM, 1992, DEVELOPMENT, V114, P545; TANG JC, 1994, DEVELOPMENT, V120, P1799; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	28	243	252	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					158	161						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816098				2022-12-01	WOS:A1995QB06300061
J	LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR				LOMBILLO, VA; STEWART, RJ; MCINTOSH, JR			MINUS-END-DIRECTED MOTION OF KINESIN-COATED MICROSPHERES DRIVEN BY MICROTUBULE DEPOLYMERIZATION	NATURE			English	Article							CYTOPLASMIC DYNEIN; MITOTIC SPINDLE; MOVEMENT; IDENTIFICATION; MICROSCOPY; INVITRO; PROTEIN	DYNAMIC changes in microtubule (MT) length have long been thought to contribute to intracellular motility(1). Both the polymerization(2) and depolymerization(3-5) of tubulin have been shown to do work in vitro, but the biochemical complexity of objects moved, such as chromosomes, has complicated the identification of proteins that couple MT dynamics with motility. Work with MTs grown from and tethered to pellicles of lysed Tetrahymena has shown that disassembly-dependent movement of chromosomes in vitro can be inhibited with antibodies against the motor domain of kinesin(6). To study proteins that can function in disassembly-dependent motion, we have refined this motility assay, replacing chromosomes with protein-coated latex microspheres. We report here the ability of several enzymes, including kinesin, to support in vitro motility of latex microspheres on disassembling Mts (Fig. 1a). The polarity of kinesin's motor activity can be reversed by MT disassembly and interactions between a motor and a MT end can either slow or speed the rate of tubulin depolymerization.	UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; ROWLAND INST SCI INC,CAMBRIDGE,MA 02142	University of Colorado System; University of Colorado Boulder			McIntosh, Richard/GLN-3533-2022					COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LOMBILLO VA, IN PRESS J CELL BIOL; LOMBILLO VA, 1993, METHOD CELL BIOL, V39, P148; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MIYAMOTO H, 1988, P TANAGUICHI INT S, V14, P220; PORTER ME, 1988, J BIOL CHEM, V263, P6759; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437	16	164	166	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					161	164		10.1038/373161a0	http://dx.doi.org/10.1038/373161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816099				2022-12-01	WOS:A1995QB06300062
J	SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M				SAKIMURA, K; KUTSUWADA, T; ITO, I; MANABE, T; TAKAYAMA, C; KUSHIYA, E; YAGI, T; AIZAWA, S; INOUE, Y; SUGIYAMA, H; MISHINA, M			REDUCED HIPPOCAMPAL LTP AND SPATIAL-LEARNING IN MICE LACKING NMDA RECEPTOR EPSILON-1 SUBUNIT	NATURE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; CHANNEL; CLONING; ANTAGONIST; EXPRESSION; MODULATION; NEURONS	THE NMDA (N-methyl-D-aspartate) receptor channel is important for synaptic plasticity, which is thought to underlie learning, memory and development(1,2). The NMDA receptor channel is formed by at least two members of the glutamate receptor (GluR) channel subunit families, the GluR epsilon (NR2) and GluR zeta (NR1) subunit families(3-8). The four epsilon subunits are distinct in distribution, properties and regulation(5-14). On the basis of the Mg2+ sensitivity and expression patterns, we have proposed that the epsilon 1 (NR2A) and epsilon 2 (NR2B) subunits play a role in synaptic plasticity(6,14). Here we show that targeted disruption of the mouse epsilon 1 subunit gene resulted in significant reduction of the NMDA receptor channel current and long-term potentiation at the hippocampal CA1 synapses. The mutant mice also showed a moderate deficiency in spatial learning. These results support the notion that the NMDA receptor channel-dependent synaptic plasticity is the cellular basis of certain forms of learning.	UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; Kyushu University; University of Tokyo; Hokkaido University; RIKEN								ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DAVIS S, 1992, J NEUROSCI, V12, P21; GRANT SG, 1992, SCIENCE, V259, P1903; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; ISHII T, 1993, J BIOL CHEM, V268, P2836; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1993, NEUROREPORT, V4, P519, DOI 10.1097/00001756-199305000-00014; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATANABE M, 1993, J COMP NEUROL, V338, P337; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHANG YX, 1994, BRAIN RES, V658, P127, DOI 10.1016/S0006-8993(09)90018-X	30	659	679	1	41	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					151	155		10.1038/373151a0	http://dx.doi.org/10.1038/373151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816096				2022-12-01	WOS:A1995QB06300059
J	SPRAY, JG; THOMPSON, LM				SPRAY, JG; THOMPSON, LM			FRICTION MELT DISTRIBUTION IN A MULTIRING IMPACT BASIN	NATURE			English	Article							SUDBURY STRUCTURE; VREDEFORT DOME; COESITE	IT is generally accepted that multi-ring basins are the consequence of very large impacts, but the mechanism by which they form is still a matter of contention(1,2). Most of what is currently known about multi-ring basins is based on remote studies of the Moon(3-5) and, to a lesser extent, Mars and Mercury(4,6). But at least two multi-ring impact basins have been recognized on Earth(7)-the Sudbury(8) (Canada) and Vredefort(9) (South Africa) impact structures-providing an opportunity to study their properties directly. Here we describe the distribution of friction melt (pseudotachylyte) in the floor of the Sudbury impact basin. Although the veins and dykes of pseudotachylyte decrease in both thickness and frequency of occurrence towards the basin periphery, the greatest volumes of friction melt appear to define four rings around the central impact melt sheet. Field evidence indicates that the rings originated as zones of large displacement, which facilitated localized frictional melting of the basin floor during the modification (collapse) stage of the cratering process. By analogy, we argue that the rings of other multi-ring impact basins are also likely to be the remnants of such large-displacement fault zones.			SPRAY, JG (corresponding author), UNIV NEW BRUNSWICK,DEPT GEOL,FREDERICTON,NB E3B 5A3,CANADA.		Spray, John/J-7504-2013	Spray, John/0000-0003-3418-6862				Baldwin R. B., 1972, Physics of the Earth and Planetary Interiors, V6, P327, DOI 10.1016/0031-9201(72)90056-8; Baldwin R. B., 1963, MEASURE MOON, P488; BUTLER HR, IN PRESS LARGE METEO; CHUBB PT, IN PRESS CAN J EARTH; Dence M.R., 1977, IMPACT EXPLOSION CRA, P247; DENCE MR, 1972, SPEC PAP GEOL ASS CA, V10, P7; DIETZ RS, 1964, J GEOL, V72, P412, DOI 10.1086/626999; Dressler B.O., 1984, ONT GEOL SURV SPEC, V1, P97; Dressler B.O., 1987, RES TERRESTRIAL IMPA, P39; DRESSLER BO, 1984, GEOL ORE DEPOSIT+, P97; DRESSLER BO, 1980, 196 ONT MIN NAT RES; FAGGART BE, 1985, SCIENCE, V230, P436, DOI 10.1126/science.230.4724.436; Grieve R. B., 1981, Proceedings of the Heartworm Symposium '80, Dallas, Texas, 23-24 February 1980., P37; GRIEVE RAF, 1991, J GEOPHYS RES-PLANET, V96, P22753, DOI 10.1029/91JE02513; Hartmann W. K., 1971, Moon, V3, P3, DOI 10.1007/BF00620390; Hartmann W.K., 1962, COMMUN LUNAR PLANET, V1, P51; HARTMANN WK, 1969, SKY TELESCOPE, V37, P4; HODGES CA, 1978, ICARUS, V34, P294, DOI 10.1016/0019-1035(78)90169-0; LAMBERT P, 1981, P LUNAR PLANET SCI, V12, P59; MARTINI JEJ, 1992, J METAMORPH GEOL, V10, P517, DOI 10.1111/j.1525-1314.1992.tb00102.x; MARTINI JEJ, 1991, EARTH PLANET SC LETT, V103, P285, DOI 10.1016/0012-821X(91)90167-G; Melosh H.J., 1989, IMPACT CRATERING GEO; MELOSH HJ, 1978, GEOPHYS RES LETT, V5, P985, DOI 10.1029/GL005i011p00985; MELOSH HJ, 1979, J GEOPHYS RES, V84, P7513, DOI 10.1029/JB084iB13p07513; MILKEREIT B, 1992, GEOLOGY, V20, P807, DOI 10.1130/0091-7613(1992)020<0807:DGOTSS>2.3.CO;2; PEREDERY WV, 1984, GEOLOGY ORE DEPOSITS, P491; PIKE RJ, 1987, EARTH MOON PLANETS, V39, P129, DOI 10.1007/BF00054060; Shand SJ., 1916, Q J GEOL SOC, V72, P198, DOI DOI 10.1144/GSL.JGS.1916.072.01-04.12; SHANKS WS, 1991, CAN J EARTH SCI, V28, P1677, DOI 10.1139/e91-149; SPEERS EC, 1947, J GEOL, V65, P497; SPRAY JG, 1993, J GEOPHYS RES-SOL EA, V98, P8053, DOI 10.1029/93JB00020; SPRAY JG, 1992, TECTONOPHYSICS, V204, P205, DOI 10.1016/0040-1951(92)90308-S; SPRAY JG, 1987, J STRUCT GEOL, V7, P49; SPUDIS PD, 1993, GEOLOGY MULTIRING IM, P263; THOMPSON LM, 1993, EOS, V74, P389; WICHMAN RW, 1993, METEORITICS, V28, P222, DOI 10.1111/j.1945-5100.1993.tb00760.x; Wood C.A., 1976, P LUNAR PLANET SCI C, P3629	37	116	117	1	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					130	132		10.1038/373130a0	http://dx.doi.org/10.1038/373130a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7816095				2022-12-01	WOS:A1995QB06300051
J	WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM				WEI, XP; GHOSH, SK; TAYLOR, ME; JOHNSON, VA; EMINI, EA; DEUTSCH, P; LIFSON, JD; BONHOEFFER, S; NOWAK, MA; HAHN, BH; SAAG, MS; SHAW, GM			VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION	NATURE			English	Article							PRIMARY HIV-1 INFECTION; POLYMERASE CHAIN-REACTION; REVERSE-TRANSCRIPTASE; MESSENGER-RNA; PLASMA; VIREMIA; DISEASE; DNA; INDIVIDUALS; RESISTANT	The dynamics of HIV-1 replication in vivo are largely unknown yet they are critical to our understanding of disease pathogenesis. Experimental drugs that are potent inhibitors of viral replication can be used to show that the composite lifespan of plasma virus and virus-producing cells is remarkably short (half-life similar to 2 days). Almost complete replacement of wild-type virus in plasma by drug-resistant variants occurs after fourteen days, indicating that HIV-1 viraemia is sustained primarily by a dynamic process involving continuous rounds of de novo virus infection and replication and rapid cell turnover.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486; MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; GENELABS TECHNOL INC,DIV HIV & EXPLORATORY RES,REDWOOD CITY,CA 94063; UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Merck & Company; Merck & Company; University of Oxford			Yang, Chen/G-1379-2010; Nowak, Martin A/A-6977-2008; Bonhoeffer, Sebastian/A-2735-2008	Bonhoeffer, Sebastian/0000-0001-8052-3925; Hahn, Beatrice/0000-0002-9400-9887; Ghosh, Sajal/0000-0002-1187-6994	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263; BAGNARELLI P, 1994, J VIROL, V68, P2495, DOI 10.1128/JVI.68.4.2495-2502.1994; BAGNARELLI P, 1992, J VIROL, V66, P7328, DOI 10.1128/JVI.66.12.7328-7335.1992; BALZARINI J, 1994, P NATL ACAD SCI USA, V91, P6599, DOI 10.1073/pnas.91.14.6599; CAO Y, IN PRESS AIDS RES HU; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KEMPF D, IN PRESS P NATN ACAD; LARDER BA, 1993, NATURE, V365, P671, DOI 10.1038/365671a0; MCLEAN AR, 1992, AIDS, V6, P71, DOI 10.1097/00002030-199201000-00009; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MYEERS GK, 1993, HUMAN RETROVIRUSES A; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PATTERSON BK, 1993, SCIENCE, V260, P976, DOI 10.1126/science.8493534; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRASAD VR, 1989, J BIOL CHEM, V284, P16689; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SIMMONDS P, 1991, J VIROL, V65, P6266, DOI 10.1128/JVI.65.11.6266-6276.1991; SMITH MS, 1993, J INFECT DIS, V167, P445, DOI 10.1093/infdis/167.2.445; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993; ZHANG YM, 1994, J VIROL, V68, P425, DOI 10.1128/JVI.68.1.425-432.1994	44	2878	2946	4	210	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 12	1995	373	6510					117	122		10.1038/373117a0	http://dx.doi.org/10.1038/373117a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QB063	7529365				2022-12-01	WOS:A1995QB06300048
J	CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE				CALVIN, JE; KLEIN, LW; VANDENBERG, BJ; MEYER, P; CONDON, JV; SNELL, RJ; RAMIREZMORGEN, LM; PARRILLO, JE			RISK STRATIFICATION IN UNSTABLE ANGINA - PROSPECTIVE VALIDATION OF THE BRAUNWALD CLASSIFICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; INTRAVENOUS NITROGLYCERIN; PECTORIS; PROPRANOLOL; THERAPY; MODELS	Objectives.-To validate the Braunwald classification of unstable angina as a predictor of in-hospital cardiac complications; to determine which factors of the Braunwald classification contributed significantly to this prediction; and to devise a method of combining these predictive factors into an overall odds ratio for complications. Design.-A validation cohort of consecutive patients followed prospectively for in-hospital cardiac complications including myocardial infarction and death. Setting.-A community-based academic medical center. Patients.-A total of 393 patients admitted consecutively to the coronary care and intermediate care units with unstable angina. Main Outcome Measures.-Major cardiac complications including death, myocardial infarction, congestive heart failure, cardiogenic shock, and severe ventricular dysrhythmias. Results.-Multiple logistic regression analysis identified four clinical factors used in the Braunwald classification that predicted the in-hospital occurrence of major cardiac complications: (1) myocardial infarction within less than 14 days (odds ratio [OR], 5.72; 95% confidence interval [CI], 1.92 to 16.97); (2) need for intravenous nitroglycerin (OR, 2.33; 95% CI, 1.31 to 4.17); (3) lack of beta-blocker or calcium channel blocker prior to admission (OR, 3.83; 95% CI, 1.55 to 9.42); and (4) baseline ST depression (OR, 2.81; 95% CI, 1.45 to 5.47). Two other clinical factors, diabetes and age, were also significant predictors. Validation of this model using parametric and nonparametric bootstrap techniques revealed excellent agreement between the CIs for adjusted ORs derived from the multiple logistic regression and those derived from the bootstrap. Conclusions.-The classification of unstable angina proposed by Braunwald includes four factors that predict risk of major in-hospital cardiac complications. Specific factors used in this classification can be combined with diabetes and age to better stratify risk of major cardiac complications in this disorder using a simpler model.			CALVIN, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CARDIOL SECT,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.							BERTOLASI CA, 1976, CHEST, V70, P596, DOI 10.1378/chest.70.5.596; BERTOLET BD, 1993, CLIN CARDIOL, V16, P116, DOI 10.1002/clc.4960160207; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRAUNWALD E, 1994, 940602 US DEP HLTH H; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALVIN JE, 1994, CLIN RES, V42, pA248; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN M, 1991, AM J CARDIOL, V67, P1368, DOI 10.1016/0002-9149(91)90467-Y; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CURFMAN GD, 1983, CIRCULATION, V67, P276, DOI 10.1161/01.CIR.67.2.276; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FREEMAN MR, 1989, AM HEART J, V117, P306, DOI 10.1016/0002-8703(89)90773-4; FUCHS J, 1990, EUR HEART J, V11, P1029, DOI 10.1093/oxfordjournals.eurheartj.a059630; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERWITZ H, 1979, CIRCULATION, V59, P707; GLANTZ SA, 1990, PRIMER APPLIED REGRE, P512; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; KAPLAN K, 1983, AM J CARDIOL, V51, P694, DOI 10.1016/S0002-9149(83)80117-9; MURPHY JJ, 1992, BRIT HEART J, V67, P395; NEUMANN FJ, 1989, BRIT HEART J, V62, P421; NORRIS RM, 1978, LANCET, V2, P907; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; WACKERS FJT, 1978, CIRCULATION, V57, P738, DOI 10.1161/01.CIR.57.4.738; 1986, BRIT HEART J, V56, P400	28	125	128	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					136	141						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799494				2022-12-01	WOS:A1995PZ68700027
J	LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH				LITWIN, MS; HAYS, RD; FINK, A; GANZ, PA; LEAKE, B; LEACH, GE; BROOK, RH			QUALITY-OF-LIFE OUTCOMES IN MEN FOR LOCALIZED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL PROSTATECTOMY; RADIATION-THERAPY; CARCINOMA; STAGE; ADENOCARCINOMA; PAIN	Objective.-To assess health-related quality of life (HRQOL) in men treated for clinically localized prostate cancer. Design.-A cross-sectional analysis of HRQOL after treatment with radical prostatectomy, pelvic irradiation, or observation alone for clinically localized prostatic adenocarcinoma, and in age-matched comparison patients. Setting.-A large managed care population in California. Subjects.-A total of 528 men, including 214 treated for clinically localized prostate cancer (41 with evidence of metastatic disease were excluded from this analysis) and 273 age-matched, ZIP code-matched comparison patients without prostate cancer. Cancer patients were analyzed in three treatment groups: radical prostatectomy (n=98), primary pelvic irradiation (n=56), and observation alone (n=60). Main Outcome Measures.-General HRQOL was measured with the RAND 36-item Health Survey 1.0. Cancer-specific HRQOL was measured with the CAncer Rehabilitation Evaluation System-Short Form and the Functional Assessment of Cancer Therapy-General form, Disease-targeted quality of life was measured with a new instrument assessing function and bother in three organ systems: sexual, urinary, and bowel. Resuls.-No differences among treatment groups were seen in comparisons of general HRQOL. Significant differences among treatment groups were seen in both function and bother in the prostate-targeted measures of sexual, urinary, and bowel domains, When cancer patients were compared with men of similar age without prostate cancer, differences were seen in the sexual, urinary, and bowel function and bother but not in general HRQOL measures. Although cancer-free men were found not to have full potency or continence, prostate cancer patients treated with surgery or radiation reported significantly worse sexual, urinary, and bower function than men without cancer. Men who had undergone nerve-sparing prostatectomy did not differ from those who had undergone standard prostatectomy, but the power to detect a difference was low. Conclusions.-Although no differences were seen in general HRQOL, three disease-targeted domains were found to differ significantly among the treatment groups and comparison patients. Even after controlling for the sexual and urinary dysfunction experienced by older men without cancer, those receiving therapeutic interventions for their prostate cancer were found to have poorer disease-targeted HRQOL. We conclude that in addition to general HRQOL, disease-targeted measures must be used to assess outcomes of care in men treated for localized prostate cancer.	UNIV CALIF LOS ANGELES, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV GERIATR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA; RAND CORP, HLTH SCI PROGRAM, SANTA MONICA, CA USA; SO CALIF PERMANENTE MED GRP, LOS ANGELES, CA 90027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; RAND Corporation; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	LITWIN, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DIV UROL, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X; Litwin, Mark/0000-0002-2318-344X				BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Cassileth B R, 1992, Qual Life Res, V1, P323, DOI 10.1007/BF00434946; CASSILETH BR, 1989, UROLOGY, V33, P57, DOI 10.1016/0090-4295(89)90108-8; CELLA D F, 1988, Comprehensive Therapy, V14, P69; Cella D F, 1990, Oncology (Williston Park), V4, P29; CELLA DF, 1987, CANCER-AM CANCER SOC, V60, P1661, DOI 10.1002/1097-0142(19871001)60:7<1661::AID-CNCR2820600740>3.0.CO;2-4; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DASILVA FC, 1993, EUR UROL, V24, P113; DASILVA FC, 1993, CANCER, V71, P1138, DOI 10.1002/1097-0142(19930201)71:3+<1138::AID-CNCR2820711436>3.0.CO;2-7; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FOSSA SD, 1992, PROSTATE, P145; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; FOWLER FJ, 1991, EUR UROL, V20, P44; Ganz P A, 1992, Qual Life Res, V1, P19, DOI 10.1007/BF00435432; GBUREK B, 1992, Journal of Urology, V147, p466A; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; HERR HW, 1993, CANCER, V71, P1143, DOI 10.1002/1097-0142(19930201)71:3+<1143::AID-CNCR2820711437>3.0.CO;2-I; JACOBSEN SJ, 1993, UROLOGY, V42, P663, DOI 10.1016/0090-4295(93)90530-N; LEIBEL SA, 1980, UROL CLIN N AM, V7, P593; LIANG MH, 1985, ARTHRITIS RHEUM, V28, P542, DOI 10.1002/art.1780280513; LITWIN MS, 1993, J UROLOGY, V149, P84, DOI 10.1016/S0022-5347(17)36005-6; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MAUSNER JS, 1974, EPIDEMIOLOGY INTRO T, P146; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; PATRICK DL, 1989, MED CARE, V27, pS217, DOI 10.1097/00005650-198903001-00018; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PAULSON DF, 1988, J UROLOGY, V140, P535, DOI 10.1016/S0022-5347(17)41712-5; PEDERSEN KV, 1993, EUR UROL, V24, P7; RAY GR, 1973, RADIOLOGY, V106, P407, DOI 10.1148/106.2.407; RIEKER P, 1993, P AN M AM SOC CLIN, V12, P452; Schag C A, 1990, Oncology (Williston Park), V4, P135; SCHAG CAC, 1991, CANCER, V68, P1406, DOI 10.1002/1097-0142(19910915)68:6<1406::AID-CNCR2820680638>3.0.CO;2-2; SCHAG CAC, 1988, CANCER REHABILITATIO; SHARP JW, 1993, CANCER, V71, P1078, DOI 10.1002/1097-0142(19930201)71:3+<1078::AID-CNCR2820711429>3.0.CO;2-Z; Steward ALSC., 1992, MEASURING FUNCTIONIN, P345; TANNOCK I, 1989, J CLIN ONCOL, V7, P590, DOI 10.1200/JCO.1989.7.5.590; Tannock I F, 1990, Oncology (Williston Park), V4, P149; TCHEKMEDYIAN NS, 1991, QUALITY LIFE CURRENT; TULSKY DS, 1990, P SOC BEHAV MED, V11, P45; VILLAVICENCIO H, 1993, EUR UROL, V24, P118; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	46	822	832	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					129	135		10.1001/jama.273.2.129	http://dx.doi.org/10.1001/jama.273.2.129			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PZ687	7799493				2022-12-01	WOS:A1995PZ68700026
J	RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP				RANGELFRAUSTO, MS; PITTET, D; COSTIGAN, M; HWANG, T; DAVIS, CS; WENZEL, RP			THE NATURAL-HISTORY OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - A PROSPECTIVE-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-DISTRESS SYNDROME; CONTROLLED CLINICAL-TRIAL; GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; SEPSIS SYNDROME; MONOCLONAL-ANTIBODY; ENDOTOXIN; DISEASE	Objective.-Define the epidemiology of the four recently classified syndromes describing the biologic response to infection: systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock. Design.-Prospective cohort study with a follow-up of 28 days or until discharge if earlier. Setting.-Three intensive care units and three general wards in a tertiary health care institution. Methods.-Patients were included if they met at least two of the criteria for SI RS: fever or hypothermia, tachycardia, tachypnea, or abnormal white blood cell count. Main Outcomes Measures.-Development of any stage of the biologic response to infection: sepsis, severe sepsis, septic shock, end-organ dysfunction, and death. Results.-During the study period 3708 patients were admitted to the survey units, and 2527 (68%) met the criteria for SIRS. The incidence density rates for SIRS in the surgical, medical, and cardiovascular intensive care units were 857, 804, and 542 episodes per 1000 patient-days, respectively, and 671, 495, and 320 per 1000 patient-days for the medical, cardiothoracic, and general surgery wards, respectively. Among patients with SIRS, 649 (26%) developed sepsis, 467 (18%) developed severe sepsis, and 110 (4%) developed septic shock. The median interval from SIRS to sepsis was inversely correlated with the number of SIRS criteria (two, three, or all four) that the patients met. As the population of patients progressed from SIRS to septic shock, increasing proportions had adult respiratory distress syndrome, disseminated intravascular coagulation, acute renal failure, and shock. Positive blood cultures were found in 17% of patients with sepsis, in 25% with severe sepsis, and in 69% with septic shock, There were also stepwise increases in mortality rates in the hierarchy from SIRS, sepsis, severe sepsis, and septic shock: 7%, 16%, 20%, and 46%, respectively. Of interest, we also observed equal numbers of patients who appeared to have sepsis, severe sepsis, and septic shock but who had negative cultures. They had been prescribed empirical antibiotics for a median of 3 days, The cause of the systemic inflammatory response in these culture-negative populations is unknown, but they had similar morbidity and mortality rates as the respective culture-positive populations. Conclusions.-This prospective epidemiologic study of SIRS and related conditions provides, to our knowledge, the first evidence of a clinical progression from SIRS to sepsis to severe sepsis and septic shock.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PREVENT MED,DIV BIOSTAT,IOWA CITY,IA 52242; UNIV HOSP GENEVA,DEPT INTERNAL MED,DIV INFECT DIS,INFECT CONTROL GRP,GENEVA,SWITZERLAND	University of Iowa; University of Iowa; University of Geneva								[Anonymous], 1992, CRIT CARE MED, V20, P864; Bone R C, 1991, Infect Dis Clin North Am, V5, P793; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRODERICK A, 1990, AM J EPIDEMIOL, V131, P734, DOI 10.1093/oxfordjournals.aje.a115558; EXLEY AR, 1990, LANCET, V335, P1275, DOI 10.1016/0140-6736(90)91337-A; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NIEDERMAN MS, 1990, CLIN CHEST MED, V11, P633; OPAL SM, 1992, OCT INT C ANT AG CHE, P372; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PARKER MM, 1983, JAMA-J AM MED ASSOC, V250, P3324, DOI 10.1001/jama.250.24.3324; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PITTET D, 1991, SEP INT C ANT AG CHE, P232; PITTET D, 1993, OCT INT C ANT AG CHE, P358; TEASDALE G, 1974, LANCET, V2, P81; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; WHERRY J, 1993, OCT INT C ANT AG CHE, P246; WOOLSON RF, 1987, STATISTICAL METHODS, P252; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1993, MONTHLY VITAL STAT R, V41, P5; 1990, SAS STAT USERS GUIDE, V2	29	1407	1512	1	81	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	1995	273	2					117	123		10.1001/jama.273.2.117	http://dx.doi.org/10.1001/jama.273.2.117			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PZ687	7799491				2022-12-01	WOS:A1995PZ68700024
J	CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ				CALVERT, R; RANDERSON, J; EVANS, P; CAWKWELL, L; LEWIS, F; DIXON, MF; JACK, A; OWEN, R; SHIACH, C; MORGAN, GJ			GENETIC ABNORMALITIES DURING TRANSITION FROM HELICOBACTER-PYLORI-ASSOCIATED GASTRITIS TO LOW-GRADE MALTOMA	LANCET			English	Note							POLYMERASE CHAIN-REACTION	The helicobacter-associated transition from chronic gastritis to MALToma (lymphoma of mucosa-associated lymphoid tissue) may require genetic change in the host. We have studied gastrectomy specimens from twelve cases of primary B-cell gastric lymphoma showing evidence of chronic gastritis and low-grade or high-grade MALToma to look for allele imbalance at microsatellites for six tumour-suppressor genes. We detected allelic imbalance at two of these loci (DCC in three, APC in two). In two DCC cases allele imbalance was seen in the transition from chronic gastritis to low-grade MALToma and in the third between low-grade and high-grade. Allele imbalance between chronic gastritis and low-grade MALToma is not necessarily causal in the transition. Rather, genetic change has occurred in the process of transformation.	LEEDS GEN INFIRM,DEPT MOLEC HAEMATOL,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds			Maestro, Roberta/P-9748-2019; Maestro, Roberta/M-1846-2015	Maestro, Roberta/0000-0002-6642-5592; Maestro, Roberta/0000-0002-6642-5592; Randerson-Moor, Juliette/0000-0003-0303-0072; morgan, gareth/0000-0002-4271-6360				CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; DEANE M, 1991, LEUKEMIA, V5, P726; ENNO A, 1994, J CLIN PATHOL, V173, pA166; GRIBBEN JG, 1991, BLOOD, V78, P3275; MCCARTHY KP, 1990, J CLIN PATHOL, V43, P429, DOI 10.1136/jcp.43.5.429; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	7	75	75	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					26	27		10.1016/S0140-6736(95)91154-5	http://dx.doi.org/10.1016/S0140-6736(95)91154-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799702				2022-12-01	WOS:A1995QA29000012
J	COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC				COLBRIDGE, MJ; BAILY, GG; DUNBAR, EM; ONG, ELC			ANTIBIOTICS CARRIED IN GENERAL-PRACTITIONERS EMERGENCY BAGS - 4 YEARS ON	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,SCH MED,INFECT DIS UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; N MANCHESTER GRP HOSP,DEPT TROP MED & INFECT DIS,MANCHESTER M8 6RB,LANCS,ENGLAND	Newcastle General Hospital; Newcastle University - UK				Ong, Edmund/0000-0002-6594-0509				BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; CARTWRIGHT K, 1992, BRIT MED J, V305, P1343; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					29	30		10.1136/bmj.310.6971.29	http://dx.doi.org/10.1136/bmj.310.6971.29			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827551	Green Published			2022-12-01	WOS:A1995QB06000028
J	COURIEL, JM				COURIEL, JM			GLUE EAR - PRESCRIBE, OPERATE, OR WAIT	LANCET			English	Editorial Material							CHILDREN				COURIEL, JM (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT MED,MANCHESTER,LANCS,ENGLAND.							BERMAN S, 1994, PEDIATRICS, V93, P353; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; GATES GA, 1987, NEW ENGL J MED, V317, P1441; MAW AR, 1994, CLIN OTOLARYNGOL, V19, P125, DOI 10.1111/j.1365-2273.1994.tb01195.x; MAW R, 1993, BMJ-BRIT MED J, V306, P756, DOI 10.1136/bmj.306.6880.756; Paradise J L, 1992, Adv Pediatr, V39, P157; 1992, EFFECTIVE HLTH CARE	8	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					3	4		10.1016/S0140-6736(95)91144-8	http://dx.doi.org/10.1016/S0140-6736(95)91144-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799705				2022-12-01	WOS:A1995QA29000003
J	FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S				FALL, CHD; VIJAYAKUMAR, M; BARKER, DJP; OSMOND, C; DUGGLEBY, S			WEIGHT IN INFANCY AND PREVALENCE OF CORONARY HEART-DISEASE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; GROWTH; DEATH; FETAL	Objective-To determine whether low birth weight and low weight at 1 year are followed by an increased prevalence of coronary heart disease in adult life. Design-A follow up study of men horn during 1920-30 whose birth weights and weights at 1 year were recorded. Setting-Hertfordshire, England. Subjects-290 men born and still living in East Hertfordshire, Main outcome measure-The prevalence of coronary heart disease, defined by the Rose/WHO chest pain questionnaire, standard electrocardiographic criteria, or history of coronary artery angioplasty or graft surgery. Results-42 (14%) men had coronary heart disease, Their mean birth weight, 7.9 lb (3600 g), was the same as that of the other men, Their mean weight at 1 year, 21.8 lb (9.9 kg), was 1 lb (454 g) lower (95% confidence interval 0.1 to 1.8, P=0.02). Percentages of men with coronary heart disease fell from 27% in those who weighed 18 lb (8.2 kg) or less at 1 year to 9% in those who weighed more than 26 lb (11.8 kg) (P value for trend=0.03). This trend occurred in both smokers and non-smokers and within each social class. Conclusion-These findings add to the evidence that coronary heart disease is ''programmed'' during early growth.			FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARMOT MG, 1986, LANCET, V2, P274; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Prineas R.J., 1982, MINNESOTA CODE MANUA; REID DD, 1974, LANCET, V1, P469; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383	19	166	170	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					17	19		10.1136/bmj.310.6971.17	http://dx.doi.org/10.1136/bmj.310.6971.17			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827546	Green Published			2022-12-01	WOS:A1995QB06000020
J	JAKEMAN, P				JAKEMAN, P			RISK OF RELAPSE IN MULTIBACILLARY LEPROSY	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							CARTEL JL, 1991, LEPROSY REV, V62, P186; 1994, WHO TECH REP SER, V847, P6; WHOCTDLEP941; 1993, LEPROSY REV, V64, P377; 1994, WHO WEEKLY EPIDEMIOL, V69, P301	5	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					4	5		10.1016/S0140-6736(95)91145-6	http://dx.doi.org/10.1016/S0140-6736(95)91145-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799708				2022-12-01	WOS:A1995QA29000004
J	JAMES, DK				JAMES, DK			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD FOCUS ON PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY				JAMES, DK (corresponding author), QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.							HAVERCAMP A, 1982, PERINATOLOGY NEONATO, V6, P75; INCH S, 1985, J ROY SOC MED, V78, P683, DOI 10.1177/014107688507800821; JAMES D, 1991, HOSPITAL UPDATE, V18, P885; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P118, DOI 10.1111/j.1471-0528.1983.tb08894.x; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; PARSBOOSINGH J, 1990, EFFECTIVE CARE PREGN, V1, P192; REID M, 1990, EFFECTIVE CARE PREGN, V1, P131; REID M, 1986, PERINATAL CARE DELIV, P486; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					37	38		10.1136/bmj.310.6971.37	http://dx.doi.org/10.1136/bmj.310.6971.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827555	Green Published			2022-12-01	WOS:A1995QB06000032
J	MANGINO, JE; MOSER, SA; WAITES, KB				MANGINO, JE; MOSER, SA; WAITES, KB			WHEN TO USE FLUCONAZOLE	LANCET			English	Editorial Material							CRYPTOCOCCAL MENINGITIS; CONTROLLED TRIAL; AMPHOTERICIN-B; PREVENT		UNIV ALABAMA,DEPT PATHOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	MANGINO, JE (corresponding author), UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL, USA.		Moser, Stephen A/A-1168-2008					BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P261, DOI 10.1177/106002809402800220; GRASELA TH, 1994, ANN PHARMACOTHER, V28, P252, DOI 10.1177/106002809402800219; HEALD A, 1994, 34TH INT C ANT AG CH; LAINE L, 1992, ANN INTERN MED, V177, P655; PERFECT JR, 1993, AM J MED, V94, P233, DOI 10.1016/0002-9343(93)90053-R; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; WINSTON DJ, 1993, ANN INTERN MED, V181, P495	13	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					6	7		10.1016/S0140-6736(95)91147-2	http://dx.doi.org/10.1016/S0140-6736(95)91147-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799720				2022-12-01	WOS:A1995QA29000006
J	OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T				OBAYASHI, T; YOSHIDA, M; MORI, T; GOTO, H; YASUOKA, A; IWASAKI, H; TESHIMA, H; KOHNO, S; HORIUCHI, A; ITO, A; YAMAGUCHI, H; SHIMADA, K; KAWAI, T			PLASMA (1-]3)-BETA-D-GLUCAN MEASUREMENT IN DIAGNOSIS OF INVASIVE DEEP MYCOSIS AND FUNGAL FEBRILE EPISODES	LANCET			English	Article							PNEUMOCYSTIS-CARINII; HUMAN-BLOOD; LIMULUS; CANDIDIASIS; IMMUNOASSAY; ENDOTOXIN	(1-->3)-beta-D-glucan is a characteristic fungal cell-wall constituent. To assess the clinical usefulness of this glucan in screening for invasive fungal infection or fungal febrile episodes, we measured the plasma concentration at the time of routine blood culture in 202 febrile episodes by means of factor G, a horseshoe-crab coagulation enzyme that is extremely sensitive to this polysaccharide. With a plasma cut-off value of 20 pg/mL, 37 of 41 of definite fungal infections (confirmed at or by microbiology) had positive results of 59 episodes of non-fungal fever, or collagen diseases had concentrations below the cut-off value (specificity 100%). Of 102 episodes of fever of unknown origin, 26 had plasma glucan concentrations of more than 20 pg/mL. With those 102 cases taken as non-fungal infections, the positive predictive Value of the test was estimated as 59% (37/63), the negative predictive value as 97% (135/139), and the efficiency as 85% (172/202). The positive predictive Value should improve if there were a sensitive gold standard that could discriminate fungal from non-fungal infections. Causative fungi included candida, aspergillus, cryptococcus, and trichosporon. Determination of plasma (1-->3)-beta-D-glucan with factor G is a highly sensitive and specific test for invasive deep mycosis and fungal febrile episodes, and will substantially benefit immunocompromised patients.	JICHI MED SCH,DEPT INTERNAL MED,DIV HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JUNTENDO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO,JAPAN; TOKYO METROPOLITAN KOMAGOME GEN HOSP,DEPT PULM DIS,TOKYO,JAPAN; UNIV TOKYO,INST MED SCI,DEPT INFECT DIS,TOKYO,JAPAN; FUKUI MED SCH,DEPT INTERNAL MED 1,FUKUI,JAPAN; CTR ADULT DIS,DEPT INTERNAL MED 5,OSAKA 537,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 2,NAGASAKI 852,JAPAN; KINKI UNIV,SCH MED,DEPT INTERNAL MED 3,OSAKA,OSAKA 577,JAPAN; YOKOHAMA CITY UNIV,SCH HOSP,DIV CLIN LAB,YOKOHAMA,KANAGAWA,JAPAN; TEIKYO UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,TOKYO,JAPAN	Jichi Medical University; Juntendo University; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo; University of Fukui; Nagasaki University; Kindai University (Kinki University); Yokohama City University; Teikyo University	OBAYASHI, T (corresponding author), JICHI MED SCH,DEPT CLIN PATHOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							EDMAN JC, 1988, NATURE, V334, P519, DOI 10.1038/334519a0; HOPWOOD V, 1991, FUNGAL INFECTION COM, P311; IWAMA A, 1993, EUR J HAEMATOL, V51, P156, DOI 10.1111/j.1600-0609.1993.tb00617.x; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P434, DOI 10.1016/0006-291X(81)91278-X; KAMMER RB, 1974, AM J MED, V56, P506, DOI 10.1016/0002-9343(74)90483-5; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; NAKAMURA A, 1991, J CLIN MICROBIOL, V29, P2363, DOI 10.1128/JCM.29.11.2363-2367.1991; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; OBAYASHI T, 1992, J MED VET MYCOL, V30, P275; OBAYASHI T, 1986, INFECT IMMUN, V53, P294, DOI 10.1128/IAI.53.2.294-297.1986; OBAYASHI T, 1987, DETECTION BACTERIAL, P357; REISS E, 1986, MOL IMMUNOLOGY MYCOT, P11; Soyama K., 1986, Japanese Journal of Medical Mycology, V27, P165; TAMURA T, 1994, CLIN CHIM ACTA, V226, P109; TANAKA S, 1991, CARBOHYD RES, V218, P167, DOI 10.1016/0008-6215(91)84095-V; VANDEVENTER SJH, 1988, LANCET, V1, P605; WALSH TJ, 1991, NEW ENGL J MED, V324, P1026, DOI 10.1056/NEJM199104113241504; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	20	398	428	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					17	20		10.1016/S0140-6736(95)91152-9	http://dx.doi.org/10.1016/S0140-6736(95)91152-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799700				2022-12-01	WOS:A1995QA29000010
J	PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R				PEARCE, N; BEASLEY, R; CRANE, J; BURGESS, C; JACKSON, R			END OF THE NEW-ZEALAND ASTHMA MORTALITY EPIDEMIC	LANCET			English	Article							BETA-AGONISTS; PRESCRIBED FENOTEROL; DEATHS	In 1989, a case-control study reported that inhaled fenoterol was associated with the epidemic of asthma deaths that had affected New Zealand since 1976. The New Zealand Department of Health issued warnings about the safety of fenoterol and restricted its availability. The associated time trends are consistent with the hypothesis that fenoterol was the main factor in the New Zealand asthma mortality epidemic. The epidemic commenced when fenoterol was introduced in 1976, and the New Zealand death rate remained the highest in the world for more than a decade. After publication of the case-control study, the death rate fell by half and has now remained low for a further 3 years (1990-92). Time-trend data do not suggest a class effect of inhaled beta-agonists in the epidemic: there was no association between beta-agonist sales and the start of the epidemic, and total sales of inhaled beta-agonists actually increased slightly during 1989-90 when the epidemic came to an end. Time-trend data are also inconsistent with the hypothesis that the epidemic may have occurred because of underprescribing of inhaled corticosteroids. Similarly, time-trend data is inconsistent with hypotheses postulating a major role of social factors such as unemployment. Data on time trends should be assessed with caution, because time trends in asthma deaths can be affected by many factors. Nevertheless, the New Zealand time trends are consistent with fenoterol being the main cause of the New Zealand asthma mortality epidemic and are inconsistent with a significant role for other suggested causes.			PEARCE, N (corresponding author), WELLINGTON SCH MED,DEPT MED,WELLINGTON ASTHMA RES GRP,POB 7343,WELLINGTON,NEW ZEALAND.			Pearce, Neil/0000-0002-9938-7852; Beasley, Richard/0000-0003-0337-406X; Jackson, Rod/0000-0001-5914-6934	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEASLEY R, 1989, NEW ZEAL MED J, V102, P294; BEASLEY R, 1991, AUST NZ J MED, V21, P753, DOI 10.1111/j.1445-5994.1991.tb01385.x; BERNSTEIN DS, 1990, OPTIM CONTR APPL MET, V11, P1, DOI 10.1002/oca.4660110102; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, BRIT MED J, V304, P1307, DOI 10.1136/bmj.304.6837.1307; Cried CP, 1993, EUR RESPIR J, V6, p426S; DAVIS P, 1994, HEALTH POLICY, V29, P113, DOI 10.1016/0168-8510(94)90010-8; GARRETT J, 1992, POSITIVE DIRECTIONS; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; HAAS JF, 1992, BRIT MED J, V304, P1634, DOI 10.1136/bmj.304.6842.1634; HENSLEY MJ, 1992, MED J AUSTRALIA, V157, P568; HENSLEY MJ, 1992, MED J AUSTRALIA, V156, P882, DOI 10.5694/j.1326-5377.1992.tb137010.x; HORWITZ RI, 1991, CHEST, V100, P1586, DOI 10.1378/chest.100.6.1586; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; JACKSON RT, 1983, NZ MED J, V96, P727; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEARCE N, 1992, NEW ENGL J MED, V327, P355; PEARCE N, 1994, JAMA-J AM MED ASSOC, V271, P822, DOI 10.1001/jama.271.11.822; Prime Ministerial Task Force on Employment, 1994, EMPLOYMENT ISSUES; SEARS MR, 1986, AM J EPIDEMIOL, V124, P1004, DOI 10.1093/oxfordjournals.aje.a114470; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STOLLEY PD, 1972, AM REV RESPIR DIS, V105, P883; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUISSA S, 1992, BRIT MED J, V305, P889, DOI 10.1136/bmj.305.6858.889; WILSON JD, 1981, LANCET, V1, P1235; WOODMAN K, 1992, CLIN PHARMACOL THER, V51, P566, DOI 10.1038/clpt.1992.64	30	137	141	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					41	44		10.1016/S0140-6736(95)91159-6	http://dx.doi.org/10.1016/S0140-6736(95)91159-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799709				2022-12-01	WOS:A1995QA29000017
J	ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE				ROONEY, CM; SMITH, CA; NG, CYC; LOFTIN, S; LI, CF; KRANCE, RA; BRENNER, MK; HESLOP, HE			USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION	LANCET			English	Article							MARROW TRANSPLANT RECIPIENTS; BONE-MARROW; IMMUNITY	Reactivation of Epstein-Barr virus (EBV) after bone-marrow transplantation leads in many cases to lymphoproliferative disease that responds poorly to standard therapy and is usually fatal. To prevent or central this complication, we prepared EBV-specific cytotoxic T-lymphocyte (CTL) lines from donor leucocytes and infused them into ten allograft recipients. Three of the patients had shown signs of EBV reactivation, with or without overt lymphoproliferation, and the others received CTL infusions as prophylaxis. No patient developed any complication that could be attributed to the CTL infusions. in the three patients with EBV reactivation, EBV DNA concentrations (measured by semiquantitative polymerase chain reaction [PCR]), which had increased 1000-fold or more, returned to the control range within 3-4 weeks of immunotherapy. The most striking consequence was the resolution of immunoblastic lymphoma in a 17-year-old patient who received four CTL infusions (two 1x10(7)/m(2) and two 5x10(7)/m(2)). Because the CTL had been genetically marked before infusion, we were able to show by PCR analysis that they persisted for 10 weeks after administration. EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PATHOL, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT MED, MEMPHIS, TN USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Brenner, Malcolm/Y-2509-2019; Heslop, Helen/AAC-9500-2020; Rooney, Cliona/ABD-5475-2021		NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765, R01CA061384, U01CA061384] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61384, CA 20180, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501; BOYLE MJ, 1991, BLOOD, V78, P3004; BRENNER MK, 1993, LANCET, V342, P1134, DOI 10.1016/0140-6736(93)92122-A; BURROWS SR, 1994, J EXP MED, V179, P1155, DOI 10.1084/jem.179.4.1155; COHEN KI, 1991, P NATL ACAD SCI USA, V86, P9558; CRAWFORD DH, 1986, TRANSPLANTATION, V42, P50, DOI 10.1097/00007890-198607000-00010; DUNCOMBE AS, 1992, BLOOD, V79, P3059; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; HESLOP HE, 1994, BLOOD, V83, P1706, DOI 10.1182/blood.V83.6.1706b.bloodjournal8361706b; HESLOP HE, 1994, HUM GENE THER, V5, P381, DOI 10.1089/hum.1994.5.3-381; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; LIEBERMAN J, 1994, NEW ENGL J MED, V330, P1231, DOI 10.1056/NEJM199404283301711; LIST AF, 1987, J CLIN ONCOL, V5, P1673, DOI 10.1200/JCO.1987.5.10.1673; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; PRENTICE HG, 1984, LANCET, V1, P472; RICKINSON AB, 1981, CANCER RES, V41, P4216; RIDDELL SR, 1992, SCIENCE, V257, P238; RIDDLER SA, 1994, BLOOD, V84, P972; ROONEY CM, IN PRESS BR J HAEMAT; SAVOIE A, 1994, BLOOD, V83, P2715; STRAUS SE, 1992, ANN INTERN MED, V118, P45; VANRHEE F, 1994, BLOOD, V83, P3377; Young L S, 1992, Semin Cancer Biol, V3, P273; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	29	951	985	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 7	1995	345	8941					9	13		10.1016/S0140-6736(95)91150-2	http://dx.doi.org/10.1016/S0140-6736(95)91150-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799740				2022-12-01	WOS:A1995QA29000008
J	VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A				VANDAMME, P; CRAMM, M; VANDERAUWERA, JC; VRANCKX, R; MEHEUS, A			HORIZONTAL TRANSMISSION OF HEPATITIS-B VIRUS	LANCET			English	Note							TRANSMISSION; CHILDREN; INFECTION; FAMILIES	In 1991-92, a cross-sectional survey in Flanders (Belgium) for hepatitis B virus (HBV) markers among 277 relatives of institutionalised mentally handicapped persons to evaluate the prevalence of hepatitis B and the risk of infection showed that relatives of an HBV positive resident were 7.6 times more likely to be infected than relatives of an HBV seronegative mentally handicapped person. HBV infection among the family members could be attributed in 83% to exposure to an HBV positive resident. This study demonstrated the importance of horizontal transmission among relatives of institutionalised mentally handicapped people, even if family contact is reduced to weekend and holiday activities. We recommend that HBV vaccination policy should be expanded to include relatives of institutionalised mentally retarded people.	INST HYG & EPIDEMIOL,B-1050 BRUSSELS,BELGIUM		VANDAMME, P (corresponding author), UNIV ANTWERP,DEPT EPIDEMIOL & COMMUNITY MED,B-2610 ANTWERP,BELGIUM.		van damme, pierre/I-4846-2013					BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199, DOI 10.1093/oxfordjournals.aje.a113406; CANCIOBELLO TP, 1982, J INFECT DIS, V146, P652, DOI 10.1093/infdis/146.5.652; DAVIS LG, 1989, LANCET, V1, P889; FRANKS AL, 1989, NEW ENGL J MED, V321, P1301, DOI 10.1056/NEJM198911093211905; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; HAYASHI J, 1987, AM J EPIDEMIOL, V125, P492, DOI 10.1093/oxfordjournals.aje.a114555; JENISON SA, 1987, J INFECT DIS, V156, P299, DOI 10.1093/infdis/156.2.299; MCPHILLIPS JC, 1984, J PEDIATR GASTR NUTR, V3, P69, DOI 10.1097/00005176-198401000-00015; VANDAMME P, 1989, LANCET, V1, P840; VANDITZHUIJSEN TJM, 1988, AM J EPIDEMIOL, V128, P629, DOI 10.1093/oxfordjournals.aje.a115010	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 7	1995	345	8941					27	29		10.1016/S0140-6736(95)91155-3	http://dx.doi.org/10.1016/S0140-6736(95)91155-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QA290	7799703				2022-12-01	WOS:A1995QA29000013
J	WALKER, P				WALKER, P			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD BE INCLUDED IN INTEGRATED TEAM CARE .15.	BRITISH MEDICAL JOURNAL			English	Article											WALKER, P (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.							STEER PJ, 1992, BRIT J OBSTET GYNAEC, V99, P415; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; 1993, CHANGING CHILDBIRTH; 1992, CHANGING CHILDBIRTH	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					36	37		10.1136/bmj.310.6971.36	http://dx.doi.org/10.1136/bmj.310.6971.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827554	Green Published			2022-12-01	WOS:A1995QB06000031
J	WRIGHT, JD; PEARL, L				WRIGHT, JD; PEARL, L			KNOWLEDGE AND EXPERIENCE OF YOUNG-PEOPLE REGARDING DRUG MISUSE, 1969-94	BRITISH MEDICAL JOURNAL			English	Article							ABUSE	Objective-To monitor young people's knowledge and experience of illicit drugs between 1969 and 1994 at intervals of five years. Design-The same anonymously completed questionnaire was used throughout. Setting-Three Wolverhampton secondary schools representing three different socioeconomic groups. Subjects-392 pupils aged 14 to 15 completed the questionnaire in 1994. Previous sample sizes were 471 in 1969, 523 in 1974, 648 in 1979, 540 in 1984, and 380 in 1989. Main outcome measures-Self reported levels of knowledge and experience of illicit drugs. Results-Over 25 years the proportion of pupils who knew someone taking drugs more than quadrupled from 15% (71/471) to 65% (254/392), and the proportion who had been offered drugs increased ninefold from 5% (24) to 45% (175). Both of these proportions more than doubled over the past five years. In 1994 the proportions of pupils mentioning ''ecstasy'' (methylenedioxymethamphetamine), amphetamines, and crack cocaine increased significantly (P<0.01) and the proportion mentioning opiates decreased significantly (P<0.01). ''Poppers'' (amyl nitrite) were mentioned for the first time. ''To feel big, to show off, look grown up'' has continued to be the main perceived reason for taking drugs. Television has continued to be the main source of information. Conclusions-In the past five years in particular young people's exposure to illicit drugs has increased dramatically. Despite more education about drugs, pupils' knowledge remains limited. Social pressures remain the first perceived reason for taking drugs. The media have a responsibility not to glamorise drugs.	UNIV WOLVERHAMPTON,WOLVERHAMPTON WV1 1SB,ENGLAND	University of Wolverhampton								ALLEN FA, 1991, CRACK BROKEN PROMISE; BALDING J, 1994, YOUNG PEOPLE 1993; BEAN PT, 1988, HLTH ED J, V47, P79; BROWN C, 1988, ILLICIT DRUG USE POR; COHEN J, 1992, PSYCHOACTIVE DRUGS H; Davies OL, 1978, DESIGN ANAL IND EXPT; FRANCIS LJ, 1993, ADDICTION, V88, P665, DOI 10.1111/j.1360-0443.1993.tb02079.x; FRASER A, 1991, DRUG MISUSE LOCAL CO; Measham F., 1993, DRUGLINK, V8, P16; SMITH C, 1992, BRIT J ADDICT, V87, P227; Swadi Harith, 1992, Eur Child Adolesc Psychiatry, V1, P156, DOI 10.1007/BF02091901; WRIGHT JD, 1976, MED SCI LAW, V16, P252, DOI 10.1177/002580247601600408; WRIGHT JD, 1981, BRIT MED J, V282, P793, DOI 10.1136/bmj.282.6266.793; WRIGHT JD, 1986, BRIT MED J, V292, P179, DOI 10.1136/bmj.292.6514.179; WRIGHT JD, 1990, BRIT MED J, V300, P99, DOI 10.1136/bmj.300.6717.99; 1993, PHS6 ST GEORG HOSP M; 1993, DRUG ED SCH; 1993, HOME OFFICE STATISTI; 1993, DRUGS SOLVENTS YOU Y	19	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					20	24		10.1136/bmj.310.6971.20	http://dx.doi.org/10.1136/bmj.310.6971.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB060	7755714	Green Published			2022-12-01	WOS:A1995QB06000022
J	BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT				BERARDI, AC; WANG, AL; LEVINE, JD; LOPEZ, P; SCADDEN, DT			FUNCTIONAL ISOLATION AND CHARACTERIZATION OF HUMAN HEMATOPOIETIC STEM-CELLS	SCIENCE			English	Article							ERYTHROPOIETIN RECEPTOR GENE; IL-6 SIGNAL TRANSDUCER; COLONY-FORMING CELLS; MURINE BONE-MARROW; LONG-TERM CULTURE; PROGENITOR CELLS; LIMITING-DILUTION; C-KIT; MONOCLONAL-ANTIBODY; SOYBEAN AGGLUTININ	Hematopoietic cells differentiate in steps marked by the acquisition or loss of specific phenotypic characteristics. Human bone marrow cells that were responsive to the early-acting cytokines Kit ligand and interleukin-3 were forced to a metabolic death. The subfraction remaining represented 1 in 10(5) bone marrow mononuclear cells, was determined to be quiescent by cell cycle analysis, and had a stem cell immunophenotype, The cells were highly enriched for long-term culture-initiating cells, were capable of secondary colony formation, and produced both myeloid and lymphoid progeny. Thus, this technically simple strategy led to the efficient purification of cells with characteristics of hematopoietic stem cells.	HARVARD UNIV, DEACONESS HOSP, SCH MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CELL SORTING FACIL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Berardi, Anna Concetta/M-6769-2019; Lopez, Peter/AAP-7234-2020; Cosset, François-Loïc/M-5862-2019	Berardi, Anna Concetta/0000-0002-5078-6158; Cosset, François-Loïc/0000-0001-8842-3726; Lopez, Peter/0000-0002-8587-7148	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044851] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL44851] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BRANDT J, 1992, BLOOD, V79, P634; BRIDDELL RA, 1992, BLOOD, V79, P3159; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; COULOMBEL L, 1983, BLOOD, V62, P291; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; EBELL W, 1985, BLOOD, V65, P1105; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORDON MY, 1985, LEUKEMIA RES, V9, P1017, DOI 10.1016/0145-2126(85)90072-4; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; INABA M, 1990, JPN J CANCER RES, V81, P1039, DOI 10.1111/j.1349-7006.1990.tb03343.x; KATAYAMA N, 1993, BLOOD, V81, P610; KRIEGLER AB, 1994, EXP HEMATOL, V22, P432; LEMIEUX ME, 1993, BLOOD, V82, pA13; LERNER C, 1990, EXP HEMATOL, V18, P114; MCNIECE IK, 1990, INT J CELL CLONING, V8, P146, DOI 10.1002/stem.5530080302; MUENCH MO, 1992, EXP HEMATOL, V20, P339; NAKAGUA Y, 1994, D26616 GENB ACC; OGATA H, 1992, BLOOD, V80, P91; PLOEMACHER RE, 1988, EXP HEMATOL, V16, P903; PLOEMACHER RE, 1989, BLOOD, V74, P2755; Pollack A, 1990, Methods Cell Biol, V33, P19; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REISNER Y, 1982, BLOOD, V59, P360; SATO N, 1993, BLOOD, V82, P3600; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SISTONEN P, 1993, HUM GENET, V92, P299, DOI 10.1007/BF00244476; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMITH C, 1991, BLOOD, V77, P2122; SPANGRUDE GJ, 1990, P NATL ACAD SCI USA, V87, P7433, DOI 10.1073/pnas.87.19.7433; SROUR EF, 1993, BLOOD, V82, P3333; STEWART FM, 1993, BLOOD, V81, P2283; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1993, BLOOD, V81, P1465; TAKIMOTO CH, 1993, J BIOL CHEM, V268, P21438; TASWELL C, 1981, J IMMUNOL, V126, P1614; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TESTA U, 1993, BLOOD, V81, P1442; TRUMPER LH, 1993, BLOOD, V81, P3097; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WOLF NS, 1993, EXP HEMATOL, V21, P614; YAMAGUCHI Y, 1993, EXP HEMATOL, V21, P1233; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZIPORI D, 1988, BLOOD, V71, P586	55	357	384	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					104	108		10.1126/science.7528940	http://dx.doi.org/10.1126/science.7528940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528940				2022-12-01	WOS:A1995QA23500040
J	COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD				COGHLAN, VM; PERRINO, BA; HOWARD, M; LANGEBERG, LK; HICKS, JB; GALLATIN, WM; SCOTT, JD			ASSOCIATION OF PROTEIN-KINASE-A AND PROTEIN-PHOSPHATASE-2B WITH A COMMON ANCHORING PROTEIN	SCIENCE			English	Article							HIGH-AFFINITY BINDING; REGULATORY SUBUNIT RII; IMMUNOCYTOCHEMICAL LOCALIZATION; POSTSYNAPTIC DENSITIES; CATALYTIC SUBUNIT; CALCINEURIN-A; RAT-BRAIN; II-BETA; CALMODULIN; PHOSPHORYLATION	Specificity of protein kinases and phosphatases may be achieved through compartmentalization with preferred substrates. In neurons, adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) is localized at postsynaptic densities by association of its regulatory subunit with an A kinase anchor protein, AKAP79. Interaction cloning experiments demonstrated that AKAP79 also binds protein phosphatase 2B, or calcineurin (CaN). A ternary complex of PKA, AKAP, and CaN was isolated from bovine brain, and colocalization of the kinase and the phosphatase was established in neurites of cultured hippocampal neurons. The putative CaN-binding domain of AKAP79 is similar to that of the immunophilin FKBP-12, and AKAP79 inhibited CaN phosphatase activity. These results suggest that both PKA and CaN are targeted to subcellular sites by association with a common anchor protein and thereby regulate the phosphorylation state of key neuronal substrates.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; ICOS CORP,BOTHELL,WA 98021	Oregon Health & Science University; Icos Corporation					NIDDK NIH HHS [DK09059] Funding Source: Medline; NIGMS NIH HHS [GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BRAUTIGAN DL, 1994, RECENT PROG HORM RES, V49, P197; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, THESIS; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HEMMINGS HC, 1989, FASEB J, V3, P1583, DOI 10.1096/fasebj.3.5.2493406; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LUDVIG N, 1990, BRAIN RES, V520, P90, DOI 10.1016/0006-8993(90)91694-C; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; WOOD JG, 1980, J CELL BIOL, V84, P66, DOI 10.1083/jcb.84.1.66	32	497	515	2	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					108	111		10.1126/science.7528941	http://dx.doi.org/10.1126/science.7528941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528941				2022-12-01	WOS:A1995QA23500041
J	POMERANTZ, JL; SHARP, PA; PABO, CO				POMERANTZ, JL; SHARP, PA; PABO, CO			STRUCTURE-BASED DESIGN OF TRANSCRIPTION FACTORS	SCIENCE			English	Article							DNA-BINDING SPECIFICITY; POU-DOMAIN; PROTEIN; REPRESSOR; SEQUENCE	Computer modeling suggested that transcription factors with novel sequence specificities could be designed by combining known DNA binding domains. This structure-based strategy was tested by construction of a fusion protein, ZFHD1,that contained zinc fingers 1 and 2 from Zif268, a short polypeptide linker, and the homeodomain from Oct-1. The fusion protein bound optimally to a sequence containing adjacent homeodomain (TA-ATTA) and zinc finger (NGGGNG) subsites. When fused to an activation domain, ZFHD1 regulated promoter activity in vivo in a sequence-specific manner. Analysis of known protein-DNA complexes suggests that many other DNA binding proteins could be designed in a similar fashion.	MIT,HARVARD DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	POMERANTZ, JL (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Pomerantz, Joel L./0000-0002-5030-1018	NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1994, CURRENT PROTOCOLS MO; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; PAVIETICH NP, 1991, SCIENCE, V252, P809; PELLETT PE, 1985, P NATL ACAD SCI USA, V82, P5870, DOI 10.1073/pnas.82.17.5870; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POMERANTZ JL, UNPUB; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WHARTON RP, 1985, NATURE, V316, P601, DOI 10.1038/316601a0; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1	20	121	179	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					93	96		10.1126/science.7809612	http://dx.doi.org/10.1126/science.7809612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809612				2022-12-01	WOS:A1995QA23500037
J	RADZICKA, A; WOLFENDEN, R				RADZICKA, A; WOLFENDEN, R			A PROFICIENT ENZYME	SCIENCE			English	Article							TRANSITION-STATE STABILIZATION; STAPHYLOCOCCAL NUCLEASE; DECARBOXYLASE; ACID; CATALYSIS; MECHANISM; RATES; 5'-PHOSPHATE; PURIFICATION; SPECIFICITY	Orotic acid is decarboxylated with a half-time (t(1/2)) of 78 million years in neutral aqueous solution at room temperature, as indicated by reactions in quartz tubes at elevated temperatures. Spontaneous hydrolysis of phosphodiester bonds, such as those present in the backbone of DNA, proceeds even more slowly at high temperatures, but the heat of activation is less positive, so that dimethyl phosphate is hydrolyzed with a t(1/2) of 130,000 years in neutral solution at room temperature. These values extend the known range of spontaneous rate constants for reactions that are also susceptible to catalysis by enzymes to more than 14 orders of magnitude. Values of the second-order rate constant k(cat)/K-m for the corresponding enzyme reactions are confined to a range of only 600-fold, in contrast. Orotidine 5'-phosphate decarboxylase, an extremely proficient enzyme, enhances the rate of reaction by a factor of 10(17) and is estimated to bind the altered substrate in the transition state with a dissociation constant of less than 5 x 10(-24) M.			RADZICKA, A (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018325, R01GM018325] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHESON SA, 1990, BIOCHEMISTRY-US, V29, P3198, DOI 10.1021/bi00465a007; ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BELL JB, 1991, J BIOL CHEM, V266, P12662; BUNTON CA, 1960, J CHEM SOC, P3293, DOI 10.1039/jr9600003293; BURGNER JW, 1984, BIOCHEMISTRY-US, V23, P3636, DOI 10.1021/bi00311a010; DEWOLF WE, 1979, J BIOL CHEM, V254, P868; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; FOX JJ, 1957, BIOCHIM BIOPHYS ACTA, V23, P295, DOI 10.1016/0006-3002(57)90331-1; FRICK L, 1987, BIOORG CHEM, V15, P100, DOI 10.1016/0045-2068(87)90011-3; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032; HAWKINSON DC, 1991, BIOCHEMISTRY-US, V30, P10849, DOI 10.1021/bi00109a007; HUNT SW, 1982, J BIOL CHEM, V257, P14240; JOHNSON FH, 1954, KINETIC BASIS MOLECU, P187; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LAIDLER KJ, 1965, CHEMICAL KINETICS, P488; LEVINE HL, 1980, BIOCHEMISTRY-US, V19, P4993, DOI 10.1021/bi00563a010; MIHEL I, 1979, J AM CHEM SOC, V101, P4349, DOI 10.1021/ja00509a050; NOBLE WJL, 1967, PROGR PHYS ORG CHEM, V5, P207; POLLACK RM, 1989, J AM CHEM SOC, V111, P6419, DOI 10.1021/ja00198a066; PUTMAN SJ, 1972, BIOCHEM J, V129, P301, DOI 10.1042/bj1290301; Roughton FJW, 1941, J AM CHEM SOC, V63, P2930, DOI 10.1021/ja01856a018; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SMILEY JA, 1991, BIOCHEMISTRY-US, V30, P6216, DOI 10.1021/bi00239a020; SMILEY JA, 1994, P NATL ACAD SCI USA, V91, P8319, DOI 10.1073/pnas.91.18.8319; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WHITAKER JR, 1986, BIOCHEMISTRY-US, V5, P386; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	33	696	707	3	175	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					90	93		10.1126/science.7809611	http://dx.doi.org/10.1126/science.7809611			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809611				2022-12-01	WOS:A1995QA23500036
J	THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R				THUT, CJ; CHEN, JL; KLEMM, R; TJIAN, R			P53 TRANSCRIPTIONAL ACTIVATION MEDIATED BY COACTIVATORS TAF(II)40 AND TAF(II)60	SCIENCE			English	Article							WILD-TYPE; BINDING PROTEIN; MDM-2 ONCOGENE; DOMAIN; GENE; EXPRESSION; INVITRO; DNA; SUPPRESSION; MUTATIONS	The tumor suppressor protein p53 is a transcriptional regulator that enhances the expression of proteins that control cellular proliferation. The multisubunit transcription factor IID (TFIID) is thought to be a primary target for site-specific activators of transcription. Here, a direct interaction between the activation domain of p53 and two subunits of the TFIID complex, TAF(II)40 and TAF(II)60, is reported. A double point mutation in the activation domain of p53 impaired the ability of this domain to activate transcription and, simultaneously, its ability to interact with both TAF(II)40 and TAF(II)60. Furthermore, a partial TFIID complex containing Drosophila TATA binding protein (dTBP), human TAF(II)250, dTAF(II)60, and dTAF(II)40 supported activation by a Gal4-p53 fusion protein in vitro, whereas TBP or a subcomplex lacking TAF(II)40 and TAF(II)60 did not. Together, these results suggest that TAF(II)40 and TAF(II)60 are important targets for transmitting activation signals between p53 and the initiation complex.			THUT, CJ (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.							BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNALECHT BD, 1991, CELL, V66, P563; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOEY T, 1993, CELL, V72, P274; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEMM RA, UNPUB; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MILLER C W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P386; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, UNPUB; TONG X, IN PRESS J VIROL; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	41	419	422	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 6	1995	267	5194					100	104		10.1126/science.7809597	http://dx.doi.org/10.1126/science.7809597			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809597				2022-12-01	WOS:A1995QA23500039
J	TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE				TRAVISANO, M; MONGOLD, JA; BENNETT, AF; LENSKI, RE			EXPERIMENTAL TESTS OF THE ROLES OF ADAPTATION, CHANCE, AND HISTORY IN EVOLUTION	SCIENCE			English	Article							ESCHERICHIA-COLI; PROGRAM	The contributions of adaptation, chance, and history to the evolution of fitness and cell size were measured in two separate experiments using bacteria. In both experiments, populations propagated in identical environments achieved similar fitnesses, regardless of prior history or subsequent chance events. In contrast, the evolution of cell size, a trait weakly correlated with fitness, was more strongly influenced by history and chance.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; UNIV CALIF IRVINE, DEPT ECOL & EVOLUTIONARY BIOL, IRVINE, CA 92717 USA	Michigan State University; University of California System; University of California Irvine			Travisano, Michael/AAI-4809-2020	Lenski, Richard/0000-0002-1064-8375				BENNETT AF, 1992, EVOLUTION, V46, P16, DOI 10.1111/j.1558-5646.1992.tb01981.x; Calder W. A, 1984, SIZE FUNCTION LIFE H; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; Fisher R.A., 1930, GENETICAL THEORY NAT; Gould S.J., 1989, WONDERFUL LIFE BURGE; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kimura M., 1983, NEUTRAL THEORY MOL E; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, ENCY MICROBIOL, V2, P125; MAYR E, 1983, AM NAT, V121, P324, DOI 10.1086/284064; OSTER G, 1982, EVOLUTION, V36, P444, DOI 10.1111/j.1558-5646.1982.tb05066.x; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; SOKAL RR, 1981, BIOMETRY, P217; Stephens D.W., 1986, pi; TRAVISANO M, IN PRESS EVOLUTION; VASI F, 1994, AM NAT, V144, P432, DOI 10.1086/285685; Williams G. C., 1992, NATURAL SELECTION DO; Wright S., 1984, THEORY GENE FREQUENC	23	357	359	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					87	90		10.1126/science.7809610	http://dx.doi.org/10.1126/science.7809610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7809610				2022-12-01	WOS:A1995QA23500035
J	WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ				WOHRL, BM; GEORGIADIS, MM; TELESNITSKY, A; HENDRICKSON, WA; LEGRICE, SFJ			FOOTPRINT ANALYSIS OF REPLICATING MURINE LEUKEMIA-VIRUS REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; AIDS	Replication complexes that contained either murine leukemia virus reverse transcriptase (MLV RT) or a variant reverse transcriptase without a ribonuclease (RNase) H domain (Delta RH MLV RT) were visualized by enzymatic footprinting. Wild-type MLV RT protected template nucleotides +6 to -27, and primer nucleotides -1 to -26 of primers that had first been extended by one or four nucleotides. Although it catalyzed DNA synthesis, Delta RH MLV RT stably bound template-primer only under conditions of reduced ionic strength and protected the duplex portion only as far as position -15. Despite altered hydrolysis profiles, both enzymes covered primarily the template-primer duplex, contradicting recent predictions based on the structure of rat DNA polymerase beta.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; RUTGERS STATE UNIV, DEPT CHEM, PISCATAWAY, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Michigan System; University of Michigan; Columbia University; Howard Hughes Medical Institute					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NCI NIH HHS [CA09021] Funding Source: Medline; NIAID NIH HHS [AI 31147] Funding Source: Medline; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; GEORGIADIS M, UNPUB; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659; OLMSTED RA, 1989, P NATL ACAD SCI USA, V86, P2448, DOI 10.1073/pnas.86.7.2448; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RAUSCH JS, UNPUB; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SKALKA AM, 1993, REVERSE TRANSCRIPTAS, P193; STEPHENS RM, 1986, SCIENCE, V231, P589, DOI 10.1126/science.3003905; TELESNITSKY A, 1993, P NATL ACAD SCI USA, V90, P1276, DOI 10.1073/pnas.90.4.1276; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1994, J BIOL CHEM, V269, P8541; WOHRL BM, UNPUB	19	49	50	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	1995	267	5194					96	99		10.1126/science.7528942	http://dx.doi.org/10.1126/science.7528942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA235	7528942				2022-12-01	WOS:A1995QA23500038
J	CHEN, GH; HOFFMAN, AS				CHEN, GH; HOFFMAN, AS			GRAFT-COPOLYMERS THAT EXHIBIT TEMPERATURE-INDUCED PHASE-TRANSITIONS OVER A WIDE-RANGE OF PH	NATURE			English	Article							DRUG DELIVERY; POLYMERS; HYDROGELS; NETWORKS; RELEASE; GELS; ACID	THERE are many potential applications of 'intelligent' aqueous polymer systems(1-8) in medicine, biotechnology, industry and in environmental problems(9-13). Many of these polymer systems undergo reversible phase transitions-for example, abrupt changes in volume-in response to external stimuli such as temperature, pH or the nature of the solvent. Most of the polymers studied previously are responsive to only one kind of stimulus. But for some applications, independent responsiveness to several factors, such as temperature and pH, may be required. Here we describe a polymer that undergoes marked solubility changes in water in response to temperature and/or pH changes, The polymer is prepared by grafting temperature-sensitive side chains onto a pH-sensitive backbone, We also find that block copolymers, in which the temperature- and pH-sensitive units alternate along the chain, show similar behaviour.	UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1993, BIOCONJUGATE CHEM, V4, P509, DOI 10.1021/bc00024a013; DONG LC, 1990, J CONTROL RELEASE, V13, P21, DOI 10.1016/0168-3659(90)90071-Z; DONG LC, 1991, J CONTROL RELEASE, V15, P141, DOI 10.1016/0168-3659(91)90072-L; Dusek K., 1993, RESPONSIVE GELS VOLU, VII; FREITAS RFS, 1987, CHEM ENG SCI, V42, P97, DOI 10.1016/0009-2509(87)80213-0; Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI [DOI 10.1080/10601326808051910, 10.1080/10601326808051910]; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; HOFFMAN AS, 1991, MRS BULL, V16, P42, DOI 10.1557/S0883769400056049; KATONO H, 1991, J CONTROL RELEASE, V16, P215, DOI 10.1016/0168-3659(91)90045-F; KISHI R, 1991, POLYMER GELS, P205; KLIER J, 1990, MACROMOLECULES, V23, P4944, DOI 10.1021/ma00225a011; KUNGWATCHAKUN D, 1988, MAKROMOL CHEM-RAPID, V9, P243; MONJI N, 1987, APPL BIOCHEM BIOTECH, V14, P107, DOI 10.1007/BF02798429; OKANO T, 1990, J CONTROL RELEASE, V11, P255, DOI 10.1016/0168-3659(90)90138-J; PARK TG, 1993, MACROMOLECULES, V26, P5045, DOI 10.1021/ma00071a010; PRIEST JH, 1987, ACS SYM SER, V350, P255; SUZUKI M, 1991, POLYMER GELS, P221; TANAKA T, 1979, POLYMER, V20, P1404, DOI 10.1016/0032-3861(79)90281-7; TAYLOR LD, 1970, J POLYM SCI A, V8, P3405	20	1162	1244	6	329	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					49	52		10.1038/373049a0	http://dx.doi.org/10.1038/373049a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800038				2022-12-01	WOS:A1995QA23900050
J	PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J				PACKER, C; COLLINS, DA; SINDIMWO, A; GOODALL, J			REPRODUCTIVE CONSTRAINTS ON AGGRESSIVE COMPETITION IN FEMALE BABOONS	NATURE			English	Article							OLIVE BABOONS; PAPIO-ANUBIS; PRIMATES; AGE	COMPETITIVE interaction between females of the same social group is characteristic of most primate species(1-3). In old World monkeys, females of high social rank maintain priority of access to scarce resources and harass low-ranking companions(1-6). But different field studies have found differing correlations between female dominance and reproductive success: several populations show an advantage of rank whereas others do not(1,3,5,7). Although such variation may reflect divergent levels of predation, food availability or social stress in different environments, female competitive ability may also be balanced by significant reproductive costs and thus be subject to strong stabilizing selection, We report here that high-ranking female baboons (Papio cynocephalus anubis) at Gombe National Park, Tanzania, enjoy shorter interbirth intervals, improved infant survival, and accelerated maturation of their daughters. These advantages, however, are countered by a significantly higher probability of miscarriage, and a proportion of high-ranking females suffer from reduced fertility.	UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,ASHWORTH LAB,EDINBURGH EH9 3JT,MIDLOTHIAN,SCOTLAND; GOMBE STREAM RES CTR,KIGOMA,TANZANIA	University of Edinburgh	PACKER, C (corresponding author), UNIV MINNESOTA,DEPT EEB,1987 UPPER BUFORD CIRCLE,ST PAUL,MN 55108, USA.							ABBOTT DH, 1987, J ZOOL, V213, P455, DOI 10.1111/j.1469-7998.1987.tb03720.x; Altmann J., 1988, P403; Altmann J., 1970, LAB ANIM DIG, V6, P7; BERCOVITCH FB, 1993, BEHAV ECOL SOCIOBIOL, V33, P313; Chapais Bernard, 1992, P29; Collins DA, 1984, INFANTICIDE COMP EVO, P193; FAIRBANKS LA, 1986, ANIM BEHAV, V34, P1710, DOI 10.1016/S0003-3472(86)80258-5; Glickman Stephen E., 1993, Perspectives in Ethology, V10, P87; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Goy R W, 1972, Recent Prog Horm Res, V28, P707; HAUSFATER G, 1982, SCIENCE, V217, P752, DOI 10.1126/science.217.4561.752; HAUSFATER G, 1975, DOMINANCE REPRODUCTI; LEE PC, 1987, J ZOOL, V213, P409, DOI 10.1111/j.1469-7998.1987.tb03717.x; NASH LT, 1976, AM J PHYS ANTHROPOL, V44, P63, DOI 10.1002/ajpa.1330440109; OWENS NW, 1976, BEHAVIOUR, V57, P241, DOI 10.1163/156853976X00541; PACKER C, 1979, ANIM BEHAV, V27, P1, DOI 10.1016/0003-3472(79)90126-X; PACKER C, 1975, NATURE, V255, P219, DOI 10.1038/255219a0; Ransom TW., 1981, BEACH TROOP GOMBE; SACKETT GP, 1975, 5TH P INT C INT PRIM; Silk J.B., 1987, P318; SMUTS B, 1989, AM J PRIMATOL, V19, P229, DOI 10.1002/ajp.1350190405; STRUM SC, 1982, AM J PRIMATOL, V3, P61, DOI 10.1002/ajp.1350030106; vom Saal F S, 1989, J Reprod Fertil, V86, P457, DOI 10.1530/jrf.0.0860457; Walters J.R., 1987, P306; Wasser S.K., 1983, P349; WASSER SK, 1993, BEHAV ECOL SOCIOBIOL, V32, P273; YALCINKAYA TM, 1993, SCIENCE, V260, P1929, DOI 10.1126/science.8391165	27	135	138	2	47	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					60	63		10.1038/373060a0	http://dx.doi.org/10.1038/373060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800039				2022-12-01	WOS:A1995QA23900054
J	SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM				SCHEFFNER, M; NUBER, U; HUIBREGTSE, JM			PROTEIN UBIQUITINATION INVOLVING AN E1-E2-E3 ENZYME UBIQUITIN THIOESTER CASCADE	NATURE			English	Article							N-END RULE; ACTIVATING ENZYME; CONJUGATING ENZYME; E6 ONCOPROTEIN; P53; E6-AP; DEGRADATION; BINDING; LIGASE; YEAST	UBIQUITINATION Of proteins involves the concerted action of the El ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin-protein ligases(1-3). It has been proposed that E3s function as 'docking proteins', specifically binding substrate proteins and specific E2s, and that ubiquitin is then transferred directly from E2s to substrates(1-5). We show here that formation of a ubiquitin thioester on E6-AP, an E3 involved in the human papillomavirus EB-induced ubiquitination of p53 (refs 6-10), is an intermediate step in E6-AP-dependent ubiquitination. The order of ubiquitin transfer is from E1 to E2, from E2 to E6-AP, and finally from E6-AP to a substrate. This cascade of ubiquitin thioester complexes suggests that E3s have a defined enzymatic activity and do not function simply as docking proteins. The cysteine residue of E6-AP responsible for ubiquitin thioester formation was mapped to a region that is highly conserved among several proteins of unknown function, suggesting that these proteins share the ability to form thioesters with ubiquitin.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	SCHEFFNER, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,NEUENHEIMER FELD 242,D-69120 HEIDELBERG,GERMANY.		Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1992, J BIOL CHEM, V267, P16403; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V13, P4129; JENTSCH S, 1992, ANNU REV GENET, V26, P177; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; PASCOLO S, 1992, YEAST, V8, P987, DOI 10.1002/yea.320081109; PICKART CM, 1985, J BIOL CHEM, V260, P1573; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	22	712	746	4	84	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					81	83		10.1038/373081a0	http://dx.doi.org/10.1038/373081a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800044	Green Submitted			2022-12-01	WOS:A1995QA23900061
J	SEUFERT, W; FUTCHER, B; JENTSCH, S				SEUFERT, W; FUTCHER, B; JENTSCH, S			ROLE OF A UBIQUITIN-CONJUGATING ENZYME IN DEGRADATION OF S-PHASE AND M-PHASE CYCLINS	NATURE			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; PROTEOLYSIS; ENCODES; KINASE; CDC28; ANAPHASE; PATHWAY; MITOSIS	CELL cycle progression in eukaryotes is controlled by the p34(cdc2/CDC28) protein kinase and its short-lived, phase-specific regulatory subunits called cyclins(1,2). In Xenopus oocytes, degradation of M-phase (B-type) cyclins is required for exit from mitosis and is mediated by the ubiquitin-dependent proteolytic system(3). Here we show that B-type-cyclin degradation in yeast involves an essential nuclear ubiquitin-conjugating enzyme, UBC9. Repression of UBC9 synthesis prevents cell cycle progression at the G2 or early M phase, causing the accumulation of large budded cells with a single nucleus, a short spindle and replicated DNA. In ubc9 mutants both CLB5, an S-phase cyclin(4,5), and CLB2, an M-phase cyclin(6,7), are stabilized. In wild-type cells the CLB5 protein is unstable throughout the cell cycle, whereas CLB2 turnover occurs only at a specific cell-cycle stage(8). Thus distinct degradation signals or regulated interaction,vith the ubiquitin-protein ligase system may determine the cell-cycle specificity of cyclin proteolysis.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Eberhard Karls University of Tubingen; Max Planck Society; Cold Spring Harbor Laboratory			Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0	30	440	454	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					78	81		10.1038/373078a0	http://dx.doi.org/10.1038/373078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800043				2022-12-01	WOS:A1995QA23900060
J	SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE				SUGAWARA, N; IVANOV, EL; FISHMANLOBELL, J; RAY, BL; WU, X; HABER, JE			DNA STRUCTURE-DEPENDENT REQUIREMENTS FOR YEAST RAD GENES IN GENE CONVERSION	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING-TYPE; NUCLEOTIDE-SEQUENCE; REPAIR; RECOMBINATION; CASSETTE; PROTEIN	IN Saccharomyces cerevisiae, HO endonuclease-induced mating-type (MAT) switching is a specialized mitotic recombination event in which MAT sequences are replaced by those copied from a distant, unexpressed donor (HML or HMR)(1,2). The donors have a chromatin structure inaccessible for both transcription and HO cleavage(1,2). Here we use physical monitoring of DNA to show that MAT switching is completely blocked at an early step in recombination in strains deleted for the DNA repair genes RAD51, RAD52, RAD54, RAD55 or RAD57. We find, however, that only RAD52 is required when the donor sequence is simultaneously not silenced and located on a plasmid. RAD51, RAD54, RAD55 and RAD57 are still required when the same transcribed donor is on the chromosome. We conclude that recombination in vivo occurs between DNA molecules in chromatin, whose structure significantly influences the outcome. RAD51, RAD54, RAD55 and RAD57 are all required to facilitate strand invasion into otherwise inaccessible donor sequences.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BRAND AH, 1985, CELL, P41; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HABER JE, 1992, TRENDS GENET, V8, P446, DOI 10.1016/0168-9525(92)90178-7; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JENSEN RE, 1984, COLD SPRING HARB SYM, V49, P97, DOI 10.1101/SQB.1984.049.01.013; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; LOVETT ST, 1987, GENETICS, V116, P547; MAHONEY DJ, 1989, MOL CELL BIOL, V9, P4621, DOI 10.1128/MCB.9.11.4621; MALONE RE, 1980, P NATL ACAD SCI-BIOL, V77, P503, DOI 10.1073/pnas.77.1.503; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; NICKOLOFF JA, 1989, J MOL BIOL, V207, P527, DOI 10.1016/0022-2836(89)90462-2; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY A, IN PRESS GENETICS; RAVEH D, 1989, MOL GEN GENET, V220, P33; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, P202; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIMPSON RT, 1993, PROGR NUCLEIC ACIDS, V40, P1896; STRATHERN JN, 1989, GENETIC RECOMBINATIO, P445; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; [No title captured]	30	160	164	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					84	86		10.1038/373084a0	http://dx.doi.org/10.1038/373084a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800045				2022-12-01	WOS:A1995QA23900062
J	UNWIN, N				UNWIN, N			ACETYLCHOLINE-RECEPTOR CHANNEL IMAGED IN THE OPEN STATE	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; DELTA-SUBUNIT; LIGAND-BINDING; ION CHANNELS; AMINO-ACIDS; H-3 CHLORPROMAZINE; CRYSTAL-STRUCTURE; TUBULAR CRYSTALS; GAMMA-SUBUNIT; AGONIST	The structure of the open-channel form of the acetylcholine receptor has been determined from electron images of Torpedo ray postsynaptic membranes activated by brief (<5 ms) mixing with droplets containing acetylcholine. Comparison with the closed-channel form shows that acetylcholine Initiates small rotations of the subunits in the extracellular domain, which trigger a change in configuration of a-helices lining the membrane-spanning pore. The open pore tapers towards the intracellular membrane face, where it is shaped by a 'barrel' of a-helices having a pronounced right-handed twist.			UNWIN, N (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BERRIMAN J, 1994, ULTRAMICROSCOPY, V56, P241, DOI 10.1016/0304-3991(94)90012-4; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRISSON A, 1984, J CELL BIOL, V99, P1202, DOI 10.1083/jcb.99.4.1202; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHARNET P, 1990, NEURON, V2, P497; COHEN BN, 1992, J GEN PHYSIOL, V100, P373, DOI 10.1085/jgp.100.3.373; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1985, J PHYSIOL-LONDON, V369, P501, DOI 10.1113/jphysiol.1985.sp015912; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; DANI JA, 1989, J NEUROSCI, V9, P844; DEROSIER DJ, 1968, NATURE, V217, P130, DOI 10.1038/217130a0; DILGER JP, 1990, BIOPHYS J, V57, P723, DOI 10.1016/S0006-3495(90)82593-5; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; HERZ JM, 1989, J BIOL CHEM, V264, P12439; Hille B., 1992, IONIC CHANNELS EXCIT; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2219; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LEE YH, 1994, BIOPHYS J, V66, P646, DOI 10.1016/S0006-3495(94)80838-0; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MATSUBARA N, 1992, BIOCHEMISTRY-US, V31, P5507, DOI 10.1021/bi00139a012; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1984, BIOPHYS J, V46, P277, DOI 10.1016/S0006-3495(84)84022-9; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TOYOSHIMA C, 1988, ULTRAMICROSCOPY, V25, P279, DOI 10.1016/0304-3991(88)90003-4; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1992, J BIOL CHEM, V267, P15770	49	886	896	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	1995	373	6509					37	43		10.1038/373037a0	http://dx.doi.org/10.1038/373037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800037				2022-12-01	WOS:A1995QA23900047
J	WADE, MJ; CHANG, NW				WADE, MJ; CHANG, NW			INCREASED MALE-FERTILITY IN TRIBOLIUM-CONFUSUM BEETLES AFTER INFECTION WITH THE INTRACELLULAR PARASITE WOLBACHIA	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; DROSOPHILA-SIMULANS; FLOUR BEETLES; INHERITANCE; POPULATIONS; SPECIATION; SYMBIONT; SPREAD	THE cytoplasmically inherited microorganism Wolbachia pipientis behaves like a sexually selected trait in its host, the flour beetle Tribolium confusum, enhancing male fertility at the expense of female fecundity. Here we show that infected females have fewer offspring than uninfected females but infected males have a large fertility advantage over uninfected males within multiply-inseminated infected or uninfected females. The male fertility effect accelerates the spread of the Wolbachia through the host population and expands the initial opportunity for hitch-hiking of host nuclear genes. Sperm competition in a host, mediated by endosymbionts, has not been previously described.			WADE, MJ (corresponding author), UNIV CHICAGO,DEPT ECOL & EVOLUT,1101 E 57TH ST,CHICAGO,IL 60637, USA.							Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEWUER JAJ, 1990, NATURE, V348, P558; HOFFMANN AA, 1988, GENETICS, V119, P435; HOLDEN PR, 1993, GENET RES, V62, P23, DOI 10.1017/S0016672300031529; KAMBHAMPATI S, 1993, EVOLUTION, V47, P673, DOI [10.2307/2410079, 10.1111/j.1558-5646.1993.tb02121.x]; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; MORAN N, 1994, TRENDS ECOL EVOL, V9, P15, DOI 10.1016/0169-5347(94)90226-7; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2649; PARK T, 1933, EXP ZOOL, V65, P17; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROBINSON T, 1994, HEREDITY, V73, P155, DOI 10.1038/hdy.1994.114; ROUSSET F, 1991, TRENDS ECOL EVOL, V6, P54, DOI 10.1016/0169-5347(91)90123-F; ROUSSET F, 1993, HEREDITY, V72, P325; STEVENS L, 1990, GENETICS, V124, P367; STEVENS L, 1993, ANIM BEHAV, V46, P305, DOI 10.1006/anbe.1993.1191; STOUTHAMER R, 1993, NATURE, V361, P66, DOI 10.1038/361066a0; SUBBARAO SK, RECENT DEV GENETICS, P313; THOMPSON JN, 1987, BIOL J LINN SOC, V32, P385, DOI 10.1111/j.1095-8312.1987.tb00439.x; TRPIS MJ, 1993, J HERED, V72, P313; TURELLI M, 1992, GENETICS, V132, P713; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; WADE MJ, 1994, J THEOR BIOL, V167, P81, DOI 10.1006/jtbi.1994.1052; WADE MJ, 1994, HEREDITY, V72, P163, DOI 10.1038/hdy.1994.23; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	28	102	108	1	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					72	74		10.1038/373072a0	http://dx.doi.org/10.1038/373072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800041				2022-12-01	WOS:A1995QA23900058
J	WIESENFELD, K; MOSS, F				WIESENFELD, K; MOSS, F			STOCHASTIC RESONANCE AND THE BENEFITS OF NOISE - FROM ICE AGES TO CRAYFISH AND SQUIDS	NATURE			English	Article							CLIMATIC TRANSITIONS; BISTABLE SYSTEMS; DEVILS-HOLE; FIELDS; INFORMATION; ESCAPE	Noise in dynamical systems is usually considered a nuisance. But in certain nonlinear systems, including electronic circuits and biological sensory apparatus, the presence of noise can in fact enhance the detection of weak signals. This phenomenon, called stochastic resonance, may find useful application in physical, technological and biomedical contexts.	UNIV MISSOURI, DEPT PHYS & ASTRON, ST LOUIS, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis	WIESENFELD, K (corresponding author), GEORGIA INST TECHNOL, SCH PHYS, ATLANTA, GA 30332 USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; Anishchenko V. S., 1992, International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, V2, P397, DOI 10.1142/S0218127492000379; ANISHCHENKO VS, 1994, INT J BIFURCAT CHAOS, V4, P441, DOI 10.1142/S0218127494000290; BENNETT WR, 1994, PHYS TODAY, V47, P23, DOI 10.1063/1.881417; BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; BULSARA A, 1993, J STAT PHYS, V70, P1, DOI 10.1007/BF01053949; BULSARA AR, 1994, PHYS REV E, V49, P4989, DOI 10.1103/PhysRevE.49.4989; CARROLL TL, 1993, PHYS REV LETT, V70, P576, DOI 10.1103/PhysRevLett.70.576; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; DYKAMAN MI, 1990, PHYS REV LETT, V65, P2606; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GAMMAITONI L, 1989, PHYS REV LETT, V62, P349, DOI 10.1103/PhysRevLett.62.349; GAMMAITONI L, 1993, PHYS REV LETT, V71, P3625, DOI 10.1103/PhysRevLett.71.3625; GHIL M, 1987, TOPICS GEOPHYSICAL 4; GINGL Z, IN PRESS EUROPHYS LE; HIBBS A, IN PRESS J APPL PHYS; HIBBS A, 1993, AIP C P, V295, P720; IMBRIE J, 1993, NATURE, V363, P531, DOI 10.1038/363531a0; JUNG P, 1989, EUROPHYS LETT, V8, P505, DOI 10.1209/0295-5075/8/6/003; JUNG P, 1993, PHYS REP, V234, P175, DOI 10.1016/0370-1573(93)90022-6; JUNG P, 1991, PHYS REV A, V44, P8032, DOI 10.1103/PhysRevA.44.8032; KELSO JAS, IN PRESS MULTISTABIL; KRUGLIKOV IL, IN PRESS BIOELECTROM; LOFSTEDT R, 1994, PHYS REV LETT, V72, P1947, DOI 10.1103/PhysRevLett.72.1947; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; Makeyev V. M., 1993, Biophysics (English Translation of Biofizika), V38, P189; MATTEUCCI G, 1991, CLIM DYNAM, V6, P67; MCNAMARA B, 1988, PHYS REV LETT, V60, P2626, DOI 10.1103/PhysRevLett.60.2626; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MOSS F, 1993, ANN NY ACAD SCI, V706, P26, DOI 10.1111/j.1749-6632.1993.tb24679.x; Necker LA., 1832, LONDON EDINBURGH, V1, P329, DOI [10.1080/14786443208647909, DOI 10.1080/14786443208647909]; NEIMAN A, 1994, PHYS REV LETT, V72, P2988, DOI 10.1103/PhysRevLett.72.2988; NICOLIS C, 1993, J STAT PHYS, V70, P3, DOI 10.1007/BF01053950; NICOLIS C, 1982, TELLUS, V34, P1, DOI 10.1111/j.2153-3490.1982.tb01786.x; PANTAZELOU E, IN PRESS INT J BIFUR; POLK C, IN PRESS 13TH P A M; RIANI M, 1994, PHYS REV LETT, V72, P3120, DOI 10.1103/PhysRevLett.72.3120; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STOCKS NG, 1993, J PHYS A-MATH GEN, V26, pL385, DOI 10.1088/0305-4470/26/7/007; TENFORDE TS, 1992, ANNU REV PUBL HEALTH, V13, P173, DOI 10.1146/annurev.publhealth.13.1.173; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WIESENFELD K, 1994, PHYS REV LETT, V72, P2125, DOI 10.1103/PhysRevLett.72.2125; WIESENFELD K, IN PRESS NUOVO CIM S; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; ZHOU T, 1990, PHYS REV A, V42, P3161, DOI 10.1103/PhysRevA.42.3161	48	1521	1540	7	138	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					33	36		10.1038/373033a0	http://dx.doi.org/10.1038/373033a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800036				2022-12-01	WOS:A1995QA23900046
J	ZHAO, C; EMMONS, SW				ZHAO, C; EMMONS, SW			A TRANSCRIPTION FACTOR CONTROLLING DEVELOPMENT OF PERIPHERAL SENSE-ORGANS IN C-ELEGANS	NATURE			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; NERVOUS-SYSTEM; CELL LINEAGES; MYC HOMOLOGY; DNA-BINDING; GENE; NEMATODE; ACHAETE; REGION	THE basic-helix-loop-helix (bHLH) proteins constitute a class of transcription factors thought to be important in the control of cell-type determination(1). These transcription factors are believed to activate the expression of cell-type-specific genes to generate stable differentiated cell types(2). The expression of bHLH proteins, in turn, is regulated by spatial cues, so that switches in cell type occur in a reproducible pattern(3). We report here that the lin-32 gene of Caenorhabditis elegans, which encodes a bHLH protein of the Drosophila achaete-scute family of transcription factors, is necessary and in some cells sufficient for specification of the neuroblast cell fate. Similarity in the function and structure of the lin-32 protein (LIN-32) to transcription factors of the achaete-scute gene family in Drosophila and vertebrates implies that this class of transcription factors functioned in a primitive ancestral form to specify neuronal cell fate, supporting the proposition that certain basic mechanisms of cell-type determination have been conserved through metazoan evolution(1).			ZHAO, C (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461, USA.							ALBERTSON DG, 1993, GENETICS, V134, P211; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; BAIRD SE, 1991, DEVELOPMENT, V113, P515; BEGLEY CG, 1989, P NATL ACAD SCI USA, V88, P10128; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; HODGKIN J, 1983, NATURE, V304, P267, DOI 10.1038/304267a0; HORVITZ HR, 1983, COLD SPRING HARB SYM, V43, P453; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PLENEFISCH JD, 1989, GENETICS, V121, P57; RUVKUN G, 1989, GENETICS, V121, P501; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	30	108	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 5	1995	373	6509					74	78		10.1038/373074a0	http://dx.doi.org/10.1038/373074a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QA239	7800042				2022-12-01	WOS:A1995QA23900059
J	BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA				BROOKS, PC; MONTGOMERY, AMP; ROSENFELD, M; REISFELD, RA; HU, TH; KLIER, G; CHERESH, DA			INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS	CELL			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; VONWILLEBRAND-FACTOR; VITRONECTIN; ADHESION; EXPRESSION; FIBRINOGEN; CARCINOMA; ATTACHMENT; MIGRATION	A single intravascular injection of a cyclic peptide or monoclonal antibody antagonist of integrin alpha(v) beta(3) disrupts ongoing angiogenesis on the chick chorioallantoic membrane (CAM). This leads to the rapid regression of histologically distinct human tumors transplanted onto the CAM. Induction of angiogenesis by a tumor or cytokine promotes vascular cell entry into the cell cycle and expression of integrin alpha(v) beta(3). After angiogenesis is initiated, antagonists of this integrin induce apoptosis of the proliferative angiogenic vascular cells, leaving preexisting quiescent blood vessels unaffected. We demonstrate therefore that ligation of integrin alpha(v) beta(3) is required for the survival and maturation of newly forming blood vessels, an event essential for the proliferation of tumors.	SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	BROOKS, PC (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA045726, R37CA050286, R01CA050286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NIAID NIH HHS [T32 AI 072 44-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BASSON CT, 1992, J CELL PHYSIOL, V153, P118, DOI 10.1002/jcp.1041530116; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; PAKU S, 1991, LAB INVEST, V65, P334; PFAFF M, 1994, J BIOL CHEM, V269, P20233; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1993, AM J PATHOL, V143, P401; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	48	2050	2230	2	95	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1157	1164		10.1016/0092-8674(94)90007-8	http://dx.doi.org/10.1016/0092-8674(94)90007-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528107				2022-12-01	WOS:A1994PZ86000007
J	MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS				MANNICK, JB; ASANO, K; IZUMI, K; KIEFF, E; STAMLER, JS			NITRIC-OXIDE PRODUCED BY HUMAN B-LYMPHOCYTES INHIBITS APOPTOSIS AND EPSTEIN-BARR-VIRUS REACTIVATION	CELL			English	Article							DNA-BINDING ACTIVITY; L-ARGININE; KAPPA-B; TYROSINE PHOSPHORYLATION; BURKITT-LYMPHOMA; ANTIMICROBIAL ACTIVITY; TRANSCRIPTION FACTOR; PHENYLARSINE OXIDE; NITROGEN-OXIDES; S-NITROSYLATION	Nitric oxide (NO) produced by murine macrophages is important in murine resistance to ectromelia virus, herpes simplex virus, and vaccinia virus infection. In contrast, NO production by human mononuclear cells has been difficult to demonstrate, and a role for NO in human responses to infection is uncertain. We report constitutive, low level, macrophage-type NO synthase (iNOS) expression in Epstein-Barr virus (EBV)-transformed human B lymphocytes and Burkitt's lymphoma cell lines. Immune NOS activity is involved in maintaining EBV latency through down-regulation of the expression of the immediate-early EBV transactivator Zta. NO also inhibits apoptosis in B lymphocyte cell lines. The effects of NO are largely independent of cGMP and influential on signaling pathways regulated by (sulfhydryl) redox status. These results suggest that NO plays a physiological role in human a cell biology by inhibiting programmed cell death and maintaining viral latency.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RESP,BOSTON,MA 02115; DUKE UNIV,MED CTR,DEPT MED,DIV RESP,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV CARDIOVASC MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Harvard University; Brigham & Women's Hospital; Duke University; Duke University; Duke University	MANNICK, JB (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.			Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02582, HL52529] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBINA JE, 1991, J SURG RES, V50, P403, DOI 10.1016/0022-4804(91)90210-D; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CAMERON ML, 1990, AM REV RESPIR DIS, V142, P1313, DOI 10.1164/ajrccm/142.6_Pt_1.1313; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CRAPO JD, 1994, J CLIN INVEST, V93, P2304, DOI 10.1172/JCI117233; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAIBATA M, 1990, J IMMUNOL, V144, P4788; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DUNCAN DD, 1989, TOXICOL APPL PHARM, V100, P485, DOI 10.1016/0041-008X(89)90296-2; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FREED BM, 1991, TOXICOL APPL PHARM, V107, P173, DOI 10.1016/0041-008X(91)90341-B; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GITSCJ DE, 1994, MOL CELL BIOL, V14, P1939; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GRANGER DL, 1991, RES IMMUNOL, V142, P570, DOI 10.1016/0923-2494(91)90104-Q; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE W, 1968, J VIROL, V2, P182, DOI 10.1128/JVI.2.3.182-191.1968; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1991, RES IMMUNOL, V142, P565, DOI 10.1016/0923-2494(91)90103-P; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KISHISHITA M, 1984, VIROLOGY, V133, P363, DOI 10.1016/0042-6822(84)90402-1; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LORSBACH RB, 1993, J BIOL CHEM, V268, P908; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; RADI R, 1991, J BIOL CHEM, V266, P4244; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; ROZSNYAY Z, 1993, IMMUNOL LETT, V37, P197, DOI 10.1016/0165-2478(93)90031-V; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SMITH CA, 1989, NATURE, V337, P161; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1994, IN PRESS CURR TOPICS; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	78	457	472	1	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 30	1994	79	7					1137	1146		10.1016/0092-8674(94)90005-1	http://dx.doi.org/10.1016/0092-8674(94)90005-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528106				2022-12-01	WOS:A1994PZ86000005
J	NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N				NANGAKU, M; SATOYOSHITAKE, R; OKADA, Y; NODA, Y; TAKEMURA, R; YAMAZAKI, H; HIROKAWA, N			KIF1B, A NOVEL MICROTUBULE PLUS END-DIRECTED MONOMERIC MOTOR PROTEIN FOR TRANSPORT OF MITOCHONDRIA	CELL			English	Article							KINESIN HEAVY-CHAIN; FAST AXONAL-TRANSPORT; BOVINE BRAIN KINESIN; SQUID GIANT-AXON; MEMBRANOUS ORGANELLES; MITOTIC SPINDLE; DROSOPHILA KINESIN; SYNAPTIC VESICLES; NERVOUS-SYSTEM; C-ELEGANS	To further elucidate the mechanism of organelle transport, we cloned a navel member of the mouse kinesin superfamily, KIF1B. This N-terminal-type motor protein is expressed ubiquitously in various kinds of tissues. In situ hybridization revealed that KIF1B is expressed abundantly in differentiated nerve cells. Interestingly, KIF1B works as a monomer, having a microtubule plus end-directed motility, Our rotary shadowing electron microscopy revealed mostly single globular structures. Immunocytochemically, KIF1B was colocalized with mitochondria in vivo. Furthermore, a subcellular fractionation study showed that KIF1B was concentrated in the mitochondrial fraction, and purified KIF1B could transport mitochondria along microtubules in vitro. These data strongly suggested that KIF1B works as a monomeric motor for anterograde transport of mitochondria.	OKINAKA MEM INST MED RES, TOKYO 105, JAPAN		NANGAKU, M (corresponding author), UNIV TOKYO, SCH MED, DEPT ANAT & CELL BIOL, TOKYO 113, JAPAN.		Okada, Yasushi/N-5067-2015	Okada, Yasushi/0000-0003-2601-3689				AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ENDOW SA, 1991, TRENDS BIOCHEM SCI, V16, P221, DOI 10.1016/0968-0004(91)90089-E; FORMAN DS, 1987, BRAIN RES, V412, P96, DOI 10.1016/0006-8993(87)91443-0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEGGENESS MH, 1978, P NATL ACAD SCI USA, V75, P3863, DOI 10.1073/pnas.75.8.3863; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1986, CELL MOTIL CYTOSKEL, V6, P458, DOI 10.1002/cm.970060504; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1986, J CELL BIOL, V103, P33, DOI 10.1083/jcb.103.1.33; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HUANG TG, 1994, J BIOL CHEM, V269, P16493; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KONDO S, 1994, J CELL BIOL, V125, P1095, DOI 10.1083/jcb.125.5.1095; LASEK RJ, 1984, J CELL BIOL, V99, pS212, DOI 10.1083/jcb.99.1.212s; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; Luckow VA, 1992, BACULOVIRUS EXPRESSI; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARTZ D, 1984, CELL MOTIL CYTOSKEL, V4, P89, DOI 10.1002/cm.970040203; MILLER RH, 1985, J CELL BIOL, V101, P2181, DOI 10.1083/jcb.101.6.2181; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PARTLOW LM, 1972, J GEN PHYSIOL, V60, P388, DOI 10.1085/jgp.60.4.388; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; Sambrook J., 1989, MOL CLONING LAB MANU; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Scholey J. M., 1993, MOTILITY ASSAYS MOTO; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STAHL WL, 1963, J CELL BIOL, V19, P293, DOI 10.1083/jcb.19.2.293; TAKEMURA R, 1991, NEUROSCIENCE, V44, P393, DOI 10.1016/0306-4522(91)90064-U; TERASAKI M, 1989, METHOD CELL BIOL, V29, P125; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V40, P559, DOI 10.1016/0092-8674(85)90204-1; VALE RD, 1989, CELL, V59, P915, DOI 10.1016/0092-8674(89)90614-4; VANBLERKOM J, 1991, P NATL ACAD SCI USA, V88, P5031, DOI 10.1073/pnas.88.11.5031; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	72	474	488	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1209	1220		10.1016/0092-8674(94)90012-4	http://dx.doi.org/10.1016/0092-8674(94)90012-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528108				2022-12-01	WOS:A1994PZ86000012
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			INFORMATION CODING IN THE OLFACTORY SYSTEM - EVIDENCE FOR A STEREOTYPED AND HIGHLY ORGANIZED EPITOPE MAP IN THE OLFACTORY-BULB	CELL			English	Article							ODORANT RECEPTOR EXPRESSION; FUNCTIONAL-ORGANIZATION; 2-DEOXYGLUCOSE METHOD; EPITHELIUM; NEURONS; RAT; PROJECTIONS; NERVES; CELLS; GENE	In the mammalian olfactory system, information from similar to 1000 different odorant receptor types is organized in the nose into four spatial zones. Each zone is a mosaic of randomly distributed neurons expressing different receptor types. in these studies, we have obtained evidence that information highly distributed in the nose is transformed in the olfactory bulb of the brain into a highly organized spatial map. We find that specific odorant receptor gene probes hybridize in situ to small, and distinct, subsets of olfactory bulb glomeruli. The spatial and numerical characteristics of the patterns of hybridization that we observe with different receptor probes indicate that, in the olfactory bulb, olfactory information undergoes a remarkable organization into a fine, and perhaps stereotyped, spatial map. In our view, this map is in essence an epitope map, whose similar to 1000 distinct components are used in a multitude of different combinations to discriminate a vast array of different odors.			RESSLER, KJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NIDCD NIH HHS [1-RO1-DC01662-01, 5-F32-DC00188-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001662, F32DC000188] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ALLISON AC, 1949, BRAIN, V72, P186, DOI 10.1093/brain/72.2.186; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; BRUNJES PC, 1994, BRAIN RES REV, V19, P146; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CLARK WL, 1957, PROC R SOC SER B-BIO, V146, P299, DOI 10.1098/rspb.1957.0013; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DAVIS L, 1992, J NEUROSCI, V12, P4867; FIRESTEIN S, 1993, CIBA F SYMP, V179, P115; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GIOIO AE, 1994, J NEUROCHEM, V63, P13; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRAZIADEI PPC, 1986, NEUROSCIENCE, V19, P1025, DOI 10.1016/0306-4522(86)90119-3; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; Kauer J.S., 1987, P205; KAUER JS, 1993, MICROSC RES TECHNIQ, V24, P157, DOI 10.1002/jemt.1070240207; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LAW MI, 1981, J NEUROSCI, V1, P741, DOI 10.1523/JNEUROSCI.01-07-00741.1981; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MONTIGRAZIADEI GA, 1980, NEUROSCIENCE, V5, P1239; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; MORI K, 1994, SEMIN CELL BIOL, V13, P771; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; ONODA N, 1992, NEUROSCI LETT, V137, P157, DOI 10.1016/0304-3940(92)90393-L; PINCHING AJ, 1971, J CELL SCI, V8, P253; PINCHING AJ, 1974, BRAIN RES, V82, P195, DOI 10.1016/0006-8993(74)90598-8; POMEROY SL, 1990, J NEUROSCI, V10, P1952; Reed Randall R., 1994, Seminars in Cell Biology, V5, P33, DOI 10.1006/scel.1994.1005; Ressler Kerry J., 1994, Current Opinion in Neurobiology, V4, P588, DOI 10.1016/0959-4388(94)90061-2; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; SALLAZ M, 1993, NEUROREPORT, V4, P55, DOI 10.1097/00001756-199301000-00014; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SCOTT JW, 1993, MICROSC RES TECHNIQ, V24, P142, DOI 10.1002/jemt.1070240206; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G. M., 1988, NEUROBIOLOGY; Shepherd G. M., 1990, SYNAPTIC ORG BRAIN, P133; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SICARD G, 1984, BRAIN RES, V292, P283, DOI 10.1016/0006-8993(84)90764-9; SKUTELLA T, 1994, MOL BRAIN RES, V23, P179, DOI 10.1016/0169-328X(94)90224-0; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STONE DM, 1991, J COMP NEUROL, V311, P223, DOI 10.1002/cne.903110205; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WALTER J, 1987, DEVELOPMENT, V101, P685	66	924	940	1	59	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 30	1994	79	7					1245	1255		10.1016/0092-8674(94)90015-9	http://dx.doi.org/10.1016/0092-8674(94)90015-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PZ860	7528109				2022-12-01	WOS:A1994PZ86000015
J	AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ				AGGLETON, JP; BLAND, JM; KENTRIDGE, RW; NEAVE, NJ			HANDEDNESS AND LONGEVITY - ARCHIVAL STUDY OF CRICKETERS	BRITISH MEDICAL JOURNAL			English	Article							LEFT-HANDERS; AGE; PREFERENCE	Objective-To test whether handedness is associated with a change in longevity. Design-Archival survey. Setting-British Isles. Subjects-All first class cricketers born before 1961 whose bowling hand was specified (right, n = 5041; left, n = 1132) in a comprehensive encyclopaedia. Main outcome measures-Bowling hand and life span. Results-Regression analysis of the 5960 players born between 1840 and 1960 (3387 dead, 2573 alive) showed no significant relation between mortality and handedness (P = 0.3). Left handedness was, however, associated with an increased likelihood of death from unnatural causes (P = 0.03, log hazard 0.37, 95% confidence interval 0.04 to 0.70). This effect was especially related to deaths during warfare (P = 0.009, log hazard 0.53, 0.13 to 0.92). Conclusion-Left handedness is not, in general, associated with an increase in mortality.	UNIV DURHAM,DEPT PSYCHOL,DURHAM DH1 3LE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND	Durham University; St Georges University London			Kentridge, Robert W/A-5430-2008	Kentridge, Robert W/0000-0003-3688-3899; Neave, Nick/0000-0002-5380-4614; Aggleton, John/0000-0002-5573-1308				AGGLETON JP, 1993, J EPIDEMIOL COMMUN H, V47, P206, DOI 10.1136/jech.47.3.206; ANDERSON MG, 1989, NATURE, V341, P112, DOI 10.1038/341112a0; ANNETT M, 1993, PERCEPT MOTOR SKILL, V76, P295, DOI 10.2466/pms.1993.76.1.295; Bailey Philip, 1993, WHOS WHO CRICKETERS; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; COREN S, 1991, PSYCHOL BULL, V109, P90, DOI 10.1037/0033-2909.109.1.90; COREN S, 1989, AM J PUBLIC HEALTH, V79, P1; COX DR, 1972, J R STAT SOC B, V34, P187; GILBERT AN, 1992, NEUROPSYCHOLOGIA, V30, P601, DOI 10.1016/0028-3932(92)90065-T; HALPERN DF, 1988, NATURE, V333, P213, DOI 10.1038/333213b0; HARRIS LJ, 1993, PSYCHOL BULL, V114, P203, DOI 10.1037/0033-2909.114.2.203; HUGDAHL K, 1993, NEUROPSYCHOLOGIA, V31, P325, DOI 10.1016/0028-3932(93)90156-T; KUHLEMEIER KV, 1991, AM J PUBLIC HEALTH, V81, P513, DOI 10.2105/AJPH.81.4.513; MARKS JS, 1991, NEW ENGL J MED, V325, P1042; PETERS M, 1991, NEUROPSYCHOLOGIA, V29, P1257, DOI 10.1016/0028-3932(91)90039-B; PETO R, 1994, BRIT MED J, V308, P408, DOI 10.1136/bmj.308.6925.408; ROTHMAN KJ, 1991, NEW ENGL J MED, V325, P1041; THORN P, 1982, CRICKET STATISTICIAN, V37, P30; THORN P, 1984, CRICKET STATISTICIAN, V45, P27; TURNER BS, 1993, BRIT MED J, V307, P1577, DOI 10.1136/bmj.307.6919.1577; WOLF PA, 1991, NEW ENGL J MED, V325, P1042; WOOD CJ, 1989, BRIT J PSYCHOL, V80, P227, DOI 10.1111/j.2044-8295.1989.tb02316.x; WOOD EK, 1988, NATURE, V335, P212, DOI 10.1038/335212a0	23	28	28	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1681	1684		10.1136/bmj.309.6970.1681	http://dx.doi.org/10.1136/bmj.309.6970.1681			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PY717	7819983	Green Published			2022-12-01	WOS:A1994PY71700007
J	ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR				ANGELINI, GD; IZZAT, MB; BRYAN, AJ; WEST, RR			HOW SENSITIVE ARE CARDIAC-SURGEONS FINGERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED, CTR PUBL HLTH STUDIES, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	ANGELINI, GD (corresponding author), UNIV BRISTOL, DEPT CARDIAC SURG, BRISTOL BS2 8HW, AVON, ENGLAND.		Izzat, Mohammad Bashar/I-1987-2019	Izzat, Mohammad Bashar/0000-0001-6758-8716; angelini, gianni/0000-0002-1753-3730				BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; LOWE CR, 1962, LANCET, V1, P1086; PAUCA AL, 1989, ANESTHESIOLOGY, V70, P935, DOI 10.1097/00000542-198906000-00009; URZUA J, 1990, ANESTHESIOLOGY, V73, P191, DOI 10.1097/00000542-199007000-00035	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1685	1686		10.1136/bmj.309.6970.1685	http://dx.doi.org/10.1136/bmj.309.6970.1685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819985	Green Published			2022-12-01	WOS:A1994PY71700009
J	BAERHEIM, A; SANDVIK, H				BAERHEIM, A; SANDVIK, H			EFFECT OF ALE, GARLIC, AND SOURED CREAM ON THE APPETITE OF LEECHES	BRITISH MEDICAL JOURNAL			English	Article											BAERHEIM, A (corresponding author), UNIV BERGEN,DIV GEN PRACTICE,ULRIKSDAL 8C,N-5009 BERGEN,NORWAY.							JOSEPH PK, 1989, INDIAN J EXP BIOL, V27, P997; Laerum O D, 1991, Tidsskr Nor Laegeforen, V111, P924; LENT CM, 1988, SCI AM, V258, P98, DOI 10.1038/scientificamerican0688-98; SANDVIK H, IN PRESS TIDSSKR NOR; 1828, EYR, V3, P57	5	7	7	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1689	1689		10.1136/bmj.309.6970.1689	http://dx.doi.org/10.1136/bmj.309.6970.1689			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819987	Green Published			2022-12-01	WOS:A1994PY71700012
J	COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG				COUNSELL, CE; CLARKE, MJ; SLATTERY, J; SANDERCOCK, PAG			THE MIRACLE OF DICE THERAPY FOR ACUTE STROKE - FACT OR FICTIONAL PRODUCT OF SUBGROUP ANALYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PUBLICATION BIAS; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; NEED	Objective-To determine whether inappropriate subgroup analysis together with chance could change the conclusion of a systematic review of several randomised trials of an ineffective treatment. Design-44 randomised controlled trials of DICE therapy for stroke were performed (simulated by rolling different coloured dice; two trials per investigator). Each roll of the dice yielded the outcome (death or survival) for that ''patient.'' Publication bias was also simulated. The results were combined in a systematic review. Setting-Edinburgh. Main outcome measure-Mortality. Results-The ''hypothesis generating'' trial suggested that DICE therapy provided complete protection against death from acute stroke. However, analysis of all the trials suggested a reduction of only 11% (SD 11) in the odds of death. A predefined subgroup analysis by colour of dice suggested that red dice therapy increased the odds by 9% (22). If the analysis excluded red dice trials and those of poor methodological quality the odds decreased by 22% (13, 2P = 0.09). Analysis of ''published'' trials showed a decrease of 23% (13, 2P = 0.07) while analysis of only those in which the trialist had become familiar with the intervention showed a decrease of 39% (17, 2P = 0 .02). Conclusion-The early benefits of DICE therapy were not confirmed by subsequent trials. A plausible (but inappropriate) subset analysis of the effects of treatment led to the qualitatively different conclusion that DICE therapy reduced mortality, whereas in truth it was ineffective. Chance influences the outcome of clinical trials and systematic reviews of trials much more than many investigators realise, and its effects may lead to incorrect conclusions about the benefits of treatment.	WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC STUDIES UNIT, OXFORD OX2 6HE, ENGLAND	University of Edinburgh; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford			sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; BEROYZ G, 1994, LANCET, V343, P619; CHAN SS, 1982, CLIN RES, V30, pA234; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; KOUDSTAAL PJ, 1988, BRIT MED J, V297, P1571, DOI 10.1136/bmj.297.6663.1571; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETO R, 1993, ANN NY ACAD SCI, V703, P314, DOI 10.1111/j.1749-6632.1993.tb26369.x; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; 1994, PREPARING MAINTAININ	20	84	88	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 24	1994	309	6970					1677	1681		10.1136/bmj.309.6970.1677	http://dx.doi.org/10.1136/bmj.309.6970.1677			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819982	Green Published			2022-12-01	WOS:A1994PY71700006
J	CURREY, J				CURREY, J			COME BACK DDT - ALL IS FORGIVEN	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1692	1692		10.1136/bmj.309.6970.1692	http://dx.doi.org/10.1136/bmj.309.6970.1692			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819990	Green Published			2022-12-01	WOS:A1994PY71700016
J	GODDARD, N; COULL, D				GODDARD, N; COULL, D			COLOR-BLIND CRICKETERS AND SNOWBALLS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether colour blindness affects batting in professional cricketers. Design-Comparison of batting averages of colour blind cricketers and those with normal vision. Setting-Players on 18 first class county cricket teams. Subjects-280 of 306 players were tested. Main outcome measures-Results of Isihara colour blindness tests. Results-Batting average for the colour blind group (12 players) was slightly lower than for players with normal vision (20.88 v 26.31). There was no difference in the number of batsmen and bowlers affected. Batting averages before and after the introduction of the white ball into Sunday League cricket did not differ significantly. Conclusions-That batting performance is not significantly impaired by colour blindness suggests that to some extent these players are self selected. Routine testing of cricketers for colour blindness is not recommended.			GODDARD, N (corresponding author), ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND.							FRINDALL B, 1994, PLAYFAIR CRICKET ANN; TREVORROPER PD, 1976, LECTURE NOTES OPHTHA	2	5	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1684	1685		10.1136/bmj.309.6970.1684	http://dx.doi.org/10.1136/bmj.309.6970.1684			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819984	Green Published			2022-12-01	WOS:A1994PY71700008
J	KNOWLES, S				KNOWLES, S			A PASSAGE THROUGH GRIEF - THE WESTERN-AUSTRALIAN RURAL PREGNANCY LOSS TEAM	BRITISH MEDICAL JOURNAL			English	Article											KNOWLES, S (corresponding author), KING EDWARD MEM HOSP WOMEN,SUBIACO,WA 6008,AUSTRALIA.								0	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1705	1708		10.1136/bmj.309.6970.1705	http://dx.doi.org/10.1136/bmj.309.6970.1705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819995	Green Published			2022-12-01	WOS:A1994PY71700024
J	MARSHALL, J; SHARP, E; BARRISON, IG				MARSHALL, J; SHARP, E; BARRISON, IG			ONCE BITTEN, TWICE SHY	BRITISH MEDICAL JOURNAL			English	Article									HEMEL HEMPSTEAD GEN HOSP,DEPT MED,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND; HEMEL HEMPSTEAD GEN HOSP,DEPT SURG,HEMEL HEMPSTEAD HP2 4AD,HERTS,ENGLAND									AZIMI P, 1990, PEDIATR INFECT DIS J, V9, P670; MOLINA JM, 1991, SCAND J INFECT DIS, V23, P659, DOI 10.3109/00365549109024289; RUMLEY RL, 1987, ANN RHEUM DIS, V46, P793, DOI 10.1136/ard.46.10.793	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1695		10.1136/bmj.309.6970.1694a	http://dx.doi.org/10.1136/bmj.309.6970.1694a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819993	Green Published			2022-12-01	WOS:A1994PY71700019
J	PINK, G				PINK, G			THE PRICE OF TRUTH	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1700	1705		10.1136/bmj.309.6970.1700	http://dx.doi.org/10.1136/bmj.309.6970.1700			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819994	Green Published			2022-12-01	WOS:A1994PY71700023
J	REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD				REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD			LATE-ACUTE VENAL ALLOGRAFT-REJECTION AND SYMPTOMLESS CYTOMEGALOVIRUS-INFECTION	LANCET			English	Note							RECIPIENTS	The role of cytomegalovirus infection in allograft injury is controversial. A subgroup of renal graft recipients who bad histologically proven late-acute rejection did not respond to conventional anti-rejection therapy (80% graft loss within 1 year). These patients showed an expansion of memory-type CD8 peripheral-blood T cells that expressed interferon-gamma mRNA and an association with clinically symptomless cytomegalovirus infection (82% PCR positive, 42% antigenaemia). Antiviral therapy with ganciclovir resulted in stable improved graft function in 17 of 21 treated patients with cytomegalovirus-associated late-acute rejection. The results underline the clinical relevance of cytomegalovirus-related graft injury and offer a novel therapeutic approach.	FREE UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM CHARITE,INST VIROL,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	REINKE, P (corresponding author), FREE UNIV BERLIN,KLINIKUM CHARITE,MED NEPHROL CLIN 5,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Reinke, Petra/0000-0003-0771-4375				ALMOND PS, 1994, TRANSPLANTATION, V55, P752; CAPPEL R, 1978, ARCH VIROL, V56, P149, DOI 10.1007/BF01317289; DOCKE WD, 1994, LANCET, V343, P268, DOI 10.1016/S0140-6736(94)91116-9; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; PLATZER C, 1909, TRANSPLANTATION, V58, P264; RAO KV, 1989, TRANSPLANTATION, V47, P290, DOI 10.1097/00007890-198902000-00019; REINKE P, 1994, TRANSPLANTATION, V58, P35, DOI 10.1097/00007890-199407150-00007; REIPERT B, 1992, CLIN EXP IMMUNOL, V89, P143; SIMMONS RL, 1970, TRANSPL P, V2, P419; Tolkoff-Rubin N E, 1992, Curr Opin Nephrol Hypertens, V1, P243, DOI 10.1097/00041552-199212000-00009	10	168	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1737	1738		10.1016/S0140-6736(94)92887-8	http://dx.doi.org/10.1016/S0140-6736(94)92887-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7741857				2022-12-01	WOS:A1994PY28100010
J	SCOTT, R; SCOTT, H				SCOTT, R; SCOTT, H			CROCODILE BITES AND TRADITIONAL BELIEFS IN KOROGWE DISTRICT, TANZANIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate why fatal crocodile bites are increasing in a Tanzanian district and the importance of traditional beliefs and superstitions in determining the residents' response to the crocodiles. Design-Information about beliefs was obtained by interview of Korogwe residents. Human and crocodile fatality statistics were obtained from the Korogwe Department of Natural Resources. Setting-Villages within Korogwe District. Subjects-Population of Korogwe District. Results-Crocodiles have been responsible for 51 deaths in the 52 months from January 1990 to April 1994. Of these, 18 deaths occurred in the first four months of 1994. Conclusions-Local beliefs and superstitions about crocodiles include those about the taming of animals, with implications concerning the choice of victim and the penalties that may ensue if a crocodile is killed. The recent rise in human fatalities is thought to relate to increasing river pollution reducing the fish supply, together with a change in social mores at the riverside which has increased the crocodiles' displeasure. A reliable pumped water supply would reduce the need to draw water and bathe in the river, and eradication of superstition would empower the villagers in the fight against a common enemy.			SCOTT, R (corresponding author), ST RAPHAELS HOSP,POB 35,TANGA,TANZANIA.								0	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1691	1692		10.1136/bmj.309.6970.1691	http://dx.doi.org/10.1136/bmj.309.6970.1691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819989	Green Published			2022-12-01	WOS:A1994PY71700015
J	WILLIAMS, R				WILLIAMS, R			DE INERTIA URBANORUM	BRITISH MEDICAL JOURNAL			English	Article																		ANDERSON D, 1991, ENERGY ENV; ANGRIST SW, 1967, ORDER CHAOS LAWS ENE; ARCHER MD, 1974, FUTURES          JUN, P261; ARCHER MD, 1991, PHOTOCHEMSITRY PHOTO; Bryant C., 1993, Biologist (London), V40, P58; CAIRNCROSS F, 1991, COSTING EARTH, P133; Cooper KH, 1970, NEW AEROBICS; FOWLER D, 1990, GREENHOUSE EFFECT TE, P10; HARRISS RC, 1989, OZONE DEPLETION GREE, P79; HOLMAN C, 1991, ROAD TRANSPORT AIR P, P11; JOUZEL J, 1993, NATURE, V364, P407, DOI 10.1038/364407a0; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; LAMB HH, 1972, CLIMATE PRESENT PAST, V1, P45; NEFTEL A, 1985, NATURE, V315, P45, DOI 10.1038/315045a0; Orwell G., 1946, COLLECTED ESSAYS JOU, V4, P127; RICE RA, 1972, TECHNOL REV, V74, P31; RILEY F, 1923, SETTLE DISTRICT N W, P29; SHINE KP, 1989, OZONE DEPLETION HLTH, P72; SMITH R, 1993, BRIT MED J, V306, P1285, DOI 10.1136/bmj.306.6888.1285; WALKER JCG, 1992, GLOBAL PLANET CHANGE, V97, P151, DOI 10.1016/0921-8181(92)90009-Y; Wilkie, 1968, MUSCLE; WILLIAMS RE, 1975, BRIT MED J, V4, P25, DOI 10.1136/bmj.4.5987.25; 1974, NEW ENCY BRITANNICA, V17, P1018; 1993, DESIGN MANUAL ROADS, V11; 1992, CLIMATE CHANGE DISCU; 1993, TRANSPORT STATISTICS, P10	26	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1741	1745		10.1136/bmj.309.6970.1741	http://dx.doi.org/10.1136/bmj.309.6970.1741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820010	Green Published			2022-12-01	WOS:A1994PY71700042
J	WYATT, JP				WYATT, JP			SQUIRREL BITES	BRITISH MEDICAL JOURNAL			English	Article											WYATT, JP (corresponding author), ROYAL HOSP SICK CHILDREN,EDINBURGH EH9 1LF,MIDLOTHIAN,SCOTLAND.							BRACKENBURY PH, 1989, ARCH EMERG MED, V6, P251; LAWTON J, 1990, NATURE, V343, P595, DOI 10.1038/343595a0; MAGEE JS, 1989, PEDIATR INFECT DIS J, V8, P123; RUSSO PK, 1981, NEW ENGL J MED, V304, P1166, DOI 10.1056/NEJM198105073041911	4	6	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1694	1694		10.1136/bmj.309.6970.1694	http://dx.doi.org/10.1136/bmj.309.6970.1694			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819992	Green Published			2022-12-01	WOS:A1994PY71700018
J	[Anonymous]				[Anonymous]			DYING FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1696	1699						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7529608				2022-12-01	WOS:A1994PY71700021
J	COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R				COMAI, L; ZOMERDIJK, JCBM; BECKMANN, H; ZHOU, S; ADMON, A; TJIAN, R			RECONSTITUTION OF TRANSCRIPTION FACTOR SL1 - EXCLUSIVE BINDING OF TBP BY SL1 OR TFIID SUBUNITS	SCIENCE			English	Article							RNA POLYMERASE-I; RIBOSOMAL-RNA; DNA-BINDING; MOLECULAR-CLONING; III PROMOTERS; TATA-LESS; PROTEIN; EXPRESSION; SPECIFICITY; COMPLEX	RNA polymerase I and II transcription factors SL1 and TFIID, respectively, are composed of the TATA-binding protein (TBP) and a set of TBP-associated factors (TAFs) responsible for promoter recognition. How the universal transcription factor TBP becomes committed to a TFIID or SL1 complex has not been known. Complementary DNAs encoding each of the three TAF(I)s that are integral components of SL1 have now been isolated. Analysis of subunit interactions indicated that the three TAF(I)s can bind individually and specifically to TBP. In addition, these TAF(I)s interact with each other to form a stable TBP-TAF complex. When TBP was bound first by either TAF(I)110, 63, or 48, subunits of TFIID such as TAF(II)250 and 150 did not bind TBP. Conversely, if TBP first formed a complex with TAF(II)250 or 150, the subunits of SL1 did not bind TBP. These results suggest that a mutually exclusive binding specificity for TBP intrinsic to SL1 and TFIID subunits directs the formation of promoter- and RNA polymerase-selective TBP-TAF complexes.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Comai, Lucio/L-5905-2019; Comai, Lucio/H-9524-2019; Zomerdijk, Joost/A-5142-2008	Comai, Lucio/0000-0003-3109-1841; Zomerdijk, Joost/0000-0003-1865-729X; Admon, Arie/0000-0003-0504-3950				BECKMANN H, UNPUB; BELL SG, UNPUB; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COMAI L, UNPUB; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EBERHARD D, 1993, NUCLEIC ACIDS RES, V21, P4180, DOI 10.1093/nar/21.18.4180; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JANZEN HM, 1992, GENE DEV, V6, P1950; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; KIM K, 1994, J BIOL CHEM, V269, P4891; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1992, GENES DEV, V5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	45	128	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1966	1972		10.1126/science.7801123	http://dx.doi.org/10.1126/science.7801123			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801123				2022-12-01	WOS:A1994PZ26700023
J	DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA				DOOLEY, CT; CHUNG, NN; WILKES, BC; SCHILLER, PW; BIDLACK, JM; PASTERNAK, GW; HOUGHTEN, RA			AN ALL D-AMINO-ACID OPIOID PEPTIDE WITH CENTRAL ANALGESIC ACTIVITY FROM A COMBINATORIAL LIBRARY	SCIENCE			English	Article							OPIATE RECEPTOR; LIGANDS	A synthetic combinatorial library containing 52,128,400 D-amino acid hexapeptides was used to identify a ligand for the mu opioid receptor. The peptide, Ac-rfwink-NH2, bears no resemblance to any known opioid peptide. Simulations using molecular dynamics, however, showed that three amino acid moieties have the same spatial orientation as the corresponding pharmacophoric groups of the opioid peptide PLO17. Ac-rfwink-NH2 was shown to be a potent agonist at the mu receptor and induced long-lasting analgesia in mice. Analgesia produced by intraperitoneally administered Ac-rfwink-NH2 was blocked by intracerebroventricular administration of naloxone, demonstrating that this peptide may cross the blood-brain barrier.	TORREY PINES INST MOLEC STUDIES,SAN DIEGO,CA 92121; HOUGHTEN PHARMACEUT INC,SAN DIEGO,CA 92121; CLIN RES INST MONTREAL,CHEM BIOL & PEPTIDE RES LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642; MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021	Torrey Pines Institute for Molecular Studies, California; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Rochester; Memorial Sloan Kettering Cancer Center					NIDA NIH HHS [DA-03742, DA-000138, DA-02615] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003742, R01DA002615, R56DA002615] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CLARK JA, 1988, MOL PHARMACOL, V34, P308; CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461; DIMAIO J, 1982, J MED CHEM, V25, P1432, DOI 10.1021/jm00354a008; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; HENDERSON G, 1972, BRIT J PHARMACOL, V46, P764, DOI 10.1111/j.1476-5381.1972.tb06901.x; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412; HOUGHTEN RA, 1993, BIOORG MED CHEM LETT, V3, P405, DOI 10.1016/S0960-894X(01)80222-5; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JIANG Q, 1992, J PHARMACOL EXP THER, V262, P526; KOSTERLITZ HW, 1968, BRIT J PHARMACOL, V33, P266, DOI 10.1111/j.1476-5381.1968.tb00988.x; PATON WDM, 1957, BRIT J PHARM CHEMOTH, V12, P119, DOI 10.1111/j.1476-5381.1957.tb01373.x; SCHILLER PW, 1978, BIOCHEM BIOPH RES CO, V85, P1332, DOI 10.1016/0006-291X(78)91149-X; SCHILLER PW, 1983, PEPTIDES STRUCTURE F, P269; VAUGHN LK, 1993, LIFE SCI, V52, P1509; YAMAZAKI T, 1993, J MED CHEM, V36, P708, DOI 10.1021/jm00058a007; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	19	144	186	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2019	2022		10.1126/science.7801131	http://dx.doi.org/10.1126/science.7801131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801131				2022-12-01	WOS:A1994PZ26700037
J	DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR				DYDA, F; HICKMAN, AB; JENKINS, TM; ENGELMAN, A; CRAIGIE, R; DAVIES, DR			CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HIV-1 INTEGRASE - SIMILARITY TO OTHER POLYNUCLEOTIDYL TRANSFERASES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; DNA INTEGRATION; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; PROTEIN INVITRO; RIBONUCLEASE-H; AIDS VIRUS; IDENTIFICATION	HIV integrase is the enzyme responsible for inserting the viral DNA into the host chromosome; it is essential for HIV replication. The crystal structure of the catalytically active core domain (residues 50 to 212) of HIV-7 integrase was determined at 2.5 Angstrom resolution. The central feature of the structure is a five-stranded beta sheet flanked by helical regions. The overall topology reveals that this domain of integrase belongs to a superfamily of polynucleotidyl transferases that includes ribonuclease H and the Holliday junction resolvase RuvC. The active site region is identified by the position of two of the conserved carboxylate residues essential for catalysis, which are located at similar positions in ribonuclease H. In the crystal, two molecules form a dimer with an extensive solvent-inaccessible interface of 1300 Angstrom(2) per monomer.	NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								[Anonymous], COMMUNICATION; ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARTYMIUK PJ, 1993, FEBS LETT, V324, P15, DOI 10.1016/0014-5793(93)81523-3; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CROUCH R J, 1990, New Biologist, V2, P771; Crouch R. J., 1982, NUCLEASES, P211; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAVIES JF, 1994, CELL, V7623, P1123; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FUREY W, 1990, AM CRYSTALLOGRAPHIC; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENKINS TC, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREMENSTOVA E, COMMUNICATION; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LIN TH, 1991, PROTEIN ENG, V4, P435, DOI 10.1093/protein/4.4.435; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NUCLEASES, 1967, DAVI, P93; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RAMAKRISHNAN V, 1993, NATURE, V262, P219; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERRATT D, 1989, MOBILE DNA, P163; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINCENT KA, 1990, NUCLEIC ACIDS RES, V18, P6045, DOI 10.1093/nar/18.20.6045; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1994, NUCLEIC ACIDS RES, V22, P2176, DOI 10.1093/nar/22.11.2176; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	81	679	711	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1981	1986		10.1126/science.7801124	http://dx.doi.org/10.1126/science.7801124			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801124				2022-12-01	WOS:A1994PZ26700027
J	HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J				HIRSCH, S; MUCKEL, E; HEEMEYER, F; VONHEIJNE, G; SOLL, J			A RECEPTOR COMPONENT OF THE CHLOROPLAST PROTEIN TRANSLOCATION MACHINERY	SCIENCE			English	Article							OUTER ENVELOPE MEMBRANE; SPINACH-CHLOROPLASTS; IMPORT APPARATUS; PEA-CHLOROPLASTS; CONTACT SITES; LOCALIZATION; IDENTIFICATION; MITOCHONDRIAL; POLYPEPTIDE; TRANSPORT	The chloroplast outer envelope protein OEP86 functions as a receptor in precursor protein translocation into chloroplasts. Sequence analysis suggests that the precursor of OEP86 is directed to the chloroplast outer envelope by a cleavable, negatively charged, and unusually long amino-terminal peptide. This presequence is unlike other potential targeting signals and suggests the existence of another membrane insertion pathway. insertion of precursor OEP86 required the hydrolysis of adenosine triphosphate and the existence of surface exposed chloroplast membrane components, and it was not competed by another precursor protein destined for the internal plastid compartments.	CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, D-24098 KIEL, GERMANY; KAROLINSKA INST, NOVUM, CTR STRUCT BIOCHEM, S-14157 HUDDINGE, SWEDEN	University of Kiel; Karolinska Institutet			von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; 				ALEFSEN H, 1994, J PLANT PHYSIOL, V144, P339, DOI 10.1016/S0176-1617(11)81196-X; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; HARLOW E, 1989, ANTIBODIES LABORATOR; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; JOYARD J, 1983, J BIOL CHEM, V258, P1; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SEEDORF M, IN PRESS PLANT J; SOLL J, 1989, PLANTA, V177, P393, DOI 10.1007/BF00403598; SOLL J, 1992, PLANT J, V2, P253, DOI 10.1111/j.1365-313X.1992.00253.x; SOLL J, 1993, PHYSIOL PLANTARUM, V87, P433, DOI 10.1111/j.1399-3054.1993.tb01752.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WAEGEMANN K, 1993, NATO ASI SERIES H, V74, P101	29	196	208	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1989	1992		10.1126/science.7801125	http://dx.doi.org/10.1126/science.7801125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801125	Green Submitted			2022-12-01	WOS:A1994PZ26700029
J	KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP				KALPANA, GV; MARMON, S; WANG, WD; CRABTREE, GR; GOFF, SP			BINDING AND STIMULATION OF HIV-1 INTEGRASE BY A HUMAN HOMOLOG OF YEAST TRANSCRIPTION FACTOR SNF5	SCIENCE			English	Article							I-HYPERSENSITIVE SITES; SACCHAROMYCES-CEREVISIAE; RETROVIRUS INTEGRATION; PROTEIN INVITRO; CHROMATIN STRUCTURE; PREFERRED TARGETS; GENES; DNA; EXPRESSION; SNF2/SWI2	Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The two-hybrid system was used to identify a human gene product that binds tightly to the human immunodeficiency virus-type 1 (HIV-1) integrase in vitro and stimulates its DNA-joining activity. The sequence of the gene suggests that the protein is a human homolog of yeast SNF5, a transcriptional activator required for high-level expression of many genes. The gene, termed INI1 (for integrase interactor 1), may encode a nuclear factor that promotes integration and targets incoming viral DNA to active genes.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; STANFORD UNIV,HOWARD HUGHES MED INST,DEPT DEV BIOL,BECKMAN CTR B207,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Stanford University			Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928; Kalpana, Ganjam/0000-0003-4111-0604	NIAID NIH HHS [U01 AI 24845] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI024845] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KALPANA GV, 1993, P NATL ACAD SCI USA, V90, P10593, DOI 10.1073/pnas.90.22.10593; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LEE MS, 1994, P NATL ACAD SCI USA, V91, P9823, DOI 10.1073/pnas.91.21.9823; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NEIGEBORN L, 1984, GENETICS, V108, P845; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; Weiss R, 1984, RNA TUMOR VIRUSES; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	40	433	459	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2002	2006		10.1126/science.7801128	http://dx.doi.org/10.1126/science.7801128			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801128				2022-12-01	WOS:A1994PZ26700033
J	MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A				MAGRELLI, A; LANGENKEMPER, K; DEHIO, C; SCHELL, J; SPENA, A			SPLICING OF THE ROLA TRANSCRIPT OF AGROBACTERIUM-RHIZOGENES IN ARABIDOPSIS	SCIENCE			English	Article							PRE-MESSENGER-RNA; INTRONS; GENE; DNA; SEQUENCES; BACTERIA; PLASMID; BACTERIOPHAGE-T4; IDENTIFICATION; EXPRESSION	The rolA gene encoded on the Ri plasmid A4 of Agrobacterium rhizogenes is one of the transferred (T-L-DNA) genes involved in the pathogenesis of hairy-root disease in plants. The function of the 100-amino acid protein product of rolA is unknown, although its expression causes physiological and developmental alterations in transgenic plants. The rolA gene of A. rhizogenes contains an intron in its untranslated leader region that has features typical of plant pre-messenger RNA introns. Transcription and splicing of the rolA pre-messenger RNA occur in the plant cell.	MAX PLANCK INST ZUCHTUNGSFORSCH,D-50829 COLOGNE,GERMANY	Max Planck Society			Magrelli, Armando/K-4330-2019; Dehio, Christoph/R-8277-2016; Magrelli, Armando/A-5478-2010; Dehio, Christoph/AAD-5572-2019	Magrelli, Armando/0000-0002-5036-3710; Dehio, Christoph/0000-0001-7288-1052; Magrelli, Armando/0000-0002-5036-3710; Dehio, Christoph/0000-0001-7288-1052				CARNEIRO M, 1993, PLANT J, V3, P785, DOI 10.1111/j.1365-313X.1993.00785.x; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; CSANK C, 1990, NUCLEIC ACIDS RES, V18, P5133, DOI 10.1093/nar/18.17.5133; DEHIO C, 1993, MOL GEN GENET, V241, P359, DOI 10.1007/BF00284689; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GOODALL GJ, 1990, PLANT MOL BIOL, V14, P727, DOI 10.1007/BF00016505; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GOODRICHBLAIR H, 1990, CELL, V63, P417, DOI 10.1016/0092-8674(90)90174-D; JANSSENS A, 1984, MOL GEN GENET, V195, P341, DOI 10.1007/BF00332769; KOVACS SA, 1993, J BACTERIOL, V175, P1871, DOI 10.1128/JB.175.7.1871-1878.1993; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MAGRELLI A, UNPUB; Maniatis T, 1989, DECONTAMINATION DILU; MICHAEL T, IN PRESS METHODS MOL; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHRODER G, 1983, EMBO J, V2, P403, DOI 10.1002/j.1460-2075.1983.tb01437.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SINKAR VP, 1988, GENE DEV, V2, P688, DOI 10.1101/gad.2.6.688; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; SLIGHTOM JL, 1986, J BIOL CHEM, V261, P108; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; WHITE FF, 1985, J BACTERIOL, V164, P33, DOI 10.1128/JB.164.1.33-44.1985; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	27	21	23	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1986	1988		10.1126/science.7528444	http://dx.doi.org/10.1126/science.7528444			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7528444				2022-12-01	WOS:A1994PZ26700028
J	PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT				PAZIN, MJ; KAMAKAKA, RT; KADONAGA, JT			ATP-DEPENDENT NUCLEOSOME RECONFIGURATION AND TRANSCRIPTIONAL ACTIVATION FROM PREASSEMBLED CHROMATIN TEMPLATES	SCIENCE			English	Article							RNA POLYMERASE-II; GAL4 DERIVATIVES; DROSOPHILA EMBRYOS; DNA-REPLICATION; DISRUPTION; INVITRO; YEAST; GAL4-VP16; ANTIREPRESSION; MECHANISM	GAL4-VP16-mediated nucleosome reconfiguration and transcriptional activation were observed with preassembled chromatin templates that contained regular and physiological nucleosome spacing. Both processes were dependent on adenosine triphosphate (ATP), although binding of GAL4-VP16 to the chromatin was ATP-independent. Factor-mediated nucleosome reconfiguration was not, however, sufficient for transcriptional activation. These experiments recreate in vitro the active participation of nucleosomal cores in the regulation of transcription that occurs in vivo, and they suggest a multistep pathway for transcriptional activation in which factor- and ATP-dependent nucleosome reconfiguration is followed by facilitation by the DNA-bound activator of transcription from the repressed chromatin template.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Pazin, Michael/0000-0002-7561-3640				AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Bulger M., 1994, METH MOL G, V5, P241; BULGER MD, UNPUB; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAVILLI G, 1993, EMBO J, V12, P4603; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; IMBALZANO AN, 1991, NATURE, V370, P481; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; KAMAKAKA RT, UNPUB; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.bi.63.070194.001405; PAZIN MJ, UNPUB; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	41	135	137	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2007	2011		10.1126/science.7801129	http://dx.doi.org/10.1126/science.7801129			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801129				2022-12-01	WOS:A1994PZ26700034
J	SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S				SALLES, FJ; LIEBERFARB, ME; WREDEN, C; GERGEN, JP; STRICKLAND, S			COORDINATE INITIATION OF DROSOPHILA DEVELOPMENT BY REGULATED POLYADENYLATION OF MATERNAL MESSENGER-RNAS	SCIENCE			English	Article							XENOPUS OOCYTE MATURATION; RECEPTOR TYROSINE KINASE; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL CONTROL; MEIOTIC MATURATION; ANTERIOR PATTERN; MOUSE OOCYTES; BODY PATTERN; EMBRYO; GENE	Pattern formation in Drosophila depends initially on the translational activation of maternal messenger RNAs (mRNAs) whose protein products determine cell fate. Three mRNAs that dictate anterior, dorsoventral, and terminal specification-bicoid, Toll, and torso, respectively-showed increases in polyadenylate [poly(A)] tail length concomitant with translation. In contrast, posteriorly localized nanos mRNA, although also translationally activated, was not regulated by poly(A) status. These results implicate at least two mechanisms of mRNA activation in flies. Studies with bicoid mRNA showed that cytoplasmic polyadenylation is necessary for translation, establishing this pathway as essential for embryogenesis. Combined, these experiments identify a regulatory pathway that can coordinate initiation of maternal pattern formation systems in Drosophila.	SUNY STONY BROOK, MED CTR, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051584] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51584] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; EPHRUSSI A, COMMUNICATION; FERRANDON D, IN PRESS CELL; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KUHN R, 1991, MECH DEVELOP, V35, P143, DOI 10.1016/0925-4773(91)90064-D; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARTIN JR, 1994, NATURE, V367, P741, DOI 10.1038/367741a0; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SALLES F, UNPUB; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; VERROTTI AC, UNPUB; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WNAG LK, 1994, DEV DYNAM, V199, P103	43	205	207	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	1994	266	5193					1996	1999		10.1126/science.7801127	http://dx.doi.org/10.1126/science.7801127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801127				2022-12-01	WOS:A1994PZ26700031
J	STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C				STANLEY, P; PACKMAN, LC; KORONAKIS, V; HUGHES, C			FATTY ACYLATION OF 2 INTERNAL LYSINE RESIDUES REQUIRED FOR THE TOXIC ACTIVITY OF ESCHERICHIA-COLI HEMOLYSIN	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; ACTINOBACILLUS-PLEUROPNEUMONIAE; CHROMOSOMAL HEMOLYSIN; VIRUS GLYCOPROTEINS; GENE; SECRETION; PROTEIN; PROHAEMOLYSIN; ACTIVATION; HLYC	Hemolysin of Escherichia coli is activated by fatty acylation of the protoxin, directed by the putative acyl transferase HlyC and by acyl carrier protein (ACP). Mass spectrometry and Edman degradation of proteolytic products from mature toxin activated in vitro with tritium-labeled acylACP revealed two fatty-acylated internal lysine residues, lysine 564 and lysine 690. Resistance of the acylation to chemical treatments suggested that fatty acid was amide linked. Substitution of the two lysines confirmed that they were the only sites of acylation and showed that although each was acylated in the absence of the other, both sites were required for in vivo toxin activity.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge; University of Cambridge				Koronakis, Vassilis/0000-0002-1353-1092				CHANG YF, 1989, DNA-J MOLEC CELL BIO, V8, P635, DOI 10.1089/dna.1.1989.8.635; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FORESTIER C, 1991, INFECT IMMUN, V59, P4212, DOI 10.1128/IAI.59.11.4212-4220.1991; FORESTIER C, 1990, INFECT IMMUN, V58, P828, DOI 10.1128/IAI.58.3.828-832.1990; FREY J, 1991, INFECT IMMUN, V59, P3026, DOI 10.1128/IAI.59.9.3026-3032.1991; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GYGI D, 1990, MOL MICROBIOL, V4, P123, DOI 10.1111/j.1365-2958.1990.tb02021.x; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HARDIE KR, 1991, MOL MICROBIOL, V5, P1669, DOI 10.1111/j.1365-2958.1991.tb01914.x; HEDO JA, 1987, J BIOL CHEM, V262, P954; HESS J, 1986, FEMS MICROBIOL LETT, V34, P1, DOI 10.1016/0378-1097(86)90261-2; HUGHES C, 1992, BIOESSAYS, V14, P519, DOI 10.1002/bies.950140804; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KORONAKIS V, 1988, NUCLEIC ACIDS RES, V16, P4789, DOI 10.1093/nar/16.11.4789; KRAIG E, 1990, INFECT IMMUN, V58, P920, DOI 10.1128/IAI.58.4.920-929.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCWHINNEY DR, 1992, J BACTERIOL, V174, P291, DOI 10.1128/jb.174.1.291-297.1992; OLSON EN, 1984, J BIOL CHEM, V259, P5364; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PELLETT S, 1990, INFECT IMMUN, V58, P822, DOI 10.1128/IAI.58.3.822-827.1990; PILLAI S, 1987, P NATL ACAD SCI USA, V84, P7654, DOI 10.1073/pnas.84.21.7654; ROWE GE, 1994, INFECT IMMUN, V62, P579, DOI 10.1128/IAI.62.2.579-588.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STANLEY P, UNPUB; STANLEY PLD, 1993, MOL MICROBIOL, V10, P781, DOI 10.1111/j.1365-2958.1993.tb00948.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUTTORP N, 1990, INFECT IMMUN, V58, P3796, DOI 10.1128/IAI.58.11.3796-3801.1990	34	167	173	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					1992	1996		10.1126/science.7801126	http://dx.doi.org/10.1126/science.7801126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801126				2022-12-01	WOS:A1994PZ26700030
J	ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R				ZOMERDIJK, JCBM; BECKMANN, H; COMAI, L; TJIAN, R			ASSEMBLY OF TRANSCRIPTIONALLY ACTIVE RNA-POLYMERASE-I INITIATION-FACTOR SL1 FROM RECOMBINANT SUBUNITS	SCIENCE			English	Article							FACTOR-TIF-IA; TATA-BINDING-PROTEIN; VACCINIA VIRUS; EXPRESSION SYSTEM; III TRANSCRIPTION; RIBOSOMAL DNA; MOUSE RDNA; PROMOTER; COMPLEX; SEQUENCES	Initiation of ribosomal RNA synthesis by RNA polymerase I requires the promoter selec tivity factor SL1, which consists of the TATA-binding protein, TBP, and three associated factors, TAF(I)s 110, 63, and 48. Here the in vivo and in vitro assembly of functional SL1 complexes from recombinant TAF(I)s and TBP are reported. Complexes containing TBP and all three TAF(I)s were as active in supporting transcription from the human ribosomal RNA gene promoter as endogenous SL1, whereas partial complexes without TBP did not efficiently direct transcription in vitro. These results suggest that TAF(I)s 110, 63, and 48, together with TBP, are necessary and sufficient to reconstitute a transcriptionally active SL1 complex.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley			Zomerdijk, Joost/A-5142-2008; Comai, Lucio/H-9524-2019; Comai, Lucio/L-5905-2019	Comai, Lucio/0000-0003-3109-1841; Zomerdijk, Joost/0000-0003-1865-729X				BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CAVANAUGH AH, 1985, NUCLEIC ACIDS RES, V13, P3357, DOI 10.1093/nar/13.9.3357; CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MISHIMA Y, 1982, NUCLEIC ACIDS RES, V10, P6659, DOI 10.1093/nar/10.21.6659; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REEDER RH, 1992, REGULATION TRANSCRIP, V1, P315; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHNAPP G, 1994, EMBO J, V13, P4028, DOI 10.1002/j.1460-2075.1994.tb06719.x; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451	26	97	99	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 23	1994	266	5193					2015	2018		10.1126/science.7801130	http://dx.doi.org/10.1126/science.7801130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PZ267	7801130				2022-12-01	WOS:A1994PZ26700036
J	CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A				CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A			A THALAMIC NUCLEUS SPECIFIC FOR PAIN AND TEMPERATURE SENSATION	NATURE			English	Article							NEURONS; AREA; CAT; STIMULI; MONKEY; TRACT	THE existence of a posterolateral thalamic relay nucleus for pain and temperature sensation was postulated in 1911, on the basis of the stroke-induced analgesia and thermanaesthesia found paradoxically in patients with thalamic pain syndrome(1). Pain or temperature sensations can be evoked in humans by electrical stimulation in a vaguely defined region of the posterolateral thalamus(2,3). Here we use anterograde tracing and single unit recordings to demonstrate that there is a distinct nucleus in the posterior thalamus of the macaque monkey that receives a dense, topographic input from spinothalamic lamina I neurons and in which almost all neurons are nociceptive- or thermoreceptive-specific. Immunohistochemical staining showed that this nucleus is defined by a dense calbindin-positive fibre plexus in the macaque, so we applied the same staining method to sections of human thalamus. We found a nearly identical fibre plexus localized within a distinct nucleus that is cytoarchitectonically homologous to the lamina I relay nucleus in the macaque thalamus. The stereotaxic coordinates of this nucleus and its location relative to the main somatosensory representation fit clinical descriptions of the pain-producing region in humans. We conclude that this is a specific thalamic nucleus for pain and temperature sensation in both monkey and human.	UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Universite de Montreal; Universite de Montreal; Linkoping University	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.		Blomqvist, Anders/K-3990-2019	Blomqvist, Anders/0000-0002-6928-4473				ANTAL M, 1990, J COMP NEUROL, V295, P467, DOI 10.1002/cne.902950310; BLOMQVIST A, 1993, J COMP NEUROL, V327, P584, DOI 10.1002/cne.903270409; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BUSHNELL MC, 1993, J NEUROPHYSIOL, V69, P739, DOI 10.1152/jn.1993.69.3.739; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; COGHILL RC, 1994, J NEUROSCI, V14, P4095; CRAIG AD, 1993, J COMP NEUROL, V331, P517, DOI 10.1002/cne.903310407; CRAIG AD, 1992, J COMP NEUROL, V322, P99, DOI 10.1002/cne.903220108; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, J COMP NEUROL, V308, P56; CRAIG AD, PROGR PAIN RES MAN, V3; Dostrovsky JO, 1992, INT C SERIES, V989, P115; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P348, DOI 10.1002/cne.902520305; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; JONES EG, 1989, EUR J NEUROSCI, V1, P222, DOI 10.1111/j.1460-9568.1989.tb00791.x; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LENZ FA, 1993, J NEUROPHYSIOL, V70, P200, DOI 10.1152/jn.1993.70.1.200; LENZ FA, 1993, BRAIN RES, V623, P235, DOI 10.1016/0006-8993(93)91433-S; PANNETON WM, 1991, J COMP NEUROL, V313, P377; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; RALSTON HJ, 1992, PAIN, V48, P107, DOI 10.1016/0304-3959(92)90137-Z; RICHARDSON DE, 1967, CONFIN NEUROL, V29, P139; White JC., 1969, PAIN NEUROSURGEON, P6	28	417	427	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					770	773		10.1038/372770a0	http://dx.doi.org/10.1038/372770a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7695716				2022-12-01	WOS:A1994PY21200050
J	LEAPE, LL				LEAPE, LL			ERROR IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; ADVERSE EVENTS; MISTAKES; CARE; PREVENTION; FAILURES				LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; BATES DW, IN PRESS J GEN INTER; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERWICK DM, 1989, MILBANK Q, V67, P262, DOI 10.2307/3350141; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; CULLEN DJ, 1992, ANESTH ANALG, V74, P181, DOI 10.1213/00000539-199202000-00002; Deming W.E., 1982, QUALITY PRODUCTIVITY; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FOLLI HL, 1987, PEDIATRICS, V79, P718; GABA DM, 1989, INT ANESTHESIOL CLIN, V27, P137, DOI 10.1097/00004311-198902730-00002; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GOPHER D, 1989, 33RD ANN M HUM FACT; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; Nightingale F., 1863, NOTES ON HOSP, V3rd; NORMAN DA, 1984, ERR IS HUMAN; ORKIN FK, 1993, MONITORING ANESTHESI; PALMER RH, 1983, MED DECIS MAKING, V3, P299, DOI 10.1177/0272989X8300300306; Perrow C., 1984, NORMAL ACCIDENTS LIV; RAJU TNK, 1989, LANCET, V2, P374; RASMUSSEN J, 1974, ERGONOMICS, V17, P293, DOI 10.1080/00140137408931355; RESON J, 1992, HUMAN ERROR; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	36	1472	1509	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1851	1857		10.1001/jama.272.23.1851	http://dx.doi.org/10.1001/jama.272.23.1851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7503827				2022-12-01	WOS:A1994PW98000034
J	CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA				CURRIE, PF; JACOB, AJ; FOREMAN, AR; ELTON, RA; BRETTLE, RP; BOON, NA			HEART-MUSCLE DISEASE-RELATED TO HIV-INFECTION - PROGNOSTIC IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL MEN; AIDS; RISK; DYSFUNCTION	Objectives-To determine the natural course of heart muscle disease in patients infected with HIV. Design-Prospective echocardiographic survey and observational study over four years. Setting-Edinburgh. Subjects-296 adults infected with HIV (mean age 32.7 years (range 21.5 to 67.6) drawn from all the major groups at risk of HIV infection in Britain. Main outcome measures-Detection of myocardial dysfunction and time to death from index echocardiogram in serial echocardiography. Results-Cardiac dysfunction was identified in 44 subjects (dilated cardiomyopathy, 13; isolated right ventricular dysfunction, 12; borderline left ventricular dysfunction, 19). Dilated cardiomyopathy was strongly associated with a CD4 cell count of < 100x10(6)/1, in contrast with the other forms of cardiac dysfunction. During the study 12/13 (92%) subjects with dilated cardiomyopathy, 5/12 (42%) with right ventricular dysfunction, and 8/19 (42%) with borderline left ventricular function died of conditions related to AIDS. Survival was significantly reduced in the subjects with dilated cardiomyopathy compared with those with normal hearts (P < 0.001). The median survival from the index echocardiogram was 101 days (95% confidence interval 42 to 146) for the subjects with cardiomyopathy compared with 472 days (383 to 560) for those with normal hearts and a CD4 cell count of < 20x10(6)/1. No significant difference existed in survival for subjects with borderline left or isolated right ventricular dysfunction. Conclusion-Even after adjustment for the significantly reduced CD4 cell count with which dilated cardiomyopathy is associated, the outlook for patients with HIV infection and dilated cardiomyopathy is poor. Isolated right and borderline left ventricular dysfunction are not associated with reduced CD4 cells counts and do not carry adverse prognostic implications.	CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,MED STAT UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	CURRIE, PF (corresponding author), ROYAL INFIRM,DEPT CARDIOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							ACIERNO LJ, 1989, J AM COLL CARDIOL, V13, P1144, DOI 10.1016/0735-1097(89)90277-5; ANDERSON DW, 1992, PATHOLOGY AIDS OTHER; CURRIE PF, 1993, Q J MED, V86, P751; DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; HERSKOWITZ A, 1994, J AM COLL CARDIOL, V24, P1025, DOI 10.1016/0735-1097(94)90865-6; HIMELMAN RB, 1989, J AM COLL CARDIOL, V13, P1030, DOI 10.1016/0735-1097(89)90256-8; HIMELMAN RB, 1989, AM J CARDIOL, V64, P1396, DOI 10.1016/0002-9149(89)90594-8; JACOB AJ, 1992, BRIT HEART J, V68, P549, DOI 10.1136/hrt.68.12.549; KINNEY EL, 1989, ANGIOLOGY, V40, P970, DOI 10.1177/000331978904001106; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; MELBYE M, 1987, LANCET, V1, P728; MONSUEZ JJ, 1988, AM J CARDIOL, V62, P1311, DOI 10.1016/0002-9149(88)90286-X; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; PHILLIPS AN, 1991, LANCET, V337, P389; WILLOUGHBY SB, 1993, AM J CARDIOL, V71, P446, DOI 10.1016/0002-9149(93)90451-H; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	20	100	102	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1605	1607		10.1136/bmj.309.6969.1605	http://dx.doi.org/10.1136/bmj.309.6969.1605			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819934	Green Published			2022-12-01	WOS:A1994PY22000014
J	POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM				POWRIE, JK; WATTS, GF; INGHAM, JN; TAUB, NA; TALMUD, PJ; SHAW, KM			ROLE OF GLYCEMIC CONTROL IN DEVELOPMENT OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							URINARY ALBUMIN EXCRETION; DELETION POLYMORPHISM; CONVERTING ENZYME; NEPHROPATHY; MELLITUS; PREVENTION; PRESSURE; GENE	Objective-To ascertain which factors determine the progression from very low rates of albumin excretion to persistent microalbuminuria in patients with insulin dependent diabetes mellitus. Design-A 10 year prospective study of a cohort of diabetic patients. Setting-Outpatient department of the Portsmouth District Hospitals. Subjects-97 patients with insulin dependent diabetes mellitus who were initially free of microalbuminuria and hypertension. Main outcome measure-Urinary albumin: creatinine ratio. Results-Eight of the 97 patients had developed microalbuminuria (urinary albumin:creatinine ratio >3 mg/mmol in three consecutive early morning samples) by the 10 year follow up. The group who developed microalbuminuria had higher baseline log(10) plasma glucose concentrations (mean (SD), 1.210 (0.122) v 0.984 (0.196) mmol/l, P < 0.001) and glycated haemoglobin concentrations (1.112% (0.069%) v 0.997% (0.076%), P < 0.001) and a younger age at onset of diabetes (10.0 (5.5) v 15.6 (7.8) years, P < 0.05). There was no difference in baseline duration of diabetes, smoking, sex, insulin dose, body mass index, serum creatinine concentration, or systolic, diastolic, or mean arterial blood pressure between the two groups. Multiple linear regression analysis showed that urinary albumin:creatinine ratio at 10 years was influenced by initial albumin: creatinine ratio (P = 0.006), initial glycated haemoglobin concentration (P = 0.002), and duration of diabetes (P = 0.045). Genotype for angiotensin converting enzyme was not related to the development of microalbuminuria nor, in a larger group of patients, the presence of any degree of diabetic nephropathy. Conclusion-In patients with insulin dependent diabetes mellitus the progression of minimal albuminuria and the development of microalbuminuria is determined primarily by poor long term glycaemic control. There is a weaker relation with longer duration of disease and younger age at onset of diabetes, but blood pressure does not seem to be implicated. Gene polymorphism for angiotensin converting enzyme is not linked to the development of microalbuminuria or established diabetic nephropathy.	UNIV WESTERN AUSTRALIA, ROYAL PERTH HOSP, PERTH, WA 6001, AUSTRALIA; QUEEN ALEXANDRA HOSP, DEPT ENDOCRINOL & DIABET, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; UNITED MED & DENT SCH, ST THOMAS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; UCL, SCH MED, DIV CARDIOVASC GENET, LONDON WC1E 6JJ, ENGLAND	Royal Perth Hospital; University of Western Australia; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; University College London; UCL Medical School	POWRIE, JK (corresponding author), UNITED MED & DENT SCH, ST THOMAS HOSP, DIV MED, LONDON SE1 7EH, ENGLAND.		Talmud, Philippa J/C-4402-2008	Watts, Gerald/0000-0003-2276-1524; Talmud, Philippa/0000-0002-5560-1933				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; EARLE K, 1992, NEW ENGL J MED, V326, P673, DOI 10.1056/NEJM199203053261005; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARRE M, 1994, DIABETES, V43, P384, DOI 10.2337/diabetes.43.3.384; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P500; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VIBERTI G, 1984, DIABETES, V33, P686, DOI 10.2337/diab.33.7.686; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1987, BRIT MED J, V295, P515, DOI 10.1136/bmj.295.6597.515; WATTS GF, 1990, DIABETES RES CLIN PR, V9, P169, DOI 10.1016/0168-8227(90)90109-7; WATTS GF, 1986, CLIN CHEM, V32, P1544; WATTS GF, 1991, Q J MED, V79, P365; WATTS GF, 1988, CLIN CHIM ACTA, V172, P191, DOI 10.1016/0009-8981(88)90323-3; WATTS GF, 1989, DIABETIC MED, V6, P25, DOI 10.1111/j.1464-5491.1989.tb01134.x; WISEMAN MJ, 1984, DIABETOLOGIA, V26, P402; YIP J, 1993, BRIT MED J, V306, P1235	24	69	70	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1608	1612		10.1136/bmj.309.6969.1608	http://dx.doi.org/10.1136/bmj.309.6969.1608			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819935	Green Published			2022-12-01	WOS:A1994PY22000015
J	SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA				SAGGARMALIK, AK; MISSOURIS, CG; GILL, JS; SINGER, DRJ; MARKANDU, ND; MACGREGOR, GA			LEFT-VENTRICULAR MASS IN NORMOTENSIVE SUBJECTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE		ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND	St Georges University London	SAGGARMALIK, AK (corresponding author), ST GEORGE HOSP,SCH MED,BLOOD PRESSURE UNIT,LONDON SW17 0RE,ENGLAND.							ABISAMRA F, 1983, AM J MED, V75, P26, DOI 10.1016/0002-9343(83)90114-6; IGLESIAS CG, 1983, AM J KIDNEY DIS, V2, P630; JOHNSTON DW, 1993, BMJ-BRIT MED J, V306, P963, DOI 10.1136/bmj.306.6883.963; TIMIO M, 1992, CLIN NEPHROL, V37, P245; ZEIER M, 1993, J AM SOC NEPHROL, V3, P1451	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1617	1618		10.1136/bmj.309.6969.1617	http://dx.doi.org/10.1136/bmj.309.6969.1617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819937	Green Published			2022-12-01	WOS:A1994PY22000018
J	STILLER, CA				STILLER, CA			POPULATION-BASED SURVIVAL RATES FOR CHILDHOOD-CANCER IN BRITAIN, 1980-91	BRITISH MEDICAL JOURNAL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; NEURO-BLASTOMA; NEUROBLASTOMA; CHEMOTHERAPY; CHILDREN; LYMPHOMA; THERAPY; PROTOCOL; UKCCSG; TRIALS	Objectives-To investigate the survival of children with cancer diagnosed during 1980-91 in order to assess the impact of developments in medical care on a Population basis. Design-Retrospective cohort study. Setting-Great-Britain. Subjects-14973 children with cancer diagnosed during 1980-91 and included in the population based National Registry of Childhood Tumours. Main outcome measures-Actuarial survival rates. Results-For all cancers combined, two year survival increased from 66% to 76% between 1980-2 and 1989-91, and five year survival increased from 57% to 65% between 1980-2 and 1986-8. Significant increases in survival rates occurred among children with acute lymphoblastic leukaemia, acute nonlymphocytic leukaemia, retinoblastoma, osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, and malignant gonadal germ cell tumours. No trend in survival was seen for children with Hodgkin's disease, central nervous system tumours, neuroblastoma, or Wilms's tumour. Conclusions-Nearly two. thirds of children who have cancer diagnosed can now expect to survive at least 10 years.			STILLER, CA (corresponding author), UNIV OXFORD,DEPT PAEDIAT,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.			Stiller, Charles/0000-0002-3006-7869				BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DUNST J, 1991, CANCER, V67, P2818, DOI 10.1002/1097-0142(19910601)67:11<2818::AID-CNCR2820671118>3.0.CO;2-Y; EDEN QB, 1992, BRIT J HAEMATOL, V82, P310, DOI 10.1111/j.1365-2141.1992.tb06423.x; HAAF H, 1993, JAHRESBERICHT 1992 D; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; HANN IM, 1990, BRIT J HAEMATOL, V76, P359, DOI 10.1111/j.1365-2141.1990.tb06368.x; HARTMANN O, 1988, J CLIN ONCOL, V6, P44, DOI 10.1200/JCO.1988.6.1.44; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; JONES PHM, 1991, BRIT J CANCER, V64, P1; KELLIE SJ, 1988, EUR J CANCER CLIN ON, V24, P903, DOI 10.1016/0277-5379(88)90200-3; MANN JR, 1989, CANCER-AM CANCER SOC, V63, P1657; MILLER BA, 1992, NIH922789 US DEP HLT; NAITO H, 1990, J PEDIATR SURG, V25, P245, DOI 10.1016/0022-3468(90)90410-B; Neglia J P, 1991, J Pediatr Oncol Nurs, V8, P59, DOI 10.1177/104345429100800207; PINKERTON CR, 1991, BRIT J CANCER, V64, P583, DOI 10.1038/bjc.1991.354; PINKERTON CR, 1990, BRIT J CANCER, V62, P319, DOI 10.1038/bjc.1990.286; PRITCHARD J, 1989, BRIT MED J, V299, P835, DOI 10.1136/bmj.299.6703.835; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; SANDERS BM, 1988, BRIT J OPHTHALMOL, V72, P576, DOI 10.1136/bjo.72.8.576; SANKILA R, 1993, EUR J CANCER, V29A, P122, DOI 10.1016/0959-8049(93)90588-7; SHAFFORD EA, 1993, BRIT J CANCER, V68, P1199, DOI 10.1038/bjc.1993.504; STEVENS M, 1993, MED PEDIATR ONCOL, V21, P554; STEVENS RF, 1992, LEUKEMIA, V6, P55; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; STILLER CA, 1994, ARCH DIS CHILD, V70, P219, DOI 10.1136/adc.70.3.219; STILLER CA, 1989, ARCH DIS CHILD, V64, P657, DOI 10.1136/adc.64.5.657; 1991, PEDIATRICS, V89, P597	32	120	120	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1612	1616		10.1136/bmj.309.6969.1612	http://dx.doi.org/10.1136/bmj.309.6969.1612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7819936	Green Published			2022-12-01	WOS:A1994PY22000016
J	AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A				AVIEZER, D; HECHT, D; SAFRAN, M; EISINGER, M; DAVID, G; YAYON, A			PERLECAN, BASAL LAMINA PROTEOGLYCAN, PROMOTES BASIC FIBROBLAST GROWTH FACTOR-RECEPTOR BINDING, MITOGENESIS, AND ANGIOGENESIS	CELL			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; NEURAL-TUBE DEFECTS; BASEMENT-MEMBRANE; MOUSE EMBRYOS; CELL-SURFACE; SEQUENCE; EXPRESSION; REQUIREMENT; PROTEIN; REGION	A survey of defined species of cell surface and extracellular matrix heparan sulfate proteoglycans (HSPG) was performed in a search for cellular proteoglycans that can promote bFGF receptor binding and biological activity. Of the various affinity-purified HSPGs tested, perlecan, the large basement membrane HSPG, is found to induce high affinity binding of bFGF both to cells deficient in HS and to soluble FGF receptors. Heparin-dependent mitogenic activity of bFGF is strongly augmented by perlecan. Monoclonal antibodies to perlecan extract the receptor binding promoting activity from active HSPG preparations. In a rabbit ear model for in vivo angiogenesis, perlecan is a potent inducer of bFGF-mediated neovascularization. These results identify perlecan as a major candidate for a bFGF low affinity, accessory receptor and an angiogenic modulator.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; AMER CYANAMID CO,DEPT CELL BIOL,DIV MED RES,PEARL RIVER,NY 10965; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM	Weizmann Institute of Science; KU Leuven								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; COPP AJ, 1988, DEVELOPMENT, V104, P285; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUELSTEIN VI, 1993, INT J CANCER, V53, P267; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Howden G F, 1980, Int Endod J, V13, P3, DOI 10.1111/j.1365-2591.1980.tb00832.x; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALI M, 1993, J BIOL CHEM, V268, P24215; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MERTENS G, 1992, J BIOL CHEM, V267, P20435; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3566; NEUMANN PE, 1994, NAT GENET, V6, P357, DOI 10.1038/ng0494-357; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RESCAN PY, 1993, AM J PATHOL, V142, P199; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALKER A, 1994, J BIOL CHEM, V269, P931; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	472	485	0	20	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1005	1013		10.1016/0092-8674(94)90031-0	http://dx.doi.org/10.1016/0092-8674(94)90031-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528102				2022-12-01	WOS:A1994PY08600010
J	BISHOP, DK				BISHOP, DK			RECA HOMOLOGS DMC1 AND RAD51 INTERACT TO FORM MULTIPLE NUCLEAR-COMPLEXES PRIOR TO MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							LYCOPERSICON-ESCULENTUM TOMATO; TWO-DIMENSIONAL SPREADS; DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX; RECOMBINATION NODULES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; SORDARIA-MACROSPORA; SOLANACEOUS PLANTS; WILD-TYPE	Dmc1 and Rad51, yeast homologs of the E. coli RecA protein, are shown by immunostaining to localize to as many as 64 sites within spread meiotic nuclei. Genetic requirements for this punctate pattern suggest It represents recombination intermediates. Dmc1 and Rad51 colocalize and are therefore likely to act together during recombination. Despite their similarities, the two proteins have specialized functions: Dmc1 complexes do not form in rad51 mutants, while Rad51 complexes are retained indefinitely in dmc1 mutants. Dmc1 and, by inference, Rad51 form complexes before synapsis as monitored by immunostaining for Zip1 protein. Analysis of zip1 mutants shows that Zip1 promotes dissociation of Dmc1 complexes. Colocalization of Dmc1 and Zip1 raises the possibility that Dmc1 and Rad51 are components of recombination nodules.			BISHOP, DK (corresponding author), UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60638, USA.				NIGMS NIH HHS [GM44794, GM50936] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ALBINI SM, 1984, EXP CELL RES, V155, P588, DOI 10.1016/0014-4827(84)90219-2; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ESPOSITO RE, 1981, MOL BIOL YEAST SACCH, P181; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; Harlow E., 1988, ANTIBODIES LAB MANUA, P553; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; KADYK LC, 1992, GENETICS, V132, P387; KING JS, 1990, GENETICS, V126, P1127; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MOENS PB, 1978, CAN J GENET CYTOL, V20, P567, DOI 10.1139/g78-066; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PRINGLE JR, 1991, METHODS ENZYMOLOGY G, P565; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; RESNICK M A, 1987, P157; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSMACDONALD P, 1994, CELL, V79; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STACK S, 1986, CHROMOSOMA, V94, P253, DOI 10.1007/BF00290853; STACK SM, 1986, AM J BOT, V73, P264, DOI 10.2307/2444181; STAHL FW, 1994, GENETICS, V138, P241; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STUDIER FW, 1992, METHOD ENZYMOL, V185, P60; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615; ZICKLER D, 1992, GENETICS, V132, P135	47	395	412	2	21	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					1081	1092		10.1016/0092-8674(94)90038-8	http://dx.doi.org/10.1016/0092-8674(94)90038-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528104				2022-12-01	WOS:A1994PY08600017
J	KAVANAUGH, WM; WILLIAMS, LT				KAVANAUGH, WM; WILLIAMS, LT			AN ALTERNATIVE TO SH2 DOMAINS FOR BINDING TYROSINE-PHOSPHORYLATED PROTEINS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL-3 KINASE; TRANSFORMING ACTIVITY; POINT MUTATIONS; PHOSPHOTYROSINE; ASSOCIATION; ACTIVATION; SEQUENCE; RESIDUES	Src homology 2 (SH2) domains bind specifically to tyrosine-phosphorylated proteins that participate in signaling by growth factors and oncogenes. A protein domain was identified that bound specifically to the tyrosine-phosphorylated form of its target protein but differs from known SH2 sequences. Phosphotyrosine-binding (PTB) domains were found in two proteins: SHC, a protein implicated in signaling through Ras; and SCK, encoded by a previously uncharacterized gene. The PTB domain of SHC specifically bound to a tyrosine-phosphorylated 145-kilodalton protein. PTB domains are an alternative to SH2 domains for specifically recruiting tyrosine-phosphorylated proteins into signaling complexes and are likely to take part in signaling by many growth factors.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NHLBI NIH HHS [K11 HL02714, R01 HL32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898, Z01HL002714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KATZAV S, 1993, ONCOGENE, V8, P1757; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAVANAUGH WM, UNPUB; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAXTON TM, 1994, J IMMUNOL, V153, P623; Summers MD, 1987, MANUAL METHODS BACUL; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	471	492	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 16	1994	266	5192					1862	1865		10.1126/science.7527937	http://dx.doi.org/10.1126/science.7527937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX383	7527937				2022-12-01	WOS:A1994PX38300035
J	SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I				SPIVAKKROIZMAN, T; LEMMON, MA; DIKIC, I; LADBURY, JE; PINCHASI, D; HUANG, J; JAYE, M; CRUMLEY, G; SCHLESSINGER, J; LAX, I			HEPARIN-INDUCED OLIGOMERIZATION OF FGF MOLECULES IS RESPONSIBLE FOR FGF RECEPTOR DIMERIZATION, ACTIVATION, AND CELL-PROLIFERATION	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING DOMAIN; EXTRACELLULAR DOMAIN; EGF RECEPTOR; HORMONE RECEPTOR; MAMMALIAN-CELLS; AFFINITY; TRANSFORMATION; ECTODOMAIN; CLONING	Heparin is required for fibroblast growth factor (FGF) stimulation of biological responses. Using isothermal titration calorimetry, we show that acidic FGF (aFGF) forms a 1:1 complex with the soluble extracellular domain of FGF receptor (FGFR). Heparin exerts its effect by binding to many molecules of aFGF. The resulting aFGF-heparin complex can bind to several receptor molecules, leading to FGFR dimerization. In two cell lines lacking endogenous heparan sulfate, exogenous heparin is required for FGFR dimerization, tyrosine kinase activation, c-fos mRNA transcription, and cell proliferation. Moreover, a synthetic heparin analog that binds monovalently to aFGF blocks FGFR dimerization, activation, and signaling via FGFR. We propose that heparin causes oligomerization of aFGF such that its binding to FGFR results in dimerization and activation. This represents a novel mechanism for transmembrane signaling and may account for the action of many heparin-bound growth factors.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; RHONE POULENC RORER, CENT RES, COLLEGEVILLE, PA 19426 USA	New York University			Dikic, Ivan/O-4650-2015	Dikic, Ivan/0000-0001-8156-9511; Lemmon, Mark/0000-0002-3379-5319; Ladbury, John/0000-0002-6328-7200	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM004725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM04725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; JAYE M, 1987, J BIOL CHEM, V262, P16612; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEV S, 1992, J BIOL CHEM, V267, P10866; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEH JI, 1993, J BIOL CHEM, V268, P9787; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	39	589	597	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 16	1994	79	6					1015	1024		10.1016/0092-8674(94)90032-9	http://dx.doi.org/10.1016/0092-8674(94)90032-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528103				2022-12-01	WOS:A1994PY08600011
J	TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL				TSUCHIDA, T; ENSINI, M; MORTON, SB; BALDASSARE, M; EDLUND, T; JESSELL, TM; PFAFF, SL			TOPOGRAPHIC ORGANIZATION OF EMBRYONIC MOTOR-NEURONS DEFINED BY EXPRESSION OF LIM HOMEOBOX GENES	CELL			English	Article							MOTONEURON PROJECTION PATTERNS; DIFFERENT SEGMENTAL LEVELS; CHICK HIND LIMB; PATHWAY SELECTION; NEURITE OUTGROWTH; PROTEIN ISL-1; SPINAL-CORD; LUMBOSACRAL LEVEL; PROXIMAL TISSUES; NERVOUS-SYSTEM	Motor neurons located at different positions in the embryonic spinal cord innervate distinct targets in the periphery, establishing a topographic neural map. The topographic organization of motor projections depends on the generation of subclasses of motor neurons that select specific paths to their targets. We have cloned a family of LIM homeobox genes in chick and show here that the combinatorial expression of four of these genes, Islet-1, Islet-2, Lim-1, and Lim-3, defines subclasses of motor neurons that segregate into columns in the spinal cord and select distinct axonal pathways. These genes are expressed prior to the formation of distinct motor axon pathways and before motor columns appear. Our results suggest that LIM homeobox genes contribute to the generation of motor neuron diversity and may confer subclasses of motor neurons with the ability to select specific axon pathways, thereby initiating the topographic organization of motor projections.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; UMEA UNIV,DEPT MICROBIOL,S-90187 UMEA,SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University					NIGMS NIH HHS [5T32GMO7367] Funding Source: Medline; NINDS NIH HHS [NS33245] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNES D, 1994, DEV BIOL, V161, P168; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DUBEY PN, 1968, J ANAT, V102, P407; EISEN JS, 1994, ANNU REV NEUROSCI, V17, P1; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERGUSON BA, 1983, J NEUROSCI, V3, P1760; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GUTMAN CR, 1993, BRAIN RES, V609, P129, DOI 10.1016/0006-8993(93)90865-K; HAMBURGER V, 1948, J COMP NEUROL, V88, P221, DOI 10.1002/cne.900880204; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HOLLYDAY M, 1980, J COMP NEUROL, V194, P143, DOI 10.1002/cne.901940108; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; Huber JF, 1936, J COMP NEUROL, V65, P43, DOI 10.1002/cne.900650109; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORZH V, 1993, DEVELOPMENT, V118, P417; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P559; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P371, DOI 10.1113/jphysiol.1978.sp012545; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER LT, 1992, NERVE GROWTH CONE, P373; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LICHTMAN JW, 1980, J PHYSIOL-LONDON, V298, P285, DOI 10.1113/jphysiol.1980.sp013081; PHELAN KA, 1990, J NEUROSCI, V10, P2699; PRASAD A, 1991, J COMP NEUROL, V307, P237, DOI 10.1002/cne.903070207; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STRAZNICKY C, 1983, ANAT EMBRYOL, V166, P209, DOI 10.1007/BF00305083; SULLIVAN G. E., 1962, AUSTRALIAN JOUR ZOOL, V10, P458, DOI 10.1071/ZO9620458; TAIRA M, 1993, DEV BIOL, V159, P245, DOI 10.1006/dbio.1993.1237; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TOSNEY KW, 1991, BIOESSAYS, V13, P17; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Wachtler F., 1992, SEMIN DEV BIOL, V3, P217; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WHITELAW V, 1983, J NEUROSCI, V3, P1199; WIGSTON DJ, 1985, J NEUROSCI, V5, P1208; WIGSTON DJ, 1982, NATURE, V299, P464, DOI 10.1038/299464a0; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YIP JW, 1990, J NEUROSCI, V10, P2476	65	859	868	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 16	1994	79	6					957	970		10.1016/0092-8674(94)90027-2	http://dx.doi.org/10.1016/0092-8674(94)90027-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PY086	7528105				2022-12-01	WOS:A1994PY08600006
J	BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB				BEEKMAN, EM; PORCELLI, SA; MORITA, CT; BEHAR, SM; FURLONG, ST; BRENNER, MB			RECOGNITION OF A LIPID ANTIGEN BY CD1-RESTRICTED ALPHA-BETA(+) T-CELLS	NATURE			English	Article							LYMPHOCYTES-T; CORD FACTOR; PEPTIDES; BIOLOGY; GENES	MAJOR histocompatibility complex (MHC) class I and class II molecules bind immunogenic peptides and present them to lymphocytes bearing the alpha beta T-cell antigen receptor (TCR)(1-4). An analogous antigen-presenting function also has been proposed for the non-MHC-encoded CDI molecules: a family of non-polymorphic, beta(2)-microglobulin-associated glycoproteins(5-8) expressed on most professional antigen-presenting cells(9-11). In support of this hypothesis, CD1 molecules are recognized by selected CD4(-)CD8(-)alpha beta or gamma delta TCR(+) T-cell clones(12-14), and we have recently shown that CD1 molecules restrict the recognition of foreign microbial antigens by alpha beta TCR(+) T cells(10). But the substantial structural divergence of CD1 from MHC class I and class II molecules(7), raises the possibility that the antigens presented by the CD1 system may differ fundamentally from those presented by MHC-encoded molecules. Here we report that a purified CD1b-restricted antigen of Mycobacterium tuberculosis presented to alpha beta TCR(+) T cells is mycolic acid, a family of alpha-branched, beta-hydroxy, long-chain fatty acids found in mycobacteria(15-16). This example of non-protein microbial antigen recognition suggests that alpha beta TCR(+) T cells recognize a broader range of antigens than previously appreciated and that at least one member of the CD1 family has evolved the ability to present lipid antigens.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	BEEKMAN, EM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, LYMPHOCYTE BIOL SECT, BOSTON, MA 02115 USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Behar, Samuel/0000-0002-3374-6699				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BEKIERKUNST A, 1971, SCIENCE, V174, P1240, DOI 10.1126/science.174.4015.1240; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHRISTIE WW, 1982, LIPID ANAL, P117; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; FLOYD MM, 1992, J CLIN MICROBIOL, V30, P1327, DOI 10.1128/JCM.30.5.1327-1330.1992; FOLCH J, 1957, J BIOL CHEM, V226, P497; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; Goren M. B., 1979, TUBERCULOSIS, P63; LECHEVALIER MP, 1977, CRC CR REV MICROBIOL, V5, P109, DOI 10.3109/10408417709102311; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; PARANT M, 1978, INFECT IMMUN, V20, P12, DOI 10.1128/IAI.20.1.12-19.1978; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RONCAROLO MG, 1988, J EXP MED, V168, P2139, DOI 10.1084/jem.168.6.2139; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TERHORST C, 1981, CELL, V23, P771, DOI 10.1016/0092-8674(81)90441-4; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0	30	867	888	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 15	1994	372	6507					691	694		10.1038/372691a0	http://dx.doi.org/10.1038/372691a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PX307	7527500				2022-12-01	WOS:A1994PX30700090
J	BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T				BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T			HEPATITIS-C INFECTION IN PATIENTS WITH PRIMARY HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH CONTAMINATED IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; INTRAVENOUS GAMMA-GLOBULIN; ALPHA-INTERFERON THERAPY; VIRUS HCV RNA; BLOOD-DONORS; IMMUNOGLOBULIN; SERUM; DEFICIENCY; GENOTYPES	Background. In Scandinavia many patients with primary hypogammaglobulinemia contracted non-A, non-B hepatitis after intravenous treatment with an immune globulin product that was later found to contain a non-A, non-B hepatitis virus. Methods. We studied the prevalence and clinical course of hepatitis C virus (HCV) infection in a group of 55 Norwegian patients with primary hypogammaglobulinemia and investigated its association with the use of contaminated immune globulin. We used the polymerase chain reaction to detect HCV RNA and performed HCV genotyping. We also analyzed the responses to treatment with interferon. Results. Of 20 patients who received the contaminated immune globulin, 17 were seropositive for HCV RNA, In addition, 1 of 35 patients not exposed to the contaminated immune globulin was HCV RNA-positive. HCV genotype V was found in all 12 patients for whom genotyping was performed, but 8 patients also had genotype II or III, or both. All HCV RNA-positive patients had abnormal results on biochemical liver tests. All liver-biopsy specimens (from 15 patients) were abnormal, with portal inflammation, bile-duct damage, and focal necrosis. In six patients there was cirrhosis. Two patients died of liver failure. In 4 of the 10 patients treated with interferon there were complete, though transient, biochemical responses, but the follow-up biopsy specimens showed evidence of histologic progression. The poorest responses to interferon were among the patients with multiple HCV genotypes. All but one patient remained positive for HCV RNA. Conclusions. In patients with primary hypogammaglobulinemia there was a high rate of HCV infection after treatment with contaminated immune globulin. In these immunocompromised patients HCV infection has a severe and rapidly progressive course, and responses to interferon are poor.	NATL HOSP NORWAY, DEPT MED A, HEPATOL & GASTROENTEROL SECT, N-0027 OSLO, NORWAY; NATL HOSP NORWAY, DEPT PATHOL, N-0027 OSLO, NORWAY; NATL INST PUBL HLTH, DEPT VIROL, OSLO, NORWAY; KAROLINSKA INST, HUDDINGE HOSP, INST CLIN VIROL, S-10401 STOCKHOLM, SWEDEN	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Karolinska Institutet	BJORO, K (corresponding author), NATL HOSP NORWAY, DEPT MED A, CLIN IMMUNOL & INFECT DIS SECT, N-0027 OSLO, NORWAY.							ALTER HJ, 1992, VIRAL HEPATITIS LIVE, P396; AUKRUST P, 1992, CLIN EXP IMMUNOL, V89, P211; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HAGIWARA H, 1992, HEPATOLOGY, V15, P37, DOI 10.1002/hep.1840150108; IWARSON S, 1987, SERODIAGN IMMUNOTHER, V1, P261; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANE RS, 1983, LANCET, V2, P974; LEVER AML, 1984, LANCET, V2, P1062; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SKAUG K, 1993, VOX SANG, V64, P215, DOI 10.1111/j.1423-0410.1993.tb03058.x; SPICKETT GP, 1991, LANCET, V337, P281, DOI 10.1016/0140-6736(91)90882-P; THOMSON BJ, 1987, LANCET, V1, P539; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; WEBSTER ADB, 1988, IMMUNOL INVEST, V17, P93, DOI 10.3109/08820138809055722; WEBSTER ADB, 1986, LANCET, V1, P322; WEILAND O, 1986, LANCET, V1, P976; WILLIAMS PE, 1989, VOX SANG, V57, P15, DOI 10.1111/j.1423-0410.1989.tb04977.x; YEI S, 1992, TRANSFUSION, V32, P824, DOI 10.1046/j.1537-2995.1992.32993110753.x; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1989, IMMUNODEFIC REV, V1, P173	32	336	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1607	1611		10.1056/NEJM199412153312402	http://dx.doi.org/10.1056/NEJM199412153312402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7526215				2022-12-01	WOS:A1994PW44600002
J	BURNS, JP; REARDON, FE; TRUOG, RD				BURNS, JP; REARDON, FE; TRUOG, RD			USING NEWLY DECEASED PATIENTS TO TEACH RESUSCITATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONSENT; INFANTS		HASSAN & REARDON, BOSTON, MA 02116 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	BURNS, JP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV PEDIAT CRIT CARE, NEMC 93, 750 WASHINGTON ST, BOSTON, MA 02111 USA.		Burns, Jeffrey P/AAW-8474-2021					ABRAMSON NS, 1981, JAMA-J AM MED ASSOC, V246, P2828; BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BRATTEBO G, 1988, LANCET, V2, P1078; Clayton M., 1992, DRAWINGS COLLECTION; FEINBERG J, 1985, HASTINGS CENT REP, V15, P31, DOI 10.2307/3561915; Iserson K V, 1991, J Emerg Med, V9, P509, DOI 10.1016/0736-4679(91)90225-5; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; Orlowski J P, 1990, J Clin Ethics, V1, P201; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ROELS L, 1991, TRANSPLANT P, V23, P903; ROSNER F, 1991, MODERN MED JEWISH ET, P313; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; 1991, JAMA-J AM MED ASSOC, V266, P2837; 1993, AM MED NEWS     0322, P10	16	46	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1652	1655		10.1056/NEJM199412153312411	http://dx.doi.org/10.1056/NEJM199412153312411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7772111				2022-12-01	WOS:A1994PW44600011
J	BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M				BAGGALEY, R; GODFREYFAUSSETT, P; MSISKA, R; CHILANGWA, D; CHITU, E; PORTER, J; KELLY, M			IMPACT OF HIV-INFECTION ON ZAMBIAN BUSINESSES	BRITISH MEDICAL JOURNAL			English	Article									MINIST HLTH,NATL AIDS CONTROL PROGRAMME,LUSAKA,ZAMBIA; UNIV LUSAKA,TEACHING HOSP,DEPT MED,ZAMBART PROJECT,LUSAKA,ZAMBIA; LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BAGGALEY, R (corresponding author), KARA COUNSELLING & TRAINING TRUST,POB 37559,LUSAKA,ZAMBIA.							BUVE A, IN PRESS AIDS; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; MURRAY CJL, 1992, HLTH ADULTS DEV WORL, P23; NKOWANE BM, 1991, AIDS, V5, pS7; PIOT P, 1992, AIDS AFRICA MANUAL P	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1549	1550		10.1136/bmj.309.6968.1549	http://dx.doi.org/10.1136/bmj.309.6968.1549			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819895	Green Published			2022-12-01	WOS:A1994PX56400021
J	DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J				DAVIES, G; PYKE, S; KINMONTH, AL; WOOD, DA; COLES, C; CRAMB, R; DURRINGTON, P; KOK, Y; LEGUEN, C; MARTEAU, T; ODWYER, A; PYKE, SMD; STEELE, DW; THOMPSON, SG; YARWOOD, J			EFFECT OF NONATTENDERS ON THE POTENTIAL OF A PRIMARY-CARE PROGRAM TO REDUCE CARDIOVASCULAR RISK IN THE POPULATION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; GENERAL-PRACTICE	Objectives-To determine the feasibility of enrolling non-attenders of a population based cardiovascular risk reduction programme (the British family heart study) into a further, similar programme and to assess the effect of non-attendance on the effectiveness of the programme. Design-Follow up of non-attenders by practice nurses, including home visits if necessary, to administer questionnaires and obtain physiological measurements. Setting-Eight general practices across England, Scotland, and Wales. Subjects-Non-attenders in a cardiovascular risk factor screening and intervention programme compared with attenders. Main outcome measures-Number of nonattenders enrolled; sociodemographic characteristics; personal and family history of coronary heart disease; cardiovascular risk factors; and total coronary risk score. Results-Data were collected from 106 (17%) of the 608 non-attending families (99 men and 42 women). Of the 543 non-attending families from five practices that attempted complete follow up, 256 had moved away or died. Only 76 were eventually enrolled into the study. The prevalence of coronary heart disease and a family history of coronary heart disease were similar among non-attenders and attenders as were the individual coronary risk factors studied except smoking. Women non-attenders were more likely to be current cigarette smokers than attenders (15/42 v 202/948, P = 0.02). Conclusions-The intensive follow up of nonattenders resulted in real intervention opportunities in only a small number. Since the effect of any intervention in a population is reduced by nonattendance audit of preventive medical programmes aimed at the population should allow for the effect of non-attenders on the overall results.	UNIV SOUTHAMPTON,FAC MED,SOUTHAMPTON,HANTS,ENGLAND; UNIV LONDON,LONDON SCH HYG & TROP MED,MED STAT UNIT,LONDON,ENGLAND	University of Southampton; University of London; London School of Hygiene & Tropical Medicine								CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367, DOI 10.1093/oxfordjournals.aje.a112633; DIFFORD F, 1987, BRIT MED J, V294, P1130, DOI 10.1136/bmj.294.6580.1130; KINMONTH AL, 1991, BRIT MED J, V303, P1060, DOI 10.1136/bmj.303.6809.1060-a; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; Rose G., 1992, STRATEGY PREVENTIVE; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WRENCH JG, 1984, J ROY COLL GEN PRACT, V34, P477; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1991, BRIT MED J, V302, P1057	10	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1553	1556		10.1136/bmj.309.6968.1553	http://dx.doi.org/10.1136/bmj.309.6968.1553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819899	Green Published			2022-12-01	WOS:A1994PX56400025
J	ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U				ISACSSON, G; REDFORS, I; WASSERMAN, D; BERGMAN, U			CHOICE OF ANTIDEPRESSANTS - QUESTIONNAIRE SURVEY OF PSYCHIATRISTS AND GENERAL-PRACTITIONERS IN 2 AREAS OF SWEDEN	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE	Objective-To identify factors that affect physicians' choice of specific antidepressant drugs in order to evaluate the validity of epidemiological studies of the risks (particularly suicide) and benefits of different compounds. Design-Questionnaire survey of 264 psychiatrists and general practitioners in an urban area and a rural area of Sweden with validation of data by independent prescription surveys. Setting-Urban area of greater Stockholm and rural county of Jamtland, Sweden. Subjects-228 physicians (86%) who answered the questionnaire. Main outcome measures-The drugs used as first line drugs of choice, as drugs of choice in particularly severe depression, and as drugs of choice for disorders other than depression. Results-Amitriptyline was the most common first line drug of choice among both psychiatrists and general practitioners. The patterns of choice of antidepressants in the two areas accorded with prescribing patterns in two independent prescription surveys. Amitriptyline was chosen even more frequently for severe depression and depression with severe insomnia. Clomipramine was chosen comparatively more often for depression with severe anxiety. Low toxicity compounds (mainly lofepramine, mianserin, and moclobemide) were more often the drug of choice in depression associated with overt risk of suicide. Amitriptyline and clomipramine were used extensively for disorders other than depression (40% and 54% of prescriptions, compared with 13-19% for some other major antidepressants). Conclusion-Patient groups treated with different antidepressant compounds may not be comparable with respect to diagnoses and severity of disease. In particular, lofepramine, mianserin, and moclobemide, and possibly amitriptyline, seem to be chosen more often for patients prone to suicide.	ORSA PRIMARY HLTH CARE CTR,ORSA,SWEDEN; KAROLINSKA HOSP,CTR SUICIDE RES & PREVENT,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	ISACSSON, G (corresponding author), HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT CLIN NEUROSCI & FAMILY MED,PSYCHIAT SECT,S-14186 HUDDINGE,SWEDEN.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BARRACLOUGH BM, 1975, PSYCHOL MED, V5, P55, DOI 10.1017/S0033291700007212; GOODE H, 1994, BRIT MED J, V308, P915; Henry J A, 1992, Eur J Med, V1, P343; ISACSSON G, 1994, BRIT MED J, V308, P506, DOI 10.1136/bmj.308.6927.506; ISACSSON G, 1992, ACTA PSYCHIAT SCAND, V85, P444, DOI 10.1111/j.1600-0447.1992.tb03209.x; ISACSSON G, 1994, BRIT MED J, V308, P916; ISOMETSA E, 1994, BRIT MED J, V308, P915, DOI 10.1136/bmj.308.6933.915; ISOMETSA ET, 1994, AM J PSYCHIAT, V151, P530; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; OHARE T, 1994, BRIT MED J, V308, P915; OWEN A, 1994, BRIT MED J, V308, P915; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; Tomson G, 1990, Lakartidningen, V87, P1483; WESSLING A, 1991, EUR J CLIN PHARMACOL, V40, P495, DOI 10.1007/BF00315229	15	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1546	1549		10.1136/bmj.309.6968.1546	http://dx.doi.org/10.1136/bmj.309.6968.1546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PX564	7819894	Green Published			2022-12-01	WOS:A1994PX56400020
J	LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H				LINDBACK, S; BROSTROM, C; KARLSSON, A; GAINES, H			DOES SYMPTOMATIC PRIMARY HIV-1 INFECTION ACCELERATE PROGRESSION TO CDC STAGE-IV DISEASE, CD4 COUNT BELOW 200 X 10(6)/1, AIDS, AND DEATH FROM AIDS	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; BISEXUAL MEN; ILLNESS; SEROCONVERTERS; PREDICTORS; ANTIBODY; COHORT; RISK	Objective-To investigate the prognostic significance of symptomatic primary HIV-1 infection. Design-Prospective study of homosexual men seroconverting to HIV in 1985 and 1986. Patients were followed up at least three times yearly with clinical examinations and T cell subset determinations for an average of 7.2 years. Setting-Research project centred on attenders for treatment and screening for HIV at the Karolinska Institute, Stockholm. Subjects-19 patients presenting with a glandular-fever-like illness associated with seroconversion to HIV and 29 asymptomatic seroconverters. Main outcome measures-Progression to Centers for Disease Control and Prevention stage IV disease, CD4 cell count below 200 x 10(6)/1, AIDS, and death from AIDS. Results-Symptomatic seroconverters were significantly more likely to develop Centers for Disease Control and Prevention stage IV disease (95% v 66%), CD4 cell counts below 200 x 10(6)/1 (84% v 55%), and AIDS (58% v 28%) and die of AIDS (53% v 7%). Conclusion-A glandular-fever-like illness associated with seroconversion to HIV-1 predicts accelerated progression to AIDS and other HIV related diseases.	KAROLINSKA INST,HUDDINGE HOSP,DEPT INFECT DIS,STOCKHOLM,SWEDEN; KAROLINSKA INST,SODER SJUKHUSET,DEPT DERMATOVENEREOL,STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,DEPT CLIN IMMUNOL,STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Swedish Institute for Infectious Disease Control								ALBERT J, 1987, J MED VIROL, V23, P67, DOI 10.1002/jmv.1890230108; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; COOPER DA, 1985, LANCET, V1, P537; GAINES H, 1987, LANCET, V1, P1249; GAINES H, 1988, BRIT MED J, V297, P1363, DOI 10.1136/bmj.297.6660.1363; GAINES H, 1990, AIDS, V4, P995, DOI 10.1097/00002030-199010000-00008; GAINES H, 1988, AIDS, V2, P11, DOI 10.1097/00002030-198802000-00002; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; LANGE JMA, 1988, AIDS, V2, P31, DOI 10.1097/00002030-198802000-00005; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; NIU MT, 1993, AIDS RES HUM RETROV, V9, P913, DOI 10.1089/aid.1993.9.913; PEDERSEN C, 1989, BRIT MED J, V299, P154, DOI 10.1136/bmj.299.6692.154; REZZA G, 1992, AIDS, V6, P421, DOI 10.1097/00002030-199204000-00010; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SIMMONDS P, 1991, LANCET, V338, P1159, DOI 10.1016/0140-6736(91)92029-2; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1987, MMWR-MORBID MORTAL W, V36, P3; 1994, LANCET, V343, P871; 1986, MMWR-MORBID MORTAL W, V35, P334	24	77	77	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1535	1537		10.1136/bmj.309.6968.1535	http://dx.doi.org/10.1136/bmj.309.6968.1535			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819891	Green Published			2022-12-01	WOS:A1994PX56400017
J	STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J				STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J			SERUM CONCENTRATIONS OF PROSTATE-SPECIFIC ANTIGEN AND ITS COMPLEX WITH ALPHA(1)-ANTICHYMOTRYPSIN BEFORE DIAGNOSIS OF PROSTATE-CANCER	LANCET			English	Article							SCREENING-TEST; ALPHA-1-ANTICHYMOTRYPSIN; ASSAY; MEN	Prostate cancer can be detected at an early, potentially curable stage by screening based on digital rectal examination and serum prostate specific antigen (PSA). The value of screening appears doubtful, based on high 10-year survival rates in selected cases of early prostate cancer, but this follow-up time may be insufficient. By linking the information on 21172 men who took part in a screening examination in Finland, 1968-73, with data from the Finnish Cancer Registry, 44 cases of prostate cancer diagnosed up to 1980 were identified. Serum samples from cancer cases and from 74 controls matched for age and time of sampling were assayed for PSA and its complex with alpha(1)-antichymotrypsin (PSA-ACT). With a cut-off for PSA of 2.5 mu g/L giving 92% specificity, 95% of the cancers developing within the first 5 years, and 52% developing in 6-10 years tested positive. As a potential screening test with a 5-year interval for men under 65, the sensitivity would be 92% and specificity 97%. The ratio of PSA-ACT to total PSA was lower in controls than in patients wih cancer. Using this ratio, we could eliminate half of the false-positive results in the range 2.5-25 mu g/L without loss of sensitivity. Cancer was typically diagnosed 5-10 years after PSA exceeded 2.5 mu g/L, and the median survival after diagnosis was 3.6 years. 10-year survivat after drawing the sample was 71% in cancer cases with a PSA concentration less than 4 mu g/L and 48% in those with higher concentrations. The corresponding figures at 15 years were 53% and 27%, and at 20 years 43% and 18%, respectively. These results suggest it is advisable to confine screening for prostate cancer to men with a life expectancy of clearly more than 10 years-ie, younger men, who have the greatest chance to benefit from early detection.	UNIV TAMPERE,DEPT PUBL HLTH,TAMPERE,FINLAND; SOCIAL INSURANCE INST,RES & DEV UNIT,HELSINKI,FINLAND; FINNISH CANC REGISTRY,HELSINKI,FINLAND	Tampere University; Finnish Cancer Registry	STENMAN, UH (corresponding author), HELSINKI UNIV HOSP,DEPT CLIN CHEM,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; AUS G, 1994, J UROLOGY, V151, P278; BABAIAN RJ, 1990, J CLIN LAB ANAL, V4, P135, DOI 10.1002/jcla.1860040212; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CARTER HB, 1992, CANCER RES, V52, P3323; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHADWICK DJ, 1991, LANCET, V338, P613; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; FELDMANN U, 1981, J CLIN CHEM CLIN BIO, V19, P121; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Knekt P, 1988, PUBLICATIONS SOCIAL, V83, P1; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LEINONEN J, 1993, CLIN CHEM, V39, P2098; LILJA H, 1991, CLIN CHEM, V37, P1618; METTLIN C, 1993, CANCER, V72, P1050, DOI 10.1002/1097-0142(19930801)72:3+<1050::AID-CNCR2820721318>3.0.CO;2-J; METTLIN C, 1993, CANCER, V72, P1701, DOI 10.1002/1097-0142(19930901)72:5<1701::AID-CNCR2820720534>3.0.CO;2-E; MILLER AB, 1991, CANCER SCREENING, P289; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; SCHMID HP, 1993, EUR UROL, V2, P60; SCHRODER FH, 1993, BRIT MED J, V306, P407, DOI 10.1136/bmj.306.6875.407; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1990, J NUCL MED ALLIED S3, V34, P249; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	217	221	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1594	1598		10.1016/S0140-6736(94)90405-7	http://dx.doi.org/10.1016/S0140-6736(94)90405-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7527116				2022-12-01	WOS:A1994PW05100008
J	WILLIAMS, A; SHAW, WC; DEVLIN, HB				WILLIAMS, A; SHAW, WC; DEVLIN, HB			PROVISION OF SERVICES FOR CLEFT-LIP AND PALATE IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,TURNER DENT SCH,DEPT ORAL HLTH & DEV,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester	WILLIAMS, A (corresponding author), ROYAL COLL SURGEONS ENGLAND,SURG AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							Congenital Malformations Worldwide, 1993, CONGENITAL MALFORMAT; DEVLIN HB, 1990, ANN R COLL SURG EN S, V73, P3; SHAW WC, 1994, FINAL REPORT REGIONA; SHAW WC, 1992, RECENT ADV PLASTICS, V4, P1; 1994, REPORT STANDING DENT	5	28	28	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 10	1994	309	6968					1552	1552		10.1136/bmj.309.6968.1552	http://dx.doi.org/10.1136/bmj.309.6968.1552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PX564	7819898	Green Published			2022-12-01	WOS:A1994PX56400024
J	DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU				DING, JM; CHEN, D; WEBER, ET; FAIMAN, LE; REA, MA; GILLETTE, MU			RESETTING THE BIOLOGICAL CLOCK - MEDIATION OF NOCTURNAL CIRCADIAN SHIFTS BY GLUTAMATE AND NO	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; CYCLIC-GMP FORMATION; SUPRACHIASMATIC NUCLEUS; RECEPTOR ANTAGONISTS; RAT HYPOTHALAMUS; GOLDEN-HAMSTER; NMDA RECEPTORS; FOS EXPRESSION; PHASE-SHIFTS; OPTIC-NERVE	Circadian rhythms of mammals are timed by an endogenous clock with a period of about 24 hours located in the suprachiasmatic nucleus (SCN) of the hypothalamus. Light synchronizes this clock to the external environment by daily adjustments in the phase of the circadian oscillation. The mechanism has been thought to involve the release of excitatory amino acids from retinal afferents to the SCN. Brief treatment of rat SCN in vitro with glutamate (Glu), N-methyl-D-aspartate (NMDA), or nitric oxide (NO) generators produced lightlike phase shifts of circadian rhythms. The SCN exhibited calcium-dependent nitric oxide synthase (NOS) activity. Antagonists of NMDA or NOS pathways blocked Glu effects in vitro, and intracerebroventricular injection of a NOS inhibitor in vivo blocked the light-induced resetting of behavioral rhythms. Together, these data indicate that Glu release, NMDA receptor activation, NOS stimulation, and NO production link light activation of the retina to cellular changes within the SCN mediating the phase resetting of the biological clock.	UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,NEUROSCI PROGRAM,URBANA,IL 61801; ARMSTRONG LAB,BIOL RHYTHMS & INTEGRAT NEUROSCI RES INST,BROOKS AFB,TX 78235	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Defense; United States Air Force					NINDS NIH HHS [NS22155, R01 NS022155] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022155] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIR S, 1992, BRAIN RES, V586, P336, DOI 10.1016/0006-8993(92)91644-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1993, LIFE SCI, V54, P61; CASTEL M, 1993, EUR J NEUROSCI, V5, P368, DOI 10.1111/j.1460-9568.1993.tb00504.x; Chen D.-Y., UNPUB; COLWELL CS, 1990, BRAIN RES, V523, P117, DOI 10.1016/0006-8993(90)91643-U; COLWELL CS, 1992, J BIOL RHYTHM, V7, P125, DOI 10.1177/074873049200700204; COSTA A, 1993, BRAIN RES, V605, P187, DOI 10.1016/0006-8993(93)91739-F; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DECOURSEY PJ, 1960, SCIENCE, V131, P33, DOI 10.1126/science.131.3392.33; DEMASTER EG, 1989, BIOCHEM BIOPH RES CO, V163, P527, DOI 10.1016/0006-291X(89)92169-4; DEVRIES MJ, 1993, BRAIN RES, V612, P213; Ding J. M., 1993, Society for Neuroscience Abstracts, V19, P1815; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; Edmunds L.N., 1988, CELLULAR MOL BASES B; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; Gillette MU, 1991, SUPRACHIASMATIC NUCL, P125; GILLETTE MU, CIBA F S, V183, P134; HALEY JE, 1992, NEURON, V8, P221; HAMADA T, 1993, AM J PHYSIOL, V265, pR1199, DOI 10.1152/ajpregu.1993.265.5.R1199; HASTINGS MH, 1985, NEUROENDOCRINOLOGY, V40, P316, DOI 10.1159/000124093; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; KAMISAKI Y, 1994, BRAIN RES, V644, P128, DOI 10.1016/0006-8993(94)90355-7; KIM YI, 1991, J PHYSIOL-LONDON, V444, P269, DOI 10.1113/jphysiol.1991.sp018877; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LIOU SY, 1986, BRAIN RES BULL, V16, P527, DOI 10.1016/0361-9230(86)90182-6; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MEDANIC M, 1992, J PHYSIOL-LONDON, V450, P629, DOI 10.1113/jphysiol.1992.sp019147; MEIJER JH, 1988, NEUROSCI LETT, V86, P177, DOI 10.1016/0304-3940(88)90567-8; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; MEIJER JH, 1993, BRAIN RES, V603, P284, DOI 10.1016/0006-8993(93)91249-R; MOFFETT JR, 1990, P NATL ACAD SCI USA, V87, P8065, DOI 10.1073/pnas.87.20.8065; MOFFETT JR, 1991, BRAIN RES, V538, P86, DOI 10.1016/0006-8993(91)90380-E; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; MOORE RY, 1971, J COMP NEUROL, V146, P1; MORIN LP, 1994, BRAIN RES REV, V67, P102; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; PITTENDRIGH CS, 1981, HDB BEHAV NEUROBIOL, V4, P59; PROSSER RA, 1989, J NEUROSCI, V9, P1073; PROSSER RA, 1989, P NATL ACAD SCI USA, V86, P6912; REA MA, 1993, J BIOL RHYTHM, V8, pS59; REA MA, 1993, AM J PHYSIOL, V265, pR1191, DOI 10.1152/ajpregu.1993.265.5.R1191; SHIBATA S, 1986, NEUROPHARMACOLOGY, V25, P403, DOI 10.1016/0028-3908(86)90235-2; SHIBATA S, 1994, AM J PHYSIOL, V267, pR360, DOI 10.1152/ajpregu.1994.267.2.R360; SHIBATA S, 1992, BRAIN RES, V597, P257, DOI 10.1016/0006-8993(92)91482-T; SHIRAKAWA T, 1994, NEUROSCI LETT, V178, P47, DOI 10.1016/0304-3940(94)90286-0; SIEGEL G, 1991, BASIC NEUROCHEMISTRY, P558; SOUTHAM E, 1992, NEUROSCI LETT, V137, P241, DOI 10.1016/0304-3940(92)90413-2; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SUMMER TL, 1984, AM J PHYSIOL, V246, pR299, DOI 10.1152/ajpregu.1984.246.3.R299; TAKEUCHI Y, 1991, BRAIN RES, V563, P127, DOI 10.1016/0006-8993(91)91524-5; VANDENPOL AN, 1991, J NEUROSCI, V11, P2087; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WATANABE A, 1994, BRAIN RES, V646, P161, DOI 10.1016/0006-8993(94)90071-X; WENDLAND B, 1994, P NATL ACAD SCI USA, V91, P2151, DOI 10.1073/pnas.91.6.2151	69	485	494	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1713	1717		10.1126/science.7527589	http://dx.doi.org/10.1126/science.7527589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527589				2022-12-01	WOS:A1994PW30800042
J	PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS				PADGETT, RA; PODAR, M; BOULANGER, SC; PERLMAN, PS			THE STEREOCHEMICAL COURSE OF GROUP-II INTRON SELF-SPLICING	SCIENCE			English	Article							TETRAHYMENA RIBOZYME; RNA-POLYMERASE; PHOSPHOROTHIOATE; STEP; SPLICEOSOME; MECHANISM; CLEAVAGE; PRODUCTS; DNA	The stereochemical specificities and reaction courses for both self-splicing steps of a group II intron have been determined by phosphorothioate substitution at the 5' and 3' splice site phosphodiester bonds. Both steps of the splicing reaction proceeded with a phosphorothioate in the Sp configuration but were blocked by the Rp diastereomer. Both steps also proceeded with inversion of stereochemical configuration around phosphorus, consistent with a concerted transesterification reaction. These results are identical to those found for nuclear precursor mRNA (pre-mRNA) splicing and provide support for the hypothesis that group II introns and nuclear pre-mRNA introns share a common evolutionary history.			PADGETT, RA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM045371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31480, GM45371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; GISH G, 1988, SCIENCE, V240, P1520, DOI 10.1126/science.2453926; GRIFFITHS AD, 1987, NUCLEIC ACIDS RES, V15, P4145, DOI 10.1093/nar/15.10.4145; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; MASCHHOFF KL, 1993, NUCLEIC ACIDS RES, V21, P5456, DOI 10.1093/nar/21.23.5456; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NELSON PS, 1984, J ORG CHEM, V49, P2314, DOI 10.1021/jo00187a003; PERLMAN PS, 1990, INTERVENING SEQUENCE, P112; PODAR M, UNPUB; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	23	93	97	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1685	1688		10.1126/science.7527587	http://dx.doi.org/10.1126/science.7527587			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527587				2022-12-01	WOS:A1994PW30800034
J	ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA				ZHOU, L; DEY, CR; WERT, SE; DUVALL, MD; FRIZZELL, RA; WHITSETT, JA			CORRECTION OF LETHAL INTESTINAL DEFECT IN A MOUSE MODEL OF CYSTIC-FIBROSIS BY HUMAN CFTR	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TRANSGENIC MICE; EXPRESSION; CRYPT; CELLS	Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). A potential animal model of CF, the CFTR(-/-) mouse, has had limited utility because most mice die from intestinal obstruction during the first month of life. Human CFTR (hCFTR) was expressed in CFTR(-/-) mice under the control of the rat intestinal fatty acid-binding protein gene promoter. The mice survived and showed functional correction of ileal goblet cell and crypt cell hyperplasia and cyclic adenosine monophosphate-stimulated chloride secretion. These results support the concept that transfer of the hCFTR gene may be a useful strategy for correcting physiologic defects in patients with CF.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229; UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	Cincinnati Children's Hospital Medical Center; University of Alabama System; University of Alabama Birmingham					NHLBI NIH HHS [HL51832, HL49004] Funding Source: Medline; NIDDK NIH HHS [DK38518] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049004, P01HL051832] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038518] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; SIEMER C, 1993, PFLUG ARCH EUR J PHY, V424, P321, DOI 10.1007/BF00384359; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; WHITSETT JA, 1992, NAT GENET, V2, P13, DOI 10.1038/ng0992-13	9	204	212	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 9	1994	266	5191					1705	1708		10.1126/science.7527588	http://dx.doi.org/10.1126/science.7527588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW308	7527588				2022-12-01	WOS:A1994PW30800040
J	GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C				GROSSHANS, J; BERGMANN, A; HAFFTER, P; NUSSLEINVOLHARD, C			ACTIVATION OF THE KINASE PELLE BY TUBE IN THE DORSOVENTRAL SIGNAL-TRANSDUCTION PATHWAY OF DROSOPHILA EMBRYO	NATURE			English	Article							DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; NUCLEAR-LOCALIZATION; PROTO-ONCOGENE; ESTABLISHMENT; PATTERN; CACTUS; MORPHOGEN; GRADIENT; RECEPTOR	THE concentration of Dorsal protein in the nucleus determines cell fate along the dorsoventral axis of the Drosophila embryo(1-13). The dorsal-group genes and the cactus gene are required for production and transmission of a localized signal an the ventral side of the embryo(4,5) which determines the position of the highest nuclear concentration of Dorsal protein(1-3) The ventralizing signal produced in somatic cells(6) is transmitted through the perivitelline space(7) to the integral membrane protein Toll(8). Inside the embryo it leads to dissociation of the cytoplasmic Dorsal-Cactus complex and subsequent nuclear localization of Dorsal protein(9,10). Two components are known to mediate the signal transduction between Toll and Dorsal-Cactus(11,12): Pelle, a serine/threonine protein kinase(13), and Tube, a protein with an unknown biochemical activity(14). Here we construct gain-of-function alleles of pelle and tube and show that pelle functions downstream of tube. In addition, Pelle and Tube interact directly with one another. We propose that Tube is a direct activator of the protein kinase Pelle.			GROSSHANS, J (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT 3,SPEMANNSTR 35,D-72076 TUBINGEN,GERMANY.		Großhans, Jörg/AAE-9387-2020	Großhans, Jörg/0000-0003-1114-9233				ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAGENMEIER S, 1992, THESIS U TUBINGEN; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; ISODA K, 1994, P NATL ACAD SCI USA, V91, P5350, DOI 10.1073/pnas.91.12.5350; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Wieschaus E., 1986, P199	30	107	112	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					563	566		10.1038/372563a0	http://dx.doi.org/10.1038/372563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527496				2022-12-01	WOS:A1994PW08200056
J	KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS				KOBZIK, L; REID, MB; BREDT, DS; STAMLER, JS			NITRIC-OXIDE IN SKELETAL-MUSCLE	NATURE			English	Article							REACTIVE OXYGEN; SARCOPLASMIC-RETICULUM; SYNTHASE; LOCALIZATION; SULFHYDRYLS; MECHANISM; OXIDATION; PROTEINS; RELEASE; FORMS	REACTIVE oxygen intermediates modulate skeletal muscle contraction(1,2), but little is known about the role of nitric oxide (NO). Here we show that rat skeletal muscle expresses neuronal-type NO synthase and that activity varies among several respiratory and limb muscles. Immunohistochemistry showed prominent staining of type II (fast) fibre cell membranes with antibodies against neuronal-type NO synthase. NO synthase activity in muscles correlated with type II fibre density. Resting diaphragm muscle produced detectable NOx, but no reactive oxygen intermediates. In contrast, actively contracting muscle generated increased levels of reactive oxygen intermediates. Contractile function was augmented by blockers of NO synthase, extracellular NO chelation, and guanylyl cyclase inhibition; it was depressed by NO donors and by increased levels of cyclic GMP. Force-frequency plots of different muscles showed an inverse correlation between NO synthase activity and force development. Our results support two physiological functions of NO in skeletal muscle. The first is to promote relaxation through the cGMP pathway(3,4). The second is to modulate increases In contraction that are dependent on reactive oxygen intermediates and which are thought to occur through reactions with regulatory thiols on the sarcoplasmic reticulum(5,6).	DUKE UNIV,MED CTR,DEPT MED,DIV PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV CARDIOVASC,DURHAM,NC 27710; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BAYLOR COLL MED,HOUSTON,TX 77030; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Duke University; Duke University; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Baylor College of Medicine; University of California System; University of California San Francisco				Stamler, Jonathan/0000-0002-6866-1572				ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BELL LC, 1991, BIOCHEM J, V273, P423, DOI 10.1042/bj2730423; BIANCHI CP, 1975, CELLULAR PHARM EXCIT, P485; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BYRD SK, 1993, FASEB J, V7, pA526; EHRENBERG A, 1960, ACTA CHEM SCAND, V14, P1684, DOI 10.3891/acta.chem.scand.14-1684; KANNER J, 1992, LIPIDS, V27, P46, DOI 10.1007/BF02537058; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; KUCERA I, 1987, BIOCHIM BIOPHYS ACTA, V894, P120, DOI 10.1016/0005-2728(87)90181-2; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; METZGER JM, 1985, J APPL PHYSIOL, V58, P1085, DOI 10.1152/jappl.1985.58.4.1085; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; REID MB, 1993, J APPL PHYSIOL, V75, P1081, DOI 10.1152/jappl.1993.75.3.1081; REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SCHERER NM, 1986, ARCH BIOCHEM BIOPHYS, V246, P589, DOI 10.1016/0003-9861(86)90314-0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1995, CELL, V78, P931; Stull J T, 1980, Adv Cyclic Nucleotide Res, V13, P39; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9; WESCOTT SL, 1985, J CYCLIC NUCL PROT, V10, P189; WU M, 1994, AM J PHYSIOL, V268, pH2108	28	837	856	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 8	1994	372	6506					546	548		10.1038/372546a0	http://dx.doi.org/10.1038/372546a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PW082	7527495				2022-12-01	WOS:A1994PW08200051
J	BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M				BARTLEY, M; POWER, C; BLANE, D; SMITH, GD; SHIPLEY, M			BIRTH-WEIGHT AND LATER SOCIOECONOMIC DISADVANTAGE - EVIDENCE FROM THE 1958 BRITISH COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; MORTALITY RISK; DISEASE; HEALTH; MIGRATION; INFANCY; SMOKING; GROWTH; DEATH; FETAL	Objective-To investigate the relation between birth weight and socioeconomic disadvantage during childhood and adolescence in a birth cohort study. Design-Longitudinal analysis of birth weight in relation to social class, household amenities and overcrowding, and financial difficulties as reported by parents at interview when participants were aged 7, 11, and 16 years; and receipt of unemployment or supplementary benefits as reported by participants at age 23. Subjects-Male participants in the 1958 birth cohort (national child development study) born to parents resident in Great Britain during the week of 3-9 March 1958. Data on birth weight and financial difficulties between birth and 23 years were available for 4321; data on housing conditions and social class at ages 7, 11 and 16 years were available for 3370. Main outcome measures-Socioeconomic disadvantage at later ages in men weighing 6 lb (2721g) or under at birth compared with those weighing over 6 lb and between fifths of the distribution of birth weight. Results-Cohort members who weighed 6 lb or under at birth were more likely to experience socioeconomic disadvantage subsequently. Those in lower fifths of the distribution were more likely to experience socioeconomic disadvantage. Conclusion-Low birth weight is associated with socioeconomic disadvantage in childhood and adolescence. Studies of the association of indicators of early development and adult disease need to take into account experiences right through from birth to adulthood if they are to elucidate the combination of risks attributable to developmental problems and socioeconomic disadvantage.	INST CHILD HLTH, DIV PUBL HLTH, LONDON WC1N 1EH, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT PSYCHIAT, LONDON W6 8RP, ENGLAND; UNIV GLASGOW, DEPT PUBL HLTH, GLASGOW G12 8RZ, LANARK, SCOTLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London; Imperial College London; University of Glasgow; University of London; University College London; UCL Medical School	BARTLEY, M (corresponding author), CITY UNIV LONDON, SOCIAL STAT RES UNIT, LONDON EC1R 0BN, ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Barker DJP, 1992, FETAL INFANT ORIGINS; BARTLEY M, 1992, SOCIOL HEALTH ILL, V14, P313; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BENTHAM G, 1988, SOC SCI MED, V26, P49, DOI 10.1016/0277-9536(88)90044-5; Brown M., 1982, DESPITE WELFARE STAT; Butler N.R., 1963, PERINATAL MORTALITY; COLLEY JRT, 1973, BRIT MED J, V3, P195, DOI 10.1136/bmj.3.5873.195; ESSEN J, 1978, CHILD CARE HLTH DEV, V4, P357, DOI 10.1111/j.1365-2214.1978.tb00095.x; ESSEN J, 1982, CONTINUITIES CHILDHO; ESSEX J, 1978, CHILD CARE HLTH DEV, V3, P41; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P163; GOLDSTEIN H, 1983, GROWING UP GB; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; KUH D, 1989, INT J EPIDEMIOL, V18, P663, DOI 10.1093/ije/18.3.663; KUH D, 1993, SOC HIST MED, V6, P101; KUH DJL, 1993, SOC SCI MED, V37, P905, DOI 10.1016/0277-9536(93)90145-T; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTYN CN, 1993, J EPIDEMIOL COMMUN H, V47, P76, DOI 10.1136/jech.47.1.76; NIE NH, 1983, STATISTICAL PACKAGE; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; PILLING D, 1990, ESCAPE DISADVANTAGE; POWER C, 1991, HLTH CLASS EARLY YEA; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH GD, 1992, LANCET, V340, P709; VERNON HM, 1939, HLTH RELATION OCCUPA; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wilkinson RG, 1986, CLASS HLTH RES LONGI, P1; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUN H, V33, P199, DOI 10.1136/jech.33.3.199	36	98	99	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	1994	309	6967					1475	1478		10.1136/bmj.309.6967.1475	http://dx.doi.org/10.1136/bmj.309.6967.1475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804048	Green Published			2022-12-01	WOS:A1994PW05300020
J	EVANS, SA; STONER, J; HARDY, C				EVANS, SA; STONER, J; HARDY, C			ARE GENERAL-PRACTITIONERS EQUIPPED TO MANAGE ACUTE SEVERE ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									MANCHESTER ROYAL INFIRM,DEPT RESP MED,MANCHESTER M13 9WL,LANCS,ENGLAND; PETERLOO MED CTR,MANCHESTER,LANCS,ENGLAND	University of Manchester								KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; MORGAN MDL, 1982, BRIT MED J, V285, P849, DOI 10.1136/bmj.285.6345.849; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; 1990, BRIT MED J, V30, P797; 1993, BRIT MED J, V306, P776	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1486	1486		10.1136/bmj.309.6967.1486	http://dx.doi.org/10.1136/bmj.309.6967.1486			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804056	Green Published			2022-12-01	WOS:A1994PW05300028
J	MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB				MICHAELS, JA; RUTTER, P; COLLIN, J; LEGG, FM; GALLAND, RB			RELATION BETWEEN RATES OF LEG AMPUTATION AND DISTAL ARTERIAL RECONSTRUCTIVE SURGERY	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford								CHESHIRE NJW, 1992, J VASC SURG, V15, P167, DOI 10.1016/0741-5214(92)70025-G; LINDHOLT JS, 1994, EUR J VASCULAR SURG, V8, P31, DOI 10.1016/S0950-821X(05)80116-1; MICHAELS JA, 1994, BRIT MED J, V309, P387, DOI 10.1136/bmj.309.6951.387; MICHAELS JA, 1994, BRIT J SURG, V81, P377, DOI 10.1002/bjs.1800810318	4	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1479	1480		10.1136/bmj.309.6967.1479a	http://dx.doi.org/10.1136/bmj.309.6967.1479a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7804051	Green Published			2022-12-01	WOS:A1994PW05300022
J	JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH				JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH			STIMULATION AND INHIBITION OF ANGIOGENESIS BY PLACENTAL PROLIFERIN AND PROLIFERIN-RELATED PROTEIN	SCIENCE			English	Article							MOUSE PLACENTA; MESSENGER-RNA; GIANT-CELLS; PROLACTIN; FAMILY; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SITE	In many mammalian species, the placenta is the site of synthesis of proteins in the prolactin and growth hormone family. Analysis of two such proteins, proliferin (PLF) and proliferin-related protein (PRP), revealed that they are potent regulators of angiogenesis; PLF stimulated and PRP inhibited endothelial cell migration in cell culture and neovascularization in vivo. The mouse placenta secretes an angiogenic activity during the middle of pregnancy that corresponds primarily to PLF, but later in gestation releases a factor that inhibits angiogenesis, which was identified as PRP. Incubation of placental tissue with PLF led to the specific binding of this hormone to capillary endothelial cells. Thus PLF and PRP may regulate the initiation and then the cessation of placental neovascularization.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center				Volpert, Olga/0000-0003-1381-5543	NCI NIH HHS [CA52750] Funding Source: Medline; NICHD NIH HHS [HD29962, HD24518] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029962, R01HD024518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CLAPP C, 1992, ENDOCRINOLOGY, V130, P1380, DOI 10.1210/en.130.3.1380; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; HORSEMAN N, COMMUNICATION; JACKSON DJC, UNPUB; LEE SJ, 1988, ENDOCRINOLOGY, V122, P1761, DOI 10.1210/endo-122-5-1761; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LINZER DIH, 1985, EMBO J, V4, P1419, DOI 10.1002/j.1460-2075.1985.tb03796.x; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LINZER DIH, 1984, P NATL ACAD SCI-BIOL, V81, P4255, DOI 10.1073/pnas.81.14.4255; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LOPEZ MF, 1993, ENDOCR J, V1, P513; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUSCAT GEO, 1991, MOL ENDOCRINOL, V5, P802, DOI 10.1210/mend-5-6-802; NILSENHAMILTON M, 1980, CELL, V20, P19, DOI 10.1016/0092-8674(80)90230-5; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RAMSEY EM, 1982, PLACENTA; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WILDER EL, 1989, MOL CELL BIOL, V9, P430, DOI 10.1128/MCB.9.2.430	22	194	200	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1581	1584		10.1126/science.7527157	http://dx.doi.org/10.1126/science.7527157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527157				2022-12-01	WOS:A1994PV01500050
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			ASSOCIATION OF INSULIN-RECEPTOR SUBSTRATE-1 WITH INTEGRINS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS; ADHESION RECEPTORS; VITRONECTIN; TYROSINE	Insulin stimulation was found to promote association of the alpha(v) beta(3) integrin (a vitronectin receptor) with insulin receptor substrate-1 (IRS-1), an intracellular protein that mediates insulin signaling by binding other signaling molecules, including growth factor receptor-bound protein 2 (Grb2) and phosphatidylinositol-3' kinase. Insulin-treated cells expressing the alpha(v) beta(3) integrin showed 2.5 times more DNA synthesis when plated on vitronectin than on other substrates, whereas cells expressing another vitronectin receptor, alpha(v) beta(5), did not show this difference. The association between integrin and IRS-1 may be a mechanism for the synergistic action of growth factor and extracellular matrix receptors.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA 42507, CA 30199, CA 28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042507, P01CA028896, P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LILIEN LE, 1990, J CELL BIOL, V111, P635; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SCHUBERT D, 1991, J CELL BIOL, V114, P841, DOI 10.1083/jcb.114.4.841; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; VUORI K, UNPUB; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	344	348	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1576	1578		10.1126/science.7527156	http://dx.doi.org/10.1126/science.7527156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527156				2022-12-01	WOS:A1994PV01500048
J	AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL				AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL			VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PIGMENT EPITHELIAL-CELLS; PERMEABILITY FACTOR; ANGIOGENESIS; NEOVASCULARIZATION; SECRETION; INSULIN; INVIVO	Background. Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific angiogenic factor whose production is increased by hypoxia. Methods. We measured the concentration of VEGF in 210 specimens of ocular fluid obtained from 164 patients undergoing intraocular surgery, using both radioimmunoassays and radioreceptor assays. Vitreous proliferative potential was measured with in vitro assays of the growth of retinal endothelial cells and with VEGF-neutralizing antibody. Results. VEGF was detected in 69 of 136 ocular-fluid samples from patients with diabetic retinopathy, 29 of 38 samples from patients with neovascularization of the iris, and 3 of 4 samples from patients with ischemic occlusion of the central retinal vein, as compared with 2 of 31 samples from patients with no neovascular disorders (P<0.001, P<0.001, and P = 0.006, respectively). The mean (+/-SD) VEGF concentration in 70 samples of ocular fluid from patients with active proliferative diabetic retinopathy (3.6+/-6.3 ng per milliliter) was higher than that in 25 samples from patients with nonproliferative diabetic retinopathy (0.1+/-0.1 ng per milliliter, P = 0.008), 41 samples from patients with quiescent proliferative diabetic retinopathy (0.2+/-0.6 ng per milliliter, P<0.001), or 31 samples from nondiabetic patients (0.1+/-0.2 ng per milliliter, P = 0.003). Concentrations of VEGF in vitreous fluid (8.8+/-9.9 ng per milliliter) were higher than those in aqueous fluid (5.6+/-8.6 ng per milliliter, P = 0.033) in all 10 pairs of samples obtained simultaneously from the same patient; VEGF concentrations in vitreous fluid declined after successful laser photocoagulation. VEGF stimulated the growth of retinal endothelial cells in vitro, as did vitreous fluid containing measurable VEGF. Stimulation was inhibited by VEGF-neutralizing antibodies. Conclusions. Our data suggest that VEGF plays a major part in mediating active intraocular neovascularization in patients with ischemic retinal diseases, such as diabetic retinopathy and retinal-vein occlusion.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OPHTHALMOL,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF SANTA BARBARA,NEUROSCI RES INST,SANTA BARBARA,CA 93106; GENENTECH INC,SAN FRANCISCO,CA; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DEPT OPHTHALMOL,BALTIMORE,MD	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Santa Barbara; Roche Holding; Genentech; Johns Hopkins University; Johns Hopkins Medicine	AIELLO, LP (corresponding author), JOSLIN DIABET CTR,BEETHAM EYE INST,DEPT OPHTHALMOL,1 JOSLIN PL,BOSTON,MA 02215, USA.		CLIHON, Residencia Medica/K-4896-2013	CLIHON, Residencia Medica/0000-0001-6734-2513	NEI NIH HHS [EY05110] Funding Source: Medline; NIDCR NIH HHS [DERC36836-08] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ADAMIS AP, 1993, INVEST OPHTH VIS SCI, V34, P1440; AIELLO LP, 1994, INVEST OPHTH VIS SCI, V35, P1868; [Anonymous], 1976, AM J OPHTHALMOL, V81, P383; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BROWN GC, 1988, INT OPHTHALMOL, V11, P239, DOI 10.1007/BF00131023; BROWN GC, 1989, RETINA, V2, P547; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GLASER BM, 1980, J CELL BIOL, V84, P298, DOI 10.1083/jcb.84.2.298; HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048; HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; MALECAZE F, 1993, INVEST OPHTH VIS SCI, V34, P1039; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; PARK JE, 1994, J BIOL CHEM, V269, P25646; PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1993, INVEST OPHTH VIS SCI, V34, P900; RAND LI, 1981, AM J MED, V70, P595, DOI 10.1016/0002-9343(81)90581-7; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHIMA D, 1993, INVEST OPHTH VIS SCI, V34, P900; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046; THIEME H, IN PRESS DIABETES; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WHITE P, 1960, DIABETES, V9, P345, DOI 10.2337/diab.9.5.345; 1991, OPHTHALMOLOGY S, V98, P741	38	2997	3212	4	147	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1480	1487		10.1056/NEJM199412013312203	http://dx.doi.org/10.1056/NEJM199412013312203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7526212				2022-12-01	WOS:A1994PU86600003
J	WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S				WARREN, RW; NAGY, L; SELEGUE, J; GATES, J; CARROLL, S			EVOLUTION OF HOMEOTIC GENE-REGULATION AND FUNCTION IN FLIES AND BUTTERFLIES	NATURE			English	Article							BITHORAX-COMPLEX; DROSOPHILA; EXPRESSION	IT has been proposed that the evolution of homeotic genes parallels, and to some degree directs, the evolution of segment diversity in the myriapod-insect lineage(1-3). But the discovery of discrete Antennapedia complex (ANT-C) and bithorax complex (BX-C) gene members in crustacea(4) chelicerates(5), annelids(6-8) and various insects(9-11), as well as in vertebrates(12), indicates that the expansion and diversification of homeotic genes preceded the diversification of arthropods and insects. How, then, have these genes influenced the evolution of body plans? To address this question, we now examine homeotic gene expression and regulation in butterflies (Lepidoptera), which, unlike flies, possess larval abdominal limbs and two pairs of wings. We show that the difference in larval limb number between these insects results from striking changes in BX-C gene regulation in the butterfly abdomen, and we deduce that the wing-patterning genes regulated by Ultrabithorax have diverged in the course of butterfly and fly evolution. These findings have general implications for the role of homeotic genes in animal evolution.	UNIV WISCONSIN, HOWARD HUGHES MED INST, MADISON, WI 53706 USA; UNIV WISCONSIN, MOLEC BIOL LAB, MADISON, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AKAM M, 1988, DEVELOPMENT, V104, P123; AKAM M, IN PRESS DEVELOPMENT; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEACHY PA, 1985, NATURE, V313, P545, DOI 10.1038/313545a0; BEEMAN RW, 1989, DEV BIOL, V133, P196, DOI 10.1016/0012-1606(89)90311-4; BIRKETSMITH SJR, 1984, PROLEGS LEGS WINGS I; CARTWRIGHT P, 1993, MOL PHYLOGENET EVOL, V2, P185, DOI 10.1006/mpev.1993.1019; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GOLDSCHMIDT RB, 1940, MATERIAL BASIS EVOLU; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, 1985, CELL, V43, P81, DOI 10.1016/0092-8674(85)90014-5; KELSH R, 1994, DEV GENET, V15, P19, DOI 10.1002/dvg.1020150104; KELSH R, 1993, DEVELOPMENT, V117, P293; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; MACIAS A, 1990, DEVELOPMENT, V110, P1197; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; PANGANIBAN G, 1994, CURR BIOL, V4, P671, DOI 10.1016/S0960-9822(00)00151-2; Raff R.A., 1983, EMBRYOS GENES EVOLUT; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANKLAND M, 1991, DEVELOPMENT, P29; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; STUART JJ, 1993, DEVELOPMENT, V117, P233; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0	31	162	168	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	1994	372	6505					458	461		10.1038/372458a0	http://dx.doi.org/10.1038/372458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV012	7840822				2022-12-01	WOS:A1994PV01200055
J	DOUGLAS, KA; REDMAN, CWG				DOUGLAS, KA; REDMAN, CWG			ECLAMPSIA IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; HYPERTENSION; MANAGEMENT; PREGNANCY	Objectives--To measure the incidence eclampsia, establish how often it is preceded by signs of pre-eclampsia, document the morbidity associated with eclampsia, and determine the maternal case fatality rates. Design-A prospective, descriptive study of every case of eclampsia in the United Kingdom in 1992. Information was collected from reviews of hospital case notes and questionnaires to general practitioners. Setting-All 279 hospitals in the United Kingdom with a consultant obstetric unit. Results-Obstetricians and midwives notified 582 possible cases, and 383 were confirmed as eclampsia. The national incidence of eclampsia was 4.9/10 000 maternities (95% confidence interval 4.5 to 5.4). Most convulsions occurred despite antenatal care (70%) and within one week of the woman's last visit to a doctor or midwife (85%). Three quarters of first seizures occurred in hospital, of which 38% developed before both proteinuria and hypertension had been documented. Forty four per cent of cases occurred postpartum, more than a third (38%) antepartum, and the remainder (18%) intrapartum. Nearly one in 50 women (1.8%) died, and 35% of all women had at least one major complication. The rate of stillbirths and neonatal deaths was 22.2/1000 and 34.1/1000, respectively. Preterm eclampsia occurred more commonly antepartum and was associated with more maternal complications and fetuses that were small for gestational age, as well as with higher rates of stillbirth and neonatal mortality. Antepartum eclampsia, which was more likely to occur preterm, was associated with a higher rate of maternal complications and a higher neonatal mortality. Both factors (gestational prematurity and antepartum occurrence) contributed independently to the severity of the outcome. Conclusion-Eclampsia occurs in nearly one in 2000 maternities in the United Kingdom and is associated with high maternal morbidity and fatality in cases. It may present unheralded by warning signs. Preterm and antenatal eclampsia seem to be particularly severe.	UNIV OXFORD, JOHN RADCLIFFE HOSP, NUFFIELD DEPT OBSTET & GYNAECOL, OXFORD OX3 9DU, ENGLAND	University of Oxford			Douglas, Kirsty/E-3083-2017	Douglas, Kirsty/0000-0003-0174-782X				CAMPBELL DM, 1980, PREGNANCY HYPERTENS, P483; CORKILL TF, 1961, PATHOL MICROBIOL, V24, P428, DOI 10.1159/000161149; DOUGLAS KA, 1992, BRIT J OBSTET GYNAEC, V99, P355, DOI 10.1111/j.1471-0528.1992.tb13745.x; DULEY I, 1992, OXFORD DATABASE PERI; EDEN TW, 1922, J OBSTET GYN BR COMM, V29, P386; Hall M, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P75; LLERA ML, 1992, AM J OBSTET GYNECOL, V166, P4; MOLLER B, 1986, ACTA OBSTET GYN SCAN, V65, P307; MOODLEY J, 1983, S AFR MED J, V63, P530; MOORE PJ, 1985, S AFR MED J, V67, P597; PORAPAKKHAM S, 1979, OBSTET GYNECOL, V54, P26, DOI 10.1097/00006250-197907000-00007; REDMAN CWG, 1993, LANCET, V341, P1451, DOI 10.1016/0140-6736(93)90890-S; REDMAN CWG, 1988, LANCET, V1, P809; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SIBAI BM, 1986, AM J OBSTET GYNECOL, V154, P581, DOI 10.1016/0002-9378(86)90605-8; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; WIGHTMAN H, 1978, BRIT MED J, V2, P235, DOI 10.1136/bmj.2.6132.235; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 1991, REPORT CONFIDENTIAL; 1994, REPORT CONFIDENTIAL	21	526	548	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 26	1994	309	6966					1395	1400		10.1136/bmj.309.6966.1395	http://dx.doi.org/10.1136/bmj.309.6966.1395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819845	Green Submitted, Green Published			2022-12-01	WOS:A1994PU76400017
J	MARTEAU, T				MARTEAU, T			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - PSYCHOLOGICAL CONSEQUENCES ARE UNCLEAR	BRITISH MEDICAL JOURNAL			English	Article							EARLY-PREGNANCY				MARTEAU, T (corresponding author), UNITED MED & DENT SCH,PSYCHOL & GENET RES GRP,LONDON SE1 9RT,ENGLAND.			Marteau, Theresa/0000-0003-3025-1129	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BRITTON J, 1991, LANCET, V338, P1524, DOI 10.1016/0140-6736(91)92341-X; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; Holland WW, 1990, SCREENING HLTH CARE; ILES S, 1989, BAILLIERE CLIN OB GY, V3, P769, DOI 10.1016/S0950-3552(89)80064-1; SUTCLIFFE M, 1993, LANCET, V342, P1174, DOI 10.1016/0140-6736(93)92158-P; WALTERS S, 1993, BRIT MED J, V306, P549, DOI 10.1136/bmj.306.6877.549; WEST R, 1993, SMOKING PREGNANCY GU, P9; 1991, LANCET, V338, P131; 1992, SMOKING YOUNG REPORT	11	6	6	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1429	1430		10.1136/bmj.309.6966.1429	http://dx.doi.org/10.1136/bmj.309.6966.1429			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PU764	7819858	Green Published			2022-12-01	WOS:A1994PU76400033
J	MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST				MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST			COLORECTAL-CANCER PROGNOSIS AND EXPRESSION OF EXON-V6-CONTAINING CD44 PROTEINS	LANCET			English	Note							METASTASIS-ASSOCIATED VARIANT; CARCINOMAS; HOMOLOG	CD44 variants containing v6 confer metastatic potential to rat carcinoma cell-lines. In man, CD44v6 is increasingly expressed during colorectal tumour progression. In 68 colorectal carcinoma patients, survival analysis showed that CD44v6 expression in the tumours was associated with tumour-related death. In patients who had an apparently radical resection of their primary tumour, CD44v6 expression had prognostic value independent of Dukes' stage. CD44v6 expression may reflect propensity for metastasis after apparently curative surgery, making adjuvant therapy an option in these patients.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL,1105 AZ AMSTERDAM,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT SURG,DELFT,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT PATHOL,DELFT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Reinier de Graaf Hospital; Reinier de Graaf Hospital				Pals, Steven/0000-0002-1419-0939				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; 1990, JAMA-J AM MED ASSOC, V264, P1444	10	302	315	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1470	1472		10.1016/S0140-6736(94)90290-9	http://dx.doi.org/10.1016/S0140-6736(94)90290-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7526103				2022-12-01	WOS:A1994PT99500009
J	PANDIT, JC				PANDIT, JC			TESTING ACUITY OF VISION IN GENERAL-PRACTICE - REACHING RECOMMENDED STANDARD	BRITISH MEDICAL JOURNAL			English	Article									TORBAY HOSP,DEPT OPHTHALMOL,TORQUAY TQ2 7AA,DEVON,ENGLAND									BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001; RAFFLE A, 1985, MED ASPECTS FITNESS; 1968, BS4274 BRIT STAND I	3	25	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1408		10.1136/bmj.309.6966.1408	http://dx.doi.org/10.1136/bmj.309.6966.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7755711	Green Published			2022-12-01	WOS:A1994PU76400020
J	RAEBURN, JA				RAEBURN, JA			SCREENING FOR CARRIERS OF CYSTIC-FIBROSIS - SCREENING BEFORE PREGNANCY IS NEEDED	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE				RAEBURN, JA (corresponding author), CITY HOSP NOTTINGHAM,CTR GENET MED,NOTTINGHAM NG5 1PD,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; MATTHEWS P, 1993, INDEPENDENT SUND AUG, P42; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; QURESHI N, 1993, BRIT MED J, V307, P816, DOI 10.1136/bmj.307.6908.816; SCRIVER CR, 1992, AM J HUM GENET, V51, P943; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; 1993, GENETIC SCREENING ET, P15; 1992, CYSTIC FIBROSIS DNA	10	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1428	1429		10.1136/bmj.309.6966.1428	http://dx.doi.org/10.1136/bmj.309.6966.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819857	Green Published			2022-12-01	WOS:A1994PU76400032
J	THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD				THAM, KY; EVANS, RJ; RUBYTHON, EJ; KINNAIRD, TD			MANAGEMENT OF VENTRICULAR-FIBRILLATION BY DOCTORS IN CARDIAC-ARREST TEAMS	BRITISH MEDICAL JOURNAL			English	Article							RESUSCITATION SKILLS; CARDIOPULMONARY		CARDIFF ROYAL INFIRM,DEPT ACCID & EMERGENCY,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								DAVID J, 1993, BRIT MED J, V306, P1578, DOI 10.1136/bmj.306.6892.1578; MORRIS F, 1991, BRIT MED J, V302, P626, DOI 10.1136/bmj.302.6777.626; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1992, RESUSCITATION, V24, P111; 1993, BRIT MED J, V306, P1589	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1409		10.1136/bmj.309.6966.1408a	http://dx.doi.org/10.1136/bmj.309.6966.1408a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819848	Green Published			2022-12-01	WOS:A1994PU76400021
J	THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM				THOMSON, JA; DAVIES, DL; MCLAREN, EH; TEASDALE, GM			10-YEAR FOLLOW-UP OF MICROPROLACTINOMA TREATED BY TRANSSPHENOIDAL SURGERY	BRITISH MEDICAL JOURNAL			English	Article							HYPERPROLACTINEMIA; PROLACTINOMA		WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; STOBHILL GEN HOSP,DEPT MED,GLASGOW G21 3UW,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,GLASGOW G51 4TF,LANARK,SCOTLAND	University of Glasgow	THOMSON, JA (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,LANARK,SCOTLAND.							BEVAN JS, 1987, CLIN ENDOCRINOL, V26, P541, DOI 10.1111/j.1365-2265.1987.tb00809.x; SCANLON MF, 1985, BRIT MED J, V291, P1547, DOI 10.1136/bmj.291.6508.1547; SERRI O, 1983, NEW ENGL J MED, V309, P280, DOI 10.1056/NEJM198308043090505; SERRI O, 1993, NEW ENGL J MED, V329, P1357, DOI 10.1056/NEJM199310283291817; THOMSON JA, 1985, BRIT MED J, V291, P1550, DOI 10.1136/bmj.291.6508.1550	5	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1409	1410		10.1136/bmj.309.6966.1409	http://dx.doi.org/10.1136/bmj.309.6966.1409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819849	Green Published			2022-12-01	WOS:A1994PU76400022
J	URWIN, G; YUAN, MF; FELDMAN, RA				URWIN, G; YUAN, MF; FELDMAN, RA			PROSPECTIVE-STUDY OF BACTERIAL-MENINGITIS IN NORTH-EAST THAMES REGION, 1991-3, DURING INTRODUCTION OF HAEMOPHILUS-INFLUENZAE VACCINE	BRITISH MEDICAL JOURNAL			English	Article							B INVASIVE DISEASE; UNITED-STATES; SURVEILLANCE; EPIDEMIOLOGY	Objective-To describe the epidemiology of primary bacterial meningitis in the North East Thames region over a three year period before and during the introduction of the vaccine for Haemophilus influenzae type b. Design-Analysis of information on cases of primary bacterial meningitis identified by microbiology laboratories in the region, with collection of case data by questionnaire. Main outcome measures-Annual incidence rates for types of meningitis according to age and ethnic group. Results-The annual incidence rates for the three major causes of bacterial meningitis in the general population were 1.9/100 000 for Neisseria meningitidis, 1.6/100 000 for Haemophilus influenzae before vaccination, and 1.0/100 000 for Streptococcus pneumoniae. Higher rates of H influenzae meningitis were found in Asians compared with white people (3.6/100 000 v 1.5/100 000, P=0.01). As a result of the vaccine programme introduced in October 1992 the number of cases of H influenzae meningitis in children under 5 years has fallen by 87%. Conclusions-Bacterial meningitis is a serious problem especially in preschool children. There are differences in the incidence of some causes of bacterial meningitis in different ethnic groups; with H influenzae type b being significantly more common among black and Asian people than among white people. The immunisation programme for H influenzae type b in the North East Thames region has been successful in reducing the incidence of this type of meningitis in Asian and white populations. The numbers were too small to evaluate in the black population.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 4NS,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT MED MICROBIOL,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; University of London; University College London								ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; BREWSTER D, 1993, HLTH B EDINB, V56, P385; CARTWRIGHT KAV, 1986, LANCET, V2, P558; FALLON RJ, 1991, BRIT MED J, V303, P1203, DOI 10.1136/bmj.303.6811.1203-b; GILLAM S, 1990, POSTGRAD MED J, V66, P989, DOI 10.1136/pgmj.66.782.989; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; MACLEOD C, 1994, CDR REV, V2, pR13; NAZARETH B, 1992, COMM DIS REP REV, V2, P13; OBRIEN H, 1994, COM DIS REP CDR REV, V2, pR17; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; RALEIGH VS, 1994, BRIT MED J, V309, P287, DOI 10.1136/bmj.309.6950.287; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; TUDORWILLIAMS G, 1989, ARCH DIS CHILD, V64, P517, DOI 10.1136/adc.64.4.517; WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316	17	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1412	1414		10.1136/bmj.309.6966.1412	http://dx.doi.org/10.1136/bmj.309.6966.1412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7819853	Green Published			2022-12-01	WOS:A1994PU76400027
J	DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI				DURING, MJ; NAEGELE, JR; OMALLEY, KL; GELLER, AI			LONG-TERM BEHAVIORAL RECOVERY IN PARKINSONIAN RATS BY AN HSV VECTOR EXPRESSING TYROSINE-HYDROXYLASE	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; AMINO-ACID DECARBOXYLASE; COLI BETA-GALACTOSIDASE; STRIATAL NEURONS; CEREBRAL-CORTEX; GENE-THERAPY; DOPAMINE; DISEASE; ORGANIZATION; INVIVO	One therapeutic approach to treating Parkinson's disease is to convert endogenous striatal cells into levo-3,4-dihydroxyphenylalanine (L-dopa)-producing cells. A defective herpes simplex virus type 1 vector expressing human tyrosine hydroxylase was delivered into the partially denervated striatum of 6-hydroxydopamine-lesioned rats, used as a model of Parkinson's disease. Efficient behavioral and biochemical recovery was maintained for 1 year after gene transfer. Biochemical recovery included increases in both striatal tyrosine hydroxylase enzyme activity and in extracellular dopamine concentrations. Persistence of human tyrosine hydroxylase was revealed by expression of RNA and immunoreactivity.	YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06510 USA; WESLEYAN UNIV, DEPT BIOL, MIDDLETOWN, CT 06457 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DIV ENDOCRINOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA	Yale University; Wesleyan University; Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	DURING, MJ (corresponding author), YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06510 USA.		During, Matthew/AAC-1388-2020; Geller, Alfred/C-6469-2012	Naegele, Janice Rae/0000-0001-5151-0543	NATIONAL EYE INSTITUTE [R29EY009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS006208, R29NS028227] Funding Source: NIH RePORTER; NEI NIH HHS [EY09749] Funding Source: Medline; NINDS NIH HHS [NS28227, NS06208] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RL, 1984, J PATHOL, V143, P241, DOI 10.1002/path.1711430403; BAKAY RAE, 1987, ANN NY ACAD SCI, V495, P623, DOI 10.1111/j.1749-6632.1987.tb23705.x; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; CASS WA, 1993, J NEUROCHEM, V61, P2269, DOI 10.1111/j.1471-4159.1993.tb07469.x; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COKER GT, 1990, MOL BRAIN RES, V8, P93, DOI 10.1016/0169-328X(90)90052-F; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; DUBACH M, 1987, NEUROSCI LETT, V75, P205, DOI 10.1016/0304-3940(87)90298-9; DURING MJ, 1992, EXP NEUROL, V115, P193, DOI 10.1016/0014-4886(92)90053-S; EMSON PC, 1990, EXP BRAIN RES, V79, P427, DOI 10.1007/BF00608254; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; FREED R, 1992, NEW ENGL J MED, V327, P1640; FREED WJ, 1980, ANN NEUROL, V8, P510, DOI 10.1002/ana.410080508; FREESE A, 1991, NUCLEIC ACIDS RES, V19, P7219, DOI 10.1093/nar/19.25.7219; GAGE FH, 1991, TRENDS NEUROSCI, V14, P328, DOI 10.1016/0166-2236(91)90156-O; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P8950, DOI 10.1073/pnas.87.22.8950; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GELLER AI, IN PRESS J NEUROCHEM; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAYCOCK JW, COMMUNICATION; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HORELLOU P, 1990, NEURON, V5, P393, DOI 10.1016/0896-6273(90)90078-T; JIAO SS, 1993, NATURE, V362, P450, DOI 10.1038/362450a0; KOSAKA T, 1987, EXP BRAIN RES, V68, P393; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LEWIS DA, 1993, NEUROSCIENCE, V54, P477, DOI 10.1016/0306-4522(93)90267-J; LI XM, 1992, J NEUROCHEM, V59, P1172, DOI 10.1111/j.1471-4159.1992.tb08363.x; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LOMBROSO PJ, 1993, J NEUROSCI, V13, P3064; MCGEOCH DJ, 1986, NUCLEIC ACIDS RES, V14, P1727, DOI 10.1093/nar/14.4.1727; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; MCGEORGE AJ, 1987, BRAIN RES, V423, P318, DOI 10.1016/0006-8993(87)90855-9; MOSCA JD, 1985, J VIROL, V56, P867, DOI 10.1128/JVI.56.3.867-878.1985; OMALLEY KL, 1987, BIOCHEMISTRY-US, V26, P6910, DOI 10.1021/bi00396a007; PERESE DA, 1989, BRAIN RES, V494, P285, DOI 10.1016/0006-8993(89)90597-0; REDMOND DE, 1986, LANCET, V1, P1125; ROBERT F, 1993, J NEUROCHEM, V60, P721, DOI 10.1111/j.1471-4159.1993.tb03207.x; ROHRER H, 1986, J NEUROSCI, V6, P2616; SCHNEIDER JS, 1994, BRAIN RES, V643, P86, DOI 10.1016/0006-8993(94)90012-4; SLADEK JR, 1988, PROG BRAIN RES, V78, P497; SMITH RE, UNPUB, P54011; Song S., UNPUB; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STAINES WA, 1981, BRAIN RES, V206, P446, DOI 10.1016/0006-8993(81)90545-X; STEVENS JG, 1987, SCIENCE, V235, P1056, DOI 10.1126/science.2434993; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TASHIRO Y, 1989, NEUROSCI LETT, V97, P6, DOI 10.1016/0304-3940(89)90130-4; TASHIRO Y, 1989, NEUROSCI LETT, V100, P29, DOI 10.1016/0304-3940(89)90655-1; VANHORNE C, 1992, J PHARMACOL EXP THER, V263, P1285; VECSEI L, 1992, NEUROLOGICAL DISORDE, P223; WANG J, 1994, J NEUROSURG, V80, P484, DOI 10.3171/jns.1994.80.3.0484; WATSON K, 1980, J GEN VIROL, V49, P149, DOI 10.1099/0022-1317-49-1-149; WESTERINK BHC, 1990, J NEUROCHEM, V54, P381, DOI 10.1111/j.1471-4159.1990.tb01884.x; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WILSON CJ, 1987, J COMP NEUROL, V263, P567, DOI 10.1002/cne.902630408; WOLFF JA, 1989, P NATL ACAD SCI USA, V86, P9011, DOI 10.1073/pnas.86.22.9011; YAHR MD, 1969, ARCH NEUROL-CHICAGO, V21, P343, DOI 10.1001/archneur.1969.00480160015001; YAHR MD, 1987, PARKINSONS DISEASE; YUREK DM, 1990, ANNU REV NEUROSCI, V13, P415, DOI 10.1146/annurev.neuro.13.1.415	62	314	336	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1399	1403		10.1126/science.266.5189.1399	http://dx.doi.org/10.1126/science.266.5189.1399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7669103	Green Accepted			2022-12-01	WOS:A1994PT63200048
J	LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW				LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW			CALCIUM-CALMODULIN MODULATION OF THE OLFACTORY CYCLIC NUCLEOTIDE-GATED CATION CHANNEL	SCIENCE			English	Article							OUTER RENAL MEDULLA; ION CHANNELS; FUNCTIONAL EXPRESSION; PHOTORECEPTOR CELLS; POTASSIUM CHANNEL; BINDING DOMAIN; PROTEIN; ACTIVATION; MEMBRANE; ROD	Although several ion channels have been reported to be directly modulated by calcium-calmodulin, they have not been conclusively shown to bind calmodulin, nor are the modulatory mechanisms understood. Study of the olfactory cyclic nucleotide-activated cation channel, which is modulated by calcium-calmodulin, indicates that calcium-calmodulin directly binds to a specific domain on the amino terminus of the channel. This binding reduces the effective affinity of the channel for cyclic nucleotides, apparently by acting on channel gating, which is tightly coupled to ligand binding. The data reveal a control mechanism that resembles those underlying the regulation of enzymes by calmodulin. The results also point to the amino-terminal part of the olfactory channel as an element for gating, which may have general significance in the operation of ion channels with similar overall structures.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OPHTHALMOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University					NATIONAL EYE INSTITUTE [R37EY006837, R01EY006837] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06837] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COLQUHOUN D, 1993, NATURE, V366, P510, DOI 10.1038/366510b0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 1992, IONIC CHANNELS EXCIT; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLAERKE DA, 1987, J MEMBRANE BIOL, V95, P105, DOI 10.1007/BF01869155; KLAERKE DA, 1987, FEBS LETT, V216, P211, DOI 10.1016/0014-5793(87)80691-9; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KRINKS MH, 1984, ADV CYCLIC NUCL PROT, V16, P31; KUBALSKI A, 1989, J MEMBRANE BIOL, V112, P91, DOI 10.1007/BF01871167; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MUNIER H, 1991, FEBS LETT, V190, P409; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; REED R, COMMUNICATION; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; SAIMI Y, 1993, HDB MEMBRANE CHANNEL, P435; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRYER L, 1987, CHEM SCRIPTA, V27B, P161; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710	53	232	237	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1348	1354		10.1126/science.266.5189.1348	http://dx.doi.org/10.1126/science.266.5189.1348			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7526466				2022-12-01	WOS:A1994PT63200034
J	LIM, WA; RICHARDS, FM; FOX, RO				LIM, WA; RICHARDS, FM; FOX, RO			STRUCTURAL DETERMINANTS OF PEPTIDE-BINDING ORIENTATION AND OF SEQUENCE SPECIFICITY IN SH3 DOMAINS	NATURE			English	Article							CRYSTAL-STRUCTURE; TYROSINE KINASES; PROTEIN; SOS; ASSOCIATION; SEVENLESS; EXCHANGE; GRB2	THE Src-homology-3 (SH3) domains of the Caenorhabditis elegans protein SEM-5 and its human and Drosophila homologues, Grb2 and Drk (refs 1-4), bind proline-rich sequences found in the nucleotide-exchange factor Sos as part of their proposed function linking receptor tyrosine kinase activation to Ras activation(5-7). Here we report the crystal structure at 2.0 Angstrom resolution of the carboxy-terminal SH3 domain from SEM-5 complexed to the mSos-derived amino-acid sequence PPPVPPRRR. The peptide is found to bind in an orientation ('minus') that is precisely opposite to that observed previously ('plus' orientation) in other SH3-peptide complexes(8,9). This novel ability of peptide-recognition proteins to recognize peptides in two distinct modes may play an important role in the signalling specificity of pathways involving SH3 domains. Comparison of this structure with other SH3 complexes reveals how a conserved binding face can be used to recognize peptides in different orientations, and why the Sos peptide binds in this particular orientation.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Howard Hughes Medical Institute; Yale University	LIM, WA (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P542; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; LI N, 1993, NATURE, V363, P83; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1987, ACTA CRYSTALLOGR A, V43, P645, DOI 10.1107/S0108767387098787; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; ROZAKISADOCK M, 1993, NATURE, V363, P79; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TERASAWA H, IN PRESS NATURE STRU; WITTEKIND M, IN PRESS BIOCHEMISTR; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZVELEBIL MJJM, 1993, Q REV BIOPHYS, V26, P333, DOI 10.1017/S0033583500002870	28	474	481	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 24	1994	372	6504					375	379		10.1038/372375a0	http://dx.doi.org/10.1038/372375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PU287	7802869				2022-12-01	WOS:A1994PU28700059
J	PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC				PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC			GENETIC AND CLINICAL MOSAICISM IN A TYPE OF EPIDERMAL NEVUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; KERATIN EXPRESSION; POINT MUTATIONS; ALPHA-SUBUNIT; HYPERKERATOSIS; SKIN; MICE; DIFFERENTIATION; ABNORMALITIES; ERYTHRODERMA	Background. Many skin disorders are characterized by a mosaic pattern, often with alternating stripes of affected and unaffected skin that follow the lines of Blaschko. These nonrandom patterns may be caused by a postzygotic mutation during embryogenesis. We studied the genetic basis of one such disorder, epidermal nevus of the epidermolytic hyperkeratotic type. Epidermolytic hyperkeratosis is an autosomal dominant blistering skin disease arising from mutations in the genes for keratin (K) 1 and 10. The offspring of patients with epidermal nevi may have generalized epidermolytic hyperkeratosis. Methods. We studied the K1 and K10 genes in blood and in the keratinocytes and fibroblasts of lesional and nonlesional skin from three patients with epidermal nevi and four of their offspring with epidermolytic hyperkeratosis. Results. In the patients with epidermal nevi, point mutations in 50 percent of the K10 alleles of epidermal cells were found in keratinocytes from lesional skin; no mutations were detected in normal skin. This mutation was-absent or underrepresented in blood and skin fibroblasts. In the offspring with epidermolytic hyperkeratosis, the same mutations as those in the parents were found in 50 percent of the K10 alleles from all cell types examined. Conclusions. Epidermal nevus of the epidermolytic hyperkeratotic type is a mosaic genetic disorder of suprabasal keratin. The correlation of mutations in the K10 gene with lesional skin and the correlation of the normal gene with normal skin provide evidence that genetic mosaicism can cause clinical mosaicism.	NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MILAN, DEPT DERMATOL, MILAN, ITALY	Northwestern University; Northwestern University; Howard Hughes Medical Institute; University of Chicago; University of Milan			Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883, K08AR001811] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR01811, R01-AR27883] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BARKER LP, 1953, AMA ARCH DERM SYPH, V67, P443, DOI 10.1001/archderm.1953.01540050007002; BLASCHKO A, 1901, VERHANDLUNGEN DTSCH; BONAFE JL, 1987, ANN DERMATOL VENER, V114, P916; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1994, AM J HUM GENET, V54, P179; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; HAPPLE R, 1990, HAUTARZT, V41, P117; HAPPLE R, 1993, ARCH DERMATOL, V129, P1460, DOI 10.1001/archderm.129.11.1460; HAPPLE R, 1985, HUM GENET, V70, P200; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; LORETTE G, 1984, ANN DERMATOL VENER, V111, P858; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; NAZZARO V, 1990, BRIT J DERMATOL, V122, P417, DOI 10.1111/j.1365-2133.1990.tb08292.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIEGER E, 1994, BRIT J DERMATOL, V130, P215, DOI 10.1111/j.1365-2133.1994.tb02903.x; ROTHNAGEL JA, 1993, HUM MOL GENET, V2, P2147, DOI 10.1093/hmg/2.12.2147; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; ROTHNAGEL JA, 1994, J INVEST DERMATOL, V102, P13, DOI 10.1111/1523-1747.ep12371723; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SYDER AJ, 1994, J CLIN INVEST, V93, P1533, DOI 10.1172/JCI117132; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; YANG JM, 1994, J INVEST DERMATOL, V102, P17, DOI 10.1111/1523-1747.ep12371725; [No title captured]	38	208	213	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1408	1415		10.1056/NEJM199411243312103	http://dx.doi.org/10.1056/NEJM199411243312103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7526210				2022-12-01	WOS:A1994PU53300003
J	PHILLIPS, DM				PHILLIPS, DM			MYCOPLASMA-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1421	1421						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7772108				2022-12-01	WOS:A1994PU53300005
J	COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A				COWAN, FM; JOHNSON, AM; ASHLEY, R; COREY, L; MINDEL, A			ANTIBODY TO HERPES-SIMPLEX VIRUS TYPE-2 AS SEROLOGICAL MARKER OF SEXUAL LIFE-STYLE IN POPULATIONS	BRITISH MEDICAL JOURNAL			English	Article							GENITAL HERPES; INFECTIONS; TRANSMISSION; PREVALENCE; FREQUENCY; RISK	Objectives-To examine the epidemiology of antibody to herpes simplex virus type 2 and to assess its suitability as a serological marker of sexual behaviour in populations with high and low prevalences. Design-Cross sectional survey. Setting-Department of genitourinary medicine and blood donation centre in central London. Subjects-Representative sample of 869 patients attending department between November 1990 and December 1991, and 1494 consecutive blood donors attending for donation between February and April 1992. Method-Participants had a blood sample taken for antibody testing with a novel type specific assay and completed a questionnaire. Results-Prevalence of antibody differed significantly between the two groups (188/833 (22.7%) clinic attenders; 102/1347 (7.6%) blood donors). In both populations antibody was strongly associated with sex, sexual orientation, years of sexual activity, number of lifetime sexual partners, and past infection with sexually transmitted diseases after other factors were controlled for. Only 130 (45%) of all those with antibody had symptoms suggestive of genital herpes, and 79 (27.4%) had had genital herpes diagnosed. Of those:without antibody to herpes simplex viruses type 1 and 2, 8.0% reported genital blisters or sores and 1.1% had had genital herpes diagnosed by a doctor. Conclusions-The strong relation between herpes simplex virus type 2 and sexual lifestyle suggests that the presence of antibody to the virus may be suitable for use as an objective, serological marker of patterns of sexual behaviour in different populations. These data show that only a minority of those infected with herpes simplex virus type 2 have a diagnosis of genital herpes or express clinical symptoms, making serological determinants of infection essential for epidemiological studies.	CHILDRENS HOSP & MED CTR, DEPT LAB MED, DIV VIROL, SEATTLE, WA 98105 USA	Seattle Children's Hospital	COWAN, FM (corresponding author), UCL, SCH MED, ACAD DEPT GENITOURINARY MED, MORTIMER ST, LONDON WC1E 6AV, ENGLAND.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Mindel, Adrian/0000-0002-8780-9982; Johnson, Anne/0000-0003-1330-7100; Cowan, Frances/0000-0003-3087-4422	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON IG, 1982, BRIT J VENER DIS, V58, P44; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COWAN FM, 1993, GENITOURIN MED, V69, P141; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LEE RM, 1990, AM BEHAV SCI, V33, P510, DOI 10.1177/0002764290033005002; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; SCOULAR A, 1990, GENITOURIN MED, V66, P226; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V268, P1702, DOI 10.1001/jama.268.13.1702; 1992, CMND1986; 1988, EGRET EPIDEMIOLOGICA; 1985, STATISTICAL PACKAGE	20	219	222	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1325	1329		10.1136/bmj.309.6965.1325	http://dx.doi.org/10.1136/bmj.309.6965.1325			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866079	Green Published			2022-12-01	WOS:A1994PT62500018
J	GUPTA, R; GUPTA, VP; AHLUWALIA, NS				GUPTA, R; GUPTA, VP; AHLUWALIA, NS			EDUCATIONAL STATUS, CORONARY HEART-DISEASE, AND CORONARY RISK FACTOR PREVALENCE IN A RURAL-POPULATION OF INDIA	BRITISH MEDICAL JOURNAL			English	Article							ASSOCIATION; MORTALITY; LEVEL; MEN	Objective-To define the association between educational level and prevalence of coronary heart disease and coronary risk factors in India. Design-Total community cross sectional survey with a doctor administered questionnaire, physical examination, and electrocardiography. Setting-A cluster of three villages in rural Rajasthan, western India. Subjects-3148 residents aged over 20 (1982 men, 1166 women) divided into various groups according to years of formal schooling. Results-Illiteracy and low educational levels were associated with less prestigious occupations (agricultural and farm labouring) and inferior housing. There was an inverse correlation of educational level with age (rank correlation: men -0.45, women -0.49). The prevalence of coronary heart disease (diagnosed by electrocardiography) was significantly higher among uneducated and less educated people and showed an inverse relation with education in both sexes. Among uneducated and less educated people there was a higher prevalence of the coronary risk factors smoking and hypertension. Educational level showed a significant inverse correlation with systolic and diastolic blood pressure. Logistic regression analysis with adjustment for age showed that educational level had an inverse relation with prevalence of electrocardiographically diagnosed coronary heart disease (odds ratio: men 0.82, women 0.53), hypertension (men 0.88, women 0.56), and smoking (men 0.73, women 0.65) but not with hypercholesterolaemia and obesity. The inverse relation of coronary heart disease with educational level abated after adjustment for smoking, physical activity, body mass index, and blood pressure (odds ratio: men 0.98, women 0.78). Conclusion-Uneducated and less educated people in rural India have a higher prevalence of coronary heart disease and of the coronary risk factors smoking and hypertension.	UNIV RAJASTHAN,DEPT STAT,JAIPUR 302004,RAJASTHAN,INDIA	University of Rajasthan	GUPTA, R (corresponding author), MONILEK HOSP & RES CTR,DEPT MED,JAWAHAR NAGAR,JAIPUR 302004,RAJASTHAN,INDIA.							ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; Dewan B D, 1974, Indian Heart J, V26, P68; Gupta R, 1994, J Assoc Physicians India, V42, P24; Gupta S P, 1975, J Assoc Physicians India, V23, P885; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; JACOBSEN BK, 1988, AM J EPIDEMIOL, V127, P923, DOI 10.1093/oxfordjournals.aje.a114895; Jajoo U N, 1988, J Assoc Physicians India, V36, P689; Joshi P P, 1993, J Assoc Physicians India, V41, P579; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROSE G, 1981, BRIT HEART J, V45, P13, DOI 10.1136/hrt.45.1.13; Rose G.A., 1982, CARDIOVASCULAR SURVE; SARVOTHAM SG, 1968, CIRCULATION, V37, P839; 1993, ARCH INTERN MED, V153, P154; 1993, STATUS HLTH RAJASTHA, P3; 1989, STRONG HEART STUDY M; 1992, J CLIN EPIDEMIOL, V45, P841	21	126	129	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1332	1336		10.1136/bmj.309.6965.1332	http://dx.doi.org/10.1136/bmj.309.6965.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866081	Green Published			2022-12-01	WOS:A1994PT62500020
J	SMITH, CP; PARLE, M; MORRIS, DJ				SMITH, CP; PARLE, M; MORRIS, DJ			IMPLEMENTATION OF GOVERNMENT RECOMMENDATIONS FOR IMMUNIZING INFANTS AT RISK OF HEPATITIS-B	BRITISH MEDICAL JOURNAL			English	Article									N MANCHESTER GRP HOSP,DEPT AUDIT,MANCHESTER M8 6RB,LANCS,ENGLAND; BOOTH HALL CHILDRENS HOSP,N MANCHESTER VIRUS LAB,MANCHESTER M9 7AA,LANCS,ENGLAND	Royal Manchester Children's Hospital	SMITH, CP (corresponding author), BOOTH HALL CHILDRENS HOSP,DEPT CHILD HLTH,MANCHESTER M9 7AA,LANCS,ENGLAND.							BIRNBAUM JM, 1992, AM J INFECT CONTROL, V20, P172, DOI 10.1016/S0196-6553(05)80142-7; BROOK MG, 1989, Q J MED, V264, P313; Waters J R, 1989, Can Dis Wkly Rep, V15, P29; 1992, IMMUNISATION INFECTI, P110	4	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1339	1339		10.1136/bmj.309.6965.1339	http://dx.doi.org/10.1136/bmj.309.6965.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866083	Green Published			2022-12-01	WOS:A1994PT62500024
J	DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW				DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW			LIGAND AND CATION-BINDING ARE DUAL FUNCTIONS OF A DISCRETE SEGMENT OF THE INTEGRIN BETA(3) SUBUNIT - CATION DISPLACEMENT IS INVOLVED IN LIGAND-BINDING	CELL			English	Article							FIBRINOGEN GAMMA-CHAIN; GLYCOPROTEIN-IIB-IIIA; CALCIUM-BINDING; PLATELET INTEGRIN; GPIIB-IIIA; VITRONECTIN RECEPTOR; ADHESION RECEPTOR; CELL-ADHESION; RECOGNITION SITE; BONE-RESORPTION	The alpha(IIb)beta(3) integrin binds Arg-Gly-Asp-containing (RGD-containing) ligands in a cation-dependent interaction. A fourteen amino acid sequence, beta(3)(118-131), and an antibody to it, inhibited ligand binding functions of alpha(IIb)beta s, and a 1:1 stoichiometric beta(3)(118-131)-RGD complex was detected by mass spectroscopy. Cation binding to Ps(118-131) was demonstrated by terbium luminescence and mass spectroscopy. Notably, ligand displaced cation from the beta(3)(118-131) peptide and also from purified alpha(IIb)beta(3). Thus, beta(3)(118-131), a highly conserved region in integrin beta subunits, binds both ligand and cation. Formation of a ternary complex between cation, ligand, and receptor, with subsequent displacement of cation from beta(3)(118-131)and a second site within the receptor, may be central to the mechanism of ligand recognition by integrins.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CORVAS INT INC, SAN DIEGO, CA 92121 USA	Scripps Research Institute	DSOUZA, SE (corresponding author), CLEVELAND CLIN FDN, DEPT MOLEC CARDIOL, CTR THROMBOSIS & VASC RES, FF20, CLEVELAND, OH 44195 USA.				NHLBI NIH HHS [HL-38292, HL-43721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R29HL043721, R01HL043721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BACA M, 1992, J AM CHEM SOC, V114, P3992, DOI 10.1021/ja00036a066; BAIROCH A, 1989, PROSITE DICT PROTEIN; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CALVETE JJ, 1988, BIOCHEM J, V250, P697, DOI 10.1042/bj2500697; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIAGONZALEZ M, 1988, J IMMUNOL METHODS, V111, P17, DOI 10.1016/0022-1759(88)90054-3; GARVEY JS, 1977, METHOD IMMUNOL, V1, P89; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; Goding JW, 1983, MONOCLONAL ANTIBODIE; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HOGUE CWV, 1992, J BIOL CHEM, V267, P13340; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HUTCHENS TW, 1992, FEBS LETT, V309, P170, DOI 10.1016/0014-5793(92)81088-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1981, BIOCHEMISTRY-US, V20, P1074, DOI 10.1021/bi00508a005; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARTINI JL, 1993, EUR J BIOCHEM, V211, P467, DOI 10.1111/j.1432-1033.1993.tb17572.x; Morrison M, 1980, Methods Enzymol, V70, P214; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PRADOS R, 1974, J INORG NUCL CHEM, V36, P689, DOI 10.1016/0022-1902(74)80135-1; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; SNYDER AP, 1981, BIOCHEMISTRY-US, V20, P3334, DOI 10.1021/bi00515a003; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINER B, 1989, J BIOL CHEM, V264, P13102; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345	55	215	217	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					659	667		10.1016/0092-8674(94)90551-7	http://dx.doi.org/10.1016/0092-8674(94)90551-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7525080				2022-12-01	WOS:A1994PT48100013
J	FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL				FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL			2 BINDING ORIENTATIONS FOR PEPTIDES TO THE SRC SH3 DOMAIN - DEVELOPMENT OF A GENERAL-MODEL FOR SH3-LIGAND INTERACTIONS	SCIENCE			English	Article							MULTIPLE QUANTUM COHERENCE; NMR-SPECTROSCOPY; C-SRC; PROTEIN; IDENTIFICATION; MAGNETIZATION; DELETIONS; RECEPTOR; SPECTRA; SITE	Solution structures of two Src homology 3 (SH3) domain-ligand complexes have been determined by nuclear magnetic resonance. Each complex consists of the SH3 domain and a nine-residue proline-rich peptide selected from a large library of ligands prepared by combinatorial synthesis. The bound ligands adopt a left-handed polyproline type II (PPII) helix, although the amino to carboxyl directionalities of their helices are opposite. The peptide orientation is determined by a salt bridge formed by the terminal arginine residues of the ligands and the conserved aspartate-99 of the SH3 domain. Residues at positions 3, 4, 6, and 7 of both peptides also intercalate into the ligand-binding site; however, the respective proline and nonproline residues show exchanged binding positions in the two complexes. These structural results led to a model for the interactions of SH3 domains with proline-rich peptides that can be used to predict critical residues in complexes of unknown structure. The model was used to identify correctly both the binding orientation and the contact and noncontact residues of a peptide derived from the nucleotide exchange factor Sos in association with the amino-terminal SH3 domain of the adaptor protein Grb2.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute			Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NIGMS NIH HHS [GM44993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, X PLOR MANUAL; BRUNGER T, 1992, X PLOR MANUAL V 3 1; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Potts W M, 1988, Oncogene Res, V3, P343; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1994, ONCOGENE, V9, P2145; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	51	753	776	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1241	1247		10.1126/science.7526465	http://dx.doi.org/10.1126/science.7526465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7526465				2022-12-01	WOS:A1994PT13200054
J	HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ				HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ			METHODS AND CONSEQUENCES OF CHANGES IN USE OF EPISIOTOMY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINEAL MANAGEMENT TRIAL; INFORMATION; DELIVERY; RATES	Objectives-To evaluate the use of feedback by graphical profiles of rates of episiotomy and the impact on clinical practice and perineal state after spontaneous vaginal deliveries assisted by midwives with different attitudes towards episiotomy. Design-Observation period in labour ward followed by feedback to midwives about their own and other midwives' use of episiotomies. The periods before and after the intervention were compared. Subjects-All women (n = 3919) delivering during the two periods who had been assisted by one of 30 midwives; each midwife supervised at least 20 deliveries during each period. Main outcome measures-Overall rates of episiotomies and indications, incidence of intact perineums, perineal lacerations, and tears of anal sphincter. Results-The overall rate of episiotomy during the observation period was 37.1% (615). During the second period the rate was 6.6% lower (95% confidence interval 3.6% to 9.6%), corresponding to a relative decrease of 17.8% (10.1% to 24.7%). Higher rates of episiotomy during the observation period were associated with larger reductions in the second period. The decrease could be explained by less use of episiotomy in deliveries with rigid perineum or impending perineal tear. Compared with the observation period, in the second period 3.2% more women (0.3% to 6.3%) had an intact perineum after delivery and 3.4% (0.4% to 6.2%) experienced perineal tears. The overall incidence of tears of the anal sphincter remained unchanged. Women had a slightly reduced incidence of tears of the anal sphincter, however, if they were delivered by midwives who reduced a medium or high initial rate of episiotomy and a tendency towards an increased incidence of tears if they were assisted by midwives who reduced low initial rates (around 20%) of episiotomy. Conclusions-Changes in the use of episiotomy induced by awareness of clinical practice among midwives seem to increase the incidence of parturients with intact perineum without a concomitant rise in tears of the anal sphincter. To avoid the increase of such tears these changes should probably be restricted to midwives with rates of episiotomies above 30%.			HENRIKSEN, TB (corresponding author), AARHUS UNIV HOSP, DEPT OBSTET & GYNAECOL, PERINATAL EPIDEMIOL RES UNIT, DK-8000 AARHUS C, DENMARK.							BUEKENS P, 1985, BRIT J OBSTET GYNAEC, V92, P820, DOI 10.1111/j.1471-0528.1985.tb03052.x; BUEKENS P, 1993, BRIT MED J, V306, P623, DOI 10.1136/bmj.306.6878.623; Elwood JM, 1988, CAUSAL RELATIONSHIPS, Vxi, P332; GLEICHER N, 1984, Journal of the American Medical Association, V252, P3273, DOI 10.1001/jama.252.23.3273; HARRISON RF, 1984, BRIT MED J, V288, P1971, DOI 10.1136/bmj.288.6435.1971; Hemminki E, 1992, Qual Assur Health Care, V4, P133; HENRIKSEN TB, 1992, BRIT J OBSTET GYNAEC, V99, P950, DOI 10.1111/j.1471-0528.1992.tb13695.x; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANTEL N, 1959, J NATL CANCER I, V22, P719; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; SCHULTZ WCMW, 1990, J PSYCHOSOM OBST GYN, V11, P119, DOI 10.3109/01674829009084408; SHIONO P, 1990, OBSTET GYNECOL, V75, P765; SLEEP J, 1987, BRIT MED J, V295, P749, DOI 10.1136/bmj.295.6601.749; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SZCZEPURA A, 1987, BRIT MED J, V294, P875, DOI 10.1136/bmj.294.6576.875; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THRANOV I, 1990, ACTA OBSTET GYN SCAN, V69, P11, DOI 10.3109/00016349009021032; YATES JM, 1984, BRIT MED J, V288, P1335; 1993, LANCET, V342, P1517; 1990, SPSS PC PLUS ADV STA, pB39	22	38	39	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1255	1258		10.1136/bmj.309.6964.1255	http://dx.doi.org/10.1136/bmj.309.6964.1255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888844	Green Published			2022-12-01	WOS:A1994PT03300017
J	NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K				NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K			ASSOCIATION BETWEEN NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND NON-HODGKINS-LYMPHOMA	BRITISH MEDICAL JOURNAL			English	Article									KOBE UNIV,SCH MED,DEPT MED,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT RADIOL,KOBE 650,JAPAN; FUKUI MED SCH,DEPT OTOLARYNGOL,FUKUI,JAPAN	Kobe University; Kobe University; University of Fukui			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				BIERMAN PJ, 1991, HEMATOLOGY BASIC PRI, P963; JACKSON RM, 1987, OTOLARYNG HEAD NECK, V97, P469, DOI 10.1177/019459988709700507; OTTER R, 1989, EUR J CANCER CLIN ON, V25, P1203, DOI 10.1016/0277-5379(89)90416-1; RAGOZZINO MW, 1983, J CHRON DIS, V36, P363, DOI 10.1016/0021-9681(83)90167-4; STOWENS D, 1981, LANCET, V2, P989	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1269	1269		10.1136/bmj.309.6964.1269	http://dx.doi.org/10.1136/bmj.309.6964.1269			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888850	Green Published			2022-12-01	WOS:A1994PT03300023
J	PENTTINEN, J				PENTTINEN, J			BACK PAIN AND RISK OF FATAL ISCHEMIC-HEART-DISEASE - 13 YEAR FOLLOW-UP OF FINNISH FARMERS	BRITISH MEDICAL JOURNAL			English	Article											PENTTINEN, J (corresponding author), KUOPIO REG INST OCCUPAT HLTH,POB 93,SF-70701 KUOPIO,FINLAND.							BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BOSHUIZEN HC, 1993, SPINE, V18, P35, DOI 10.1097/00007632-199301000-00007; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; NUWAYHID IA, 1993, AM J EPIDEMIOL, V137, P539, DOI 10.1093/oxfordjournals.aje.a116707; SVENSSON HO, 1983, SPINE, V8, P277, DOI 10.1097/00007632-198304000-00008	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1267	1268		10.1136/bmj.309.6964.1267	http://dx.doi.org/10.1136/bmj.309.6964.1267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888848	Green Published			2022-12-01	WOS:A1994PT03300021
J	SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE				SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE			ROLE OF TCR ZETA-CHAIN IN T-CELL DEVELOPMENT AND SELECTION	SCIENCE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; ACTIVATION; EXPRESSION; COMPLEX; THYMOCYTES; LACKING; DOMAIN; RAG-1; TAIL	Signals mediated by the T cell receptor (TCR) are required for thymocyte maturation and selection. To examine the role of TCR zeta chain signals in development, TCR expression was restored in zeta-deficient mice with transgenic zeta chains that partially or completely lacked sequences required for signal transduction. The zeta chain played a role in thymic development by promoting TCR surface expression, but zeta-mediated signals were not essential because TCRs that contained signaling-deficient zeta chains promoted T cell maturation and transduced signals associated with thymic selection.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SHORES, EW (corresponding author), US FDA, CTR BIOL, DIV HEMATOL PROD, BETHESDA, MD 20892 USA.							BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORES EW, UNPUB; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TESTI R, 1989, J IMMUNOL, V143, P1123; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	33	129	130	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1047	1050		10.1126/science.7526464	http://dx.doi.org/10.1126/science.7526464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7526464				2022-12-01	WOS:A1994PQ92400046
J	ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR				ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR			ALTERNATIVE PATHWAY OF INSULIN SIGNALING IN MICE WITH TARGETED DISRUPTION OF THE IRS-1 GENE	NATURE			English	Article							GROWTH FACTOR-I; STIMULATES TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; PROTEIN; MUSCLE; TRANSMISSION; EXPRESSION	THE principal substrate for the insulin and insulin-like growth factor-1 (IGF-1) receptors is the cytoplasmic protein insulin-receptor substrate-1 (IRS-1/pp185)(1-7). After tyrosine phosphorylation at several sites, IRS-1 binds to and activates phosphatidylinositol-3'-OH kinase (PI(3)K)(8-11) and several other proteins containing SH2 (Src-homology 2) domains(12-14). To elucidate the role of IRS-1 in insulin/IGF-1 action, we created IRS-1-deficient mice by targeted gene mutation. These mice had no IRS-1 and shelved no evidence IRS-1 phosphorylation or IRS-1-associated PI(3)K activity. They also had a 50 per cent reduction in intrauterine growth, impaired glucose tolerance, and a decrease in insulin/IGF-1-stimulated glucose uptake in vivo and in vitro. The residual insulin/ IGF-1 action correlated with the appearance of a new tyrosine-phosphorylated protein (IRS-2) which binds to PI(3)K, but is slightly larger than and immunologically distinct from IRS-1. Our results provide evidence for IRS-1-dependent and IRS-1-independent pathways of insulin/IGF-1 signalling and for the existence of an alternative substrate of these receptor kinases.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Johnson, Randall/AAM-1189-2021	Kahn, Ronald/0000-0002-7583-9228; Johnson, Randall/0000-0002-4084-6639				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PAPAIOANNOU V, 1993, GENE TARGETING PRACT; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHEPHERD PR, 1993, J BIOL CHEM, V269, P22232; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	31	1048	1071	0	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					186	190		10.1038/372186a0	http://dx.doi.org/10.1038/372186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526222				2022-12-01	WOS:A1994PQ68800058
J	IOST, I; DREYFUS, M				IOST, I; DREYFUS, M			MESSENGER-RNAS CAN BE STABILIZED BY DEAD-BOX PROTEINS	NATURE			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MESSENGER-RNA; LACZ GENE; TRANSLATION; TRANSCRIPTION; INITIATION; EXPRESSION; HELICASE; DEGRADATION	EUBACTERIAL messenger RNAs are synthesized and translated simultaneously; moreover the speed of ribosomes usually matches that of RNA polymerase(1,2). We report here that when in Escherichia coli the host RNA polymerase is replaced by the eightfold faster bacteriophage T7 enzyme for the transcription of the lacZ gene, the beta-galactosidase yield per transcript is depressed 100-fold. But the overexpression of DEAD-box proteins(3) greatly improves this low yield by stabilizing the corresponding transcripts. More generally, it stabilizes inefficiently translated E. coli mRNAs. Ribosome-free mRNA regions, such as those lying behind the fast T7 enzyme or between successive ribosomes on inefficiently translated transcripts, are often unstable(4) and we propose that DEAD-box proteins protect them from endonucleases. These results pinpoint the importance of transcription-translation synchronization for mRNA stability, and reveal an undocumented property of DEAD-box RNA helicases. These proteins have been implicated in a variety of processes involving RNA(5) but not mRNA stability.	ECOLE NORMALE SUPER, CNRS D1302, GENET MOLEC LAB, F-75230 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Iost, Isabelle/M-7149-2014	Iost, Isabelle/0000-0001-9061-4177				BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; CHEVRIERMILLER M, 1990, NUCLEIC ACIDS RES, V18, P5787, DOI 10.1093/nar/18.19.5787; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IOST I, 1992, J BACTERIOL, V174, P619, DOI 10.1128/jb.174.2.619-622.1992; JACQUET M, 1971, J MOL BIOL, V60, P453, DOI 10.1016/0022-2836(71)90181-1; KALMAN M, 1991, NEW BIOL, V3, P886; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOPEZ PJ, 1994, NUCLEIC ACIDS RES, V22, P1186, DOI 10.1093/nar/22.7.1186; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MILLER OL, 1970, SCIENCE, V169, P392, DOI 10.1126/science.169.3943.392; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Petersen C, 1993, CONTROL MESSENGER RN, P117; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; Putzer Harald, 1995, P293; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUEBER D, 1982, EMBO J, V1, P1399, DOI 10.1002/j.1460-2075.1982.tb01329.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; YARCHUK O, 1991, BIOCHIMIE, V73, P1533, DOI 10.1016/0300-9084(91)90188-7	29	107	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	1994	372	6502					193	196		10.1038/372193a0	http://dx.doi.org/10.1038/372193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526223				2022-12-01	WOS:A1994PQ68800060
J	HOLTON, JB; LEONARD, JV				HOLTON, JB; LEONARD, JV			CLOUDS STILL GATHERING OVER GALACTOSEMIA	LANCET			English	Editorial Material							URIDINE-DIPHOSPHATE GALACTOSE; DEFICIENCY		INST CHILD HLTH,LONDON CTR PAEDIAT ENDOCRINOL & METAB,METAB UNIT,LONDON,ENGLAND	University of London; University College London	HOLTON, JB (corresponding author), UNIV BRISTOL,DEPT CHILD HLTH,BRISTOL BS8 1TH,AVON,ENGLAND.							ALLEN JT, 1980, LANCET, V1, P603; BAKKER HD, 1993, INT PEDIATR, V8, P135; Elsas LJ, 1993, INT PEDIATR, V8, P101; HOLTON JB, 1993, J PEDIATR-US, V123, P1009, DOI 10.1016/S0022-3476(05)80404-4; HOLTON JB, 1994, 32ND ANN S SOC STUD; JACOBS C, 1988, PRENAT DIAGN, V8, P641; KAUFMAN FR, 1994, J PEDIATR-US, V125, P225, DOI 10.1016/S0022-3476(94)70197-0; KEEVILL NJ, 1994, J INHERIT METAB DIS, V17, P23, DOI 10.1007/BF00735392; MATTISON DR, 1993, GALACTOSEMIA NEW FRO, P109; NG WG, 1989, J INHERIT METAB DIS, V12, P257, DOI 10.1007/BF01799215; ORNSTEIN KS, 1992, PEDIATR RES, V31, P508, DOI 10.1203/00006450-199205000-00020; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1989, METABOLIC BASIS INHE, P453; SEGAL S, 1993, INT PEDIATR, V8, P125; Waggoner D. D., 1993, INT PEDIAT, V8, P97; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; 1984, LANCET, V2, P1379	17	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1242	1243		10.1016/S0140-6736(94)90745-5	http://dx.doi.org/10.1016/S0140-6736(94)90745-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7526095				2022-12-01	WOS:A1994PP70100003
J	MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C				MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C			DETERMINATION OF INTRINSIC TRANSCRIPTION TERMINATION EFFICIENCY BY RNA-POLYMERASE ELONGATION RATE	SCIENCE			English	Article							ESCHERICHIA-COLI RNA; OPERON LEADER REGION; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; PAUSE SITE; INVITRO; RHO; GENE; REQUIREMENTS; SEQUENCES	Transcription terminators recognized by several RNA polymerases include a DNA segment encoding uridine-rich RNA and, for bacterial RNA polymerase, a hairpin loop located immediately upstream. Here, mutationally altered Escherichia coli RNA polymerase enzymes that have different termination efficiencies were used to show that the extent of transcription through the uridine-rich encoding segment is controlled by the substrate concentration of nucleoside triphosphate. This result implies that the rate of elongation determines the probability of transcript release. Moreover, the position of release sites suggests an important spatial relation between the RNA hairpin and the boundary of the terminator.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison								ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FISHER RF, 1983, J BIOL CHEM, V258, P8146; Friedman DI., 1983, LAMBDA 2, P21; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, J BACTERIOL, V173, P1554; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCDOWELL JC, UNPUB; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	31	107	112	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					822	825		10.1126/science.7526463	http://dx.doi.org/10.1126/science.7526463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7526463				2022-12-01	WOS:A1994PP75300046
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			MODEL FOR AN RNA TERTIARY INTERACTION FRONT THE STRUCTURE OF AN INTERMOLECULAR COMPLEX BETWEEN A GAAA TETRALOOP AND AN RNA HELIX	NATURE			English	Article							ARCHITECTURE; SEQUENCE; LOOPS	IN large structured RNAs, RNA hairpins in which the strands of the duplex stem are connected by a tetraloop of the consensus sequence 5'-GNRA (where N is any nucleotide, and R is either G or A) are unusually frequent(1). In group I introns there is a covariation in sequence between nucleotides in the third and fourth positions of the loop with specific distant base pairs in putative RNA duplex stems(2): GNAA loops correlate with successive 5'-C-C.G-G base pairs in stems, whereas GNGA loops correlate with 5'-C-U.G-A. This has led to the suggestion that GNRA tetraloops may be involved in specific long-range tertiary interactions, with each A in position 3 or 4 of the loop interacting with a C-G base pair in the duplex, and G in position 3 interacting with a U-A base pair. This idea is supported experimentally for the GAAA loop of the P5b extension of the group I intron of Tetrahymena thermophila(3) and the L9 GUGA terminal loop of the td intron of bacteriophage T4 (ref. 4). NMR has revealed the overall structure of the tetraloop for 12-nucleotide hairpins with GCAA and GAAA loops(5) and models have been proposed for the interaction of GNRA tetraloops with base pairs in the minor groove of A-form RNA(2,4). Here we describe the crystal structure of an intermolecular complex between a GAAA tetraloop and an RNA helix. The interactions we observe correlate with tbe specificity of GNRA tetraloops inferred from phylogenetic studies, suggesting that this complex is a legitimate model for intramolecular tertiary interactions mediated by GNRA tetraloops in large structured RNAs.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University								HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	6	262	264	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					111	113		10.1038/372111a0	http://dx.doi.org/10.1038/372111a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7526219				2022-12-01	WOS:A1994PQ34800085
J	KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF				KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF			LACK OF ASSOCIATION BETWEEN CHOLESTEROL AND CORONARY HEART-DISEASE MORTALITY AND MORBIDITY AND ALL-CAUSE MORTALITY IN PERSONS OLDER THAN 70 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; SERUM-CHOLESTEROL; CARDIOVASCULAR-HEALTH; PLASMA-LIPIDS; RISK-FACTORS; MEN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; DESIGN	Objectives.-To determine whether elevated serum cholesterol level is associated with all-cause mortality, mortality from coronary heart disease, or hospitalization for acute myocardial infarction and unstable angina in persons older than 70 years. Also, to evaluate the association between low levels of high-density lipoprotein cholesterol (HDL-C) and elevated ratio of serum cholesterol to HDL-C with these outcomes. Design.-Prospective, community-based cohort study with yearly interviews. Participants.-A total of 997 subjects who were interviewed in 1988 as part of the New Haven, Conn, cohort of the Established Population for the Epidemiologic Study of the Elderly (EPESE) and consented to have blood drawn. Main Outcome Measures.-The risk factor-adjusted odds ratios of the 4-year incidence of all-cause mortality, mortality from coronary heart disease, and hospitalization for myocardial infarction or unstable angina were calculated for the following: subjects with total serum cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dL) compared with subjects with cholesterol levels less than 5.20 mmol/L (<200 mg/dL); subjects in the lowest tertile of HDL-C level compared with those in the highest tertile; and subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C level compared with those in the lowest tertile. Results.-Elevated total serum cholesterol level, low HDL-C, and high total serum cholesterol to HDL-C ratio were not associated with a significantly higher rate of all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina after adjustment for cardiovascular risk factors. The risk factor-adjusted odds ratio for all-cause mortality was 0.99 (95% confidence interval [Cl], 0.56 to 2.69) for the group who had cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dl) compared with the group that had levels less than 5.20 mmol/L (<200 mg/dL); 1.00 (95% Cl, 0.59 to 1.70) for the group in the lowest tertile of HDL-C compared with those in the highest tertile; and 1.03 (95% Cl, 0.62 to 1.71) for subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C compared with those in the lowest tertile. Conclusions.-Our findings do not support the hypothesis that hypercholesterolemia or low HDL-C are important risk factors for all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina in this cohort of persons older than 70 years.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, CHRON DIS EPIDEMIOL SECT, NEW HAVEN, CT 06520 USA; UNIV CONNECTICUT, SCH MED, DIV CARDIOL, FARMINGTON, CT USA	Yale University; University of Connecticut	KRUMHOLZ, HM (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,CARDIOVASC MED SECT, 333 CEDAR ST, POB 208017, NEW HAVEN, CT 06520 USA.		, Harlan/AAI-2875-2020		NIA NIH HHS [1T-32-AG-0-0153, R01-AG-1-1042] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011042, T32AG000153] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CURB JD, 1986, J AM GERIATR SOC, V34, P773, DOI 10.1111/j.1532-5415.1986.tb03980.x; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; ETTINGER WH, 1992, CIRCULATION, V86, P858, DOI 10.1161/01.CIR.86.3.858; Freeman Daniel H. Jr., 1992, P46; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAFONEK SD, 1990, ANN INTERN MED, V112, P723, DOI 10.7326/0003-4819-112-10-723; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1979, CIRCULATION, V60, P427; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEEMAN T, 1993, AM J EPIDEMIOL, V138, P1037, DOI 10.1093/oxfordjournals.aje.a116822; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WONG ND, 1991, ANN INTERN MED, V115, P687, DOI 10.7326/0003-4819-115-9-687; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1971, 5TH WORK GROUP ISCH; 1991, AGING AM, P273; 1988, INT CLASSIFICATON DI; 1977, JAMA-J AM MED ASSOC, V237, P2385	31	365	370	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1335	1340		10.1001/jama.272.17.1335	http://dx.doi.org/10.1001/jama.272.17.1335			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7772105				2022-12-01	WOS:A1994PP02000027
J	GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC				GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC			INEFFICIENT GENE-TRANSFER BY ADENOVIRUS VECTOR TO CYSTIC-FIBROSIS AIRWAY EPITHELIA OF MICE AND HUMANS	NATURE			English	Article							ION-TRANSPORT DEFECT; CHLORIDE TRANSPORT; TRANSGENIC MICE; EXPRESSION; THERAPY; INVIVO; MODEL; CFTR	THE success of adenoviral vectors for gene therapy of lung disease in cystic fibrosis (CF) depends on efficient transfer of the complementary DNA encoding the correct version of the cystic fibrosis transmembrane regulator (CFTR) to the affected columnar epithelial cells lining the airways of the lung. Pre-clinical studies in vitro suggest that low doses of adenovirus vectors carrying this CFTR cDNA fan correct defective Cl- transport in cultured human CF airway epithelia(1). Here He use mice carrying the disrupted CF gene(2) to test the efficacy of this transfer system in vivo. We find that even repeated high doses can only partially (50%) correct the CF defect in Cl- transport in vivo and do not correct the Na+ transport defect at all. We investigated this discrepancy between the in vivo and in vitro transfer efficiency using CF mouse and human samples, and found that it reflects a difference in the susceptibility to adenovirus-5 transduction of the epithelial cell types dosed in vivo (columnar) and in vitro (basal-cell-like). These studies indicate that more efficient adenoviral gene-transfer vectors and/or refinement of dosing strategies are needed for therapy of CF lung disease.	UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104	University of Pennsylvania	GRUBB, BR (corresponding author), UNIV N CAROLINA,CTR CF PULM RES & TREATMENT,CHAPEL HILL,NC 27599, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R01 DK047967] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047967] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; CUTTING GR, 1992, NAT GENET, V2, P4, DOI 10.1038/ng0992-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GROSS EA, 1982, J ANAT, V135, P83; GRUBB B, 1994, AM J PHYSIOL, V268, pC1478; HARKEMA JR, 1991, LUNG BIOL HLTH DIS, V0055, P00003; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; SHIMIZU T, 1992, AM J RESP CELL MOL, V7, P30, DOI 10.1165/ajrcmb/7.1.30; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	28	316	330	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					802	806		10.1038/371802a0	http://dx.doi.org/10.1038/371802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7523956				2022-12-01	WOS:A1994PP01800061
J	MCCANN, RM; HALL, WJ; GROTHJUNCKER, A				MCCANN, RM; HALL, WJ; GROTHJUNCKER, A			COMFORT CARE FOR TERMINALLY ILL PATIENTS - THE APPROPRIATE USE OF NUTRITION AND HYDRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARENTERAL-NUTRITION; ELDERLY PATIENTS; CANCER; DEPRIVATION	Objective.-To determine the frequency of symptoms of hunger and thirst in a group of terminally ill patients and determine whether these symptoms could be palliated without forced feeding, forced hydration, or parenteral alimentation. Design.-Prospective evaluation of consecutively admitted terminally ill patients treated in a comfort care unit. Setting.-Ten-bed comfort care unit in a 471-bed long-term care facility. Participants.-Mentally aware, competent patients with terminal illnesses monitored from time of admission to time of death while residing in the comfort care unit. Main Outcome Measures.-Symptoms of hunger, thirst, and dry mouth were recorded, and the amounts and types of food and fluids necessary to relieve these symptoms were documented. The subjective level of comfort was assessed longitudinally in all patients. Results.-Of the 32 patients monitored during the 12 months of study, 20 patients (63%) never experienced any hunger, white 11 patients (34%) had symptoms only initially. Similarly, 20 patients (62%) experienced either no thirst or thirst only initially during their terminal illness. In all patients, symptoms of hunger, thirst, and dry mouth could be alleviated, usually with smalt amounts of food, fluids, and/or by the application of ice chips and lubrication to the lips. Comfort care included use of narcotics for relief of pain or shortness of breath in 94% of patients. Conclusions.-In this series, patients terminally ill with cancer generally did not experience hunger and those who did needed only small amounts of food for alleviation. Complaints of thirst and dry mouth were relieved with mouth care and sips of liquids far less than that needed to prevent dehydration. Food and fluid administration beyond the specific requests of patients may play a minimal role in providing comfort to terminally ill patients.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; ST JOHNS HOME, ROCHESTER, NY USA	University of Rochester								[Anonymous], 1992, ANN INTERN MED, V117, P947; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; CLAMON GH, 1985, CANCER TREAT REP, V69, P167; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FELIG P, 1970, NEW ENGL J MED, V282, P166; Gershan J A, 1985, Crit Care Nurse, V5, P32; HAMM RJ, 1984, PHYSIOL BEHAV, V33, P499, DOI 10.1016/0031-9384(84)90176-8; HAMM RJ, 1985, PHYSIOL BEHAV, V35, P879, DOI 10.1016/0031-9384(85)90254-9; HARDY C, 1986, J AM GERIATR SOC, V34, P219, DOI 10.1111/j.1532-5415.1986.tb04207.x; HEBER D, 1986, CANCER-AM CANCER SOC, V58, P1867, DOI 10.1002/1097-0142(19861015)58:8+<1867::AID-CNCR2820581413>3.0.CO;2-A; KERNDT PR, 1982, WESTERN J MED, V137, P379; KORETZ RL, 1984, J CLIN ONCOL, V2, P534, DOI 10.1200/JCO.1984.2.5.534; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MCHUGH JT, 1990, ISSUES LAW MED, V6, P89; NIXON DW, 1981, CANCER TREAT REP, V65, P121; NORBERG A, 1980, BRIT MED J, V280, P377, DOI 10.1136/bmj.280.6211.377; OWEN OE, 1983, CLIN ENDOCRINOL META, V12, P359, DOI 10.1016/S0300-595X(83)80046-2; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRINTZ LA, 1988, GERIATRICS, V43, P84; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; VANDERPOOL H, 1978, ENCY BIOETHICS, P1373; 1988, GUIDELINES WITHHOLDI; 1989, WITHHOLDING WITHDRAW	27	327	336	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1263	1266		10.1001/jama.272.16.1263	http://dx.doi.org/10.1001/jama.272.16.1263			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7523740				2022-12-01	WOS:A1994PN06800031
J	BURTON, JL				BURTON, JL			KERATIN GENES AND EPIDERMOLYTIC HYPERKERATOSIS	LANCET			English	Editorial Material							ICHTHYOSIS BULLOSA; SIEMENS; DIFFERENTIATION				BURTON, JL (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT DERMATOL,BRISTOL,AVON,ENGLAND.							CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; KREMER H, 1994, J INVEST DERMATOL, V103, P286, DOI 10.1111/1523-1747.ep12394414; LANE EB, 1994, CURR OPIN GENET DEV, V4, P412, DOI 10.1016/0959-437X(94)90030-2; LEIGH IM, 1993, ARCH DERMATOL, V129, P1571, DOI 10.1001/archderm.129.12.1571; MCLEAN WHI, 1994, J INVEST DERMATOL, V103, P277, DOI 10.1111/1523-1747.ep12394307; MURDOCH ME, 1990, CLIN EXP DERMATOL, V15, P53, DOI 10.1111/j.1365-2230.1990.tb02021.x; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; ROTHNAGEL JA, 1994, NAT GENET, V7, P485, DOI 10.1038/ng0894-485; STEIJLEN PM, 1990, ARCH DERMATOL RES, V282, P1, DOI 10.1007/BF00505636; STEIJLEN PM, 1994, J INVEST DERMATOL, V103, P282, DOI 10.1111/1523-1747.ep12394335; TRAUPE H, 1986, J AM ACAD DERMATOL, V14, P1000, DOI 10.1016/S0190-9622(86)70123-0; VAKILZADEH F, 1991, BRIT J DERMATOL, V124, P191, DOI 10.1111/j.1365-2133.1991.tb00432.x; 1993, LANCET, V339, P29	14	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1103	1104		10.1016/S0140-6736(94)90626-2	http://dx.doi.org/10.1016/S0140-6736(94)90626-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7523811				2022-12-01	WOS:A1994PN06600005
J	DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ				DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ			RESCUE OF T-CELL-SPECIFIC V(D)J RECOMBINATION IN SCID MICE BY DNA-DAMAGING AGENTS	SCIENCE			English	Article							ANTIGEN RECEPTOR GENES; STRAND BREAK REPAIR; PRE-B CELLS; COMBINED IMMUNODEFICIENCY MICE; COMBINED IMMUNE-DEFICIENCY; LIGHT CHAIN GENES; BETA-CHAIN; THYMOCYTE DEVELOPMENT; JUNCTIONAL SEQUENCES; MOUSE THYMOCYTES	Assembly of antigen receptor V (variable), D (diversity), and J (joining) gene segments requires lymphocyte-specific genes and ubiquitous DNA repair activities. Severe combined immunodeficient (SCID) mice are defective in general double-strand (ds) DNA break repair and V(D)J coding joint formation, resulting in arrested lymphocyte development. A single treatment of newborn SCID mice with DNA-damaging agents restored functional, diverse, T cell receptor beta chain coding joints, as well as development and expansion oi thymocytes expressing both CD4 and CD8 coreceptors, but did not promote B cell development. Thymic lymphoma developed in all mice treated with DNA-damaging agents, suggesting an Interrelation between V(D)J recombination, dsDNA break repair, and lymphomagenesis.	HOSP SICK CHILDREN, RES INST, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	DANSKA, JS (corresponding author), HOSP SICK CHILDREN, RES INST, DIV SURG RES, TORONTO M5G 1X8, ON, CANADA.		Pflumio, Francoise/E-2074-2017	Pflumio, Francoise/0000-0001-8995-596X; Dick, John/0000-0002-9527-8317				BARRY TS, 1991, J EXP MED, V173, P167, DOI 10.1084/jem.173.1.167; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; Chabner B., 1990, CANC CHEMOTHERAPY PR, P341; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DANSKA JS, UNPUB; DISNEY JE, 1992, CYTOGENET CELL GENET, V59, P39, DOI 10.1159/000133196; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HABU S, 1987, EUR J IMMUNOL, V17, P1467, DOI 10.1002/eji.1830171013; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOTLOFF DB, 1993, INT IMMUNOL, V5, P383, DOI 10.1093/intimm/5.4.383; KOTLOFF DB, 1993, J EXP MED, V178, P1981, DOI 10.1084/jem.178.6.1981; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEVELT CN, 1993, J EXP MED, V178, P1867, DOI 10.1084/jem.178.6.1867; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; PFLUMIO F, 1993, INT IMMUNOL, V5, P1509, DOI 10.1093/intimm/5.12.1509; PFLUMIO F, UNPUB; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHORES EW, 1993, J IMMUNOL, V150, P1263; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; [No title captured]	68	114	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					450	455		10.1126/science.7524150	http://dx.doi.org/10.1126/science.7524150			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7524150				2022-12-01	WOS:A1994PN27200039
J	OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J				OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J			ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA	CELL			English	Article							PRIMARY TUMOR REMOVAL; CONCOMITANT IMMUNITY; ENDOTHELIAL-CELLS; RESIDUAL TUMOR; GROWTH-FACTOR; PLASMINOGEN; RESISTANCE; BINDING; CANCER; MICE	The phenomenon of inhibition of tumor growth by tumor mass has been repeatedly studied, but without elucidation of a satisfactory mechanism. In our animal model, a primary tumor inhibits its remote metastases. After tumor removal, metastases neovascularize and grow. When the primary tumor is present, metastatic growth is suppressed by a circulating angiogenesis inhibitor. Serum and urine from tumor-bearing mice, but not from controls, specifically inhibit endothelial cell proliferation. The activity copurifies with a 38 kDa plasminogen fragment that we have sequenced and named angiostatin. A corresponding fragment of human plasminogen has similar activity. Systemic administration of angiostatin, but not intact plasminogen, potently blocks neovascularization and growth of metastases. We here show that the inhibition of metastases by a primary mouse tumor is mediated, at least in part, by angiostatin.	HARVARD UNIV,SCH MED,DEPT BIOL CELULAR,BOSTON,MA 02115; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195	Harvard University; Harvard Medical School; Harvard University; University of Washington; University of Washington Seattle	OREILLY, MS (corresponding author), CHILDRENS HOSP,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [P01-CA45548] Funding Source: Medline; NHLBI NIH HHS [HL40711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apolant, 1905, BERL KLIN WSCHR, V42, P871; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bashford EF, 1907, P R SOC LOND B-CONTA, V79, P164, DOI 10.1098/rspb.1907.0014; BICHEL P, 1971, EUR J CANCER, V7, P349, DOI 10.1016/0014-2964(71)90079-X; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BONFIL RD, 1988, INT J CANCER, V41, P415, DOI 10.1002/ijc.2910410317; BRUNSCHW.A, 1965, ANN SURG, V162, P416, DOI 10.1097/00000658-196509000-00011; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEWYS WD, 1972, CANCER RES, V32, P374; ELLEMAN CJ, 1977, J NATL CANCER I, V59, P925, DOI 10.1093/jnci/59.3.925; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; FISHER B, 1989, CANCER RES, V49, P1996; FISHER B, 1983, CANCER RES, V43, P1488; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSHON RK, 1967, NATURE, V213, P674, DOI 10.1038/213674a0; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORELIK E, 1978, INT J CANCER, V21, P617, DOI 10.1002/ijc.2910210512; GORELIK E, 1981, INT J CANCER, V27, P847, DOI 10.1002/ijc.2910270618; GORELIK E, 1983, CANCER RES, V43, P138; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GORELLK E, 1980, J NATL CANCER I, V65, P1257; GREENE HSN, 1960, CANCER RES, V20, P1094; GUNDUZ N, 1979, CANCER RES, V39, P3861; HIMMELE JC, 1986, J CANCER RES CLIN, V111, P160, DOI 10.1007/BF00400757; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; HOWARD JM, 1963, SURG GYNECOL OBSTET, V117, P567; ICHINOSE A, 1992, BIOCHEMISTRY-US, V31, P3113, DOI 10.1021/bi00127a011; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOIKE A, 1963, CANCER, V16, P1065, DOI 10.1002/1097-0142(196308)16:8<1065::AID-CNCR2820160814>3.0.CO;2-O; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANGE PH, 1980, CANCER-AM CANCER SOC, V45, P1498, DOI 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7; LAUSCH RN, 1969, INT J CANCER, V4, P226, DOI 10.1002/ijc.2910040213; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P273, DOI 10.1097/00001721-199008000-00004; Marie P., 1910, B ASS FR ETUD CANC, V3, P19; MILAS L, 1974, CANCER RES, V34, P61; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHR U, 1968, NATURE, V220, P138, DOI 10.1038/220138a0; MUTHUKKARUPPAN V, 1979, SCIENCE, V28, P1416; NAKAJIMA K, 1993, J NEUROCHEM, V61, P2155, DOI 10.1111/j.1471-4159.1993.tb07454.x; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OBESO J, 1990, LAB INVEST, V63, P259; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROTHBARTH K, 1977, EUR J CANCER, V13, P1195, DOI 10.1016/0014-2964(77)90021-4; ROUNDS DE, 1970, CANCER RES, V30, P2847; RUGGIERO RA, 1985, BRIT J CANCER, V51, P37, DOI 10.1038/bjc.1985.6; RUGGIERO RA, 1990, CANCER RES, V50, P7159; SCHATTEN WE, 1958, CANCER, V11, P455, DOI 10.1002/1097-0142(195805/06)11:3<455::AID-CNCR2820110303>3.0.CO;2-3; SIMPSONHERREN L, 1976, CANCER TREAT REP, V60, P1749; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P191; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tyzzer EE, 1913, J MED RES, V28, P309; WARREN BA, 1977, PROGR CANC RES THERA, P185; WEISSBACH L, 1992, BIOCHEM BIOPH RES CO, V186, P1108, DOI 10.1016/0006-291X(92)90861-E; WOODRUFF M, 1990, CELLULAR VARIATION A; WOODRUFF M, 1980, INTERACTIONS CANCER; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YUHAS JM, 1974, CANCER RES, V34, P2005; [No title captured]	77	2836	3231	3	144	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					315	328		10.1016/0092-8674(94)90200-3	http://dx.doi.org/10.1016/0092-8674(94)90200-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7525077				2022-12-01	WOS:A1994PN63000015
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONFERENCE ON FDA-REGULATED PRODUCTS AND PREGNANT-WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-01	WOS:A1994PL21200010
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO REQUIRE FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, FED REGISTER, V59, P48708	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-01	WOS:A1994PL21200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PSA TEST IS APPROVED FOR USE IN CONJUNCTION WITH DIGITAL RECTAL EXAMINATION AS AID IN PROSTATE-CANCER DETECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-01	WOS:A1994PL21200008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REPORTS OF SKIN INJURIES FOLLOWING HIGH X-RAY DOSE INTERVENTIONAL PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V5, P71	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-01	WOS:A1994PL21200007
J	BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ				BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ			STAINING OF AMYLOID PRECURSOR PROTEIN TO STUDY AXONAL DAMAGE IN MILD HEAD-INJURY	LANCET			English	Note							DEGENERATION	The most common definition of cerebral concussion is that of a transient loss of neurological function without macroscopic or microscopic abnormality in the brain. However, some patients have persistent symptoms and subtle neuropsychological deficits, particularly affecting memory. We have studied five patients aged 59-89 years who sustained mild concussive head injury and died of other causes (2-99 days post-injury). Immunostaining with an antibody to amyloid precursor protein, a marker oi fast axonal transport, showed multifocal axonal injury in all five. All had axonal damage in the fornices, which are important in memory function.	UNIV ADELAIDE,NHMRC RD ACCID RES UNIT,ADELAIDE,SA,AUSTRALIA	University of Adelaide	BLUMBERGS, PC (corresponding author), INST MED & VET SCI,NEUROPATHOL LAB,POB 14,ADELAIDE,SA 5001,AUSTRALIA.							Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRONWALL D, 1974, LANCET, V2, P605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RYAN GA, 1994, J TRAUMA, V36, P469	10	360	368	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1055	1056		10.1016/S0140-6736(94)91712-4	http://dx.doi.org/10.1016/S0140-6736(94)91712-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7523810				2022-12-01	WOS:A1994PL85200012
J	HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR				HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR			A NOVEL MUTATION IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH PULMONARY-DISEASE BUT NORMAL SWEAT CHLORIDE CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDUCTANCE REGULATOR GENE; POLYMERASE CHAIN-REACTION; ION PERMEABILITY; SUBJECTS INVIVO; MESSENGER-RNA; CFTR; GLANDS; ACTIN; DNA	Background. Many patients with chronic pulmonary disease similar to that seen in cystic fibrosis have normal (or nondiagnostic) sweat chloride values. It has been difficult to make the diagnosis of cystic fibrosis in these patients because no associated mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been identified. Methods. We evaluated 23 patients with pulmonary disease characteristic of cystic fibrosis but with sweat chloride concentrations in the normal range. Mutations in the CFTR gene were sought by direct sequencing of polymerase chain reaction-amplified nasal epithelial messenger RNA and by testing the functioning of affected epithelium. Results. A cytidine phosphate guanosine dinucleotide C-to-T point mutation in intron 19 of the CFTR gene, termed 3849+10 kb C to TI was identified in 13 patients from eight unrelated families. This mutation was found in patients from three different ethnic groups with three different extended haplotypes. The mutation leads to the creation of a partially active splice site in intron 19 and to the insertion into most CFTR transcripts of a new 84-base-pair ''exon,'' containing an in-frame stop codon, between exons 19 and 20. Normally spliced transcripts were also detected at a level approximately 8 percent of that found in normal subjects. This mutation is associated with abnormal nasal epithelial and sweat acinar epithelial function. Conclusions. We have identified a point mutation in intron 19 of CFTR and abnormal epithelial function in patients who have cystic fibrosis-like lung disease but normal sweat chloride values. The identification of this mutation indicates that this syndrome is a form of cystic fibrosis. Screening for the mutation should prove diagnostically useful in this population of patients.	UNIV N CAROLINA, DEPT MED, DIV PULM DIS, CHAPEL HILL, NC 27599 USA; APPL TECHNOL GENET CORP, MALVERN, PA USA; UNIV N CAROLINA, DIV MOLEC PATHOL, CHAPEL HILL, NC USA; CHILDRENS HOSP, MED CTR, CINCINNATI, OH USA; DUKE UNIV, DEPT PEDIAT, DURHAM, NC 27706 USA; LONG ISL JEWISH MED CTR, SCHNEIDER CHILDRENS HOSP, NEW HYDE PK, NY 11042 USA; COLUMBIA PRESBYTERIAN MED CTR, DIV PEDIAT PULM, NEW YORK, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cincinnati Children's Hospital Medical Center; Duke University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Columbia University; NewYork-Presbyterian Hospital			Highsmith, William E/B-6175-2008		NCRR NIH HHS [RR000046] Funding Source: Medline; NHLBI NIH HHS [HL34322] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET AL, 1988, NEW ENGL J MED, V318, P50; BIJMAN J, 1984, AM J PHYSIOL, V247, pC3, DOI 10.1152/ajpcell.1984.247.1.C3; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; CHENG TC, 1984, P NATL ACAD SCI-BIOL, V81, P2821, DOI 10.1073/pnas.81.9.2821; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COOPER DN, 1990, HUM GENET, V85, P55; DAVIS PB, 1983, AM REV RESPIR DIS, V128, P34, DOI 10.1164/arrd.1983.128.1.34; DAVIS PB, 1980, AM J MED, V69, P643, DOI 10.1016/0002-9343(80)90482-9; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRIEDMAN KJ, 1991, CLIN CHEM, V37, P753; GIBSON LE, 1959, PEDIATRICS, V23, P545; GILBERT F, 1992, PEDIATR PULM S, V14, P240; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES M, 1983, CLIN RES, V31, pA858; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RIORDAN JR, 1989, SCIENCE, V245, P1437; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SATO K, 1988, J LAB CLIN MED, V111, P511; SHWACHMAN H, 1972, BIRTH DEFECTS ORGINA, P102; STERN RC, 1978, JAMA-J AM MED ASSOC, V239, P2676, DOI 10.1001/jama.239.25.2676; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, V2, P2281	38	344	351	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					974	980		10.1056/NEJM199410133311503	http://dx.doi.org/10.1056/NEJM199410133311503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521937	Green Submitted			2022-12-01	WOS:A1994PK50400003
J	OAKLANDER, AL; EKENBERG, SJ				OAKLANDER, AL; EKENBERG, SJ			SMALL-SCALE MAGNETIC ISOLATION OF MESSENGER-RNA AND SYNTHESIS OF CDNA IN 96-WELL PLATES	NATURE			English	Article							REVERSE-TRANSCRIPTASE-PCR	Multiple small biological samples can be simultaneously prepared for RT-PCR by magnetically isolating mRNA and synthesizing cDNA in 96-well plates. The resulting accuracy, high throughput and ease of use facilitate commercial and clinical applications.	PROMEGA CORP,MADISON,WI	Promega Corporation	OAKLANDER, AL (corresponding author), JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205, USA.							Chelly Jamel, 1994, P97; Dilworth D D, 1992, PCR Methods Appl, V1, P279; HOPPE BL, 1992, BIOTECHNIQUES, V12, P679; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; NORTHRUP MA, 1993, 7TH P INT C SOL STAT; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; Yamaguchi M, 1992, PCR Methods Appl, V1, P286	7	8	9	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					631	632		10.1038/371631a0	http://dx.doi.org/10.1038/371631a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523954				2022-12-01	WOS:A1994PL55900060
J	STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R				STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R			TRANSMISSIBILITY OF PSEUDOMONAS-CEPACIA INFECTION IN CLINIC PATIENTS AND LUNG-TRANSPLANT RECIPIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIELD GEL-ELECTROPHORESIS; POLYMERASE CHAIN-REACTION; MOLECULAR EPIDEMIOLOGY; PREOPERATIVE ASSESSMENT; COLONIZATION; ADHESIN; GENE	Background. In patients with cystic fibrosis, infection with Pseudomonas cepacia is associated with poor outcomes. However, the extent of person-to-person transmission and the source of P. cepacia infection after lung transplantation are not well defined. Using DNA-based typing systems, we sought to determine the genetic relatedness of P. cepacia infection at one cystic fibrosis center. Methods. We analyzed 65 P. cepacia isolates gathered over a period of eight years at a single cystic fibrosis center from 17 clinic patients and from 5 patients who underwent double-lung transplantation. The isolates were analyzed by ribotyping and chromosomal fingerprinting based on pulsed-field gel electrophoresis. Results. Analyses of serial isolates revealed that each clinic patient and transplant recipient harbored a different P. cepacia clone that was persistent. In the transplant recipients, the preoperative and postoperative isolates were identical. In the two patients with disseminated infection after lung transplantation, isolates from multiple sites were identical and indicated clonal expansion of the previous respiratory P. cepacia strain. Pulsed-field gel electrophoresis proved both more discriminative and more practical than ribotyping as a means of defining the genetic relatedness of the P. cepacia isolates. Conclusions. Our serial analyses in patients with cystic fibrosis at one center found distinct strains of P. cepacia persistently infecting each patient and no evidence of person-to-person transmission of this organism. P. cepacia infection after lung transplantation was due to the persistence of the strain present before transplantation.	BOSTON UNIV,SCH MED,MOLEC GENET SECT,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON CITY HOSP,BOSTON,MA; UNIV N CAROLINA,SCH MED & HOSP,CTR CYST FIBROSIS,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CLIN MICROBIOL LAB,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CHAPEL HILL,NC	Boston University; Boston University; Boston Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Egan, Thomas/0000-0002-1382-8881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050838] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; ARBEIT RD, 1990, J INFECT DIS, V161, P230, DOI 10.1093/infdis/161.2.230; ARTHUR M, 1989, INFECT IMMUN, V57, P314, DOI 10.1128/IAI.57.2.314-321.1989; ARTHUR M, 1989, INFECT IMMUN, V57, P303, DOI 10.1128/IAI.57.2.303-313.1989; ARTHUR M, 1990, INFECT IMMUN, V58, P471, DOI 10.1128/IAI.58.2.471-479.1990; BERG KL, 1987, J BACTERIOL, V169, P1691, DOI 10.1128/jb.169.4.1691-1701.1987; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; DEHOYOS AL, 1992, J THORAC CARDIOV SUR, V103, P295; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; HERITIER F, 1992, EUR RESPIR J, V5, P1262; HOPFL P, 1989, EUR J BIOCHEM, V185, P355, DOI 10.1111/j.1432-1033.1989.tb15123.x; Knight S R, 1992, Semin Thorac Cardiovasc Surg, V4, P107; KOSTMAN JR, 1992, J CLIN MICROBIOL, V30, P2084, DOI 10.1128/JCM.30.8.2084-2087.1992; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; LIPUMA JJ, 1988, J PEDIATR-US, V113, P859, DOI 10.1016/S0022-3476(88)80018-0; MORRISON DL, 1990, CLIN CHEST MED, V11, P207; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NOYES BE, 1994, J PEDIATR-US, V124, P261, DOI 10.1016/S0022-3476(94)70315-9; PREVOST G, 1992, J CLIN MICROBIOL, V30, P967, DOI 10.1128/JCM.30.4.967-973.1992; RABKIN CS, 1989, REV INFECT DIS, V11, P600; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; SCOTT J, 1988, LANCET, V2, P192; SNELL GI, 1993, CHEST, V103, P466, DOI 10.1378/chest.103.2.466; THOMASSEN MJ, 1985, AM REV RESPIR DIS, V131, P791; THOMASSEN MJ, 1986, AM REV RESPIR DIS, V134, P669	29	88	89	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					981	987		10.1056/NEJM199410133311504	http://dx.doi.org/10.1056/NEJM199410133311504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521938				2022-12-01	WOS:A1994PK50400004
J	VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L				VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L			CRYSTAL-STRUCTURE OF AN BACTERIOPHAGE-RNA COAT PROTEIN-OPERATOR COMPLEX	NATURE			English	Article							TURNIP CRINKLE VIRUS; BINDING SITE; RESOLUTION; SYNTHETASE; OLIGORIBONUCLEOTIDES; RECOGNITION; MECHANISM; MS2	THE RNA bacteriophage MS2 is a convenient model system for the study-of protein-RNA interactions, The MS2 coat protein achieves control of two distinct processes-sequence-specific RNA encapsidation and repression of replicase translation-by binding to an RNA stem-loop structure of 19 nucleotides containing the initiation codon of the replicase gene. The binding of a coat protein diner to this hairpin shuts off synthesis of the viral replicase(1), switching the viral replication cycle to virion assembly rather than continued replication. The operator fragment alone can trigger self-assembly of the phage capsid at low protein concentrations and a complex of about 90 RNA operator fragments per protein capsid has been described(2). We report here the crystal structure at 3.0 Angstrom resolution of a complex between recombinant MS2 capsids and the 19-nucleotide RNA fragment. It is the first example of a structure at this resolution for a sequence-specific protein-RNA complex apart from the transfer RNA synthetase complexes(3-5). The structure shows sequence-specific interactions between conserved residues on the protein and RNA bases essential for binding.	UNIV LEEDS, DEPT GENET, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	VALEGARD, K (corresponding author), UPPSALA UNIV, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.			Stonehouse, Nicola/0000-0003-1146-5519; Stockley, Peter/0000-0002-1360-2751	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; BECKETT D, 1988, J MOL BIOL, V204, P939, DOI 10.1016/0022-2836(88)90053-8; BECKETT D, 1988, J MOL BIOL, V204, P927, DOI 10.1016/0022-2836(88)90052-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIM F, 1994, J BIOL CHEM, V269, P9006; MASTICO RA, 1993, J GEN VIROL, V74, P541, DOI 10.1099/0022-1317-74-4-541; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; PEABODY DS, 1989, NUCLEIC ACIDS RES, V17, P6017, DOI 10.1093/nar/17.15.6017; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; STOCKLEY PG, 1993, BIOCHEM SOC T, V21, P627, DOI 10.1042/bst0210627; TALBOT SJ, 1990, NUCLEIC ACIDS RES, V18, P3521, DOI 10.1093/nar/18.12.3521; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185	28	327	331	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					623	626		10.1038/371623a0	http://dx.doi.org/10.1038/371623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523953				2022-12-01	WOS:A1994PL55900057
J	BEHRENS, RH; ROBERTS, JA				BEHRENS, RH; ROBERTS, JA			IS TRAVEL PROPHYLAXIS WORTH WHILE - ECONOMIC APPRAISAL OF PROPHYLACTIC MEASURES AGAINST MALARIA, HEPATITIS-A, AND TYPHOID IN TRAVELERS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; HEALTH	Objectives-To estimate the costs and benefits of prophylaxis against travel acquired malaria, typhoid fever, and hepatitis A in United Kingdom residents during 1991. Design-Retrospective analysis of national epidemiological and economic data. Main outcome measures-Incidence of travel associated infections in susceptible United Kingdom residents per visit; costs of prophylaxis provision from historical data; benefits to the health sector, community, and individuals in terms of avoided morbidity and mortality based on hospital and community costs of disease. Results-The high incidence of imported malaria (0.70%) and the low costs of providing chemoprophylaxis resulted in a cost-benefit ratio of 0.19 for chloroquine and proguanil and 0.57 for a regimen containing mefloquine. Hepatitis A infection occurred in 0.05% of visits and the cost of prophylaxis invariably exceeded the benefits for immunoglobulin (cost-benefit ratio 5.8) and inactivated hepatitis A vaccine (cost-benefit ratio 15.8). Similarly, low incidence of typhoid (0.02%) and its high cost gave whole cell killed, polysaccharide Vi, and oral Ty 21a typhoid vaccines cost-benefit ratios of 18.1, 18.0, and 22.0 respectively. Conclusions-Fewer than one third of travellers receive vaccines but the total cost of providing typhoid and hepatitis A prophylaxis of pound 25.8m is significantly higher than the treatment costs to the NHS (pound 1.03m) of cases avoided by prophylaxis. Neither hepatitis A prophylaxis nor typhoid prophylaxis is cost effective, but costs of treating malaria greatly exceed costs of chemoprophylaxis, which is therefore highly cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1T 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BEHRENS, RH (corresponding author), HOSP TROP DIS,TRAVEL CLIN,LONDON NW1 0PE,ENGLAND.							BEHRENS RH, 1990, T ROY SOC TROP MED H, V84, P611, DOI 10.1016/0035-9203(90)90123-V; BEHRENS RH, 1993, T ROY SOC TROP MED H, V87, P361; BRADDICK MR, 1993, PUBLIC HEALTH, V107, P193, DOI 10.1016/S0033-3506(05)80441-X; Bradley D J, 1993, Commun Dis Rep CDR Rev, V3, pR25; COSSAR JH, 1990, J INFECTION, V21, P27, DOI 10.1016/0163-4453(90)90600-D; Cumberland N S, 1994, J R Army Med Corps, V140, P71; DAVIDSON RN, 1993, J INFECTION, V26, P348, DOI 10.1016/0163-4453(93)96241-H; FORBES A, 1988, J ROY COLL PHYS LOND, V22, P237; MARIN A, 1983, 3 BANKS REV, V138, P20; Paris J A, 1992, Commun Dis Rep CDR Rev, V2, pR43; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; POLAKOFF S, 1990, J INFECTION, V21, P111, DOI 10.1016/0163-4453(90)90853-Z; STEFFEN R, 1991, T ROY SOC TROP MED H, V85, P156, DOI 10.1016/0035-9203(91)90005-J; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; TILZEY AJ, 1991, BMJ-BRIT MED J, V302, P1552, DOI 10.1136/bmj.302.6792.1552; WOODRUFF BA, 1991, JAMA-J AM MED ASSOC, V265, P756, DOI 10.1001/jama.265.6.756; ZUCKERMAN AJ, 1991, BRIT MED J, V303, P991, DOI 10.1136/bmj.303.6808.991-a; 1991, MA6 GOV STAT SERV CE; 1993, EMPLOYMENT GAZET JUN, P50; 1991, COMMUNICABLE DISEASE; 1990, GENERAL MED PRACTITI; 1994, INT TRAVEL HLTH VACC, P41; 1992, IMMUNISATION INFECTI; 1991, CHEM DRUGGIST, V32	25	83	84	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					918	922		10.1136/bmj.309.6959.918	http://dx.doi.org/10.1136/bmj.309.6959.918			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7726905	Green Published			2022-12-01	WOS:A1994PL78100018
J	BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM				BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM			CRYSTAL-STRUCTURE AND MOLECULAR-STRUCTURE OF A COLLAGEN-LIKE PEPTIDE AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							TRIPLE-HELICAL PEPTIDE; CIRCULAR-DICHROISM; N-PROTEINASE; SUBSTITUTION; CHAIN; CONFORMATION; REFINEMENT; KINK; PARAMETERS; CYSTEINE	The structure of a protein triple helix has been determined at 1.9 angstrom resolution by x-ray crystallographic studies of a collagen-like peptide containing a single substitution of the consensus sequence. This peptide adopts a triple-helical structure that confirms the basic features determined from fiber diffraction studies on collagen: supercoiling of polyproline II helices and interchain hydrogen bonding that follows the model II of Rich and Crick. In addition, the structure provides new information concerning the nature of this protein fold. Each triple helix is surrounded by a cylinder of hydration, with an extensive hydrogen bonding network between water molecules and peptide acceptor groups. Hydroxyproline residues have a critical role in this water network. The interaxial spacing of triple helices in the crystal is similar to that in collagen fibrils, and the water networks linking adjacent triple helices in the crystal structure are likely to be present in connective tissues. The breaking of the repeating (X-Y-Gly), pattern by a Gly-->Ala substitution results in a subtle alteration of the conformation, with a local untwisting of the triple helix. At the substitution site, direct interchain hydrogen bonds are replaced with interstitial water bridges between the peptide groups. Similar conformational changes may occur in Gly-->X mutated collagens responsible for the diseases osteogenesis imperfecta, chondrodysplasias, and Ehlers-Danlos syndrome IV.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick			Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Berman, Helen/0000-0002-3337-0660	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021589] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 19626] Funding Source: Medline; NIGMS NIH HHS [GM 21589] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BELLA J, UNPUB; BERG RA, 1970, J BIOL CHEM, V245, P5759; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMPBELLSMITH PJ, 1978, ACTA CRYSTALLOGR A, V34, P3; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fair C K, 1990, MOLEN; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; FRASER RDB, 1983, J MOL BIOL, V167, P497, DOI 10.1016/S0022-2836(83)80347-7; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MACRAE TP, 1973, CONFORMATION FIBROUS; MILLER MH, 1976, J POLYM SCI POL SYM, P171; OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICH A, 1955, NATURE, V176, P915, DOI 10.1038/176915a0; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SAKAKIBARA S, 1972, J MOL BIOL, V65, P371, DOI 10.1016/0022-2836(72)90288-4; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VOGEL BE, 1988, J BIOL CHEM, V263, P19249	35	845	866	3	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					75	81		10.1126/science.7695699	http://dx.doi.org/10.1126/science.7695699			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7695699				2022-12-01	WOS:A1994PK58200028
J	CHENG, HJ; FLANAGAN, JG				CHENG, HJ; FLANAGAN, JG			IDENTIFICATION AND CLONING OF ELF-1, A DEVELOPMENTALLY EXPRESSED LIGAND FOR THE MEK4 AND SEK RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH-FACTOR; KIT LIGAND; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; MOUSE; ENCODES; GENE; TRANSMEMBRANE; MUTANT	Mek4 and Sek are tyrosine kinases with expression patterns in the mouse embryo that suggest important functions in early development. However, like all Eph family kinases, both were identified as orphan receptors without known ligands. We show that Mek4 and Sek soluble receptor-alkaline phosphatase fusion proteins can be used in a procedure termed RAP in situ to identify regions of ligand expression in the mouse embryo. Based on this spatial information, a cDNA expression library was prepared, and was screened with the fusion proteins to identify Eph ligand family-1 (ELF-1). In cell lines and embryos, ELF-1 is membrane bound by a phosphatidylinositol tail, a feature that may account for unique biological functions. Its sequence is homologous with B61, a ligand for the Eck kinase, defining a family of related ligands. The expression domains of ELF-1, Mek4 and Sek indicate potential roles in embryonic patterning.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; 	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029417, R37HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; NIETO MA, 1992, DEVELOPMENT, V116, P1137; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZIPURSKY SL, 1992, COLD SPRING HARB SYM, V57, P381, DOI 10.1101/SQB.1992.057.01.043; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	38	254	278	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					157	168		10.1016/0092-8674(94)90408-1	http://dx.doi.org/10.1016/0092-8674(94)90408-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522971				2022-12-01	WOS:A1994PK58500016
J	GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA				GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA			STUDIES WITH A XENOPUS BMP RECEPTOR SUGGEST THAT VENTRAL MESODERM-INDUCING SIGNALS OVERRIDE DORSAL SIGNALS IN-VIVO	CELL			English	Article							SERINE THREONINE KINASE; BONE MORPHOGENETIC PROTEIN-4; TRANSFORMING GROWTH-FACTOR; EARLY AMPHIBIAN EMBRYOS; DAUER LARVA DEVELOPMENT; TGF-BETA; ACTIVIN RECEPTOR; INOSITOL PHOSPHATES; EXPRESSION CLONING; MESSENGER-RNAS	We report the isolation of a Xenopus BMP receptor that is expressed maternally in the appropriate location to play a role in mesoderm induction. This receptor binds both BMP-2 and BMP-4 with high affinity. A truncated form of this BMP receptor specifically blocks BMP-4 signaling. Expression of this truncated BMP receptor during embryogenesis converts ventral mesoderm to dorsal mesoderm. Contrary to the popularly held view that ventral is the ground state for all mesoderm, our results suggest that formation of ventral mesoderm requires an active signal and that, in the absence of this ventral signal, dorsal mesoderm is formed.	GENET INST INC,CAMBRIDGE,MA 02140		GRAFF, JM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HELNKOFF S, 1987, METHOD ENZYMOL, V154, P156; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1993, ONCOGENE, V8, P2879; THIES RS, 1992, ENDOCRINOLOGY, V130, P1319; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WILSON P, 1994, IN PRESS CURR BIOL; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	66	436	445	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					169	179		10.1016/0092-8674(94)90409-X	http://dx.doi.org/10.1016/0092-8674(94)90409-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522972				2022-12-01	WOS:A1994PK58500017
J	MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH				MIKI, Y; SWENSEN, J; SHATTUCKEIDENS, D; FUTREAL, PA; HARSHMAN, K; TAVTIGIAN, S; LIU, QY; COCHRAN, C; BENNETT, LM; DING, W; BELL, R; ROSENTHAL, J; HUSSEY, C; TRAN, T; MCCLURE, M; FRYE, C; HATTIER, T; PHELPS, R; HAUGENSTRANO, A; KATCHER, H; YAKUMO, K; GHOLAMI, Z; SHAFFER, D; STONE, S; BAYER, S; WRAY, C; BOGDEN, R; DAYANANTH, P; WARD, J; TONIN, P; NAROD, S; BRISTOW, PK; NORRIS, FH; HELVERING, L; MORRISON, P; ROSTECK, P; LAI, M; BARRETT, JC; LEWIS, C; NEUHAUSEN, S; CANNONALBRIGHT, L; GOLDGAR, D; WISEMAN, R; KAMB, A; SKOLNICK, MH			A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1	SCIENCE			English	Article							FAMILIAL BREAST; ZINC FINGER; WILMS-TUMOR; ATAXIA-TELANGIECTASIA; DNA-BINDING; WT1 GENE; CHROMOSOME-17Q21; IDENTIFICATION; MUTATIONS; P53	A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods. Probable predisposing mutations have been detected in five of eight kindreds presumed to segregate BRCA1 susceptibility alleles. The mutations include an 11-base pair deletion, a 1-base pair insertion, a stop codon, a missense substitution, and an inferred regulatory mutation. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino-terminal region, but is otherwise unrelated to previously described proteins, identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology.	UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; MYRIAD GENET,SALT LAKE CITY,UT 84108; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; UNIV UTAH,MED CTR,DEPT INTERNAL MED,SALT LAKE CITY,UT 84132; MCGILL UNIV,DEPT MED GENET,MONTREAL H3G 1A4,PQ,CANADA; ELI LILLY & CO,LILLY RES LABS,INDIANAPOLIS,IN 46285; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84108	Utah System of Higher Education; University of Utah; Myriad Genetics, Inc; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Utah System of Higher Education; University of Utah; McGill University; Eli Lilly; Utah System of Higher Education; University of Utah			Pinheiro, Maísa/E-7424-2012; Lewis, Cathryn/M-8766-2019; Narod, Steven A/AAA-6112-2022; Lewis, Cathryn M/A-5225-2010	Lewis, Cathryn/0000-0002-8249-8476; Lewis, Cathryn M/0000-0002-8249-8476; Miki, Yoshio/0000-0003-0114-392X; albright, lisa/0000-0003-2602-3668	NCI NIH HHS [CA-48711, CA-54936, CA-55914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055914, R03CA054936, P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; ANDERSON DM, UNPUB; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CANNONALBRIGHT LA, 1994, CANCER RES, V54, P2378; CLAUS EB, 1991, AM J HUM GENET, V48, P232; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEUNTEUN J, 1993, AM J HUM GENET, V52, P736; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; GOLDGAR DE, UNPUB; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN S, IN PRESS CANCER RES; NEUHAUSEN SL, IN PRESS HUM MOL GEN; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Sambrook J., 1989, MOL CLONING LAB MANU; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SIMARD J, 1993, HUM MOL GENET, V2, P1193, DOI 10.1093/hmg/2.8.1193; SMITH HS, 1993, J CELL BIOCH SG, V14, P144; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SU LK, 1993, CANCER RES, V53, P2728; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THOMAS A, IN PRESS IMA J MATH; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; WESTIN G, 1984, P NATL ACAD SCI-BIOL, V81, P3811, DOI 10.1073/pnas.81.12.3811; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; 1994, CANCER FACTS FIGURES, P13	44	4856	5078	3	428	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					66	71		10.1126/science.7545954	http://dx.doi.org/10.1126/science.7545954			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7545954				2022-12-01	WOS:A1994PK58200026
J	SEIWERT, SD; STUART, K				SEIWERT, SD; STUART, K			RNA EDITING - TRANSFER OF GENETIC INFORMATION FROM GRNA TO PRECURSOR MESSENGER-RNA IN-VITRO	SCIENCE			English	Article							AUG INITIATION CODONS; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; KINETOPLASTID MITOCHONDRIA; B TRANSCRIPTS; INVITRO; MOLECULES; NUCLEOTIDES; URIDINES; SEQUENCE	RNA editing in the mitochondrion of Trypanosoma brucei extensively alters the adenosine triphosphate synthase (ATPase) subunit 6 precursor messenger RNA (pre-mRNA) by addition of 447 uridines and removal of 28 uridines. in vivo, the guide RNA gA6[14] is thought to specify the deletion of two uridines from the editing site closest to the 3' end. in this study, an in vitro system was developed that accurately removed uridines from this editing site in synthetic ATPase 6 pre-mRNA when gA6[14] and ATP were added. Mutations in both the guide RNA and the pre-mRNA editing site suggest that base-pairing interactions control the number of uridines deleted in vitro. Thus, guide RNAs are required for RNA editing and for the transfer of genetic information to pre-mRNAs.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	Center for Infectious Disease Research; Yale University; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM 42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1993, ALTERATION PROTEIN C; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HARDY SF, 1984, NATURE, V308, P375, DOI 10.1038/308375a0; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HERNANDEZ N, 1983, CELL, V35, P89, DOI 10.1016/0092-8674(83)90211-8; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; Maniatis T., 1982, MOL CLONING; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; SEIWERT S, UNPUB; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SHU HH, 1994, NUCLEIC ACIDS RES, V22, P1696, DOI 10.1093/nar/22.9.1696; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	41	131	133	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					114	117		10.1126/science.7524149	http://dx.doi.org/10.1126/science.7524149			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7524149				2022-12-01	WOS:A1994PK58200036
J	BRAKE, AJ; WAGENBACH, MJ; JULIUS, D				BRAKE, AJ; WAGENBACH, MJ; JULIUS, D			NEW STRUCTURAL MOTIF FOR LIGAND-GATED ION CHANNELS DEFINED BY AN IONOTROPIC ATP RECEPTOR	NATURE			English	Article							PHEOCHROMOCYTOMA CELLS; FUNCTIONAL EXPRESSION; MAMMALIAN NEURONS; POTASSIUM CHANNEL; NERVOUS-SYSTEM; SMOOTH-MUSCLE; PC12 CELLS; CURRENTS; CONDUCTANCE; CALCIUM	THE adenosine-5'-triphosphate (ATP) molecule is an extracellular messenger in neural and non-neural tissues, where it activates several cell-surface-receptor subtypes, including G-protein-coupled receptors and ligand-gated ion channels(1). ATP-gated channels (termed P-2X receptors) have been characterized on smooth muscle cells and autonomic and sensory neurons, where they mediate membrane depolarization and, in some cases, Ca2+ entry(2). P-2X receptors are functionally heterogeneous, but resemble acetylcholine- and serotonin-gated channels with respect to ion selectivity and kinetic parameters of channel gating. We report here that despite such close functional similarities, the deduced sequence of a cloned P-2X receptor predicts an unusual subunit structure resembling voltage-insensitive cation channels. Thus, the P-2X receptor provides a striking example of convergent evolution, whereby proteins have been fashioned with similar functional properties from subunits having very different structural characteristics. There is sequence similarity between the ATP receptor and RP-2, a gene activated in thymocytes undergoing programmed cell. death(3). RP-2 may encode a receptor for ATP or another metabolite released during apoptosis.	UNIV CALIF SAN FRANCISCO,SILVIO CONTE CTR NEUROSCI RES,CELL BIOL PROGRAM & NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BRAKE, AJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIEL DD, 1990, PFLUG ARCH EUR J PHY, V415, P651, DOI 10.1007/BF02584001; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LI CY, 1993, P NATL ACAD SCI USA, V90, P8264, DOI 10.1073/pnas.90.17.8264; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NAKAZAWA K, 1991, PFLUG ARCH EUR J PHY, V418, P214, DOI 10.1007/BF00370517; NAKAZAWA K, 1993, J GEN PHYSIOL, V101, P377, DOI 10.1085/jgp.101.3.377; NAKAZAWA K, 1990, NEUROSCI LETT, V119, P5, DOI 10.1016/0304-3940(90)90741-Q; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	29	841	861	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					519	523		10.1038/371519a0	http://dx.doi.org/10.1038/371519a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523952				2022-12-01	WOS:A1994PK58900057
J	VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G				VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G			NEW CLASS OF LIGAND-GATED ION-CHANNEL DEFINED BY P-2X RECEPTOR FOR EXTRACELLULAR ATP	NATURE			English	Article							PROGRAMMED CELL-DEATH; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; TRANSMISSION	EXTRACELLULAR ATP exerts its effects through P-2 purinoceptors(1): these are ligand-gated ion channels (P-2X)(2,3) or G-protein-coupled receptors (P-2Y, P-2U)(4). ATP at P-2X receptors mediates synaptic transmission between neurons(5-7) and from neurons to smooth muscle(1), being responsible, for example, for sympathetic vasoconstriction in small arteries and arterioles(8,9) We have now cloned a complementary DNA encoding the P-2X receptor from rat vas deferens and expressed it in Xenopus oocytes and mammalian cells. ATP activates a cation-selective ion channel with relatively high calcium permeability. Structural predictions suggest that the protein (399 amino acids long) is mostly extracellular and contains only two transmembrane domains plus a pore-forming motif which resembles that of potassium channels. The P-2X receptor thus defines a new family of ligand-gated ion channels.			VALERA, S (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AUIX,PLAN OUATES,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACHIO MP, IN PRESS PHARM THERA; ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BO XN, 1992, J BIOL CHEM, V267, P17581; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, BRIT J PHARMACOL, V106, P242, DOI 10.1111/j.1476-5381.1992.tb14323.x; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; NORTH RA, IN PRESS HDB RECEPTO, V2; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SPRANZI E, 1993, BLOOD, V82, P1578; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZIGANSHIN AU, 1994, BRIT J PHARMACOL, V111, P923, DOI 10.1111/j.1476-5381.1994.tb14827.x; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207	30	885	907	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					516	519		10.1038/371516a0	http://dx.doi.org/10.1038/371516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523951				2022-12-01	WOS:A1994PK58900056
J	WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F				WILLIAMSON, BD; MAN, KC; DAOUD, E; NIEBAUER, M; STRICKBERGER, SA; MORADY, F			RADIOFREQUENCY CATHETER MODIFICATION OF ATRIOVENTRICULAR-CONDUCTION TO CONTROL THE VENTRICULAR RATE DURING ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NODAL REENTRANT TACHYCARDIA; SLOW-PATHWAY; ABLATION REGISTRY; JUNCTION; ENERGY; ANTERIOR; DEATH	Background. In some patients with atrial fibrillation, the Ventricular rate may be difficult to control with medications. We evaluated a radiofrequency catheter technique to modify atrioventricular conduction in atrial fibrillation in order to control the ventricular rate without creating pathologic atrioventricular block. Methods. We studied 19 consecutive patients with atrial fibrillation and uncontrolled ventricular rates refractory to drug therapy. They had had atrial fibrillation for a mean (+/-SD) of 5.5+/-4.9 years, had had 4.9+/-0.9 unsuccessful drug trials, and were 62+/-5 years old. Before the procedure, the maximal ventricular rate during exercise was 180+/-39 beats per minute. A total of 11+/-5 radiofrequency-energy applications were delivered to the posterior septal or midseptal right atrium, near the ostium of the coronary sinus. Results. Successful control of the ventricular rate without pathologic atrioventricular block was achieved in 14 of the 19 patients (74 percent). Persistent third-degree atrioventricular block requiring a permanent pacemaker occurred inadvertently in four patients (21 percent). Atrioventricular conduction was intentionally ablated in one patient. The 14 patients who had successful modification of conduction had persistent reductions in maximal ventricular rate during exercise (rate at three months, 126+/-24 beats per minute; P<0.01). These patients had resolution of symptoms related to rapid rates during 8+/-2 months of follow-up. One patient had a recurrence of a rapid ventricular rate but was again asymptomatic after a second modification procedure. One patient with dilated cardiomyopathy died suddenly, five months after a successful procedure. Conclusions. A catheter technique to modify atrioventricular conduction without creating pathologic atrioventricular block is feasible in the majority of patients with symptomatic atrial fibrillation and a rapid ventricular rate refractory to drug therapy.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV CARDIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								AKHTAR M, 1991, ANN INTERN MED, V114, P499, DOI 10.7326/0003-4819-114-6-499; BHARATI S, 1985, CHEST, V88, P883, DOI 10.1378/chest.88.6.883; EVANS GT, 1987, PACE, V10, P1395; EVANS GT, 1991, CIRCULATION, V84, P1924, DOI 10.1161/01.CIR.84.5.1924; FLECK RP, 1993, PACE, V16, P377, DOI 10.1111/j.1540-8159.1993.tb01597.x; GALLAGHER JJ, 1982, NEW ENGL J MED, V306, P194, DOI 10.1056/NEJM198201283060402; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; HAISSAGUERRE M, 1992, CIRCULATION, V85, P2162, DOI 10.1161/01.CIR.85.6.2162; HUANG SK, 1987, J AM COLL CARDIOL, V9, P349, DOI 10.1016/S0735-1097(87)80388-1; HUANG SKS, 1989, CIRCULATION, V80, P951, DOI 10.1161/01.CIR.80.4.951; JACKMAN WM, 1991, CIRCULATION, V83, P1562, DOI 10.1161/01.CIR.83.5.1562; JACKMAN WM, 1992, NEW ENGL J MED, V327, P313, DOI 10.1056/NEJM199207303270504; JANSE MJ, 1993, J CARDIOVASC ELECTR, V4, P561, DOI 10.1111/j.1540-8167.1993.tb01244.x; JAZAYERI MR, 1992, CIRCULATION, V85, P1318, DOI 10.1161/01.CIR.85.4.1318; KALBFLEISCH SJ, 1994, J AM COLL CARDIOL, V23, P716, DOI 10.1016/0735-1097(94)90759-5; KAY GN, 1992, CIRCULATION, V85, P1675, DOI 10.1161/01.CIR.85.5.1675; KUNZE KP, 1988, AM J CARDIOL, V61, P657, DOI 10.1016/0002-9149(88)90788-6; LANGBERG JJ, 1993, CIRCULATION, V87, P1551, DOI 10.1161/01.CIR.87.5.1551; LANGBERG JJ, 1991, AM J CARDIOL, V67, P142, DOI 10.1016/0002-9149(91)90436-O; LANGBERG JJ, 1989, CIRCULATION, V80, P1527, DOI 10.1161/01.CIR.80.6.1527; MITRANI RD, 1993, J AM COLL CARDIOL, V21, P432, DOI 10.1016/0735-1097(93)90686-U; MORADY F, 1993, J AM COLL CARDIOL, V21, P102, DOI 10.1016/0735-1097(93)90723-E; SCHEINMAN MM, 1984, CIRCULATION, V70, P1024, DOI 10.1161/01.CIR.70.6.1024; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SOUSA J, 1991, CIRCULATION, V84, P567, DOI 10.1161/01.CIR.84.2.567; THAKUR RK, 1993, J AM COLL CARDIOL, V22, P1706, DOI 10.1016/0735-1097(93)90600-6; WATHEN M, 1992, AM J CARDIOL, V70, P886, DOI 10.1016/0002-9149(92)90732-E; WU DL, 1993, J AM COLL CARDIOL, V21, P1612, DOI 10.1016/0735-1097(93)90376-C; YEUNGLAIWAH JA, 1991, J AM COLL CARDIOL, V18, P1753, DOI 10.1016/0735-1097(91)90516-C	29	209	211	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					910	917		10.1056/NEJM199410063311404	http://dx.doi.org/10.1056/NEJM199410063311404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	7848418				2022-12-01	WOS:A1994PJ41900004
J	DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M				DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M			HIGH PREVALENCE OF SERUM ANTIBODIES TO HEPATITIS-C VIRUS IN PATIENTS WITH HASHIMOTOS-THYROIDITIS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		HOP JEAN VERDIER,SERV HEPATOGASTROENTEROL,F-93140 BONDY,FRANCE; HOP ST ANTOINE,IMMUNOL LAB,F-75012 PARIS,FRANCE; HOP AVICENNE,SERV MICROBIOL,F-93000 BOBIGNY,FRANCE; HOP LA PITIE SALPETRIERE,NUCL MED SERV,F-75013 PARIS,FRANCE; HOP ST ANTOINE,SERV ENDOCRINOL,F-75012 PARIS,FRANCE; HOP JEAN VERDIER,SERV ENDOCRINOL,F-93140 BONDY,FRANCE; HOP COCHIN,CLIN IMMUNOL LAB,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Deny, Paul/C-6099-2011					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CIAMPOLILLO A, 1989, LANCET, V1, P1096; ESTEBAN JI, 1992, PROGR LIVER DISEASE, P219; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; MANNS MP, 1993, PROGRESS IN HEPATOLOGY 93, P79	5	30	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					846	847		10.1136/bmj.309.6958.846	http://dx.doi.org/10.1136/bmj.309.6958.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524874	Green Published			2022-12-01	WOS:A1994PK50100022
J	MACPHERSON, AJS; BJARNASON, I				MACPHERSON, AJS; BJARNASON, I			COLONOCYTES IN BARRETTS METAPLASIA	LANCET			English	Editorial Material							ULCERATIVE-COLITIS				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT MED,LONDON,ENGLAND.							DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DAS KM, 1993, J IMMUNOL, V150, P2487; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					903	904		10.1016/S0140-6736(94)92264-0	http://dx.doi.org/10.1016/S0140-6736(94)92264-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7523804				2022-12-01	WOS:A1994PJ28700005
J	MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E				MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E			HEPATITIS-C IN ASYMPTOMATIC BRITISH BLOOD-DONORS WITH INDETERMINATE SEROPOSITIVITY	BRITISH MEDICAL JOURNAL			English	Article							VIRUS		UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM,ENGLAND; UNIV BIRMINGHAM,DEPT INFECT,BIRMINGHAM,ENGLAND; W MIDLANDS REG HLTH AUTHOR,BLOOD TRANSFUS SERV,BIRMINGHAM,W MIDLANDS,ENGLAND; REG VIROL LABS,E BIRMINGHAM,ENGLAND	University of Birmingham; University of Birmingham	MUTIMER, DJ (corresponding author), QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Neuberger, James/ABG-3010-2020					CHEMELLO L, 1993, HEPATOLOGY, V17, P179, DOI 10.1002/hep.1840170203; FOLLETT EAC, 1992, LANCET, V339, P928, DOI 10.1016/0140-6736(92)90964-5; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; SCHEUER PJ, 1992, HEPATOLOGY, V15, P567, DOI 10.1002/hep.1840150402; SERFATY L, 1993, HEPATOLOGY, V17, P183, DOI 10.1002/hep.1840170204	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					847	848		10.1136/bmj.309.6958.847	http://dx.doi.org/10.1136/bmj.309.6958.847			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524875	Green Published			2022-12-01	WOS:A1994PK50100023
J	SHAW, AD; SJOLIN, SU; MCQUEEN, MM				SHAW, AD; SJOLIN, SU; MCQUEEN, MM			LESSON OF THE WEEK - CRUSH SYNDROME FOLLOWING UNCONSCIOUSNESS - NEED FOR URGENT ORTHOPEDIC REFERRAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE-RENAL-FAILURE; TRAUMATIC RHABDOMYOLYSIS; LIMB COMPRESSION		ROYAL INFIRM, ORTHOPAED TRAUMA UNIT, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh								BETTER OS, 1990, NEW ENGL J MED, V322, P825; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; HEPPENSTALL RB, 1988, CLIN ORTHOP RELAT R, V226, P138; KIKTA MJ, 1987, ARCH SURG-CHICAGO, V122, P1078; MATSEN FA, 1975, CLIN ORTHOP RELAT R, P8, DOI 10.1097/00003086-197511000-00003; MUBARAK S, 1975, CLIN ORTHOP RELAT R, P81, DOI 10.1097/00003086-197511000-00012; OWEN CA, 1979, NEW ENGL J MED, V300, P1169, DOI 10.1056/NEJM197905243002101; RON D, 1984, ARCH INTERN MED, V144, P277, DOI 10.1001/archinte.144.2.277; RORABECK CH, 1981, J TRAUMA, V21, P446; [No title captured]	10	32	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					857	859		10.1136/bmj.309.6958.857	http://dx.doi.org/10.1136/bmj.309.6958.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7695702	Green Published			2022-12-01	WOS:A1994PK50100028
J	BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D				BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D			ALIGNMENT AND SENSITIVE DETECTION OF DNA BY A MOVING INTERFACE	SCIENCE			English	Article							NUCLEIC-ACIDS; GEL-ELECTROPHORESIS; MAGNETIC BEADS; MOLECULES; HYBRIDIZATION; MICROSCOPY; ASSEMBLIES	In a process called ''molecular combing,'' DNA molecules attached at one end to a solid surface were extended and aligned by a receding air-water interface and left to dry on the surface. Molecular combing was observed to extend the length of the bacteriophage lambda DNA molecule to 21.5 +/- 0.5 micrometers (unextended length, 16.2 micrometers). With the combing process, it was possible to (i) extend a chromosomal Escherichia coli DNA fragment (10(6) base pairs) and (ii) detect a minute quantity of DNA (10(3) molecules). These results open the way for a faster physical mapping of the genome and for the detection of small quantities of target DNA from a population of molecules.	ECOLE NORMALE SUPER,PHYS STAT LAB,F-75005 PARIS,FRANCE; ECOLE NORMALE SUPER,PHYS MAT CONDENSEE LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	BENSIMON, A (corresponding author), INST PASTEUR,F-75015 PARIS,FRANCE.		heslot, françois/AAF-9406-2021; Bensimon, David/E-7768-2015	Bensimon, David/0000-0003-1971-9907; Croquette, Vincent/0000-0003-1400-0039				BENSIMON D, UNPUB; BRZOSKA JB, 1992, NATURE, V360, P719, DOI 10.1038/360719a0; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DICKERSON RE, 1983, COLD SPRING HARB SYM, V47, P13; GUESDON JL, 1992, J IMMUNOL METHODS, V150, P33, DOI 10.1016/0022-1759(92)90063-Y; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; INNIS MA, 1990, PCR PROTOCOLS; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, P24; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; LABROUSSE H, 1982, J IMMUNOL METHODS, V48, P133, DOI 10.1016/0022-1759(82)90188-0; LANGDALE JA, 1985, GENE, V36, P201, DOI 10.1016/0378-1119(85)90175-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUND V, 1988, NUCLEIC ACIDS RES, V16, P10861, DOI 10.1093/nar/16.22.10861; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; YANAGIDA M, 1986, APPLICATIONS FLUORES, P321; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	27	690	766	3	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2096	2098		10.1126/science.7522347	http://dx.doi.org/10.1126/science.7522347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522347				2022-12-01	WOS:A1994PJ91200031
J	NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U				NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U			PADLOCK PROBES - CIRCULARIZING OLIGONUCLEOTIDES FOR LOCALIZED DNA DETECTION	SCIENCE			English	Article							ALPHA-SATELLITE DNA; LIGASE; HYBRIDIZATION; GENE	Nucleotide sequence information derived from DNA segments of the human and other genomes is accumulating rapidly. However, it frequently proves difficult to use such short DNA segments to identify clones in genomic libraries or fragments in blots of the whole genome or for in situ analysis of chromosomes. Oligonucleotide probes, consisting of two target-complementary segments, connected by a linker sequence, were designed. Upon recognition of the specific nucleic acid molecule the ends of the probes were joined through the action of a ligase, creating circular DNA molecules catenated to the target sequence. These probes thus provide highly specific detection with minimal background.	BIOMED CTR,DEPT MED GENET,BEIJER LAB,S-75123 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,S-75007 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Samiotaki, Martina/B-3851-2018; Landegren, Ulf D/A-8197-2019	Samiotaki, Martina/0000-0001-9952-0636; Nilsson, Mats/0000-0001-9985-0387				ALVES AM, 1988, NUCLEIC ACIDS RES, V16, P8723, DOI 10.1093/nar/16.17.8723; BALDINI A, 1990, AM J HUM GENET, V46, P784; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; DOLINNAYA NG, 1993, NUCLEIC ACIDS RES, V21, P5403, DOI 10.1093/nar/21.23.5403; Higgins N P, 1979, Methods Enzymol, V68, P50; JASCHKE A, 1993, TETRAHEDRON LETT, V34, P301, DOI 10.1016/S0040-4039(00)60572-5; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Maniatis T., 1982, MOL CLONING; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; Nilsson M., UNPUB; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PRAKASH G, 1992, J AM CHEM SOC, V114, P3523, DOI 10.1021/ja00035a056; RIORDAN JR, 1989, SCIENCE, V245, P1066; SUND C, 1988, NUCLEOS NUCLEOT, V7, P655, DOI 10.1080/07328318808056303; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	16	547	711	11	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2085	2088		10.1126/science.7522346	http://dx.doi.org/10.1126/science.7522346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522346				2022-12-01	WOS:A1994PJ91200027
J	CYSTER, JG; HARTLEY, SB; GOODNOW, CC				CYSTER, JG; HARTLEY, SB; GOODNOW, CC			COMPETITION FOR FOLLICULAR NICHES EXCLUDES SELF-REACTIVE CELLS FROM THE RECIRCULATING B-CELL REPERTOIRE	NATURE			English	Article							LYMPHOCYTES-B; TRANSGENIC MICE; BONE-MARROW; CLONAL DELETION; GENES; EXPRESSION; TOLERANCE; LYSOZYME; ANTIGEN; MOUSE	Two different approaches to follow clones of B lymphocytes in a diverse preimmune repertoire reveal a new process for eliminating self-reactive cells in the periphery which depends on competition between cells with different specificities. A key feature of this censoring mechanism is the selective exclusion of self-antigen-binding B cells from the normal migration route into lymphoid follicles, resulting in their premature death. This is a striking example of homeostasis by cellular competition for limiting niches and may explain the paradoxical association between immunodeficiency and autoimmunity.	STANFORD UNIV, BECKMAN CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	CYSTER, JG (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AUGUST CS, 1989, IMMUNOLOGICAL DISORD, P634; BELL EB, 1975, EUR J IMMUNOL, V5, P1; BONA CA, 1988, ANNU REV IMMUNOL, V6, P327, DOI 10.1146/annurev.iy.06.040188.001551; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; FORSTER I, 1991, EUR J IMMUNOL, V21, P1779, DOI 10.1002/eji.1830210732; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HOWARD JC, 1972, J EXP MED, V135, P185, DOI 10.1084/jem.135.2.185; Kearney J F, 1992, Int Rev Immunol, V8, P247, DOI 10.3109/08830189209055577; KOOPMAN G, 1992, IMMUNOL REV, V126, P21, DOI 10.1111/j.1600-065X.1992.tb00629.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LORTAN JE, 1987, EUR J IMMUNOL, V17, P1311, DOI 10.1002/eji.1830170914; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MAKELA O, 1965, IMMUNOLOGY, V8, P539; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PELLAS TC, 1990, AM J ANAT, V187, P347, DOI 10.1002/aja.1001870404; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SMITHGILL SJ, 1987, J IMMUNOL, V139, P4135; SPRENT J, 1972, EUR J IMMUNOL, V2, P384, DOI 10.1002/eji.1830020420; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	47	476	478	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					389	395		10.1038/371389a0	http://dx.doi.org/10.1038/371389a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	7522305				2022-12-01	WOS:A1994PJ28500033
J	RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH				RIDKER, PM; VAUGHAN, DE; STAMPFER, MJ; GLYNN, RJ; HENNEKENS, CH			ASSOCIATION OF MODERATE ALCOHOL-CONSUMPTION AND PLASMA-CONCENTRATION OF ENDOGENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CARDIOVASCULAR MORTALITY; FIBRINOLYTIC-ACTIVITY; PLATELET-AGGREGATION; CIRCADIAN VARIATION; HDL CHOLESTEROL; ARTERY DISEASE; BLOOD-LIPIDS	Objective.-To assess whether an association exists between moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator (t-PA), a serine protease that plays a central role in the regulation of intravascular fibrinolysis. Design.-Survey of self-reported alcohol consumption and plasma fibrinolytic capacity, controlled for lipid and nonlipid cardiac risk factors. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 631 apparently healthy male physicians aged 40 to 84 years with no history of myocardial infarction, stroke, or transient cerebral ischemia. Main Outcome Measure.-Plasma concentration of t-PA antigen. Results.-A direct association was found between alcohol consumption and plasma level of t-PA antigen, such that mean plasma levels of t-PA antigen for daily, weekly, monthly, and rare or never drinkers were 10.9, 9.7, 9.1, and 8.1 ng/mL, respectively (P trend=.0002). The relation between alcohol consumption and t-PA antigen level was not materially changed in analyses that adjusted for total cholesterol and high-density lipoprotein cholesterol or nonlipid cardiovascular risk factors including age, body mass index, parental history of coronary heart disease, exercise frequency, and systolic and diastolic blood pressure. Conclusions.-These data indicate a positive association between moderate alcohol intake and plasma level of endogenous t-PA antigen that is independent of high-density lipoprotein cholesterol. This finding supports the hypothesis that changes in fibrinolytic potential may be an important mechanism whereby moderate alcohol consumption decreases risk of heart disease.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKANO T, 1984, RES ADV ALCOHOL DRUG, V8, P209; ANDREOTTI F, 1991, CHRONOBIOL INT, V8, P336, DOI 10.3109/07420529109059170; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BRIDGES AB, 1993, BRIT HEART J, V69, P121; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BURR ML, 1986, BRIT J NUTR, V56, P81, DOI 10.1079/BJN19860087; CASTELLI WP, 1977, LANCET, V2, P153; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DIEHL AK, 1988, ATHEROSCLEROSIS, V69, P145, DOI 10.1016/0021-9150(88)90008-1; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; ELMER O, 1984, HAEMOSTASIS, V14, P223; ERNST N, 1980, CIRCULATION, V62, P41; FRIEDMAN GD, 1993, NEW ENGL J MED, V329, P1882, DOI 10.1056/NEJM199312163292510; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HARTUNG GH, 1983, JAMA-J AM MED ASSOC, V249, P747, DOI 10.1001/jama.249.6.747; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1978, AM J EPIDEMIOL, V107, P196, DOI 10.1093/oxfordjournals.aje.a112525; ISO H, 1993, THROMB HAEMOSTASIS, V70, P475; JACKSON R, 1992, AM J EPIDEMIOL, V136, P819, DOI 10.1093/aje/136.7.819; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1990, ALCOHOL HEALTH RES W, V14, P289; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MIKHAILIDIS DP, 1983, BRIT MED J, V287, P1495, DOI 10.1136/bmj.287.6404.1495; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1992, CIRCULATION, V85, P1822, DOI 10.1161/01.CIR.85.5.1822; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1993, ARTERIOSCLER THROMB, V13, P1587, DOI 10.1161/01.ATV.13.11.1587; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SMOKOVITIS A, 1988, HAEMOSTASIS, V18, P146; SMOKOVITIS A, 1991, ALCOHOL, V8, P17, DOI 10.1016/0741-8329(91)91152-R; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; SUMI H, 1988, ALCOHOL ALCOHOLISM, V23, P33; THORNTON J, 1983, LANCET, V2, P819; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; VEENSTRA J, 1990, THROMB HAEMOSTASIS, V63, P345; VEENSTRA J, 1990, FIBRINOLYSIS, V2, P64; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; [No title captured]	53	262	265	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					929	933		10.1001/jama.272.12.929	http://dx.doi.org/10.1001/jama.272.12.929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	7794308				2022-12-01	WOS:A1994PG73700019
J	HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA				HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA			EFFECTS OF CEREBRAL-ISCHEMIA IN MICE DEFICIENT IN NEURONAL NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							L-ARGININE; GUANYLATE-CYCLASE; ARTERY OCCLUSION; BRAIN; STIMULATION; MECHANISMS	The proposal that nitric oxide (NO) or its reactant products mediate toxicity in brain remains controversial in part because of the use of nonselective agents that block NO formation in neuronal, glial, and vascular compartments. In mutant mice deficient in neuronal NO synthase (NOS) activity, infarct volumes decreased significantly 24 and 72 hours after middle cerebral artery occlusion, and the neurological deficits were less than those in normal mice. This result could not be accounted for by differences in blood flow or vascular anatomy. However, infarct size in the mutant became larger after endothelial NOS inhibition by nitro-L-arginine administration. Hence, neuronal NO production appears to exacerbate acute ischemic injury, whereas vascular NO protects after middle cerebral artery occlusion. The data emphasize the importance of developing selective inhibitors of the neuronal isoform.	MASSACHUSETTS GEN HOSP,STROKE RES LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,NEUROSURG SERV,BOSTON,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02129; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIOVASC RES CTR,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital			Moskowitz, Michael A/D-9916-2011	Dalkara, Turgay/0000-0003-3943-7819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NINDS NIH HHS [NS2636, NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DALKARA T, 1994, AM J PHYSIOL, V267, pH678, DOI 10.1152/ajpheart.1994.267.2.H678; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DALKARA T, UNPUB; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG Z, UNPUB; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IRIKURA K, 1994, AM J PHYSIOL, V267, pH837, DOI 10.1152/ajpheart.1994.267.2.H837; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIKAWA E, 1992, AM J PHYSIOL, V263, pH1632, DOI 10.1152/ajpheart.1992.263.5.H1632; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MOSKOWITZ MA, UNPUB; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PANAHIAN N, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WARD R, 1990, J ANAT, V173, P87; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	33	1396	1468	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1883	1885		10.1126/science.7522345	http://dx.doi.org/10.1126/science.7522345			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522345				2022-12-01	WOS:A1994PH25800038
J	ROOT, MJ; MACKINNON, R				ROOT, MJ; MACKINNON, R			2 IDENTICAL NONINTERACTING SITES IN AN ION-CHANNEL REVEALED BY PROTON-TRANSFER	SCIENCE			English	Article							INDUCED CURRENT FLUCTUATIONS; OLFACTORY RECEPTOR NEURONS; NUCLEOTIDE-GATED CHANNEL; CALCIUM CHANNELS; CRYSTAL-STRUCTURE; ACTIVATED CHANNEL; DIVALENT-CATIONS; 2.0-A RESOLUTION; K+ CHANNELS; PERMEATION	The functional consequences of single proton transfers occurring in the pore of a cyclic nucleotide-gated channel were observed with patch recording techniques. These results led to three conclusions about the chemical nature of ion binding sites in the conduction pathway: The channel contains two identical titratable sites, even though there are more than two (probably four) identical subunits; the sites are formed by glutamate residues that have a pK(a) (where K-a is the acid constant) of 7.6; and protonation of one site does not perturb the pK(a) of the other. These properties point to an unusual arrangement of carboxyl side-chain residues in the pore of a cation channel.	HARVARD UNIV, SCH MED, BIOPHYS PROGRAM, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROOT, MJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM083113] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM083113, GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1991, ANN NY ACAD SCI, V635, P18, DOI 10.1111/j.1749-6632.1991.tb36477.x; Bell R. P., 1973, PROTON CHEM; Caldin E. F., 1975, PROTON TRANSFER REAC; Caspar D L, 1990, Adv Biophys, V26, P157, DOI 10.1016/0065-227X(90)90011-H; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; Fersht A., 1985, ENZYME STRUCTURE MEC; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Jencks W.P., 1987, CATALYSIS CHEM ENZYM; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOHLER HH, 1979, J THEOR BIOL, V79, P381, DOI 10.1016/0022-5193(79)90354-0; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MANGANI S, 1992, J MOL BIOL, V223, P573, DOI 10.1016/0022-2836(92)90671-6; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; PENTZ L, 1967, J AM CHEM SOC, V89, P6931, DOI 10.1021/ja01002a022; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHUMAKER MF, 1990, BIOPHYS J, V58, P975, DOI 10.1016/S0006-3495(90)82442-5; SIELECKI AR, 1979, J MOL BIOL, V134, P781, DOI 10.1016/0022-2836(79)90486-8; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TYERMAN SD, 1992, BIOPHYS J, V61, P736, DOI 10.1016/S0006-3495(92)81878-7; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; ZUFALL F, 1993, J NEUROPHYSIOL, V69, P1758, DOI 10.1152/jn.1993.69.5.1758	33	139	143	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1852	1856		10.1126/science.7522344	http://dx.doi.org/10.1126/science.7522344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522344				2022-12-01	WOS:A1994PH25800029
J	BRAM, RJ; CRABTREE, GR				BRAM, RJ; CRABTREE, GR			CALCIUM SIGNALING IN T-CELLS STIMULATED BY A CYCLOPHILIN B-BINDING PROTEIN	NATURE			English	Article							CYCLOSPORINE-A; ANTIGEN RECEPTOR; TYROSINE KINASE; LYMPHOCYTES-T; ACTIVATION; CALCINEURIN; IDENTIFICATION; TRANSDUCTION; EXPRESSION; PREDICTION	THE immunosuppressant drug cyclosporin A blocks a calcium-dependent signal from the T-cell receptor (TCR) that normally leads to T-cell activation(1-3). When bound to cyclophilin, cyclosporin A binds and inactivates the key signalling intermediate calcineurin(4-6). To identify potential cellular homologues of cyclosporin A that might regulate calcium signalling, we have cloned human genes encoding cyclophilin B-binding-proteins using the yeast two-hybrid system(7,8). One gene product, when overexpressed in Jurkat T cells, specifically induced transcription from the interleukin-2 enhancer, by activating the T-cell-specific transcription factors NF-AT and NF-IL2A. This protein, termed calcium-signal modulating cyclophilin ligand (CAML), acts downstream of the TCR and upstream of calcineurin by causing an influx of calcium. CAML appears to be a new participant in the calcium-signal transduction pathway, implicating cyclophilin B in calcium signalling, even in the absence of cyclosporin.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PATHOL, STANFORD, CA 94305 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute; Stanford University; Stanford University	BRAM, RJ (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; June C H, 1990, Methods Cell Biol, V33, P37; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1983, IMMUNOLOGY, V50, P441; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	30	146	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					355	358		10.1038/371355a0	http://dx.doi.org/10.1038/371355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522304				2022-12-01	WOS:A1994PH25400059
J	SHARKEY, J; BUTCHER, SP				SHARKEY, J; BUTCHER, SP			IMMUNOPHILINS MEDIATE THE NEUROPROTECTIVE EFFECTS OF FK506 IN FOCAL CEREBRAL-ISCHEMIA	NATURE			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; CYCLOSPORINE-A; NITRIC-OXIDE; IMMUNOSUPPRESSANT FK506; GLUTAMATE NEUROTOXICITY; LYMPHOCYTES-T; BRAIN; COMPLEXES; ISCHEMIA; RAPAMYCIN	THE immunosuppressive action of the drug FK506 involves inhibition of calcineurin in T-lymphocytes by a complex of FK506 and an FK506 binding protein, FKBP 12(1,2), a member of the immunophilin protein family(3,4). The functional role of brain immunophilins is, however, unclear(5,6). We show here that FK506 is a powerful neuroprotective agent in an in vivo model of focal cerebral ischaemia when administered up to 60 min post-occlusion. The minimum effective neuroprotective dose is comparable with the immunosuppressant dose in humans(7), suggesting. that FK506 may have clinical potential for the treatment of stroke. Although the related immunosuppressants rapamycin and cyclosporin failed to reduce brain damage, the finding that rapamycin pretreatment blocked the effect of FK506 confirms a role for immunophilins in the neuroprotective mechanism.			SHARKEY, J (corresponding author), UNIV EDINBURGH,FUJISAWA INST NEUROSCI,DEPT PHARMACOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.			Sharkey, John/0000-0001-8288-1857				ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; ASAMI M, 1993, BIOCHEM BIOPH RES CO, V192, P1388, DOI 10.1006/bbrc.1993.1570; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUNG J, 1991, TRANSPLANT P, V23, P2977; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKAI H, 1993, J BIOCH, V113, P292; NAGASAWA H, 1989, STROKE, V20, P150; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; PARK CK, 1989, ANN NEUROL, V20, P150; SCHNEIBER SL, 1991, SCIENCE, V251, P283; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; SHARKEY J, IN PRESS J AUTONOM T; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SLEKULERKA JJ, 1989, NATURE, V341, P755; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0	29	436	468	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					336	339		10.1038/371336a0	http://dx.doi.org/10.1038/371336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522303				2022-12-01	WOS:A1994PH25400053
J	ALLEN, K; BLASCOVICH, J				ALLEN, K; BLASCOVICH, J			EFFECTS OF MUSIC ON CARDIOVASCULAR REACTIVITY AMONG SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESPONSES; STRESS	Objective.-To determine the effects of surgeon-selected and experimenter-selected music on performance and autonomic responses of surgeons during a standard laboratory psychological stressor. Design.-Within-subjects laboratory experiment. Setting.-Hospital psychophysiology laboratory. Participants.-A total of 50 male surgeons aged 31 to 61 years, who reported that they typically listen to music during surgery, volunteered for the study. Main Outcome Measurements.-Cardiac responses, hemodynamic measures, electrodermal autonomic responses, task speed, and accuracy. Results.-Autonomic reactivity for all physiological measures was significantly less in the surgeon-selected music condition than in the experimenter-selected music condition, which in turn was significantly less than in the no-music control condition. Likewise, speed and accuracy of task performance were significantly better in the surgeon-selected music condition than in the experimenter-selected music condition, which was also significantly better than the no-music control condition. Conclusion.-Surgeon-selected music was associated with reduced autonomic reactivity and improved performance of a stressful nonsurgical laboratory task in study participants.	SUNY BUFFALO,DEPT PSYCHOL,AMHERST,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	ALLEN, K (corresponding author), SUNY BUFFALO,CTR STUDY BIOBEHAV & SOCIAL ASPECTS HLTH,PK HALL,AMHERST,NY 14260, USA.							ALLEN KM, 1991, J PERS SOC PSYCHOL, V61, P582, DOI 10.1037/0022-3514.61.4.582; ALLEN MT, 1987, PSYCHOPHYSIOLOGY, V24, P648, DOI 10.1111/j.1469-8986.1987.tb00345.x; BARGER DA, 1979, J MUSIC THER, V16, P158, DOI 10.1093/jmt/16.4.158; Beck S L, 1991, Oncol Nurs Forum, V18, P1327; BLASCOVICH J, 1992, J PERS SOC PSYCHOL, V63, P164, DOI 10.1037/0022-3514.63.1.164; BLASCOVICH J, 1993, J PERS SOC PSYCHOL, V64, P165, DOI 10.1037/0022-3514.64.2.165; CHETTA HD, 1981, J MUSIC THER, V18, P74, DOI 10.1093/jmt/18.2.74; DAINOW E, 1977, J RES MUSIC EDUC, V25, P211, DOI 10.2307/3345305; DAVISROLLINS C, 1987, HEART LUNG, V19, P29; DEGOOD DE, 1976, BIOFEEDBACK SELF-REG, V1, P373; GUZZETTA CE, 1989, HEART LUNG, V18, P606; Heitz L, 1992, J Post Anesth Nurs, V7, P22; Katkin E. S., 1993, CARDIOVASCULAR REACT; KELSEY RM, 1991, PSYCHOPHYSIOLOGY, V28, P619, DOI 10.1111/j.1469-8986.1991.tb01005.x; LANDRETH JE, 1974, J RES MUSIC EDUC, V22, P4, DOI 10.2307/3344613; LEVY O, 1964, TWILIGHT IDOLS, V16, P6; LOCSIN RGRAC, 1981, J ADV NURS, V6, P19, DOI 10.1111/j.1365-2648.1981.tb03091.x; MATTHEWS KA, 1986, HDB STRESS REACTIVIT; ORNSTEIN R, 1989, HLTH PLEASURES; OYAMA T, 1987, MUSIK MED MUSIC MED, P223; PERETTI PO, 1975, J PSYCHOL, V89, P183, DOI 10.1080/00223980.1975.9915750; PERETTI PO, 1974, J RES MUSIC EDUC, V22, P278, DOI 10.2307/3344765; RAUSCHER FH, 1993, NATURE, V365, P6; SHAPIRO AG, 1987, MUSIK MED, P227; SIFER KJ, 1991, AJR AM J ROENTGENOL, V156, P403; STEVENS K, 1990, J ADV NURS, V15, P1045, DOI 10.1111/j.1365-2648.1990.tb01985.x; STOUDENMIRE J, 1975, J CLIN PSYCHOL, V31, P490, DOI 10.1002/1097-4679(197507)31:3<490::AID-JCLP2270310328>3.0.CO;2-E; TANIOKA F, 1987, MUSIK MED, P199; Thayer J., 1983, PSYCHOMUSICOLOGY, V3, P44, DOI DOI 10.1037/H0094256; TOMAKA J, 1993, J PERS SOC PSYCHOL, V65, P248, DOI 10.1037/0022-3514.65.2.248; TOMAKA J, 1992, PERS SOC PSYCHOL B, V18, P616, DOI 10.1177/0146167292185012; Turner J., 1992, INDIVIDUAL DIFFERENC; UPDIKE PA, 1987, ANN PLAS SURG, V19, P29, DOI 10.1097/00000637-198707000-00004; WEBSTER C, 1973, AUST OCCUP THER J, V20, P9; Whipple B, 1992, Sch Inq Nurs Pract, V6, P43; ZIMNY GH, 1963, AM J PSYCHOL, V76, P311, DOI 10.2307/1419170	36	120	120	1	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					882	884		10.1001/jama.272.11.882	http://dx.doi.org/10.1001/jama.272.11.882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	7811324				2022-12-01	WOS:A1994PG18200028
J	BISHOP, MC				BISHOP, MC			ALTERNATIVES ARE STILL UNPROVED	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERTROPHY; PROSTATECTOMY; RESECTION				BISHOP, MC (corresponding author), CITY HOSP,NOTTINGHAM NG5 1PB,ENGLAND.							ABRAMS PH, 1979, J UROLOGY, V121, P640, DOI 10.1016/S0022-5347(17)56918-9; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BDESHA AS, 1993, BRIT MED J, V306, P1293, DOI 10.1136/bmj.306.6888.1293; DOLL HA, 1993, BRIT J UROL, V72, P322, DOI 10.1111/j.1464-410X.1993.tb00727.x; EVANS JWH, 1992, BMJ-BRIT MED J, V304, P666, DOI 10.1136/bmj.304.6828.666; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NEAL DE, 1990, BRIT J UROL, V66, P449, DOI 10.1111/j.1464-410X.1990.tb14986.x; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705	8	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					717	718		10.1136/bmj.309.6956.717	http://dx.doi.org/10.1136/bmj.309.6956.717			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524873	Green Published			2022-12-01	WOS:A1994PH40700023
J	KIRBY, RS				KIRBY, RS			ARE THE DAYS OF TRANSURETHRAL RESECTION OF PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA NUMBERED - UROLOGISTS MUST GRASP THE FUTURE .3.	BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTION; FINASTERIDE				KIRBY, RS (corresponding author), ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND.							GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KIRBY RS, 1993, EUR UROL, V24, P20; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; LEPOR H, 1991, Journal of Urology, V145, p362A; NEAL DE, 1989, BRIT MED J, V299, P762, DOI 10.1136/bmj.299.6702.762; Ng J., 1993, Journal of Urology, V149, p449A; NORRIS JP, 1993, J UROLOGY, V150, P1612, DOI 10.1016/S0022-5347(17)35857-3; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	10	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					716	717		10.1136/bmj.309.6956.716	http://dx.doi.org/10.1136/bmj.309.6956.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524872	Green Published			2022-12-01	WOS:A1994PH40700022
J	KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS				KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS			SCREENING FOR PROSTATE-CANCER - A DECISION-ANALYTIC VIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL RETROPUBIC PROSTATECTOMY; TERM FOLLOW-UP; STAGE-A ADENOCARCINOMA; DEFINITIVE RADIOTHERAPY; PELVIC LYMPHADENECTOMY; EXPECTANT MANAGEMENT; DETECTION-PROJECT; NATURAL COURSE; CARCINOMA; COMPLICATIONS	Objective.-To determine the clinical and economic effects of screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS), and digital rectal examination (DRE). Design.-Decision analytic cost-utility analysis comparing four screening strategies with a strategy of not screening. We assumed that the cancer detection rate and stage distribution were predicted by each combination of tests and that localized cancer was treated with radical prostatectomy. For each strategy, we calculated life expectancy, quality-adjusted life expectancy (QALE), and cost-utility ratios for unselected and high-prevalence populations. Data.-Probabilities and rates for clinical events were gathered from published data. We assessed utilities by the time-trade-off method using urologists, radiation oncologists, and internists as subjects. The Clinical Cost Manager at the New England Medical Center provided cost data. Results.-ln unselected men between the ages of 50 and 70 years, screening with PSA or TRUS prolonged unadjusted life expectancy but diminished QALE. Screening with DRE alone yielded no reduction in mortality at any age. All programs increased costs. Results were sensitive only to assumptions about the efficacy of treatment. In high-prevalence populations, screening produced a similar pattern: gains in unadjusted life expectancy, losses in QALE, and increased costs. Conclusions.-Our analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer. Screening may result in poorer health outcomes and will increase costs dramatically. Assessment of comorbidity, risk attitude, and valuation of sexual function may identify individuals who will benefit from screening, but selecting high-prevalence populations will not improve the benefit of screening.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO, ON, CANADA; UNIV TORONTO, DEPT HLTH ADM, TORONTO M5S 1A1, ON, CANADA; UNIV TORONTO, DEPT UROL, TORONTO, ON, CANADA; TORONTO HOSP, CTR PROSTATE, TORONTO M5T 2S8, ON, CANADA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ON, CANADA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Tufts Medical Center; Tufts University	KRAHN, MD (corresponding author), TORONTO HOSP, CLIN EPIDEMIOL UNIT, EN G-248, 200 ELIZABETH ST, TORONTO M5G 2C4, ON, CANADA.			Eckman, Mark/0000-0001-8253-269X; Krahn, Murray/0000-0001-5836-397X				ADOLFSSON J, 1991, J UROLOGY, V146, P96, DOI 10.1016/S0022-5347(17)37722-4; ADOLFSSON J, 1990, BRIT J UROL, V65, P611, DOI 10.1111/j.1464-410X.1990.tb14829.x; BABAIAN RJ, 1992, CANCER, V69, P1195; BAGSHAW MA, 1990, UROL CLIN N AM, V17, P787; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BLUTE ML, 1989, J UROLOGY, V142, P1262, DOI 10.1016/S0022-5347(17)39051-1; BLUTE ML, 1986, J UROLOGY, V136, P840, DOI 10.1016/S0022-5347(17)45098-1; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOWERSOX J, 1992, J NATL CANCER I, V84, P1857, DOI 10.1093/jnci/84.24.1857; Burks D A, 1992, Henry Ford Hosp Med J, V40, P89; BYAR DP, 1981, UROLOGY, V17, P7; CANTRELL BB, 1981, J UROLOGY, V125, P516, DOI 10.1016/S0022-5347(17)55092-2; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; DAVIES AH, 1990, EUR UROL, V18, P117; DAYAL HH, 1982, J CHRON DIS, V35, P553, DOI 10.1016/0021-9681(82)90074-1; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DORR VJ, 1993, ARCH INTERN MED, V153, P2529, DOI 10.1001/archinte.153.22.2529; EDDY DM, 1983, CANCER, V51, P2440, DOI 10.1002/1097-0142(19830615)51:12+<2440::AID-CNCR2820511309>3.0.CO;2-M; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FINCHAM SM, 1990, PROSTATE, V17, P189, DOI 10.1002/pros.2990170303; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FORMAN JD, 1986, INT J RADIAT ONCOL, V12, P185, DOI 10.1016/0360-3016(86)90092-1; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER JE, 1985, UROLOGY, V24, P243; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GIBBONS RP, 1984, J UROLOGY, V131, P73, DOI 10.1016/S0022-5347(17)50210-4; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GONZALEZ EF, 1992, 14TH ANN M SOC MED D; GREEN CJ, 1993, PROSTATE SPECIFIC AN; HANKS GE, 1991, ACTA ONCOL, V30, P231, DOI 10.3109/02841869109092359; IGEL TC, 1987, J UROLOGY, V137, P1189, DOI 10.1016/S0022-5347(17)44445-4; Jewett H J, 1975, Urol Clin North Am, V2, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KINSEY AC, 1948, SEXUAL BEHAV HUMAN M, P218; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LANGE PH, 1987, J UROLOGY, V138, P348, DOI 10.1016/S0022-5347(17)43143-0; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAWRENCE RS, 1992, SCREENING PROSTATE C, P1; LEANDRI P, 1992, J UROLOGY, V147, P883, DOI 10.1016/S0022-5347(17)37412-8; LEPOR H, 1989, J UROLOGY, V141, P82, DOI 10.1016/S0022-5347(17)40596-9; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LOWE BA, 1988, J UROLOGY, V140, P1345, DOI 10.1016/S0022-5347(17)42040-4; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MEBANE C, 1990, J NATL MED ASSOC, V82, P782; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; MIDDLETON AW, 1987, J UROLOGY, V138, P1185, DOI 10.1016/S0022-5347(17)43544-0; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MIDDLETON RG, 1986, J UROLOGY, V136, P422, DOI 10.1016/S0022-5347(17)44890-7; MILLER AB, 1989, WORLD J SURG, V13, P79, DOI 10.1007/BF01671158; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; NEWLING D, 1992, PROSTATE S4, V19, P139; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; PATTERSON DE, 1984, UROLOGY, V23, P243, DOI 10.1016/S0090-4295(84)90038-4; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PILEPICH M V, 1988, NCI (National Cancer Institute) Monographs, P61; PILEPICH MV, 1981, INT J RADIAT ONCOL, V7, P1341, DOI 10.1016/0360-3016(81)90029-8; RITCHIE AWS, 1989, BRIT J UROL, V64, P511, DOI 10.1111/j.1464-410X.1989.tb05289.x; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; SCHELLHAMMER PF, 1990, UROL CLIN N AM, V17, P835; SCHUMAN LM, 1980, PREV MED, V9, P630, DOI 10.1016/0091-7435(80)90035-3; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; STEINECK G, 1991, SCAND J UROL NEPHROL, P121; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALSH PC, 1987, CANCER, V60, P526, DOI 10.1002/1097-0142(19870801)60:3+<526::AID-CNCR2820601515>3.0.CO;2-9; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; Weinstein MC, 1980, CLIN DECISION ANAL; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; ZHANG G, 1991, J UROLOGY, V146, P99, DOI 10.1016/S0022-5347(17)37723-6; ZINCKE H, 1991, J UROLOGY, V146, P1053, DOI 10.1016/S0022-5347(17)37999-5; 1989, GUIDE CLIN PREVENTIV, P63; 1991, CAN MED ASSOC J, V145, P413	83	321	323	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					773	780		10.1001/jama.272.10.773	http://dx.doi.org/10.1001/jama.272.10.773			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	7521400				2022-12-01	WOS:A1994PF18800025
J	BILGRAMI, S; GREENBERG, BR				BILGRAMI, S; GREENBERG, BR			WHY SO MANY OPERATIONS FOR LOCALIZED PROSTATE-CANCER	LANCET			English	Editorial Material									VET AFFAIRS MED CTR,NEWINGTON,CT	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	BILGRAMI, S (corresponding author), UNIV CONNECTICUT,CTR HLTH,DIV HEMATOL ONCOL,FARMINGTON,CT, USA.							ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; BADALAMENT RA, 1991, DISEASE A MONTH, V37, P203; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1994, UROLOGY, V43, P488, DOI 10.1016/0090-4295(94)90236-4; MOORE MJ, 1988, J CLIN ONCOL, V6, P1736, DOI 10.1200/JCO.1988.6.11.1736; PEZZINO G, 1994, J NATL CANCER I, V86, P1083, DOI 10.1093/jnci/86.14.1083	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	701		10.1016/S0140-6736(94)92202-0	http://dx.doi.org/10.1016/S0140-6736(94)92202-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7521501				2022-12-01	WOS:A1994PF18700004
J	PEAD, L; MASKELL, R				PEAD, L; MASKELL, R			STUDY OF URINARY-TRACT INFECTION IN CHILDREN IN ONE HEALTH DISTRICT	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD; WOMEN	Objective-To determine the number of children who had urine specimens sent for culture, who had infections or sterile pyuria, and who were investigated further. To relate the laboratory findings to the results of imaging. Design-One year survey of urine specimens submitted to a laboratory; review of previous and subsequent laboratory reports; review of the findings of imaging of the urinary tract. Setting-Portsmouth and South East Hampshire health district. Subjects-An estimated population of 89 086 children aged 12 years or under. Main outcome measures-Urine bacterial count and results of imaging. Results-12 551 urine specimens were submitted from 7450 children, 3138 boys and 4312 girls. 2238 children had infection or sterile pyuria at least once during the study (13.9/1000 boys, 37/1000 girls). 996 (45%) of the children with infection or sterile pyuria underwent some form of imaging. 128 children who;had infection or sterile pyuria were already known to have urinary tract abnormalities and 114 children had newly identified abnormalities (1.0/1000 boys, 1.5/1000 girls). 50 (44%) of the children with newly detected abnormalities had no pyuria and 48 (42%) had bacterial counts below 10(8)/1. Eight children who had sterile pyuria on presentation were found to have abnormalities on imaging. Conclusions-Urinary tract infection is much commoner in children than is widely believed. Low bacterial counts, the absence of pyuria, or a finding of sterile pyuria should not be disregarded.	ST MARYS HOSP,PUBL HLTH LAB,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND									ASSCHER AW, 1973, LANCET, V2, P1; BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; CHIU N-C, 1989, Acta Paediatrica Sinica, V30, P225; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; KASS EH, 1957, ARCH INTERN MED, V100, P709, DOI 10.1001/archinte.1957.00260110025004; KUNIN CM, 1964, MEDICINE, V43, P91; KUNIN CM, 1993, ANN INTERN MED, V119, P454, DOI 10.7326/0003-4819-119-6-199309150-00002; MASKELL R, 1989, J INFECTION, V19, P207, DOI 10.1016/S0163-4453(89)90669-5; MASKELL R, 1989, BRIT J UROL, V63, P7, DOI 10.1111/j.1464-410X.1989.tb05113.x; MASKELL R, 1982, URINARY TRACT INFECT, P24; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; 1975, ARCH DIS CHILD, V50, P90; 1991, JR COLL PHYSICIANS L, V25, P36	15	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					631	634		10.1136/bmj.309.6955.631	http://dx.doi.org/10.1136/bmj.309.6955.631			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	7695692	Green Published			2022-12-01	WOS:A1994PG02000017
J	DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N				DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N			CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CANCER SYNDROME; WILD-TYPE; EXPRESSION; INHIBITOR; MUTANT; TRANSFORMATION; PROTEIN; FAMILY; CYCLE	As normal cells progress toward malignancy, they must switch to an angiogenic phenotype to attract the nourishing vasculature that they depend on for their growth. In cultured fibroblasts from Li-Fraumeni patients, this switch was found to coincide with loss of the wild-type allele of the p53 tumor suppressor gene and to be the result of reduced expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis. Transfection assays revealed that p53 can stimulate the endogenous TSP-1 gene and positively regulate TSP-1 promoter sequences. These data indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Tainsky, Michael/0000-0002-0261-831X; Volpert, Olga/0000-0003-1381-5543	NATIONAL CANCER INSTITUTE [R01CA064239, P01CA034936] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA34936, CA64239, CA52750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; DAMERON KM, IN PRESS COLD SPRING; DAMERON KM, UNPUB; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1992, PRINCESS TAKAMATSU S, V22, P339; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GANNON JV, 1991, NATURE, V349, P802; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAINSKY MA, UNPUB; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	34	1259	1314	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 9	1994	265	5178					1582	1584		10.1126/science.7521539	http://dx.doi.org/10.1126/science.7521539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521539				2022-12-01	WOS:A1994PF33600036
J	PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P				PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P			MUTATIONS IN AQUAPORIN-1 IN PHENOTYPICALLY NORMAL HUMANS WITHOUT FUNCTIONAL CHIP WATER CHANNELS	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; XENOPUS OOCYTES; RAT-KIDNEY; LOCALIZATION; EXPRESSION; FAMILY; GENE; ERYTHROCYTES; ORGANIZATION; APPEARANCE	The gene aquaporin-1 encodes channel-forming integral protein (CHIP), a member of a large family of water transporters found throughout nature. Three rare individuals were identified who do not express CHIP-associated Colton blood group antigens and whose red cells exhibit low osmotic water permeabilities. Genomic DNA analyses demonstrated that two individuals were homozygous for different nonsense mutations (exon deletion or frameshift), and the third had a missense mutation encoding a nonfunctioning CHIP molecule. Surprisingly, none of the three suffers any apparent clinical consequence, which raises questions about the physiologicai importance of CHIP and implies that other mechanisms may compensate for its absence.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213; GAMMA BIOL,HOUSTON,TX 77092	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033991, R37HL048268, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, R37DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1994, J CLIN INVEST, V94, P1050, DOI 10.1172/JCI117419; AGRE P, 1993, AM J PHYSIOL, V265, pF463; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CHRISPEELS MJ, 1994, J CELL BIOCH SA, V18, P80; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ENGEL A, 1994, CURR OPIN STRUC BIOL, V4, P545, DOI 10.1016/S0959-440X(94)90217-8; Finkelstein A., 1987, WATER MOVEMENT LIPID; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LACEY PA, 1987, TRANSFUSION, V27, P268, DOI 10.1046/j.1537-2995.1987.27387235637.x; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; OPPERMAN CH, 1994, SCIENCE, V263, P221, DOI 10.1126/science.263.5144.221; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, IN PRESS P NATL ACAD; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANOS CH, IN PRESS BIOCH BIOPH; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	34	251	257	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1585	1587		10.1126/science.7521540	http://dx.doi.org/10.1126/science.7521540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521540				2022-12-01	WOS:A1994PF33600037
J	WU, HH; WILLIAMS, CV; MCLOON, SC				WU, HH; WILLIAMS, CV; MCLOON, SC			INVOLVEMENT OF NITRIC-OXIDE IN THE ELIMINATION OF A TRANSIENT RETINOTECTAL PROJECTION IN DEVELOPMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RECEPTOR ANTAGONISTS DISRUPT; RETINAL GANGLION-CELLS; MOUSE CENTRAL NEURONS; NMDA RECEPTORS; INTERCELLULAR MESSENGER; ACTIVATED CHANNELS; NADPH DIAPHORASE; IMPULSE ACTIVITY; DEVELOPING CHICK	The adult pattern of axonal connections from the eye to the brain arises during development through the refinement of a roughly ordered set of connections. In the chick visual system, refinement normally results in the loss of the ipsilateral retinotectal connections. Inhibition of nitric oxide synthesis reduced the loss of these transient connections. Because nitric oxide is expressed by tectal cells with which retinal axons connect and because reduction of nitric oxide synthesis by tectal cells resulted in a change in the connections of retinal axons, nitric oxide probably serves as a messenger from tectal cells back to retinal axons during development.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL EYE INSTITUTE [R01EY005371, T32EY007133] Funding Source: NIH RePORTER; NEI NIH HHS [EY05371, EY07133] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1994, NEURON, V12, P155, DOI 10.1016/0896-6273(94)90160-0; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JESSELL TM, 1993, CELL 72 NEURON S, V10, P1; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MATTSON MP, 1987, J NEUROSCI, V7, P4034; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCLOON SC, 1982, EXP BRAIN RES, V45, P277; MCLOON SC, 1982, SCIENCE, V215, P1418, DOI 10.1126/science.7063855; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NELSON PG, 1989, SCIENCE, V244, P565; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Prusky G., 1992, Society for Neuroscience Abstracts, V18, P1311; REH TA, 1985, J NEUROSCI, V5, P1132; SANDELL JH, 1985, J COMP NEUROL, V238, P466, DOI 10.1002/cne.902380410; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WILLIAMS CV, 1991, J NEUROSCI, V11, P445; WU HH, IN PRESS SOC NEUR AB; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	53	210	213	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1593	1596		10.1126/science.7521541	http://dx.doi.org/10.1126/science.7521541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521541				2022-12-01	WOS:A1994PF33600040
J	SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A				SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A			IDENTIFICATION OF A TRANSLOCATED PROTEIN SEGMENT IN A VOLTAGE-DEPENDENT CHANNEL	NATURE			English	Article							COLICIN-E1 ION CHANNEL; PLANAR LIPID BILAYERS; HELICAL HAIRPIN; MEMBRANE; TOPOGRAPHY	VOLTAGE-GATED channels undergo a conformational change in response to changes in transmembrane voltage. Here we use site-directed biotinylation to create conformation-sensitive sites on colicin Ia, a bacteriocidal protein that forms a voltage-sensitive membrane channel, which can be monitored by electrophysiological methods(1,2). We investigated a model of gating developed for the partly homologous colicin E1 that is based on the insertion of regions of the protein into the membrane in response to cis-positive voltages(3-6). Site-directed cysteine mutagenesis, followed by chemical modification, was used to attach a biotin molecule covalently to a series of unique sites on colicin Ia. The modified protein was incorporated into planar lipid membranes, where the introduced biotin moiety served as a site to bind the water-soluble protein streptavidin, added to one side of the membrane or the other. Our results show that colicin gating is associated with the translocation across the membrane of a segment of the protein of at least 31 amino acids.			SLATIN, SL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461, USA.							ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DUCHE D, 1994, J BIOL CHEM, V269, P6332; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PATTUS F, 1990, EXPERIENTIA, V46, P180; QIU XQ, 1994, J BIOL CHEM, V269, P7483; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	19	153	157	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					158	161		10.1038/371158a0	http://dx.doi.org/10.1038/371158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7521016				2022-12-01	WOS:A1994PF19100064
J	PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF				PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF			TOWARDS A VACCINE FOR RHEUMATIC-FEVER - IDENTIFICATION OF A CONSERVED TARGET EPITOPE ON M-PROTEIN OF GROUP-A STREPTOCOCCI	LANCET			English	Article							GROUP-A STREPTOCOCCI; NUCLEOTIDE-SEQUENCE; PROTECTIVE IMMUNOGENICITY; MUCOSAL COLONIZATION; SYNTHETIC PEPTIDE; HEART-DISEASE; TYPE-5; IMMUNIZATION; SPECIFICITY; FRAGMENT	Rheumatic fever and rheumatic heart disease remain very common in developing countries, and a vaccine to protect against these disorders would have a great impact on public health. A vaccine must target the M protein of group A streptococci (Streptococcus pyogenes), but until lately immunity was thought to be strain-specific and dependent on antibodies to the variable serotype-specific regions of the protein. Experiments in animals have suggested the conserved region of the M protein as a possible alternative target for protective antibodies. We constructed a 20-aminoacid peptide (peptide 145) within the conserved region of the carboxyl terminus of the protein. In mice the peptide induced serum antibodies that could opsonise reference type 5 streptococci. By enzyme-linked immunosorbent assay, positive responses to peptide 145 were obtained with serum from 77 (90%) of 86 Aboriginal subjects and 135 (81%) of 167 Thai subjects living in areas with high exposure to streptococci. Only 10 (14%) of 71 Caucasian subjects with low exposure to streptococci showed positive responses. There was no difference in the proportion positive between subjects with rheumatic heart disease and control groups (other or no heart disease). Antibodies to peptide 145 were able to opsonise isolates of streptococci from Aboriginal and Thai subjects with acute rheumatic fever as well as reference strains. This highly conserved part of the M protein may be a suitable target for vaccines to prevent steptococcal infections and their sequelae.	QUEENSLAND INST MED RES,MOLEC IMMUNOL LAB,BRISBANE,QLD 4029,AUSTRALIA; MENZIES SCH HLTH RES,CASUARINA,NT,AUSTRALIA; INST ENVIRONM SCI & RES LTD,WELLINGTON,NEW ZEALAND; PRINCE CHARLES HOSP,BRISBANE,QLD 4032,AUSTRALIA; CHIANG MAI UNIV,DEPT PEDIAT,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,DEPT MED,CHIANG MAI 50000,THAILAND	QIMR Berghofer Medical Research Institute; Charles Darwin University; Menzies School of Health Research; Institute of Environmental Science & Research (ESR) - New Zealand; Prince Charles Hospital; Chiang Mai University; Chiang Mai University								BEACHEY EH, 1984, P NATL ACAD SCI-BIOL, V81, P2203, DOI 10.1073/pnas.81.7.2203; BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BEACHEY EH, 1986, J IMMUNOL, V136, P2287; BEACHEY EH, 1987, J EXP MED, V166, P647, DOI 10.1084/jem.166.3.647; BEACHEY EH, 1973, INFECT IMMUN, V8, P19, DOI 10.1128/IAI.8.1.19-24.1973; BEACHEY EH, 1988, VACCINE, V6, P192, DOI 10.1016/S0264-410X(88)80027-6; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BESSEN D, 1990, J IMMUNOL, V145, P1251; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; BRENNAN RE, 1990, MED J AUSTRALIA, V153, P335, DOI 10.5694/j.1326-5377.1990.tb136942.x; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; CURRIE B, 1993, MED J AUSTRALIA, V153, P609; DALE JB, 1986, J EXP MED, V163, P1191, DOI 10.1084/jem.163.5.1191; DALE JB, 1983, J EXP MED, V158, P1727, DOI 10.1084/jem.158.5.1727; Devanesen D, 1986, HLTH INDICATORS NO T; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOSE DG, 1969, AUST PAEDIATR J, V5, P209; LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525; MACDONALD KT, 1989, MED J AUSTRALIA, V150, P503, DOI 10.5694/j.1326-5377.1989.tb136596.x; MARTIN DR, 1983, NEW ZEAL MED J, V96, P298; MILLER L, 1988, J BIOL CHEM, V263, P5668; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; PHORNPHUTKUL C, 1981, CHIANG MAI MED B, V23, P275; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; PRUKSAKORN S, 1990, CHIANG MAI MED B, V29, P15; RELF WA, 1992, J CLIN MICROBIOL, V30, P3190, DOI 10.1128/JCM.30.12.3190-3194.1992; ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5; Shulman ST, 1984, CIRCULATION, V69, p203A; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; 1992, B WORLD HEALTH ORGAN, V70, P213	31	72	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					639	642		10.1016/S0140-6736(94)92083-4	http://dx.doi.org/10.1016/S0140-6736(94)92083-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7520963				2022-12-01	WOS:A1994PE38600008
J	LORSCH, JR; SZOSTAK, JW				LORSCH, JR; SZOSTAK, JW			IN-VITRO EVOLUTION OF NEW RIBOZYMES WITH POLYNUCLEOTIDE KINASE-ACTIVITY	NATURE			English	Article							STRANDED-DNA MOLECULES; INVITRO SELECTION; RNA ENZYME; CLEAVAGE; RECOGNITION; TETRAHYMENA; POLYMERASE; CATALYSIS; SEQUENCE; LIGANDS	We have isolated a large number of polynucleotide kinase ribozymes from a pool of RNA molecules consisting of an ATP-binding domain flanked by regions of random sequence. Different classes of kinases catalyse the transfer of the gamma-thiophosphate of ATP-gamma S to the 5'-hydroxyl or to internal 2'-hydroxyls. An engineered version of one class is able to catalyse the transfer of thiophosphate from ATP-gamma S to the 5'-hydroxyl of an exogenous oligoribonucleotide substrate with multiple turnover, thus acting as a true enzyme.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	LORSCH, JR (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA.			Lorsch, Jon/0000-0002-4521-4999				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRESLOW R, 1968, J AM CHEM SOC, V90, P7376, DOI 10.1021/ja01028a054; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DOMDEY H, 1979, ANAL BIOCHEM, V98, P346, DOI 10.1016/0003-2697(79)90152-0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; RAMIREZ F, 1980, J ORG CHEM, V45, P4748, DOI 10.1021/jo01311a038; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; ZAUG AJ, 1986, BIOCHEMISTRY-US, V25, P4478, DOI 10.1021/bi00364a002; ZIMMERMAN SB, 1981, ENZYMES, V14, P315	39	218	243	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					31	36		10.1038/371031a0	http://dx.doi.org/10.1038/371031a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7521014				2022-12-01	WOS:A1994PE38100041
J	PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R				PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R			USE OF A RAPID ASSAY OF SUBFORMS OF CREATINE-KINASE MB TO DIAGNOSE OR RULE OUT ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEST PAIN; INITIAL ELECTROCARDIOGRAM; MARATHON RUNNERS; SKELETAL-MUSCLE; ISOENZYME; PLASMA; EMERGENCY; ADMISSION; SERUM; UNIT	Background. Ruling out myocardial infarction in patients coming to the emergency room with chest pain is hindered by the lack of a specific early diagnostic marker. Less than 30 percent of patients admitted to coronary care units have infarction, resulting in substantial unnecessary expenditures. We developed a rapid assay of the subforms of creatine kinase MB (OK-MB) and prospectively analyzed its sensitivity and specificity in diagnosing myocardial infarction in the first six hours after the onset of chest pain. Methods. In 1110 consecutive patients who came to the emergency room with chest pain, blood samples were collected every 30 to 60 minutes until at least 6 hours after the onset of symptoms; in patients who were then admitted to the hospital, samples were collected every 4 hours for up to 48 hours. The samples were analyzed for CK-MB subforms, and the diagnosis of myocardial infarction was confirmed by conventional CK-MB analysis. Results. Of the 1110 patients evaluated, 121 had myocardial infarction. The sensitivity of the assay of OK-MB subforms to detect myocardial infarction in the first six hours after the onset of symptoms was 95.7 percent, as compared with only 48 percent for the conventional CK-MB assay; the specificity was 93.9 percent among patients hospitalized without myocardial infarction and 96.2 percent among those sent home. Among the patients with myocardial infarction, definitive results of the subform assay were available a mean (+/-SD) of 1.22+/-1.17 hours after their arrival in the emergency room. Conclusions. The assay of CK-MB subforms reliably detected myocardial infarction within the first six hours after the onset of symptoms, and its use could reduce admission to the coronary care unit by 50 to 70 percent, thereby reducing costs.	BAYLOR COLL MED, DEPT MED, CARDIOL SECT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, CRIT CARE SECT, HOUSTON, TX 77030 USA; CHRIST HOSP, DEPT MED, CARDIOL SECT, CINCINNATI, OH 45219 USA	Baylor College of Medicine; Baylor College of Medicine; Christ Hospital - Ohio					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNESLEY TM, 1985, CLIN CHEM, V31, P402; APPLE FS, 1986, CLIN CHEM, V32, P41; APPLE FS, 1984, CLIN CHEM, V30, P413; Armitage P, 1987, STAT METHODS MED RES, V2, P117; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; FESMIRE FM, 1989, ARCH INTERN MED, V149, P1294, DOI 10.1001/archinte.149.6.1294; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FRIEDMAN DL, 1993, CLIN CHEM, V39, P1598; GASPOZ JM, 1991, AM J CARDIOL, V68, P145, DOI 10.1016/0002-9149(91)90734-3; GEORGE S, 1984, J BIOL CHEM, V259, P2667; GIBLER WB, 1990, ANN EMERG MED, V19, P1359, DOI 10.1016/S0196-0644(05)82598-3; GIBLER WB, 1991, ANN EMERG MED, V20, P420; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRACE A, 1982, CLIN CHIM ACTA, V123, P59, DOI 10.1016/0009-8981(82)90114-0; GRENADIER E, 1983, AM HEART J, V105, P408, DOI 10.1016/0002-8703(83)90357-5; HENRY PD, 1975, CLIN CHEM, V21, P844; HEYNDRICKX GR, 1985, J AM COLL CARDIOL, V6, P1299, DOI 10.1016/S0735-1097(85)80216-3; JAFFE AS, 1986, CIRCULATION, V74, P105, DOI 10.1161/01.CIR.74.1.105; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; MARMOR A, 1981, AM J CARDIOL, V48, P603, DOI 10.1016/0002-9149(81)90137-5; MICHAEL LH, 1985, AM J PHYSIOL, V248, pH350, DOI 10.1152/ajpheart.1985.248.3.H350; MORELLI RL, 1983, CIRCULATION, V67, P1283, DOI 10.1161/01.CIR.67.6.1283; OHMAN EM, 1990, CIRCULATION, V82, P1073, DOI 10.1161/01.CIR.82.3.1073; PRAGER NA, 1992, J AM COLL CARDIOL, V20, P414, DOI 10.1016/0735-1097(92)90111-Y; PULEO PR, 1990, CIRCULATION, V82, P759, DOI 10.1161/01.CIR.82.3.759; PULEO PR, 1989, CLIN CHEM, V35, P1452; ROBERTS R, 1988, CHEST, V93, pS3; SELKER HP, 1989, AM J MED, V87, P491; STARK ME, 1987, ARCH INTERN MED, V147, P843, DOI 10.1001/archinte.147.5.843; TURI ZG, 1985, AM J CARDIOL, V55, P1463, DOI 10.1016/0002-9149(85)90954-3; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; WEVERS RA, 1978, CLIN CHIM ACTA, V86, P323, DOI 10.1016/0009-8981(78)90388-1; WU AHB, 1989, CLIN CHEM, V35, P1752; YASMINEH WG, 1978, CLIN CHEM, V24, P1985; YOUNG MJ, 1987, ARCH INTERN MED, V147, P1219, DOI 10.1001/archinte.147.7.1219; 1984, AM HEART ASS MONOGRA, V100, P77	40	245	251	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					561	566		10.1056/NEJM199409013310901	http://dx.doi.org/10.1056/NEJM199409013310901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	7702648				2022-12-01	WOS:A1994PD69900001
J	CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL				CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL			REGULATORY T-CELL CLONES INDUCED BY ORAL TOLERANCE - SUPPRESSION OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; DRIVEN BYSTANDER SUPPRESSION; IMMUNE-RESPONSES; TRANSGENIC MICE; EFFECTOR-CELLS; IGA PRODUCTION; LYMPHOCYTES; TOLERIZATION; ANTIGENS	Experimental autoimmune encephalomyelitis (EAE) is a cell-mediated autoimmune disease that serves as an animal model for multiple sclerosis. Oral administration of myelin basic protein (MBP) suppresses EAE by inducing peripheral tolerance. T cell clones were isolated from the mesenteric lymph nodes of SJL mice that had been orally tolerized to MBP. These clones were CD4(+) and were structurally identical to T helper cell type 1 (T(H)1) encephalitogenic CD4(+) clones in T cell receptor usage, major histocompatibility complex restriction, and epitope recognition. However, they produced transforming growth factor-beta with various amounts of interleukin-4 and interleukin-10 and suppressed EAE induced with either MBP or proteolipid protein. Thus, mucosally derived T(H)2-like clones induced by oral antigen can actively regulate immune responses in vivo and may represent a different subset of T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030843, R01NS030843, R37NS030843, R01NS029352] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR/A143220] Funding Source: Medline; NINDS NIH HHS [NS30843, NS29352] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSABBAGH A, IN PRESS EUR J IMMUN; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chen Y, UNPUB; CHEN YH, 1994, J IMMUNOL, V152, P3; CHIN YH, 1992, J IMMUNOL, V148, P1106; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; FRIEDMAN R, 1994, P NATL ACAD SCI USA, V91, P6688; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GERSHON RK, 1970, IMMUNOLOGY, V18, P723; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREGERSON DS, 1993, J IMMUNOL, V151, P5751; JENKINS MK, 1990, J IMMUNOL, V144, P16; KARPUS WJ, 1992, EUR J IMMUNOL, V22, P1757, DOI 10.1002/eji.1830220714; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KIM PH, 1990, J IMMUNOL, V144, P3411; LIDER O, 1989, J IMMUNOL, V142, P748; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1993, J IMMUNOL, V151, P7307; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; PRABHUDAS M, UNPUB; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; YAMAMURA M, 1991, SCIENCE, V254, P5029	39	1641	1719	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1237	1240		10.1126/science.7520605	http://dx.doi.org/10.1126/science.7520605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520605				2022-12-01	WOS:A1994PD42200039
J	FINCK, BK; LINSLEY, PS; WOFSY, D				FINCK, BK; LINSLEY, PS; WOFSY, D			TREATMENT OF MURINE LUPUS WITH CTLA4IG	SCIENCE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; MONOCLONAL-ANTIBODY; CTLA-4; CD28; ANTIGEN; LIGAND; RECEPTOR; INTERLEUKIN-2; PROLIFERATION	The interaction of B7-related molecules on antigen-presenting cells with CD28 or CTLA-4 antigens on T cells provides a second signal for T cell activation. Selective inhibition of the B7-CD28 or B7-CTLA-4 interactions produces antigen-specific T cell unresponsiveness in vitro and suppresses immune function in vivo. To determine whether selective inhibition of the B7-CD28 or B7-CTLA-4 interactions could suppress spontaneous autoimmune disease, a B7-binding protein was generated by genetic fusion of the extracellular domain of murine CTLA-4 to the Fe portion of a mouse immunoglobulin G2a monoclonal antibody (muCTLA4lg). In lupus-prone NZB/NZW filial generation (F-1) mice, treatment with muCTLA4lg blocked autoantibody production and prolonged life, even when treatment was delayed until the most advanced stage of clinical illness. These findings suggest a possible role for human CTLA4lg in the treatment of autoimmune diseases in humans.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; VET ADM MED CTR,SAN FRANCISCO,CA 94121; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Bristol-Myers Squibb								AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; FELL HP, 1992, J BIOL CHEM, V267, P15552; FINCK BK, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Isaacs J D, 1990, Semin Immunol, V2, P449; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEDBETTER JA, 1990, BLOOD, V75, P1531; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MORELAND LW, 1994, ARTHRITIS RHEUM, V37, P834, DOI 10.1002/art.1780370610; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NORTON SD, 1992, J IMMUNOL, V149, P1556; RONCHESE F, 1994, J EXP MED, V179, P809, DOI 10.1084/jem.179.3.809; STEINBERG AD, 1991, ANN INTERN MED, V115, P548, DOI 10.7326/0003-4819-115-7-548; SWAIN SL, 1984, J IMMUNOL, V132, P1118; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALLACE PM, IN PRESS TRANSPLANTA; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	26	629	695	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1225	1227		10.1126/science.7520604	http://dx.doi.org/10.1126/science.7520604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520604				2022-12-01	WOS:A1994PD42200035
J	LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J				LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J			CYTOLYTIC T-CELL CYTOTOXICITY IS MEDIATED THROUGH PERFORIN AND FAS LYTIC PATHWAYS	NATURE			English	Article							LYMPHOCYTES-T; APOPTOSIS; ANTIBODY; MICE	THE recent generation of perforin knock-out mice(1,2) has demonstrated a crucial role for the pore-forming perforin in cytolytic T-lymphocyte (CTL)-mediated cytolysis. Perforin-deficient mice failed to clear lymphocytic choriomeningitis virus in vivo, yet substantial killing activity still remained in perforin-free CTLs in vitro, indicating the presence of (a) further lytic pathway(s). Fas is an apoptosis-signalling receptor molecule on the surface of a number of different cells. Here we report that both perforin-deficient and Fas-ligand-deficient CTLs show impaired lytic activity on all target cells tested, The killing activity was completely abolished when both pathways were inactivated by using target cells from Fas-receptor-deficient lpr mice and perforin-free CTL effector cells. Fas-ligand-based killing activity was triggered upon T-cell receptor occupancy and was directed to the cognate target cell. Thus, two complementary, specific cytotoxic mechanisms are functional in CTLs, one based on the secretion of lytic proteins and one which depends on cell-surface ligand-receptor interaction.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne								CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, P3121; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; ITOH N, 1993, J EXP MED, V178, P461; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KUPFER A, 1986, J EXP MED, V163, P489, DOI 10.1084/jem.163.3.489; LOWIN B, IN PRESS P NATN ACAD; MARYANSKI JL, 1980, J IMMUNOL, V124, P42; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421	19	961	980	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					650	652		10.1038/370650a0	http://dx.doi.org/10.1038/370650a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	7520535				2022-12-01	WOS:A1994PD31000050
J	EVANS, P; GRAY, DP				EVANS, P; GRAY, DP			VALUE OF SCREENING FOR SECONDARY CAUSES OF HYPERLIPIDEMIA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, P (corresponding author), UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BRUNZELL JD, 1988, CECIL TXB MED, P1143; Gray D J, 1979, J R Coll Gen Pract, V29, P666; LEWIS B, 1987, OXFORD TXB MED, V9, P111; 1992, 55 ROYAL COLL GEN PR; 1988, EUR HEART J, V9, P571	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					509	510		10.1136/bmj.309.6953.509	http://dx.doi.org/10.1136/bmj.309.6953.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	7755687	Green Published			2022-12-01	WOS:A1994PD30800018
J	PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC				PATEL, P; MENDALL, MA; KHULUSI, S; MOLINEAUX, N; LEVY, J; MAXWELL, JD; NORTHFIELD, TC			SALIVARY ANTIBODIES TO HELICOBACTER-PYLORI - SCREENING DYSPEPTIC PATIENTS BEFORE ENDOSCOPY	LANCET			English	Note								Diagnostic tests on saliva have advantages compared with those on serum. In 119 consecutive dyspeptic patients referred for endoscopy we developed and validated an enzyme-linked immunosorbent assay to detect salivary immunoglobulins to Helicobacter pylori. Salivary IgG distinguished positive and negative cases (p < 0.0001), but salivary IgA did not. The optimum performance of salivary IgG (85%) was similar to that of serum IgG (90%) and better than that of salivary IgA. Using our assay and a history of regular use of non-steroidal anti-inflammatories in screening patients under 45 years, we detected all peptic ulcers while saving 39% of endoscopies.	UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT MED,LONDON SW17 0RE,ENGLAND	St Georges University London								ALEMOHAMMAD MM, 1993, J CLIN MICROBIOL, V31, P2174, DOI 10.1128/JCM.31.8.2174-2177.1993; HOLDSTOCK G, 1979, BRIT MED J, V1, P457, DOI 10.1136/bmj.1.6161.457; MARSHALL BJ, 1984, LANCET, V1, P1311; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; PARRY JV, 1987, LANCET, V2, P72, DOI 10.1016/S0140-6736(87)92737-1; PATEL P, 1993, GUT, V34, pS36; RATHBONE BJ, 1986, GUT, V27, P642, DOI 10.1136/gut.27.6.642; WILLIAMS B, 1988, LANCET, V2, P1349; 1993, LANCET, V341, P1359; 1988, LANCET, V1, P576	10	95	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					511	512		10.1016/S0140-6736(94)91899-6	http://dx.doi.org/10.1016/S0140-6736(94)91899-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7802777				2022-12-01	WOS:A1994PC53500010
J	KLOC, M; ETKIN, LD				KLOC, M; ETKIN, LD			DELOCALIZATION OF VG1 MESSENGER-RNA FROM THE VEGETAL CORTEX IN XENOPUS-OOCYTES AFTER DESTRUCTION OF XLSIRT RNA	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; CELL-FORMATION; LAEVIS; ABLATION; PROTEIN; EMBRYOS; NANOS; XLGV7; OSKAR; EGGS	The Xlsirts are a family of transcribed repeat sequence genes that do not code for protein. Xlsirt RNAs become localized to the vegetal cortex of Xenopus oocytes early in oogenesis, before the localization of the messenger RNA Vg1, which encodes a transforming growth factor-beta-like molecule involved in mesoderm formation, and coincident with the localization of Xcat2 transcripts, which encode a nanos-like molecule. Destruction of the localized Xlsirts by injection of antisense oligodeoxynucleotides into stage 4 oocytes resulted in the release of Vg1 transcripts but not Xcat2 transcripts from the vegetal cortex. Xlsirt RNAs, which may be a structural component of the vegetal cortex, are a crucial part of a genetic pathway necessary for the proper localization of Vg1 that leads to subsequent normal pattern formation.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Kloc, Malgorzata/AAF-6982-2020					DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; King Jr Martin Luther, COMMUNICATION; KLOC M, 1989, DEVELOPMENT, V107, P899; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KLOC M, UNPUB; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MORGAN R, 1993, NUCLEIC ACIDS RES, V21, P4615, DOI 10.1093/nar/21.19.4615; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH RC, 1990, DEVELOPMENT, V110, P769; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	128	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1101	1103		10.1126/science.7520603	http://dx.doi.org/10.1126/science.7520603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	7520603				2022-12-01	WOS:A1994PC53900039
J	BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W				BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W			INSURANCE-RELATED DIFFERENCES IN THE RISK OF RUPTURED APPENDIX	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEE-FOR-SERVICE; RANDOMIZED CONTROLLED TRIAL; HEALTH-INSURANCE; RESOURCE UTILIZATION; HOSPITAL PATIENTS; PRENATAL-CARE; MEDICAL-CARE; MASSACHUSETTS; COVERAGE; OUTCOMES	Background. We studied differences in the incidence of appendiceal perforation in patients with acute appendicitis according to their insurance coverage. Methods. In a retrospective analysis of hospital-discharge data, we examined the likelihood of ruptured appendix among adults 18 to 64 years old who were hospitalized for acute appendicitis in California from 1984 to 1989. Results. After controlling for age, sex, psychiatric diagnoses, substance abuse, diabetes, poverty, race or ethnic group, and hospital characteristics, we found that ruptured appendix was more likely among both Medicaid-covered and uninsured patients with appendicitis than among patients with private capitated coverage (odds ratios, 1.49 [95 percent confidence interval, 1.41 to 1.59] and 1.46 [95 percent confidence interval, 1.39 to 1.54], respectively). After adjustment for the above factors, the risk of appendiceal rupture associated with a lack of private in-surance was elevated at both county and other hospitals, but admission to a county hospital was an independent risk factor. In all income groups, appendiceal rupture was more likely with fee-for-service than capitated private coverage (overall odds ratio, 1.20 [95 percent confidence interval, 1.15 to 1.25]). Conclusions. Among patients with appendicitis an increased risk of ruptured appendix may be due to insurance-related delays in obtaining medical care. Both organizational and financial features of Medicaid and various types or levels of private third-party coverage may be involved. The significant association between ruptured appendix and insurance coverage after adjustment for socioeconomic differences suggests barriers to receiving medically necessary acute care that should be considered in current deliberations on health policy.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,DEPT MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT SURG,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.							ADAY LA, 1984, ACCESS MED CARE; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BILLINGS J, 1990, CONSIDERATION USE SM; BLUMBERG MS, 1991, 169504 HOSP RES ED T; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; BRENDER JD, 1985, PEDIATRICS, V76, P301; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BUCHMAN TG, 1984, SURG GYNECOL OBSTET, V158, P260; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FOSSETT JW, 1992, J HEALTH POLIT POLIC, V17, P273, DOI 10.1215/03616878-17-2-273; FOSSETT JW, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350079; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HUTTON N, 1985, EFFECTIVENESS MED CA, P120; KLEIN SR, 1988, POSTGRAD MED, V83, P247; LUCKMANN R, 1990, AM J EPIDEMIOL, V131, P1102; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Pieper R, 1986, Acta Chir Scand Suppl, V530, P51; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; RICCI MA, 1988, AM SURGEON, V54, P273; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHER KS, 1980, SURG GYNECOL OBSTET, V150, P535; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WAY LW, 1988, CURRENT SURGICAL DIA, P556; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; 1991, INT CLASSIFICATION D; 1985, SAS USERS GUIDE STAT; 1989, 1989 1990 DIRECTORY	50	195	196	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					444	449		10.1056/NEJM199408183310706	http://dx.doi.org/10.1056/NEJM199408183310706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB501	7880234	Bronze			2022-12-01	WOS:A1994PB50100006
J	LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A				LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A			THE PROGNOSTIC VALUE OF C-REACTIVE PROTEIN AND SERUM AMYLOID-A PROTEIN IN SEVERE UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ACUTE-PHASE RESPONSE; A-PROTEIN; NATURAL-HISTORY; SILENT ISCHEMIA; INFLAMMATION; MACROPHAGES	Background. The pathogenesis of unstable angina is poorly understood, and predicting the prognosis is problematic. Evidence suggests that there may be active inflammation, possibly in the coronary arteries, in this syndrome. We therefore studied the prognostic value of measurements of the circulating acute-phase reactants C-reactive protein and serum amyloid A protein, which are sensitive indicators of inflammation. Methods. We measured C-reactive protein, serum amyloid A protein, creatine kinase, and cardiac troponin T in 32 patients with chronic stable angina, 31 with severe unstable angina, and 29 with acute myocardial infarction. Results. At the time of hospital admission, creatine kinase and cardiac troponin T levels were normal in all the patients, but the levels of C-reactive protein and serum amyloid A protein were greater than or equal to 0.3 mg per deciliter (exceeding the 90th percentile of the normal distribution) in 4 of the patients with stable angina (13 percent), 20 of the patients with unstable angina (65 percent), and 22 of the patients with acute myocardial infarction (76 percent). The 20 patients with unstable angina who had levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter had more ischemic episodes in the hospital than those with levels <0.3 mg per deciliter (mean [+/-SD] number of episodes per patient, 4.8+/-2.5 vs. 1.8+/-2.4; P = 0.004); 5 patients subsequently had a myocardial infarction, 2 died, and 12 required immediate coronary revascularization. In contrast, no deaths or myocardial infarction occurred among the 11 patients with levels of acute-phase reactants <0.3 mg per deciliter, and only 2 of them required coronary revascularization. Among the patients admitted with a diagnosis of acute myocardial infarction, unstable angina preceded infarction in 14 of the 22 patients (64 percent) with levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter but in none of the 7 patients with levels <0.3 mg per deciliter. Conclusions. Elevation of C-reactive protein and serum amyloid A protein at the time of hospital admission predicts a poor outcome in patients with unstable angina and may reflect an important inflammatory component in the pathogenesis of this condition.	UNIV CATTOLICA SACRO CUORE, IST MICROBIOL, ROME, ITALY; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, LONDON, ENGLAND	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	LIUZZO, G (corresponding author), UNIV CATTOLICA SACRO CUORE, IST CARDIOL, LARGO AGOSTINO GEMELLI 8, I-00168 ROME, ITALY.		LIUZZO, GIOVANNA/J-8090-2018	LIUZZO, GIOVANNA/0000-0002-5714-0907; biasucci, luigi m/0000-0002-6921-6497				ANDREOTTI F, 1990, J AM COLL CARDIOL, V16, P1553, DOI 10.1016/0735-1097(90)90300-E; Baroldi G, 1988, Am J Cardiovasc Pathol, V2, P159; BAUSSERMAN LL, 1989, CLIN CHIM ACTA, V184, P297, DOI 10.1016/0009-8981(89)90063-6; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; CARRY M, 1992, CIRCULATION, V85, P230, DOI 10.1161/01.CIR.85.1.230; CIABATTONI G, 1993, J AM COLL CARDIOL, V21, P1377, DOI 10.1016/0735-1097(93)90312-O; DEBEER FC, 1982, BRIT HEART J, V47, P239; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P756, DOI 10.1016/S0735-1097(87)80267-X; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; JUHANVAGUE I, 1989, ARTERIOSCLEROSIS, V9, P362, DOI 10.1161/01.ATV.9.3.362; KOHCHI K, 1985, CIRCULATION, V71, P709, DOI 10.1161/01.CIR.71.4.709; KUSHNER I, 1978, J CLIN INVEST, V61, P235, DOI 10.1172/JCI108932; LANGER A, 1989, J AM COLL CARDIOL, V13, P1495, DOI 10.1016/0735-1097(89)90338-0; LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130; MARHAUG G, 1986, ACTA MED SCAND, V220, P303; MAURY CPJ, 1988, J CLIN PATHOL, V41, P1263, DOI 10.1136/jcp.41.12.1263; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SATO T, 1987, ATHEROSCLEROSIS, V68, P191, DOI 10.1016/0021-9150(87)90198-5; SERNERI GGN, 1992, CIRCULATION, V86, P790, DOI 10.1161/01.CIR.86.3.790; SHAINKINKESTENBAUM R, 1986, J CLIN PATHOL, V39, P635, DOI 10.1136/jcp.39.6.635; SHINE B, 1981, CLIN CHIM ACTA, V117, P13, DOI 10.1016/0009-8981(81)90005-X; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; WALLSH E, 1986, TEX HEART I J, V13, P105; WILKINS J, 1994, CLIN CHEM, V40, P1284; YOSHIMOTO T, 1992, J IMMUNOL, V148, P3596; 1987, WHO TECH REP SER, V760, P21	35	1925	2049	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					417	424		10.1056/NEJM199408183310701	http://dx.doi.org/10.1056/NEJM199408183310701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	7880233				2022-12-01	WOS:A1994PB50100001
J	PALLER, AS				PALLER, AS			HISTOLOGY OF LIPOID PROTEINOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							METABOLISM; INVITRO; SKIN				PALLER, AS (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL, USA.							BAUER EA, 1981, J INVEST DERMATOL, V76, P119, DOI 10.1111/1523-1747.ep12525454; FLEISCHMAJER R, 1984, J INVEST DERMATOL, V82, P252, DOI 10.1111/1523-1747.ep12260200; FLEISCHMAJER R, 1969, J INVEST DERMATOL, V52, P495, DOI 10.1038/jid.1969.84; HARPER JI, 1985, BRIT J DERMATOL, V113, P145, DOI 10.1111/j.1365-2133.1985.tb02056.x; MOY LS, 1987, J AM ACAD DERMATOL, V16, P1193, DOI 10.1016/S0190-9622(87)70157-1; NEWTON JA, 1991, CLIN EXP DERMATOL, V16, P350, DOI 10.1111/j.1365-2230.1991.tb00399.x; OLSEN DR, 1988, J INVEST DERMATOL, V90, P734, DOI 10.1111/1523-1747.ep12560934; SHORE RN, 1974, ARCH DERMATOL, V110, P591, DOI 10.1001/archderm.110.4.591	8	14	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	565						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	7519275				2022-12-01	WOS:A1994PB22900039
J	ARAFAH, BM				ARAFAH, BM			DECREASED LEVOTHYROXINE REQUIREMENT IN WOMEN WITH HYPOTHYROIDISM DURING ANDROGEN THERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; HYPOTHYROIDISM; LEVOTHYROXINE; ANDROGENS; FLUOHOMESTERONE	THYROXINE-BINDING GLOBULIN; NORMAL MEN; ESTROGEN	Objective: To determine the effects of androgen administration on measures of thyroid function and thyroid hormone replacement doses in women with breast cancer. Design: Consecutive patients with metastatic, hormone-dependent breast cancer who were eligible for androgen treatment. Interventions: Androgen therapy (fluoxymesterone, 10 mg orally twice daily) was continued for as long as it was effective in controlling tumor growth. Patients: 7 patients with no known thyroid disease and 4 others receiving long-term treatment for hypothyroidism. Measurements: Serum levels of total and free thyroxine (T-4), thyroid-stimulating hormone (TSH), and T-4-binding globulin were determined before and every 4 weeks after androgen therapy was initiated. Results: Within 4 weeks of androgen administration to the seven patients without thyroid disease, serum levels of total T-4 and T-4-binding globulin decreased (P < 0.001), whereas the calculated free thyroxine index and measured free hormone levels remained unchanged. Six to 12 weeks after androgen therapy was discontinued, all seven patients remained clinically euthyroid, and serum levels returned to baseline values. In contrast, clinical hyperthyroidism developed shortly after androgen was administered to four patients who received long-term thyroid hormone replacement therapy. Within 4 weeks of treatment, the serum free T-4 level increased in each of the four patients, whereas the TSH level decreased. Thyroid hormone doses had to be reduced by 25% to 50% to maintain euthyroidism. Conclusions: The study documents the reversible effects of androgens on thyroid hormone levels and indicates the need to reduce thyroid replacement doses in women during androgen therapy. Monitoring thyroid hormone levels in patients receiving replacement therapy and perhaps in those with autonomous thyroid function is necessary after androgen therapy.			ARAFAH, BM (corresponding author), UNIV CLEVELAND HOSP, DIV CLIN & MOLEC ENDOCRINOL, 11100 EUCLID AVE, ROOM 3128 LAKESIDE, CLEVELAND, OH 44106 USA.							AIN KB, 1987, J CLIN ENDOCR METAB, V65, P689, DOI 10.1210/jcem-65-4-689; BRAVERMA.LE, 1968, J CLIN ENDOCR METAB, V28, P831, DOI 10.1210/jcem-28-6-831; BRAVERMAN LE, 1967, J CLIN ENDOCR METAB, V27, P389, DOI 10.1210/jcem-27-3-389; CAMPBELL MJ, 1989, BRIT MED J, P71; FEDERMAN DD, 1958, J CLIN INVEST, V37, P1024, DOI 10.1172/JCI103683; FELDMAN EB, 1960, J CLIN ENDOCR METAB, V20, P842, DOI 10.1210/jcem-20-6-842; KIRSCHNE.MA, 1972, ACTA ENDOCRINOL-COP, V70, P342, DOI 10.1530/acta.0.0700342; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MANNI A, 1981, CANCER, V48, P2507, DOI 10.1002/1097-0142(19811201)48:11<2507::AID-CNCR2820481127>3.0.CO;2-E; MORLEY JE, 1981, J CLIN ENDOCR METAB, V52, P173, DOI 10.1210/jcem-52-2-173; REFETOFF S, 1976, J CLIN INVEST, V57, P485, DOI 10.1172/JCI108301; Robbins J, 1978, Recent Prog Horm Res, V34, P477; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181	16	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					247	251		10.7326/0003-4819-121-4-199408150-00002	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518657				2022-12-01	WOS:A1994PB10200002
J	GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML				GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML			EFFICACY AND SAFETY OF CONTROLLED-RELEASE NIACIN IN DYSLIPOPROTEINEMIC VETERANS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERLIPIDPROTEINEMIA; NIACIN; DELAYED-ACTION PREPARATIONS; HEPATITIS, TOXIC; DIABETES MELLITUS	DENSITY-LIPOPROTEIN CHOLESTEROL; NICOTINIC-ACID; HEPATIC-FAILURE; DRUG; THERAPY; TRIGLYCERIDES; MECHANISM; INGESTION; BENEFIT; RATIO	Objective: To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia. Design: A retrospective cohort study. Setting: A Department of Veterans Affairs Medical Center. Patients: A consecutive sample of 969 predominantly elderly male veterans treated for dyslipoproteinemia with controlled-release niacin between October 1988 and October 1991. Main Outcome Measures: Primary outcomes were lipid levels and lipoprotein cholesterol response, alterations in levels of hepatic enzymes and blood chemistry test results, and characterization of niacin-induced hepatotoxicity abstracted from the patient's medical, laboratory, and pharmacy records. Results: 93% (896 of 969) of the cohort was evaluable. Patients (age, 61.7 years [9.4 years], mean [SD]) were treated for 1 to 36 months (13.0 months [9.7 months]) with an average maintenance dose of 1.67 g/d (0.8 g/d). Niacin was discontinued in 48.5% (435 of 896) of the patients primarily because of adverse effects. Poor glycemic control led to discontinuation in 40.6% (43 of 106) of the patients with diabetes mellitus. The lipoprotein response was dose-related and favorable (levels of total cholesterol, -19.10/b; low-density lipoprotein cholesterol, -24.0%; high-density lipoprotein cholesterol, +5.7%; and triglycerides, -32.5%). Statistically but not clinically meaningful dose-related increases were seen in levels of liver enzymes and serum glucose (aspartate aminotransferase, +29%; alanine aminotransferase, +23%; alkaline phosphatase, +25%; and glucose, +7%; P= 0.0001). Twenty of 896 (12.2%) and 42 of 896 (4.7%) patients met biochemical criteria for probable and for possible or probable niacin-induced hepatotoxicity, respectively. Predisposing factors included high dose, alcohol use, preexisting liver disease, and concurrent oral sulfonylurea therapy. Conclusions: Controlled-release niacin is effective in treating dyslipoproteinemia in selected middle-aged and elderly veterans, but approximately one half of patients discontinued the drug because of adverse effects or other causes including noncompliance. Niacin should be avoided in patients with hepatic dysfunction or a history of liver disease, patients with diabetes mellitus, and patients who abuse alcohol. Because controlled-release niacin seems to be more potent than crystalline niacin, product substitution without dose adjustment should be avoided.	UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	GRAY, DR (corresponding author), VET AFFAIRS MED CTR 119, 5901 E 7TH ST, LONG BEACH, CA 90822 USA.			Kashyap, Moti/0000-0002-0052-8302				ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CHRISTENSEN N, 1961, JAMA-J AM MED ASSOC, V177, P546, DOI 10.1001/jama.1961.03040340010003; ETCHASON JA, 1991, MAYO CLIN PROC, V66, P23, DOI 10.1016/S0025-6196(12)61171-9; FERENCHICK G, 1989, AM J MED SCI, V298, P191, DOI 10.1097/00000441-198909000-00009; FIGGE HL, 1988, PHARMACOTHERAPY, V8, P287; FIGGE HL, 1988, J CLIN PHARMACOL, V28, P1136, DOI 10.1002/j.1552-4604.1988.tb05731.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GARG A, 1990, JAMA-J AM MED ASSOC, V264, P723, DOI 10.1001/jama.264.6.723; GRUNDY SM, 1981, J LIPID RES, V22, P24; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HENKIN Y, 1991, AM J MED, V91, P239, DOI 10.1016/0002-9343(91)90122-E; HENKIN Y, 1990, JAMA-J AM MED ASSOC, V264, P241, DOI 10.1001/jama.264.2.241; HODIS HN, 1990, JAMA-J AM MED ASSOC, V264, P181, DOI 10.1001/jama.1990.03450020033012; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LASAGNA L, 1994, JAMA-J AM MED ASSOC, V271, P709, DOI 10.1001/jama.271.9.709; LAVIE CJ, 1992, AM J CARDIOL, V69, P1083, DOI 10.1016/0002-9149(92)90868-Y; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MULLIN GE, 1989, ANN INTERN MED, V111, P253, DOI 10.7326/0003-4819-111-3-253; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NEUVONEN PJ, 1991, BRIT J CLIN PHARMACO, V32, P473, DOI 10.1111/j.1365-2125.1991.tb03933.x; PARSONS WB, 1961, ARCH INTERN MED, V107, P653, DOI 10.1001/archinte.1961.03620050019003; SQUIRES RW, 1992, MAYO CLIN PROC, V67, P855, DOI 10.1016/S0025-6196(12)60824-6; STERN RH, 1991, CLIN PHARMACOL THER, V50, P66, DOI 10.1038/clpt.1991.104	31	47	49	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					252	258		10.7326/0003-4819-121-4-199408150-00003	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7741833				2022-12-01	WOS:A1994PB10200003
J	KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC				KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC			DIDANOSINE RESISTANCE IN HIV-INFECTED PATIENTS SWITCHED FROM ZIDOVUDINE TO DIDANOSINE MONOTHERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; DRUG RESISTANCE; ZIDOVUDINE; DIDANOSINE; ANTIGENS, CD4	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; POLYMERASE CHAIN-REACTION; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; REDUCED SENSITIVITY; TYPE-1; MUTATIONS; AZT; RNA	Objective: To determine the frequency and pattern of development of specific drug resistance mutations for human immunodeficiency virus (HIV) reverse transcriptase in patients switched from zidovudine to didanosine therapy and to examine the relation of the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene to CD4(+) T-cell changes and virus burden. Design: Retrospective analysis of all patients enrolled at Stanford University in protocols where patients were switched from zidovudine to didanosine monotherapy. Setting: A university hospital. Patients: 64 patients infected with HIV who were switched from zidovudine to didanosine monotherapy. Patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex, or were asymptomatic (mean [+/-SD] starting CD4(+) T-cell count of 129 +/- 88 cells/mm(3)). Measurements: Serial serum specimens were tested for the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene and for a zidovudine resistance mutation at codon 215 using selective polymerase chain reactions (PCR). Serum HIV RNA levels were determined by quantitative PCR. CD4(+) T-cell counts were determined at serial time points. Results: By 24 weeks of didanosine therapy, the proportion of patients with the didanosine resistance mutation at codon 74 increased from 0% to 56% (36 of 64). In contrast, the proportion of patients with the zidovudine resistance mutation at codon 215 decreased from 84% at the start to 59% after 24 weeks of didanosine therapy (a 25% decrease, 95% lower CI, 15%; P < 0.0001). Patients who developed the codon 74 mutation had a greater decrease in CD4(+) T cells after the development of the mutation than did patients without the mutation (P < 0.001). In addition, after 24 weeks of didanosine, patients who developed the codon 74 mutation had a greater serum HIV RNA burden than patients who remained wild type (did not have the mutation) at codon 74 (225 000 compared with 82 400 HIV RNA copies/mL serum; P = 0.01). Conclusions: Among patients infected with HIV who had advanced disease and were switched from zidovudine to didanosine therapy, more than one half developed the didanosine resistance mutation at codon 74 by 24 weeks of didanosine therapy. Patients who developed the codon 74 mutation had a greater decline in CD4(+) T cells after the development of the mutation and had a greater serum virus burden than did patients without the codon 74 mutation.			KOZAL, MJ (corresponding author), STANFORD UNIV, MED CTR, DIV INFECT DIS, ROOM S-156, STANFORD, CA 94305 USA.		Merigan, Thomas/AGQ-7464-2022	, Michael/0000-0002-7719-7396; katzenstein, david/0000-0002-8593-4560; Kozal, Michael/0000-0002-3100-8254	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027666, P30AI027762] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27666, AI-27762] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAQUILA RT, 1993, 1ST NAT C HUM RETR R; DAVEY RT, 1993, P NATL ACAD SCI USA, V90, P5608, DOI 10.1073/pnas.90.12.5608; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPPES JC, 1992, 8 INT C AIDS AMST; KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MAYERS DL, 1993, 1ST NAT C HUM RETR R; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; REICHMAN RC, 1993, ANTIVIR RES, V20, P267, DOI 10.1016/0166-3542(93)90071-P; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMAN DD, 1992, 8 INT C AIDS AMST, P3576; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1989, LANCET, V1, P983; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; Winters M A, 1992, PCR Methods Appl, V1, P257; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993	34	60	61	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					263	268		10.7326/0003-4819-121-4-199408150-00005	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518658				2022-12-01	WOS:A1994PB10200005
J	MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR				MUIR, KW; SQUIRE, IB; ALWAN, W; LEES, KR			ANTICARDIOLIPIN ANTIBODIES IN AN UNSELECTED STROKE POPULATION	LANCET			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL-ISCHEMIA; ANTI-CARDIOLIPIN; ASSOCIATION; THROMBOSIS; INFARCTION; COAGULATION; PREVALENCE; FEATURES	A pathogenetic role in thrombotic disease, particularly in young people, has been postulated for anticardiolipin antibody (ACA). We have carried out a prospective controlled study of 262 unselected patients with acute stroke and 226 controls to assess the prevalence and relation to age and vascular risk factors of ACA. Titres of IgG, IgA, or IgM ACA were above the upper normal limit in 38% of patients. The proportions of patients and controls with raised titres did not differ significantly (13 vs 8% IgG, 22 vs 29% IgA, 11 vs 7% IgM). IgG titres were higher among patients than among controls (mean 3.88 vs 2.86 u/mL [95% CI for difference 0.62-0.87], p=0.0004), whereas IgA and IgM titres were lower in patients than in controls (IgA 4.82 vs 5.98 u/mL [1.12-1.60], p = 0.01; IgM 3.00 vs 3.64 u/mL [1.01-1.45], p = 0.04). However, within age tertiles the only significant difference between patients and controls for IgG ACA was in the oldest tertile. Analysis by number of risk factors for stroke showed a significant difference between the groups only for subjects with one risk factor. IgA and IgM ACA titres were higher among controls only in those with no vascular risk factors.	UNIV GLASGOW,WESTERN INFIRM,DEPT IMMUNOL,GLASGOW G11 6NT,SCOTLAND	University of Glasgow	MUIR, KW (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,SCOTLAND.		Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X				ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1992, ANN RHEUM DIS, V51, P147, DOI 10.1136/ard.51.2.147; BABIKIAN VL, 1990, STROKE, V21, P1268; BABIKIAN VL, 1992, STROKE S1, V23, P133; BAKIMER R, 1992, J CLIN INVEST, V89, P1558, DOI 10.1172/JCI115749; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CHAKRAVARTY KK, 1991, Q J MED, V79, P397; CHANCELLOR AM, 1991, J NEUROL, V238, P401, DOI 10.1007/BF00319860; CZLONKOWSKA A, 1992, ACTA NEUROL SCAND, V86, P304, DOI 10.1111/j.1600-0404.1992.tb05090.x; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; GREAVES M, 1993, J NEUROL NEUROSUR PS, V56, P433, DOI 10.1136/jnnp.56.5.433; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1990, AM J CLIN PATHOL, V94, P476, DOI 10.1093/ajcp/94.4.476; HART RG, 1984, STROKE, V15, P114, DOI 10.1161/01.STR.15.1.114; HESS DC, 1991, NEUROLOGY, V41, P525, DOI 10.1212/WNL.41.4.525; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; KUSHNER MJ, 1990, STROKE, V21, P295, DOI 10.1161/01.STR.21.2.295; LEVINE SR, 1990, NEUROLOGY, V40, P1181, DOI 10.1212/WNL.40.8.1181; MANOUSSAKIS MN, 1987, CLIN EXP IMMUNOL, V69, P557; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MONTALBAN J, 1991, STROKE, V22, P750, DOI 10.1161/01.STR.22.6.750; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NENCINI P, 1992, STROKE, V23, P189, DOI 10.1161/01.STR.23.2.189; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TRIMBLE M, 1990, AM J MED, V88, P593, DOI 10.1016/0002-9343(90)90523-G; VLACHOYIANNOPOULOS PG, 1992, EUR J CLIN INVEST, V22, P482, DOI 10.1111/j.1365-2362.1992.tb01494.x; 1993, STROKE S1, V24, P120	29	91	93	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					452	456		10.1016/S0140-6736(94)91775-2	http://dx.doi.org/10.1016/S0140-6736(94)91775-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7818647				2022-12-01	WOS:A1994PB76100015
J	OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW				OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW			RELATIVE CONCENTRATIONS OF ENDOTOXIN-BINDING PROTEINS IN BODY-FLUIDS DURING INFECTION	LANCET			English	Article							PERMEABILITY-INCREASING PROTEIN; GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDE; SEPSIS; DISEASE; MECHANISMS; LPS	Endotoxin initiates the systemic inflammatory response, haemodynamic changes, and multi-organ failure that may occur as a consequence of systemic gram-negative bacterial infection. The serum protein lipopolysaccharide-binding protein (LBP) binds to the lipid A component of bacterial endotoxin and facilitates its delivery to the CD14 antigen on the macrophage, where proinflammatory cytokines are released and a cascade of host mediators is initiated. The neutrophil granular protein bactericidal/permeability-increasing protein (BPI) competes with LBP for endotoxin binding and functions as a molecular antagonist of LBP-endotoxin interactions. We have measured concentrations of both proteins in body fluids from 49 consecutive patients. In 16 of 17 samples of fluid from closed-space infections, BPI was present in greater concentration than LBP (median BPI/LBP ratio 7.6 [95% CI 2.32-22.1]), The ratio of BPI and LBP was not significantly different from 1.0 in abdominal fluid from 10 patients with peritonitis (ratio 0.235 [0.18-0.47]), whereas the BPI/LBP ratio was low in 22 non-infected body fluids (0.01 [0.001-0.04]) and concentrations of both proteins approached those in normal human plasma. BPI concentrations were directly correlated with the quantity of neutrophils within clinical samples (r(s) = 0.81, p < 0.0001). Thus, within abscess cavities BPI is available in sufficient quantities for effective competition with LBP for endotoxin. BPI may attenuate the local inflammatory response and the systemic toxicity of endotoxin release during gram-negative infections.	BROWN UNIV,SCH MED,PAWTUCKET,RI; INCYTE PHARMACEUT,PALO ALTO,CA; CLEVELAND CLIN FDN,CLEVELAND,OH	Brown University; Incyte; Cleveland Clinic Foundation	OPAL, SM (corresponding author), MEM HOSP RHODE ISL,DIV INFECT DIS,111 BREWSTER ST,PAWTUCKET,RI 02860, USA.							BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GRAY PW, 1989, J BIOL CHEM, V264, P9595; HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; MARRA MN, 1992, J IMMUNOL, V148, P532; MARRA MN, 1990, J IMMUNOL, V144, P622; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; OPAL SM, 1991, CLIN RES, V30, pA451; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RIVEAU GR, 1987, J CLIN MICROBIOL, V25, P889, DOI 10.1128/JCM.25.5.889-892.1987; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; WEISS J, 1980, J CLIN INVEST, V65, P619, DOI 10.1172/JCI109707; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664; WILDE CG, IN PRESS J BIOL CHEM; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	22	77	78	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					429	431		10.1016/S0140-6736(94)91767-1	http://dx.doi.org/10.1016/S0140-6736(94)91767-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7520106				2022-12-01	WOS:A1994PB76100007
J	BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG				BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG			NMR SOLUTION STRUCTURE OF A PEPTIDE NUCLEIC-ACID COMPLEXED WITH RNA	SCIENCE			English	Article							DNA; PNA; SPECTROSCOPY; INHIBITION; ANTISENSE; PROTEINS; OLIGONUCLEOTIDES; MACROMOLECULES; POLYAMIDE; EFFICIENT	Peptide nucleic acids (PNA) incorporating nucleic acid bases into an achiral polyamide backbone bind to DNA in a sequence-dependent manner. The structure of a PNA-ribonucleic acid (RNA) complex was determined with nuclear magnetic resonance methods. A hexameric PNA formed a 1:1 complex with a complementary RNA that is an antiparallel, right-handed double helix with Watson-Crick base pairing similar to the ''A'' form structure of RNA duplexes. The achiral PNA backbone assumed a distinct conformation upon binding that differed from previously proposed models and provides a basis for further structure-based design of antisense agents.			BROWN, SC (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.							ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P7518, DOI 10.1073/pnas.90.16.7518; ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P9542, DOI 10.1073/pnas.90.20.9542; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P81; BAX A, 1989, METHOD ENZYMOL, V176, P164; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BUCHARDT O, 1993, TRENDS BIOTECHNOL, V11, P384, DOI 10.1016/0167-7799(93)90097-S; CHANDRASEKARAN R, 1989, LANDOLTBORNSTEIN NUC, V7, P55; COHEN JS, 1989, OLIGODEOXYNUCLEOTIDE; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P114; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JONES AS, 1973, TETRAHEDRON, V29, P2293, DOI 10.1016/S0040-4020(01)93352-6; KELLOGG GW, 1992, J MAGN RESON, V98, P176, DOI 10.1016/0022-2364(92)90122-N; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PINES O, 1986, TRENDS GENET, P284; SKLENAR V, 1987, J MAGN RESON, V75, P352, DOI 10.1016/0022-2364(87)90041-2; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Thomson S., UNPUB; UHLMANN E, 1990, CHEM REV, V90, P544; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZYDOWSKY TM, 1988, J ORG CHEM, V53, P5607, DOI 10.1021/jo00259a003	34	214	231	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					777	780		10.1126/science.7519361	http://dx.doi.org/10.1126/science.7519361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7519361				2022-12-01	WOS:A1994PA37200032
J	WANG, TW; DONAHOE, PK; ZERVOS, AS				WANG, TW; DONAHOE, PK; ZERVOS, AS			SPECIFIC INTERACTION OF TYPE-I RECEPTORS OF THE TGF-BETA FAMILY WITH THE IMMUNOPHILIN FKBP-12	SCIENCE			English	Article							TRANSMEMBRANE SERINE KINASE; GROWTH-FACTOR-BETA; PROTEIN-KINASE; THREONINE KINASE; ACTIVIN; COMPLEX; EXPRESSION; CLONING	Transforming growth factor-beta (TGF-beta) family members bind to receptors that consist of heteromeric serine-threonine kinase subunits (type I and type II). In a yeast genetic screen, the immunophilin FKBP-12, a target of the macrolides FK506 and rapamycin, interacted with the type I receptor for TGF-beta and with other type I receptors. Deletion, point mutation, and co-immunoprecipitation studies further demonstrated the specificity of the interaction. Excess FK506 competed with type I receptors for binding to FKBP-12, which suggests that these receptors share or overlap the macrolide binding site on FKBP-12, and therefore they may represent its natural ligand. The specific interaction between the type I receptors and FKBP-12 suggests that FKBP-12 may play a role in type I receptor-mediated signaling.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NCI NIH HHS [CA17393] Funding Source: Medline; NICHD NIH HHS [NICHD P-30 HD28138, NICHD P-32 HD07396] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAZEN P, 1993, CELL, V75, P681; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; WANG TW, UNPUB; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI Y, 1993, DNA SEQUENCE, V3, P297; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	21	308	336	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					674	676		10.1126/science.7518616	http://dx.doi.org/10.1126/science.7518616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7518616				2022-12-01	WOS:A1994NZ53800037
J	BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA				BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA			COUNTING POLYMERS MOVING THROUGH A SINGLE-ION CHANNEL	NATURE			English	Article							PROBING ALAMETHICIN CHANNELS; WATER-SOLUBLE POLYMERS; MEMBRANES; MODEL	THE change in conductance of a small electrolyte-filled capillary owing to the passage of sub-micrometre-sized particles has long been used for particle counting and sizing. A commercial device for such measurements, the Coulter counter, is able to detect particles of sizes down to several tenths of a micrometre(1-3). Nuclepore technology (in which pores are etched particle tracks) has extended the lower limit of size detection to 60-nm particles by using a capillary of diameter 0.45 mu m (ref. 4). Here we show that natural channel-forming peptides incorporated into a bilayer lipid membrane can be used to detect the passage of single molecules with gyration radii as small as 5-15 Angstrom. From our experiments with alamethicin pores we infer both the average number and the diffusion coefficients of poly(ethylene glycol) molecules in the pore. Our approach provides a means of observing the statistics and mechanics of flexible polymers moving within the confines of precisely defined single-molecule structures.	NIH,DCRT,STRUCT BIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD SCI,INST NUCL PHYS,ST PETERSBURG 188350,RUSSIA; OFF NAVAL RES,ARLINGTON,VA 22217	National Institutes of Health (NIH) - USA; National Research Centre - Kurchatov Institute; Institute of High Energy Physics - IHEP; Russian Academy of Sciences; United States Department of Defense; United States Navy	BEZRUKOV, SM (corresponding author), NIDDK,DIV INTRAMURAL RES,BETHESDA,MD 20892, USA.							ALLEN T, 1967, PARTICLE SIZE ANAL, P110; BALASUBRAMANIAN TM, 1981, J AM CHEM SOC, V103, P6127, DOI 10.1021/ja00410a024; BEAN CP, 1972, MEMBRANES, P1; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BEZRUKOV SM, IN PRESS ADV CHEM SE, V235; BUNVILLE LG, 1984, MODERN METHODS PARTI, P1; COUPER A, 1969, T FARADAY SOC, V65, P2486, DOI 10.1039/tf9696502486; DEBLOIS RW, 1977, J COLLOID INTERF SCI, V61, P323, DOI 10.1016/0021-9797(77)90395-2; FEHER G, 1973, P NATL ACAD SCI USA, V70, P870, DOI 10.1073/pnas.70.3.870; GORDON LGM, 1975, PHILOS T ROY SOC B, V270, P433, DOI 10.1098/rstb.1975.0021; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; HEINEMANN SH, 1989, BIOCHIM BIOPHYS ACTA, V987, P8, DOI 10.1016/0005-2736(89)90448-3; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; KUBITSCHEK HE, 1958, NATURE, V182, P234, DOI 10.1038/182234a0; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; SANSOM MSP, 1993, EUR BIOPHYS J BIOPHY, V22, P105, DOI 10.1007/BF00196915; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1	20	333	386	0	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					279	281		10.1038/370279a0	http://dx.doi.org/10.1038/370279a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7518571				2022-12-01	WOS:A1994NZ22900058
J	DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF				DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF			ROLE OF SELECTINS IN DEVELOPMENT OF ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Article							LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; LUNG INJURY; SUPERNATANTS; NEUTROPHILS; RISK	The acute lung injury of adult respiratory distress syndrome (ARDS) is characterised by inflammatory cell accumulation and activation in the lung. Selectins are a family of adhesion molecules implicated in leucocyte-endothelial adhesion, whose receptors can exist in a cleaved, soluble form. We investigated whether circulating soluble selectin adhesion molecules, obtained from ARDS at-risk patients, were associated with subsequent ARDS development. 82 patients, at risk of ARDS, were enrolled from three well-defined groups (multiple trauma, pancreatitis, perforated bowel). Plasma samples were obtained on hospital presentation and soluble L, E, and P, selectins were quantified with a sandwich enzyme-linked immunosorbent assay (ELISA). 14 patients subsequently developed ARDS. Initial plasma soluble L-selectin (sL-selectin) levels were significantly lower in patients who progressed to ARDS compared to those who did not (p = 0.0001; 95% Cl for mean in ARDS patients as percent of that in non-ARDS patients, 27-61%). Moreover concentrations were lower than in 62 normal volunteers (range 0.37-6.55, median 1.83 mu g/mL, n = 62), suggesting that a selective reduction of sL-selectin correlates with susceptibility. In addition, a significant correlation was found between low values of sL-selectin and indices of subsequent lung injury including requirement for ventilation (p = 0.0001) and degree of respiratory failure (p = 0.0001). A significant correlation was also found between low values of sL-selectin and patient mortality(p = 0.002). These results elucidate the inflammatory cell endothelial interactions in the early stages of ARDS and may be of prognostic value.	UNIV EDINBURGH,RAYNE LAB,RESP MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ACCID & EMERGENCY,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	University of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Donnelly, Seamas/0000-0001-7145-1843; Dransfield, Ian/0000-0001-5848-7059	NCI NIH HHS [CA54464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054464, R55CA054464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DONNELLY SC, 1992, EUR RESPIR J, V5; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MCEVER R, 1989, J CLIN INVEST, V112, P491; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NEWMAN W, 1993, J IMMUNOL, V150, P644; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROCKER GM, 1989, LANCET, V1, P120; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218	29	216	221	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					215	219		10.1016/S0140-6736(94)92995-5	http://dx.doi.org/10.1016/S0140-6736(94)92995-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7518025				2022-12-01	WOS:A1994NY06000007
J	FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA				FREEMANTLE, N; HOUSE, A; SONG, F; MASON, JM; SHELDON, TA			PRESCRIBING SELECTIVE SEROTONIN REUPTAKE INHIBITORS AS STRATEGY FOR PREVENTION OF SUICIDE	BRITISH MEDICAL JOURNAL			English	Article							ANTIDEPRESSANTS; OVERDOSE; TOXICITY; RATES; TRIAL; RISK; CARE	Objective-To evaluate a policy to reduce the incidence of suicide by means of changing the prescribing of antidepressants from the older tricycle antidepressants to the routine first line use of selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants. Design-Cost effectiveness analysis with sensitivity analyses using observational data on costs, volume of prescribing, deaths, and toxicity. Setting-United Kingdom primary care. Interventions-Selective serotonin reuptake inhibitors or newer tricyclic and related antidepressants compared with the use of older tricyclics. Main outcome measures-Cost per life saved and cost per Life year saved. Results-The potential number of lives which may be saved from a switch to the routine first line use of selective serotonin reuptake inhibitors is between 300 and 450 each year. The cost per life year gained ranges from pound 19 000 to pound 173 000, depending on the assumptions used. The cost per life year gained through the use of the newer tricyclic and related antidepressants is considerably lower. Conclusions-The cost per life year gained through avoiding suicides by the routine first line use of serotonin reuptake inhibitors is likely to be high. The new tricyclics and related drugs are of similar toxicity to the serotonin reuptake inhibitors but are considerably cheaper and so are more cost effective for this purpose. Further research is required on such prescribing. Because of the great uncertainties the shift to considerably more expensive options must be further investigated.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; LEEDS GEN INFIRM,DEPT LIASON PSYCHIAT,LEEDS,W YORKSHIRE,ENGLAND	University of York - UK; Leeds General Infirmary; University of Leeds	FREEMANTLE, N (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Sheldon, Trevor/AAK-7088-2021; anand, amit/A-7222-2009; Song, Fujian/B-3516-2013; Mason, James M/D-9904-2011	Sheldon, Trevor/0000-0002-7479-5913; Mason, James M/0000-0001-9210-4082; House, Allan/0000-0001-8721-8026; Freemantle, Nick/0000-0001-5807-5740				BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; CLARKE PR, 1991, EC ANAL SCREENING BR; CLARKE RV, 1987, J EPIDEMIOL COMMUN H, V41, P114, DOI 10.1136/jech.41.2.114; DIEKSTRA RFW, 1989, ACTA PSYCHIAT SCAND, V79, P268, DOI 10.1111/j.1600-0447.1989.tb10257.x; EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; FARMER RDT, 1989, ACTA PSYCHIAT SCAND, V80, P25, DOI 10.1111/j.1600-0447.1989.tb03044.x; FAWCETT J, 1987, AM J PSYCHIAT, V144, P35; FRADD SO, 1992, BRIT MED J, V305, P366, DOI 10.1136/bmj.305.6849.366-c; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GOLDSTEIN RB, 1991, ARCH GEN PSYCHIAT, V48, P618; HENRY J, 1989, ACTA PSYCHIAT S S354, V90, P37; Henry J A, 1992, Eur J Med, V1, P343; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LIN EHB, 1989, J GEN INTERN MED, V4, P1, DOI 10.1007/BF02596482; MILNE S, 1993, BRIT MED J, V306, P1126, DOI 10.1136/bmj.306.6885.1126-b; MONTGOMERY S, 1992, GENERAL PRACTIT 0522, P68; MONTGOMERY SA, 1988, INT CLIN PSYCHOPHARM, V3, P15; POKORNY AD, 1983, ARCH GEN PSYCHIAT, V40, P249; ROY A, 1983, ARCH GEN PSYCHIAT, V40, P971; SAINSBURY P, 1980, SUICIDE SYNDROME, P38; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; TUBMAN TRJ, 1990, BRIT MED J, V301, P842, DOI 10.1136/bmj.301.6756.842; 1992, BMA RPS24 BRIT NED A; 1993, EFFECTIVE HLTH CARE, V5; 1993, DRUG THER B, V31, P57; 1990, MORTALITY STATISTICS; 1992, GUIDELINES TREATING; 1992, HLTH NATION; 1993, ANATOMICAL THERAPEUT; 1986, BREAST CANCER SCREEN; 1993, HLTH NATION KEY AREA	35	85	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					249	253		10.1136/bmj.309.6949.249	http://dx.doi.org/10.1136/bmj.309.6949.249			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ180	7832842	Green Published			2022-12-01	WOS:A1994NZ18000021
J	HUISMAN, GW; KOLTER, R				HUISMAN, GW; KOLTER, R			SENSING STARVATION - A HOMOSERINE LACTONE-DEPENDENT SIGNALING PATHWAY IN ESCHERICHIA-COLI	SCIENCE			English	Article							CELL-DIVISION GENES; STREPTOMYCES-AMBOFACIENS; SIGMA-FACTOR; STRUCTURAL IDENTIFICATION; LUMINESCENCE SYSTEM; MANDELATE RACEMASE; ERWINIA-CAROTOVORA; CARBON-STARVATION; KATF; AUTOINDUCER	When nutrients become limiting, many bacteria differentiate and become resistant to environmental stresses. For Escherichia coli, this process is mediated by the sigma(s) subunit of RNA polymerase. Expression of sigma(s) was induced by homoserine lactone, a metabolite synthesized from intermediates in threonine biosynthesis. Homoserine lactone-dependent synthesis of oS was prevented by overexpression of a newly identified protein, RspA. The function of homoserine lactone derivatives in many cell density-dependent phenomena and the similarity of RspA to a Streptomyces ambofaciens protein suggest that synthesis of homoserine lactone may be a general signal of starvation.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Huisman, Gjalt/0000-0003-1955-1120				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BERG CM, 1992, GENE, V113, P9, DOI 10.1016/0378-1119(92)90664-B; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAO JG, 1989, J BIOL CHEM, V264, P21670; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, pCH87; DUNLAP PV, 1992, J BACTERIOL, V174, P2440, DOI 10.1128/jb.174.8.2440-2448.1992; EBERHARD A, 1981, BIOCHEMISTRY-US, V20, P2444, DOI 10.1021/bi00512a013; EBERHARD A, 1991, ARCH MICROBIOL, V155, P294, DOI 10.1007/BF00252215; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GALINIER A, 1991, GENE, V97, P149, DOI 10.1016/0378-1119(91)90024-6; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HOFFMAN M, 1991, SCIENCE, V251, P31, DOI 10.1126/science.1986411; HUISMAN G, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P21; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUO AA, UNPUB; LEBLOND P, 1989, J BACTERIOL, V171, P419, DOI 10.1128/jb.171.1.419-423.1989; LOEWEN PC, 1993, J BACTERIOL, V175, P2150, DOI 10.1128/JB.175.7.2150-2153.1993; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1993, J BACTERIOL, V175, P2143, DOI 10.1128/JB.175.7.2143-2149.1993; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; MRACHKO G, UNPUB; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NEIDHART DJ, 1990, NATURE, V347, P692, DOI 10.1038/347692a0; NGUYEN LH, 1993, BIOCHEMISTRY-US, V32, P11112, DOI 10.1021/bi00092a021; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PIPER KR, 1993, NATURE, V362, P448, DOI 10.1038/362448a0; PIRHONEN M, 1993, EMBO J, V12, P2467, DOI 10.1002/j.1460-2075.1993.tb05901.x; PSSADOR L, 1993, SCIENCE, V260, P1127; ROBINSON AC, 1984, J BACTERIOL, V160, P546, DOI 10.1128/JB.160.2.546-555.1984; RON EZ, 1975, J BACTERIOL, V124, P243, DOI 10.1128/JB.124.1.243-246.1975; SCHELLHORN HE, 1992, J BACTERIOL, V174, P4769, DOI 10.1128/JB.174.14.4769-4776.1992; SCHNEIDER D, 1993, J GEN MICROBIOL, V139, P2559, DOI 10.1099/00221287-139-11-2559; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIMONET JM, 1992, GENE, V115, P49, DOI 10.1016/0378-1119(92)90539-2; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WYMAN A, 1975, J BIOL CHEM, V250, P3904; ZAMBRANO MM, 1993, SCIENCE, V259, P1757, DOI 10.1126/science.7681219; ZHANG LH, 1993, NATURE, V362, P446, DOI 10.1038/362446a0	45	184	197	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					537	539		10.1126/science.7545940	http://dx.doi.org/10.1126/science.7545940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7545940				2022-12-01	WOS:A1994NY21600035
J	KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P				KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P			FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; TARGET-CELLS; MICE; APOPTOSIS; LYSIS; LYMPHOCYTES; LYMPHOMA; ANTIGEN; DEFECTS	Two molecular mechanisms of T cell-mediated cytotoxicity, one perforin-based, the other Fas-based, have been demonstrated. To determine the extent of their contribution to T cell-mediated cytotoxicity, a range of effector cells from normal control or perforin-deficient mice were tested against a panel of target cells with various levels of Fas expression. All cytotoxicity observed was due to either of these mechanisms, and no third mechanism was detected. Thus, the perforin- and Fas-based mechanisms may account for all T cell-mediated cytotoxicity in short-term in vitro assays.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE; UNIV ZURICH,INST EXPTL IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Zurich; Novartis; Sandoz			Golstein, Pierre/A-4954-2014; Nagata, Shigekazu/AAG-3203-2019	Golstein, Pierre/0000-0003-1750-3483; Nagata, Shigekazu/0000-0001-9758-8426				BERKE G, 1972, J EXP MED, V135, P1334, DOI 10.1084/jem.135.6.1334; Berke G, 1980, Prog Allergy, V27, P69; BERKE G, 1989, FUNDAMENTAL IMMUNOLO, P735; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DOHERTY PC, 1978, J EXP MED, V148, P534, DOI 10.1084/jem.148.2.534; DUKE RC, 1991, APOPTOSIS MOL BASIS, P209; Golstein P, 1977, Contemp Top Immunobiol, V7, P273; GOLSTEIN P, IN PRESS APOPTOSIS I; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; Henney C S, 1977, Contemp Top Immunobiol, V7, P245; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; Martz E, 1977, Contemp Top Immunobiol, V7, P301; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Perlmann P, 1969, Adv Immunol, V11, P117, DOI 10.1016/S0065-2776(08)60479-4; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, UNPUB; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JDE, 1989, PHYSIOL REV, V69, P250, DOI 10.1152/physrev.1989.69.1.250	31	1435	1477	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					528	530		10.1126/science.7518614	http://dx.doi.org/10.1126/science.7518614			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518614				2022-12-01	WOS:A1994NY21600031
J	ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC				ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC			ENDOTHELIAL NOS AND THE BLOCKADE OF LTP BY NOS INHIBITORS IN MICE LACKING NEURONAL NOS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; PLATELET-ACTIVATING-FACTOR; HIPPOCAMPAL SLICES; INTERCELLULAR MESSENGER; RAT HIPPOCAMPUS; CARBON-MONOXIDE; ENHANCEMENT; STIMULATION; RELEASE	Long-term potentiation (LTP) is a persistent increase in synaptic strength implicated in certain forms of learning and memory. In the CA1 region of the hippocampus, LTP is thought to involve the release of one or more retrograde messengers from the postsynaptic cell that act on the presynaptic terminal to enhance transmitter release. One candidate retrograde messenger is the membrane-permeant gas nitric oxide (NO), which in the brain is released after activation of the neuronal-specific NO synthase isoform (nNOS). To assess the importance of NO in hippocampal synaptic plasticity, LTP was examined in mice where the gene encoding nNOS was disrupted by gene targeting. In nNOS(-) mice, LTP induced by weak intensity tetanic stimulation was normal except for a slight reduction in comparison to that in wild-type mice and was blocked by NOS inhibitors, just as it was in wild-type mice. Immunocytochemical studies indicate that in the nNOS(-) mice as in wild-type mice, the endothelial form of NOS (eNOS) is expressed in CA1 neurons. These findings suggest that eNOS, rather than nNOS, generates NO within the postsynaptic cell during LTP.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Columbia University; Howard Hughes Medical Institute; Columbia University; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH045923, R01MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-45923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BON C, 1992, EUR J NEUROSCI, V4, P420, DOI 10.1111/j.1460-9568.1992.tb00891.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FURTINE ES, 1993, BIOCHEMISTRY-US, V32, P8512; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LUMRAGAN JT, 1993, NEUROSCIENCE, V57, P973, DOI 10.1016/0306-4522(93)90042-E; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NATHAN C, 1992, FASEB J, V3, P31; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHMIDT HH, 1992, J HISTOCHEM CYTOCHEM, V90, P1439; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; Schweizer F. E., 1993, Society for Neuroscience Abstracts, V19, P241; SHUMAN EM, 1993, SEMIN NEUROSCI, V5, P207; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	45	374	382	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					542	546		10.1126/science.7518615	http://dx.doi.org/10.1126/science.7518615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518615				2022-12-01	WOS:A1994NY21600037
J	KEENEY, RL				KEENEY, RL			DECISIONS ABOUT LIFE-THREATENING RISKS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY				KEENEY, RL (corresponding author), UNIV SO CALIF,LOS ANGELES,CA 90089, USA.							BEAUCHAMP TS, 1982, PHILOS ETHICS; GRAHAM JD, 1992, RISK ANAL, V12, P333, DOI 10.1111/j.1539-6924.1992.tb00684.x; GRAHAM JD, 1986, RISK EVALUATION MANA, P503; KEENEY RL, 1984, RISK ANAL, V4, P117, DOI 10.1111/j.1539-6924.1984.tb00941.x; KEENEY RL, 1990, RISK ANAL, V10, P147, DOI 10.1111/j.1539-6924.1990.tb01029.x; Kitagawa EM, 1973, DIFFERENTIAL MORTALI, V80, P532; MACRAE J, 1992, COMMUNICATION   0310; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; WILDAVSKY A, 1980, PUBLIC INTEREST, V60, P23; Wildavsky A.B., 1988, SEARCHING SAFETY, Vfirst	11	30	30	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					193	196		10.1056/NEJM199407213310311	http://dx.doi.org/10.1056/NEJM199407213310311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW797	7794298				2022-12-01	WOS:A1994NW79700011
J	MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP				MACKENZIE, WR; HOXIE, NJ; PROCTOR, ME; GRADUS, MS; BLAIR, KA; PETERSON, DE; KAZMIERCZAK, JJ; ADDISS, DG; FOX, KR; ROSE, JB; DAVIS, JP			A MASSIVE OUTBREAK IN MILWAUKEE OF CRYPTOSPORIDIUM INFECTION TRANSMITTED THROUGH THE PUBLIC WATER-SUPPLY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; SURFACE-WATER; GIARDIA; IMMUNOCOMPETENT; TRANSMISSION; DIARRHEA	Background. Early in the spring of 1993 there was a widespread outbreak of acute watery diarrhea among the residents of Milwaukee. Methods. We investigated the two Milwaukee water-treatment plants, gathered data from clinical laboratories on the results of tests for enteric pathogens, and examined ice made during the time of the outbreak for cryptosporidium oocysts. We surveyed residents with confirmed cryptosporidium infection and a sample of those with acute watery diarrhea consistent with cryptosporidium infection. To estimate the magnitude of the outbreak, we also conducted a survey using randomly selected telephone numbers in Milwaukee and four surrounding counties. Results. There were marked increases in the turbidity of treated water at the city's southern water-treatment plant from March 23 until April 9, when the plant was shut down. Cryptosporidium oocysts were identified in water from ice made in southern Milwaukee during these weeks. The rates of isolation of other enteric pathogens remained stable, but there was more than a 100-fold increase in the rate of isolation of cryptosporidium. The median duration of illness was 9 days (range, 1 to 55). The median maximal number of stools per day was 12 (range, 1 to 90). Among 285 people surveyed who had laboratory-confirmed cryptosporidiosis, the clinical manifestations included watery diarrhea (in 93 percent), abdominal cramps (in 84 percent), fever (in 57 percent), and vomiting (in 48 percent). We estimate that 403,000 people had watery diarrhea attributable to this outbreak. Conclusions. This massive outbreak of watery diarrhea was caused by cryptosporidium oocysts that passed through the filtration system of one of the city's water-treatment plants. Water-quality standards and the testing of patients for cryptosporidium were not adequate to detect this outbreak.	WISCONSIN DEPT HLTH & SOCIAL SERV, BUR PUBL HLTH, MADISON, WI 53703 USA; CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; MILWAUKEE DEPT HLTH, MILWAUKEE, WI USA; BUR LABS, MILWAUKEE, WI USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of South Florida; United States Environmental Protection Agency			Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				ALPERT G, 1986, PEDIATRICS, V77, P152; ARROWOOD MJ, 1989, J CLIN MICROBIOL, V27, P1490, DOI 10.1128/JCM.27.7.1490-1495.1989; BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; COLBOURNE JS, 1989, 1989 P AM WAT WORKS, P275; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GALLAGHER MM, 1989, AM J PUBLIC HEALTH, V79, P39, DOI 10.2105/AJPH.79.1.39; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; JOSEPH C, 1991, EPIDEMIOL INFECT, V107, P509, DOI 10.1017/S0950268800049207; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1992, APPL ENVIRON MICROB, V58, P780; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; LELAND D, 1993, J AM WATER WORKS ASS, V85, P34; MA P, 1983, J INFECT DIS, V147, P824, DOI 10.1093/infdis/147.5.824; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; NAVIN TR, 1984, REV INFECT DIS, V6, P313; NIME FA, 1976, GASTROENTEROLOGY, V70, P592; PALIT C, 1983, SOCIOL METHOD RES, V12, P169, DOI 10.1177/0049124183012002005; PALIT D, 1988, CASS CATI VERSION 3; PALMER SR, 1990, BRIT MED J, V300, P774, DOI 10.1136/bmj.300.6727.774; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; ROSE JB, 1989, APPL ENVIRON MICROB, V55, P3189, DOI 10.1128/AEM.55.12.3189-3196.1989; ROSE JB, 1991, ENVIRON SCI TECHNOL, V25, P1393, DOI 10.1021/es00020a005; ROSE JB, 1990, METHODS INVESTIGATIO, P223; SKEELS MR, 1990, AM J PUBLIC HEALTH, V80, P305, DOI 10.2105/AJPH.80.3.305; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	32	1385	1438	5	174	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					161	167		10.1056/NEJM199407213310304	http://dx.doi.org/10.1056/NEJM199407213310304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	7818640				2022-12-01	WOS:A1994NW79700004
J	SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH				SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH			RAFT1 - A MAMMALIAN PROTEIN THAT BINDS TO FKBP12 IN A RAPAMYCIN-DEPENDENT FASHION AND IS HOMOLOGOUS TO YEAST TORS	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; CYCLOSPORINE-A; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	The immunosuppressants rapamycin and FK506 bind to the same intracellular protein, the immunophilin FKBP12. The FKBP12-FK506 complex interacts with and inhibits the Ca2+-activated protein phosphatase calcineurin. The target of the FKBP12-rapamycin complex has not yet been identified. We report that a protein complex containing 245 kDa and 35 kDa components, designated rapamycin and FKBP12 targets 1 and 2 (RAFT1 and RAFT2), interacts with FKBP12 in a rapamycin-dependent manner. Sequences (330 amino acids total) of tryptic peptides derived from the 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2549 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively. We propose that RAFT1 is the direct target of FKBP12-rapamycin and a mammalian homolog of the TOR proteins.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SABATINI, DM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.			Erdjument-Bromage, Hediye/0000-0003-0224-3594; /0000-0002-1446-7256	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALTIN JG, 1991, J BIOL CHEM, V266, P5401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLANAR MA, 1992, NATURE, V256, P1014; BOREL JF, 1986, PROG ALLERGY, V38, P9; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ELICONE C, 1994, IN PRESS J CHROMATOG, V676; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MORICE WG, 1993, J BIOL CHEM, V268, P22737; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	54	1178	1245	3	54	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					35	43		10.1016/0092-8674(94)90570-3	http://dx.doi.org/10.1016/0092-8674(94)90570-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	7518356				2022-12-01	WOS:A1994NX32800006
J	BENOWITZ, NL; HENNINGFIELD, JE				BENOWITZ, NL; HENNINGFIELD, JE			ESTABLISHING A NICOTINE THRESHOLD FOR ADDICTION - THE IMPLICATIONS FOR TOBACCO REGULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CIGARETTE-SMOKING; CARBON-MONOXIDE; TAR; YIELDS; EXPOSURE; BIOAVAILABILITY; SMOKERS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94110; NATL INST DRUG ABUSE,BALTIMORE,MD 21224	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002277, P50DA001696, R37DA002277] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02277, DA01696] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1994, PREVENTING TOBACCO U; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, 1991, CLIN PHARMACOL THER, V49, P270, DOI 10.1038/clpt.1991.28; BENOWITZ NL, IN PRESS CLIN PHARM; COULTAS DB, 1993, AM REV RESPIR DIS, V148, P435, DOI 10.1164/ajrccm/148.2.435; FIORE MC, 1992, MED CLIN N AM, V76, P289, DOI 10.1016/S0025-7125(16)30354-6; GORI GB, 1985, REGUL TOXICOL PHARM, V5, P314, DOI 10.1016/0273-2300(85)90045-5; GUYATT AR, 1989, PSYCHOPHARMACOLOGY, V99, P80, DOI 10.1007/BF00634457; HENNINGFIELD JE, 1990, BRIT J ADDICT, V85, P279; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P466, DOI 10.1007/BF02247423; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; RUSSELL MAH, 1982, BRIT J ADDICT, V77, P145; SHIFFMAN S, 1989, PSYCHOPHARMACOLOGY, V97, P539, DOI 10.1007/BF00439561; SHIFFMAN S, 1990, ARCH GEN PSYCHIAT, V47, P333; STEPNEY R, 1980, BRIT J ADDICT, V75, P81; 1988, DHHS PHS CDC888406 P	21	378	387	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					123	125		10.1056/NEJM199407143310212	http://dx.doi.org/10.1056/NEJM199407143310212			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW712	7818638				2022-12-01	WOS:A1994NW71200012
J	MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE				MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE			REGULATING PHYSICIAN-ASSISTED DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; LIFE; SUICIDE; PATIENT; DOCTOR; AID		GENESEE HOSP,ROCHESTER,NY 14607; MICHIGAN STATE UNIV,E LANSING,MI 48824; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH,WASHINGTON,DC 20001; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	Michigan State University; Johns Hopkins University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MILLER, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,BOX 348,CHARLOTTESVILLE,VA 22908, USA.		Brody, Howard/GQA-6310-2022					ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; EGAN T, 1994, NY TIMES        0307, pA1; Glantz L H, 1987, Law Med Health Care, V15, P231; GOMEZ CF, 1991, REGULATING DEATH; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin Lawrence O, 1993, J Law Med Ethics, V21, P94, DOI 10.1111/j.1748-720X.1993.tb01234.x; Margolick David, 1994, N Y Times Web, pB8; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; MEIER D, 1994, PHYSICIAN ASSISTED D, P5; MILLER FG, 1993, PERSPECT BIOL MED, V36, P159; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL T. E., 1993, DEATH DIGNITY; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; TENHAVE HA, 1992, EUTHANASIA NORMAL ME, V22, P34; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, HARVARD LAW REV, V105, P2021	21	103	104	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					119	123		10.1056/NEJM199407143310211	http://dx.doi.org/10.1056/NEJM199407143310211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	7516037				2022-12-01	WOS:A1994NW71200011
J	LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J				LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J			MICROVESSEL COUNT AND CEREBROSPINAL-FLUID BASIC FIBROBLAST GROWTH-FACTOR IN CHILDREN WITH BRAIN-TUMORS	LANCET			English	Article							CAPILLARY ENDOTHELIAL-CELLS; CONTRAST ENHANCEMENT; ANGIOGENESIS; METASTASIS; AFFINITY; MEMBRANE; BINDING; CULTURE; TUMORS	Tumour growth is angiogenesis-dependent; brain tumours have more intense neovascularisation than other tumours and produce basic fibroblast growth factor, a potent angiogenic mediator. Because little is known about the release of basic fibroblast growth factor from brain tumours into extracellular fluids, we tested cerebrospinal fluid (CSF) from 26 children and young adults with brain tumours and 18 controls for basic fibroblast growth factor and for proliferative activity on cultured capillary endothelial cells. We also measured the density of microvessels in tumours by immunohistochemical staining. Basic fibroblast growth factor was detected in the CSF of 62% (16 of 26) patients with brain tumours but in none of the controls. Specimens with basic fibroblast growth factor stimulated DNA synthesis of capillary endothelial cells in vitro. Endothelial proliferative activity was blocked by neutralising antibodies to basic fibroblast growth factor. Basic fibroblast growth factor correlated with mitogenic activity in CSF in vitro (p less than or equal to 0.0001), and with density of microvessels in histological sections (p less than or equal to 0.005). A microvessel count of greater than or equal to 68 per 200 x field was associated with tumour recurrence (p = 0.005) and with mortality (p = 0.02). Basic fibroblast growth factor in brain tumours may mediate angiogenesis as measured by microvessel density in histological sections, so has potential as both a marker for neoplasia and a target for tumour treatments. Furthermore, evaluation of cerebrospinal fluid basic fibroblast growth factor, along with microvessel quantitation in biopsied tumours, may provide improved prognostic information for the management of patients with brain tumours.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT NEUROSURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; TAKEDA CHEM IND LTD, OSAKA 532, JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Takeda Chemical Industries				Yu, Channing/0000-0002-3231-2565	NCI NIH HHS [5T32CA09535-06, CA37395-09] Funding Source: Medline; NINDS NIH HHS [NINDS NS-92-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037395, T32CA009535, R01CA037395] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGNER SH, 1992, J NEUROPATH EXP NEUR, V51, P235, DOI 10.1097/00005072-199205000-00001; BREM H, 1980, SURG FORUM, V31, P471; BREM S, 1992, CANCER, V70, P2673, DOI 10.1002/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO;2-F; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; Finklestein S P, 1990, Restor Neurol Neurosci, V1, P387, DOI 10.3233/RNN-1990-1603; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HESSELINK JR, 1988, RADIOL CLIN N AM, V26, P873; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LOPEZPOUSA S, 1981, EXPERIENTIA, V37, P413; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAKAGAWA H, 1992, J NEURO-ONCOL, V12, P111; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; RAK JW, IN PRESS J CELL PHYS; Russell D., 1989, PATHOLOGY TUMORS NER; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1991, METHOD ENZYMOL, V198, P91; SHING Y, 1992, INVEST OPHTH VIS SCI, V33, pA1683; TAKAHASHI A, 1993, NEUROSCI LETT, V160, P214, DOI 10.1016/0304-3940(93)90416-I; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WATANABE H, 1991, BIOCHEM BIOPH RES CO, V175, P229, DOI 10.1016/S0006-291X(05)81224-0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZAGZAG D, 1989, AM J ROENTGENOL, V153, P141, DOI 10.2214/ajr.153.1.141	30	200	214	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					82	86		10.1016/S0140-6736(94)91280-7	http://dx.doi.org/10.1016/S0140-6736(94)91280-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7516992				2022-12-01	WOS:A1994NV73200008
J	BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS				BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS			BETA(2)-MICROGLOBULIN-INDEPENDENT MHC CLASS IB MOLECULE EXPRESSED BY HUMAN INTESTINAL EPITHELIUM	SCIENCE			English	Article							T-CELL RECEPTOR; INTRAEPITHELIAL LYMPHOCYTES; SURFACE EXPRESSION; IMMUNE RECOGNITION; HEAVY-CHAINS; BETA-2-MICROGLOBULIN; ANTIGEN; CD1; ASSOCIATION; COMPLEX	A major histocompatibility complex class Ib protein, CD1d, is expressed by human intestinal epithelial cells (IECs) and is a ligand for CD8(+) T cells. CD1d was found to be expressed on the surface of human IECs as a 37-kilodalton protein that was beta(2)-microglobulin (beta(2)M) independent with no N-linked carbohydrate. Transfection into a beta(2)M(-) cell line confirmed that CD1d could be expressed at the cell surface in the absence of beta(2)M. These data indicate that IECs use a specialized pathway for CD1d synthesis and that a beta(2)M-independent class Ib protein may be the normal ligand for some intestinal T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Colgan, Sean P./B-4573-2009		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33911] Funding Source: Medline; NIDDK NIH HHS [R01 DK44319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIOT M, 1986, J IMMUNOL, V136, P1752; BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RL, UNPUB; BLUMBERG RS, 1993, J IMMUNOL, V150, P5144; BLUMBERG RS, 1991, EUR J IMMUNOL, V21, P473, DOI 10.1002/eji.1830210233; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CAPPS GG, 1993, J IMMUNOL, V151, P159; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HEDRICK SM, 1992, CELL, V70, P177, DOI 10.1016/0092-8674(92)90092-Q; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HRLOW E, 1988, ANTIBODIES, P641; KATZOUMI P, 1993, AM J PHYSIOL, V264, pC1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1985, J IMMUNOL, V134, P423; MIYAZAKI J, 1986, J EXP MED, V163, P856, DOI 10.1084/jem.163.4.856; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SYDORA BC, 1993, J IMMUNOL, V150, P2179; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUNK J, 1992, GASTROENTEROLOGY, V102, P69, DOI 10.1016/0016-5085(92)91785-3; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	39	146	147	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					259	262		10.1126/science.7517575	http://dx.doi.org/10.1126/science.7517575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517575				2022-12-01	WOS:A1994NV95700044
J	DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM				DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM			HOMOZYGOUS HUMAN TAP PEPTIDE TRANSPORTER MUTATION IN HLA CLASS-I DEFICIENCY	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMERS PCR-SSP; T-CELLS; COMBINED IMMUNODEFICIENCY; DEFECTIVE EXPRESSION; ANTIGEN PRESENTATION; BARE LYMPHOCYTE; SURFACE; REGION; MICE	Human lymphocyte antigen (HLA) class I proteins of the major histocompatibility complex are largely dependent for expression on small peptides supplied to them by transporter associated with antigen processing (TAP) protein. An inherited human deficiency in the TAP transporter was identified in two siblings suffering from recurrent respiratory bacterial infections. The expression on the cell surface of class I proteins was very low, whereas that of CD1a was normal, and the cytotoxicity of natural killer cells was affected. In addition, CD8(+) alpha beta T cells were present in low but significant numbers and were cytotoxic in the most severely affected sibling, who also showed an increase in CD4(+)CD8(+) T cells and gamma delta T cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; INST CURIE,INSERM,U255,F-75231 PARIS,FRANCE; UNIV STRASBOURG,HOP HAUTEPIERRE,SERV PEDIAT,F-67098 STRASBOURG,FRANCE; UNIV STRASBOURG 1,INSERM,U74,F-67085 STRASBOURG,FRANCE; UNIV STRASBOURG 1,SYNTHELABO,FAC MED,COMMUN LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,HEMATOL NORMALE & PATHOL LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,INSERM,U311,F-67085 STRASBOURG,FRANCE	Cancer Research UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	DELASALLE, H (corresponding author), CTR REG TRANSFUS SANGUINE,HISTOCOMPATIBIL LAB,F-67085 STRASBOURG,FRANCE.		De La Salle, Henri/H-9353-2016; Cazenave, Jean-Pierre/AAE-2935-2019	De La Salle, Henri/0000-0001-5136-0776; salamero, jean/0000-0002-2610-5826				APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BIRON CA, 1988, NAT IMMUN CELL GROW, V7, P47; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; DELASALLE H, UNPUB; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; DOHERTY PC, 1993, CURR OPIN IMMUNOL, V5, P479, DOI 10.1016/0952-7915(93)90026-O; FURUKAWA S, 1992, BLOOD, V80, P3253; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3; HEEMELS MT, 1993, CURR BIOL, V3, P380, DOI 10.1016/0960-9822(93)90208-6; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; LAMOUSESMITH E, 1993, J IMMUNOL, V151, P6283; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAEDA H, 1985, IMMUNOGENETICS, V21, P549, DOI 10.1007/BF00395879; MARCADET A, 1985, NEW ENGL J MED, V312, P1287, DOI 10.1056/NEJM198505163122004; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURPHY GF, 1983, BRIT J DERMATOL, V108, P423, DOI 10.1111/j.1365-2133.1983.tb04594.x; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PAYNE R, 1983, HUM IMMUNOL, V6, P219, DOI 10.1016/0198-8859(83)90095-2; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; RAULET DH, 1994, ADV IMMUNOL, V55, P381; RITTIG MG, 1994, INT ARCH ALLERGY IMM, V103, P4, DOI 10.1159/000236598; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SALA P, 1993, BLOOD, V82, P1546; SCHUURMAN RKB, 1979, CLIN IMMUNOL IMMUNOP, V14, P418, DOI 10.1016/0090-1229(79)90094-1; SEAMAN WE, 1981, J CLIN INVEST, V67, P1324, DOI 10.1172/JCI110161; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUGIYAMA Y, 1986, CHEST, V89, P398, DOI 10.1378/chest.89.3.398; Sugiyama Y, 1989, Nihon Kyobu Shikkan Gakkai Zasshi, V27, P980; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; TONGIO MM, UNPUB; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VARDAL F, 1986, TISSUE ANTIGENS, V28, P301; ZETTERQUIST H, 1992, HUM IMMUNOL, V34, P64, DOI 10.1016/0198-8859(92)90086-3; ZIJILSTA M, 1992, J EXP MED, V175, P885; 1980, TISSUE ANTIGENS, V16, P335	54	252	255	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					237	241		10.1126/science.7517574	http://dx.doi.org/10.1126/science.7517574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517574				2022-12-01	WOS:A1994NV95700038
J	WRIGHT, N; CAPLAN, R; PAYNE, S				WRIGHT, N; CAPLAN, R; PAYNE, S			COMMUNITY SURVEY OF LONG-TERM DAYTIME USE OF BENZODIAZEPINES	BRITISH MEDICAL JOURNAL			English	Article									LINCOLN CTY HOSP,PETER HODGKINSON CTR,LINCOLN LN2 5QY,ENGLAND; MAPPERLEY HOSP,NOTTINGHAM NG3 6AA,ENGLAND									ASHTON H, 1989, BRIT J ADDICT, V84, P541; TAYLOR D, 1987, BENZODIAZEPINES CURR, P13; TYRER P, 1990, J AFFECT DISORDERS, V19, P53, DOI 10.1016/0165-0327(90)90009-W; Tyrer P J, 1984, Br Med J (Clin Res Ed), V288, P1101; 1988, CURRENT PROBLEMS, V21, P1	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					27	28		10.1136/bmj.309.6946.27	http://dx.doi.org/10.1136/bmj.309.6946.27			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NV891	7802775	Green Published			2022-12-01	WOS:A1994NV89100020
J	GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ				GUERINA, NG; HSU, HW; MEISSNER, HC; MAGUIRE, JH; LYNFIELD, R; STECHENBERG, B; ABROMS, I; PASTERNACK, MS; HOFF, R; EATON, RB; GRADY, GF; CHEESEMAN, SH; MCINTOSH, K; MEDEARIS, DN; ROBB, R; WEIBLEN, BJ			NEONATAL SEROLOGIC SCREENING AND EARLY TREATMENT FOR CONGENITAL TOXOPLASMA-GONDII INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-CULTURE; PREGNANCIES; MANAGEMENT	Background. Most infants with congenital Toxoplasma gondii infection have no symptoms at birth, but many will have retinal disease or neurologic abnormalities later in life. Early detection and treatment of congenital toxoplasmosis may reduce these sequelae. Methods. In Massachusetts since January 1986, and in New Hampshire since July 1988, newborns have been screened for intrauterine infection with T. gondii by means of an IgM capture immunoassay of blood specimens routinely collected for screening for metabolic disorders. Congenital infection is confirmed by assays for specific IgG and IgM antibodies in serum from infants and their mothers. For this study, infants with serologic evidence of infection underwent extensive clinical evaluation and received one year of treatment. Results. Through June 1992, 100 of 635,000 infants tested had positive screening tests. Congenital infection was confirmed in 52 infants, 50 of whom were identified only through neonatal screening and not through initial clinical examination. However, after the serologic results became available, more detailed examinations revealed abnormalities of either the central nervous system or the retina in 19 of 48 infants evaluated (40 percent). After treatment, only 1 of 46 children had a neurologic deficit (hemiplegia attributable to a cerebral lesion present at birth). Thirty-nine treated children had follow-up ophthalmologic examinations when one to six years old; four (10 percent) had eye lesions that may have developed postnatally (a macular lesion in one child and minor retinal scars in three). Conclusions. Routine neonatal screening for toxoplasmosis identifies congenital infections that are subclinical, and early treatment may reduce the severe long-term sequelae.	CHILDRENS HOSP, DIV INFECT DIS, BOSTON, MA 02115 USA; CHILDRENS HOSP, DIV NEWBORN MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NEWTON WELLESLEY HOSP, DIV NEONATOL, NEWTON, MA USA; MASSACHUSETTS STATE LAB INST, NEW ENGLAND REG NEWBORN SCREENING PROGRAM, BOSTON, MA USA; TUFTS UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT INFECT DIS, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, PEDIAT INFECT DIS UNIT, BOSTON, MA 02114 USA; BAYSTATE MED CTR, DIV PEDIAT INFECT DIS, SPRINGFIELD, MA 01107 USA; UNIV MASSACHUSETTS, MED CTR, DEPT NEUROL, WORCESTER, MA 01655 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Newton Wellesley Hospital; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Baystate Medical Center; University of Massachusetts System; University of Massachusetts Worcester	GUERINA, NG (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT INFECT DIS, DIV NEWBORN MED, NEMC 44, 750 WASHINGTON ST, BOSTON, MA 02111 USA.							BONADIO WA, 1992, PEDIATR INFECT DIS J, V11, P589, DOI 10.1097/00006454-199207000-00015; CHANG CH, 1972, J PEDIATR-US, V81, P790, DOI 10.1016/S0022-3476(72)80106-9; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P855; COUVREUR J, 1984, ANN PEDIATR-PARIS, V31, P815; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DEROUIN F, 1987, J CLIN MICROBIOL, V25, P1597, DOI 10.1128/JCM.25.9.1597-1600.1987; DEVROEDE M, 1979, ACTA PAEDIATR SCAND, V68, P761, DOI 10.1111/j.1651-2227.1979.tb18453.x; HOFF R, 1990, ALB BIR DEF, P169; HSU HW, 1992, SCAND J INFECT DIS, P59; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; KOPPE JG, 1986, LANCET, V1, P254; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; NAOT Y, 1981, J PEDIATR-US, V98, P32, DOI 10.1016/S0022-3476(81)80528-8; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROBERTS T, 1990, J AM VET MED ASSOC, V196, P249; SEVER JL, 1988, PEDIATRICS, V82, P181; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; WEIBLEN BJ, 1993, LABORATORY METHODS N, P191; WILSON CB, 1980, PEDIATRICS, V66, P767	19	289	311	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1994	330	26					1858	1863		10.1056/NEJM199406303302604	http://dx.doi.org/10.1056/NEJM199406303302604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT530	7818637				2022-12-01	WOS:A1994NT53000004
J	LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J				LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J			MYELINATION IN THE ABSENCE OF MYELIN-ASSOCIATED GLYCOPROTEIN	NATURE			English	Article							CELL-ADHESION MOLECULES; EMBRYONIC STEM-CELLS; SCHWANN-CELLS; PERIAXONAL SPACE; MICE; GENE; MAG; L1	THE hypothesis that myelin-associated glycoprotein (MAG) initiates myelin formation is based in part on observations that MAG has an adhesive role in interactions between oligodendrocytes and neurons(1). Furthermore, the over- or underexpression of MAG in transfected Schwann cells in vitro leads to accelerated myelination(2) or hypomyelination(3), respectively. Here we test this idea by creating a null mutation in the mag locus and deriving mice that are totally deficient in MAG expression at the RNA and protein level. In adult mutant animals the degree of myelination and its compaction are normal, whereas the organization of the periaxonal region is partially impaired. Mutant animals show a subtle intention tremor. Our findings do not support the widely held view that MAG is critical for myelin formation but rather indicate that MAG is necessary for maintenance of the cytoplasmic collar and periaxonal space of myelinated fibres.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X5, ON, CANADA; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA; MCGILL UNIV, ROYAL VICTORIA HOSP, MONTREAL H3A 1A1, PQ, CANADA	University of Toronto; Cleveland Clinic Foundation; McGill University; Royal Victoria Hospital	LI, CM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Roder, John/G-6468-2013					ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; GERLAI R, 1993, BEHAV BRAIN RES, V55, P51, DOI 10.1016/0166-4328(93)90006-C; HIRANO A, 1983, PROG NEUROPATH, V5, P99; HUNTINGFORD F, 1984, STUDY ANIMAL BEHAVIO; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; Kirschner D., 1984, MYELIN, P51; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OWENS GC, 1991, NEURON, V7, P565, DOI 10.1016/0896-6273(91)90369-B; OWENS GC, 1990, J CELL BIOL, V111, P1171, DOI 10.1083/jcb.111.3.1171; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V98, P1272, DOI 10.1083/jcb.98.4.1272; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; TROPAK MB, 1988, MOL BRAIN RES, V4, P143, DOI 10.1016/0169-328X(88)90006-X; UMERMORI H, 1994, NATURE, V367, P572; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; WOOD PM, 1990, J NEUROSCI, V10, P3635; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	27	308	310	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					747	750		10.1038/369747a0	http://dx.doi.org/10.1038/369747a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7516497				2022-12-01	WOS:A1994NU58100061
J	ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A				ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A			PREVALENCE OF HEPATITIS-C ANTIBODIES IN CLINICAL HEALTH-CARE WORKERS	LANCET			English	Article							VIRUS-INFECTION; NEEDLESTICK INJURY; HCV; BLOOD; RISK	Health-care workers are known to be at risk from occupational transmission of blood-borne viruses, including hepatitis C. There may be serious implications following infection with hepatitis C including possible transmission to patients. We determined the prevalence of hepatitis C virus (HCV) antibodies among health-care workers at risk of occupational contact with blood and body fluids and among source patients in reported blood-exposure incidents. Anonymised stored blood samples from health-care workers immunised against hepatitis B virus since 1991 (n=1053) and blood samples from source patients in needlestick injuries (retrospective and prospective) since 1989 (n=373) were analysed. 3 (0.28%) of the serum samples from health-care workers were found to be anti-HCV-positive. 17 (8.5%) of 200 source patients tested retrospectively between January 1989 and January 1992, and 24 (13.9%) of 173 source patients tested prospectively between January 1992 and June 1993 were anti-HCV-positive. During the second period, 15 (10.6%) of 142 source patients tested for human immunodeficiency virus (HIV) were positive and 7 (3.8%) of 184 source patients tested for hepatitis B surface antigen were positive. 6 of 24 (25%) HCV-infected patients were diagnosed only after the incident; for hepatitis B, 2 (33%) of patients were diagnosed after the incident, and for HIV all patients were previously diagnosed. The seroprevalence of HCV among these health-care workers is no higher than that reported in blood donors. This suggests that there has not been significant occupational transmission of HCV to these health-care workers despite the high prevalence of HCV (often covert) among source patients in reported blood exposure in the same hospital.	ROYAL FREE NHS TRUST,OCCUPAT HLTH UNIT,LONDON,ENGLAND; ROYAL FREE NHS TRUST,DEPT VIROL,DIV COMMUNICABLE DIS,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; COCKCROFT A, 1990, BRIT J IND MED, V47, P199; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; GARSON JA, 1991, LANCET, V335, P1419; HERBERT AM, 1992, LANCET, V339, P304; JOCHEN ABB, 1992, LANCET, V339, P304, DOI 10.1016/0140-6736(92)91373-G; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MACLENNAN S, 1992, LANCET, V339, P131, DOI 10.1016/0140-6736(92)91048-D; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; OAKLEY K, 1992, BRIT MED J, V304, P949, DOI 10.1136/bmj.304.6832.949; RYAN KE, 1994, BRIT MED J, V308, P696, DOI 10.1136/bmj.308.6930.696; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; VAGLIA A, 1990, LANCET, V336, P1315, DOI 10.1016/0140-6736(90)92997-V; WEST DJ, 1984, AM J MED SCI, V287, P26, DOI 10.1097/00000441-198403000-00006; 1988, MMWR-MORBID MORTAL W, V37, P377; 1993, COMMUNICAB DIS REP, V3, pR135	18	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1618	1620		10.1016/S0140-6736(94)93064-3	http://dx.doi.org/10.1016/S0140-6736(94)93064-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7516460				2022-12-01	WOS:A1994NU35400017
J	FREY, PA; WHITT, SA; TOBIN, JB				FREY, PA; WHITT, SA; TOBIN, JB			A LOW-BARRIER HYDROGEN-BOND IN THE CATALYTIC TRIAD OF SERINE PROTEASES	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; ACTIVE-SITE; ALPHA-CHYMOTRYPSIN; HISTIDINE; PROTON; STABILIZATION; IMIDAZOLE; TRYPSIN; ENZYME; ACID	Spectroscopic properties of chymotrypsin and model compounds indicate that a low-barrier hydrogen bond participates in the mechanism of serine protease action. A low-barrier hydrogen bond between N delta 1 of His(57) and the beta-carboxyl group of Asp(102) in chymotrypsin can facilitate the formation of the tetrahedral adduct, and the nuclear magnetic resonance properties of this proton indicate that it is a low-barrier hydrogen bond. These conclusions are supported by the chemical shift of this proton, the deuterium isotope effect on the chemical shift, and the properties of hydrogen-bonded model compounds in organic solvents, including the hydrogen bond in cis-urocanic acid, in which the imidazole ring is internally hydrogen-bonded to the carboxyl group.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison	FREY, PA (corresponding author), UNIV WISCONSIN,GRAD SCH,INST ENZYME RES,MADISON,WI 53705, USA.				NIDDK NIH HHS [DK 28607] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028607, R37DK028607] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHOVCHIN WW, 1985, P NATL ACAD SCI USA, V82, P7948, DOI 10.1073/pnas.82.23.7948; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BREZINSKI B, 1981, ORG MAGN RESONANCE, V15, P78; CLARK JH, 1983, J CHEM SOC CHEM COMM, P136, DOI 10.1039/c39830000136; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DEGASZAFRAN Z, 1981, ORG MAGN RESONANCE, V16, P214, DOI 10.1002/mrc.1270160310; EDELBACHER S, 1943, HOPPESEYLERS Z PHYSL, V279, P63; EMSLEY J, 1980, CHEM SOC REV, V9, P91, DOI 10.1039/cs9800900091; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GUNNARSSON G, 1976, CHEM PHYS LETT, V38, P96, DOI 10.1016/0009-2614(76)80264-3; GUTHRIE JP, 1993, J AM CHEM SOC, V115, P11569, DOI 10.1021/ja00077a063; HALKIDES CJ, 1993, J AM CHEM SOC, V115, P3332, DOI 10.1021/ja00061a043; HENDERSON R, 1971, BIOCHEM J, V124, P13, DOI 10.1042/bj1240013; Hibbert Frank., 1990, ADV PHYS ORG CHEM, V26, P255; Jencks W. P., 1970, HDB BIOCH, pJ187; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; KOSSIAKOFF AA, 1981, BIOCHEMISTRY-US, V20, P6462, DOI 10.1021/bi00525a027; LIANG TC, 1987, BIOCHEMISTRY-US, V26, P7603, DOI 10.1021/bi00398a011; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P4627, DOI 10.1021/bi00615a008; MARKLEY JL, 1978, BIOCHEMISTRY-US, V17, P46; MORRISON H, 1980, J CHROMATOGR, V183, P83, DOI 10.1016/S0378-4347(00)81402-4; MURTHY ASN, 1970, J CHEM SOC A, P1251, DOI 10.1039/j19700001251; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROBILLAR.G, 1974, J MOL BIOL, V86, P541, DOI 10.1016/0022-2836(74)90179-X; ROBILLARD G, 1972, J MOL BIOL, V71, P507, DOI 10.1016/0022-2836(72)90366-X; ROGERS GA, 1974, J AM CHEM SOC, V96, P2473, DOI 10.1021/ja00815a028; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; ZEEGERSHUYSKENS T, 1990, J MOL LIQ, V46, P263, DOI 10.1016/0167-7322(90)80059-S; ZIMMERMAN SC, 1991, TETRAHEDRON, V47, P2649, DOI 10.1016/S0040-4020(01)81797-X	32	706	718	7	108	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1927	1930		10.1126/science.7661899	http://dx.doi.org/10.1126/science.7661899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7661899				2022-12-01	WOS:A1994NT84700044
J	MAYOR, S; ROTHBERG, KG; MAXFIELD, FR				MAYOR, S; ROTHBERG, KG; MAXFIELD, FR			SEQUESTRATION OF GPI-ANCHORED PROTEINS IN CAVEOLAE TRIGGERED BY CROSS-LINKING	SCIENCE			English	Article							FOLATE-BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; CELL-SURFACE; MEMBRANE-PROTEINS; MOLECULES; 5'-NUCLEOTIDASE; RECEPTOR	Glycosyl-phosphatidylinositol (GPI)-anchored proteins have been reported to reside in clusters collected over small membrane invaginations called caveolae. The detection of different GPI-anchored proteins with fluorescently labeled monoclonal antibodies showed that these proteins are not constitutively concentrated in caveolae; they enter these structures independently after cross-linking with polyclonal secondary antibodies. Analysis of the cell surface distribution of the GPI-anchored folate receptor by electron microscopy confirms these observations. Thus, multimerization of GPI-anchored proteins regulates their sequestration in caveolae, but in the absence of agents that promote clustering they are diffusely distributed over the plasma membrane.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019; Eckhardt, Erik/G-1567-2010	Maxfield, Fred/0000-0003-4396-8866; 	NIDDK NIH HHS [DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson Richard G., 1993, Trends in Cell Biology, V3, P69, DOI 10.1016/0962-8924(93)90065-9; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CONEY LR, 1991, CANCER RES, V51, P6125; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1992, LIPID MODIFICATION P, P83; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P627; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x; WIDNELL CC, 1982, CELL, V28, P61, DOI 10.1016/0092-8674(82)90375-0; XU XX, 1991, J BIOL CHEM, V266, P17040; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065	33	449	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1948	1951		10.1126/science.7516582	http://dx.doi.org/10.1126/science.7516582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516582				2022-12-01	WOS:A1994NT84700050
J	SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J				SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J			CRYSTAL-STRUCTURE OF RAT DNA-POLYMERASE-BETA - EVIDENCE FOR A COMMON POLYMERASE MECHANISM	SCIENCE			English	Article							ESCHERICHIA-COLI; BINDING DOMAIN; REVERSE-TRANSCRIPTASE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; KLENOW FRAGMENT; RNA-POLYMERASE; IDENTIFICATION; PROTEIN; SYNTHETASE	Structures of the 31-kilodalton catalytic domain of rat DNA polymerase beta (pol beta) and the whole 39-kilodalton enzyme were determined at 2.3 and 3.6 angstrom resolution, respectively. The 31-kilodalton domain is composed of fingers, palm, and thumb subdomains arranged to form a DNA binding channel reminiscent of the polymerase domains of the Klenow fragment of Escherichia coli DNA polymerase I, HIV-1 reverse transcriptase, and bacteriophage T7 RNA polymerase. The amino-terminal 8-kilodalton domain is attached to the fingers subdomain by a flexible hinge. The two invariant aspartates found in all polymerase sequences and implicated in catalytic activity have the same geometric arrangement within structurally similar but topologically distinct palms, indicating that the polymerases have maintained, or possibly re-evolved, a common nucleotidyl transfer mechanism. The location of Mn2+ and deoxyadenosine triphosphate in pot beta confirms the role of the invariant aspartates in metal ion and deoxynucleoside triphosphate binding.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	SAWAYA, MR (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093, USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA17374] Funding Source: Medline; NIEHS NIH HHS [ES06839] Funding Source: Medline; NIGMS NIH HHS [GM10928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRUNGER A, 1992, X PLOR MANUAL; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; COLL M, 1991, EMBO J, V10, P1; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRASAD R, IN PRESS J BIOL CHEM; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STRAUSS P, 1993, FASEB J, V7, pA1291; SWINDELLS MB, 1993, NATURE, V362, P299, DOI 10.1038/362299a0; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	52	415	428	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1930	1935		10.1126/science.7516581	http://dx.doi.org/10.1126/science.7516581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516581				2022-12-01	WOS:A1994NT84700045
J	HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC				HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC			VIRUS-SPECIFIC CD8+ T-CELL MEMORY DETERMINED BY CLONAL BURST SIZE	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SENDAI VIRUS; INVIVO; MICE; EXPRESSION; INFLUENZA; INFECTION; IMMUNITY; ANTIGEN; BETA	Although some viruses, particularly the herpes viruses, may never be eliminated from the body(1), others like influenza A, regularly reinfect humans and boost waning crossreactive CD8(+) T-cell immunity(2). Prolonged T-cell memory is found for viruses that are unlikely to be re-encountered and which do not persist in the host genome(3-5), indicating that CD8(+) T-cell memory might be independent dent of continued (or sporadic) antigenic exposure. A feature of virus-specific CD8(+) T-cell memory is that antigen-specific cytotoxic T-lymphocyte precursors (CTLp) are greatly increased and remain high throughout life. The idea that persistence of the inducing antigen is essential is based on experiments in which adoptively transferred CD8(+) memory T cells could not be detected for more than a few weeks in naive recipient mice without secondary challenge(6,7). Here we show that restimulation of such chimaeric mice with an inducing Sendai virus antigen increases the clonal burst size more than 7-fold within 8 days, making memory CTLp easier to detect in the longer term. We find that Sendai-virus-specific CTLp are maintained for >250 days in irradiated uninfected recipients, including reconstituted beta(2)-microglobulin(-/-) mice. To determine whether a source of viral peptide can persist after primary infection, we gave Sendai-virus-specific Thy1.1(+) memory spleen cells to naive mice that had been minimally depleted of Thy1.2(+) T cells, or to comparable recipients that had recovered from infection with Sendai virus or influenza virus. Although antibody against Sendai virus was never found in the naive recipients, Sendai-virus-specific CD8(+) memory T cells were maintained equally well in each case for >100 days after cell transfer. We find so evidence for persisting depots of viral protein that might feed into the endogenous processing pathway and maintain virus-specific CD8(+) T-cell memory.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & IMMUNOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital			Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BURTON GF, 1993, J IMMUNOL, V150, P31; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; DOHERTY PC, 1981, IMMUNOL REV, V58, P37, DOI 10.1111/j.1600-065X.1981.tb00349.x; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; DOHERTY PC, 1989, IMMUNOLOGY, V66, P631; DOHERTY PC, 1994, STRATEGIES VACCINE D, P51; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FRASER JD, 1987, IMMUNOGENETICS, V26, P31, DOI 10.1007/BF00345451; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HOU S, 1992, J IMMUNOL, V149, P1319; HOU S, 1993, J IMMUNOL, V150, P5494; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KING CC, 1990, J VIROL, V64, P5611, DOI 10.1128/JVI.64.11.5611-5616.1990; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MCMICHAEL AJ, 1983, LANCET, V2, P762; Moss D J, 1992, Semin Immunol, V4, P97; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; SEDGWICK JD, 1986, J IMMUNOL METHODS, V87, P37, DOI 10.1016/0022-1759(86)90341-8; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	28	465	475	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					652	654		10.1038/369652a0	http://dx.doi.org/10.1038/369652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516039				2022-12-01	WOS:A1994NT45900056
J	LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R				LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R			CYTOTOXIC T-CELL MEMORY WITHOUT ANTIGEN	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PERSISTING ANTIGEN; SELECTION	Memory is a hallmark of the immune system and ever since its recognition there has been considerable interest in understanding how immunity is maintained(1-5). The current model is that long-term memory is dependent on persistent antigenic stimulation(6-11). We report here results that challenge this view and provide evidence that antigen is not essential for the maintenance of CD8(+) T-cell memory. We show that memory CD8(+) cytotoxic T lymphocytes persist indefinitely in the absence of priming antigen, retain the memory phenotype (CD44(hi)), and provide protection against virus challenge. These findings suggest a re-evaluation of our current thinking on mechanisms involved in maintaining immunity and have implications towards designing effective vaccination strategies.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								Ahmed R, 1992, Semin Immunol, V4, P105; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D; CELADA F, 1971, PROG ALLERGY, V15, P223; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; MACDONALD HR, 1990, CURR TOP MICROBIOL, V159, P97; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; Matloubian M., 1993, J VIROL, V67, P7340; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PAUL W, 1993, FUNDAMENTAL IMMUNOLO, P1211; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TABI Z, 1988, CELL IMMUNOL, V113, P268, DOI 10.1016/0008-8749(88)90026-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; TEW JG, 1980, IMMUNOL REV, V53, P175; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; ZINKERNAGEL RM, 1990, CURR TOP MICROBIOL, V159, P65	21	583	595	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					648	652		10.1038/369648a0	http://dx.doi.org/10.1038/369648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516038				2022-12-01	WOS:A1994NT45900055
J	ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M				ENDERS, G; MILLER, E; CRADOCKWATSON, J; BOLLEY, I; RIDEHALGH, M			CONSEQUENCES OF VARICELLA AND HERPES-ZOSTER IN PREGNANCY - PROSPECTIVE-STUDY OF 1739 CASES	LANCET			English	Article							VIRUS-INFECTIONS; ZOSTER VIRUS	In a joint prospective study in Germany and the United Kingdom between 1980 and 1993, 1373 women who had varicella and 366 who had herpes tester during the first 36 weeks of gestation were followed up.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; INST VIROL INFEKTIOL & EPIDEMIOL,D-70192 STUTTGART,GERMANY; WITHINGTON HOSP,PUBL HLTH LAB,MANCHESTER M20 8LR,LANCS,ENGLAND	Public Health England								ALKALAY AL, 1987, J PEDIATR-US, V111, P320, DOI 10.1016/S0022-3476(87)80447-X; CRADOCKWATSON JE, 1991, CURRENT TOPICS CLIN, P1; DASILVA O, 1990, PEDIATR INFECT DIS J, V9, P854; ENDERS G, 1985, POSTGRAD MED J, V61, P23; GOTTARDI H, 1991, GEBURTSH FRAUENHEILK, V51, P63, DOI 10.1055/s-2008-1026335; HAAKE DA, 1990, REV INFECT DIS, V12, P788; HIGA K, 1987, OBSTET GYNECOL, V69, P214; KANGRO HO, 1988, EPIDEMIOL INFECT, V101, P187, DOI 10.1017/S0950268800029344; LAFORET EG, 1947, NEW ENGL J MED, V236, P534, DOI 10.1056/NEJM194704102361504; MEHRAEIN Y, 1991, GEBURTSH FRAUENHEILK, V51, P984, DOI 10.1055/s-2008-1026249; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; Miller E., 1993, Reviews in Medical Microbiology, V4, P222; MILLER E, 1989, LANCET, V2, P371; MILLER E, 1993, LANCET, V341, P308, DOI 10.1016/0140-6736(93)92663-E; PUCHHAMMERSTOCK.E, 1994, IN PRESS J PERINAT M, V22; SCHARF A, 1990, J PERINAT MED, V18, P317	16	335	357	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1548	1551		10.1016/S0140-6736(94)92943-2	http://dx.doi.org/10.1016/S0140-6736(94)92943-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7802767				2022-12-01	WOS:A1994NR32900013
J	SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK				SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK			THE EPIDEMIOLOGY OF TUBERCULOSIS IN SAN-FRANCISCO - A POPULATION-BASED STUDY USING CONVENTIONAL AND MOLECULAR METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; LENGTH-POLYMORPHISM ANALYSIS; COMPLEX STRAINS; TRANSMISSION; OUTBREAK; TOOL; INFECTION; SEQUENCE; IS6110	Background. The epidemiology of tuberculosis in urban populations is changing. Combining conventional epidemiologic techniques with DNA fingerprinting of Mycobacterium tuberculosis can improve the understanding of how tuberculosis is transmitted. Methods. We used restriction-fragment-length polymorphism (RFLP) analysis to study M. tuberculosis isolates from all patients reported to the tuberculosis registry in San Francisco during 1991 and 1992. These results were interpreted along with clinical, demographic, and epidemiologic data. Patients infected with the same strains were identified according to their RFLP patterns, and patients with identical patterns were grouped in clusters. Risk factors for being in a cluster were analyzed. Results. Of 473 patients studied, 191 appeared to have active tuberculosis as a result of recent infection. Tracing of patients' contacts with the use of conventional methods identified links among only 10 percent of these patients. DNA fingerprinting, however, identified 44 clusters, 20 of which consisted of only 2 persons and the largest of which consisted of 30 persons. In patients under 60 years of age, Hispanic ethnicity (odds ratio, 3.3; P = 0.02), black race (odds ratio, 2.3; P = 0.02), birth in the United States (odds ratio, 5.8; P < 0.001), and a diagnosis of the acquired immunodeficiency syndrome (odds ratio, 1.8; P = 0.04) were independently associated with being in a cluster. Further study of patients in clusters confirmed that poorly compliant patients with infectious tuberculosis have a substantial adverse effect on the control of this disease. Conclusions. Despite an efficient tuberculosis-control program, nearly a third of new cases of tuberculosis in San Francisco are the result of recent infection. Few of these instances of transmission are identified by conventional contact tracing.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,DIV TB CONTROL,SAN FRANCISCO,CA	Howard Hughes Medical Institute; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health	SMALL, PM (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MED,DIV INFECT DIS & GEOG MED,RM 251,STANFORD,CA 94305, USA.		Daley, Charles L./AAC-3231-2021	Parsonnet, Julie/0000-0001-7342-5366	NIAID NIH HHS [R0I-AI34238-01, K08 AI01137-01] Funding Source: Medline; PHS HHS [U52-CCU 900454] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001137, R01AI034238] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHEVRELDELLAGI D, 1993, J CLIN MICROBIOL, V31, P2446, DOI 10.1128/JCM.31.9.2446-2450.1993; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; GODFREYFAUSSETT P, 1992, BRIT MED J, V305, P221, DOI 10.1136/bmj.305.6847.221; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HORWITZ O, 1973, HEALTH SERV REP, V88, P493, DOI 10.2307/4594837; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RASTOGI N, 1992, EUR J CLIN MICROBIOL, V11, P901, DOI 10.1007/BF01962370; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; TAKAHASHI M, 1993, MICROBIOL IMMUNOL, V37, P289, DOI 10.1111/j.1348-0421.1993.tb03212.x; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993; 1993, AM REV RESPIR DIS, V146, P1623; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, MMWR-MORBID MORTAL W, V41, P507; 1993, TUBERCULOSIS STATIST	28	1027	1056	1	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1703	1709		10.1056/NEJM199406163302402	http://dx.doi.org/10.1056/NEJM199406163302402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7910661				2022-12-01	WOS:A1994NR10900002
J	TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T				TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T			EXCITATION-CONTRACTION UNCOUPLING AND MUSCULAR DEGENERATION IN MICE LACKING FUNCTIONAL SKELETAL-MUSCLE RYANODINE-RECEPTOR GENE	NATURE			English	Article							CALCIUM RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; MOLECULAR-CLONING; TARGETED MUTATION; MYOGENIN GENE; DNA; CDNA; INACTIVATION; EXPRESSION	CONTRACTION of skeletal muscle is triggered by the release of Ca2+ from the sarcoplasmic reticulum (SR) after depolarization of transverse tubules(1,2). The ryanodine receptor exists as a 'foot' protein in the junctional gap between the sarcoplasmic reticulum and the transverse tubule in skeletal muscle, and is proposed to function as a calcium-release channel during excitation-contraction (E-C) coupling(3-6). Previous complementary DNA-cloning studies have defined three distinct subtypes of the ryanodine receptor in mammalian tissues, namely skeletal muscle, cardiac and brain types(7-12). We report here mice with a targeted mutation in the skeletal muscle ryanodine receptor gene. Mice homozygous for the mutation die perinatally with gross abnormalities of the skeletal muscle. The contractile response to electrical stimulation under physiological conditions is totally abolished in the mutant muscle, although ryanodine receptors other than the skeletal-muscle type seem to exist because the response to caffeine is retained. Our results show that the skeletal muscle ryanodine receptor is essential for both muscular maturation and E-C coupling, and also imply that the function of the skeletal muscle ryanodine receptor during E-C coupling cannot be substituted by other subtypes of the receptor.	INT INST ADV STUDIES,KYOTO 604,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NATL INST FITNESS & SPORTS,DEPT PHYSIOL,KANOYA,KAGOSHIMA 89123,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; National Institute Fitness & Sports Kanoya; Japanese Foundation for Cancer Research			Noda, Tetsuo/B-1667-2016; Minowa, Osamu/AAM-1238-2020; Tuluc, Petronel/C-2527-2011	Takeshima, Hiroshi/0000-0003-4525-3725				BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GLIANNINI G, 1992, SCIENCE, V257, P91; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KLAUS MM, 1983, DEV BIOL, V99, P152, DOI 10.1016/0012-1606(83)90262-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR AP, 1990, CELL, V62, P1073; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NUMA S, 1990, COLD SPRING HARB SYM, V40, P1; OTSU K, 1990, J BIOL CHEM, V265, P13472; PAI AC, 1965, DEV BIOL, V11, P82, DOI 10.1016/0012-1606(65)90038-2; PAI AC, 1965, DEV BIOL, V11, P93, DOI 10.1016/0012-1606(65)90039-4; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO A, 1986, J CELL BIOL, V103, P741; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1979, METHOD ENZYMOL, V88, P152; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	34	329	337	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					556	559		10.1038/369556a0	http://dx.doi.org/10.1038/369556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7515481				2022-12-01	WOS:A1994NR29400048
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW RULE ON LABELING FOODS AS HEALTHY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-01	WOS:A1994NP95900004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED NON-SMALL-CELL LUNG-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-01	WOS:A1994NP95900007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW DEVICE APPROVED FOR USE BY PARAPLEGICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-01	WOS:A1994NP95900006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PACLITAXEL APPROVED FOR TREATMENT OF CERTAIN BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-01	WOS:A1994NP95900005
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND THE RISK FOR DUODENAL AND GASTRIC-ULCERATION	ANNALS OF INTERNAL MEDICINE			English	Article						HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; DUODENAL ULCER; PEPTIC ULCER	CAMPYLOBACTER-PYLORI; GASTRODUODENAL DISEASE; SURFACE-PROTEINS; PATHOGENESIS; ERADICATION; RECURRENCE; HAWAII; INFLAMMATION; CARCINOMA; ULCERS	Objective: To determine whether a preexisting Helicobacter pylori infection increases the risk for developing duodenal or gastric ulcer. Design: A nested case-control study based on a cohort of 5443 Japanese-American men who had a physical examination and a phlebotomy from 1967 to 1970. Setting: All 10 general hospitals on the Hawaiian island of Oahu. Patients: 150 patients with gastric ulcer and 65 patients with duodenal ulcer identified in the cohort of study participants after a hospital surveillance period of more than 20 years. Measurements: Stored serum specimens from patients and from matched controls were tested for the presence of serum IgG antibody to H. pylori using enzyme-linked immunosorbent assay. st Results: 93% of the 150 patients with gastric ulcer and 78% of the matched controls had a positive antibody level for H. pylori-specific IgG, yielding an odds ratio of 3.2 (95% Cl, 1.6 to 6.5). For duodenal ulcer, 92% of the 65 patients and 78% of the matched controls had a positive test result, yielding an odds ratio of 4.0 (Cl, 1.1 to 14.2). As the level of antibody to H. pylori increased, a statistically significant increase was noted in the risk for gastric and duodenal ulcer. The association with H. pylori infection was statistically significant for both types of ulcer, even when the diagnosis was made 10 or more years after the serum sample had been obtained. Conclusion: Preexisting H. pylori infection increases the risk for subsequent development of either duodenal or gastric ulcer disease.	UNIV CINCINNATI, SCH MED, DEPT PATHOL, CINCINNATI, OH 45267 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA	University System of Ohio; University of Cincinnati; Vanderbilt University	NOMURA, A (corresponding author), KUAKINI MED CTR, JAPAN HAWAII CANC STUDY, 347 N KUAKINI ST, HONOLULU, HI 96817 USA.			Perez Perez, Guillermo/0000-0002-0131-5798	NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 33644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, EPIDEMIOLOGIC RES; BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1992, J BIOL CHEM, V267, P10570; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; MACMAHON B, 1970, EPIDEMIOLOGY PRINCIP, P207; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1988, LANCET, V2, P1437; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; RABENECK L, 1991, AM J MED, V91, P566; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; STEER HW, 1984, GUT, V25, P1203, DOI 10.1136/gut.25.11.1203; STEMMERMANN GN, 1968, JNCI-J NATL CANCER I, V41, P627; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; WORMSLEY KG, 1989, SCAND J GASTROENTERO, V24, P53, DOI 10.3109/00365528909091736; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	38	288	297	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					977	981		10.7326/0003-4819-120-12-199406150-00001	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	7741826				2022-12-01	WOS:A1994NQ96400001
J	BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF				BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF			ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE	LANCET			English	Note							IRON; L1	The iron chelator deferiprone (L1) reduces tissue iron stores in iron-loaded patients. Three of sixteen patients treated with deferiprone developed joint pain and swelling without evidence of systemic lupus erythematosus (SLE). Articular cartilage, synovial hypertrophy and iron deposition, and synovial lining cell proliferation, with no inflammatory or allergic reaction, were observed on synovial exploration and biopsy. Symptoms resolved partly or completely during continued drug administration. We hypothesise that deferiprone-induced shifts of iron to synovium resulted in tissue damage, accelerated by free-radical formation during incomplete complexation of iron and this bidentate chelator. This deferiprone-associated symptom complex is not associated with drug-induced SLE, and does not progress in severity during continued therapy.	HOSP SICK CHILDREN,DEPT PEDIAT,HAEMOGLOBINOPATHY PROGRAM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,TORONTO HOSP,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV ALBERTA,MCCALG CTR JOINT INJURY & ARTHRITIS RES,CALGARY,AB,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta			Olivieri, Nancy/AAI-2250-2020	Inman, Robert/0000-0002-4750-1422				AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALREFAIE FN, 1992, BLOOD, V80, P592; BERDOUKAS V, 1991, LANCET, V337, P672, DOI 10.1016/0140-6736(91)92483-I; BERKOVITCH M, 1992, BLOOD S1, V80, pA7; BLAKE DR, 1981, LANCET, V2, P1142; BRITTENHAM GM, 1992, BLOOD, V80, P569; GRATWICK GM, 1978, ANN INTERN MED, V88, P494, DOI 10.7326/0003-4819-88-4-494; HERSHKO C, 1991, BLOOD, V77, P2049; MAGARO M, 1990, ANN RHEUM DIS, V49, P268, DOI 10.1136/ard.49.4.268-b; MEHTA J, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90906-6	10	58	60	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1471	1472		10.1016/S0140-6736(94)92585-2	http://dx.doi.org/10.1016/S0140-6736(94)92585-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911181				2022-12-01	WOS:A1994NQ41500012
J	BURNS, DN; GELLERT, GA; CRONE, RK				BURNS, DN; GELLERT, GA; CRONE, RK			TUBERCULOSIS IN EASTERN-EUROPE AND THE FORMER SOVIET-UNION - HOW CONCERNED SHOULD WE BE	LANCET			English	Editorial Material									PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA		BURNS, DN (corresponding author), NIH,BETHESDA,MD 20892, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CHEN LC, 1992, LANCET, V339, P1465, DOI 10.1016/0140-6736(92)92044-G; ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1994, WHOTB94176 DOC; 1993, MMWR-MORBID MORTAL W, V42, P696	8	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1445	1446		10.1016/S0140-6736(94)92576-3	http://dx.doi.org/10.1016/S0140-6736(94)92576-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911172				2022-12-01	WOS:A1994NQ41500003
J	HOPKINS, KD; LEHMANN, ED; GOSLING, RG				HOPKINS, KD; LEHMANN, ED; GOSLING, RG			AORTIC COMPLIANCE MEASUREMENTS - A NONINVASIVE INDICATOR OF ATHEROSCLEROSIS	LANCET			English	Editorial Material							WAVE VELOCITY; CORONARY		ST THOMAS HOSP,DIV MED,LONDON,ENGLAND; GUYS HOSP,DIV RADIOL SCI,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	HOPKINS, KD (corresponding author), GUYS HOSP,DEPT OBSTET & GYNAECOL,LONDON SE1 9RT,ENGLAND.							CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1993, CIRCULATION, V87, P17; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FURBERG CD, 1993, CIRCULATION, V87, P82; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Kelly R, 1989, J VASC MED BIOL, V3, P142; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; PEARSON TA, 1993, CIRCULATION, V87, P2; PROBSTFIELD JL, 1993, CIRCULATION, V87, P74; ROBERTS JC, 1959, CIRCULATION, V20, P511, DOI 10.1161/01.CIR.20.4.511; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700	12	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1447	1447		10.1016/S0140-6736(94)92577-1	http://dx.doi.org/10.1016/S0140-6736(94)92577-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911173				2022-12-01	WOS:A1994NQ41500004
J	NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A				NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A			CESAREAN-SECTION AND RISK OF VERTICAL TRANSMISSION OF HIV-1 INFECTION	LANCET			English	Article							CESAREAN-SECTION; WOMEN; SECRETIONS	Indirect evidence suggests that a significant proportion of vertical transmission of HIV infection occurs late in pregnancy or during delivery. Caesarean section, therefore, may protect the fetus from infection. We looked at 1254 HIV-infected mothers and their children and the effects of different modes of delivery on transmission risk. We also included a detailed assessment of confounding factors associated with transmission risk. Women who had caesarean sections were more advanced in their disease progression which may cause the protective effect of caesarean section to be underestimated. When this and other potential confounding factors were taken into account, caesarean section was estimated to halve the rate of transmission. This finding is important in the design of studies to evaluate treatments aimed at reducing mother-to-child transmission.	UNIV PADUA,PADUA,ITALY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,W-1000 BERLIN,GERMANY; CITY HOSP EDINBURGH,EDINBURGH,SCOTLAND; CTR REPROD BIOL,EDINBURGH,SCOTLAND; HOSP LA PAZ,MADRID,SPAIN; HOSP LA FE,E-46009 VALENCIA,SPAIN; ACAD MED CENTRUM,AMSTERDAM,NETHERLANDS; KAROLINSKA INST,HUDDINGE HOSP,S-10401 STOCKHOLM,SWEDEN; DANDERYD HOSP,STOCKHOLM,SWEDEN; CENT MICROBIOL LAB,STOCKHOLM,SWEDEN; IST GIANNINA GASLINI,I-16148 GENOA,ITALY; HOP ST PIERRE & ERASME,BRUSSELS,BELGIUM; HOSP DEL MAR,BARCELONA,SPAIN; OSPED SAN PAOLO,MILAN,ITALY; POLICLIN S ORSOLA,BOLOGNA,ITALY; UNIV BRESCIA,BRESCIA,ITALY; UNIV ROMA LA SAPIENZA,ROME,ITALY; UNIV CATTOLICA SACRO CUORE,ROME,ITALY; OSPED L SACCO,MILAN,ITALY; POLICLIN SAN MATTEO,I-27100 PAVIA,ITALY; CLIN MANGIAGALLI,MILAN,ITALY; CLIN DE MARCHI,MILAN,ITALY	University of Padua; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hospital Universitario La Paz; Hospital Universitari i Politecnic La Fe; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Danderyds Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; Universite Libre de Bruxelles; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; San Paolo-Polo Universitaria Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Brescia; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; Luigi Sacco Hospital; IRCCS Fondazione San Matteo	NEWELL, ML (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Grossi, Enzo/AAF-7765-2020; De Rossi, Anita/Q-4845-2019; Giaquinto, Carlo/AAB-5016-2020; Spinillo, Arsenio/AAB-9315-2022; Newell, Marie-Louise/AAE-8222-2019; Plebani, Alessandro/C-8593-2011; De Rossi, A./L-3128-2015	De Rossi, Anita/0000-0001-6435-7509; Spinillo, Arsenio/0000-0002-7755-1084; Newell, Marie-Louise/0000-0002-1074-7699; De Rossi, A./0000-0001-6435-7509; GIAQUINTO, CARLO/0000-0001-9365-0413; Alimenti, Ariane/0000-0003-4999-8230; Dunn, David/0000-0003-1836-4446				[Anonymous], MMWR; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Chiodo F, 1986, Lancet, V1, P739; CHOO V, 1994, LANCET, V343, P533, DOI 10.1016/S0140-6736(94)91477-X; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; DEMUYLDER X, 1993, HEALTH POLICY PLANN, V8, P101, DOI 10.1093/heapol/8.2.101; FUITH LC, 1992, LANCET, V339, P1603, DOI 10.1016/0140-6736(92)91863-4; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V2, P1270; PECKHAM C, 1993, MEASURES DECREASE RI, P1; RUBIN DB, 1991, STATS MED, V110, P585; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157; SLADE MS, 1975, SURGERY, V78, P363; SMITH JR, 1991, BRIT J OBSTET GYNAEC, V98, P124, DOI 10.1111/j.1471-0528.1991.tb13356.x; TOVO PA, 1993, LANCET, V342, P630, DOI 10.1016/0140-6736(93)91753-9; VILLARI P, 1993, ONLINE J CURR CLIN T; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P225	21	135	139	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1464	1467						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911178				2022-12-01	WOS:A1994NQ41500009
J	NITTI, VW				NITTI, VW			INTRAVESICAL CAPSAICIN FOR TREATMENT OF NEUROGENIC BLADDER	LANCET			English	Editorial Material							SPINAL-CORD INJURY; MICTURITION; REFLEX				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KOLDEWIJN EL, 1994, J UROLOGY, V151, P955, DOI 10.1016/S0022-5347(17)35133-9; MAGGI CA, 1989, J UROLOGY, V142, P150, DOI 10.1016/S0022-5347(17)38701-3; MAGGI CA, 1989, NEUROSCIENCE, V31, P745, DOI 10.1016/0306-4522(89)90438-7; MCGUIRE EJ, 1991, NEUROUROL URODYNAM, V10, P223, DOI 10.1002/nau.1930100302; MCGUIRE EJ, 1994, J UROLOGY, V151, P965, DOI 10.1016/S0022-5347(17)35135-2; MCGUIRE EJ, 1983, J UROLOGY, V129, P775, DOI 10.1016/S0022-5347(17)52357-5; SIRLS LT, 1994, J UROLOGY, V151, P946, DOI 10.1016/S0022-5347(17)35131-5	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1448	1448		10.1016/S0140-6736(94)92578-X	http://dx.doi.org/10.1016/S0140-6736(94)92578-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911174				2022-12-01	WOS:A1994NQ41500005
J	SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R				SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R			PATTERNS OF DONOR-TYPE MICROCHIMERISM AFTER HEART-TRANSPLANTATION	LANCET			English	Note							ALLOGRAFTS; CHIMERISM; LIVER	Allogeneic microchimerism of donor-type has been demonstrated in stable patients in the long-term after organ transplantation. We have analysed microchimerism in shin and blood of 47 heart-transplanted patients after transplantation with polymerase-chain-reaction amplification specific for donor HLA-DRB1. Microchimerism was detectable in 50% of the patients in the first 6 months, in 100% between 6 months and 2 years, and in 58% in the third postoperative year or later. The state of chimerism was not related to acute or chronic rejections. Patterns of microchimerism after heart transplantation may be dynamic, but any association with clinical and immunological variables remains to be elucidated.	HANNOVER MED SCH,THORAX HERZ & GEFASSCHIRURG KLIN,D-30623 HANNOVER,GERMANY	Hannover Medical School	SCHLITT, HJ (corresponding author), HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30623 HANNOVER,GERMANY.		Schlitt, Hans J./ABG-4368-2020					BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; LARSEN CP, 1990, ANN SURG, V212, P308, DOI 10.1097/00000658-199009000-00009; QIAN S, IN PRESS HEPATOLOGY; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P951, DOI 10.1097/00007890-199310000-00033; SCHLITT HJ, 1992, TRANSPLANTATION, V56, P1001; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V	10	130	132	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1469	1471		10.1016/S0140-6736(94)92584-4	http://dx.doi.org/10.1016/S0140-6736(94)92584-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911180				2022-12-01	WOS:A1994NQ41500011
J	SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF				SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF			PERIPHERAL MICROCHIMERISM IN LONG-TERM CADAVERIC-KIDNEY ALLOGRAFT RECIPIENTS	LANCET			English	Note							TRANSPLANTATION; CHIMERISM; TOLERANCE	Microchimerism after allogeneic organ transplantation may be a mechanism for induction of donor-specific graft acceptance. However, the frequency of chimerism and its relevance in long-term tolerance are uncertain. We studied 15 long-surviving (more than 20 years) cadaveric-kidney transplant recipients for the systemic presence of donor alleles with allele-specific genomic amplification of DRB1 and H-Y loci. Microchimerism was observed in 1 case in peripheral blood and in 4 cases in shin. Chimerism and number of HLA alleles shared by donor and recipient were not correlated. This low frequency of microchimerism in long-term kidney allograft recipients raises doubts about a major participation of chimerism in donor-specific tolerance.	HOP NECKER ENFANTS MALAD,INSERM,U25,F-75015 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV TRANSPLANTAT RENALE,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV DERMATOL,F-75730 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite				Caillat-Zucman, Sophie/0000-0002-4535-3550				COLLINS RH, 1993, NEW ENGL J MED, V328, P762, DOI 10.1056/NEJM199303183281104; DALLMAN MJ, 1993, IMMUNOL REV, V133, P5, DOI 10.1111/j.1600-065X.1993.tb01507.x; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121	10	115	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1468	1469		10.1016/S0140-6736(94)92583-6	http://dx.doi.org/10.1016/S0140-6736(94)92583-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911179				2022-12-01	WOS:A1994NQ41500010
J	WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P				WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P			STRUCTURE OF THE EQUINE INFECTIOUS-ANEMIA VIRUS TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSACTIVATION RESPONSE RNA; HIV-1 TAT; CIRCULAR-DICHROISM; LENTIVIRUS TAT; SEQUENCE; PEPTIDES; BINDING; REGION; RECOGNITION	Trans-activator (Tat) proteins regulate the transcription of lentiviral DNA in the host cell genome. These RNA binding proteins participate in the life cycle of all known lentiviruses, such as the human immunodeficiency viruses (HIV) or the equine infectious anemia virus (EIAV). The consensus RNA binding motifs [the trans-activation responsive element (TAR)] of HIV-1 as well as EIAV Tat proteins are well characterized. The structure of the 75-amino acid EIAV Tat protein in solution was determined by two- and three-dimensional nuclear magnetic resonance methods and molecular dynamics calculations. The protein structure exhibits a well-defined hydrophobic core of 15 amino acids that serves as a scaffold for two flexible domains corresponding to the NH2- and COOH-terminal regions. The core region is a strictly conserved sequence region among the known Tat proteins. The structural data can be used to explain several of the observed features of Tat proteins.	UNIV BAYREUTH,LEHRSTUHL BIOPOLYMERE,D-95440 BAYREUTH,GERMANY; UNIV BAYREUTH,BAYREUTHER INST MAKROMOLEK FORSCH,D-95440 BAYREUTH,GERMANY; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY	University of Bayreuth; University of Bayreuth; Tel Aviv University; Sackler Faculty of Medicine; Ruprecht Karls University Heidelberg			Willbold, Dieter/A-6280-2013; Rösch, Paul/I-5445-2014	Willbold, Dieter/0000-0002-0065-7366; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X				BRUNGER AT, 1993, X PLOR 3 1; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; DERSE D, 1992, VIROLOGY, V194, P530; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; HERRMANN F, UNPUB; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFFMAN DW, 1993, BIOCHEMISTRY-US, V32, P1096, DOI 10.1021/bi00055a015; KASHANSHI F, 1993, NATURE, V267, P295; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; NOIMAN S, 1991, VIROLOGY, V184, P521, DOI 10.1016/0042-6822(91)90422-8; PATAK D, 1992, CURR OPIN STRUCT BIO, V2, P115; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAINER L, 1985, NATURE, V313, P277; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	44	45	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1584	1587		10.1126/science.7515512	http://dx.doi.org/10.1126/science.7515512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7515512				2022-12-01	WOS:A1994NQ28500034
J	MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T				MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T			SH2 DOMAIN SPECIFICITY AND ACTIVITY MODIFIED BY A SINGLE RESIDUE	NATURE			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTORS; SIGNALING GENE SEM-5; TRANSFORMING PROTEIN; SRC; BINDING; GRB2; TRANSDUCTION; RECOGNITION	MANY intracellular targets of protein-tyrosine kinases possess Src homology 2 (SH2) domains that directly recognize phosphotyrosine-containing sites on autophosphorylated growth factor receptors and cytoplasmic proteins, and thereby mediate the activation of biochemical signalling pathways(1-7) SH2 domains possess relatively well conserved residues that form the phosphotyrosine-binding pocket(8-11), and more variable residues that are implicated in determining binding specificity by recognition of the three amino acids carboxy-terminal to phosphotyrosine (the +1 to +3 positions)(5,7,12,13). One such residue, occupying the EF1 position of the +3-binding pocket, is a Thr in the SH2 domain of the Src tyrosine kinase(12), but is predicted to be a Trp in the SH2 domain of the Sem-5/drk/Grb2 adaptor protein(5). Here eve report that changing this residue in the Src SH2 domain from Thr to Trp switches its selectivity to resemble that of the Sem-5-/drk/Grb2 SH2 domain. Furthermore, this mutant Src SH2 domain effectively substitutes for the SH2 domain of the Sem-5 protein in activation of the Ras pathway in vivo. These results identify a residue that can modify SH2 selectivity, and indicate that the biological activity of an SH2 domain correlates with its binding specificity.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA; YALE UNIV, BOYER CTR MOLEC MED, NEW HAVEN, CT 06536 USA	University of Toronto; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Virginia; University of Virginia; Yale University	MARENGERE, LEM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Pawson, Tony J/E-4578-2013; Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1984, MOL CELL BIOL, V14, P1147; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAWSON T, 1993, J CURR BIOL, V4, P434; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V764, P773; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	172	182	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					502	505		10.1038/369502a0	http://dx.doi.org/10.1038/369502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515480	Green Submitted			2022-12-01	WOS:A1994NQ28600062
J	MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC				MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC			INVOLVEMENT OF A CALCINEURIN/INHIBITOR-1 PHOSPHATASE CASCADE IN HIPPOCAMPAL LONG-TERM DEPRESSION	NATURE			English	Article							PROTEIN PHOSPHATASES; AREA CA1; PHOSPHORYLATION; IDENTIFICATION; MEMORY	LONG-TERM potentiation (LTP) is a synaptic mechanism thought to be involved in learning and memory(1). Long-term depression (LTD), an activity-dependent decrease in synaptic efficacy, may be an equally important mechanism which permits neural networks to store information more effectively(2,3). One form of LTD that has been observed in the hippocampus(4) requires activation of postsynaptic NMDA (N-methyl-D-aspartate) receptors(4,5), a change in postsynaptic calcium concentration(5), and activation of postsynaptic serine/threonine protein phosphatase 1 (PP1) or 2A (PP2A)(6). The mechanism by which PP1 or PP2A is regulated by synaptic activity is unclear because these protein phosphatases are not directly influenced by calcium concentration. LTD induction may require activation of a more complex protein phosphatase cascade consisting of the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, its phosphoprotein substrate, inhibitor-1, and PP1(7,8). We tested this hypothesis using calcineurin inhibitors as well as different forms of inhibitor-1 loaded into postsynaptic cells. Our results suggest a signalling pathway in which calcineurin dephosphorylates and inactivates inhibitor-1. This in turn increases PP1 activity and contributes to the generation of LTD.	UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Cohen P, 1988, CALMODULIN; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85	17	874	897	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					486	488		10.1038/369486a0	http://dx.doi.org/10.1038/369486a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515479				2022-12-01	WOS:A1994NQ28600057
J	HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR				HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR			PULMONARY IMMUNOPATHOLOGY OF SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; ASSOCIATION; TEMPERATURE; RECOGNIZES; TISSUES; ANTIGEN	Sudden infant death syndrome (SIDS) is the most common cause of postneonatal mortality in the UK. Pathological investigations have shown evidence suggestive of respiratory obstruction with subsequent hypoxia leading to death. We examined 48 infants who died of SIDS and 30 who died of other, non-pulmonary, causes and identified pulmonary eosinophil and neutrophil leucocytes, mast cells, and T and B lymphocytes by immunocytochemistry. Positively stained cells were counted in the parenchyma and around the bronchi without knowledge of the tissue source. The results showed three times more eosinophils in the lungs of infants who died of SIDS (27.61 vs 7.91 [99% CI 1.76-5.87] cells/mm(2) for parenchyma) accompanied by increased T lymphocytes and B lymphocytes. There were more peribronchial mast cells in the SIDS group (22.1 vs 14.7 [1.03-2.10] cells/mm(2)) and insignificant differences in neutrophils and parenchymal mast cells. There were significant associations between eosinophil, B lymphocyte, and T lymphocyte numbers. These findings provide evidence for an abnormal T lymphocyte-mediated pulmonary inflammatory response In SIDS. Products of eosinophil degranulation can cause epithelial damage and pulmonary oedema, which could cause the respiratory obstruction and hypoxia associated with SIDS.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton								BECKWITH JB, 1970, SUDDEN INFANT DEATH, P83; BERRY PJ, 1992, J CLIN PATHOL S, V45, pS11; BONSER RSA, 1978, INT J EPIDEMIOL, V7, P335, DOI 10.1093/ije/7.4.335; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAMPBELL MJ, 1989, MED J AUSTRALIA, V151, P365, DOI 10.5694/j.1326-5377.1989.tb101216.x; CLARK JW, 1979, J PEDIATR-US, V95, P85, DOI 10.1016/S0022-3476(79)80094-3; COOMBS RRA, 1990, CLIN EXP ALLERGY, V20, P359, DOI 10.1111/j.1365-2222.1990.tb02794.x; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CUNNINGHAM AS, 1975, J PEDIATR-US, V87, P426, DOI 10.1016/S0022-3476(75)80650-0; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; HILTON JMN, 1989, PAEDIAT FORENSIC MED, P156; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; MASON DY, 1990, AM J PATHOL, V136, P1215; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MIRCHANDANI HG, 1984, J FORENSIC SCI, V29, P425; NAEYE RL, 1976, AM J CLIN PATHOL, V66, P526, DOI 10.1093/ajcp/66.3.526; NELSON EAS, 1988, NEW ZEAL MED J, V101, P443; NORTON AJ, 1986, J CLIN PATHOL, V39, P399, DOI 10.1136/jcp.39.4.399; OPENSHAW PJM, 1992, INT IMMUNOL, V4, P493, DOI 10.1093/intimm/4.4.493; PULFORD KAF, 1988, J CLIN PATHOL, V41, P853, DOI 10.1136/jcp.41.8.853; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROWEN JL, 1991, AM REV RESPIR DIS, V142, P215; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; STEWART S, 1985, J PATHOL, V145, P53, DOI 10.1002/path.1711450105; STRIMER R, 1969, J AMER MED ASSOC, V209, P1493, DOI 10.1001/jama.209.10.1493; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; UREN EC, 1980, MED J AUSTRALIA, V1, P417, DOI 10.5694/j.1326-5377.1980.tb134996.x; WALLS AF, 1990, J PATHOL, V162, P119, DOI 10.1002/path.1711620204; WILLIAMS AL, 1984, BRIT MED J, V288, P1491, DOI 10.1136/bmj.288.6429.1491; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859; 1992, OFFICE POPULATIO DH6	31	50	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1390	1392		10.1016/S0140-6736(94)92523-2	http://dx.doi.org/10.1016/S0140-6736(94)92523-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910883				2022-12-01	WOS:A1994NP95500009
J	KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N				KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N			MERCURY, NOT SULFUR-DIOXIDE, POISONING AS CAUSE OF SMELTER DISEASE IN INDUSTRIAL-PLANTS PRODUCING SULFURIC-ACID	LANCET			English	Article								Several episodes of ''smelter disease'', previously assumed to be caused by sulphur dioxide (SO2) poisoning, have been reported in workers replacing pipes in sulphuric acid manufacturing plants. One such incident, affecting 20 men, was recorded in Akita, Japan, in July, 1993, but the protection these workers used suggested that some cause other than SO2 needed to be looked for. 10 workers were affected despite wearing respirators with SO2 cartridges, the symptoms including dyspnoea, diarrhoea, colicky pain, muscle pain and eczema with erythema. Subsequently 10 other workers using face masks with supplied air were affected, though without respiratory symptoms. Sludge in the piping contained mercuric sulphate, and mercury fumes resulted when pipes were cut with gas burners. Blood and urine measurements confirmed heavy exposure to the metal, and simulation experiments in rats showed that skin absorption was likely too. The masks with supplied air ought to have excluded both SO2 and mercury fumes. The only way to avoid smelter disease reliably is to wear an encapsulated suit that prevents inhalation and skin absorption of industrial toxins.	SAKATA CITY HOSP,DEPT DERMATOL,MORIOKA,IWATE,JAPAN; IWATE PREFECTURAL LAB ENVIRONM SCI,MORIOKA,IWATE,JAPAN		KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							ELBERGER SY, 1993, HDB MED TOXICOLOGY, P285; HARA I, 1975, OSAKA FU KOEIKENKENK, V13, P31; SEATON A, 1978, BRIT J IND MED, V35, P258; WINDHOLZ M, 1983, MERCK INDEX, P841	4	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1411	1412		10.1016/S0140-6736(94)92530-5	http://dx.doi.org/10.1016/S0140-6736(94)92530-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910889				2022-12-01	WOS:A1994NP95500016
J	LIN, JP; BROWN, JK; WALSH, EG				LIN, JP; BROWN, JK; WALSH, EG			PHYSIOLOGICAL MATURATION OF MUSCLES IN CHILDHOOD	LANCET			English	Article								Little is known about the motor muscle physiology of growing children and it has been assumed that increasing motor dexterity and speed correspond solely to brain maturation, although there is evidence that muscles mature from studies of other mammalian species. Such a finding in children would throw light on the possible mechanics of motor delays in speech, hand function, athletic, and musical skills as well as helping towards a better understanding of pathological motor disorders such as the cerebral palsies. Our non-invasive observations of soleus-muscle relaxation times in healthy children suggest that a child's muscles are initially slow to relax but relaxation doubles in speed up to adult rates by early adolescence. Half-relaxation times halved from about 90 ms at age 3 to about 40 ms at age 10. On the basis of these studies, we suggest that muscle maturation rate-limits motor tasks; which should be borne in mind when considering motor development in muscles and when attempting to determine the effects of early brain or spinal cord damage. Such methods of measuring the dynamics of muscle open up new areas of research and offer the possibility of developing operationally-defined in-vivo measurements for use in motor assessment and for following up the effects on muscle or treatments such as physiotherapy, orthotics, surgery, and drugs.	ROYAL HOSP SICK CHILDREN, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PHYSIOL, EDINBURGH, SCOTLAND	University of Edinburgh			Lin, Jean-Pierre/R-3779-2019	Lin, Jean-Pierre/0000-0001-9314-2259				BARRY JA, 1994, EXP PHYSIOL, V79, P515, DOI 10.1113/expphysiol.1994.sp003784; BROOKE MH, 1969, NEUROLOGY, V19, P591, DOI 10.1212/WNL.19.6.591; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; DAVIES CTM, 1983, J APPL PHYSIOL, V55, P191, DOI 10.1152/jappl.1983.55.1.191; EYRE JA, 1991, J PHYSIOL-LONDON, V434, P441, DOI 10.1113/jphysiol.1991.sp018479; GARNETT RAF, 1979, J PHYSIOL-LONDON, V287, P33, DOI 10.1113/jphysiol.1979.sp012643; KALVERBOER AF, 1993, MOTOR DEV EARLY LATE; MALINA RM, 1991, GROWTH MATURATION PH, P115; MARGRETH A, 1980, PLASTICITY MUSCLE, P193; PARKER DF, 1990, ANN HUM BIOL, V17, P199, DOI 10.1080/03014469000000962; PETTE D, 1980, PLASTICITY MUSCLE; SALE D, 1982, J APPL PHYSIOL, V52, P1636, DOI 10.1152/jappl.1982.52.6.1636; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; WALSH EG, 1993, EXP PHYSIOL, V78, P531, DOI 10.1113/expphysiol.1993.sp003704; WALSH EG, 1992, CLIN DEV MED SERIES, V125, P26; WATTS C, 1992, J PHYSIOL-LONDON, V452, pP273	16	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	1994	343	8910					1386	1389		10.1016/S0140-6736(94)92522-4	http://dx.doi.org/10.1016/S0140-6736(94)92522-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910882				2022-12-01	WOS:A1994NP95500008
J	LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D				LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D			HIV-1/HIV-2 SERONEGATIVITY IN HIV-1 SUBTYPE-O INFECTED PATIENTS	LANCET			English	Note								Nine patients with atypical HIV-1 western blot profiles were diagnosed as having HIV-1 subtype O infection. All the patients were living in France; eight originated from Cameroon and one from France. Lymphocyte DNA amplification by the polymerase chain reaction was only positive when HIV-1 subtype O specific primers were used. Preliminary sequence analysis of amplified products and serological reactivity against a specific subtype O synthetic env peptide confirmed HIV-1 subtype O infection. HIV-1/HIV-2 enzyme-linked immunosorbent assays, especially those based on env peptides or on the sandwich format, can be negative in HIV-1 subtype O infection.	BICHAT CLAUDE BERNARD HOSP,DEPT VIROL,VIROL LAB,F-75877 PARIS 18,FRANCE; ALFRED FOURNIER INST,PARIS,FRANCE; COCHIN HOSP,INSERM,U363,ICGM,PARIS,FRANCE; NATL BLOOD TRANSFUS INST,PARIS,FRANCE; ROBERT DEBRE HOSP,DEPT MICROBIOL,REIMS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Reims								AGUT H, 1992, LANCET, V340, P681, DOI 10.1016/0140-6736(92)92226-6; GURTLER LG, 1994, J VIROL, V68, P1581; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994	5	210	214	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1393	1394		10.1016/S0140-6736(94)92524-0	http://dx.doi.org/10.1016/S0140-6736(94)92524-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910884				2022-12-01	WOS:A1994NP95500010
J	PALMER, JP				PALMER, JP			WHAT IS THE BEST WAY TO PREDICT IDDM	LANCET			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; INSULIN; RELATIVES; AUTOANTIBODIES; ASSAY		UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle	PALMER, JP (corresponding author), VET AFFAIRS MED CTR,SEATTLE,WA 98108, USA.							ATKINSON MA, 1993, J CLIN INVEST, V91, P350, DOI 10.1172/JCI116192; BJORK E, 1994, DIABETES, V43, P161, DOI 10.2337/diabetes.43.1.161; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; GREENBAUM CJ, 1992, J CLIN ENDOCR METAB, V74, P1040, DOI 10.1210/jc.74.5.1040; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KRISCHER JP, 1993, J CLIN ENDOCR METAB, V77, P743, DOI 10.1210/jc.77.3.743; PALMER JP, 1993, DIABETES REV, V1, P104; ROBERT JJ, 1991, DIABETES CARE, V14, P718, DOI 10.2337/diacare.14.8.718	9	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1377	1378		10.1016/S0140-6736(94)92519-4	http://dx.doi.org/10.1016/S0140-6736(94)92519-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910879				2022-12-01	WOS:A1994NP95500005
J	SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M				SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M			IS PROTECTION AGAINST SHIGELLOSIS INDUCED BY NATURAL INFECTION WITH PLESIOMONAS-SHIGELLOIDES	LANCET			English	Article							PEACE-CORPS VOLUNTEERS; DIARRHEAL DISEASE; ESCHERICHIA-COLI; UNITED-STATES; IMMUNIZATION; TEMPERATURE; ANTIBODIES; TRAVELERS; AEROMONAS; CHILDREN	Shigellosis due to Shigella sonnei is rare among people growing up and living in developing countries; however, infections due to S sonnei becomes more common than those due to S flexneri as societies develop economically. The relation between risk of S sonnei infection and economic development may be explained by the exposure of developing-country populations to Plesiomonas shigelloides. P shigelloides is often found in surface water, and one serotype (serotype 17) possesses a cell-wall lipopolysaccharide identical to that of S sonnei. Thus, exposure to P shigelloides by drinking contaminated water may immunise populations to S sonnei. As economic development occurs, water quality improves and populations become susceptible to S sonnei. Although drinking pure water has many advantages, immunisation against S sonnei may be one benefit of traditional water sources.	JOHNS HOPKINS UNIV,DEPT COMPARAT MED,BALTIMORE,MD 21205; UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742	Johns Hopkins University; University System of Maryland; University of Maryland College Park	SACK, DA (corresponding author), JOHNS HOPKINS UNIV,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCRR NIH HHS [RR00130] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR000130] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHMED F, 1992, PEDIATRICS, V90, P406; AHMED ZU, 1990, VACCINE, V8, P153, DOI 10.1016/0264-410X(90)90139-D; AKMAN M, 1965, TURKISH J PEDIATR, V7, P155; ALDOVA E, 1987, ZBL BAKT-INT J MED M, V265, P253; ALDOVA E, 1987, J HYG EPIDEMIOL IMMU, V31, P76; ARAI T, 1980, J HYG-CAMBRIDGE, V84, P203, DOI 10.1017/S002217240002670X; BRENDEN RA, 1988, REV INFECT DIS, V10, P303; CHOWDHURY K A, 1988, Journal of Diarrhoeal Diseases Research, V6, P221; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; COHEN D, 1991, INT J EPIDEMIOL, V20, P546, DOI 10.1093/ije/20.2.546; Ekwall E, 1988, SERODIAGN IMMUNOTHER, V2, P47; FERGUSON WW, 1947, J BACTERIOL, V54, P179, DOI 10.1128/JB.54.2.179-181.1947; FERRECCIO C, 1991, AM J EPIDEMIOL, V134, P614, DOI 10.1093/oxfordjournals.aje.a116134; GAINES S, 1968, MIL MED, V133, P114, DOI 10.1093/milmed/133.2.114; GOMES TAT, 1991, J INFECT DIS, V164, P331, DOI 10.1093/infdis/164.2.331; GORDON JE, 1964, B WORLD HEALTH ORGAN, V31, P1; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HERRINGTON DA, 1987, INFECT IMMUN, V55, P979, DOI 10.1128/IAI.55.4.979-985.1987; HOLMBERG SD, 1986, ANN INTERN MED, V105, P690, DOI [10.7326/0003-4819-105-5-690, 10.7326/0003-4819-105-5-683]; HOLMBERG SD, 1984, REV INFECT DIS, V6, P633; HOUNG HSH, 1992, J BACTERIOL, V174, P5910, DOI 10.1128/jb.174.18.5910-5915.1992; HUQ A, 1991, CAN J MICROBIOL, V37, P800, DOI 10.1139/m91-138; JOSEPH S W, 1988, Journal of Diarrhoeal Diseases Research, V6, P80; KAGALWALLA AF, 1992, PEDIATR INFECT DIS J, V11, P215, DOI 10.1097/00006454-199203000-00009; KAIN KC, 1989, J CLIN MICROBIOL, V27, P998, DOI 10.1128/JCM.27.5.998-1001.1989; KHAN MU, 1985, INT J EPIDEMIOL, V14, P607, DOI 10.1093/ije/14.4.607; KHARDORI N, 1988, ANNU REV MICROBIOL, V42, P395, DOI 10.1146/annurev.mi.42.100188.002143; KWAGA JKP, 1988, MICROBIOLOGICA, V11, P165; LEE LA, 1991, J INFECT DIS, V164, P894, DOI 10.1093/infdis/164.5.894; LOPEZBREA M, 1983, T ROY SOC TROP MED H, V77, P140, DOI 10.1016/0035-9203(83)90047-0; Matsushita S, 1991, Kansenshogaku Zasshi, V65, P857; RUTALA WA, 1982, LANCET, V1, P739; SACK D A, 1988, Journal of Diarrhoeal Diseases Research, V6, P107; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; SAYEED S, 1989, Bangladesh Journal of Microbiology, V6, P7; SAYEED S, 1992, J MED MICROBIOL, V37, P382, DOI 10.1099/00222615-37-6-382; TSUKAMOTO T, 1978, J HYG-CAMBRIDGE, V80, P275, DOI 10.1017/S0022172400053638; VANDEVERG LL, 1992, J INFECT DIS, V166, P158, DOI 10.1093/infdis/166.1.158	39	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1413	1415		10.1016/S0140-6736(94)92531-3	http://dx.doi.org/10.1016/S0140-6736(94)92531-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910890	hybrid			2022-12-01	WOS:A1994NP95500017
J	STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J				STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J			FACTORS INFLUENCING THE NATURAL-HISTORY OF COLORECTAL LIVER METASTASES	LANCET			English	Article							HEPATIC METASTASES; REGIONAL CHEMOTHERAPY; CARCINOMA; CANCER; RESECTION; SURVIVAL; INTRAARTERIAL; PROGNOSIS; TRIAL; COLON	Palliative treatment of unresectable colorectal liver metastases is common and often justified with reference to historical data on the natural history of the disease. However, in view of the improved diagnostic accuracy of modern imaging techniques, these previously published series do not provide sufficient guidance to judge the prognostic efficacy of palliative treatment. In the late 1970s we started prospectively to collect data on consecutive patients with colorectal liver metastases according to a standard protocol. We now present data derived from this series on factors that may affect outcome in untreated patients. Between January, 1980, and December, 1990, 1099 consecutive patients were recorded, of whom 566 (51.5%) received no treatment for their hepatic tumour. Excluding 34 early deaths and 48 patients with a second malignant tumour, 484 patients provided the basis for analysis. All patients were followed up to July 1, 1993, or death. At the closing date of the study only 1 untreated patient was still alive. The impact of various factors on survival was analysed by univariate and multivariate analyses. Six independent determinants of survival were identified in the following order: percentage liver volume replaced by tumour (LVRT), grade of malignancy of the primary tumour, presence of extra hepatic disease, mesenteric lymph-node involvement, serum carcino-embryonic antigen, and age. The subsequent combination of the independently significant factors, separately for patients with up to or more than 25% LVRT, yielded a prognostic tree that displayed median survival times of various subgroups of 3.8 to 21.3 months. These findings provide a framework to estimate the survival expectancy of untreated patients, thereby allowing improved assessment of the prognostic significance of palliative therapeutic approaches.	UNIV ERLANGEN NURNBERG,CHIRURG KLIN & POLIKLIN,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ADSON MA, 1987, WORLD J SURG, V11, P511, DOI 10.1007/BF01655817; ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647; BALCH CM, 1984, CHIRURG, V55, P485; BENGMARK S, 1969, CANCER, V23, P198, DOI 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J; BENGTSSON G, 1981, AM J SURG, V141, P586, DOI 10.1016/0002-9610(81)90057-X; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CHANG AE, 1989, J SURG ONCOL, V40, P245, DOI 10.1002/jso.2930400409; FINAN PJ, 1985, BRIT J SURG, V72, P373, DOI 10.1002/bjs.1800720514; FLANAGAN L, 1967, AM J SURG, V113, P551, DOI 10.1016/0002-9610(67)90206-1; GENNARI L, 1986, ANN SURG, V203, P49, DOI 10.1097/00000658-198601000-00009; GOSLIN R, 1982, DIS COLON RECTUM, V25, P749, DOI 10.1007/BF02553304; HUNT TM, 1990, BRIT J SURG, V77, P779; JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1; LAHR CJ, 1983, J CLIN ONCOL, V1, P720, DOI 10.1200/JCO.1983.1.11.720; NIELSEN J, 1971, ACTA CHIR SCAND, V137, P463; PETRELLI NJ, 1984, DIS COLON RECTUM, V27, P249, DOI 10.1007/BF02553797; PETTAVEL J, 1984, LIVER METASTASES, P154; SAFI F, 1989, CANCER-AM CANCER SOC, V64, P379, DOI 10.1002/1097-0142(19890715)64:2<379::AID-CNCR2820640207>3.0.CO;2-8; SCHEELE J, 1990, BRIT J SURG, V77, P1241, DOI 10.1002/bjs.1800771115; SCHEELE J, 1991, SURGERY, V110, P13; SCHEELE J, 1991, ZBL CHIR, V116, P1215; SUGARBAKER PH, 1986, J SURG ONCOL, V31, P94, DOI 10.1002/jso.2930310204; WAGNER JS, 1984, ANN SURG, V199, P502, DOI 10.1097/00000658-198405000-00002; WANEBO HJ, 1978, AM J SURG, V135, P81, DOI 10.1016/0002-9610(78)90014-4; Wood C B, 1976, Clin Oncol, V2, P285; WOOD CB, 1984, LIVER METASTASIS BAS, P47	26	578	606	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1405	1410		10.1016/S0140-6736(94)92529-1	http://dx.doi.org/10.1016/S0140-6736(94)92529-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7515134				2022-12-01	WOS:A1994NP95500015
J	TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ				TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ			ANTIBODIES TO GLUTAMIC-ACID DECARBOXYLASE AS PREDICTORS OF INSULIN-DEPENDENT DIABETES-MELLITUS BEFORE CLINICAL ONSET OF DISEASE	LANCET			English	Article							ISLET CELL ANTIBODIES; AUTOANTIBODIES; CHILDREN; MARKERS; GABA; MICE; GAD	We have done a study designed to ascertain the effectiveness of measuring antibodies to glutamic acid decarboxylase (anti-GAD) in predicting insulin-dependent diabetes mellitus (IDDM). Anti-GAD was measured-in prediabetic sera from 151 women aged 20-39 years with newly diagnosed diabetes mellitus who had been identified through a nationwide diabetes register. Multiple serum samples had been collected from these women up to 10 years before the clinical onset of diabetes during their earlier pregnancies. Anti-GAD was measured with a radioimmunoprecipitation assay. Anti-GAD was detected in 82% of 28 women with IDDM, in 36% of 11 women with non-insulin-dependent diabetes mellitus, and in 5% of 112 women with gestational diabetes mellitus. In a random sample of 100 non-diabetic young Finnish women, none had anti-GAD. The sensitivity of the anti-GAD assay for predicting IDDM was 82.1% and the specificity was 100%. The longest time of anti-GAD positivity before clinical onset of IDDM was 10 years. Once positive, anti-GAD levers remained stable and no patients became negative after a positive test during the prediabetic period. Anti-GAD is a valuable early predictive marker and is associated with a very high risk for development of IDDM.	INT DIABET INST,CAULFIELD,VIC,AUSTRALIA; MONASH UNIV,CTR MOLEC BIOL & MED,CLAYTON,VIC 3168,AUSTRALIA; NATL PUBL HLTH INST,OULU,FINLAND	Monash University; Finland National Institute for Health & Welfare	TUOMILEHTO, J (corresponding author), NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,MANNERHELMINTIE 166,SF-00300 HELSINKI,FINLAND.		Mackay, Ian R/A-7228-2010; Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776				ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BINGLEY PJ, 1993, DIABETES CARE, V16, P45, DOI 10.2337/diacare.16.1.45; BLOHME G, 1993, DIABETOLOGIA, V35, P56; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; CATALANO PM, 1990, DIABETES CARE, V13, P478, DOI 10.2337/diacare.13.5.478; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CHRISTIE M, 1988, DIABETOLOGIA, V31, P597, DOI 10.1007/BF00264766; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; Harris M.I, 1992, INT TEXTB DIABETES M, P3; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LANDINOLSSON M, 1993, DIABETOLOGIA, V36, pA99; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCOTT RS, 1991, DIABETIC MED, V8, P1; SERJEANTSON SW, 1993, HUM IMMUNOL, V38, P97, DOI 10.1016/0198-8859(93)90525-6; SERJEANTSON SW, 1992, DIABETOLOGIA, V35, P996, DOI 10.1007/BF00401432; THIVOLET C, 1992, DIABETOLOGIA, V35, P570, DOI 10.1007/BF00400486; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; TUOMILEHTOWOLF E, 1993, BRIT MED J, V307, P155, DOI 10.1136/bmj.307.6897.155; TUOMILEHTOWOLF E, 1991, ANN MED, V23, P481, DOI 10.3109/07853899109150507; WILKIN T, 1985, LANCET, V1, P480; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x	29	161	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1383	1385		10.1016/S0140-6736(94)92521-6	http://dx.doi.org/10.1016/S0140-6736(94)92521-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910881				2022-12-01	WOS:A1994NP95500007
J	LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J				LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J			ARABIDOPSIS ABA RESPONSE GENE ABI1 - FEATURES OF A CALCIUM-MODULATED PROTEIN PHOSPHATASE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; THALIANA L HEYNH; ABSCISIC-ACID; COLD-ACCLIMATION; GUARD-CELLS; EXPRESSION; ACTIVATOR; MUTATIONS; STOMATA; CLONING	The Arabidopsis ABI1 locus is essential for a wide spectrum of abscisic acid (ABA) responses throughout plant development. Here, ABI1 was shown to regulate stomatal aperture in leaves and mitotic activity in root meristems. The ABI1 gene was cloned and predicted to encode a signaling protein. Although its carboxyl-terminal domain is related to serine-threonine phosphatase 2C, the ABI1 protein has a unique amino-terminal extension containing an EF hand calcium-binding site. These results suggest that the ABI1 protein is a Ca2+-modulated phosphatase and functions to integrate ABA and Ca2+ signals with phosphorylation-dependent response pathways.	INST SCI VEGETALES, CNRS, UPR 40, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Morris, Peter/0000-0003-0919-6305				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BOUVIERDURAND M, 1989, PLANT PHYSIOL BIOCH, V27, P511; BOUVIERDURAND M, UNPUB; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINKELSTEIN RR, 1990, PLANT PHYSIOL, V94, P1172, DOI 10.1104/pp.94.3.1172; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILMOUR SJ, 1991, PLANT MOL BIOL, V17, P1233, DOI 10.1007/BF00028738; GILROY S, 1992, CURR PLANT SCI BIOT, V13, P105; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LANG V, 1992, PLANT MOL BIOL, V20, P951, DOI 10.1007/BF00027165; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LEUNG J, 1991, J MOL BIOL, V219, P175, DOI 10.1016/0022-2836(91)90560-S; LEUNG J, UNPUB; LEVI M, 1990, PHYSIOL PLANTARUM, V79, P231; LEVI M, 1993, IN VITRO CELL DEV-PL, V29P, P47, DOI 10.1007/BF02632250; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MCAINSH MR, 1991, ABSCISIC ACID PHYSL, P137; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PUTNOKY P, 1990, J BACTERIOL, V172, P5450, DOI 10.1128/jb.172.9.5450-5458.1990; SCHNALL JA, 1992, PLANT PHYSIOL, V100, P216, DOI 10.1104/pp.100.1.216; SCHROEDER JI, 1992, PHILOS T R SOC B, V338, P83, DOI 10.1098/rstb.1992.0131; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; Staiger C, 1993, CURR OPIN CELL BIOL, V5, P226, DOI 10.1016/0955-0674(93)90107-2; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VARTANIAN N, 1994, PLANT PHYSIOL, V104, P761, DOI 10.1104/pp.104.2.761; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	44	652	683	4	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1448	1452		10.1126/science.7910981	http://dx.doi.org/10.1126/science.7910981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910981				2022-12-01	WOS:A1994NP22100039
J	MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A				MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A			DE-NOVO AND INHERITED DELETIONS OF THE 5Q13 REGION IN SPINAL MUSCULAR ATROPHIES	SCIENCE			English	Article							WERDNIG-HOFFMANN DISEASE; GENE; CHILDHOOD; CONTIG	Spinal muscular atrophies (SMAs) represent the second most common fatal autosomal recessive disorder after cystic fibrosis. Childhood spinal muscular atrophies are divided into severe (type I) and mild forms (types II and III). By a combination of genetic and physical mapping, a yeast artificial chromosome contig of the 5q13 region spanning the disease locus was constructed that showed the presence of low copy repeats in this region. Allele segregation was analyzed at the closest genetic loci detected by markers C212 and C272 in 201 SMA families. Inherited and de novo deletions were observed in nine unrelated SMA patients. Moreover, deletions were strongly suggested in at least 18 percent of SMA type I patients by the observation of marked heterozygosity deficiency for the loci studied. These results indicate that deletion events are statistically associated with the severe form of spinal muscular atrophy.	HOP NECKER ENFANTS MALAD,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS,FRANCE; GENETHON,EVRY,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Zeviani, Massimo/K-2891-2014; Lefebvre, Suzie/D-5092-2017; Zeviani, Massimo/AAU-2632-2021	Zeviani, Massimo/0000-0002-9067-5508; Le Paslier, Denis/0000-0003-4335-9956; BERNARD, BENICHOU/0000-0002-9331-0926				BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DANIELS RJ, 1992, GENOMICS, V12, P335, DOI 10.1016/0888-7543(92)90382-3; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAUSMANOWAPETRUSEWICZ I, 1985, J MED GENET, V22, P350, DOI 10.1136/jmg.22.5.350; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P764; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Munsat TL., 1991, NEUROMUSCULAR DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; PEARN J, 1978, J MED GENET, V15, P403; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; ZERRES K, 1988, THESIS U BONN	20	290	299	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1474	1477		10.1126/science.7910982	http://dx.doi.org/10.1126/science.7910982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910982				2022-12-01	WOS:A1994NP22100047
J	STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF				STOKOE, D; MACDONALD, SG; CADWALLADER, K; SYMONS, M; HANCOCK, JF			ACTIVATION OF RAF AS A RESULT OF RECRUITMENT TO THE PLASMA-MEMBRANE	SCIENCE			English	Article							PROTEIN-KINASE KINASE; SIGNAL-TRANSDUCTION; IN-VITRO; ASSOCIATION; P21(RAS); CELLS; TRANSFORMATION; SUFFICIENT; COMPLEXES; PATHWAY	The small guanine nucleotide binding protein Ras participates in a growth promoting signal transduction pathway. The mechanism by which interaction of Ras with the protein kinase Raf leads to activation of Raf was studied. Raf was targeted to the plasma membrane by addition of the COOH-terminal localization signals of K-ras. This modified form of Raf (RafCAAX) was activated to the same extent as Raf coexpressed with oncogenic mutant Ras. Plasma membrane localization rather than farnesylation or the presence of the additional COOH-terminal sequence accounted for the activation of RafCAAX. The acti vation of RafCAAX was completely independent of Ras; it was neither potentiated by oncogenic mutant Ras nor abrogated by dominant negative Ras. Raf, once recruited to the plasma membrane, was not anchored there by Ras; most activated Raf in cells was associated with plasma membrane cytoskeletal elements, not the lipid bilayer. Thus, Ras functions in the activation of Raf by recruiting Raf to the plasma membrane where a separate, Ras-independent, activation of Raf occurs.	ONXY PHARMACEUT,RICHMOND,CA 94806					Hancock, John/0000-0003-0542-4710				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CADWALLADER K, IN PRESS MOL CELL BI; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACDONALD SG, UNPUB; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	29	901	917	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1463	1467		10.1126/science.7811320	http://dx.doi.org/10.1126/science.7811320			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7811320				2022-12-01	WOS:A1994NP22100044
J	WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J				WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J			INHIBITION OF HEPATIC CHYLOMICRON REMNANT UPTAKE BY GENE-TRANSFER OF A RECEPTOR ANTAGONIST	SCIENCE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; MULTIFUNCTIONAL RECEPTOR; CULTURED-CELLS; HIGH-AFFINITY; IN-VIVO	The low density lipoprotein receptor-related protein (LRP) has been proposed to mediate in concert with the LDL receptor (LDLR) the uptake of dietary lipoproteins into the hepatocytes. This hypothesis was tested by transient inactivation of LRP in vivo. Receptor-associated protein (RAP), a dominant negative regulator of LRP function, was transferred by an adenoviral vector to the livers of mice lacking LDLR (LDLR(-/-)). The inactivation of LRP by RAP was associated with a marked accumulation of chylomicron remnants in LDLR(-/-) mice and to a lesser degree in normal mice, suggesting that both LDLR and LRP are involved in remnant clearance.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHOI SY, 1993, J BIOL CHEM, V268, P15804; GAMBLE W, 1978, J LIPID RES, V19, P1068; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GOFF SP, 1993, CURR OPIN GENET DEV, V3, P71, DOI 10.1016/S0959-437X(05)80343-0; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JI ZS, 1993, J BIOL CHEM, V268, P10160; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LEBOEUF RC, 1990, J LIPID RES, V31, P91; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCOTT J, 1989, MOL BIOL MED, V6, P65; SHAFI S, 1994, J LIPID RES, V35, P709; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, UNPUB; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	46	264	265	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1471	1474		10.1126/science.7515194	http://dx.doi.org/10.1126/science.7515194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7515194				2022-12-01	WOS:A1994NP22100046
J	CHRISTOFORI, G; NAIK, P; HANAHAN, D				CHRISTOFORI, G; NAIK, P; HANAHAN, D			A 2ND SIGNAL SUPPLIED BY INSULIN-LIKE GROWTH-FACTOR-II IN ONCOGENE-INDUCED TUMORIGENESIS	NATURE			English	Article							BETA-CELL TUMORS; TRANSGENIC MICE; INDUCTION; TISSUES; PROTEIN; LINEAGE; GENE	TRANSGENIC mice expressing the simian virus-40 large T-antigen (Tag) under the control of the insulin gene regulatory region offer a useful model for tumorigenesis(1,2). All the islets of Langerhans express Tag, although there is at first no aberrant proliferation. Over half of the islets become hyperplastic, however, and neovascularization of a further subset (about 10%)(3) leads eventually to formation of highly vascularized solid tumours in 1-2% of islets by about 14 weeks of age. Here we show that the initial proliferative switch is correlated with focal activation of insulin-like growth factor II (IGF-II). Transfection with an antisense oligonucleotide to the IGF-II messenger RNA interferes with tumour cell proliferation in vitro, and transgenic mice homozygous for a disruption of the IGF-II gene develop tumours with reduced malignancy and a higher incidence of apoptosis. Several signals, in this case including an oncoprotein and a growth/survival factor, thus appear to be needed to elicit hyperproliferation.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DECHIARA TM, 1990, NATURE, V345, P75; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERGUSONSMITH AC, 1991, NATURE, V351, P155; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GARCIA RL, 1989, AM J PATHOL, V134, P733; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRINGTON EA, IN PRESS EMBO J; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEROITH D, 1991, INSULIN LIKE GROWTH; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMITH KM, 1990, J LIPID RES, V31, P995; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X	24	382	395	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					414	418		10.1038/369414a0	http://dx.doi.org/10.1038/369414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910953				2022-12-01	WOS:A1994NP17400061
J	KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ				KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ			CYTOTOXIC T-CELL ACTIVITY ANTAGONIZED BY NATURALLY-OCCURRING HIV-1 GAG VARIANTS	NATURE			English	Article							LYMPHOCYTES-T; RECEPTOR; PEPTIDES; INDIVIDUALS; RECOGNITION; VIRUS	MOST asymptomatic individuals infected with HIV-1 have a cytotoxic T lymphocyte (CTL) response to the virus Gag proteins which can be demonstrated in vitro(1,2). Epitopes have been mapped in p17 Gag and p24 Gag restricted by HLA-B8 (p17-3 and p24-13) and -B27 (p24-14)(2,3). Viruses isolated from patients who make CTL responses to these peptides vary within the genetic sequences encoding these epitopes and some mutations lead to reduction in killing activity in vitro(4). This mas attributed to either failure of the variant epitope to bind major histocompatibility complex class I or failure of T-cell receptors to bind the presented peptide. But peptide variants of class I-restricted epitopes cause 'antagonism', that is, the presence of a variant epitope (in the form of peptide) inhibits normal lysis of targets presenting the original epitope(5,6). This mirrors similar findings in class II-restricted systems(7-10). Here we report that naturally occurring variant forms of p17-3, p24-13 and p24-14 may cause antagonism of CTL lines derived from the same individuals. The effect is present if the epitopes are derived from synthetic peptides and when they are processed from full-length proteins expressed by either recombinant vaccinia constructs or replicating HIV.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; RADCLIFFE INFIRM,DEPT GENITOURINARY MED,OXFORD OX3 7LJ,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LV,ENGLAND	University of Oxford; Radcliffe Infirmary	KLENERMAN, P (corresponding author), UNIV OXFORD,NUFFIELD DEPT CLIN MED,DIV MOLEC SCI,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021	Rosenberg, William/0000-0002-2732-2304; Lalloo, David/0000-0001-7680-2200; Daenke, Susan/0000-0003-3290-6627; klenerman, paul/0000-0003-4307-9161	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; MACKETT M, 1984, J VIROL, V49, P854; Maniatis T., 1982, MOL CLONING; MYERS G, 1992, HUMAN RETROVIRUSES A; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NIXON DF, 1991, AIDS, V5, P1049; OSTROV D, 1993, J IMMUNOL, V150, P4277; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1947; ROWLANDJONES SL, 1993, EUR J IMMUNOL, V23, P1999, DOI 10.1002/eji.1830230841; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	18	401	409	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					403	407		10.1038/369403a0	http://dx.doi.org/10.1038/369403a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7515165				2022-12-01	WOS:A1994NP17400058
J	WANG, SX; HAZELRIGG, T				WANG, SX; HAZELRIGG, T			IMPLICATIONS FOR BCD MESSENGER-RNA LOCALIZATION FROM SPATIAL-DISTRIBUTION OF EXU PROTEIN IN DROSOPHILA OOGENESIS	NATURE			English	Article							MESSENGER-RNA LOCALIZATION; BICOID RNA; GENE; MICROTUBULES; DIFFERENTIATION; MORPHOGEN; TRANSPORT; GRADIENT; PATTERN; EMBRYOS	SUBCELLULAR RNA localization in different cell types leads to asymmetric distribution of proteins in these cells(1,2). The localization of bicoid (bcd) messenger RNA to the anterior pole of the developing Drosophila oocyte gives rise in embryogenesis to a steep concentration gradient of the bcd protein(3-6), a transcription factor that activates expression of zygotic genes needed for anterior development(7-9). The exuperantia (exu) gene is necessary for this localization of bcd mRNA(3,4). Here we express a chimaeric gene encoding a fusion between the Acquorea victoria green fluorescent protein (GPP)(10) and the exu protein (Exu) in female germ cells, and find that the fusion protein fluoresces strongly in both live and fixed cells during Drosophila oogenesis. The fusion protein rescues an exu null allele, restoring full fertility to females, and is expressed and localized in a temporal and spatial pattern similar to native Exu. The high sensitivity of the GFP tag provides important ne,v details on the subcellular localization of Exu. The fusion protein is found in particles concentrated at ring canals, where transport occurs between nurse cells and the oocyte. Drugs such as colchicine and taxol that affect microtubule stability alter localization of the particles. We propose that the particles are ribonucleoprotein complexes or vesicles which transport bcd mRNA along microtubules and target it to the anterior oocyte cortex.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel CS, 1992, DROS INF SERV, V71, P150; WAM RM, 1986, EXP CELL RES, V157, P355; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	25	424	474	3	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					400	403		10.1038/369400a0	http://dx.doi.org/10.1038/369400a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910952				2022-12-01	WOS:A1994NP17400057
J	KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS				KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS			TAKAYASU ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NORTH-AMERICAN PATIENTS; SURGICAL-TREATMENT; ANGIOGRAPHIC FINDINGS; DISEASE; AORTOARTERITIS; GRANULOMATOSIS; INVOLVEMENT; AORTITIS; METHOTREXATE; SARCOIDOSIS	Objective: To evaluate prospectively the clinical features, angiographic findings, and response to treatment of patients with Takayasu arteritis. Design: 60 patients with Takayasu arteritis were studied at the National Institute of Allergy and Infectious Diseases between 1970 and 1990 and were followed for 6 months to 20 years (median follow-up, 5.3 years). Measurements: Data on clinical features, angiographic and laboratory findings, disease course, and response to therapy were all recorded and stored in a computer-based retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Results: In our series of patients, Takayasu arteritis was more common in Asian persons compared with persons from other racial groups. Females (97%) were most frequently affected. The median age at disease onset was 25 years. Juveniles had a delay in diagnosis that was about four times that of adults. The clinical presentation ranged from asymptomatic to catastrophic with stroke. The most common clinical finding was a bruit. Hypertension was most often associated with renal artery stenosis. Only 33% of all patients had systemic symptoms on presentation. Sixty-eight percent of patients had extensive vascular disease; stenotic lesions were 3.6-fold more common than were aneurysms (98% compared with 27%). The erythrocyte sedimentation rate was not a consistently reliable surrogate marker of disease activity. Surgical bypass biopsy specimens from clinically inactive patients showed histologically active disease in 44% of patients. Although clinically significant palliation usually occurred after angioplasty or bypass of severely stenotic vessels, restenosis was common. Medical therapy was required for 80% of patients, whereas 20% had monophasic self-limiting disease. Immunosuppressive treatment with glucocorticoids alone or in combination with a cytotoxic agent failed to induce remission in one fourth of patients; about half of those who achieved remission later relapsed. Conclusions: In North America, Takayasu arteritis is a rare disease. It is heterogeneous in presentation, progression, and response to therapy. Current laboratory markers of disease activity are insufficiently reliable to guide management. Most patients require repeated and, at times, prolonged courses of therapy. Although mortality was low, substantial morbidity occurred in most patients.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGE WASHINGTON UNIV HOSP, WASHINGTON, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University			Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				ABE K, 1976, JPN HEART J, V17, P1; ACHAR KN, 1986, AM J GASTROENTEROL, V81, P1215; ASKUPMARK E, 1961, ACTA MED SCAND, V169, P467; ASO T, 1992, HEART VESSELS S, V7, P15; CHUGH KS, 1992, AM J NEPHROL, V12, P1, DOI 10.1159/000168409; CIPRIANO PR, 1977, AM J CARDIOL, V39, P744, DOI 10.1016/S0002-9149(77)80139-2; DANARAJ TJ, 1959, CIRCULATION, V20, P856, DOI 10.1161/01.CIR.20.5.856; DEUTSCH V, 1974, AM J ROENTGENOL, V122, P13, DOI 10.2214/ajr.122.1.13; DIGIACOMO V, 1985, ANGIOLOGY, V36, P70, DOI 10.1177/000331978503600202; FRAGA A, 1972, ARTHRITIS RHEUM, V15, P617, DOI 10.1002/art.1780150608; GIORDANO JM, 1991, SURGERY, V109, P252; HALL S, 1985, MEDICINE, V64, P89, DOI 10.1097/00005792-198503000-00002; HE NS, 1990, CHINESE MED J-PEKING, V103, P666; HOFFMAN GS, 1992, ARTHRITIS RHEUM, V35, P1322, DOI 10.1002/art.1780351113; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; ISAACSON C, 1961, J PATHOL BACTERIOL, V81, P69, DOI 10.1002/path.1700810109; ISHIKAWA K, 1988, J AM COLL CARDIOL, V12, P964, DOI 10.1016/0735-1097(88)90462-7; ISHIKAWA K, 1982, AM J CARDIOL, V50, P1293, DOI 10.1016/0002-9149(82)90466-0; JUDGE RD, 1962, AM J MED, V32, P379, DOI 10.1016/0002-9343(62)90128-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHRAISHI MM, 1992, ARTHRITIS RHEUM, V35, P573, DOI 10.1002/art.1780350514; KUMAR S, 1989, CARDIOVASC INTER RAD, V12, P321, DOI 10.1007/BF02575430; LAGNEAU P, 1987, ANN SURG, V205, P157, DOI 10.1097/00000658-198702000-00010; LANDE A, 1976, NEW YORK STATE J MED, V76, P1477; LEE J, 1990, HLA SYSTEM; LEE KS, 1967, ACTA PAEDIATR SCAND, V56, P526, DOI 10.1111/j.1651-2227.1967.tb15418.x; LENHOFF SJ, 1982, POSTGRAD MED J, V58, P386, DOI 10.1136/pgmj.58.680.386; LUPIH E, 1975, CHEST, V67, P69, DOI 10.1378/chest.67.1.69; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; MAEDA S, 1983, ACTA PATHOL JAPON, V33, P183; Matsumura A, 1992, Heart Vessels Suppl, V7, P120, DOI 10.1007/BF01744557; MENDELOFF AI, 1980, INFLAMM BOWEL DIS, P5; MEVORACH D, 1992, ANN RHEUM DIS, V51, P904, DOI 10.1136/ard.51.7.904; MORIUCHI J, 1982, HUM IMMUNOL, V4, P87, DOI 10.1016/0198-8859(82)90054-4; NAKAO K, 1967, CIRCULATION, V35, P1141, DOI 10.1161/01.CIR.35.6.1141; NUMANO F, 1982, JPN CIRC J, V46, P184, DOI 10.1253/jcj.46.184; NUSINOW SR, 1984, ARTHRITIS RHEUM, V27, P1405, DOI 10.1002/art.1780271211; PAJARI R, 1986, THORAC CARDIOV SURG, V34, P176, DOI 10.1055/s-2007-1020404; ROSE AG, 1980, ARCH PATHOL LAB MED, V104, P231; ROSE CD, 1990, J RHEUMATOL, V17, P102; Sabba C, 1990, Am J Cardiovasc Pathol, V3, P95; SEN PK, 1973, MONOGRAPH BASED STUD; SHARMA S, 1991, BRIT J RADIOL, V64, P690, DOI 10.1259/0007-1285-64-764-690; SHARMA S, 1990, CLIN RADIOL, V42, P177, DOI 10.1016/S0009-9260(05)81929-4; SHARMA S, 1992, AM J ROENTGENOL, V158, P417, DOI 10.2214/ajr.158.2.1346073; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SUBRAMANYAN R, 1989, CIRCULATION, V80, P429, DOI 10.1161/01.CIR.80.3.429; TAKAGI A, 1989, J CARDIOVASC SURG, V30, P553; VINIJCHAIKUL K, 1967, AM J MED, V43, P15, DOI 10.1016/0002-9343(67)90145-3; VOLKMAN DJ, 1982, NEW ENGL J MED, V306, P464, DOI 10.1056/NEJM198202253060806; WAERN AU, 1983, ANGIOLOGY, V34, P311; Weaver F A, 1992, Heart Vessels Suppl, V7, P154, DOI 10.1007/BF01744562; WEAVER RL, 1990, WAVE MOTION, V12, P129, DOI 10.1016/0165-2125(90)90034-2; WONG VCW, 1983, AM J MED, V75, P597, DOI 10.1016/0002-9343(83)90439-4; WOOLF AD, 1987, ANN RHEUM DIS, V46, P441, DOI 10.1136/ard.46.6.441; YAMADA I, 1992, AM J ROENTGENOL, V159, P263, DOI 10.2214/ajr.159.2.1352939; YAMATO M, 1986, RADIOLOGY, V161, P329, DOI 10.1148/radiology.161.2.2876459; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHENG DY, 1990, CHINESE MED J-PEKING, V103, P536; 1990, AM SOC HISTOCOMPATIB; 1992, HEART VESSELS S, V7, P1; 1990, NATIONAL DATA BOOK, P77	63	1299	1424	0	35	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					919	929		10.7326/0003-4819-120-11-199406010-00004	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	7909656				2022-12-01	WOS:A1994NN11000004
J	DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J				DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J			RECOVERY DESPITE IMPAIRED CEREBRAL PERFUSION IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							LIVER-TRANSPLANTATION	We report 4 patients with fulminant hepatic failure who developed prolonged intracranial hypertension (> 35 mm Hg for 24-38 h) that was refractpty to standard therapy and associated with impaired cerebral perfusion pressure (< 50 mm Hg for 2-72 h). All survived with complete neurological recovery. Refractory elevation of intracranial pressure and reduced cerebral perfusion pressure are generally thought to contra-indicate liver transplantation in hepatic failure and are indications to withdraw support. Our observations challenge this concept.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			Neuberger, James/ABG-3010-2020					ALMDAL T, 1989, SCAND J GASTROENTERO, V24, P299, DOI 10.3109/00365528909093050; DONOVAN JP, 1992, HEPATOLOGY, V16, P267, DOI 10.1002/hep.1840160138; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LLIDOFSKY SD, 1992, HEPATOLOGY, V16, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MUNOZ SJ, 1993, TRANSPLANTATION, V55, P1071, DOI 10.1097/00007890-199305000-00025; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	9	44	45	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1329	1330		10.1016/S0140-6736(94)92471-6	http://dx.doi.org/10.1016/S0140-6736(94)92471-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910328				2022-12-01	WOS:A1994NN21700014
J	GODDARD, CJR; WARNES, TW				GODDARD, CJR; WARNES, TW			PRIMARY BILIARY-CIRRHOSIS - HOW SHOULD WE EVALUATE NEW TREATMENTS	LANCET			English	Editorial Material							CONTROLLED TRIAL; PROGNOSIS; COLCHICINE; MODEL				GODDARD, CJR (corresponding author), MANCHESTER ROYAL INFIRM,LIVER UNIT,MANCHESTER,LANCS,ENGLAND.							BABBS C, 1988, LANCET, V1, P1021; BIRCHER J, 1983, SEMIN LIVER DIS, V3, P275, DOI 10.1055/s-2008-1040780; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; HEATHCOTE EJ, 1994, HEPATOLOGY, V10, P1149; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; POUPON RE, 1994, HEPATOLOGY, V19, P635, DOI 10.1002/hep.1840190314; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WIESNER RH, 1988, HEPATOLOGY, V8, P668, DOI 10.1002/hep.1840080339	14	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1306		10.1016/S0140-6736(94)92461-9	http://dx.doi.org/10.1016/S0140-6736(94)92461-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910318				2022-12-01	WOS:A1994NN21700004
J	HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C				HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C			PARALYTIC POLIOMYELITIS - SEASONED STRATEGIES, DISAPPEARING DISEASE	LANCET			English	Article							ORAL POLIO VACCINE; ERADICATION; EFFICACY; PROGRESS; COUNTRIES; BRAZIL	With more than 2 years having elapsed since the last case of paralytic poliomyelitis occurred in the Western Hemisphere, significant progress has been made towards the global eradication of wild polioviruses. Poliomyelitis is disappearing from Europe, North Africa, Southern Africa, the Middle East, China, and the Pacific. Reported poliomyelitis cases declined to 15 587 cases in 1992. Current eradication strategies recommended by the World Health Organization include national mass campaigns administering oral poliovaccine to all children under 5 years of age, enhanced surveillance to detect cases of acute flaccid paralysis, creating a network of laboratories for viral diagnosis, and targeted immunisation to areas and populations where poliovirus transmission is likely to persist. The major obstacles to eradication include inadequate political support for eradication and insufficient funding, especially for the purchase of vaccine. With additional support for the international eradication effort, epidemics of poliomyelitis will cease in developing countries, and industrialised countries will be able to save the large sums spent each year on poliovaccine and rehabilitation.	CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30341 USA; WHO, BIOL UNIT, CH-1211 GENEVA, SWITZERLAND; PAN AMER HLTH ORG, EXPANDED PROGRAMME IMMUNIZAT, WASHINGTON, DC USA	Centers for Disease Control & Prevention - USA; World Health Organization; Pan American Health Organization	HULL, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 4, SWITZERLAND.							ANDRUS JK, 1992, B WORLD HEALTH ORGAN, V70, P591; [Anonymous], 1992, Wkly Epidemiol Rec, V67, P341; BIELLIK RJ, 1992, B WORLD HEALTH ORGAN, V70, P79; CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19, DOI 10.1093/tropej/35.1.19; CRUZ RR, 1984, REV INFECT DIS, V6, pS408; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; FOX JP, 1984, REV INFECT DIS, V6, pS352; GEAR JHS, 1984, REV INFECT DIS, V6, pS379; JOHN TJ, 1976, BRIT MED J, V1, P812, DOI 10.1136/bmj.1.6013.812; LEMON SM, 1991, PROG MED VIROL, V38, P42; Mandke B V, 1990, Indian J Public Health, V34, P200; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MELNICK JL, 1992, EPIDEMIOL INFECT, V108, P1; MODLIN JF, 1991, PEDIATR INFECT DIS J, V10, P976, DOI 10.1097/00006454-199112000-00031; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1993, LANCET, V342, P1461, DOI 10.1016/0140-6736(93)92936-N; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PLOTKIN SA, 1991, PEDIATR INFECT DIS J, V10, P979, DOI 10.1097/00006454-199112000-00032; RICHARDSON G, 1993, RD P ICAAC WASH; RISI JB, 1984, REV INFECT DIS, V6, pS400; SABIN AB, 1980, B WORLD HEALTH ORGAN, V58, P141; SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001; SATTAR SA, 1991, VIRUSES WASTEWATER T, P91; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1984, 1984 BELL C NEW YORK; 1993, WKLY EPIDEMIOL REC, V68, P222; 1993, CAN COMMUN DIS REP, V19, P57; 1993, B PAHO, V27, P287; 1992, WKLY EPIDEMIOL REC, V67, P336	36	167	169	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1331	1337		10.1016/S0140-6736(94)92472-4	http://dx.doi.org/10.1016/S0140-6736(94)92472-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910329				2022-12-01	WOS:A1994NN21700015
J	JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I				JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I			BLOOD-TESTS FOR DETECTION OF ALCOHOLIC CAUSE OF ACUTE-PANCREATITIS	LANCET			English	Note							LIPASE AMYLASE RATIO; DRINKING; MARKER; SERUM; MEN	We investigated the ability of various blood markers to detect an alcoholic cause of acute pancreatitis. Serum carbohydrate-deficient transferrin (CDT) was significantly correlated with reported 2 month and 7 day ethanol consumptions and was significantly higher in 42 patients with alcoholic acute pancreatitis and in 24 patients with possibly alcoholic acute pancreatitis than in 20 patients with non-alcoholic disease. At a cutoff over 17 U/L, the specificity of CDT was 100% and the sensitivity was 75% to detect an alcoholic cause of acute pancreatitis. The lipase/amylase ratio index, erythrocyte mean corpuscular volume, and gamma glutamyl transferase could not distinguish alcoholic from non-alcoholic acute pancreatitis.	TAMPERE UNIV HOSP, DEPT SURG, SF-33250 TAMPERE, FINLAND; UNIV TAMPERE, DEPT CLIN MED, SF-33101 TAMPERE, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN CHEM, TAMPERE, FINLAND; ALKO LTD, BIOMED RES CTR, TAMPERE, FINLAND	Tampere University; Tampere University Hospital; Tampere University; Tampere University; Tampere University Hospital								CHICK J, 1981, LANCET, V1, P1249; GUMASTE VV, 1991, GASTROENTEROLOGY, V101, P1361, DOI 10.1016/0016-5085(91)90089-4; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; NORONHA M, 1981, AM J GASTROENTEROL, V76, P114; PEZZILLI R, 1993, DIGEST DIS SCI, V38, P1265, DOI 10.1007/BF01296077; SILLANAUKEE P, 1993, ALCOHOL CLIN EXP RES, V17, P230, DOI 10.1111/j.1530-0277.1993.tb00754.x; Sillanaukee P, 1992, SUOM LAAKARILEHTI, V31, P2919; STIBLER H, 1991, CLIN CHEM, V37, P2029; STIBLER H, 1991, ALCOHOL ALCOHOLISM, P451; Stibler H, 1980, Subst Alcohol Actions Misuse, V1, P247	10	42	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1328	1329		10.1016/S0140-6736(94)92470-8	http://dx.doi.org/10.1016/S0140-6736(94)92470-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910327				2022-12-01	WOS:A1994NN21700013
J	KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S				KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S			HTLV-I PROVIRAL DNA IN UMBILICAL-CORD BLOOD OF BABIES BORN TO CARRIER MOTHERS	LANCET			English	Note							CELL LEUKEMIA-VIRUS; POLYMERASE CHAIN-REACTION; TO-CHILD TRANSMISSION; ANTIBODY; ANTIGEN; MILK	Human T-lymphotropic virus type I (HTLV-I) in cord blood raises the possibility of intrauterine transmission as an alternative pathway to transmission via breast milk. However, none of 7 children with HTLV-I proviral DNA positive cord blood had seroconverted by 24-48 months. Contamination of cord blood by maternal blood was precluded on the basis of viral load and IgA concentration. Thus cord blood proviral DNA is not a hallmark of intrauterine infection. Moreover, none of the cord blood samples of 9 formula-fed children later confirmed to be infected was positive for HTLV-I, indicating that intrauterine infection is not a likely candidate as an alternative pathway.	NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGASAKI 852,JAPAN; TOTTORI UNIV,FAC MED,DEPT VIROL,YONAGO,TOTTORI 683,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Tottori University	KATAMINE, S (corresponding author), NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN.							HINO S, 1987, LANCET, V2, P158; HINO S, 1985, JPN J CANCER RES, V76, P474; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; SAITO S, 1990, JPN J CANCER RES, V81, P890, DOI 10.1111/j.1349-7006.1990.tb02663.x; SATOW YI, 1991, LANCET, V338, P915, DOI 10.1016/0140-6736(91)91775-P; TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1326	1327		10.1016/S0140-6736(94)92469-4	http://dx.doi.org/10.1016/S0140-6736(94)92469-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910326				2022-12-01	WOS:A1994NN21700012
J	LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF				LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF			ARREST OF PRETERM LABOR AND PROLONGATION OF GESTATION WITH GLYCERYL TRINITRATE, A NITRIC-OXIDE DONOR	LANCET			English	Note							INDOMETHACIN	13 women admitted consecutively in preterm labour were recruited to an observational study of the effect of glyceryl trinitrate (GTN) patches on uterine contractions and prolongation of pregnancy. All twenty episodes of preterm labour (at 23-33 weeks' gestation) responded. 1 patient delivered because of cervical incompetence despite cessation of uterine contractions. The mean prolongation of pregnancy was 34 days. 8 babies have been born so far, and are progressing well. GTN patches appear to be a safe, well-tolerated, and non-invasive method of suppressing uterine contractions in preterm labour.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT MED,LONDON SE5 8RX,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; GlaxoSmithKline; Wellcome Research Laboratories			Brown, Richard/I-3851-2019	Brown, Richard/0000-0002-5476-2698				BIVINS HA, 1993, AM J OBSTET GYNECOL, V169, P1065, DOI 10.1016/0002-9378(93)90055-N; BOOTSTAYLOR B, 1994, AM J OBSTET GYNECO S, V179, P281; GREENSPOON JS, 1991, LANCET, V338, P124, DOI 10.1016/0140-6736(91)90122-6; Hankins G.D.V., 1991, CRITICAL CARE OBSTET, P231; IZUMI H, 1993, AM J OBSTET GYNECOL, V169, P1327, DOI 10.1016/0002-9378(93)90301-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; RAMSAY B, 1994, EUR J CLIN INVEST, V24, P76, DOI 10.1111/j.1365-2362.1994.tb02064.x; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; 1992, NEW ENGL J MED, V327, P308	10	176	183	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1325	1326		10.1016/S0140-6736(94)92468-6	http://dx.doi.org/10.1016/S0140-6736(94)92468-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910325				2022-12-01	WOS:A1994NN21700011
J	LIFSON, AR				LIFSON, AR			PREVENTING HIV - HAVE WE LOST OUR WAY	LANCET			English	Editorial Material							RISK-FACTORS; DRUG-USERS; AIDS; TRANSMISSION; PROSTITUTES				LIFSON, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1993, MMWR, V42, P869; BINSON D, 1993, FAM PLANN PERSPECT, V25, P268, DOI 10.2307/2136144; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MANN JM, 1992, AIDS WORLD CAMBRIDGE; MICHAELS D, 1992, JAMA-J AM MED ASSOC, V268, P3456, DOI 10.1001/jama.268.24.3456; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; SIMOES EAF, 1993, J ACQ IMMUN DEF SYND, V6, P1030; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; 1993, SOCIAL IMPACT AIDS U; 1992, MMWR, V41, P1; 1994, MMWR, V43, P155	15	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1306	1308		10.1016/S0140-6736(94)92462-7	http://dx.doi.org/10.1016/S0140-6736(94)92462-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910319				2022-12-01	WOS:A1994NN21700005
J	TREASURE, T				TREASURE, T			THE PULMONARY AUTOGRAFT AS AN AORTIC-VALVE REPLACEMENT	LANCET			English	Editorial Material											TREASURE, T (corresponding author), ST GEORGE HOSP,LONDON,ENGLAND.							ELKINS RC, 1994, NEW ENGL J MED, V330, P59, DOI 10.1056/NEJM199401063300111; KOUCHOUKOS NT, 1994, NEW ENGL J MED, V330, P1, DOI 10.1056/NEJM199401063300101; ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E; ROSS D, 1991, ANN THORAC SURG, V52, P1346, DOI 10.1016/0003-4975(91)90032-L; ROSS DN, 1967, LANCET, V2, P956	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1308	1308		10.1016/S0140-6736(94)92463-5	http://dx.doi.org/10.1016/S0140-6736(94)92463-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910320				2022-12-01	WOS:A1994NN21700006
J	WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B				WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B			CONTINENT COLONIC CONDUIT FOR RECTAL EVACUATION IN SEVERE CONSTIPATION	LANCET			English	Article							IDIOPATHIC CONSTIPATION; OUTLET OBSTRUCTION; ANISMUS; PROCTOCOLECTOMY; APPENDIX; SURGERY; ENEMA	We describe a new operation for the treatment of rectal evacuatory disorders: a continent colonic conduit, incorporating an intussuscepted valve, was constructed from the sigmoid colon. Intubation of the conduit allowed irrigation and evacuation of the distal colon and rectum. Initially all 10 patients reported a reduction in time taken and the discomfort involved in completing evacuation. The number of stools passed per week increased in 9 out of 10 patients, from a median of 1.5 (range 0.25-7) to a median of 7 (range 3-7) postoperatively. Subsequently, 3 patients developed complications, 2 of whom required conversion to an ileostomy. Overall, the colonic conduit procedure was successful in treating the rectal evacuatory disorder in 7 patients, failed in 2, and 1 patient has a temporary defunctioning ileostomy. The procedure is a relatively simple surgical alternative for the treatment of a condition which is often resistant to conservative measures.			WILLIAMS, NS (corresponding author), ROYAL LONDON HOSP,SURG UNIT,LONDON E1 1BB,ENGLAND.							DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203; HALLAN RI, 1988, LANCET, V2, P714; HOSIE KB, 1990, BRIT J SURG, V77, P801, DOI 10.1002/bjs.1800770726; HUGHES ESR, 1981, AUST NZ J SURG, V51, P144, DOI 10.1111/j.1445-2197.1981.tb05926.x; KAMM MA, 1988, BRIT J SURG, V75, P661, DOI 10.1002/bjs.1800750713; KOCK NG, 1969, ARCH SURG-CHICAGO, V99, P223; LESTAR B, 1991, INT J COLORECTAL DIS, V6, P202, DOI 10.1007/BF00341391; MALONE PS, 1990, LANCET, V336, P1217, DOI 10.1016/0140-6736(90)92834-5; MARTELLI H, 1978, GASTROENTEROLOGY, V75, P623; MITROFANOFF P, 1980, CHIR PEDIATR, V21, P297; NICHOLLS RJ, 1988, DIS COLON RECTUM, V31, P968, DOI 10.1007/BF02554897; PRESTON DM, 1985, DIGEST DIS SCI, V30, P413, DOI 10.1007/BF01318172; RYAN JA, 1985, AM J SURG, V149, P636, DOI 10.1016/S0002-9610(85)80145-8; SQUIRE R, 1993, J PEDIATR SURG, V28, P1012, DOI 10.1016/0022-3468(93)90505-F; TAYLOR T, 1989, BRIT MED J, V299, P300, DOI 10.1136/bmj.299.6694.300; WASSERMAN I F, 1964, Dis Colon Rectum, V7, P87, DOI 10.1007/BF02616902; WEXNER SD, 1991, DIS COLON RECTUM, V34, P851, DOI 10.1007/BF02049695; WHEELER RA, 1991, BRIT J SURG, V78, P1283, DOI 10.1002/bjs.1800781103; WILLIAMS NS, 1980, BRIT MED J, V281, P107, DOI 10.1136/bmj.281.6233.107; WILLIAMS NS, SURGICAL THERAPY CON, P757; YOSHIOKA K, 1987, BRIT J SURG, V74, P373, DOI 10.1002/bjs.1800740516	21	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1321	1324		10.1016/S0140-6736(94)92467-8	http://dx.doi.org/10.1016/S0140-6736(94)92467-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910324				2022-12-01	WOS:A1994NN21700010
J	WRIGHT, EC				WRIGHT, EC			A LESSON IN NONCOMPLIANCE	LANCET			English	Editorial Material																		BABIKER IE, 1986, PSYCHIAT DEV, V4, P329; GREENBERG RN, 1984, CLIN THER, V65, P590; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; WALKER R, 1992, PHARM J, V249, P695; 1994, J PEDIATR, V124, P383	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1305		10.1016/S0140-6736(94)92460-0	http://dx.doi.org/10.1016/S0140-6736(94)92460-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN217	7910317				2022-12-01	WOS:A1994NN21700003
J	GAVIS, ER; LEHMANN, R				GAVIS, ER; LEHMANN, R			TRANSLATIONAL REGULATION OF NANOS BY RNA LOCALIZATION	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; POSTERIOR DETERMINANT NANOS; POLE CELL-FORMATION; DROSOPHILA-MELANOGASTER; MATERNAL GENE; EMBRYONIC POLARITY; ANTERIOR PATTERN; GERM PLASM; OSKAR; PROTEIN	LOCALIZATION of the maternally synthesized nanos (nos) RNA to the posterior pole of the Drosophila embryo provides the source for a posterior-to-anterior gradient of Nos protein(1,2). Correct spatial regulation of nos activity is essential for normal pattern formation. High local concentrations of Nos protein in the posterior of the embryo are necessary to inhibit translation of the transcription factor Hunchback in this region(3,4), ana thus permit expression of genes required for abdomen formation (see ref. 5 for review). By contrast, misexpression of Nos protein at the anterior of the embryo prevents translation of the anterior morphogen Bicoid, suppressing head and thorax development(1,6-9). Posterior localization of nos RNA is mediated by sequences within the nos 3' untranslated region (3'UTR)(1) and requires the function of eight genes of the 'posterior group'(2,6). Although the unlocalized nos RNA is stable in embryos from females mutant for any of the posterior group genes, these embryos appear to lack nos activity because they develop the abdominal defects characteristic of embryos produced by nos mutant females(2,6,10-14). We report here that unlocalized nos RNA is translationally repressed. Translational repression is mediated by the nos 3'UTR and can be alleviated either by replacement of the 3'UTR with heterologous 3'UTR sequences or by posterior localization. Thus, RNA localization provides a novel mechanism for translational regulation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GAVIS, ER (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Gavis, Elizabeth/0000-0003-0251-0760; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; Evans T.C., 1992, Seminars in Developmental Biology, V3, P381; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1991, DEVELOPMENT, V112, P1077; GAVIS ER, IN PRESS ADV DEV BIO, V3; HULSKAMP M, 1991, BIOESSAYS, V13, P261, DOI 10.1002/bies.950130602; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P808; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	30	242	246	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	1994	369	6478					315	318		10.1038/369315a0	http://dx.doi.org/10.1038/369315a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514276				2022-12-01	WOS:A1994NN10900048
J	GHADIRI, MR; GRANJA, JR; BUEHLER, LK				GHADIRI, MR; GRANJA, JR; BUEHLER, LK			ARTIFICIAL TRANSMEMBRANE ION CHANNELS FROM SELF-ASSEMBLING PEPTIDE NANOTUBES	NATURE			English	Article							SYNTHETIC PROTEINS; MEMBRANES; TRANSPORT; VESICLES; DESIGN; GRAMICIDIN; LIPOSOMES; BILAYERS; MODEL	NATURALLY occurring membrane channels and pores are formed from a large family of diverse proteins, peptides and organic secondary metabolites whose vital biological functions include control of ion flow, signal transduction, molecular transport and production of cellular toxins. But despite the availability of a large amount of biochemical information about these molecules(1), the design and synthesis of artificial systems that can mimic the biological function of natural compounds remains a formidable task(2-12). Here we present a simple strategy for the design of artificial membrane ion channels based on a self-assembled cylindrical beta-sheet peptide architecture(13). Our systems-essentially stacks of peptide rings-display good channel-mediated ion-transport activity with rates exceeding 10(7) ions s(-1), rivalling the performance of many naturally occurring counterparts. Such molecular assemblies should find use in the design of novel cytotoxic agents, membrane transport vehicles and drug-delivery systems.	SCRIPPS RES INST, DEPT MOLEC BIOL & CELL BIOL, LA JOLLA, CA 92307 USA	Scripps Research Institute	GHADIRI, MR (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92307 USA.		Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504				AKERFELDT KS, 1993, ACCOUNTS CHEM RES, V26, P191, DOI 10.1021/ar00028a009; ALLEN LC, 1975, P NATL ACAD SCI USA, V72, P4701, DOI 10.1073/pnas.72.12.4701; ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; CARMICHAEL VE, 1989, J AM CHEM SOC, V111, P767, DOI 10.1021/ja00184a075; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1544, DOI 10.1021/bi00509a021; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1539, DOI 10.1021/bi00509a020; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUHRHOP JH, 1988, J AM CHEM SOC, V110, P6840, DOI 10.1021/ja00228a037; FYLES TM, 1993, J AM CHEM SOC, V115, P12315, DOI 10.1021/ja00079a011; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GROVE A, 1993, J AM CHEM SOC, V115, P5919, DOI 10.1021/ja00067a004; Hille B., 1992, IONIC CHANNELS EXCIT; JAYASURIYA N, 1990, J AM CHEM SOC, V112, P5844, DOI 10.1021/ja00171a026; KHAZANOVICH N, IN PRESS J AM CHEM S; LAUGER P, 1985, ANGEW CHEM INT EDIT, V24, P905, DOI 10.1002/anie.198509051; LAUGER P, 1985, ANGEW CHEM, V97, P939; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; NABEDRYK E, 1982, BIOPHYS J, V38, P243, DOI 10.1016/S0006-3495(82)84555-4; NAKANO A, 1990, J AM CHEM SOC, V112, P1287, DOI 10.1021/ja00159a083; New R. R., 1990, LIPOSOMES; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pregel M. J., 1992, ANGEW CHEM, V104, P1695; PREGEL MJ, 1992, ANGEW CHEM INT EDIT, V31, P1637, DOI 10.1002/anie.199216371; ROKS MFM, 1992, MACROMOLECULES, V25, P5398, DOI 10.1021/ma00046a042; ROVERO P, 1991, TETRAHEDRON LETT, V32, P2639, DOI 10.1016/S0040-4039(00)78806-X; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007	32	808	842	7	261	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					301	304		10.1038/369301a0	http://dx.doi.org/10.1038/369301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514275				2022-12-01	WOS:A1994NN10900043
J	HENGARTNER, MO; HORVITZ, HR				HENGARTNER, MO; HORVITZ, HR			ACTIVATION OF C-ELEGANS CELL-DEATH PROTEIN CED-9 BY AN AMINO-ACID SUBSTITUTION IN A DOMAIN CONSERVED IN BCL-2	NATURE			English	Article							CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; FOLLICULAR LYMPHOMA; GENE; TRANSLOCATION; EXPRESSION; NEMATODE; CLONING	THE Caenorhabditis elegans gene ced-9 and the human protooncogene bcl-2 both of which protect cells from programmed cell death, are members of the same gene family(1-11). ced-9 and bcl-2 were discovered because of the effects of dominant gain-of-function mutations(12-14). Such bcl-2 mutations, which are commonly found in follicular lymphoma, are translocations that result in overexpression of a normal Bcl-2 protein in B cells(1,13-16) Here we report that, by contrast, the ced-9(n1950) gain-of-function mutation affects the open reading frame of ced-9 and results in a glycine-to-glutamate substitution in a region highly conserved among all ced-9/bcl-2 family members. We conclude that this glycine has an important function in ced-9 regulation, and we suggest that alteration of this glycine in other members of the ced-9/bcl-2 family might lead to oncogenic activation. We also present genetic evidence suggesting that the CED-9 protein might exist in two distinct forms that have opposite effects on cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Hengartner, Michael O/E-6235-2011; Hengartner, Michael O/A-7058-2008	Hengartner, Michael/0000-0002-7584-596X				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, IN PRESS CURR OPIN G; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	28	153	158	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					318	320		10.1038/369318a0	http://dx.doi.org/10.1038/369318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910376				2022-12-01	WOS:A1994NN10900049
J	MERINEY, SD; GRAY, DB; PILAR, GR				MERINEY, SD; GRAY, DB; PILAR, GR			SOMATOSTATIN-INDUCED INHIBITION OF NEURONAL CA2+ CURRENT MODULATED BY CGMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CHICK SENSORY NEURONS; CALCIUM CURRENT; GANGLION NEURONS; CILIARY GANGLION; BINDING PROTEIN; CHANNELS; ACTIVATION; PATHWAYS	NEUROTRANSMITTER release is frequently regulated by peptides that modulate neuronal calcium channels. Whole-cell recordings show that the ion permeability(1) and voltage dependence(2) of these channels are controlled by a membrane-associated pathway involving GTP-binding proteins. Here we use perforated-patch recordings to show that, in addition to this pathway, the peptide somatostatin inhibits the calcium current in chick ciliary ganglion neurons by a second soluble pathway involving a cyclic GMP-dependent protein kinase (cGMP-PK). This somatostatin inhibition of Ca2+ current did not desensitize and was not characterized by the slowing of Ca2+-current activation (kinetic slowing) observed in whole-cell recordings. When cGMP-PK was inhibited, somatostatin inhibition of Ca2+ current resembled that observed with whole-cell recordings. cGMP agonists mimic the effect of somatostatin only in perforated patch recordings. An endogenous cGMP-PK therefore forms part of the mechanism by which somatostatin induces a sustained inhibition of neuronal calcium channels.	UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,STORRS,CT 06269	University of Connecticut								ASHKENAZIE A, 1987, SCIENCE, V238, P272; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BLEY KR, 1990, NEURON, V2, P379; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; DRYER SE, 1991, NEUROSCIENCE, V44, P663, DOI 10.1016/0306-4522(91)90086-4; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GOLARD A, 1993, J NEUROSCI, V13, P3884; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; GRAY DB, 1990, J NEUROSCI, V10, P2687; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; KASAI H, 1989, PFLUG ARCH EUR J PHY, V414, P145, DOI 10.1007/BF00580956; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; PENINGTON NJ, 1991, J NEUROSCI, V11, P3594, DOI 10.1523/jneurosci.11-11-03594.1991; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SAH DWY, 1990, J NEUROSCI, V10, P136; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; WENTZEK LAF, 1993, J NEUROSCI, V13, P3143; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	25	126	127	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					336	339		10.1038/369336a0	http://dx.doi.org/10.1038/369336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910377				2022-12-01	WOS:A1994NN10900055
J	NELSON, BH; LORD, JD; GREENBERG, PD				NELSON, BH; LORD, JD; GREENBERG, PD			CYTOPLASMIC DOMAINS OF THE INTERLEUKIN-2 RECEPTOR BETA-CHAIN AND GAMMA-CHAIN MEDIATE THE SIGNAL FOR T-CELL PROLIFERATION	NATURE			English	Article							IL-2 RECEPTOR; TYROSINE KINASE; FUNCTIONAL COMPONENT; GM-CSF; TRANSDUCTION; ACTIVATION; BINDING; PHOSPHORYLATION; INVOLVEMENT; EXPRESSION	The interleukin-2 (IL-2R) consists of three distinct chains (alpha, beta, gamma) which bind IL-2 and generate a proliferative signal in T cells(1). To define the mechanism of receptor activation, chimaeric receptors were constructed from the intracellular region of either IL-2R beta or IL-2R gamma and the extracellular region of c-kit, a receptor tyrosine kinase that homodimerizes on binding stem cell factor (SCF)(2). We report here that binding of SCF to the beta-chain chimaera induced proliferation of the pro-B-cell line BA/F3, but not T cells. But in T cells expressing both the beta- and gamma-chain chimaeras, SCF induced proliferation and tyrosine phosphorylation characteristic of the native IL-2R signal. Chimaeric IL-2 receptor beta and gamma chains constructed with the heterodimeric extracellular regions of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) also provided the IL-2R signal. Thus, heterodimerization of the cytoplasmic domains of n-2R beta and -gamma appears necessary and sufficient for signalling in T cells.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	NELSON, BH (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST M758,SEATTLE,WA 98104, USA.		Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539				ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEV S, 1992, J BIOL CHEM, V267, P15970; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MOREAU JL, 1987, EUR J IMMUNOL, V17, P929, DOI 10.1002/eji.1830170706; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	30	294	310	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					333	336		10.1038/369333a0	http://dx.doi.org/10.1038/369333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514277				2022-12-01	WOS:A1994NN10900054
J	CAUL, EO				CAUL, EO			SMALL ROUND STRUCTURED VIRUSES - AIRBORNE TRANSMISSION AND HOSPITAL CONTROL	LANCET			English	Editorial Material											CAUL, EO (corresponding author), PUBL HLTH LAB,REG VIRUS LAB,BRISTOL,AVON,ENGLAND.							Caul E. O., 1993, PHLS Microbiology Digest, V10, P2; CAUL E O, 1988, P139; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; GELLERT GA, 1994, LANCET, V343, P609; GREEN SM, IN PRESS J GEN VIROL; GREENBERG HB, 1979, LANCET, V1, P55; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; KAPIKIAN AZ, 1994, VIRAL INFECT GASTROI, P471; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; Zahorsky J., 1929, ARCH PEDIAT, V46, P391	11	140	144	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1240	1242		10.1016/S0140-6736(94)92146-6	http://dx.doi.org/10.1016/S0140-6736(94)92146-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910270				2022-12-01	WOS:A1994NM14400004
J	CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE				CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE			LONG-TERM NEOPLASIA RISK AFTER AZATHIOPRINE TREATMENT IN INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; HUMAN PAPILLOMAVIRUS; ULCERATIVE-COLITIS; CANCER	The incidence of various cancers, especially non-Hodgkin lymphoma (NHL), is higher among patients who receive azathioprine for immunosuppression after organ transplants than in the general population. We have studied the risk of neoplasia after azathioprine in 755 patients treated for inflammatory bowel disease. The patients received 2 mg/kg daily for a median of 12.5 months (range 2 days to 15 years) between 1962 and 1991; median follow-up was 9 years (range 2 weeks to 29 years). Overall there was no significant excess of cancer: 31 azathioprine-treated patients developed cancer before age 85 compared with 24.3 expected from rates in the general population (observed/expected ratio 1.27, p=0.186). There was a difference in the frequency of colorectal (13) and anal (2) carcinomas (expected 2.27; ratio 6.7, p=0.00001); these tumours are recognised complications of chronic inflammatory bowel disease. There were 2 cases of invasive cervical cancer (expected 0.5), but no case of NHL. Among patients with extensive chronic ulcerative colitis there was no difference in cancer frequency between 86 who had received azathioprine and 180 matched patients who had never received it. Thus, azathioprine treatment does not substantially increase the risk of cancer in inflammatory bowel disease.	ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH,CANC RES CAMPAIGN,EPIDEMIOL GRP,OXFORD,ENGLAND	Imperial College London; Radcliffe Infirmary; University of Oxford								ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; CHURCH JM, 1985, DIS COLON RECTUM, V26, P361; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; Gelb A, 1983, Am J Gastroenterol, V78, P316; GLICK SN, 1984, RADIOLOGY, V153, P337, DOI 10.1148/radiology.153.2.6484163; GREENSTEIN AJ, 1981, CANCER, V48, P2742, DOI 10.1002/1097-0142(19811215)48:12<2742::AID-CNCR2820481231>3.0.CO;2-P; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; GYDE SN, 1980, GUT, V21, P1024, DOI 10.1136/gut.21.12.1024; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KINLEN LJ, 1992, AUTOIMMUNITY, V5, P363; KORELITZ BI, 1983, AM J GASTROENTEROL, V78, P44; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; SOMERVILLE KW, 1984, GUT, V25, P1124, DOI 10.1136/gut.25.10.1124; WEEDON DD, 1973, NEW ENGL J MED, V289, P1099, DOI 10.1056/NEJM197311222892101	18	412	416	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1249	1252		10.1016/S0140-6736(94)92150-4	http://dx.doi.org/10.1016/S0140-6736(94)92150-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910274				2022-12-01	WOS:A1994NM14400008
J	FARROW, S				FARROW, S			ALLELIC VARIATION AND THE VITAMIN-D RECEPTOR	LANCET			English	Editorial Material							MESSENGER-RNA; EXPRESSION				FARROW, S (corresponding author), UCL, SCH MED, DEPT MED, LONDON W1N 8AA, ENGLAND.							BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653	6	30	33	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1242	1242		10.1016/S0140-6736(94)92147-4	http://dx.doi.org/10.1016/S0140-6736(94)92147-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910271				2022-12-01	WOS:A1994NM14400005
J	LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F				LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F			INFLUENCE OF MUTATION IN HUMAN APOLIPOPROTEIN A-1 GENE PROMOTER ON PLASMA LDL CHOLESTEROL RESPONSE TO DIETARY-FAT	LANCET			English	Article							A-I GENE; POLYMORPHISM; REGION; CIII; TRANSCRIPTION; INTERVENTION; ASSOCIATION; CLUSTER; SITES	The plasma lipid response to changes in dietary fat and cholesterol can vary between individuals. At present, responders cannot be identified in advance. An adenine to guanine (A-->G) mutation in the promoter of the apolipoprotein A1 gene (apoA-1) has been suggested as affecting plasma high-density lipoprotein cholesterol. In 50 young men we examined the effect of the same mutation on the responses of both high and low density lipoprotein cholesterol to low-fat diet. The frequency for the A allele was 0.14. Subjects were fed a low-fat diet for 25 days, followed by a diet rich in monounsaturated fatty acid (MUFA, 22% out of 40% fat) for 28 days and lipoproteins were measured at the end of each diet. There were no differences in initial total cholesterol between subjects with the G/G mutation (170 mg/dL: 100 mg/dL= 2.59 mmol/L)) and the G/A mutation (169 mg/dL) genotypes. After consumption of the high monounsaturated fat diet, significant increases were noted in plasma LDL cholesterol (10 mg/dL, p=0.035) in the G/A subjects but not in the G/G subjects (1 mg/dL, p=0.996). These differences showed that a significant diet-gene interaction (p=0.015) existed. No differences were observed on HDL cholesterol between groups. Plasma low-density lipoprotein cholesterol responsiveness to diet may be explained by variation at the apoA-1 gene locus.	TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,BOSTON,MA 02111; HOSP UNIV REINA SOFIA,CORDOBA,SPAIN	Tufts University; United States Department of Agriculture (USDA); Hospital Universitario Reina Sofia - Cordoba			Jimenez, Francisco Perez/AAJ-9559-2021; Marin Hinojosa, Carmen/AFO-1294-2022; Lopez-Miranda, Jose/Y-8306-2019; Ordovas, Jose/B-8727-2013	Marin Hinojosa, Carmen/0000-0003-2884-4806; Lopez-Miranda, Jose/0000-0002-8844-0718; Perez Jimenez, Francisco/0000-0001-9808-1280; Salas-Coronas, Joaquin/0000-0002-4302-7022; Perez-Jimenez, Francisco/0000-0001-7499-7681; Ordovas, Jose/0000-0002-7581-5680				BLANGERO J, 1990, AM J HUM GENET, V47, P414; CLARKSON TB, 1980, CHILDHOOD PREVENTION, P127; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; JEENAH M, 1990, MOL BIOL MED, V7, P233; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KEYS A, 1957, LANCET, V2, P959; MANTTARI M, 1991, METABOLISM, V40, P217, DOI 10.1016/0026-0495(91)90179-Z; MCCALL MR, 1994, ARTERIOSCLER THROMB, V14, P248, DOI 10.1161/01.ATV.14.2.248; PAGANI F, 1990, J LIPID RES, V31, P1371; PAGANI F, 1992, EUR J EPIDEMIOL, V8, P54, DOI 10.1007/BF00145350; PAN XM, 1993, J VASC SURG, V18, P161, DOI 10.1016/0741-5214(93)90595-D; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULHAYASE H, 1992, HUM GENET, V88, P439, DOI 10.1007/BF00215679; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; SIGURDSSON G, 1992, ARTERIOSCLER THROMB, V12, P1017, DOI 10.1161/01.ATV.12.9.1017; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; TIKKANEN MJ, 1990, CLIN GENET, V37, P327, DOI 10.1111/j.1399-0004.1990.tb03514.x; TUTEJA R, 1992, FEBS LETT, V304, P98, DOI 10.1016/0014-5793(92)80597-A; TYBJAERGHANSEN A, 1993, ATHEROSCLEROSIS, V100, P157, DOI 10.1016/0021-9150(93)90202-6; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1990, GENET EPIDEMIOL, V7, P261, DOI 10.1002/gepi.1370070405; 1993, JAMA-J AM MED ASSOC, V269, P3015	25	76	77	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1246	1249		10.1016/S0140-6736(94)92149-0	http://dx.doi.org/10.1016/S0140-6736(94)92149-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910273				2022-12-01	WOS:A1994NM14400007
J	MCSHANE, R; HOPE, T; WILKINSON, J				MCSHANE, R; HOPE, T; WILKINSON, J			TRACKING PATIENTS WHO WANDER - ETHICS AND TECHNOLOGY	LANCET			English	Editorial Material									JOHN RADCLIFFE HOSP,OXFORD PRACTICE SKILLS PROJECT,OXFORD,ENGLAND; RADCLIFFE INFIRM,OXFORD,ENGLAND; OXFORDSHIRE DEPT SOCIAL SERV,ABINGDON,OXON,ENGLAND	University of Oxford; Radcliffe Infirmary								BALLARD CG, 1987, INT J GERIATRIC PSYC, V2, P207; Beauchamp T.L., 1989, PRINCIPLES BIOMEDICA, V3rd; HOPE RA, 1990, INT J GERIATR PSYCH, V5, P239, DOI 10.1002/gps.930050406; LANGLEY GE, 1981, BRIT MED J, V283, P1376, DOI 10.1136/bmj.283.6303.1376; PITT B, 1987, INT J GERIATR PSYCH, V2, P207, DOI 10.1002/gps.930020402; SANFORD J, 1975, BRIT MED J, V3, P473; 1993, PEOPLE NOT PARCELS D	7	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1274	1274		10.1016/S0140-6736(94)92159-8	http://dx.doi.org/10.1016/S0140-6736(94)92159-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM144	7910283				2022-12-01	WOS:A1994NM14400017
J	MICHIE, C; HARVEY, D				MICHIE, C; HARVEY, D			CAN EXPRESSION OF CD45RO, A T-CELL SURFACE-MOLECULE, BE USED TO DETECT CONGENITAL INFECTION	LANCET			English	Note							LYMPHOCYTES; ANTIGEN	Exclusion or confirmation of congenital infection can be difficult in newborn infants. The presence of an infective organism in a fetus leads to activation of fetal T lymphocytes. We have examined expression of isoforms of a T-cell surface molecule, CD45RO, in 119 infants, 8 of whom had an intrauterine infection diagnosed antenatally. CD45RO was expressed on fewer than 10% of T cells in control infants and on more than 17% of T cells from infants with known infection (p<0.006). This method allows screening of infants for infection by a range of organisms as a cause of their infection.			MICHIE, C (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,LONDON W12 0NN,ENGLAND.							AKBAR AN, 1988, J IMMUNOL, V140, P2171; ERBER WN, 1984, LANCET, V1, P1042; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FROEBEL KS, 1991, AIDS, V5, P97, DOI 10.1097/00002030-199101000-00015; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PARKER DJ, 1988, J IMMUNOL METHODS, V110, P37, DOI 10.1016/0022-1759(88)90080-4; RUDD P, 1988, CLIN OBSTET GYNAECOL, V2, P55; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; UEHARA T, 1992, BLOOD, V80, P452	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1259	1260		10.1016/S0140-6736(94)92153-9	http://dx.doi.org/10.1016/S0140-6736(94)92153-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910277				2022-12-01	WOS:A1994NM14400011
J	MOULTON, C; PENNYCOOK, AG				MOULTON, C; PENNYCOOK, AG			RELATION BETWEEN GLASGOW COMA SCORE AND COUGH REFLEX	LANCET			English	Note								How unconscious does a patient need to be, to be intubated without drugs? In 76 comatose patients (Glasgow coma score [GCS] less than or equal to 8) who were treated consecutively in an emergency department, the integrity of the cough reflex was not related to GCS. All comatose patients must be treated as if their airway is compromised but even at the lowest coma scores, there are many patients whose airway reflexes are sufficiently intact to make procedures such as endotracheal intubation difficult and dangerous without drugs. The state of the airway should be assessed independently of conscious level.	MANCHESTER ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, MANCHESTER M13 9WL, LANCS, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON, HANTS, ENGLAND	University of Manchester; University of Southampton								[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; ATKINSON RS, 1987, SYNOPSIS ANAESTHESIA, P165; BRADLEY RD, 1987, OXFORD TXB MED, V2; KULIG K, 1982, LANCET, V1, P565; MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240; MURPHY PJ, 1993, BRIT J ANAESTH, V70, P131, DOI 10.1093/bja/70.2.131; PONTOPPIDAN H, 1960, JAMA-J AM MED ASSOC, V174, P2209, DOI 10.1001/jama.1960.03030180029007; SEKIZAWA K, 1990, LANCET, V335, P1228, DOI 10.1016/0140-6736(90)92758-A; YATES DW, 1985, LECTURE NOTES ACCIDE, P8; 1989, ADV TRAUMA LIFE SUPP, P31	10	63	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1261	1262		10.1016/S0140-6736(94)92155-5	http://dx.doi.org/10.1016/S0140-6736(94)92155-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910279				2022-12-01	WOS:A1994NM14400013
J	NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M				NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M			ACTIVE OR RECENT PARVOVIRUS B19 INFECTION IN CHILDREN WITH KAWASAKI-DISEASE	LANCET			English	Note								Because parvovirus B19 occasionally causes some of the features typical of Kawasaki disease, we investigated B19 involvement in 15 children with Kawasaki disease. Active or recent B19 infection, as shown by B19-DNAaemia, positive B19-specific IgM antibodies, or both, was diagnosed in 10 patients (67%). A high frequency of all major criteria for diagnosis of Kawasaki disease (60%), anaemia (60%), coronary aneurysms (30%), and arthropathy (30%) was found in children with B19-associated Kawasaki disease. Thus B19 may have a pathogenic role in the development of Kawasaki disease, with other predisposing factors.	UNIV ROMA LA SAPIENZA,INST PAEDIAT,ROME,ITALY; CNR,INST EXPTL MED,ROME,ITALY; UNIV BOLOGNA,INST MICROBIOL,BOLOGNA,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Bologna								KATO H, 1992, LANCET, V340, P1127, DOI 10.1016/0140-6736(92)93152-D; KURTZMAN GJ, 1989, J CLIN INVEST, V84, P1114, DOI 10.1172/JCI114274; LEVIN M, 1991, ARCH DIS CHILD, V66, P1369, DOI 10.1136/adc.66.12.1369; MORTIMER PP, 1985, LANCET, V2, P730; MUSIANI M, 1993, J MED VIROL, V40, P157, DOI 10.1002/jmv.1890400214; NIGRO G, 1993, AIDS, V7, P288, DOI 10.1097/00002030-199302000-00026; PLUMMER FA, 1985, NEW ENGL J MED, V313, P74, DOI 10.1056/NEJM198507113130203; ROWLEY AH, 1991, ADV PEDIATR, P51; ZERBINI M, 1993, J VIROL METHODS, V40, P157	9	112	115	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1260	1261		10.1016/S0140-6736(94)92154-7	http://dx.doi.org/10.1016/S0140-6736(94)92154-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910278				2022-12-01	WOS:A1994NM14400012
J	PAPANEK, PJ				PAPANEK, PJ			HOW CLEAN SHOULD THE OCEAN BE FOR SWIMMERS	LANCET			English	Editorial Material							WATER-QUALITY				PAPANEK, PJ (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA, USA.							CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CABELLI VJ, 1983, EPA800180031 HLTH EF; CHEUNG WHS, 1990, EPIDEMIOL INFECT, V105, P139, DOI 10.1017/S0950268800047737; CORBETT SJ, 1993, AM J PUBLIC HEALTH, V83, P1701, DOI 10.2105/AJPH.83.12.1701; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; FLEISHER JM, 1991, RES J WATER POLLUT C, V63, P259; GOLD M, 1990, ASSESSMENT INPUTS FE; HAILE RW, 1992, STUDY DESIGN INVESTI; KEBABJIAN R, 1994, J ENVIRON HEALTH, V56, P15; 1990, OCEAN HLTH STUDY STU	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1238	1239		10.1016/S0140-6736(94)92144-X	http://dx.doi.org/10.1016/S0140-6736(94)92144-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910268				2022-12-01	WOS:A1994NM14400002
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			POSTSYNAPTIC INDUCTION AND PRESYNAPTIC EXPRESSION OF HIPPOCAMPAL LONG-TERM DEPRESSION	SCIENCE			English	Article							RAT VISUAL-CORTEX; CALCIUM CHANNELS; AREA CA1; NITRIC-OXIDE; POTENTIATION; ENHANCEMENT; INVOLVEMENT; RECEPTORS; BLOCKADE; SLICES	Long-term depression (LTD) is an activity-dependent decrease in synaptic efficacy that together with its counterpart, long-term potentiation, is thought to be an important cellular mechanism for learning and memory in the mammalian brain. The induction of LTD in hippocampal CA1 pyramidal neurons in neonatal rats is shown to depend on postsynaptic calcium ion entry through L-type voltage-gated calcium channels paired with the activation of metabotropic glutamate receptors. Although induced postsynaptically, LTD is due to a long-term decrease in transmitter release from presynaptic terminals. This suggests that LTD is likely to require the production of a retrograde messenger.			BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOLSHAKOV VY, UNPUB; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Davies C. H., 1993, Society for Neuroscience Abstracts, V19, P276; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELLIOT LS, 1993, NATURE, V361, P634; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.neuro.12.1.85; IZUMI Y, 1993, NEUROREPORT, V4, P1131; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; STANTON PK, 1991, NEUROSCI LETT, V127, P61, DOI 10.1016/0304-3940(91)90895-Z; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	40	414	424	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1148	1152		10.1126/science.7909958	http://dx.doi.org/10.1126/science.7909958			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7909958				2022-12-01	WOS:A1994NM14600033
J	BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR				BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR			STABILIZATION OF CALCIUM-RELEASE CHANNEL (RYANODINE RECEPTOR) FUNCTION BY FK506-BINDING PROTEIN	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; MOLECULAR-CLONING; SMOOTH-MUSCLE; MALIGNANT HYPERTHERMIA; ENDOPLASMIC-RETICULUM; PROLYL ISOMERASE; PLANAR BILAYERS; FEET STRUCTURES; CYCLOSPORINE-A	FK506-binding protein (FKBP12) was originally identified as the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin. The cellular function of FKBP12, a ubiquitously expressed 12,000-dalton proline isomerase, has been unknown. FKBP12 copurifies with the 565,000-dalton ryanodine receptor (RyR), four of which form intracellular Ca2+ release channels of the sarcoplasmic and endoplasmic reticula. By coexpressing the RyR and FKBP12 in insect cells, we have demonstrated that FKBP12 modulates channel gating by increasing channels with full conductance levels (by >400%), decreasing open probability after caffeine activation (from 0.63 +/- 0.09 to 0.04 +/- 0.02), and increasing mean open time (from 4.4 +/- 0.6 ms to 75 +/- 41 ms). FK506 or rapamycin, inhibitors of FKBP12 isomerase activity, reverse these stabilizing effects. These results provide the first natural cellular function for FKBP12, and establish that the functional Ca2+ release channel complex includes FKBP12.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06030	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Connecticut; University of Connecticut	BRILLANTES, AMB (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,PROGRAM MOLEC MED,NEW YORK,NY 10029, USA.		/AAX-8408-2021	/0000-0001-9657-9704; Ondrias, Karol/0000-0001-8329-3563; Ondriasova, Elena/0000-0002-2990-990X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHU A, 1990, MOL PHARMACOL, V37, P735; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1983, J MUSCLE RES CELL M, V4, P233, DOI 10.1007/BF00712033; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLO B, 1993, BLOOD, V81, P783; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE YS, 1991, J MEMBRANE BIOL, V122, P155, DOI 10.1007/BF01872638; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RANATUNGA KW, 1982, J PHYSIOL-LONDON, V329, P465, DOI 10.1113/jphysiol.1982.sp014314; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1989, AM J PHYSIOL, V256, P328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH KA, 1988, INTERLEUKIN, V2, P1; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIEBOSCH A, 1990, TRANSPLANT P, V22, P1652; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WHITING PH, 1991, TRANSPLANTATION, V52, P203, DOI 10.1097/00007890-199108000-00004; WILLIAMS AJ, 1992, J MUSCLE RES CELL M, V13, P7, DOI 10.1007/BF01738423; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	75	692	707	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					513	523		10.1016/0092-8674(94)90214-3	http://dx.doi.org/10.1016/0092-8674(94)90214-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514503				2022-12-01	WOS:A1994NM83200007
J	CONNELL, GJ; YARUS, M				CONNELL, GJ; YARUS, M			RNAS WITH DUAL-SPECIFICITY AND DUAL RNAS WITH SIMILAR SPECIFICITY	SCIENCE			English	Article							RIBOSOMAL-RNA; TETRAHYMENA; POLYMERASE; SUBSTRATE; STABILITY; ACID; DNA	The biological role of RNA is delimited by its possible reactions, which can be explored by selection. A comparison of selected RNAs that bind one ligand with those that bind two related ligands suggests that a single nucleotide substitution can expand binding specificity. An RNA site with dual (joint) specificity has adenine and cytosine bases whose pK(a)'s appear shifted upward, thereby mimicking an efficient general acid-base catalyst. The joint site also contains two conserved, looped arginine-coding triplets implicated in arginine site formation. Two selected joint RNAs are identical in some regions and distinct in others. The distinct regions, like some peptides, seem to function similarly without being similar in primary structure.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Yarus, Michael/Q-9813-2019					ALTMAN S, 1986, BIOCHEMISTRY-US, V25, P1205, DOI 10.1021/bi00354a002; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, UNPUB; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HARTLEY BS, 1974, S SOC GEN MICROBIOL, V24, P151; HENDLER S, 1970, BIOCHEMISTRY-US, V9, P4141, DOI 10.1021/bi00823a017; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; LEGAULT P, UNPUB; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PFEUFFER T, 1975, J BIOL CHEM, V250, P867; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	104	116	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	1994	264	5162					1137	1141		10.1126/science.7513905	http://dx.doi.org/10.1126/science.7513905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7513905				2022-12-01	WOS:A1994NM14600030
J	ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R				ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R			LACK OF NEUROTROPHIN-3 LEADS TO DEFICIENCIES IN THE PERIPHERAL NERVOUS-SYSTEM AND LOSS OF LIMB PROPRIOCEPTIVE AFFERENTS	CELL			English	Article							DORSAL-ROOT GANGLIA; EXPRESSING MESSENGER-RNA; GROWTH-FACTOR FAMILY; SENSORY NEURONS; MOLECULAR-CLONING; BRAIN; RAT; SURVIVAL; BDNF; RECEPTORS	Neurotrophin-3-deficient (NT-3-deficient) mice were generated by gene targeting. Mutant mice displayed severe movement defects of the limbs, and most died shortly after birth. Substantial portions of peripheral sensory and sympathetic neurons were lost while motor neurons were not affected. Significantly, spinal proprioceptive afferents and their peripheral sense organs (muscle spindles and Golgi tendon organs) were completely absent in homozygous mutant mice. This correlated with a loss of parvalbumin and carbonic anhydrase-positive neurons in the dorsal root ganglion. No gross abnormalities were seen in Pacinian corpuscles, cutaneous afferents containing substance P and calcitonin gene-related peptide, and deep nerve fibers in the joint capsule and tendon. Importantly, the number of muscle spindles in heterozygous mutant mice was half of that in control mice, indicating that NT-3 is present at limiting concentrations in the embryo.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118	Massachusetts Institute of Technology (MIT); Boston University	ERNFORS, P (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025796] Funding Source: NIH RePORTER; NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NINDS NIH HHS [5-R01-NS25796] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ARUMAE U, 1993, J CELL BIOL, V122, P1053, DOI 10.1083/jcb.122.5.1053; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CARR PA, 1989, BRAIN RES, V497, P163, DOI 10.1016/0006-8993(89)90983-9; CARR PA, 1993, BRAIN RES BULL, V30, P209, DOI 10.1016/0361-9230(93)90246-8; CARR PA, 1989, NEUROSCIENCE, V33, P363, DOI 10.1016/0306-4522(89)90216-9; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; ERNFORS P, 1994, IN PRESS PROG BRAIN; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; HALLBOOK F, 1991, NEURON, V6, P1; HENDERSON CE, 1993, NATURE, V363, P213; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HORYLEE F, 1993, P NATL ACAD SCI USA, V90, P2613, DOI 10.1073/pnas.90.7.2613; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KRINKE G, 1978, ACTA NEUROPATHOL, V43, P213; KRINKE G, 1980, NEUROTOXICOLOGY, V2, P13; KUCERA J, 1990, DEVELOPMENT, V110, P483; KUCERA J, 1992, ANAT EMBRYOL, V186, P301; LEE KF, 1994, IN PRESS DEVELOPMENT; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAYEUX V, 1991, DEV BRAIN RES, V71, P201; MU XJ, 1993, J NEUROSCI, V13, P4029; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; Ranson SW, 1931, J COMP NEUROL, V52, P341, DOI 10.1002/cne.900520206; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; STERMAN AB, 1980, ANN NEUROL, V7, P354, DOI 10.1002/ana.410070413; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WIESENDANGER M, 1964, ACTA PHYSIOL SCAND, V62, P160, DOI 10.1111/j.1748-1716.1964.tb03964.x; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; ZELENA J, 1957, J EMBRYOL EXP MORPH, V5, P283	59	608	619	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					503	512		10.1016/0092-8674(94)90213-5	http://dx.doi.org/10.1016/0092-8674(94)90213-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514502				2022-12-01	WOS:A1994NM83200006
J	LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R				LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R			ODD OZ - A NOVEL DROSOPHILA PAIR RULE GENE	CELL			English	Article							ELEMENT INSERTIONAL MUTAGENESIS; MEDIATED ENHANCER DETECTION; HOMOEOTIC MUTATIONS; EXPRESSION; PROTEIN; TENASCIN; PATTERN; SEGMENTATION; MELANOGASTER; POLARITY	We have identified a novel pair rule gene in Drosophila, odd Oz (odz). Every odd-numbered body segment is deleted in odz mutant embryos. The odz gene product is strongly expressed in the embryonic central nervous system and heart, and both of these tissues are malformed in mutant embryos. odz represents the only known pair rule gene that does not encode a transcription factor. Instead, it encodes a protein with EGF-like repeats homologous to those of the extracellular matrix protein tenascin. The protein is also a putative transmembrane tyrosine kinase substrate. On the basis of its structure, odz must act in a cellularized embryo. This is consistent with odz expression, whose temporal appearance is indicative of a very late-acting pair rule gene.			LEVINE, A (corresponding author), BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1990, MECH DEVELOP, V33, P1, DOI 10.1016/0925-4773(90)90130-E; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HAYNIE JL, 1983, DEV BIOL, V100, P399, DOI 10.1016/0012-1606(83)90234-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KENNISON JA, 1987, GENETICS, V116, P75; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1983, GENETICS, V105, P357; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; Wieschaus E., 1986, P199; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; ZAK NB, 1990, DEVELOPMENT, V109, P865; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	128	131	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					587	598		10.1016/0092-8674(94)90220-8	http://dx.doi.org/10.1016/0092-8674(94)90220-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514504				2022-12-01	WOS:A1994NM83200013
J	SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P				SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P			DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; PERFORMANCE LIQUID-CHROMATOGRAPHY; BACTERIAL TRANSPORT PROTEINS; MONOCLONAL-ANTIBODIES; CHINESE-HAMSTER; CELLS; EXPRESSION; VINBLASTINE; VINCRISTINE; FAMILY	We have generated mice homozygous for a disruption of the mdr1a (also called mdr3) gene, encoding a drug-transporting P-glycoprotein. The mice were viable and fertile and appeared phenotypically normal, but they displayed an increased sensitivity to the centrally neurotoxic pesticide ivermectin (100-fold) and to the carcinostatic drug vinblastine (3-fold). By comparison of mdr1a (+/+) and (-/-) mice, we found that the mdr1a P-glycoprotein is the major P-glycoprotein in the blood-brain barrier and that its absence results in elevated drug levels in many tissues (especially in brain) and in decreased drug elimination. Our findings explain some of the side effects in patients treated with a combination of carcinostatics and P-glycoprotein inhibitors and indicate that these inhibitors might be useful in selectively enhancing the access of a range of drugs to the brain.	NETHERLANDS CANC INST,DEPT CLIN CHEM,1066 CX AMSTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT PHARM,1066 EC AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Slotervaart Hospital	SCHINKEL, AH (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Van Tellingen, Olaf/A-1344-2014	Van Tellingen, Olaf/0000-0002-1037-6269				AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BRADBURY MWB, 1985, CIRC RES, V57, P213, DOI 10.1161/01.RES.57.2.213; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FISHER MH, 1992, ANNU REV PHARMACOL, V32, P537, DOI 10.1146/annurev.pa.32.040192.002541; FORD JM, 1990, PHARMACOL REV, V42, P155; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOLDSTEIN GW, 1986, SCI AM, V255, P70; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREIG NH, 1990, CANCER CHEMOTH PHARM, V26, P263, DOI 10.1007/BF02897227; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HORTON JK, 1989, BIOCHEM PHARMACOL, V38, P1727, DOI 10.1016/0006-2952(89)90405-X; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; LADURON PM, 1979, BIOCHEM PHARMACOL, V28, P2161, DOI 10.1016/0006-2952(79)90198-9; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; PULLIAM JD, 1985, VET MED-US, V80, P33; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAEKI T, 1993, J BIOL CHEM, V268, P6077; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUGAWARA I, 1988, CANCER RES, V48, P1926; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1992, J BIOL CHEM, V267, P24248; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; VANTELLINGEN O, 1993, CANCER CHEMOTH PHARM, V32, P286, DOI 10.1007/BF00686174; VANTELLINGEN O, 1993, CANCER RES, V53, P2061	58	1916	1979	1	131	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					491	502		10.1016/0092-8674(94)90212-7	http://dx.doi.org/10.1016/0092-8674(94)90212-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7910522				2022-12-01	WOS:A1994NM83200005
J	LIEBERMAN, DN; MODY, I				LIEBERMAN, DN; MODY, I			REGULATION OF NMDA CHANNEL FUNCTION BY ENDOGENOUS CA2+-DEPENDENT PHOSPHATASE	NATURE			English	Article							D-ASPARTATE RECEPTORS; OKADAIC ACID; PROTEIN PHOSPHATASE; CENTRAL NEURONS; RAT-BRAIN; CALCINEURIN; ACTIVATION; GLUTAMATE; DEPHOSPHORYLATION; HIPPOCAMPUS	PROTEIN kinases modulate the activity of several ligand-gated ion channels(1), including the NMDA (N-methyl-D-aspartate)(2) subtype of glutamate receptor. Although phosphorylation and dephosphorylation of glutamate receptors may participate in several lasting physiological and pathological alterations of neuronal excitability(3-7), the physiological control of this cycle for NMDA channels has not yet been established. Using cell-attached recordings in acutely dissociated adult rat dentate gyrus granule cells, we now demonstrate that inhibitors of an endogenous serine/threonine phosphatase prolong the duration of single NMDA channel openings, bursts, clusters and superclusters. Okadaic acid, a non-selective phosphatase inhibitor, prolongs channel openings only at a concentration that inhibits the Ca2+/calmodulin-dependent phosphatase 2B (calcineurin)(8), and is ineffective when Ca2+ entry through NMDA channels is prevented. Furthermore, FK506, an inhibitor of calcineurin(9,10), mimics the effects of okadaic acid. Thus in adult neurons, calcineurin, activated by calcium entry through native NMDA channels, shortens the duration of channel openings. Simulated synaptic currents(11) were enhanced after phosphatase inhibition, which is consistent with the importance of phosphorylation of the NMDA-receptor complex in the short- and longterm control of neuronal excitability.	UNIV TEXAS,SW MED CTR,DEPT ANESTESIOL & PAIN MANAGEMENT,DALLAS,TX 75235; STANFORD UNIV,SCH MED,GRAD PROGRAM NEUROSCI,STANFORD,CA 94305	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University								ABDULGHANI M, 1991, P NATL ACAD SCI USA, V88, P1803, DOI 10.1073/pnas.88.5.1803; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774, DOI 10.1152/jn.1993.69.5.1774; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOHR G, 1993, J NEUROSCI, V13, P3612; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; POLLI JW, 1991, DEV BRAIN RES, V63, P105, DOI 10.1016/0165-3806(91)90071-P; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	425	435	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					235	239		10.1038/369235a0	http://dx.doi.org/10.1038/369235a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514273				2022-12-01	WOS:A1994NM06700057
J	SALI, A; SHAKHNOVICH, E; KARPLUS, M				SALI, A; SHAKHNOVICH, E; KARPLUS, M			HOW DOES A PROTEIN FOLD	NATURE			English	Article							GLOBULAR-PROTEINS; DYNAMICS	THE number of all possible conformations of a polypeptide chain is too large to be sampled exhaustively. Nevertheless, protein sequences do fold into unique native states in seconds (the Levinthal paradox). To determine how the Levinthal parades is resolved, we use a lattice Monte Carlo model in which the global minimum (native state) is known. The necessary and sufficient condition for folding in this model is that the native state be a pronounced global minimum on the potential surface. This guarantees thermodynamic stability of the native state at a temperature where the chain does not get trapped in local minima. Folding starts by a rapid collapse from a random-coil state to a random semi-compact globule. It then proceeds by a slow, rate-determining search through the semicompact states to find a transition state from which the chain folds rapidly to the native state. The elements of the folding mechanism that lead to the resolution of the Levinthal parades are the reduced number of conformations that need to be searched in the semicompact globule (similar to 10(10) versus similar to 10(16) for the random coil) and the existence of many (similar to 10(3)) transition states. The results have evolutionary implications and suggest principles for the folding of real proteins.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CREIGHTON TE, 1992, PROTEIN FOLDING; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DILORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025; GO N, 1984, ADV BIOPHYS, V18, P149, DOI 10.1016/0065-227X(84)90010-8; GO N, 1981, BIOPOLYMERS, V20, P1013; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HONEYCUTT JD, 1992, BIOPOLYMERS, V32, P695, DOI 10.1002/bip.360320610; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; Levinthal C., 1969, MOSSB SPECTR BIOL SY, V67, P22; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; METROPOLIS N, 1953, J CHEM PHYS, V21, P1098; MIYAZAWA S, 1985, MACROMOLECULES, V18, P534, DOI 10.1021/ma00145a039; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; STETTER KO, 1992, FRONTIERS OF LIFE, P195; SYKES MF, 1963, J CHEM PHYS, V39, P410, DOI 10.1063/1.1734262; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697	22	849	860	3	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					248	251		10.1038/369248a0	http://dx.doi.org/10.1038/369248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7710478				2022-12-01	WOS:A1994NM06700061
J	WAGA, S; STILLMAN, B				WAGA, S; STILLMAN, B			ANATOMY OF A DNA-REPLICATION FORK REVEALED BY RECONSTITUTION OF SV40 DNA-REPLICATION IN-VITRO	NATURE			English	Article							SIMIAN VIRUS-40 DNA; POLYMERASE-ALPHA-PRIMASE; LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; FACTOR-C; INVITRO REPLICATION; ACCESSORY PROTEINS; INITIATION	Complete enzymatic replication of DNA from the simian virus 40 origin has been reconstituted with T antigen and highly purified cellular proteins. DNA polymerase-alpha/primase functions primarily to synthesize RNA-DNA primers for initiation of DNA replication at the origin and for priming each Okazaki fragment. A polymerase switching mechanism requiring replication factor C and the proliferating cell nuclear antigen allows two molecules of DNA polymerase-delta to replicate both strands of the double helix conjointly.			WAGA, S (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Stillman, Bruce/0000-0002-9453-4091; Waga, Shou/0000-0003-4986-8735				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1988, CANCER CELL, V6, P1; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DENIS D, 1993, MOL CELL BIOL, V13, P2882, DOI 10.1128/MCB.13.5.2882; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ELIASSON R, 1978, J BIOL CHEM, V253, P7469; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WAGA S, IN PRESS J BIOL CHEM; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	50	510	516	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					207	212		10.1038/369207a0	http://dx.doi.org/10.1038/369207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7910375				2022-12-01	WOS:A1994NM06700048
J	WANG, YT; SALTER, MW				WANG, YT; SALTER, MW			REGULATION OF NMDA RECEPTORS BY TYROSINE KINASES AND PHOSPHATASES	NATURE			English	Article							LONG-TERM POTENTIATION; EXCITATORY AMINO-ACIDS; PHOSPHORYLATION; ACTIVATION; INHIBITOR; NEURONS; CELLS	PROTEIN-TYROSINE kinases (PTKs) and protein-tyrosine phosphatases (PTPs) are key enzymes in signal-transduction pathways for a wide range of cellular processes(1,2). PTKs and PTPs are highly expressed in the central nervous system(3), which is consistent with the importance of tyrosine phosphorylation in neuronal function(4-6). Protein phosphorylation is known to be involved in the regulation of neurotransmitter receptors(7,8), but the effects of tyrosine phosphorylation on neurotransmitter receptor function in the central nervous system are unknown. Here we present evidence that in mammalian central neurons tyrosine phosphorylation regulates the function of the NMDA (N-methyl-D-aspartate) receptor, a subtype of excitatory amino-acid receptor(9,10). NMDA-receptor-mediated whole-cell currents and intracellular Ca2+ responses are depressed by inhibition of PTKs. Conversely, NMDA currents are potentiated by intracellular application of the well characterized PTK pp60(c-src). NMDA currents are also potentiated by intracellular administration of an inhibitor of PTPs. Protein-tyrosine phosphorylation is a new mechanism for regulating NMDA receptors and may be important in neuronal development, plasticity and toxicity.	HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; WAGER KR, 1991, CURR OPIN NEUROBIOL, V1, P65; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	24	624	648	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					233	235		10.1038/369233a0	http://dx.doi.org/10.1038/369233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514272				2022-12-01	WOS:A1994NM06700056
J	BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS				BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS			NOVEL PATTERN OF P53 GENE-MUTATIONS IN AN AMERICAN BLACK COHORT WITH HIGH MORTALITY FROM BREAST-CANCER	LANCET			English	Note								The pattern of acquired mutations in the p53 gene can be used to study differences in factors contributing to carcinogenesis. We investigated mutations in exons 5-9 and adjacent intronic regions in 47 breast cancers of black women from Michigan, a population with the highest breast-cancer mortality in the US. The 16 mutations detected differed from those of other populations. In particular, the black women had an excess of A:T-->G:C transitions compared with rural white US midwest women. While the causes of the different pattern of acquired mutation remain to be determined, this molecular epidemiological approach detects the consequences of mutagenic processes in specific populations. Mutation patterns will constrain hypotheses to mechanisms consistent with the observed biochemical alterations.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; SOUTHFIELD ONCOL INST,SOUTHFIELD,MI	Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 5 R01 CA56881-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; COLES C, 1992, CANCER RES, V52, P5291; GOSTOUT B, 1993, HUM MOL GENET, V2, P293, DOI 10.1093/hmg/2.3.293; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JONES PA, 1991, CANCER RES, V51, P3617; RIES LAG, 1991, DHEW NIH912789 PUBL; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	10	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1195	1197		10.1016/S0140-6736(94)92403-1	http://dx.doi.org/10.1016/S0140-6736(94)92403-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909871				2022-12-01	WOS:A1994NL17500012
J	LILLEYMAN, JS; LENNARD, L				LILLEYMAN, JS; LENNARD, L			MERCAPTOPURINE METABOLISM AND RISK OF RELAPSE IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; MAINTENANCE CHEMOTHERAPY; 6-MERCAPTOPURINE; CHILDREN	Many months' treatment with daily oral mercaptopurine is an important part of therapy for nearly all children with lymphoblastic leukaemia (ALL). Even when prescribed the same dose based on body surface area, patients have widely different intracellular concentrations of drug metabolites. Whether this variation matters in terms of disease control is not yet clear. To find out, we followed up a large group of children with ALL in whom mercaptopurine-derived thioguanine nucleotides in the red cells were measured during treatment with an identical dose of mercaptopurine early in first remission. 172 unselected children (100 boys, 72 girls) were recruited between 1980 and 1992. At median follow-up of 5 years from diagnosis 42 (24%) had relapsed; 30 had erythrocyte thioguanine nucleotide concentrations below the group median (284 pmol per 8 x 10(8) erythrocytes) and 12 had values above the median. The actuarial relapse-free survival at 5 years was 63% in the below-median group and 84% in the above-median group (difference 21% [95% Cl 3-39%], p = 0.0018). Multivariate analysis showed that erythrocyte thioguanine nucleotide concentration was independent of other prognostic variables including age, leukaemia immunophenotype, white-blood-cell count at diagnosis, trial protocol, and sex. Whatever the cause, in childhood ALL variable formation of intracellular mercaptopurine metabolites seems to be clinically important. Therapeutic schedules that include long-term daily oral mercaptopurine might be more effective if such metabolites are monitored.	UNIV SHEFFIELD,CHILDRENS HOSP,DEPT PAEDIAT,PAEDIAT HAEMATOL SECT,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,PHARMACOL & THERAPEUT SECT,SHEFFIELD,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield; University of Sheffield			Lennard, Lynne/E-1131-2011					ADAMSON PC, 1990, NEW ENGL J MED, V323, P1565; BOSTROM B, 1993, AM J PEDIAT HEMATOL, V15, P80; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DAVIES HA, 1993, BRIT MED J, V306, P1239, DOI 10.1136/bmj.306.6887.1239; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; GUERCIOLINI R, 1991, CLIN PHARMACOL THER, V50, P663, DOI 10.1038/clpt.1991.205; HALE JP, 1991, ARCH DIS CHILD, V66, P462, DOI 10.1136/adc.66.4.462; HAYDER S, 1989, THER DRUG MONIT, V11, P617, DOI 10.1097/00007691-198911000-00001; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LENNARD L, 1992, J CHROMATOGR-BIOMED, V583, P83, DOI 10.1016/0378-4347(92)80347-S; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1993, BRIT J CLIN PHARMACO, V36, P277, DOI 10.1111/j.1365-2125.1993.tb00365.x; LENNARD L, 1987, LANCET, V2, P785; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; PINKEL D, 1993, J CLIN ONCOL, V11, P1826, DOI 10.1200/JCO.1993.11.9.1826; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; ZIMM S, 1983, NEW ENGL J MED, V308, P1005, DOI 10.1056/NEJM198304283081705; [No title captured]	21	190	195	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1188	1190		10.1016/S0140-6736(94)92400-7	http://dx.doi.org/10.1016/S0140-6736(94)92400-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909868				2022-12-01	WOS:A1994NL17500009
J	NORTHRIDGE, DB; HALL, RJC				NORTHRIDGE, DB; HALL, RJC			POST-MYOCARDIAL-INFARCTION EXERCISE TESTING IN THE THROMBOLYTIC ERA	LANCET			English	Editorial Material							PROGNOSTIC VALUE; SOON; RISK				NORTHRIDGE, DB (corresponding author), UNIV WALES HOSP,DEPT CARDIOL,CARDIFF,WALES.							ARNOLD AER, 1993, EUR HEART J, V14, P306, DOI 10.1093/eurheartj/14.3.306; DEBELDER MA, 1988, BRIT HEART J, V60, P377; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; PATERSON RE, 1983, AM J CARDIOL, V51, P361; PEART I, 1989, BRIT HEART J, V61, P231; PICCALO G, 1992, AM J CARDIOL, V70, P31, DOI 10.1016/0002-9149(92)91385-H; STEVENSON R, 1993, BRIT HEART J, V70, P415; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1175	1176		10.1016/S0140-6736(94)92396-5	http://dx.doi.org/10.1016/S0140-6736(94)92396-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909864				2022-12-01	WOS:A1994NL17500005
J	PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M				PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M			RAPID MOLECULAR METHOD FOR PRENATAL DETECTION OF DOWNS-SYNDROME	LANCET			English	Note							PCR	We have evaluated a rapid method that allows prenatal detection of Down's syndrome in less than 24 hours. DNA from uncultured amniotic fluid, fetal blood, and tissue samples was amplified with the small tandem repeat (STR) marker D21S11. Quantitative analysis of fluorescent STR products with evaluation of their sizes provided clear evidence for trisomy 21. Whilst most normal samples showed two amplification peaks of equal size, Down's syndrome samples were characterised by either th ree STR peaks or two peaks with a ratio of 2:1. Co-amplification with a non-polymorphic sequence allowed analysis of Samples that were homozygous for the 21-derived STRs.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; GRAZ UNIV,DEPT OBSTET & GYNECOL,GRAZ,AUSTRIA	University of London; King's College London; University of Graz			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Sherlock, Jon/0000-0001-5475-2361				Ferre F, 1992, PCR Methods Appl, V2, P1; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; LUBIN MB, 1991, MOL CELL PROBE, V5, P307, DOI 10.1016/0890-8508(91)90054-N; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; SHARMA V, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67-a	6	115	152	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1197	1198		10.1016/S0140-6736(94)92404-X	http://dx.doi.org/10.1016/S0140-6736(94)92404-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909872				2022-12-01	WOS:A1994NL17500013
J	PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR				PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR			ASSOCIATION OF INTRATUMORAL PHARMACOKINETICS OF FLUOROURACIL WITH CLINICAL-RESPONSE	LANCET			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; 5-FLUOROURACIL; INVIVO; METABOLISM; TOXICITY	In-vivo fluorine-19 nuclear magnetic resonance spectroscopy (NMRS) allows non-invasive, real-time, chemical identification of specific fluorinated compounds inside human tumours after administration of fluorouracil (5-fluorouracil). Kinetic measures of the administered drug and metabolites allow estimation of the tumoral half-life of fluorouracil. We studied 57 patients by F-19 NMRS immediately after they had received 600 mg/m(2) fluorouracil intravenously. Serial spectra were acquired with the surface coil positioned on the shin above the tumour. We defined an intratumoral half-life of fluorouracil of 20 min or more as indicating trapping of the drug, based on the blood half-life of 8-12 min. 19 patients had intratumoral half-lives indicating trapping of fluorouracil, 27 had half-lives less than 20 min, and 11 had no detectable fluorouracil in their rumours. 8 of 9 evaluable patients whose tumours showed trapping had partial responses to chemotherapy that included fluorouracil compared with only 2 of 25 patients whose tumours did not trap the drug (p = 0.000021). F-19 NMRS can identify patients likely to respond to chemotherapy with fluorouracil and could be used clinically to tailor optimum treatment.	ST VINCENTS MED CTR,MRI SECT,LOS ANGELES,CA; UNIV SO CALIF,RADIOPHARM PROGRAM,LOS ANGELES,CA; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA; UNIV SO CALIF,DEPT RADIOL,LOS ANGELES,CA; CENT LOS ANGELES COMMUNITY CLIN ONCOL PROGRAM,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California	PRESANT, CA (corresponding author), ST VINCENTS MED CTR,LOS ANGELES ONCOL INST,CTR NONINVAS PHARMACOL,BOX 57992,2131 W 3RD ST,LOS ANGELES,CA 90057, USA.		Wiseman MD, Charles/AHC-6808-2022; Blayney, Douglas/AAK-2920-2020	Blayney, Douglas/0000-0002-7931-4533	NATIONAL CANCER INSTITUTE [R01CA056138, U10CA035200, R55CA048255] Funding Source: NIH RePORTER; NCI NIH HHS [1-R55-CA-48255, CA-35200, CA-56138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLGER M, 1987, OPERATIONAL INSTRUCT; COHEN JL, 1974, CANCER CHEMOTH REP 1, V58, P723; COUSTERE C, 1991, CANCER CHEMOTH PHARM, V28, P123, DOI 10.1007/BF00689701; ELTAHTAWY A, 1991, CANCER RES, V51, P5806; FINDLAY MPN, 1993, ANN ONCOL, V4, P597, DOI 10.1093/oxfordjournals.annonc.a058595; GUERQUIN-KERN JL, 1991, CANCER RES, V51, P5770; MCSHEEHY PMJ, 1989, BRIT J CANCER, V60, P303, DOI 10.1038/bjc.1989.275; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PRESANT CA, 1990, J CLIN ONCOL, V8, P1868, DOI 10.1200/JCO.1990.8.11.1868; PRESANT CA, 1993, P AM CLIN ONCOL, V11, P501; SCHLEMMER HP, 1991, RADIOLOGY, V181, P210; VALLABHAJOSULA SR, 1982, EUR J NUCL MED, V7, P462; WALUCH V, 1992, P ANN M SOC MAGNETIC, V11, P3616; WOHLHUETER RM, 1980, J CELL PHYSIOL, V104, P309, DOI 10.1002/jcp.1041040305; WOLF W, 1987, MAGN RESON IMAGING, V5, P165, DOI 10.1016/0730-725X(87)90016-6; WOLF W, 1990, P NATL ACAD SCI USA, V87, P492, DOI 10.1073/pnas.87.1.492; WOLF W, 1993, P AACR, V34, P2365	17	162	164	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1184	1187		10.1016/S0140-6736(94)92399-X	http://dx.doi.org/10.1016/S0140-6736(94)92399-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909867				2022-12-01	WOS:A1994NL17500008
J	QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST				QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST			EFFECT OF HELICOBACTER-PYLORI ERADICATION ON G-CELL AND D-CELL DENSITY IN CHILDREN	LANCET			English	Article							CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; UREASE ACTIVITY; GASTRIN; SOMATOSTATIN; HYPERGASTRINEMIA; AMOXYCILLIN; ACID	Helicobacter pylori infection is associated with abnormalities in serum gastrin concentration, antral gastrin and somatostatin content, and D-cell density in adults. We have studied the effects of H pylori infection in children. We studied 13 children positive for H pylori and 7 negative children. The median antral somatostatin content was significantly lower in the positive than in the negative group (0.69 [range 0.35-0.91] vs 1.31 [0.73-1.67] ng/mg, p = 0.007). Both antral and serum gastrin concentrations were significantly higher in the positive group (30.1 [15.3-83.6] vs 14.8 [13.8-28.8] ng/mg, p = 0.008; and 89.9 [59.4-313.2] vs 29.5 [13.9-71.1] pg/mL, p = 0.006). Treatment to eradicate H pylori was successful in 11 of the 13 positive patients. With eradication antral somatostatin increased to within the normal range (by a median of 0.41 [0.21-0.86] ng/mg to 1.10 [0.81-1.55] ng/mg, p = 0.016). Serum and antral gastrin decreased (by 37.1 [5.5-265.2] pg/mL to 52.8 [21.4-267.5] ng/mg, p = 0.001; and by 8.0 [2.0-47.2] ng/mg to 22.1 [10.9-37.5] ng/mg, p = 0.001). Eradication of H pylori also significantly increased antral D-cell density (8 [5-22] to 15 [9-22] cells per mm, p = 0.031) and decreased G-cell density (138 [89-161] to 88 [33-121] cells per mm, p = 0.016). The hypergastrinaemia in children positive for H pylori may be due to a deficiency of antral somatostatin, which inhibits gastrin synthesis and release.	UNIV FED MINAS GERAIS, FAC MED, DEPT PATHOL, BELO HORIZONTE, MG, BRAZIL; UNIV FED MINAS GERAIS, FAC MED, DEPT PEDIAT, BELO HORIZONTE, MG, BRAZIL	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	QUEIROZ, DMM (corresponding author), UNIV FED MINAS GERAIS, FAC MED, RES BACTERIOL LAB, AVE ALFREDO BALENA 190-464, BR-30130100 BELO HORIZONTE, MG, BRAZIL.		Moura, Sílvia B/K-7344-2012; Queiroz, Dulciene/AAU-9386-2020; Rocha, Gifone A/N-6913-2018	Queiroz, Dulciene/0000-0003-1334-9423; Rocha, Gifone A/0000-0002-1858-3166				ARNOLD R, 1980, CLIN GASTROENTEROL, V9, P733; BRYANT MG, 1982, RADIOIMMUNOASSAY GUT, P336; CARVALHO AST, 1991, BRAZ J MED BIOL RES, V24, P163; CHITTAJALLU RS, 1991, GUT, V32, P1286, DOI 10.1136/gut.32.11.1286; ELNUJUMI AM, 1991, GUT, V32, P866, DOI 10.1136/gut.32.8.866; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; GRAHAM DY, 1993, GASTROENTEROLOGY, V104, P1655, DOI 10.1016/0016-5085(93)90642-P; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P394; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; LEVI S, 1989, LANCET, V1, P1167; MAHONY MJ, 1990, ARCH DIS CHILD, V65, P1212; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; NAKANISHI T, 1993, AM J GASTROENTEROL, V88, P440; ODERDA G, 1989, ARCH DIS CHILD, V64, P326, DOI 10.1136/adc.64.3.326; ODERDA G, 1989, LANCET, V1, P690; QUEIROZ DMM, 1993, SCAND J GASTROENTERO, V28, P858, DOI 10.3109/00365529309103125; QUEIROZ DMM, 1987, J CLIN MICROBIOL, V25, P2378, DOI 10.1128/JCM.25.12.2378-2379.1987; SCHUSDZIARRA V, 1983, SCAND J GASTROENTERO, V18, P69; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; STERNBERG LA, 1986, IMMUNOCYTOCHEMISTRY; WILLIAMS G, 1988, HORM METAB RES, V20, P668, DOI 10.1055/s-2007-1010913; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; YEUNG CK, 1990, J PEDIATR GASTR NUTR, V10, P357, DOI 10.1097/00005176-199004000-00016	25	49	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	1994	343	8907					1191	1193		10.1016/S0140-6736(94)92401-5	http://dx.doi.org/10.1016/S0140-6736(94)92401-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909869				2022-12-01	WOS:A1994NL17500010
J	TAS, S; ABDELLA, NA				TAS, S; ABDELLA, NA			BLOOD-PRESSURE, CORONARY-ARTERY DISEASE, AND GLYCEMIC CONTROL IN TYPE-2 DIABETES-MELLITUS - RELATION TO APOLIPOPROTEIN-CIII GENE POLYMORPHISM	LANCET			English	Note							APO-CIII; HYPERTRIGLYCERIDEMIA; MECHANISM	The apolipoprotein CIII allele S2 is associated with hypertriglyceridaemia and myocardial infarction. 15 subjects with type 2 diabetes mellitus and the S2 allele had significantly greater systolic blood pressure than 48 without this allele (mean 142 [SD 10]) vs 129 [14] mm Hg), despite being on antihypertensives more frequently. S2 patients showed better glycaemic control (glycated haemoglobin [HbA(1C)] 8.4 [2.0] vs 9.9 [2.0]%). Stepwise multiple regression indicated S2 as an independent predictor of both blood pressure and HbA(1C). These findings suggest mechanisms for relations between glucose and triglyceride metabolism and blood pressure.	KUWAIT UNIV,FAC MED,DEPT PATHOL,KUWAIT,KUWAIT; KUWAIT UNIV,FAC MED,DEPT MED,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT CLIN LABS,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT MED,KUWAIT,KUWAIT	Kuwait University; Kuwait University; Mubarak Al-Kabeer Hospital; Mubarak Al-Kabeer Hospital								AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FELBER JP, 1990, HORM METAB RES, V22, P11; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; OBRIEN T, 1993, MAYO CLIN PROC, V68, P141, DOI 10.1016/S0025-6196(12)60161-X; SHOULDERS CC, 1991, ATHEROSCLEROSIS, V87, P239, DOI 10.1016/0021-9150(91)90026-Y; TAS S, 1989, CLIN CHEM, V35, P256; TAS S, 1991, LANCET, V337, P113, DOI 10.1016/0140-6736(91)90770-P; TAS S, 1990, CLIN CHEM, V36, P1825	10	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1194	1195		10.1016/S0140-6736(94)92402-3	http://dx.doi.org/10.1016/S0140-6736(94)92402-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909870				2022-12-01	WOS:A1994NL17500011
J	SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB				SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB			ENHANCER POINT MUTATION RESULTS IN A HOMEOTIC TRANSFORMATION IN DROSOPHILA	SCIENCE			English	Article							BITHORAX COMPLEX; ANTENNAPEDIA GENE; EXPRESSION; HUNCHBACK; ULTRABITHORAX; SEGMENTATION; PRODUCTS; PROTEINS; EMBRYOS; KRUPPEL	In Drosophila, the misexpression or altered activity of genes from the bithorax complex results in homeotic transformations. One of these genes, abd-A, normally specifies the identity of the second through fourth abdominal segments (A2 to A4). In the dominant Hyperabdominal mutations (Hab), portions of the third thoracic segment (T3) are transformed toward A2 as the result of ectopic abd-A expression. Sequence analysis and deoxyribonuclease I footprinting demonstrate that the misexpression of abd-A in two independent Hab mutations results from the same single base change in a binding site for the gap gene Kruppel protein. These results establish that the spatial limits of the homeotic genes are directly regulated by gap gene products.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506				Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CELNIKER SE, 1993, P NATL ACAD SCI USA, V90, P1566, DOI 10.1073/pnas.90.4.1566; CRIBBS DL, 1992, GENETICS, V132, P699; CURTIS D, 1989, GENETICS, V122, P653; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.genet.21.1.285; DUNCAN I, COMMUNICATION; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, UNPUB; Kaufman T C, 1990, Adv Genet, V27, P309; KAZAZIAN HH, 1986, COLD SPRING HARB SYM, V51, P371, DOI 10.1101/SQB.1986.051.01.045; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lewis Edith, COMMUNICATION; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Pankratz Michael J., 1993, P467; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; QIAN S, 1993, EMBO J, V12, P3865, DOI 10.1002/j.1460-2075.1993.tb06065.x; REINITZ J, 1990, DEV BIOL, V140, P57, DOI 10.1016/0012-1606(90)90053-L; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SHIMELL M, UNPUB; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, UNPUB; SIMON J, 1993, DEV BIOL, V158, P134; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WHITE RAH, 1985, NATURE, V318, P567, DOI 10.1038/318567a0; ZHANG CC, 1991, DEVELOPMENT, V113, P1171	43	77	77	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					968	971		10.1126/science.7909957	http://dx.doi.org/10.1126/science.7909957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	7909957				2022-12-01	WOS:A1994NK97400036
J	VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR				VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR			GENETICALLY BASED N-ACETYLTRANSFERASE METABOLIC POLYMORPHISM AND LOW-LEVEL ENVIRONMENTAL EXPOSURE TO CARCINOGENS	NATURE			English	Article							EXFOLIATED UROTHELIAL CELLS; HEMOGLOBIN ADDUCTS; DNA ADDUCTS; URINARY MUTAGENICITY; CIGARETTE SMOKERS; SMOKING; ACETYLATION; PHENOTYPE; CANCER	THE metabolic activation or inactivation of carcinogens varies considerably in human populations, and is partly genetically determined(1,2). Inter-individual variability in the susceptibility to carcinogens may be particularly important at low degrees of environmental exposure. Examples of probable human carcinogens that present widespread low-dose exposures are environmental tobacco smoke and diesel exhaust(3,4). We have determined levels of DNA adducts in bladder cells and of 4-aminobiphenyl-haemoglobin adducts in 97 volunteers, together with the N-acetylation non-inducible phenotype, the corresponding genotype, and the levels of nicotine-cotinine in the urine. We find that among the slow acetylators, 4-aminobiphenyl adducts were higher than in rapid acetylators at low or null nicotine-cotinine levels, whereas the difference between slow and rapid acetylators was less evident at increasing nicotine-cotinine levels. The N-acetyltransferase genotype is highly predictive of the acetylation phenotype. Our results indicate that the clearance of low-dose carcinogens is decreased in the genetically based slow-acetylator phenotype. Such genetic modulation of low-dose environmental risks is relevant to 'risk assessment' procedures.	MAIN HOSP,I-10126 TURIN,ITALY; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY; NCI,GENET EPIDEMIOL BRANCH,ROCKVILLE,MD 20892; NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; NATL CTR TOXICOL RES,JEFFERSON,AR 72079; UNIV MILAN,IST MED LAVORO,I-20122 MILAN,ITALY; INT AGCY RES CANC,F-69372 LYON,FRANCE; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV CINCINNATI,DEPT ENVIRONM HLTH,CINCINNATI,OH	Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); University of Milan; World Health Organization; International Agency for Research on Cancer (IARC); Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	VINEIS, P (corresponding author), UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,CANC EPIDEMIOL UNIT,I-10126 TURIN,ITALY.		Shields, Peter G/I-1644-2012					[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; BARTSCH H, 1990, JNCI-J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BRYANT MS, 1988, P NATL ACAD SCI USA, V85, P9788, DOI 10.1073/pnas.85.24.9788; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; Case R A, 1966, Ann R Coll Surg Engl, V39, P213; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; TALASKA G, 1990, CARCINOGENESIS, V11, P639, DOI 10.1093/carcin/11.4.639; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; TALASKA G, 1991, CANCER EPIDEM BIOMAR, V1, P61; VINEIS P, 1990, CANCER RES, V50, P3002; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; 1989, IARC MONOGRAPHS EVAL, V46	15	270	274	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					154	156		10.1038/369154a0	http://dx.doi.org/10.1038/369154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	7909916				2022-12-01	WOS:A1994NK97100051
J	BANATVALA, JE; CHRYSTIE, IL				BANATVALA, JE; CHRYSTIE, IL			HIV SCREENING IN PREGNANCY - UK TAGS	LANCET			English	Editorial Material											BANATVALA, JE (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT VIROL,LONDON,ENGLAND.							ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; Chrystie I, 1992, Health Trends, V24, P13; DAVISON CF, 1993, AIDS CARE, V5, P135, DOI 10.1080/09540129308258593; GOUDEAU A, 1989, PARS TOURS COOPERATI; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MEADOWS J, 1992, LANCET, V339, P622; SIMMONDS RJ, 1992, 41ST EP INT SERV ANN, P35; 1992, IMMUNISATION INFECTI, P114; 1994, CLIN ALERT IMPORTANT; 1992, DEP HLTH GUIDANCE PL; 1993, AIDS SURVEILLANCE EU, V37, P20	14	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1113	1114		10.1016/S0140-6736(94)90230-5	http://dx.doi.org/10.1016/S0140-6736(94)90230-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910227				2022-12-01	WOS:A1994NK73000004
J	BENTON, EC				BENTON, EC			WARTS IN BUTCHERS - A CAUSE FOR CONCERN	LANCET			English	Editorial Material											BENTON, EC (corresponding author), ROYAL INFIRM,DEPT DERMATOL,EDINBURGH,SCOTLAND.							COGGON D, 1989, BRIT J IND MED, V46, P188; DEVILLIERS EM, 1989, ARCH DERMATOL, V125, P1590, DOI 10.1001/archderm.125.11.1590; KEEFE M, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06875.x; KEEFE M, 1994, BRIT J DERMATOL, V130, P9, DOI 10.1111/j.1365-2133.1994.tb06874.x; MELCHERS W, 1993, J CLIN MICROBIOL, V31, P2547, DOI 10.1128/JCM.31.9.2547-2549.1993; RUDLINGER R, 1989, BRIT J DERMATOL, V120, P375, DOI 10.1111/j.1365-2133.1989.tb04163.x; STEHRGREEN PA, 1993, INT J EPIDEMIOL, V22, P294, DOI 10.1093/ije/22.2.294; YOUSEM SA, 1992, CANCER-AM CANCER SOC, V69, P693, DOI 10.1002/1097-0142(19920201)69:3<693::AID-CNCR2820690316>3.0.CO;2-Y	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1114	1114		10.1016/S0140-6736(94)90231-3	http://dx.doi.org/10.1016/S0140-6736(94)90231-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910228				2022-12-01	WOS:A1994NK73000005
J	DECOSAS, J				DECOSAS, J			FIGHTING AIDS OR RESPONDING TO THE EPIDEMIC - CAN PUBLIC-HEALTH FIND ITS WAY	LANCET			English	Editorial Material											DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,POB 9698,KOTOKA INT AIRPORT,ACCRA,GHANA.							SCHEPERHUGHES N, 1993, LANCET, V342, P965, DOI 10.1016/0140-6736(93)92006-F	1	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1145	1146		10.1016/S0140-6736(94)90241-0	http://dx.doi.org/10.1016/S0140-6736(94)90241-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK730	7910238				2022-12-01	WOS:A1994NK73000015
J	KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H				KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H			SUDDEN HEARING-LOSS ASSOCIATED WITH INTERFERON	LANCET			English	Note							ALPHA-INTERFERON; DISEASE; CANCER	With the increasing long-term use of interferon, several new adverse effects have been recognised. We have prospectively assessed auditory function in 49 patients receiving interferon, after we saw a case of sudden sensorineural hearing loss during interferon therapy. Auditory disability (tinnitus, hearing loss, or both) occurred in 22 patients (45%) during treatment with audiometry-documented sensorineural hearing loss in 18 (37%). The auditory disability often developed in the late stage of treatment and resolved in all patients within 7-14 days after discontinuation of interferon.	NAGASAKI CHUO NATL HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; NAGASAKI CHUO NATL HOSP,INST CLIN RES,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT INTERNAL MED,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT NEUROL,NAGASAKI,JAPAN	Japanese Red Cross Medical Center; Japanese Red Cross Medical Center; Japanese Red Cross Medical Center	KANDA, Y (corresponding author), NAGASAKI UNIV,SCH MED,DEPT OTOLARYNGOL,1-7-1 SAKAMOTO,NAGASAKI 852,JAPAN.							BURMAN P, 1985, LANCET, V2, P100; CALVET MC, 1979, NATURE, V278, P558, DOI 10.1038/278558a0; COLE RR, 1988, AM J OTOL, V9, P211; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; GUYER DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P350, DOI 10.1001/archopht.1993.01090030068041; KIRKWOOD JM, 1984, J CLIN ONCOL, V2, P336, DOI 10.1200/JCO.1984.2.4.336; QUESADA JR, 1986, J CLIN ONCOL, V4, P234, DOI 10.1200/JCO.1986.4.2.234; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; SCHATTNER A, 1988, AM J MED SCI, V295, P532, DOI 10.1097/00000441-198806000-00007	9	52	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1134	1135		10.1016/S0140-6736(94)90237-2	http://dx.doi.org/10.1016/S0140-6736(94)90237-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910234				2022-12-01	WOS:A1994NK73000011
J	SPRAY, DC				SPRAY, DC			CMTX1 - A GAP JUNCTION GENETIC-DISEASE	LANCET			English	Editorial Material							GROWTH; CELLS; INVIVO; CDNA		ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Yeshiva University; Albert Einstein College of Medicine	SPRAY, DC (corresponding author), ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY, USA.			Spray, David/0000-0001-8368-5073				BAI S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P197, DOI 10.1016/0167-4781(93)90145-4; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; CHANSON M, 1993, J GEN PHYSIOL, V102, P925, DOI 10.1085/jgp.102.5.925; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P185; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; IONASESCU V, 1994, HUM MOL GENET, V3, P355, DOI 10.1093/hmg/3.2.355; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MESNIL M, 1993, PROG CELL R, V3, P311; NAUS CCG, 1992, CANCER RES, V52, P4208; SAFFITZ JE, 1993, CIRCULATION, V87, P1742, DOI 10.1161/01.CIR.87.5.1742; SPRAY DC, 1992, BIOPHYS J, V62, P48, DOI 10.1016/S0006-3495(92)81774-5; SPRAY DC, 1994, ION CHANNELS CARDIOV, P185; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; TETZLAFF W, 1982, J NEUROCYTOL, V11, P839, DOI 10.1007/BF01153522; Warner A., 1992, Seminars in Cell Biology, V3, P81	18	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1111	1112		10.1016/S0140-6736(94)90229-1	http://dx.doi.org/10.1016/S0140-6736(94)90229-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910226				2022-12-01	WOS:A1994NK73000003
J	NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J				NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J			CONTROL OF CELL BEHAVIOR DURING VERTEBRATE DEVELOPMENT BY SLUG, A ZINC-FINGER GENE	SCIENCE			English	Article							NEURAL CREST; ADHESION; ANTIBODIES; CADHERIN; ENCODES	Slug, a vertebrate gene encoding a zinc finger protein of the Snail family, is expressed in the neural crest and in mesodermal cells emigrating from the primitive streak. Early chick embryos were incubated with antisense oligonucleotides to chick Slug. These oligonucleotides specifically inhibit the normal change in cell behavior that occurs at the two sites in the emerging body plan in which the gene is expressed. This change, which is the transition from epithelial to mesenchymal character, occurs at the formation of mesoderm during gastrulation and on emigration of the neural crest from the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; CSIC,INST CAJAL,E-28002 MADRID,SPAIN	MRC National Institute for Medical Research; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)			Nieto, M. Angela/A-6531-2008	Nieto, M. Angela/0000-0002-3538-840X; Wilkinson, David/0000-0001-6757-7080				BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bellairs R., 1987, P123; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BRONNERFRASER M, 1992, DEV BIOL, V153, P291, DOI 10.1016/0012-1606(92)90114-V; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; COOKE J, UNPUB; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Le Douarin N, 1973, Dev Biol, V30, P217, DOI 10.1016/0012-1606(73)90061-4; Le Douarin N.M., 1982, NEURAL CREST; LELIEVRE C, 1975, J EMBRYOL EXP MORPH, V31, P125; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIETO MA, 1992, DEVELOPMENT, V116, P227; SARGENT MG, 1990, DEVELOPMENT, V109, P963; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA G, 1989, DEVELOPMENT, V106, P806; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	26	615	629	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					835	839		10.1126/science.7513443	http://dx.doi.org/10.1126/science.7513443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	7513443				2022-12-01	WOS:A1994NJ94900031
